



(11) **EP 3 589 628 B1**

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention of the grant of the patent:
07.05.2025 Bulletin 2025/19

(21) Application number: **18761960.6**

(22) Date of filing: **01.03.2018**

(51) International Patent Classification (IPC):
C07D 403/08 ^(2006.01) **C07F 9/572** ^(2006.01)
A61K 31/404 ^(2006.01) **A61K 31/4184** ^(2006.01)
A61P 9/00 ^(2006.01) **A61P 11/00** ^(2006.01)
A61P 19/00 ^(2006.01) **A61P 27/00** ^(2006.01)
A61P 43/00 ^(2006.01)

(52) Cooperative Patent Classification (CPC):
C07F 9/65583; C07D 401/14; C07D 403/14;
C07D 405/14; C07D 413/14; C07D 417/14;
C07D 471/04; C07D 498/08; C07D 498/10;
C07D 519/00; C07F 9/6561; Y02A 50/30

(86) International application number:
PCT/US2018/020528

(87) International publication number:
WO 2018/160889 (07.09.2018 Gazette 2018/36)

(54) **ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS**

ARYL-, HETEROARYL- UND HETEROCYCLISCHE VERBINDUNGEN ZUR BEHANDLUNG VON MEDIZINISCHEN ERKRANKUNGEN

COMPOSÉS PHARMACEUTIQUES ARYLE, HÉTÉROARYLES ET HÉTÉROCYCLIQUES POUR LE TRAITEMENT DE TROUBLES MÉDICAUX

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR

(30) Priority: **01.03.2017 US 201762465782 P**
02.03.2017 US 201762466301 P

(43) Date of publication of application:
08.01.2020 Bulletin 2020/02

(60) Divisional application:
21208059.2 / 3 985 002

(73) Proprietor: **Achillion Pharmaceuticals, Inc.**
Boston, MA 02210 (US)

(72) Inventors:
• **WILES, Jason, Allan**
Boston, MA 02210 (US)
• **PHADKE, Avinash, S.**
Boston, MA 02210 (US)

- **DESHPANDE, Milind**
Boston, MA 02210 (US)
- **AGARWAL, Atul**
Boston, MA 02210 (US)
- **CHEN, Dawei**
Boston, MA 02210 (US)
- **GADHACHANDA, Venkat, Rao**
Boston, MA 02210 (US)
- **HASHIMOTO, Akihiro**
Boston, MA 02210 (US)
- **PAIS, Godwin**
Boston, MA 02210 (US)
- **WANG, Qiuping**
Boston, MA 02210 (US)
- **WANG, Xiangzhu**
Boston, MA 02210 (US)
- **BARRISH, Joel, Charles**
Boston, MA 02210 (US)
- **GREENLEE, William**
Boston, MA 02210 (US)
- **EASTMAN, Kyle, J.**
Boston, MA 02210 (US)

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 3 589 628 B1

(74) Representative: **Bassil, Nicholas Charles et al**
Kilburn & Strode LLP
Lacon London
84 Theobalds Road
London WC1X 8NL (GB)

(56) References cited:
WO-A1-2014/002057 **WO-A1-2017/035353**
US-A1- 2015 239 838 **US-A1- 2015 239 895**
US-B1- 6 653 340

Description**Field of the Invention**

- 5 **[0001]** This invention provides aryl, heteroaryl and heterocyclic drugs to treat medical disorders, such as complement-mediated disorders.

Background of the Invention

- 10 **[0002]** The complement system is a part of the innate immune system which does not adapt to changes over the course of the host's life, but is recruited and used by the adaptive immune system. For example, it assists, or complements, the ability of antibodies and phagocytic cells to clear pathogens. This sophisticated regulatory pathway allows rapid reaction to pathogenic organisms while protecting host cells from destruction. Over thirty proteins and protein fragments make up the complement system. These proteins act through opsonization (enhancing phagocytosis of antigens), chemotaxis (attracting macrophages and neutrophils), cell lysis (rupturing membranes of foreign cells), and agglutination (clustering and binding of pathogens together).

- 15 **[0003]** The complement system has three pathways: classical, alternative, and lectin. Complement Factor D plays an early and central role in activation of the alternative pathway of the complement cascade. Activation of the alternative complement pathway is initiated by spontaneous hydrolysis of a thioester bond within C3 to produce C3(H₂O), which associates with Factor B to form the C3(H₂O)B complex. Complement Factor D acts to cleave Factor B within the C3(H₂O) B complex to form Ba and Bb. The Bb fragment remains associated with C3(H₂O) to form the alternative pathway C3 convertase C3(H₂O)Bb. Additionally, C3b generated by any of the C3 convertases also associates with Factor B to form C3bB, which Factor D cleaves to generate the later stage alternative pathway C3 convertase C3bBb. This latter form of the alternative pathway C3 convertase may provide important downstream amplification within all three of the defined complement pathways, leading ultimately to the recruitment and assembly of additional factors in the complement cascade pathway, including the cleavage of C5 to C5a and C5b. C5b acts in the assembly of factors C6, C7, C8, and C9 into the membrane attack complex, which can destroy pathogenic cells by lysing the cell.

- 20 **[0004]** The dysfunction of or excessive activation of complement has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer. For example, activation of the alternative pathway of the complement cascade contributes to the production of C3a and C5a, both potent anaphylatoxins, which also have roles in a number of inflammatory disorders. Therefore, in some instances, it is desirable to decrease the response of the complement pathway, including the alternative complement pathway. Some examples of disorders mediated by the complement pathway include age-related macular degeneration (AMD), paroxysmal nocturnal hemoglobinuria (PNH), multiple sclerosis, and rheumatoid arthritis.

- 25 **[0005]** Age-related macular degeneration (AMD) is a leading cause of vision loss in industrialized countries. Based on a number of genetic studies, there is evidence of the link between the complement cascade and macular degeneration. Individuals with mutations in the gene encoding complement Factor H have a fivefold increased risk of macular degeneration and individuals with mutations in other complement factor genes also have an increased risk of AMD. Individuals with mutant Factor H also have increased levels of C-reactive protein, a marker of inflammation. Without adequate functioning Factor H, the alternative pathway of the complement cascade is overly activated leading to cellular damage.

- 30 **[0006]** Paroxysmal nocturnal hemoglobinuria (PNH) is a non-malignant, hematological disorder characterized by the expansion of hematopoietic stem cells and progeny mature blood cells that are deficient in some surface proteins. PNH erythrocytes are not capable of modulating their surface complement activation, which leads to the typical hallmark of PNH - the chronic activation of complement mediated intravascular anemia. Currently, only one product, the anti-C5 monoclonal antibody eculizumab, has been approved in the U.S. for treatment of PNH. However, many of the patients treated with eculizumab remain anemic, and many patients continue to require blood transfusions. In addition, treatment with eculizumab requires life-long intravenous injections.

- 35 **[0007]** Additional complement-mediated disorders include those classified under component 3 glomerulopathy (C3G). C3G is a recently defined entity comprised of dense deposit disease (DDD) and C3 glomerulonephritis (C3GN) which encompasses a population of chronic kidney diseases wherein elevated activity of the alternative complement pathway and terminal complement pathway results in glomerular deposits made solely of complement C3 and no immunoglobulin (Ig).

- 40 **[0008]** Immune-complex membranoproliferative glomerulonephritis (IC-MPGN) is a renal disease which shares many clinical, pathologic, genetic and laboratory features with C3G, and therefore can be considered a sister disease of C3G. In the majority of patients with IC-MPGN, an underlying disease or disorder-most commonly infections, autoimmune diseases, or monoclonal gammopathies-are identified to which the renal disease is secondary. Patients with idiopathic IC-MPGN can have low C3 and normal C4 levels, similar to those observed in C3G, as well as many of the same genetic or

acquired factors that are associated with abnormal alternative pathway activity. Although there are current hypotheses suggesting that the majority of IC-MPGN is attributable to over activity of the classical pathway, those patients with a low C3 and a normal C4 are likely to have significant overactivity of the alternative pathway. IC-MPGN patients with a low C3 and a normal C4 may benefit from alternative pathway inhibition.

[0009] Other disorders that have been linked to the complement cascade include atypical hemolytic uremic syndrome (aHUS), hemolytic uremic syndrome (HUS), abdominal aortic aneurysm, hemodialysis complications, hemolytic anemia, or hemodialysis, neuromyelitis optica (NMO), myasthenia gravis (MG), fatty liver, nonalcoholic steatohepatitis (NASH), liver inflammation, cirrhosis, liver failure, dermatomyositis, and amyotrophic lateral sclerosis.

[0010] Factor D is an attractive target for inhibition or regulation of the complement cascade due to its early and essential role in the alternative complement pathway, and for its potential role in signal amplification within the classical and lectin complement pathways. Inhibition of Factor D effectively interrupts the pathway and attenuates the formation of the membrane attack complex.

[0011] While initial attempts have been made to develop inhibitors of Factor D, there are currently no clinically approved small molecule Factor D inhibitors. Examples of Factor D inhibitor compounds are described in the following disclosures.

[0012] Biocryst Pharmaceuticals US Pat. No. 6,653,340 titled "Compounds useful in the complement, coagulate and kallikrein pathways and method for their preparation" describes fused bicyclic ring compounds that are potent inhibitors of Factor D. Development of the Factor D inhibitor BCX1470 was discontinued due to lack of specificity and short half-life of the compound.

[0013] Novartis PCT patent publication WO2012/093101 titled "Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration" describes certain Factor D inhibitors. Additional Factor D inhibitors are described in Novartis PCT patent publications WO2013/164802, WO2013/192345, WO2014/002051, WO2014/002052, WO2014/002053, WO2014/002054, WO2014/002057, WO2014/002058, WO2014/002059, WO2014/005150, WO2014/009833, WO2014/143638, WO2015/009616, WO2015/009977, and WO2015/066241.

[0014] A paper published by Novartis titled "Structure-Based Library Design and Fragment Screening for the Identification of Reversible Complement Factor D Protease Inhibitors" (Vulpetti et al., J. Med. Chem. 10.1021/acs.jmedchem.6b01684) describes an *in silico* active site mapping for regions that contribute to a large fraction of binding energy using the Factor D crystal structure and NMR-based screening (structure-based drug design (SBDD) and fragment-based screening (FBD)). Another Novartis paper titled "Small-molecule factor D inhibitors targeting the alternative complement pathway" (Maibaum et al., Nat. Chem. Bio. 2016;12;1105) discloses small-molecule inhibitors designed by use of a structure-based design approach in combination with fragment-based screening.

[0015] Lifesci Pharmaceuticals PCT patent publication WO2017/098328 titled "Therapeutic Inhibitory Compounds" describes various Factor D inhibitors with variations in the central core ring heterocycle ring. PCT patent publication WO2018/015818 is also titled "Therapeutic Inhibitory Compounds" and describes Factor D inhibitors without cyclic central core.

[0016] Bristol-Myers Squibb PCT patent publication WO2004/045518 titled "Open chain prolyl urea-related modulators of androgen receptor function" describes open chain prolyl urea and thiourea related compounds for the treatment of androgen receptor-associated conditions, such as age-related diseases, for example, sarcopenia.

[0017] Japan Tobacco Inc. PCT patent publication WO1999/048492 titled "Amide derivatives and nociceptin antagonists" describes compounds with a proline-like core and aromatic substituents connected to the proline core through amide linkages useful for the treatment of pain.

[0018] Ferring B.V. and Yamanouchi Pharmaceutical Co. ITD. PCT patent publication WO1993/020099 titled "CCK and/or gastrin receptor ligands" describes compounds with a proline-like core and heterocyclic substituents connected to the proline core through amide linkages for the treatment of, for example, gastric disorders or pain.

[0019] Alexion Pharmaceuticals PCT patent publication WO1995/029697 titled "Methods and compositions for the treatment of glomerulonephritis and other inflammatory diseases" discloses antibodies directed to C5 of the complement pathway for the treatment of glomerulonephritis and inflammatory conditions involving pathologic activation of the complement system. Alexion Pharmaceutical's anti-C5 antibody eculizumab (Soliris®) is currently the only complement-specific antibody on the market, and is the first and only approved treatment for paroxysmal nocturnal hemoglobinuria (PNH).

[0020] On February 25, 2015, Achillion Pharmaceuticals filed PCT Patent Application No. PCT/US2015/017523 and U.S. Patent Application No. 14/631,090 titled "Alkyne Compounds for Treatment of Complement Mediated Disorders"; PCT Patent Application No. PCT/US2015/017538 and U.S. Patent Application No. 14/631,233 titled "Amide Compounds for Treatment of Complement Mediated Disorders"; PCT Patent Application No. PCT/US2015/017554 and U.S. Patent Application No. 14/631,312 titled "Amino Compounds for Treatment of Complement Mediated Disorders"; PCT Patent Application No. PCT/US2015/017583 and U.S. Patent Application No. 14/631,440 titled "Carbamate, Ester, and Ketone Compounds for Treatment of Complement Mediated Disorders"; PCT Patent Application No. PCT/US2015/017593 and U.S. Patent Application No. 14/631,625 titled "Aryl, Heteroaryl, and Heterocyclic Compounds for Treatment of Complement Mediated Disorders"; PCT Patent Application No. PCT/US2015/017597 and U.S. Patent Application No. 14/631,683

titled "Ether Compounds for Treatment of Complement Mediated Disorders"; PCT Patent Application No. PCT/US2015/017600 and U.S. Patent Application No. 14/631,785 titled "Phosphonate Compounds for Treatment of Complement Mediated Disorders"; and PCT Patent Application No. PCT/US2015/017609 and U.S. Patent Application No. 14/631,828 titled "Compounds for Treatment of Complement Mediated Disorders" and U.S. Patent Application No. 14/630,959 titled "Factor D Inhibitors Useful for Treating Infectious Disorders."

[0021] Additional complement factor D inhibitors are described in U.S. Patent Nos. 9,828,396; 9,695,205; 9,598,446; 9,732,103; 9,796,741; 9,732,104; 9,663,543; 9,758,537; and 9,643,986; International Publication Nos. WO 2015/130784; WO 2015/130795; WO 2015/130806; WO 2015/130830; WO 2015/130838; WO 2015/130842; WO 2015/130845; and WO 2015/130854; and U.S. Patent Publication Nos. US 2017-0298084; US 2016-0362398; US 2017-0189410; US 2017-0298085; US 2018-0030075; US 2016-0362399; US 2018-0022766; US 2016-0362433; US 2017-0260219; US 2016-0362432; US 2018-0022767; US 2016-0361329; and US 2017-0226142; all owned by Achillion Pharmaceuticals, Inc.

[0022] Given the wide variety of medical disorders that are caused by detrimental immune or inflammatory responses, new compounds are needed for medical treatment.

Cited documents


[0023] WO 2017/035353 describes aryl, heteroaryl and heterocyclic compounds for treatment of medical disorders.

[0024] WO 2014/002057 describes pyrrolidine derivatives and their use as complement pathway modulators.

SUMMARY

[0025] The present invention is defined in the appended claims.


[0026] The presently claimed invention provides a compound selected from:



5

10


15



20

25


30



35

40

45



50

55

5

10

15

20

25

30










35


40

45


50

55





5




10

15

20


25



30

35


40



45

50

55



5

10

15

20

25

30


35

40

45

50

55



5

10

15

20

25

30


35

40

45

50

55



5

10

15

20

25

30




35

40

45

50

55



5

10

15

20

25

30


35


40

45

50

55





5

10

15

20

25

30


35

40

45

50

55



5

10

15

20

25

30





35

40

45

50


55



5

10


15



20

25

30




35

40

45

50



55

5

10

15

20

25

30


35


40

45

50

55





5

10

15

20

25

30


35


40

45

50

55





or a pharmaceutically acceptable salt thereof.

[0027] The technical information set out below may in some respects go beyond the scope of the presently claimed invention, which is defined by the appended claims. The additional technical information is provided to place the actual invention in a broader technical context and to illustrate possible related technical developments. Such additional technical information which does not fall within the scope of the appended claims is not part of the presently claimed invention.

[0028] Described herein is a compound of Formula I, Formula II, or Formula III or a pharmaceutically acceptable salt, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition, wherein at least one of R¹² or R¹³ on the A group is an aryl, heteroaryl or heterocycle substituent, which is R³². In one embodiment, the compound or its salt or composition, as described herein is for use to treat a medical disorder which is an inflammatory or immune condition, a disorder mediated by the complement cascade (including a dysfunctional cascade), a disorder or abnormality of a cell that adversely affects the ability of the cell to engage in or respond to normal complement activity including the alternative complement pathway, or an undesired complement-mediated response to a medical treatment, such as surgery or other medical procedure or a pharmaceutical or biopharmaceutical drug administration, a blood transfusion, or other allogenic tissue or fluid administration.

[0029] These compounds can be used to treat medical conditions in a host in need thereof, typically a human. The active compound may act as an inhibitor of the complement factor D cascade. In one embodiment, a compound described herein or a pharmaceutically acceptable salt, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition, for use in the treatment of such a disorder is provided that includes the administration of an effective amount of the compound described herein or a pharmaceutically acceptable salt, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition, as described in more detail below.

[0030] In certain embodiments, compounds are provided that have minimal effect on BSEP (bile salt export pump protein) (e.g., with an IC₅₀ of greater than about 20, 30, 40, 50, 60, 75 or 100 μM or greater), or with a therapeutic index of BSEP relative to complement D inhibition (e.g., IC₅₀ inhibition of BSEP/IC₅₀ inhibition of complement D inhibitor), of about at least 50, 100, 200, 300, 400, 500, 750 or 1000 or greater). BSEP inhibition correlates with cholestatic drug-induced liver injury. Certain compounds of the present invention with low BSEP inhibition have at least one R²⁰¹.

[0031] In some embodiments, the compounds of the present invention exhibit minimal hydrolysis of the amide bond between the C ring and the B ring *in vivo*, for example, by including a proline that has a cis-substituent relative to the proline-carbonyl bond directed toward the B-ring. In certain embodiments, the cis-substituent is in the Q3 position or the Q2 position or is a group that bridges Q3 and Q2.

[0032] It has also been discovered that including a B-ring substituent in the position ortho to the amide (for example 2-(L1)-3-methyl-6-substituted-pyridine or 2-(L1)-3-cyclopropyl-6-substituted-pyridine) may decrease the potential for formation of reactive metabolites.

[0033] Also described herein is an R³⁰¹ acylated embodiment of an active compound of the invention is provided that exhibits extended half-life or other advantageous pharmacokinetic properties, which may be achieved by albumin stabilization *in vivo*. In certain embodiments, the acylated analogue can include several linking moieties in linear, branched or cyclic manner. In certain embodiments, either one or a series of amino acids is used as a linker to a terminal fatty acid. In one non-limiting example a non-natural amino acid, for example 8-amino-3,6-dioxaoctanoic acid (one or several in sequence) is covalently bound to the selected complement D inhibitor of the present invention through a functional group such as a carboxylic acid, sulfonyl, hydroxyl or amino group. See generally Lau, et al., "Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide", J. Med. Chem., 2015, 58, 7370-7380. In this embodiment, the 8-amino-3,6-dioxaoctanoic acid or similar molecule is covalently linked to an aliphatic acid, including but not limited to a C₁₆, C₁₈, C₂₀ aliphatic acid, or a dicarboxylic acid, including but not limited to a C₈, C₁₀, C₁₂, C₁₄, C₁₆, C₁₈ or C₂₀ diacid. One or more amino acids can also be used in the selected configuration to add length or functionality. More

generally, nonlimiting embodiments include the use of a divalent linker moiety such as a dicarboxylic acid, amino acid, diamine, hydroxycarboxylic acid, hydroxyamine, di-hydroxy compound, or other compound that has at least two functional groups that can link the parent molecule with another linking moiety, and which may be albumin stabilized *in vivo*. In some embodiments, 2, 3, 4 or 5 linking moieties are covalently bound in sequence, branched or cyclic fashion to the parent compound. In some embodiments, an R³⁰¹ acyl group is located in a position of the active compound that does not significantly adversely affect the complement D inhibition of the molecule, for example, as (i) a substituent on the R³² group or (ii) a substituent on a C-ring, such as proline, or as a substituent on a substituent on the C-ring, such as on an R¹, R² or R³ substituent, including for example, on a bridged moiety such as a fused cyclopropyl on the proline ring. In certain embodiments, the acyl group has an aliphatic or heteroaliphatic carbon range of C₁₂, C₁₄, C₁₆, C₁₈, C₂₀, C₂₂ or C₂₄.

[0034] In one embodiment, the disorder is associated with the alternative complement cascade pathway. In yet another embodiment, the disorder is associated with the complement classical pathway. In a further embodiment, the disorder is associated with the complement lectin pathway. Alternatively, the active compound or its salt may act through a different mechanism of action than the complement cascade, or in particular as a complement factor D inhibitor, to treat the disorder described herein.

[0035] In one embodiment, a compound for use in a method for the treatment of C3 glomerulonephritis (C3G) is provided that includes the administration of an effective amount of the compound described herein, or a pharmaceutically acceptable salt, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition, to a host. In one embodiment, a compound for use in a method for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) is provided that includes the administration of an effective amount of the compound described herein, or a pharmaceutically acceptable salt, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition to a host. In another embodiment, a compound for use in a method for the treatment of wet or dry age-related macular degeneration (AMD) in a host is provided that includes the administration of an effective amount of the compound described herein, or a pharmaceutically acceptable salt, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition. In another embodiment, a compound for use in a method for the treatment of rheumatoid arthritis in a host is provided that includes the administration of an effective amount of the compound described herein, or a pharmaceutically acceptable salt, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition. In another embodiment, a compound for use in a method for the treatment of multiple sclerosis in a host is provided that includes the administration of an effective amount of the compound described herein, or a pharmaceutically acceptable salt, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition.

[0036] In other embodiments, an active compound or its salt as described herein can be for use to treat fatty liver and conditions stemming from fatty liver, nonalcoholic steatohepatitis (NASH), liver inflammation, cirrhosis, and liver failure, dermatomyositis, or amyotrophic lateral sclerosis.

[0037] The active compound or its pharmaceutically acceptable salt, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition, as disclosed herein is also useful for administration in combination (in the same or a different dosage form) or alternation with a second pharmaceutical agent for use in ameliorating or reducing a side effect of the second pharmaceutical agent. For example, in one embodiment, the active compound may be used in combination with an adoptive cell transfer therapy to reduce an inflammatory response associated with such therapy, for example, a cytokine mediated response such as cytokine response syndrome. In one embodiment, the adoptive cell transfer therapy is a chimeric antigen receptor T-Cell (CAR T) or a dendritic cell used to treat a hematologic or solid tumor, for example, a B-cell related hematologic cancer. In one embodiment, the hematologic or solid tumor is acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), pancreatic cancer, glioblastoma, or a cancer that expresses CD19. In one embodiment, the associated inflammatory response is a cytokine mediated response.

[0038] Another embodiment is provided that includes the administration of an effective amount of an active compound or a pharmaceutically acceptable salt, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition to a host to treat an ocular, pulmonary, gastrointestinal, or other disorder that can benefit from topical or local delivery.


[0039] Any of the compounds described herein can be administered to the eye in any desired form of administration, including via intravitreal, intrastromal, intracameral, sub-tenon, sub-retinal, retro-bulbar, peribulbar, suprachoroidal, choroidal, subchoroidal, conjunctival, subconjunctival, episcleral, posterior juxtascleral, scleral, circumcorneal, and tear duct injections, or through a mucus, mucin, or a mucosal barrier, in an immediate or controlled release fashion. In certain embodiments, the active compound includes a lipophilic group, such as a lipophilic acyl group, which is delivered to the eye in a polymeric drug delivery system such as polylactic acid, polylactide-co-glycolide, polyglycolide or other erodible polymer, or a combination thereof, or in another type of lipophilic material for ocular delivery. In some embodiments, the lipophilic active molecule is more soluble in the polymeric or other form of delivery system than in ocular fluid.

[0040] In other embodiments of the invention, an active compound provided herein can be for use to treat or prevent a disorder in a host mediated by complement factor D, or by an excessive or detrimental amount of the complement-C3

amplification loop of the complement pathway. As examples, the invention includes compounds for use in methods to treat or prevent complement associated disorders that are induced by antibody-antigen interactions, a component of an immune or autoimmune disorder or by ischemic injury. The invention also provides compounds for use in methods to decrease inflammation or an immune response, including an autoimmune response, where mediated or affected by factor D.

[0041] In another embodiment, a compound is provided for use in treating a host, typically a human, with a disorder mediated by the complement system, that includes administration of a prophylactic antibiotic or vaccine to reduce the possibility of a bacterial infection during the treatment using one of the compounds described herein. In certain embodiments, the host, typically a human, is given a prophylactic vaccine prior to, during or after treatment with one of the compounds described herein. In certain embodiments, the host, typically a human, is given a prophylactic antibiotic prior to, during or after treatment with one of the compounds described herein. In some embodiments, the infection is a meningococcal infection (e.g., septicemia and/or meningitis), an *Aspergillus* infection, or an infection due to an encapsulated organism, for example, *Streptococcus pneumoniae* or *Haemophilus influenza* type b (Hib), especially in children. In other embodiments, the vaccine or antibiotic is administered to the patient after contracting an infection due to, or concomitant with inhibition of the complement system.

[0042] The disclosure provides a compound of Formula I, Formula II, or Formula III:



or a pharmaceutically acceptable salt, isotopic analog, or isolated isomer thereof optionally in pharmaceutically acceptable carrier;
wherein:

A is selected from A1, A2, and A3;

B is selected from B1, B2, and B3;

or B is B4;

B4 is separately defined below;


C is selected from C1, C2, C3, and C4;

or C is C5;

C5 is separately defined below;

and wherein for compounds of Formula I at least one of the following limitations is present: A is A3, B is B3, or C is C4;

C1 is



Q¹ is N(R¹), C(R¹R^{1'}), C(R¹R^{1'})C(R¹R^{1'}), C(R¹R^{1'})C(R¹R^{1'})C(R¹R^{1'}), S or O;

Q² is C(R²R^{2'}), C(R²R^{2'})C(R²R^{2'}), C(R²R^{2'})C(R²R^{2'})C(R²R^{2'}), N(R²), S, O, or C(R²R^{2'})O;

Q³ is N(R³), S, O, C(R³R^{3'}), C(R³R^{3'})C(R³R^{3'}), or C(R³R^{3'})C(R³R^{3'})C(R³R^{3'});

X¹ and X² are independently N, CH, or CZ;

or X¹ and X² together are C=C;


wherein X¹ is directly bound to L3 and X² is directly bound to L; and

wherein Q¹, Q², Q³, X¹, and X² are selected such that a stable compound results;

Z is F, Cl, NH₂, CH₃, CH₂D, CHD₂, or CD₃;

R¹, R^{1'}, R², R^{2'}, R³, and R^{3'} are independently selected at each occurrence, as appropriate, and only where a stable compound results, from hydrogen, R²⁰¹, R³⁰¹, halogen (and specifically fluoro, chloro, bromo), hydroxyl, nitro, cyano, amino, alkyl including C₁-C₆alkyl, alkenyl including C₂-C₆alkenyl, alkynyl including C₂-C₆alkynyl, alkoxy including C₁-C₆alkoxy, alkanoyl including C₂-C₆alkanoyl, thioalkyl including C₁-C₆alkylthio, hydro-

$\text{xyC}_1\text{-C}_6\text{alkyl}$, $\text{aminoC}_1\text{-C}_6\text{alkyl}$, $\text{-C}_0\text{-C}_4\text{alkylNR}^9\text{R}^{10}$, -C(O)OR^9 , -OR^1 , $\text{-NR}^9\text{R}^{10}$, -OC(O)R^9 , $\text{-NR}^9\text{C(O)R}^{10}$, $\text{-C(O)NR}^9\text{R}^{10}$, $\text{-OC(O)NR}^9\text{R}^{10}$, $\text{-NR}^9\text{C(O)OR}^{10}$, haloalkyl including $\text{C}_1\text{-C}_6\text{haloalkyl}$, and $\text{C}_1\text{-C}_6\text{haloalkoxy}$;
 or R^1 and $\text{R}^{1'}$ are taken together to form a 3- to 6-membered carbocyclic spiro ring or a 3- to 6-membered heterocyclic spiro ring containing 1 or 2 heteroatoms independently selected from N, O, or S;
 or R^3 and $\text{R}^{3'}$ are taken together to form a 3- to 6-membered carbocyclic spiro ring or a 3- to 6-membered heterocyclic spiro ring containing 1 or 2 heteroatoms independently selected from N, O, or S;
 or R^2 and $\text{R}^{2'}$ are taken together to form a 3- to 6-membered carbocyclic spiro ring or a 3- to 6-membered heterocyclic spiro ring;
 wherein, each of the above spiro rings may be optionally substituted with 1 or more substituents independently selected from R^{201} , halogen (and in particular F), hydroxyl, cyano, -COOH , alkyl including $\text{C}_1\text{-C}_4\text{alkyl}$ (and in particular methyl), alkenyl including $\text{C}_2\text{-C}_4\text{alkenyl}$, alkynyl including $\text{C}_2\text{-C}_4\text{alkynyl}$, alkoxy including $\text{C}_1\text{-C}_6\text{alkoxy}$, alkanoyl, including $\text{C}_2\text{-C}_4\text{alkanoyl}$, hydroxy $\text{C}_1\text{-C}_4\text{alkyl}$, (mono- and di-alkylamino) $\text{C}_1\text{-C}_4\text{alkyl}$, $\text{-C}_0\text{-C}_4\text{alkyl(C}_3\text{-C}_7\text{cycloalkyl)}$, $\text{-O-alkyl(C}_3\text{-C}_7\text{cycloalkyl)}$, haloalkyl including $\text{C}_1\text{-C}_6\text{haloalkyl}$, and haloalkoxy including $\text{C}_1\text{-C}_6\text{haloalkoxy}$;
 or in an alternative embodiment, each of the above spiro rings may be optionally substituted with an aryl ring;
 or R^1 and R^2 are taken together to form a 3-membered carbocyclic ring, a 4- to 6-membered carbocyclic or aryl ring, or a 4- to 6-membered heterocyclic or heteroaryl ring containing 1 or 2 heteroatoms independently selected from N, O, and S;
 or R^2 and R^3 are taken together to form a 3- to 6-membered carbocyclic or aryl ring or a 3- to 6-membered heterocyclic or heteroaryl ring;
 wherein each of which fused R^1 and R^2 or R^2 and R^3 rings, or generally R^1 , R^2 , R^3 , $\text{R}^{1'}$, $\text{R}^{2'}$, or $\text{R}^{3'}$, are optionally substituted with 1 or more substituents independently selected from R^{201} , halogen (and in particular F), hydroxyl, cyano, -COOH , alkyl including $\text{C}_1\text{-C}_4\text{alkyl}$ (and in particular methyl), alkenyl including $\text{C}_2\text{-C}_4\text{alkenyl}$, alkynyl including $\text{C}_2\text{-C}_4\text{alkynyl}$, alkoxy including $\text{C}_1\text{-C}_4\text{alkoxy}$, alkanoyl including $\text{C}_2\text{-C}_4\text{alkanoyl}$, hydroxy $\text{C}_1\text{-C}_4\text{alkyl}$, (mono- and di-alkylamino) $\text{C}_0\text{-C}_4\text{alkyl}$, alkyl($\text{C}_3\text{-C}_7\text{cycloalkyl}$) including $\text{-C}_1\text{-C}_4\text{alkyl(C}_3\text{-C}_7\text{cycloalkyl)}$, $\text{-O-(C}_3\text{-C}_7\text{cycloalkyl)}$, haloalkyl including $\text{C}_1\text{-C}_6\text{haloalkyl}$, and haloalkoxy including $\text{C}_1\text{-C}_6\text{haloalkoxy}$;
 or R^1 and $\text{R}^{1'}$ are taken together to form a carbonyl group;
 or R^2 and $\text{R}^{2'}$ are taken together to form a carbonyl group;
 or R^3 and $\text{R}^{3'}$ are taken together to form a carbonyl group;
 or R^1 and R^2 are taken together to form a carbon-carbon double bond;
 or R^2 and R^3 are taken together to form a carbon-carbon double bond;
 R and R' are independently selected from H, R^{201} , alkyl, cycloalkyl, cycloalkylalkyl, heterocycle, heterocycloalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl;
 or in an alternative embodiment, R , R' , and R'' are independently selected from R^{301} , heteroalkyl, H, R^{201} , alkyl, cycloalkyl, cycloalkylalkyl, heterocycle, heterocycloalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl, and heteroaliphatic;
 R^9 and R^{10} are independently selected from hydrogen, alkyl including $\text{C}_1\text{-C}_6\text{alkyl}$, $\text{(C}_3\text{-C}_7\text{cycloalkyl)C}_0\text{-C}_4\text{alkyl}$, $\text{-C}_0\text{-C}_4\text{alkyl(C}_3\text{-C}_7\text{cycloalkyl)}$, and $\text{-O-C}_0\text{-C}_4\text{alkyl(C}_3\text{-C}_7\text{cycloalkyl)}$;
 C_2 is selected from:



q is 0, 1, 2 or 3;

r is 1, 2 or 3;

R^{44} , $\text{R}^{44'}$, R^{45} , $\text{R}^{45'}$ are independently selected at each occurrence, as appropriate, and only where a stable compound results, from hydrogen, R^{201} , halogen (and specifically fluoro, chloro, bromo), hydroxyl, nitro, cyano, amino, alkyl including $\text{C}_1\text{-C}_6\text{alkyl}$, alkenyl including $\text{C}_2\text{-C}_6\text{alkenyl}$, alkynyl including $\text{C}_2\text{-C}_6\text{alkynyl}$, alkoxy including $\text{C}_1\text{-C}_6\text{alkoxy}$, alkanoyl including $\text{C}_2\text{-C}_6\text{alkanoyl}$, thioalkyl including $\text{C}_1\text{-C}_6\text{alkylthio}$, hydroxy $\text{C}_1\text{-C}_6\text{alkyl}$, amino $\text{C}_1\text{-C}_6\text{alkyl}$, $\text{-C}_0\text{-C}_4\text{alkylNR}^9\text{R}^{10}$, -C(O)OR^9 , -OC(O)R^9 , $\text{-NR}^9\text{C(O)R}^{10}$, $\text{-C(O)NR}^9\text{R}^{10}$, $\text{-OC(O)NR}^9\text{R}^{10}$, $\text{-NR}^9\text{C(O)OR}^{10}$, haloalkyl including $\text{C}_1\text{-C}_6\text{haloalkyl}$, and $\text{C}_1\text{-C}_6\text{haloalkoxy}$;

or R^{44} and $\text{R}^{44'}$ or R^{45} and $\text{R}^{45'}$, or two R^{47} groups are taken together to form a carbonyl group;

or R^{44} and $\text{R}^{44'}$ or R^{45} and $\text{R}^{45'}$ substituted 3- to 6-membered carbocyclic spiro ring or a 3- to 6-membered heterocyclic spiro ring containing 1 or 2 heteroatoms independently selected from N, O, or S;


wherein, each of the above spiro rings may be optionally substituted with 1 or more substituents independently

selected from R^{201} , halogen (and in particular F), hydroxyl, cyano, -COOH; alkyl including C_1 - C_4 alkyl (and in particular methyl), alkenyl including C_2 - C_4 alkenyl, alkynyl including C_2 - C_4 alkynyl, alkoxy including C_1 - C_6 alkoxy, alkanoyl including C_2 - C_4 alkanoyl, hydroxy C_1 - C_4 alkyl, (mono- and di-alkylamino) C_1 - C_4 alkyl, - C_0 - C_4 alkyl(C_3 - C_7 cycloalkyl), -O-alkyl(C_3 - C_7 cycloalkyl), haloalkyl including C_1 - C_6 haloalkyl, and haloalkoxy including C_1 - C_6 haloalkoxy;


or R^{44} and R^{45} or $R^{44'}$ and $R^{45'}$ are taken together to form a 4- to 6-membered carbocyclic or aryl ring or a 4- to 6-membered heterocyclic or heteroaryl ring; each of which ring may be optionally substituted with 1 or more substituents;

each of which fused rings or generally R^{44} , $R^{44'}$, R^{45} , or $R^{45'}$ are optionally substituted with 1 or more substituents independently selected from R^{201} , halogen (and in particular F), hydroxyl, cyano, -COOH, alkyl including C_1 - C_4 alkyl (and in particular methyl), alkenyl including C_2 - C_4 alkenyl, alkynyl including C_2 - C_4 alkynyl, alkoxy including C_1 - C_4 alkoxy, alkanoyl including C_2 - C_4 alkanoyl, hydroxy C_1 - C_4 alkyl, (mono- and di-alkylamino) C_0 - C_4 alkyl, alkyl(C_3 - C_7 cycloalkyl) including - C_1 - C_4 alkyl(C_3 - C_7 cycloalkyl), -O-(C_3 - C_7 cycloalkyl), haloalkyl including C_1 - C_6 haloalkyl, and haloalkoxy including C_1 - C_6 haloalkoxy;


C_3 is selected from:




and q




X³ is C(R¹R^{1'});
 X⁴ is N or CH;
 X^{4a} is N, CH or CZ;
 X⁵ and X⁶ are C(R¹R^{1'});
 or X⁴ and X⁵ or X⁵ and X⁶ together are C=C;
 X⁷ is SO or SO₂;
 X⁸ is C(R¹R^{1'}) or N(R⁴³);
 X^{5a} is independently selected from C(R¹R^{1'}) and O;
 Q⁴ is N or CH;
 Q⁵ is N(R⁴⁷) or C(R⁴⁶R^{46'});
 Q^{5a} is independently selected from C(R⁴⁷R^{47'}), N(R⁴⁷), O, S, SO, and SO₂;
 Q⁶ is N(R⁴⁷), C(R⁴⁶R^{46'}), S, or O;
 Q⁷ is C(R⁴⁶R^{46'}), S or N(R⁴⁷);
 Q⁸, Q⁹, Q¹⁰, Q¹¹ and Q¹² are each independently C(R²R^{2'}), S, SO, SO₂, O, N(R²), B(R⁵⁰), or Si(R⁴⁹)₂;
 R⁴⁰ is hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, heterocycle, heterocycloalkyl, aryl, arylalkyl, heteroaryl, or heteroarylalkyl wherein each group can be optionally substituted;
 R⁴² is halo, hydroxy, alkoxy including C₁-C₆alkoxy, haloalkoxy including C₁-C₆haloalkoxy, -SH, or -S(C₁-C₆alkyl);
 R⁴³ is hydrogen, acyl, alkyl, cycloalkyl, cycloalkylalkyl, heterocycle, heterocycloalkyl, aryl, arylalkyl, heteroaryl, or heteroarylalkyl wherein each group can be optionally substituted;
 R⁴⁶ and R^{46'} are independently hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, heterocycle, heterocycloalkyl, aryl, arylalkyl, heteroaryl, or heteroarylalkyl wherein each group can be optionally substituted;
 or R⁴⁶ and R^{46'} are taken together to form an optionally substituted 3- to 6-membered carbocyclic spiro ring or a 3- to 6-membered heterocyclic spiro ring containing 1 or 2 heteroatoms independently selected from N, O, or S;
 R⁴⁷ is hydrogen, acyl, alkyl, cycloalkyl, cycloalkylalkyl, heterocycle, heterocycloalkyl, aryl, arylalkyl, heteroaryl, or heteroarylalkyl wherein each group can be optionally substituted;
 or two R⁴⁷ groups are taken together to form a carbonyl group;
 R⁴⁹ is halo, hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, heterocycle, heterocycloalkyl, aryl, arylalkyl, heteroaryl, or heteroarylalkyl wherein each group can be optionally substituted R⁵⁰ is hydroxy or C₁-C₆alkoxy;
 or X¹ and Q⁸ or Q⁸ and Q⁹ or Q⁹ and Q¹⁰ or Q¹⁰ and Q¹¹ or Q¹¹ and Q¹² or Q¹² and X² can form a carbon-carbon double bond;
 or two Q^{5a} groups or a X^{4a} and a Q^{5a} group can form a carbon-carbon double bond;
 and where any of these groups may be further optionally substituted as that term is defined in the Terminology Section below, if desired to achieve the target effect, results in a stable compound that makes chemical sense to the skilled artisan, and the group is not redundant (i.e., as known in the art, alkyl substituted with alkyl is redundant; however, for example, alkoxy substituted with alkoxy is not redundant);
 or the central core moiety, C3, is a small mimetic of a beta-turn such as a benzodiazepine, a Friedinger lactam, a 2-oxo-1,3-oxazolidine-4-carboxylate or a β-D-glucose scaffold. See, De Marco, R. et al., "In-peptide synthesis of di-oxazolidinone and dehydroamino acid-oxazolidinone motifs as β-turn inducers", J. Org. Biomol. Chem., 2013, 11, 4316-4326, Hirschmann, R.F. et al., The β-D-Glucose Scaffold as a β-Turn Mimetic, Accounts Chem. Res., 2009, 42, 1511-1520 and Smith, A.B. et al., Accounts of Chem. Res., 2011, 44, 180-193. In another embodiment, the central core moiety, C, can comprise a reverse turn mimetic that can include, but is not limited to; a non-peptidic residue, a metal chelation based mimic, or a foldamer. See, Nair, R.V. et al., "Synthetic turn mimetics and hairpin nucleators: Quo Vadimus?", Chem. Comm., 2014, 50, 13874-13884. In some embodiments, the central core moiety, C, can comprise a conformationally constrained cyclic amino acid including but not limited to a (S)- or (R)-α-trifluoromethyl pyroglutamic acid derivative. See, Chaume, G. et al., "Concise access to enantiopure (S)- or (R)-α-trifluoromethyl pyroglutamic acids from ethyl trifluoropyruvate-base chiral CF₃-oxazolidines (Fox)", J. Fluor. Chem., 2008, 129, 1104-1109 and Andre, C. et al., "(S)-ABOC: A Rigid Bicyclic β-Amino Acid as Turn Inducer", Org. Lett., 2012, 14, 960-963. In some embodiments, the central core moiety, C, can comprise a monomeric unit of a foldamer such as, but not limited to an oxazolidin-2-one. See, Tomasii, C., Angelicim G. and Castellucci, N., "Foldamers Based on Oxazolidin-2-ones", Eur. J. Org. Chem., 2011, 3648-3669;
 C4 is selected from:



or C4 is selected from:



or C4 is selected from:




30


//

is a single or double bond;

C5 is selected from:



A1 is selected from:



5

10

15

20

25

30


35

40

45

50

55



or A1 is selected from:


















15




25








5





10




15





20




25




30




35




40





45




50






55








or A3 is selected from:






or A3 is selected from:






, and




;


or A3 is selected from:




,




,




,




,




,



,




, and




;


or A3 is selected from:



or A3 is selected from:



or A3 is selected from:



X⁵¹, X⁵², and X⁵³ are independently selected from N, CR³¹, and CR²⁰¹;

wherein at least one of X⁵¹, X⁵², and X⁵³ is selected from CR²⁰¹;

X⁵⁴, X⁵⁵, and X⁵⁶ are independently selected from N, CR³¹, and CR²⁰¹;

R¹⁰⁴ is selected from R²⁰¹, C₁-C₄ alkyl, C₃-C₆ cycloalkyl, C₁-C₄ haloalkyl, deuterium, -CO₂H, CO₂R⁹, heteroaryl, F, Cl, Br, and cyano;

R²⁰¹ is selected from aminoalkyl-, alkylaminoalkyl-, heterocycloalkyl-, and hydroxyalkyl; -alkyl-O-alkyl including -CH₂OCH₃, -alkyl-S-alkyl, -alkyl-N(alkyl)-alkyl, -alkyl-NH-alkyl, -aliphatic-O-aliphatic, -aliphatic-S-aliphatic, -aliphatic-N(aliphatic)-aliphatic, -aliphatic-NH-aliphatic, -aliphatic-O-heterocycle, -aliphatic-S-heterocycle, -aliphatic-N(aliphatic)-heterocycle, -aliphatic-NH-heterocycle, -alkyl-NHC(O)haloalkyl, -alkyl-NR⁹C(O)haloalkyl, -alkyl-C(O)NHhaloalkyl, -alkyl-C(O)NR⁹haloalkyl, -alkyl-NHC(O)haloalkyl, -alkyl-NR⁹C(O)aliphatic, -alkyl-C(O)NHaliphatic, -alkyl-NR⁹C(O)aliphatic, -alkyl-NHC(O)aliphatic, -substituted alkyl-N(R⁹)-substituted alkyl, alkyl-heteroaryl, -alkyl-O-haloalkyl, heteroaryl, heterocycle, alkyl-heterocycle, -N(aliphatic)₂; and wherein each R²⁰¹ can be optionally substituted as defined in the Terminology section below, and wherein R²⁰¹ can be optionally substituted with R³⁰¹, which can be directly linked to R²⁰¹ or can be linked to R²⁰¹ through an amino, hydroxyl, thio, carboxylic acid, phosphate, phosphonate or sulfonate linkage;

[0043] In an alternative embodiment, R²⁰¹ is selected from R³⁰¹, -alkyl-CN, -alkyl-NR⁹C(O)alkenyl, -alkyl-SO₂-alkyl; and -alkyl-S(O)NR⁹-alkyl;

[0044] In an alternative embodiment, R²⁰¹ is substituted with an oxime, and -C(O)Oalkyl;

[0045] R²⁰² is selected from aryl, heteroaryl, and heterocycle, wherein the aryl, heteroaryl, or heterocycle ring is substituted with R²⁰¹;

[0046] R³⁰¹ is selected from the following:


i. The residue of a fatty acid. Examples are short chain fatty acids with 3, 4, or 5 aliphatic carbons, medium-chain fatty acids with aliphatic tails of 6, 7, 8, 9, 10, 11 or 12 carbons, long chain fatty acids, which have aliphatic tails of 13, 14, 15, 16, 17, 18, 19, 20, 21 or 22 carbons, or a very long fatty acid, which has 22, 23, 24, 25, 26, 27, or 28 or more aliphatic carbons. The aliphatic chain can be saturated, mono-unsaturated, di-unsaturated, tri-unsaturated, polyunsaturated, or alkynyl. Unsaturated fatty acids can be used in a cis or trans configuration, and include, but are not limited to oleic acid, ω 6 fatty acid such as linoleic acid, ω 3 fatty acid such as α -linolenic acid, docosahexaenoic acid, stearidonic acid, eicosapentaenoic acid, docosapentaenoic acid, eicosatetraenoic acid, myristoleic acid, palmitoleic acid, sapienic acid, elaidic acid, vaccenic acid, gadoleic acid, eicosenoic acid, nervonic acid, eicosadienoic acid, docasadienoic acid, linolenic acid, t-linolenic acid, pinolenic acid, eleosteric acid, β -eleostearic acid, mead acid, eicosatrienoic acid, linoleic acid, linoelaidic acid, α -linolenic acid, arachidonic acid, erucic acid and docosahexaenoic acid. Nonlimiting examples of saturated fatty acids that can be used to provide the prodrugs of the present invention are caprylic acid, capric acid, lauric acid, myristic acid, palmitic, stearic acid, arachidic acid, behenic acid, lignoceric acid and cerotic acid.

ii. The residue of an amino acid that is naturally occurring or synthetic, and includes for example, α , β γ or δ amino acids. Naturally occurring amino acids include those found in proteins, e.g., glycine, alanine, valine, leucine, isoleucine, methionine, phenylalanine, tryptophan, proline, serine, threonine, cysteine, tyrosine, asparagine, glutamine, aspartate, glutamate, lysine, arginine and histidine. In some embodiments, the amino acid is in the L-configuration. Alternatively, the amino acid can be used in the D-configuration or in a mixture of L- and D-. Alternatively, the amino acid can be a derivative of alanyl, valinyl, leucinyl, isoleucinyl, prolinyl, phenylalaninyl, tryptophanyl, methioninyl, glycyl, serinyl, threoninyl, cysteinyl, tyrosinyl, asparaginyl, glutaminyl, aspartoyl, glutaroyl, lysinyl, argininyl, histidinyl, β -alanyl, β -valinyl, β -leucinyl, β -isoleucinyl, β -prolinyl, β -phenylalaninyl, β -tryptophanyl, β -methioninyl, β -glycyl, β -serinyl, β -threoninyl, β -cysteinyl, β -tyrosinyl, β -asparaginyl, β -glutaminyl, β -aspartoyl, β -glutaroyl, β -lysyl, β -argininyl or β -histidinyl. Additional amino acids include selenocysteine, pyrrolysine, N-formylmethionine, γ -aminobutyric acid (GABA), δ -aminolevulinic acid, aminobenzoic acid (including 4-aminobenzoic acid), aminoisobutyric acid, dehydroalanine, cystathionine, lanthionine, djenkolic acid, diaminopimelic acid, norvaline, alloisoleucine, t-leucine, α -amino-heptanoic acid, pipercolic acid, α , β -diaminopropionic acid, α , γ -diaminobutyric acid, ornithine, glutamic acid, allothreonine, homocysteine, β -aminobutyric acid, α -aminoisobutyric acid, isovaline, sarcosine, N-ethylglycine, N-propylglycine, N-isopropyl glycine, N-methyl alanine, N-ethyl alanine, N-methyl- β -alanine, isoserine, norleucine, homoserine, O-methyl-homoserine, O-ethyl-homoserine, homonorleucine, carboxyglutamic acid, hydroxyproline, hypusine, pyroglutamic acid, and α -hydroxy- γ -aminobutyric acid.

iii. The residue of a non-naturally occurring amino acid with an extended length between the amino group and the carboxylic acid, which can be used either alone or as a linker to another prodrug moiety. Examples include amino acids wherein the amino and carboxylic acid are separated by an aliphatic or heteroaliphatic moiety (nonlimiting example is 8-amino-3,6-dioxaoctanoic acid), for example an alkyl, alkenyl, alkynyl, ethylene glycol, propylene glycol, alkylene glycol, or the like, moiety, e.g., with 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 or more straight, branched or cyclic atoms or moieties (e.g., alkylene glycol moieties), as appropriate to provide the desired properties. In some embodiments, the amino acid has one or more internal amine, carbonyl, carboxy, oxo, thio, phosphate or phosphonate moieties in the heteroaliphatic chain.

iv. The residue of one or a series of amino acids linked to a terminal fatty acid or to an endcap like hydrogen or alkyl. In one non-limiting example, 8-amino-3,6-dioxaoctanoic acid (one or several in sequence) is covalently bound to the selected complement D inhibitor of the present invention through a functional group such as a carboxylic acid, sulfonyl, hydroxyl or amino group. See generally Lau, et al., "Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semiglutide", J. Med. Chem., 2015, 58, 7370-7380. The 8-amino-3,6-dioxaoctanoic acid is covalently linked to an aliphatic acid, including but not limited to a C16, C18, C20 aliphatic acid, or a dicarboxylic acid, including but not limited to a C8, C10, C12, C14, C16, C18 or C20 diacid. One or more amino acids can also be used in the selected configuration to add length or functionality.

[0047] R⁴, R⁵, and R⁶ are selected from hydrogen, -JCHO, -JC(O)NH₂, -JC₂-C₆alkanoyl, -JC(O)NH(CH₃), -J-COOH, -JP(O)(OR⁹)₂, -JOC(O)R⁹, -JC(O)OR⁹, -JC(O)N(CH₂CH₂R⁹)(R¹⁰), -JNR⁹C(O)R¹⁰, -JSO₂NH₂, -JS(O)NH₂, -JC(CH₂)₂F, -JCH(CF₃)NH₂, -JC(O)C₀-C₂alkyl(C₃-C₇cycloalkyl), -JNR⁹(C₂-C₆alkanoyl), -JNR⁹C(O)NR⁹R¹⁰, -JSO₂(C₁-C₆alkyl), -JSO₂(C₁-C₆haloalkyl), -JSO₂NR⁷R⁷, -JSO=NH(C₁-C₆alkyl), -J-nitro, -J-halogen, -J-hydroxyl, -J-phenyl, a 5- to 6-membered heteroaryl, -J-cyano, -J-cyanoimino, -J-amino, -J-imino, -C₁-C₆alkyl, -C₀-C₄alkyl(C₃-C₇heterocycloalkyl), -C₀-C₄alkyl(C₃-C₇cycloalkyl),



each of which R⁴, R⁵ and R⁶ other than hydrogen, nitro, halogen, cyano, cyanoimino, or -CHO, is optionally substituted with one or more of amino, imino, halogen, hydroxyl, cyano, cyanoimino, alkyl including C₁-C₆alkyl, alkoxy including C₁-C₆alkoxy, -C₀-C₂alkyl(mono- and di-C₁-C₄alkylamino), -C₁-C₆haloalkyl, and haloalkoxy including C₁-C₆haloalkoxy;

J is independently selected from a covalent bond, alkylene including C₁-C₄alkylene, O-alkylene including -OC₁-C₄alkylene, alkenylene including C₂-C₄alkenylene, and alkynylene C₂-C₄alkynylene;

R^{6'} is hydrogen, halogen, hydroxyl, C₁-C₄alkyl, -C₀-C₄alkyl(C₃-C₇cycloalkyl), or C₁-C₄alkoxy;

or R⁶ and R^{6'} may be taken together to form an oxo, vinyl, or imino group;

R⁷ is hydrogen, alkyl including C₁-C₆alkyl, or -C₀-C₄alkyl(C₃-C₇cycloalkyl);

R⁸ and R^{8'} are selected from hydrogen, halogen, hydroxyl, alkyl including C₁-C₆alkyl, -C₀-C₄alkyl(C₃-C₇cycloalkyl), alkoxy including C₁-C₆alkoxy, and (C₁-C₄alkylamino)C₀-C₂alkyl;

or R⁸ and R^{8'} are taken together to form an oxo group;

or R⁸ and R^{8'} are taken together with the carbon that they are bonded to form a 3-membered carbocyclic ring;

R¹⁶ is independently selected from hydrogen, halogen, hydroxyl, nitro, cyano, -C₁-C₆alkyl, alkenyl including C₂-C₆alkenyl, alkanoyl including C₂-C₆alkanoyl, alkoxy including C₁-C₆alkoxy,

-C₀-C₄alkyl(mono- and di-C₁-C₆alkylamino), -C₀-C₄alkyl(C₃-C₇cycloalkyl), haloalkyl including C₁-C₆haloalkyl, and haloalkoxy including C₁-C₆haloalkoxy;

R¹⁹ is hydrogen, alkyl including C₁-C₆alkyl, alkenyl including C₂-C₆alkenyl, alkanoyl including C₂-C₆alkanoyl, -SO₂C₁-C₆alkyl, (mono- and di-C₁-C₆alkylamino)C₁-C₄alkyl, -C₀-C₄alkyl(C₃-C₇cycloalkyl), -C₀-C₄alkyl(C₃-C₇heterocycloalkyl), -C₀-C₄alkyl(aryl), or C₀-C₄alkyl(heteroaryl), wherein each R¹⁹ other than hydrogen is optionally substituted with one or more substituents independently selected from halogen, hydroxyl, amino, -COOH, and -C(O)OC₁-C₄alkyl;

X^{11} is N or CR¹¹;

X^{12} is N or CR¹²:

X^{13} is N or CR¹³;

X^{14} is N or CR^{14} ;

wherein no more than 2 of X^{11} , X^{12} , X^{13} , and X^{14} are N;

wherein one of R^{12} and R^{13} is R^{32} and the other is R^{31} or R^{32} ;

and wherein if there is no R^{13} and no R^{32} on the A ring then R^{12} is R^{32} ;

and wherein if there is no R^{12} and no R^{32} on the A ring then R^{13} is R^{32} :

R³¹ is independently selected from hydrogen, halogen, hydroxyl, nitro, cyano, amino, -COOH, haloalkyl including C₁-C₆haloalkyl, haloalkoxy including C₁-C₆haloalkoxy, alkyl including C₁-C₆alkyl, -C₀-C₄alkyl(C₃-C₇cycloalkyl), alkenyl including C₂-C₆alkenyl, alkanoyl including C₂-C₆alkanoyl, alkoxy including C₁-C₆alkoxy, alkenyloxy including C₂-C₆alkenyloxy, -C(O)OR⁹, thioalkyl including C₁-C₆thioalkyl, -C₀-C₄alkylNR⁹R¹⁰, -C(O)NR⁹R¹⁰, -SO₂R⁹, -SO₂NR⁹R¹⁰, -OC(O)R⁹, and -C(NR⁹)NR⁹R¹⁰, each of which R³¹ other than hydrogen, halogen, hydroxyl, nitro, cyano, haloalkyl including C₁-C₆haloalkyl, and C₁-C₆haloalkoxy is optionally substituted with one or more substituents independently selected from halogen, hydroxyl, nitro, cyano, amino, -COOH, -C(O)NR⁹R¹⁰, haloalkyl including C₁-C₆haloalkyl, haloalkoxy including C₁-C₆haloalkoxy, phenyl, and 4- to 7-membered heterocycle containing 1, 2, or 3 heteroatoms independently selected from N, O, and S; each of which phenyl or 4- to 7-membered heterocycle is optionally substituted with one or more substituents independently selected from halogen, hydroxyl, nitro, cyano, alkyl including C₁-C₆alkyl, alkenyl including C₂-C₆alkenyl, alkanoyl including C₂-C₆alkanoyl, alkoxy including C₁-C₆alkoxy, (mono- and di-C₁-C₆alkylamino)C₀-C₄alkyl, alkylester including C₁-C₆alkylester, -C₀-C₄alkyl)(C₃-C₇cycloalkyl), C₁-C₆haloalkyl, and haloalkoxy including C₁-C₆haloalkoxy;

R³² is selected from aryl, heteroaryl, and heterocycle wherein the aryl, heteroaryl, or heterocycle ring can be optionally substituted;

in one embodiment R³² is substituted with R³⁰¹, -CH₂-R³⁰¹, or R²⁰¹.

R¹¹, R¹⁴, and R¹⁵ are independently selected from hydrogen, halogen, hydroxyl, nitro, cyano, -O(PO)(OR⁹)₂, -O(PO)(OR⁹)₂, alkyl including C₁-C₆alkyl, alkenyl including C₂-C₆alkenyl, alkynyl including C₂-C₆alkynyl, C₂-C₆alkenyl(aryl), C₂-C₆alkenyl(cycloalkyl), C₂-C₆alkenyl(heterocycle), C₂-C₆alkenyl(heteroaryl), C₂-C₆alkynyl(aryl), C₂-C₆alkynyl(cycloalkyl), C₂-C₆alkynyl(heterocycle), C₂-C₆alkynyl(heteroaryl), alkanoyl including C₂-C₆alkanoyl, alkoxy including C₁-C₆alkoxy, thioalkyl including C₁-C₆thioalkyl, -C₀-C₄alkyl(mono- and di-C₁-C₆alkylamino), -C₀-C₄alkyl(C₃-C₇cycloalkyl), -C-C₄alkoxy(C₃-C₇cycloalkyl), haloalkyl including C₁-C₆haloalkyl, and haloalkoxy including C₁-C₆haloalkoxy;

X¹⁵ is NH, O, or S;

X¹⁶ is CR¹²;

X¹⁷ is N or CR¹³;

X¹⁸ is CR¹²;

X¹⁹ is N or CR¹³;

X²⁰ is NH or O;

X²¹ is N or CR¹⁴;

X²² is N or CR¹³;

X²³ is CR¹²;

X²⁴ is O or S;

X²⁶ is N or CR⁴¹;

X²⁷ is CR¹², NH, or O;

X²⁸ is N or CH;

X³⁰ is N or CR⁵;

X³¹ is N, C(R⁵⁴)₂, or CR⁵⁴;

X³² is NH, C(R⁵⁴)₂, or CR⁵⁴;

X³³ is -CO-, -SO-, or -SO₂-;

X³⁴ is CHR¹³, NH, O, or S;

wherein no more than 2 of X²⁸ are N;

R⁴¹ is hydrogen, alkyl including C₁-C₆alkyl, or -(C₀-C₂alkyl)(C₃-C₅cycloalkyl);

R⁴⁸ and R^{48a} is selected from hydrogen, halogen, hydroxyl, nitro, cyano, amino, alkyl including C₁-C₆alkyl, haloalkyl including C₁-C₆haloalkyl, alkenyl including C₂-C₆alkenyl, alkynyl including C₂-C₆alkynyl, thioalkyl including C₁-C₆thioalkyl, alkoxy including C₁-C₆alkoxy, -JC₃-C₇cycloalkyl, -B(OH)₂, -JC(O)NR⁹R²³, -JO-SO₂OR²¹, -C(O)(CH₂)₁₋₄S(O)R²¹, -O(CH₂)₁₋₄S(O)NR²¹R²², -JOP(O)(OR²¹)(OR²²), -JP(O)(OR²¹)(OR²²), -JOP(O)(OR²¹)R²², -JP(O)(OR²¹)R²², -JOP(O)R²¹R²², -JP(O)R²¹R²², -JSP(O)(OR²¹)(OR²²), -JSP(O)(OR²¹)(R²²), -JSP(O)(R²¹)(R²²), -JNR⁹P(O)(NHR²¹)(NHR²²), -JNR⁹P(O)(OR²¹)(NHR²²), -JNR⁹P(O)(OR²¹)(OR²²), -JC(S)R²¹, -JNR²¹SO₂R²², -JNR⁹S(O)NR¹⁰R²², -JNR⁹SO₂NR¹⁰R²², -JSO₂NR⁹COR²², -JSO₂NR⁹CONR²¹R²², -JNR²¹SO₂R²², -JC(O)NR²¹SO₂R²², -JC(NH₂)=NR²², -JCH(NH₂)NR⁹S(O)₂R²², -JOC(O)NR²¹R²², -JNR²¹C(O)OR²², -JNR²¹OC(O)R²², -(CH₂)₁₋₄C(O)NR²¹R²², -JC(O)NR²⁴R³⁰, -JNR⁹C(O)R²¹, -JC(O)R²¹, -JNR⁹C(O)NR¹⁰R²², -CCR²¹, -(CH₂)₁₋₄OC(O)R²¹, -JC(O)OR²³, and R¹⁰³; each of which R⁴⁸ may be optionally substituted with one or more substituents selected from halogen, hydroxyl, nitro, cyano, amino, oxo, -B(OH)₂, -Si(CH₃)₃, -COOH, -CONR⁹R¹⁰, -P(O)(OH)₂, alkyl including C₁-C₆alkyl, -C₀-C₄alkyl(C₃-C₇cycloalkyl), C₁-C₆alkoxy, -C₀-C₄alkyl(mono- and di-C₁-C₄alkyl)NR⁹R¹⁰, alkylester including C₁-C₆alkylester, C₁-C₄alkylamino, C₁-C₄hydroxylalkyl, haloalkyl including C₁-C₆haloalkyl, -OC(O)R⁹, -NR⁹C(O)R¹⁰, -C(O)NR⁹R¹⁰, -OC(O)NR⁹R¹⁰, -NR⁹C(O)OR¹⁰, haloalkyl including C₁-C₆haloalkyl, S(O)=NHR²¹, SF₅, JC(R⁹)=NR²¹, SO₂OR²¹, and haloalkoxy including C₁-C₆haloalkoxy;


R¹⁰³ is independently C₁-C₄ alkyl, C₃-C₆ cycloalkyl, fluorine, chlorine, or bromine;


R⁵⁴ is hydrogen, alkyl including C₁-C₆alkyl, alkenyl including C₂-C₆alkenyl, alkynyl including C₂-C₆alkynyl, alkoxy including C₁-C₆alkoxy, C₂-C₆alkynyl, alkanoyl including C₂-C₆alkanoyl, thioalkyl including C₁-C₆thioalkyl, hydroxyC₁-C₆alkyl, aminoC₁-C₆alkyl, -C₀-C₄alkyl(C₃-C₇cycloalkyl), (phenyl)C₀-C₄alkyl-, (heterocycloalkyl)C₀-C₄alkyl or (heteroaryl)C₀-C₄alkyl- wherein each R⁵⁴ is optionally substituted;

s is 1 or 2;

L is selected from L1 and L2;

L1 is a bond,








R^{17} is hydrogen, alkyl including C_1 - C_6 alkyl, or $-C_0$ - C_4 alkyl(C_3 - C_7 cycloalkyl);


R^{18} and $R^{18'}$ are independently selected from hydrogen, halogen, hydroxymethyl, and methyl;

m is 0, 1, 2, or 3;

L_2 is selected from:



and



or L2 is selected from an optionally substituted monocyclic or bicyclic carbocyclic; an optionally substituted monocyclic or bicyclic carbocyclic-oxy group; an optionally substituted monocyclic or bicyclic heterocycle group having 1, 2, 3, or 4 heteroatoms independently selected from N, O, and S and from 4 to 7 ring atoms per ring, an optionally substituted $-(C_0-C_4alkyl)(aryl)$; an optionally substituted $-(C_0-C_4alkyl)(5\text{-membered heteroaryl})$; an optionally substituted $-(C_0-C_4alkyl)(6\text{-membered heteroaryl})$; an optionally substituted $-(C_0-C_4alkyl)(8\text{-membered heteroaryl})$; an optionally substituted $-(C_0-C_4alkyl)(9\text{-membered heteroaryl})$; and $-(C_0-C_4alkyl)(10\text{-membered heteroaryl})$;

q is 1, 2 or 3;

R^{51} is CH_3 , CH_2F , CHF_2 or CF_3 ;

R^{53} is cyano, nitro, hydroxyl, or alkoxy including $C_1-C_6alkoxy$;

X^{29} can be O or S;

L3 is $-C(O)-$, $-C(S)-$, $-P(O)OH-$, $-S(O)-$, $-S(O)_2-$, or $-C(R^{52})_2-$;

each R^{52} is independently selected from halo, hydrogen, or optionally substituted alkyl including C_1-C_6alkyl ; or two R^{52} groups are taken together to form a 3- to 6-membered carbocyclic spiro ring or a 3- to 6-membered heterocyclic spiro ring containing 1 or 2 heteroatoms independently selected from N, O, or S;

B1 is heteroaryl; aryl; biphenyl, a monocyclic or bicyclic carbocycle; a monocyclic or bicyclic carbocyclic-oxy group; a monocyclic, bicyclic, or tricyclic heterocycle group having 1, 2, 3, or 4 heteroatoms independently selected from Boron, Si, N, O, and S and from 4 to 8 ring atoms per ring; alkenyl including $C_2-C_6alkenyl$; or alkynyl including $C_2-C_6alkynyl$; each of which B1 is optionally substituted with one or more substituents independently selected from R^{33} , R^{34} , R^{35} , and R^{36} ;

R^{33} is independently selected from halogen, hydroxyl, $-COOH$, cyano, alkyl including C_1-C_6alkyl , alkanoyl including $C_2-C_6alkanoyl$, alkoxy including $C_1-C_6alkoxy$, $-C_0-C_4alkylNR^9R^{10}$, $-SO_2R^9$, haloalkyl including $C_1-C_6haloalkyl$, $S(O)=NHR^{21}$, SF_5 , and $JC(R^9)=NR^{21}$, and haloalkoxy including $C_1-C_6haloalkoxy$;

R^{34} is independently selected from nitro, alkenyl including $C_2-C_6alkenyl$, alkynyl including $C_2-C_6alkynyl$, thioalkyl including $C_1-C_6thioalkyl$, $-JC_3-C_7cycloalkyl$, $-JB(OH)_2$, $-JC(O)NR^9R^{23}$, $-JOSO_2OR^{21}$, $-JC(O)(CH_2)_{1-4}S(O)R^{21}$, $-O(CH_2)_{1-4}S(O)NR^{21}R^{22}$, $-JOP(O)(OR^{21})(OR^{22})$, $-JP(O)(OR^{21})(OR^{22})$, $-JOP(O)(OR^{21})R^{22}$, $-JP(O)(OR^{21})R^{22}$, $-JOP(O)R^{21}R^{22}$, $-JP(O)R^{21}R^{22}$, $-JSP(O)(OR^{21})(OR^{22})$, $-JSP(O)(OR^{21})R^{22}$, $-JSP(O)(R^{21})(R^{22})$, $-JNR^9P(O)(NHR^{21})(NHR^{22})$, $-JNR^9P(O)(OR^{21})(NHR^{22})$, $-JNR^9P(O)(OR^{21})(OR^{22})$, $-JC(S)R^{21}$, $-JNR^{21}SO_2R^{22}$, $-JNR^9S(O)NR^{10}R^{22}$, $-JNR^9SO_2NR^{10}R^{22}$, $-JSO_2NR^9COR^{22}$, $-JSO_2NR^9CONR^{21}R^{22}$, $-JNR^{21}SO_2R^{22}$, $-JC(O)NR^{21}SO_2R^{22}$, $-JC(NH_2)=NR^{22}$, $-JCH(NH_2)NR^9S(O)_2R^{22}$, $-JOC(O)NR^{21}R^{22}$, $-JNR^{21}C(O)OR^{22}$, $-JNR^{21}OC(O)R^{22}$, $-(CH_2)_{1-4}C(O)NR^{21}R^{22}$, $-JC(O)R^{24}R^{30}$, $-JNR^9C(O)R^{21}$, $-JC(O)R^{21}$, $-JNR^9C(O)NR^{10}R^{22}$, $-CCR^{21}$, $-(CH_2)_{1-4}OC(O)R^{21}$, $-S(O)_2OR^{21}$, and $-JC(O)OR^{23}$; each of which R^{34} may be unsubstituted or substituted with one or more substituents independently selected from halogen, hydroxyl, nitro, cyano, amino, oxo, $-B(OH)_2$, $-Si(CH_3)_3$, $-COOH$, $-CONR^9R^{10}$, $-P(O)(OH)_2$, C_1-C_6alkyl , $-C_0-C_4alkyl(C_3-C_7cycloalkyl)$, alkoxy including $C_1-C_6alkoxy$, $-C_0-C_2alkyl(mono\text{- and }di\text{-}C_1-C_4alkylamino)$, $C_1-C_6alkylester$, $C_1-C_4alkylamino$, $C_1-C_4hydroxylalkyl$, haloalkyl including $C_1-C_6haloalkyl$, and $C_1-C_6haloalkoxy$;

R^{35} is independently selected from naphthyl, naphthyloxy, indanyl, (4- to 7-membered heterocycloalkyl) C_0-C_4alkyl containing 1 or 2 heteroatoms selected from N, O, and S, and bicyclic heterocycle containing 1, 2, or 3 heteroatoms independently selected from N, O, and S, and containing 4- to 8- ring atoms in each ring; each of which R^{35} is optionally substituted with one or more substituents independently selected from halogen, hydroxyl, nitro, cyano, C_1-C_6alkyl , alkenyl including $C_2-C_6alkenyl$, alkanoyl including $C_2-C_6alkanoyl$, alkoxy including $C_1-C_6alkoxy$, $C_1-C_6alkylester$, $-C_0-C_4alkyl(C_3-C_7cycloalkyl)$, $-SO_2R^9$, haloalkyl including $C_1-C_6haloalkyl$, and haloalkoxy including $C_1-C_6haloalkoxy$;

R^{36} is independently selected from tetrazolyl, (phenyl) C_0-C_2alkyl , (phenyl) $C_1-C_6alkoxy$, phenoxy, and 5- or 6-membered heteroaryl containing 1, 2, or 3 heteroatoms independently selected from N, O, Boron, Si, and S, each of which R^{36} is optionally substituted with one or more substituents independently selected from halogen, hydroxyl, nitro, cyano, alkyl including C_1-C_6alkyl , alkenyl including $C_2-C_6alkenyl$, alkanoyl including $C_2-C_6alkanoyl$, alkoxy including $C_1-C_6alkoxy$, $C_1-C_6alkylester$, $-C_0-C_4alkyl(C_3-C_7cycloalkyl)$, $-SO_2R^9$, $-OSi(CH_3)_2C(CH_3)_3$, $-Si(CH_3)_2C(CH_3)_3$, haloalkyl including $C_1-C_6haloalkyl$, and haloalkoxy including $C_1-C_6haloalkoxy$;

in an alternative embodiment R^{36} is a bicyclic heteroaryl such as a 9-membered heteroaryl;

R^{21} and R^{22} are independently selected from hydrogen, hydroxyl, cyano, amino, C_1-C_6alkyl , haloalkyl including $C_1-C_6haloalkyl$, alkoxy including $C_1-C_6alkoxy$, $(C_3-C_7cycloalkyl)C_0-C_4alkyl$, (phenyl) C_0-C_4alkyl , $-C_1-C_4alkylO-C(O)OC_1-C_6alkyl$, $-C_1-C_4alkylOC(O)C_1-C_6alkyl$, $-C_1-C_4alkylC(O)OC_1-C_6alkyl$, (4- to 8-membered heterocycloalkyl) C_0-C_4alkyl having 1, 2, or 3 heteroatoms independently selected from N, O, and S, and (5- or 6-membered unsaturated or aromatic heterocycle) C_0-C_4alkyl having 1, 2, or 3 heteroatoms independently selected from N, O, and S, and each R^{21} and R^{22} can be optionally substituted;

or R^{21} and R^{22} can be taken together to form a carbocyclic or heterocyclic ring;

R²³ is independently selected at each occurrence from alkyl including C₁-C₆alkyl, haloalkyl including C₁-C₆haloalkyl, (aryl)C₀-C₄alkyl, (C₃-C₇cycloalkyl)C₀-C₄alkyl, (phenyl)C₀-C₄alkyl, (4- to 8-membered heterocycle)C₀-C₄alkyl having 1, 2, or 3 heteroatoms independently selected from N, O, and S, and (5- or 6- membered unsaturated or aromatic heterocycle)C₀-C₄alkyl having 1, 2, or 3 heteroatoms independently selected from N, O, and S, wherein each R²³ can be optionally substituted;

R²⁴ and R³⁰ are taken together with the nitrogen to which they are attached to form a 4- to 7-membered monocyclic heterocycle, or a 6- to 10- membered bicyclic heterocycle group having fused, spiro, or bridged rings, wherein each ring can be optionally substituted;

B2 is selected from:

- a 4-membered carbocycle fused to a 5- or 6- membered heteroaryl having 1, 2, or 3 heteroatoms independently selected from N, O, and S; wherein the 4-5 or 4-6 ring system can be optionally substituted;
- (optionally substituted alkyl)-(optionally substituted cycloalkyl), (optionally substituted alkenyl)-(optionally substituted cycloalkyl), or (optionally substituted alkynyl)-(optionally substituted cycloalkyl);
- a 4-membered carbocycle fused to a 6-membered aryl ring wherein the 4-6 ring system can be optionally substituted;
- (cycloalkyl)-(optionally substituted aryl), (cycloalkyl)-(optionally substituted heteroaryl), (cycloalkyl)-(optionally substituted heterocycle), (alkyl)-alkenyl, cycloalkyl-alkenyl;
- alkyl, alkyl(alkynyl), each of which can be optionally substituted;

wherein B2 can be further substituted 1, 2, 3, or 4 times or more with the substituents independently selected from R³³, R³⁴, R³⁵, R³⁶, and R⁴⁸;


B3 is a monocyclic or bicyclic carbocycle; a monocyclic or bicyclic carbocyclic-oxy group; a monocyclic, bicyclic, or tricyclic heterocycle group having 1, 2, 3, or 4 heteroatoms independently selected from Boron, Si, N, O, and S and from 4 to 8 ring atoms per ring; alkenyl including C₂-C₆alkenyl; alkynyl including C₂-C₆alkynyl; -(C₀-C₄alkyl) (aryl); -(C₀-C₄alkyl)(heteroaryl); or -(C₀-C₄alkyl)(biphenyl), each of which B3 is substituted with at least one R²⁰¹ and optionally substituted with one or more substituents independently selected from R³³, R³⁴, R³⁵, and R³⁶;

B4 is a six membered heteroaryl ring with at least two substituents selected from R²⁵, R²⁶, R²⁷ and R²⁸;

or B4 is a six membered heteroaryl ring with at least three substituents selected from R²⁵, R²⁶, R²⁷ and R²⁸;

or B4 is a pyridine with at least two substituents selected from R²⁵, R²⁶, R²⁷ and R²⁸;

or B4 is selected from:



R²⁵, R²⁶, R²⁷, and R²⁸ are independently selected from halogen, hydroxyl, nitro, cyano, alkyl including C₁-C₆alkyl, alkenyl including C₂-C₆alkenyl, alkanoyl including C₂-C₆alkanoyl, alkoxy including C₁-C₆alkoxy, thioalkyl including C₁-C₆thioalkyl, (mono- and di-C₁-C₆alkylamino)C₀-C₄alkyl, (C₃-C₇cycloalkyl)C₀-C₄alkyl, (aryl)C₀-C₄alkyl-, (heteroaryl)C₀-C₄alkyl-, and -C₀-C₄alkoxy(C₃-C₇cycloalkyl); each of which R²⁵, R²⁶, R²⁷, and R²⁸ other than hydrogen, halogen, hydroxyl, nitro, cyano, is unsubstituted or substituted with one or more substituents independently selected from halogen, hydroxyl, amino, alkoxy including C₁-C₆alkoxy, haloalkyl including C₁-C₆haloalkyl, (C₃-C₇cycloalkyl)C₀-C₄alkyl-, and haloalkoxy including C₁-C₆haloalkoxy;

or R²⁵, R²⁶, R²⁷, and R²⁸ are independently selected from tetrazole, halogen, hydroxyl, nitro, cyano, alkyl including C₁-C₆alkyl, alkenyl including C₂-C₆alkenyl, alkanoyl including C₂-C₆alkanoyl, alkoxy including C₁-C₆alkoxy, thioalkyl including C₁-C₆thioalkyl, (mono- and di-C₁-C₆alkylamino)C₀-C₄alkyl, (C₃-C₇cycloalkyl)C₀-C₄alkyl, (aryl)C₀-C₄alkyl-, (heteroaryl)C₀-C₄alkyl-, and -C₀-C₄alkoxy(C₃-C₇cycloalkyl); each of which R²⁵, R²⁶, R²⁷, and R²⁸ other than hydrogen, halogen, hydroxyl, nitro, cyano, is unsubstituted or substituted with one or more substituents independently selected from halogen, hydroxyl, amino, alkoxy including C₁-C₆alkoxy, haloalkyl including C₁-C₆haloalkyl, (C₃-C₇cycloalkyl)C₀-C₄alkyl-, and haloalkoxy including C₁-C₆haloalkoxy;

and wherein any of these groups may be further optionally substituted as that term is defined in the Terminology Section below, if desired to achieve the target effect, results in a stable compound that makes chemical sense to the skilled artisan, and the group is not redundant (i.e., as known in the art, alkyl substituted with alkyl is redundant; however for examples, alkoxy substituted with alkoxy is not redundant); and

wherein any of the structures illustrated herein, e.g., A1, A2, A3, B1, B2, B3, B4, C1, C2, C3, C4, C5, L, L3, or any

of the R moieties, can be optionally independently substituted with 0, 1, 2, 3, or 4, as appropriate, R⁴⁸ substituents.

[0048] Pharmaceutical compositions comprising a compound or salt described herein together with a pharmaceutically acceptable carrier are also disclosed.

[0049] The present invention thus includes at least the following features:

- a. a compound as described herein, or a pharmaceutically acceptable salt, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition,
- b. a compound as described herein, or a pharmaceutically acceptable salt, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition, for use in treating or preventing a disorder including but not limited to the development of fatty liver and conditions stemming from fatty liver, such as nonalcoholic steatohepatitis (NASH), liver inflammation, cirrhosis, or liver failure; dermatomyositis; amyotrophic lateral sclerosis; cytokine or inflammatory reactions in response to biotherapeutics (e.g. CAR T-cell therapy); paroxysmal nocturnal hemoglobinuria (PNH), rheumatoid arthritis, multiple sclerosis, age-related macular degeneration (AMD), retinal degeneration, other ophthalmic diseases (e.g., geographic atrophy), a respiratory disease or a cardiovascular disease;
- c. a pharmaceutically acceptable composition of a compound described herein, or its pharmaceutically acceptable salt, isotopic analog, N-oxide, or isolated isomer thereof in a pharmaceutically acceptable carrier;
- d. a compound described herein, or a pharmaceutically acceptable salt, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition, for use in treating or preventing a disorder mediated by the complement pathway, and for example, cascade Factor D;
- e. a process for manufacturing a medicament intended for the therapeutic use for treating or preventing a disorder, or generally for treating or preventing disorders mediated by complement cascade Factor D, characterized in that a compound as described herein is used in the manufacture;
- f. a compound as described herein or a salt thereof as described herein in substantially pure form (e.g., at least 90 or 95%);
- g. a compound as described herein, or a pharmaceutically acceptable salt, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a carrier to form a pharmaceutically acceptable composition, for use in treating a medical disorder which is an inflammatory or immune condition, a disorder mediated by the complement cascade (including a dysfunctional cascade), a disorder or abnormality of a cell that adversely affects the ability of the cell to engage in or respond to normal complement activity, or an undesired complement-mediated response to a medical treatment, such as surgery or other medical procedure or a pharmaceutical or biopharmaceutical drug administration, a blood transfusion, or other allogenic tissue or fluid administration.
- h. For each of (a) through (g) above, and otherwise herein, each assembly of moieties in the Figures and each active compound made therefrom or its use is considered and deemed specifically and individually disclosed, as such depiction is for convenience of space only and not intended to describe a only a genus or even a subgenus for such indication.

BRIEF DESCRIPTION OF FIGURES

[0050]

FIG. 1 is the six-step procedure to synthesize intermediate *tert*-butyl (1*R*,3*S*,5*R*)-3-((6-bromo-3-methylpyridin-2-yl) carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexane-2-carboxylate.

FIG. 2 is the two-step synthesis of intermediate 2-bromo-3-fluoro-5-methylpyridine 1-oxide (Compound 3 in FIG. 2).

FIG. 3 is the three-step procedure to synthesize the intermediate *tert*-butyl 2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetate.

FIG. 4 is a seven-step procedure to synthesize the intermediate 2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1*H*-pyrazolo [3,4-*c*]pyridin-1-yl)acetic acid.

FIG. 5 is the two-step procedure to synthesize the intermediate *tert*-butyl 2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1*H*-pyrazolo[3,4-*c*]pyridin-1-yl)acetate.

FIG. 6 is the six-step procedure to synthesize intermediate (S)-3-fluoro-4-methylpent-3-en-2-amine hydrochloric acid salt.

FIG. 7 is the six-step procedure to synthesize intermediate (R)-1-((R)-2,2-dichlorocyclopropyl)ethan-1-amine hydrochloric acid salt.

FIG. 8 is the expanded eight-step synthesis of Compound **208** shown in Scheme 153.

FIG. 9 is the eight-step procedure to synthesize (1*R*,3*S*,5*R*)-2-(2-(3-acetyl-7-methyl-5-(2-(oxetan-3-yl)pyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide.

FIG. 10 is a four-step procedure to synthesize (1*R*,3*S*,5*R*)-*N*-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-(2-(7-methyl-5-(2-methylpyrimidin-5-yl)-3-(oxetan-3-yl)-1*H*-indazol-1-yl)acetyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide.

FIG. 11 is a three-step procedure to synthesize (1*R*,3*S*,5*R*)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1*H*-pyrazolo[3,4-*c*]pyridin-1-yl)acetyl)-*N*-((*S*)-3-fluoro-4-methylpent-3-en-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide.

FIG. 12 is a seven-step procedure to synthesize Compound **100**.

FIG. 13 is a three-step procedure for synthesizing Compound **50** and is an alternative to a synthesis shown in Scheme 45.

FIG. 14 is the expanded six-step synthesis of Compound **107** shown in Scheme 80.

FIG. 15A is the eight-step procedure to synthesize intermediate 2-(3-acetyl-7-methyl-5-(2-(3-((trimethylsilyl)oxy)oxetan-3-yl)pyrimidin-5-yl)-1*H*-indazol-1-yl)acetic acid.

FIG. 15B is the final two steps of a synthesis of (1*R*,3*S*,5*R*)-2-(2-(3-acetyl-5-(2-(3-hydroxyoxetan-3-yl)pyrimidin-5-yl)-7-methyl-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide from the intermediate shown in FIG. 18A.

FIG. 16 is the eight-step procedure to synthesize (1*R*,3*S*,5*R*)-2-(2-(3-acetyl-5-(2-(3-fluorooxetan-3-yl)pyrimidin-5-yl)-7-methyl-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide.

FIG. 17 is a schematic showing the various potential attachment points for R³⁰¹ functionality on the A-ring, B-ring, C-ring, or heteroaryl-containing R₃₂ group. X₉ as used in FIG. 17 is selected from -CH₂-, -O-, -NH-, and -Nalkyl-.

FIGS. 18A, 18B, 18C, 18D, 18E, 18F, 18G, 18H, 18I, 18J, 18K, 18L, 18M, 18N, 18O, 18P, 18Q, 18R, 18S, 18T, 18U, and 18V are examples of compounds that exemplify Formula I, Formula II, or Formula III.

FIG. 19 depicts Formula I, Formula II, and Formula III.

DETAILED DESCRIPTION

TERMINOLOGY

[0051] Compounds are described using standard nomenclature. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in the art to which this invention belongs.

[0052] The compounds described herein include enantiomers, mixtures of enantiomers, diastereomers, tautomers, racemates and other isomers, such as rotamers, as if each is specifically described, unless otherwise indicated or otherwise excluded by context.

[0053] The terms "a" and "an" do not denote a limitation of quantity, but rather denote the presence of at least one of the referenced item. The term "or" means "and/or". Recitation of ranges of values are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. The endpoints of all ranges are included within the range and independently combinable. All methods described herein can be performed in a suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of examples, or exemplary language (e.g., "such as"), is intended merely to better illustrate the invention and does not pose a limitation on the scope of the invention unless otherwise claimed. Unless defined otherwise, technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in the art to which this invention belongs.

[0054] The present invention includes compounds described herein with at least one desired isotopic substitution of an atom, at an amount above the natural abundance of the isotope, i.e., enriched. Isotopes are atoms having the same atomic number but different mass numbers, i.e., the same number of protons but a different number of neutrons.

[0055] Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, and chlorine, such as ²H, ³H, ¹¹C, ¹³C, ¹⁴C, ¹⁵N, ¹⁸F, ³¹P, ³²P, ³⁵S, ³⁶Cl, ¹²⁵I respectively. In one embodiment, isotopically labelled compounds can be used in metabolic studies (with ¹⁴C), reaction kinetic studies (with, for example ²H or ³H), detection or imaging techniques, such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT) including drug or substrate tissue distribution assays, or in radioactive treatment of patients. In particular, an ¹⁸F labeled compound may be particularly desirable for PET or SPECT studies. Isotopically labeled compounds of this invention can generally be prepared by carrying out the procedures disclosed in the schemes or in the examples and preparations described below by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent.

[0056] By way of general example and without limitation, isotopes of hydrogen, for example, deuterium (²H) and tritium (³H) may optionally be used anywhere in described structures that achieves the desired result. Alternatively or in addition, isotopes of carbon, e.g., ¹³C and ¹⁴C, may be used. In one embodiment, the isotopic substitution is replacing hydrogen with

a deuterium at one or more locations on the molecule to improve the performance of the drug, for example, the pharmacodynamics, pharmacokinetics, biodistribution, half-life, stability, AUC, T_{max}, C_{max}, etc. For example, the deuterium can be bound to carbon in a location of bond breakage during metabolism (an α -deuterium kinetic isotope effect) or next to or near the site of bond breakage (a β -deuterium kinetic isotope effect).

[0057] Isotopic substitutions, for example deuterium substitutions, can be partial or complete. Partial deuterium substitution means that at least one hydrogen is substituted with deuterium. In certain embodiments, the isotope is 80, 85, 90, 95 or 99% or more enriched in an isotope at any location of interest. In one embodiment deuterium is 80, 85, 90, 95 or 99% enriched at a desired location. Unless otherwise stated, the enrichment at any point is above natural abundance. And in an embodiment is enough to alter a detectable property of the drug in a human.

[0058] In one embodiment, the substitution of a hydrogen atom for a deuterium atom can be provided in any of A1, A1', A2, B1, B1', B2, B3, B4, C1, C1', C2, C3, C4, L1, L1', L2, L2', L4 or L5. In one embodiment, the substitution of a hydrogen atom for a deuterium atom occurs within any R group. In one embodiment the R group is selected from any of R¹, R^{1'}, R², R^{2'}, R³, R^{3'}, R⁴, R^{4'}, R⁵, R⁶, R^{6'}, R⁷, R⁸, R^{8'}, R⁹, R¹⁰, R¹¹, R¹², R¹³, R¹⁴, R¹⁵, R¹⁶, R¹⁷, R¹⁸, R^{18'}, R¹⁹, R²¹, R²², R²³, R²⁵, R²⁶, R²⁷, R²⁸, R³⁰, R³¹, R³², R³³, R³⁴, R³⁵, R³⁶, R⁴⁰, R⁴¹, R⁴², R⁴³, R⁴⁴, R^{44'}, R⁴⁵, R^{45'}, R⁴⁶, R^{46'}, R⁴⁷, R⁴⁸, R^{48a}, R⁴⁹, R⁵⁰, R⁵¹, R⁵², R⁵³, R⁵⁴, R¹⁰³, R¹⁰⁴, R²⁰¹, R²⁰², and R³⁰¹. For example, when any of R groups are, or contain for example through substitution, methyl, ethyl, or methoxy, the alkyl residue may be deuterated (in nonlimiting embodiments, CD₃, CH₂CD₃, CD₂CD₃, CDH₂, CD₂H, CD₃, CHDCH₂D, CH₂CD₃, CHDCHD₂, OCDH₂, OCD₂H, or OCD₃ etc.). In certain other embodiments, an R group has a " " or an "a" designation, which in one embodiment can be deuterated. In certain other embodiments, when two substituents of the central core ring are combined to form a cyclopropyl ring, the unsubstituted methylene carbon may be deuterated.

[0059] The compound of the present invention may form a solvate with solvents (including water). Therefore, in one embodiment, the invention includes a solvated form of the active compound. The term "solvate" refers to a molecular complex of a compound of the present invention (including a salt thereof) with one or more solvent molecules. Nonlimiting examples of solvents are water, ethanol, dimethyl sulfoxide, acetone and other common organic solvents. The term "hydrate" refers to a molecular complex comprising a compound of the invention and water. Pharmaceutically acceptable solvates in accordance with the invention include those wherein the solvent of crystallization may be isotopically substituted, e.g. D₂O, d₆-acetone, d₆-DMSO. A solvate can be in a liquid or solid form.

[0060] A dash ("-") that is not between two letters or symbols is used to indicate a point of attachment for a substituent. For example, -(C=O)NH₂ is attached through carbon of the keto (C=O) group.

[0061] The term "substituted", as used herein, means that any one or more hydrogens on the designated atom or group is replaced with a moiety selected from the indicated group, provided that the designated atom's normal valence is not exceeded and the resulting compound is stable. For example, when the substituent is oxo (i.e., =O) then two hydrogens on the atom are replaced. For example a pyridyl group substituted by oxo is a pyridone. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds or useful synthetic intermediates.

[0062] A stable active compound refers to a compound that can be isolated and can be formulated into a dosage form with a shelf life of at least one month. A stable manufacturing intermediate or precursor to an active compound is stable if it does not degrade within the period needed for reaction or other use. A stable moiety or substituent group is one that does not degrade, react or fall apart within the period necessary for use. Nonlimiting examples of unstable moieties are those that combine heteroatoms in an unstable arrangement, as typically known and identifiable to those of skill in the art.

[0063] Any suitable group may be present on a "substituted" or "optionally substituted" position that forms a stable molecule and meets the desired purpose of the invention and includes, but is not limited to, e.g., halogen (which can independently be F, Cl, Br or I); cyano; hydroxyl; nitro; azido; alkanoyl (such as a C₂-C₆ alkanoyl group); carboxamide; alkyl, cycloalkyl, alkenyl, alkynyl, alkoxy, aryloxy such as phenoxy; thioalkyl including those having one or more thioether linkages; alkylsulfinyl; alkylsulfonyl groups including those having one or more sulfonyl linkages; aminoalkyl groups including groups having more than one N atoms; aryl (e.g., phenyl, biphenyl, naphthyl, or the like, each ring either substituted or unsubstituted); arylalkyl having for example, 1 to 3 separate or fused rings and from 6 to about 14 or 18 ring carbon atoms, with benzyl being an exemplary arylalkyl group; arylalkoxy, for example, having 1 to 3 separate or fused rings with benzyloxy being an exemplary arylalkoxy group; or a saturated or partially unsaturated heterocycle having 1 to 3 separate or fused rings with one or more N, O or S atoms, or a heteroaryl having 1 to 3 separate or fused rings with one or more N, O or S atoms, e.g. coumarinyl, quinolinyl, isoquinolinyl, quinazolinyl, pyridyl, pyrazinyl, pyrimidinyl, furanyl, pyrrolyl, thienyl, thiazolyl, triazinyl, oxazolyl, isoxazolyl, imidazolyl, indolyl, benzofuranyl, benzothiazolyl, tetrahydrofuran, tetrahydropyranyl, piperidinyl, morpholinyl, piperazinyl, and pyrrolidinyl. Such groups may be further substituted, e.g. with hydroxy, alkyl, alkoxy, halogen and amino. In certain embodiments "optionally substituted" includes one or more substituents independently selected from halogen, hydroxyl, amino, cyano, -CHO, -COOH, -CONH₂, alkyl including C₁-C₆alkyl, alkenyl including C₂-C₆alkenyl, alkynyl including C₂-C₆alkynyl, -C₁-C₆alkoxy, alkanoyl including C₂-C₆alk-anoyl, C₁-C₆alkylester, (mono- and di-C₁-C₆alkylamino)C₀-C₂alkyl, haloalkyl including C₁-C₆haloalkyl, hydroxyC₁-C₆alk-yl, ester, carbamate, urea, sulfonamide, -C₁-C₆alkyl(heterocyclo), C₁-C₆alkyl(heteroaryl), -C₁-C₆alkyl(C₃-C₇cycloalkyl), O-C₁-C₆alkyl(C₃-C₇cycloalkyl), B(OH)₂, phosphate, phosphonate and haloalkoxy including C₁-C₆haloalkoxy.

[0064] "Alkyl" is a branched or straight chain saturated aliphatic hydrocarbon group. In one embodiment, the alkyl contains from 1 to about 12 carbon atoms, more generally from 1 to about 6 carbon atoms or from 1 to about 4 carbon atoms. In one embodiment, the alkyl contains from 1 to about 8 carbon atoms. In certain embodiments, the alkyl is C₁-C₂, C₁-C₃, C₁-C₄, C₁-C₅ or C₁-C₆. The specified ranges as used herein indicate an alkyl group having each member of the range described as an independent species. For example, the term C₁-C₆ alkyl as used herein indicates a straight or branched alkyl group having from 1, 2, 3, 4, 5, or 6 carbon atoms and is intended to mean that each of these is described as an independent species. For example, the term C₁-C₄alkyl as used herein indicates a straight or branched alkyl group having from 1, 2, 3, or 4 carbon atoms and is intended to mean that each of these is described as an independent species. When C₀-C_n alkyl is used herein in conjunction with another group, for example, (C₃-C₇cycloalkyl)C₀-C₄ alkyl, or -C₀-C₄alkyl(C₃-C₇cycloalkyl), the indicated group, in this case cycloalkyl, is either directly bound by a single covalent bond (C₀alkyl), or attached by an alkyl chain in this case 1, 2, 3, or 4 carbon atoms. Alkyls can also be attached via other groups such as heteroatoms as in -O-C₀-C₄alkyl(C₃-C₇cycloalkyl). Examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, n-pentyl, isopentyl, *tert*-pentyl, neopentyl, n-hexyl, 2-methylpentane, 3-methylpentane, 2,2-dimethylbutane, 2,3-dimethylbutane, and hexyl. In one embodiment, the alkyl group is optionally substituted as described above. In one embodiment, trimethylsilyl can be used instead of t-butyl.

[0065] "Aliphatic" refers to a saturated or unsaturated, straight, branched, or cyclic hydrocarbon. "Aliphatic" is intended herein to include, but is not limited to, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, and cycloalkynyl moieties, and thus incorporates each of these definitions. In one embodiment, "aliphatic" is used to indicate those aliphatic groups having 1-20 carbon atoms. The aliphatic chain can be, for example, mono-unsaturated, di-unsaturated, tri-unsaturated, poly-unsaturated, or alkynyl. Unsaturated aliphatic groups can be in a cis or trans configuration. In one embodiment, the aliphatic group contains from 1 to about 12 carbon atoms, more generally from 1 to about 6 carbon atoms or from 1 to about 4 carbon atoms. In one embodiment, the aliphatic group contains from 1 to about 8 carbon atoms. In certain embodiments, the aliphatic group is C₁-C₂, C₁-C₃, C₁-C₄, C₁-C₅ or C₁-C₆. The specified ranges as used herein indicate an aliphatic group having each member of the range described as an independent species. For example, the term C₁-C₆ aliphatic as used herein indicates a straight or branched alkyl, alkenyl, or alkynyl group having from 1, 2, 3, 4, 5, or 6 carbon atoms and is intended to mean that each of these is described as an independent species. For example, the term C₁-C₄ aliphatic as used herein indicates a straight or branched alkyl, alkenyl, or alkynyl group having from 1, 2, 3, or 4 carbon atoms and is intended to mean that each of these is described as an independent species. In one embodiment, the aliphatic group is substituted with one or more functional groups that results in the formation of a stable moiety.

[0066] The term "heteroaliphatic" refers to an aliphatic moiety that contains at least one heteroatom in the chain, for example, an amine, carbonyl, carboxy, oxo, thio, phosphate, phosphonate, nitrogen, phosphorus, silicon, or boron atoms in place of a carbon atom. In one embodiment, the only heteroatom is nitrogen. In one embodiment, the only heteroatom is oxygen. In one embodiment, the only heteroatom is sulfur. "Heteroaliphatic" is intended herein to include, but is not limited to, heteroalkyl, heteroalkenyl, heteroalkynyl, heterocycloalkyl, heterocycloalkenyl, and heterocycloalkynyl moieties. In one embodiment, "heteroaliphatic" is used to indicate a heteroaliphatic group (cyclic, acyclic, substituted, unsubstituted, branched or unbranched) having 1-20 carbon atoms. In one embodiment, the heteroaliphatic group is optionally substituted in a manner that results in the formation of a stable moiety. Nonlimiting examples of heteroaliphatic moieties are polyethylene glycol, polyalkylene glycol, amide, polyamide, polylactide, polyglycolide, thioether, ether, alkyl-heterocycle-alkyl, -O-alkyl-O-alkyl, alkyl-O-haloalkyl, etc.

[0067] In one embodiment, when a term is used that includes "alk" it should be understood that "cycloalkyl" or "carbocyclic" can be considered part of the definition, unless unambiguously excluded by the context. For example and without limitation, the terms alkyl, alkenyl, alkynyl, alkoxy, alkanoyl, alkenloxy, haloalkyl, aminoalkyl, alkylene, alkenylene, alkynylene, etc. can all be considered to include the cyclic forms of alkyl, unless unambiguously excluded by context.

[0068] "Alkenyl" is a branched or straight chain aliphatic hydrocarbon group having one or more carbon-carbon double bonds that may occur at a stable point along the chain. Nonlimiting examples are C₂-C₈alkenyl, C₂-C₇alkenyl, C₂-C₆alkenyl, C₂-C₅alkenyl and C₂-C₄alkenyl. The specified ranges as used herein indicate an alkenyl group having each member of the range described as an independent species, as described above for the alkyl moiety. Examples of alkenyl include, but are not limited to, ethenyl and propenyl. In one embodiment, the alkenyl group is optionally substituted as described above.

[0069] "Alkynyl" is a branched or straight chain aliphatic hydrocarbon group having one or more carbon-carbon triple bonds that may occur at any stable point along the chain, for example, C₂-C₈alkynyl or C₂-C₆alkynyl. The specified ranges as used herein indicate an alkynyl group having each member of the range described as an independent species, as described above for the alkyl moiety. Examples of alkynyl include, but are not limited to, ethynyl, propynyl, 1-butylnyl, 2-butylnyl, 3-butylnyl, 1-pentylnyl, 2-pentylnyl, 3-pentylnyl, 4-pentylnyl, 1-hexynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl and 5-hexynyl. In one embodiment, the alkynyl group is optionally substituted as described above.

[0070] "Alkylene" is a bivalent saturated hydrocarbon. Alkylenes, for example, can be a 1, 2, 3, 4, 5, 6, 7 to 8 carbon moiety, 1 to 6 carbon moiety, or an indicated number of carbon atoms, for example C₁-C₂alkylene, C₁-C₃alkylene,

C₁-C₄alkylene, C₁-C₅alkylene, or C₁-C₆alkylene.

[0071] "Alkenylene" is a bivalent hydrocarbon having at least one carbon-carbon double bond. Alkenylenes, for example, can be a 2 to 8 carbon moiety, 2 to 6 carbon moiety, or an indicated number of carbon atoms, for example C₂-C₄alkenylene.

[0072] "Alkynylene" is a bivalent hydrocarbon having at least one carbon-carbon triple bond. Alkynylenes, for example, can be a 2 to 8 carbon moiety, 2 to 6 carbon moiety, or an indicated number of carbon atoms, for example C₂-C₄alkynylene.

[0073] "Alkoxy" is an alkyl group as defined above covalently bound through an oxygen bridge (-O-). Examples of alkoxy include, but are not limited to, methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, 2-butoxy, t-butoxy, n-pentoxy, 2-pentoxy, 3-pentoxy, isopentoxy, neopentoxy, n-hexoxy, 2-hexoxy, 3-hexoxy, and 3-methylpentoxy. Similarly an "alkylthio" or a "thioalkyl" group is an alkyl group as defined above with the indicated number of carbon atoms covalently bound through a sulfur bridge (-S-). In one embodiment, the alkoxy group is optionally substituted as described above.

[0074] "Alkenyloxy" is an alkenyl group as defined covalently bound to the group it substitutes by an oxygen bridge (-O-).

[0075] "Alkanoyl" is an alkyl group as defined above covalently bound through a carbonyl (C=O) bridge. The carbonyl carbon is included in the number of carbons, that is C₂alkanoyl is a CH₃(C=O)- group. In one embodiment, the alkanoyl group is optionally substituted as described above.

[0076] "Alkylester" is an alkyl group as defined herein covalently bound through an ester linkage. The ester linkage may be in either orientation, e.g., a group of the formula -O(C=O)alkyl or a group of the formula -(C=O)Oalkyl.

[0077] "Amide" or "carboxamide" is -C(O)NR^aR^b wherein R^a and R^b are each independently selected from hydrogen, alkyl, for example, alkyl including C₁-C₆alkyl, alkenyl, for example, C₂-C₆alkenyl, alkynyl, for example, C₂-C₆alkynyl, -C₀-C₄alkyl(C₃-C₇cycloalkyl), -C₀-C₄alkyl(C₃-C₇heterocycloalkyl), -C₀-C₄alkyl(aryl), and -C₀-C₄alkyl(heteroaryl); or together with the nitrogen to which they are bonded, R^a and R^b can form a C₃-C₇heterocyclic ring. In one embodiment, the R^a and R^b groups are each independently be optionally substituted as described herein.

[0078] "Carbocyclic group", "carbocyclic ring", or "cycloalkyl" is a saturated or partially unsaturated (i.e., not aromatic) group containing all carbon ring atoms. A carbocyclic group typically contains 1 ring of 3 to 7 carbon atoms or 2 fused rings each containing 3 to 7 carbon atoms. Cycloalkyl substituents may be pendant from a substituted nitrogen or carbon atom, or a substituted carbon atom that may have two substituents can have a cycloalkyl group, which is attached as a spiro group. Examples of carbocyclic rings include cyclohexenyl, cyclohexyl, cyclopentenyl, cyclopentyl, cyclobutenyl, cyclobutyl and cyclopropyl rings. In one embodiment, the carbocyclic ring is optionally substituted as described above. In one embodiment, the cycloalkyl is a partially unsaturated (i.e., not aromatic) group containing all carbon ring atoms. In another embodiment, the cycloalkyl is a saturated group containing all carbon ring atoms.

[0079] "Carbocyclic-oxy group" is a monocyclic carbocyclic ring or a mono- or bi-cyclic carbocyclic group as defined above attached to the group it substitutes via an oxygen, -O-, linker.

[0080] "Haloalkyl" indicates both branched and straight-chain alkyl groups substituted with 1 or more halogen atoms, up to the maximum allowable number of halogen atoms. Examples of haloalkyl include, but are not limited to, trifluoromethyl, monofluoromethyl, difluoromethyl, 2-fluoroethyl, and penta-fluoroethyl.

[0081] "Haloalkoxy" indicates a haloalkyl group as defined herein attached through an oxygen bridge (oxygen of an alcohol radical).

[0082] "Hydroxyalkyl" is an alkyl group as previously described, substituted with at least one hydroxyl substituent.

[0083] "Aminoalkyl" is an alkyl group as previously described, substituted with at least one amino substituent.

[0084] "Halo" or "halogen" indicates independently, any of fluoro, chloro, bromo or iodo.

[0085] "Aryl" indicates an aromatic group containing only carbon in the aromatic ring or rings. In one embodiment, the aryl group contains 1 to 3 separate or fused rings and is 6 to about 14 or 18 ring atoms, without heteroatoms as ring members. When indicated, such aryl groups may be further substituted with carbon or non-carbon atoms or groups. Such substitution may include fusion to a 4 to 7 or a 5 to 7-membered saturated or partially unsaturated cyclic group that optionally contains 1, 2 or 3 heteroatoms independently selected from N, O, B, P, Si and/or S, to form, for example, a 3,4-methylenedioxyphenyl group. Aryl groups include, for example, phenyl and naphthyl, including 1-naphthyl and 2-naphthyl. In one embodiment, aryl groups are pendant. An example of a pendant ring is a phenyl group substituted with a phenyl group. In one embodiment, the aryl group is optionally substituted as described above.

[0086] The term "heterocycle," or "heterocyclic ring" as used herein refers to a saturated or a partially unsaturated (i.e., having one or more double and/or triple bonds within the ring without aromaticity) carbocyclic moiety of 3 to about 12, and more typically 3, 4, 5, 6, 7, 8 to 10 ring atoms in which at least one ring atom is a heteroatom selected from nitrogen, oxygen, phosphorus sulfur, silicon and boron, the remaining ring atoms being C, where one or more ring atoms is optionally substituted independently with one or more substituents described above. A heterocycle may be a monocycle having 3 to 7 ring members (2 to 6 carbon atoms and 1 to 4 heteroatoms selected from N, O, P, S, Si and B) or a bicycle having 6 to 10 ring members (4 to 9 carbon atoms and 1 to 6 heteroatoms selected from N, O, P, S, Si and B), for example: a bicyclo [4,5], [5,5], [5,6], or [6,6] system. In one embodiment, the only heteroatom is nitrogen. In one embodiment, the only heteroatom is oxygen. In one embodiment, the only heteroatom is sulfur, boron or silicon. Heterocycles are described in Paquette, Leo A.; "Principles of Modern Heterocyclic Chemistry" (W. A. Benjamin, New York, 1968), particularly Chapters 1, 3, 4, 6, 7, and

9; "The Chemistry of Heterocyclic Compounds, A series of Monographs" (John Wiley & Sons, New York, 1950 to present), in particular Volumes 13, 14, 16, 19, and 28; and J. Am. Chem. Soc. (1960) 82:5566. Examples of heterocyclic rings include, but are not limited to, pyrrolidinyl, dihydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, dihydropyranyl, tetrahydrothiopyranyl, piperidino, piperidonyl, morpholino, thiomorpholino, thioxanyl, piperazinyl, homopiperazinyl, azetidiny, oxetanyl, thietanyl, homopiperidinyl, oxepanyl, thiepanyl, oxazepinyl, diazepinyl, thiazepinyl, 2-pyrrolinyl, 3-pyrrolinyl, indolinyl, 2H-pyranyl, 4H-pyranyl, dioxanyl, 1,3-dioxolanyl, pyrazolinyl, dithianyl, dithiolanyl, dihydropyranyl, dihydrothienyl, dihydrofuranyl, dihydroisoquinolinyl, tetrahydroisoquinolinyl, pyrazolidinylimidazolinyl, imidazolidinyl, 2-oxa-5-azabicyclo[2.2.2]octane, 3-oxa-8-azabicyclo[3.2.1]octane, 8-oxa-3-azabicyclo[3.2.1]octane, 6-oxa-3-azabicyclo[3.1.1]heptane, 2-oxa-5-azabicyclo[2.2.1]heptane, 3-azabicyclo[3.1.0]hexanyl, 3-azabicyclo[4.1.0]heptanyl, azabicyclo[2.2.2]hexanyl, 3H-indolyl, quinoliziny, N-pyridyl ureas, and pyrrolopyrimidine. Spiro moieties are also included within the scope of this definition. Examples of a heterocyclic group wherein 1 or 2 ring carbon atoms are substituted with oxo (=O) moieties are pyrimidinonyl and 1,1-dioxo-thiomorpholinyl. The heterocycle groups herein are optionally substituted independently with one or more substituents described herein, for example, 1, 2, or 3 substituents.

[0087] "Heterocycloxy group" is a monocyclic heterocyclic ring or a bicyclic heterocyclic group as described previously linked to the group it substitutes via an oxygen, -O-, linker.

[0088] "Heteroaryl" refers to a stable monocyclic, bicyclic, or multicyclic aromatic ring which contains from 1 to 3, or in some embodiments from 1, 2, or 3 heteroatoms selected from N, O, S, B or P with remaining ring atoms being carbon, or a stable bicyclic or tricyclic system containing at least one 5, 6, or 7 membered aromatic ring which contains from 1 to 3, or in some embodiments from 1 to 2, heteroatoms selected from N, O, S, B or P with remaining ring atoms being carbon. In one embodiment, the only heteroatom is nitrogen. In one embodiment, the only heteroatom is oxygen. In one embodiment, the only heteroatom is sulfur. Monocyclic heteroaryl groups typically have from 5, 6, or 7 ring atoms. In some embodiments bicyclic heteroaryl groups are 8- to 10-membered heteroaryl groups, that is, groups containing 8 or 10 ring atoms in which one 5, 6, or 7 member aromatic ring is fused to a second aromatic or non-aromatic ring. When the total number of S and O atoms in the heteroaryl group exceeds 1, these heteroatoms are not adjacent to one another. In one embodiment, the total number of S and O atoms in the heteroaryl group is not more than 2. In another embodiment, the total number of S and O atoms in the aromatic heterocycle is not more than 1. Examples of heteroaryl groups include, but are not limited to, pyridinyl (including, for example, 2-hydroxypyridinyl), imidazolyl, imidazopyridinyl, pyrimidinyl (including, for example, 4-hydroxypyrimidinyl), pyrazolyl, triazolyl, pyrazinyl, furyl, thienyl, isoxazolyl, thiazolyl, oxadiazolyl, oxazolyl, isothiazolyl, pyrrolyl, quinolinyl, isoquinolinyl, tetrahydroisoquinolinyl, indolyl, benzimidazolyl, benzofuranyl, cinnolinyl, indazolyl, indoliziny, phthalazinyl, pyridazinyl, triazinyl, isoindolyl, pteridinyl, purinyl, oxadiazolyl, triazolyl, thiadiazolyl, thiadiazolyl, furazanyl, benzofurazanyl, benzothiofenyl, benzothiazolyl, benzoxazolyl, quinazolinyl, quinoxalinyl, naphthyridinyl, tetrahydrofuranyl, and furopyridinyl. Heteroaryl groups are optionally substituted independently with one or more substituents described herein. "Heteroaryloxy" is a heteroaryl group as described bound to the group it substituted via an oxygen, -O-, linker.

[0089] "Heterocycloalkyl" is a fully saturated heterocycle as defined herein. It may have, for example, include 1, 2, 3, or 4 heteroatoms independently selected from N, S, O, Si and B with the remaining ring atoms being carbon. In a typical embodiment, nitrogen is the heteroatom. Monocyclic heterocycloalkyl groups typically have from 3 to about 8 ring atoms or from 4 to 6 ring atoms.

[0090] The term "mono- and/ or di-alkylamino" indicate a secondary or tertiary alkylamino group, wherein the alkyl groups are independently selected as defined herein. The point of attachment of the alkylamino group is on the nitrogen. Examples of mono- and di-alkylamino groups include ethylamino, dimethylamino, and methyl-propyl-amino.

[0091] A "dosage form" means a unit of administration of an active agent. Examples of dosage forms include tablets, capsules, injections, suspensions, liquids, emulsions, implants, particles, spheres, creams, ointments, suppositories, inhalable forms, transdermal forms, buccal, sublingual, topical, gel, mucosal, and the like. A "dosage form" can also include an implant, for example an optical implant.

[0092] "Pharmaceutical compositions" are compositions comprising at least one active agent, and at least one other substance, such as a carrier. "Pharmaceutical combinations" are combinations of at least two active agents which may be combined in a single dosage form or provided together in separate dosage forms with instructions that the active agents are to be used together to treat any disorder described herein.

[0093] A "pharmaceutically acceptable salt" is a derivative of the disclosed compound in which the parent compound is modified by making inorganic and organic, pharmaceutically acceptable, acid or base addition salts thereof. The salts of the present compounds can be synthesized from a parent compound that contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting free acid forms of these compounds with a stoichiometric amount of the appropriate base (such as Na, Ca, Mg, or K hydroxide, carbonate, bicarbonate, or the like), or by reacting free base forms of these compounds with a stoichiometric amount of the appropriate acid. Such reactions are typically carried out in water or in an organic solvent, or in a mixture of the two. Generally, non-aqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are typical, where practicable. Salts of the present compounds further include solvates of the compounds and of the compound salts.

[0094] Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. The pharmaceutically acceptable salts include salts which are acceptable for human consumption and the quaternary ammonium salts of the parent compound formed, for example, from inorganic or organic acids. Examples, of such salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pantoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, mesylic, esylic, besylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, $\text{HOOC}-(\text{CH}_2)_n-\text{COOH}$ where n is 0-4, and the like, or using a different acid that produces the same counterion. Lists of additional suitable salts may be found, e.g., in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., p. 1418 (1985).

[0095] The term "carrier" applied to pharmaceutical compositions/combinations of the invention refers to a diluent, excipient, or vehicle with which an active compound is provided.

[0096] A "pharmaceutically acceptable excipient" means an excipient that is useful in preparing a pharmaceutical composition/combination that is generally safe, acceptable for human consumption, and neither biologically nor otherwise inappropriate for administration to a host, typically a human. In one embodiment, an excipient is used that is acceptable for veterinary use.

[0097] A "patient" or "host" or "subject" is a human or non-human animal in need of treatment or prevention of any of the disorders as specifically described herein, including but not limited to by modulation of the complement Factor D pathway or with a condition that is treatable with one of the compounds described herein. Typically the host is a human. A "patient" or "host" or "subject" also refers to for example, a mammal, primate (e.g., human), cows, sheep, goat, horse, dog, cat, rabbit, rat, mice, bird and the like.

[0098] "Providing a compound with at least one additional active agent," for example, in one embodiment can mean that the compound and the additional active agent(s) are provided simultaneously in a single dosage form, provided concomitantly in separate dosage forms, or provided in separate dosage forms for administration. In one embodiment, the compound administrations are separated by some amount of time that is within the time in which both the compound and the at least one additional active agent are within the blood stream of a patient. In certain embodiments the compound and the additional active agent need not be prescribed for a patient by the same medical care worker. In certain embodiments the additional active agent or agents need not require a prescription. Administration of the compound or the at least one additional active agent can occur via any appropriate route, for example, oral tablets, oral capsules, oral liquids, inhalation, injection, suppositories, parenteral, sublingual, buccal, intravenous, intraaortal, transdermal, polymeric controlled delivery, non-polymeric controlled delivery, nano or microparticles, liposomes, and/or topical contact. In one embodiment, the instructions for administration in a form of combination therapy is provided in the drug labeling.

[0099] A "therapeutically effective amount" of a pharmaceutical composition/combination of this invention means an amount effective, when administered to a host, provides a therapeutic benefit such as an amelioration of symptoms or reduction or diminution of the disease itself. In one embodiment, a therapeutically effective amount is an amount sufficient to prevent a significant increase or will significantly reduce the detectable level of complement Factor D in the patient's blood, serum, or tissues.

DETAILED DESCRIPTION OF THE ACTIVE COMPOUNDS

N-OXIDES

[0100] In certain embodiments, any of the active compounds can be provided in its N-oxide form to a patient in need thereof. In one embodiment, an N-oxide of an active compound or a precursor of the active compound is used in a manufacturing scheme. In yet another embodiment, the N-oxide is a metabolite of administration of one of the active compounds herein, and may have independent activity. The N-oxide can be formed by treating the compound of interest with an oxidizing agent, for example a suitable peroxyacid or peroxide, to generate an N-oxide compound. For example, a heteroaryl group, for example a pyridyl group, can be treated with an oxidizing agent such as sodium percarbonate in the presence of a rhenium-based catalyst under mild reaction conditions to generate an N-oxide compound. A person skilled in the art will understand that appropriate protecting groups may be necessary to carry out the chemistry. See, Jain, S.L. et al., "Rhenium-Catalyzed Highly Efficient Oxidations of Tertiary Nitrogen Compounds to N-Oxides Using Sodium Percarbonate as Oxygen Source, Synlett, 2261-2663, 2006.


[0101] In one embodiment the N-oxide is in the A-Ring. In one embodiment the N-oxide is in the B-Ring. In one embodiment the N-oxide is on the R^{32} group.

[0102] In other embodiments, any of the active compounds with a sulfur can be provided in its sulfoxide or sulfone form to a patient in need thereof. In a different embodiment, a sulfoxide or sulfone of one of the active compounds or a precursor of the active compound is used in a manufacturing scheme. A sulfur atom in a selected compound as described herein can be

oxidized to form a sulfoxide



or a sulfone



using known methods. For example, the compound 1,3,5-triazo-2,4,6-triphosphorine-2,2,4,4,6,6-tetrachloride (TAPC) is an efficient promoter for the oxidation of sulfides to sulfoxides. See, Bahrami, M. et al., "TAPC-Promoted Oxidation of sulfides and Deoxygenation of Sulfoxides", J. Org. Chem., 75, 6208-6213 (2010). Oxidation of sulfides with 30% hydrogen peroxide catalyzed by tantalum carbide provides sulfoxides in high yields, see, Kirihaara, A., et al., "Tantalum Carbide or Niobium Carbide Catalyzed Oxidation of Sulfides with Hydrogen Peroxide: Highly Efficient and Chemoselective Syntheses of Sulfoxides and Sulfones", Synlett, 1557-1561 (2010). Sulfides can be oxidized to sulfones using, for example, niobium carbide as the catalyst, see, Kirihaara, A., et al., "Tantalum Carbide or Niobium Carbide Catalyzed Oxidation of Sulfides with Hydrogen Peroxide: Highly Efficient and Chemoselective Syntheses of Sulfoxides and Sulfones", Synlett, 1557-1561 (2010). Urea-hydrogen peroxide adduct is a stable inexpensive and easily handled reagent for the oxidation of sulfides to sulfones, see Varma, R.S. and Naicker, K.P., "The Urea-Hydrogen Peroxide Complex: Solid-State Oxidative Protocols for Hydroxylated Aldehydes and Ketones (Dakin Reaction), Nitriles, Sulfides, and Nitrogen Heterocycles", Org. Lett., 1, 189-191 (1999). One skilled in the art will appreciate that other heteroatoms, such as nitrogen, may need to be protected and then deprotected while carrying out the oxidation of a sulfur atom to produce the desired compound.

PHARMACEUTICAL PREPARATIONS

[0103] Active compounds described herein can be administered to a host in need thereof as the neat chemical, but are more typically administered as a pharmaceutical composition that includes an effective amount for a host, typically a human, in need of such treatment of an active compound as described herein or its pharmaceutically acceptable salt, isotopic analog, N-oxide, or isolated isomer thereof. Thus, in one embodiment, the disclosure provides pharmaceutical compositions comprising an effective amount of compound or pharmaceutically acceptable salt, isotopic analog, N-oxide, or isolated isomer thereof together with at least one pharmaceutically acceptable carrier for any of the uses described herein. The pharmaceutical composition may contain a compound or salt as the only active agent, or, in an alternative embodiment, the compound and at least one additional active agent.

[0104] An effective amount of an active compound as described herein, or the active compound described herein in combination or alternation with, or preceded by, concomitant with or followed by another active agent, can be used in an amount sufficient to (a) inhibit the progression of a disorder mediated by the complement pathway, including an inflammatory, immune, including an autoimmune, disorder or complement Factor D related disorder; (b) cause a regression of an inflammatory, immune, including an autoimmune, disorder or complement Factor D related disorder; (c) cause a cure of an inflammatory, immune, including an autoimmune, disorder or complement Factor D related disorder; or inhibit or prevent the development of an inflammatory, immune, including an autoimmune, disorder or complement Factor D related disorder.

[0105] Accordingly, an effective amount of an active compound or its salt or composition described herein will provide a sufficient amount of the active agent when administered to a patient to provide a clinical benefit.

[0106] The exact amount of the active compound or pharmaceutical composition described herein to be delivered to the host, typically a human, in need thereof, will be determined by the health care provider to achieve the desired clinical benefit.

[0107] In certain embodiments the pharmaceutical composition is in a dosage form that contains from about 0.1 mg to about 2000 mg, from about 10 mg to about 1000 mg, from about 100 mg to about 800 mg, or from about 200 mg to about 600 mg of the active compound and optionally from about 0.1 mg to about 2000 mg, from about 10 mg to about 1000 mg, from about 100 mg to about 800 mg, or from about 200 mg to about 600 mg of an additional active agent in a unit dosage form. Examples are dosage forms with at least about 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 10, 15, 20, 25, 50, 75, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 900, 1000, 1100, 1200, 1250, 1300, 1400, 1500, or 1600 mg of active compound, or its salt. In one embodiment, the dosage form has at least about 1mg, 5 mg, 10 mg, 25 mg, 50 mg, 75 mg, 100 mg, 200 mg, 400 mg, 500 mg, 600 mg, 1000mg, 1200 mg, or 1600 mg of active compound, or its salt. The amount

of active compound in the dosage form is calculated without reference to the salt. The dosage form can be administered, for example, once a day (q.d.), twice a day (b.i.d.), three times a day (t.i.d.), four times a day (q.i.d.), once every other day (Q2d), once every third day (Q3d), as needed, or any dosage schedule that provides treatment of a disorder described herein.

[0108] The pharmaceutical composition may for example include a molar ratio of the active compound and an additional active agent that achieves the desired result. For example, the pharmaceutical composition may contain a molar ratio of about 0.5:1, about 1:1, about 2:1, about 3:1 or from about 1.5:1 to about 4:1 of an additional active agent in combination with the active compound (additional active agent: active compound), or its salt, described herein. In one embodiment, the additional active agent is an anti-inflammatory or immunosuppressing agent.

[0109] Compounds disclosed herein or used as described herein may be administered orally, topically, parenterally, by inhalation or spray, sublingually, via implant, including ocular implant, transdermally, via buccal administration, rectally, as an ophthalmic solution, injection, including ocular injection, intravenous, intra-aortal, intracranial, subdermal, intraperitoneal, subcutaneous, transnasal, sublingual, intrathecal, or rectal or by other means, in dosage unit formulations containing conventional pharmaceutically acceptable carriers. For ocular delivery, the compound can be administered, as desired, for example, as a solution, suspension, or other formulation via intravitreal, intrastromal, intracameral, sub-tenon, sub-retinal, retro-bulbar, peribulbar, suprachoroidal, subchoroidal, choroidal, conjunctival, subconjunctival, episcleral, periorcular, transscleral, retrobulbar, posterior juxtascleral, circumcorneal, or tear duct injections, or through a mucus, mucin, or a mucosal barrier, in an immediate or controlled release fashion or via an ocular device, injection, or topically administered formulation, for example a solution or suspension provided as an eye drop.

[0110] The pharmaceutical composition may be formulated as any pharmaceutically useful form, e.g., as an aerosol, a cream, a gel, a gel cap, a pill, a microparticle, a nanoparticle, an injection or infusion solution, a capsule, a tablet, a syrup, a transdermal patch, a subcutaneous patch, a dry powder, an inhalation formulation, in a medical device, suppository, buccal, or sublingual formulation, parenteral formulation, or an ophthalmic solution or suspension. Some dosage forms, such as tablets and capsules, are subdivided into suitably sized unit doses containing appropriate quantities of the active components, e.g., an effective amount to achieve the desired purpose.

[0111] Pharmaceutical compositions, and methods of manufacturing such compositions, suitable for administration as contemplated herein are known in the art. Examples of known techniques include, for example, US Patent Nos. 4,983,593, 5,013,557, 5,456,923, 5,576,025, 5,723,269, 5,858,411, 6,254,889, 6,303,148, 6,395,302, 6,497,903, 7,060,296, 7,078,057, 7,404,828, 8,202,912, 8,257,741, 8,263,128, 8,337,899, 8,431,159, 9,028,870, 9,060,938, 9,211,261, 9,265,731, 9,358,478, and 9,387,252.

[0112] The pharmaceutical compositions contemplated here can optionally include a carrier. Carriers must be of sufficiently high purity and sufficiently low toxicity to render them suitable for administration to the patient being treated. The carrier can be inert or it can possess pharmaceutical benefits of its own. The amount of carrier employed in conjunction with the compound is sufficient to provide a practical quantity of material for administration per unit dose of the compound.

Classes of carriers include, but are not limited to binders, buffering agents, coloring agents, diluents, disintegrants, emulsifiers, fillers, flavorants, glidants, lubricants, pH modifiers, preservatives, stabilizers, surfactants, solubilizers, tableting agents, and wetting agents. Some carriers may be listed in more than one class, for example vegetable oil may be used as a lubricant in some formulations and a diluent in others. Exemplary pharmaceutically acceptable carriers include sugars, starches, celluloses, powdered tragacanth, malt, gelatin; talc, and vegetable oils. Examples of other matrix materials, fillers, or diluents include lactose, mannitol, xylitol, microcrystalline cellulose, calcium diphosphate, and starch. Examples of surface active agents include sodium lauryl sulfate and polysorbate 80. Examples of drug complexing agents or solubilizers include the polyethylene glycols, caffeine, xanthene, gentisic acid and cyclodextrins. Examples of disintegrants include sodium starch glycolate, sodium alginate, carboxymethyl cellulose sodium, methyl cellulose, colloidal silicon dioxide, and croscarmellose sodium. Examples of binders include methyl cellulose, microcrystalline cellulose, starch, and gums such as guar gum, and tragacanth. Examples of lubricants include magnesium stearate and calcium stearate. Examples of pH modifiers include acids such as citric acid, acetic acid, ascorbic acid, lactic acid, aspartic acid, succinic acid, phosphoric acid, and the like; bases such as sodium acetate, potassium acetate, calcium oxide, magnesium oxide, trisodium phosphate, sodium hydroxide, calcium hydroxide, aluminum hydroxide, and the like, and buffers generally comprising mixtures of acids and the salts of said acids. Optional other active agents may be included in a pharmaceutical composition, which do not substantially interfere with the activity of the compound of the present invention.

[0113] In certain embodiments, the pharmaceutical composition for administration further includes a compound or salt of Formula I, II, or III and optionally comprises one or more of a phosphoglyceride; phosphatidylcholine; dipalmitoyl phosphatidylcholine (DPPC); dioleoylphosphatidyl ethanolamine (DOPE); dioleoyloxypropyltriethylammonium (DOTMA); dioleoylphosphatidylcholine; cholesterol; cholesterol ester; diacylglycerol; diacylglycerolsuccinate; diphosphatidyl glycerol (DPPG); hexanadecanol; fatty alcohol such as polyethylene glycol (PEG); polyoxyethylene-9-lauryl ether; a surface active fatty acid, such as palmitic acid or oleic acid; fatty acid; fatty acid monoglyceride; fatty acid diglyceride; fatty acid amide; sorbitan trioleate (Span®85) glycocholate; sorbitan monolaurate (Span®20); polysorbate 20 (Tween®20); polysorbate 60 (Tween®60); polysorbate 65 (Tween®65); polysorbate 80 (Tween®80); polysorbate 85 (Tween®85); poly-

oxyethylene monostearate; surfactin; a poloxomer; a sorbitan fatty acid ester such as sorbitan trioleate; lecithin; lysolecithin; phosphatidylserine; phosphatidylinositol; sphingomyelin; phosphatidylethanolamine (cephalin); cardiolipin; phosphatidic acid; cerebroside; dicetylphosphate; dipalmitoylphosphatidylglycerol; stearylamine; dodecylamine; hexadecyl-amine; acetyl palmitate; glycerol ricinoleate; hexadecyl stearate; isopropyl myristate; tyloxapol; poly(ethylene glycol) 5000-phosphatidylethanolamine; poly(ethylene glycol)400-monostearate; phospholipid; synthetic and/or natural detergent having high surfactant properties; deoxycholate; cyclodextrin; chaotropic salt; ion pairing agent; glucose, fructose, galactose, ribose, lactose, sucrose, maltose, trehalose, cellobiose, mannose, xylose, arabinose, glucuronic acid, galacturonic acid, mannuronic acid, glucosamine, galatosamine, and neuramic acid; pullulan, cellulose, microcrystalline cellulose, hydroxypropyl methylcellulose (HPMC), hydroxycellulose (HC), methylcellulose (MC), dextran, cyclodextran, glycogen, hydroxyethylstarch, carageenan, glycon, amylose, chitosan, N,O-carboxymethylchitosan, algin and alginic acid, starch, chitin, inulin, konjac, glucomannan, pustulan, heparin, hyaluronic acid, curdlan, and xanthan, mannitol, sorbitol, xylitol, erythritol, maltitol, and lactitol, a pluronic polymer, polyethylene, polycarbonate (e.g. poly(1,3-dioxan-2-one)), polyanhydride (e.g. poly(sebacic anhydride)), polypropylfumerate, polyamide (e.g. polycaprolactam), polyacetal, polyether, polyester (e.g., polylactide, polyglycolide, polylactide-co-glycolide, polycaprolactone, polyhydroxyacid (e.g. poly((β -hydroxyalkanoate))), poly(orthoester), polycyanoacrylate, polyvinyl alcohol, polyurethane, polyphosphazene, polyacrylate, polymethacrylate, polyurea, polystyrene, and polyamine, polylysine, polylysine-PEG copolymer, and poly(ethyleneimine), poly(ethylene imine)-PEG copolymer, glycerol monocaprylocaprate, propylene glycol, Vitamin E TPGS (also known as d- α -Tocopheryl polyethylene glycol 1000 succinate), gelatin, titanium dioxide, polyvinylpyrrolidone (PVP), hydroxypropyl methyl cellulose (HPMC), hydroxypropyl cellulose (HPC), methyl cellulose (MC), block copolymers of ethylene oxide and propylene oxide (PEO/PPO), polyethyleneglycol (PEG), sodium carboxymethylcellulose (NaCMC), hydroxypropylmethyl cellulose acetate succinate (HPMCAS).

[0114] In some embodiments, the pharmaceutical preparation may include polymers for controlled delivery of the described compounds, including, but not limited to pluronic polymers, polyesters (e.g., polylactic acid, poly(lactic-co-glycolic acid), polycaprolactone, polyvalerolactone, poly(1,3-dioxan-2-one)); polyanhydrides (e.g., poly(sebacic anhydride)); polyethers (e.g., polyethylene glycol); polyurethanes; polymethacrylates; polyacrylates; and polycyanoacrylates. In some embodiments, polymers may be modified with polyethylene glycol (PEG), with a carbohydrate, and/or with acyclic polyacetals derived from polysaccharides. See, e.g., Papisov, 2001, ACS Symposium Series, 786:301.

[0115] The compounds of the present invention can be formulated as particles. In one embodiment the particles are or include microparticles. In an alternative embodiment the particles are or include nanoparticles.

[0116] In an additional alternative embodiment, common techniques for preparing particles include, but are not limited to, solvent evaporation, solvent removal, spray drying, phase inversion, coacervation, and low temperature casting. Suitable methods of particle formulation are briefly described below. Pharmaceutically acceptable excipients, including pH modifying agents, disintegrants, preservatives, and antioxidants, can optionally be incorporated into the particles during particle formation.

[0117] In one embodiment, the particles are derived through a solvent evaporation method. In this method, a compound described herein (or polymer matrix and one or more compounds described herein) is dissolved in a volatile organic solvent, such as methylene chloride. The organic solution containing a compound described herein is then suspended in an aqueous solution that contains a surface active agent such as poly(vinyl alcohol). The resulting emulsion is stirred until most of the organic solvent evaporated, leaving solid nanoparticles or microparticles. The resulting nanoparticles or microparticles are washed with water and dried overnight in a lyophilizer. Nanoparticles with different sizes and morphologies can be obtained by this method.

[0118] Pharmaceutical compositions which contain labile polymers, such as certain polyanhydrides, may degrade during the fabrication process due to the presence of water. For these polymers, methods which are performed in completely or substantially anhydrous organic solvents can be used to make the particles.

[0119] Solvent removal can also be used to prepare particles from a compound that is hydrolytically unstable. In this method, the compound (or polymer matrix and one or more compounds) is dispersed or dissolved in a volatile organic solvent such as methylene chloride. This mixture is then suspended by stirring in an organic oil (such as silicon oil) to form an emulsion. Solid particles form from the emulsion, which can subsequently be isolated from the supernatant. The external morphology of spheres produced with this technique is highly dependent on the identity of the drug.

[0120] In one embodiment an active compound as described herein is administered to a patient in need thereof as particles formed by solvent removal. In another embodiment the present invention provides particles formed by solvent removal comprising a compound of the present invention and one or more pharmaceutically acceptable excipients as defined herein. In another embodiment the particles formed by solvent removal comprise a compound of the present invention and an additional therapeutic agent. In a further embodiment the particles formed by solvent removal comprise a compound of the present invention, an additional therapeutic agent, and one or more pharmaceutically acceptable excipients. In another embodiment any of the described particles formed by solvent removal can be formulated into a tablet and then coated to form a coated tablet. In an alternative embodiment the particles formed by solvent removal are formulated into a tablet but the tablet is uncoated.

[0121] In one embodiment, the particles are derived by spray drying. In this method, a compound (or polymer matrix and one or more compounds) is dissolved in an organic solvent such as methylene chloride. The solution is pumped through a micronizing nozzle driven by a flow of compressed gas, and the resulting aerosol is suspended in a heated cyclone of air, allowing the solvent to evaporate from the micro droplets, forming particles. Microparticles and nanoparticles can be obtained using this method.

[0122] In one embodiment an active compound as described herein is administered to a patient in need thereof as a spray dried dispersion (SDD). In another embodiment the present invention provides a spray dried dispersion (SDD) comprising a compound of the present invention and one or more pharmaceutically acceptable excipients as defined herein. In another embodiment the SDD comprises a compound of the present invention and an additional therapeutic agent. In a further embodiment the SDD comprises a compound of the present invention, an additional therapeutic agent, and one or more pharmaceutically acceptable excipients. In another embodiment any of the described spray dried dispersions can be coated to form a coated tablet. In an alternative embodiment the spray dried dispersion is formulated into a tablet but is uncoated. Particles can be formed from the active compound as described herein using a phase inversion method. In this method, the compound (or polymer matrix and one or more active compounds) is dissolved in a suitable solvent, and the solution is poured into a strong non-solvent for the compound to spontaneously produce, under favorable conditions, microparticles or nanoparticles. The method can be used to produce nanoparticles in a wide range of sizes, including, for example, from nanoparticles to microparticles, typically possessing a narrow particle size distribution.

[0123] In one embodiment, an active compound as described herein is administered to a patient in need thereof as particles formed by phase inversion. In another embodiment the present invention provides particles formed by phase inversion comprising a compound of the present invention and one or more pharmaceutically acceptable excipients as defined herein. In another embodiment the particles formed by phase inversion comprise a compound of the present invention and an additional therapeutic agent. In a further embodiment the particles formed by phase inversion comprise a compound of the present invention, an additional therapeutic agent, and one or more pharmaceutically acceptable excipients. In another embodiment any of the described particles formed by phase inversion can be formulated into a tablet and then coated to form a coated tablet. In an alternative embodiment the particles formed by phase inversion are formulated into a tablet but the tablet is uncoated.

[0124] Techniques for particle formation using coacervation are known in the art, for example, as described in GB-B-929 406; GB-B-929 40 1; and U.S. Patent Nos. 3,266,987, 4,794,000, and 4,460,563. Coacervation involves the separation of a compound (or polymer matrix and one or more compounds) solution into two immiscible liquid phases. One phase is a dense coacervate phase, which contains a high concentration of the compound, while the second phase contains a low concentration of the compound. Within the dense coacervate phase, the compound forms nanoscale or microscale droplets, which harden into particles. Coacervation may be induced by a temperature change, addition of a non-solvent or addition of a micro-salt (simple coacervation), or by the addition of another polymer thereby forming an interpolymer complex (complex coacervation).

[0125] In one embodiment an active compound as described herein is administered to a patient in need thereof as particles formed by coacervation. In another embodiment the present invention provides particles formed by coacervation comprising a compound of the present invention and one or more pharmaceutically acceptable excipients as defined herein. In another embodiment the particles formed by coacervation comprise a compound of the present invention and an additional therapeutic agent. In a further embodiment the particles formed by coacervation comprise a compound of the present invention, an additional therapeutic agent, and one or more pharmaceutically acceptable excipients. In another embodiment any of the described particles formed by coacervation can be formulated into a tablet and then coated to form a coated tablet. In an alternative embodiment the particles formed by coacervation are formulated into a tablet but the tablet is uncoated.

[0126] Methods for very low temperature casting of controlled release microspheres are described in U.S. Patent No. 5,019,400 to Gombotz et al. In this method, the compound is dissolved in a solvent. The mixture is then atomized into a vessel containing a liquid non-solvent at a temperature below the freezing point of the drug solution which freezes the compound droplets. As the droplets and non-solvent for the compound are warmed, the solvent in the droplets thaws and is extracted into the non-solvent, hardening the microspheres.

[0127] In one embodiment, a compound of the present invention is administered to a patient in need thereof as particles formed by low temperature casting. In another embodiment the present invention provides particles formed by low temperature casting comprising a compound of the present invention and one or more pharmaceutically acceptable excipients as defined herein. In another embodiment the particles formed by low temperature casting comprise a compound of the present invention and an additional therapeutic agent. In a further embodiment the particles formed by low temperature casting comprise a compound of the present invention, an additional therapeutic agent, and one or more pharmaceutically acceptable excipients. In another embodiment any of the described particles formed by low temperature casting can be formulated into a tablet and then coated to form a coated tablet. In an alternative embodiment the particles formed by low temperature casting are formulated into a tablet but the tablet is uncoated.

[0128] In one aspect of the present invention, an effective amount of an active compound as described herein is

incorporated into a nanoparticle, e.g. for convenience of delivery and/or extended release delivery. The use of materials in nanoscale provides one the ability to modify fundamental physical properties such as solubility, diffusivity, blood circulation half-life, drug release characteristics, and/or immunogenicity. A number of nanoparticle-based therapeutic and diagnostic agents have been developed for the treatment of cancer, diabetes, pain, asthma, allergy, and infections. These nanoscale agents may provide more effective and/or more convenient routes of administration, lower therapeutic toxicity, extend the product life cycle, and ultimately reduce health-care costs. As therapeutic delivery systems, nanoparticles can allow targeted delivery and controlled release.

[0129] In addition, nanoparticle-based compound delivery can be used to release compounds at a sustained rate and thus lower the frequency of administration, deliver drugs in a targeted manner to minimize systemic side effects, or deliver two or more drugs simultaneously for combination therapy to generate a synergistic effect and suppress drug resistance. A number of nanotechnology-based therapeutic products have been approved for clinical use. Among these products, liposomal drugs and polymer-based conjugates account for a large proportion of the products. See, Zhang, L., et al., *Nanoparticles in Medicine: Therapeutic Applications and Developments*, Clin. Pharm. and Ther., 83(5):761-769, 2008.

[0130] Methods for producing nanoparticles are known in the art. For example, see Muller, R.H., et al., *Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art*, Eur. H. Pharm. Biopharm., 50:161-177, 2000; US 8,691,750 to Consien et al.; WO 2012/145801 to Kanwar, US 8,580,311 to Armes, S. et al.; Petros, R.A. and DeSimone, J.M., *Strategies in the design of nanoparticles for therapeutic applications*, Nature Reviews/Drug Discovery, vol. 9:615-627, 2010; US 8,465,775; US 8,444,899; US 8,420,124; US 8,263,129; US 8,158,728; 8,268,446; Pellegrino et al., 2005, Small, 1:48; Murray et al., 2000, Ann. Rev. Mat. Sci., 30:545; and Trindade et al., 2001, Chem. Mat., 13:3843. Additional methods have been described in the literature (see, e.g., Doubrow, Ed., *"Microcapsules and Nanoparticles in Medicine and Pharmacy"*, CRC Press, Boca Raton, 1992; Mathiowitz et al., 1987, J. Control. Release, 5:13; Mathiowitz et al., 1987, *Reactive Polymers*, 6:275; and Mathiowitz et al., 1988, J. Appl. Polymer Sci., 35:755; U.S. Pat. Nos. 5,578,325 and 6,007,845; P. Paolicelli et al., *"Surface-modified PLGA-based Nanoparticles that can Efficiently Associate and Deliver Virus-like Particles"* Nanomedicine. 5(6):843-853 (2010)), U.S. Pat. No. 5,543,158 to Gref et al., or WO publication WO2009/051837 by Von Andrian et al. Zauner et al., 1998, Adv. Drug Del. Rev., 30:97; and Kabanov et al., 1995, *Bioconjugate Chem.*, 6:7; (PEI; Boussif et al., 1995, Proc. Natl. Acad. Sci., USA, 1995, 92:7297), and poly(amidoamine) dendrimers (Kukowska-Latallo et al., 1996, Proc. Natl. Acad. Sci., USA, 93:4897; Tang et al., 1996, *Bioconjugate Chem.*, 7:703; and Haensler et al., 1993, *Bioconjugate Chem.*, 4:372; Putnam et al., 1999, *Macromolecules*, 32:3658; Barrera et al., 1993, J. Am. Chem. Soc., 115:11010; Kwon et al., 1989, *Macromolecules*, 22:3250; Lim et al., 1999, J. Am. Chem. Soc., 121:5633; and Zhou et al., 1990, *Macromolecules*, 23:3399). Examples of these polyesters include poly(L-lactide-co-L-lysine) (Barrera et al., 1993, J. Am. Chem. Soc., 115:11010), poly(serine ester) (Zhou et al., 1990, *Macromolecules*, 23:3399), poly(4-hydroxy-L-proline ester) (Putnam et al., 1999, *Macromolecules*, 32:3658; and Lim et al., 1999, J. Am. Chem. Soc., 121:5633), and poly(4-hydroxy-L-proline ester) (Putnam et al., 1999, *Macromolecules*, 32:3658; and Lim et al., 1999, J. Am. Chem. Soc., 121:5633; U.S. Pat. No. 6,123,727; U.S. Pat. No. 5,804,178; U.S. Pat. No. 5,770,417; U.S. Pat. No. 5,736,372; U.S. Pat. No. 5,716,404; U.S. Pat. No. 6,095,148; U.S. Pat. No. 5,837,752; U.S. Pat. No. 5,902,599; U.S. Pat. No. 5,696,175; U.S. Pat. No. 5,514,378; U.S. Pat. No. 5,512,600; U.S. Pat. No. 5,399,665; U.S. Pat. No. 5,019,379; U.S. Pat. No. 5,010,167; U.S. Pat. No. 4,806,621; U.S. Pat. No. 4,638,045; and U.S. Pat. No. 4,946,929; Wang et al., 2001, J. Am. Chem. Soc., 123:9480; Lim et al., 2001, J. Am. Chem. Soc., 123:2460; Langer, 2000, Acc. Chem. Res., 33:94; Langer, 1999, J. Control. Release, 62:7; and Uhrich et al., 1999, Chem. Rev., 99:3181; Concise Encyclopedia of Polymer Science and Polymeric Amines and Ammonium Salts, Ed. by Goethals, Pergamon Press, 1980; Principles of Polymerization by Odian, John Wiley & Sons, Fourth Edition, 2004; Contemporary Polymer Chemistry by Allcock et al., Prentice-Hall, 1981; Deming et al., 1997, Nature, 390:386; and in U.S. Pat. Nos. 6,506,577, 6,632,922, 6,686,446, and 6,818,732; C. Astete et al., *"Synthesis and characterization of PLGA nanoparticles"* J. Biomater. Sci. Polymer Edn, Vol. 17, No. 3, pp. 247-289 (2006); K. Avgoustakis *"Pegylated Poly(Lactide) and Poly(Lactide-Co-Glycolide) Nanoparticles: Preparation, Properties and Possible Applications in Drug Delivery"* Current Drug Delivery 1:321-333 (2004); C. Reis et al., *"Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticles"* Nanomedicine 2:8-21 (2006); P. Paolicelli et al., *"Surface-modified PLGA-based Nanoparticles that can Efficiently Associate and Deliver Virus-like Particles"* Nanomedicine. 5(6):843-853 (2010); U.S. Pat. No. 6,632,671 to Unger Oct. 14, 2003.

[0131] In one embodiment, the polymeric particle is between about 0.1 nm to about 10000 nm, between about 1 nm to about 1000 nm, between about 10 nm and 1000 nm, between about 1 and 100 nm, between about 1 and 10 nm, between about 1 and 50 nm, between about 100 nm and 800 nm, between about 400 nm and 600 nm, or about 500 nm. In one embodiment, the micro-particles are no more than about 0.1 nm, 0.5 nm, 1.0 nm, 5.0 nm, 10 nm, 25 nm, 50 nm, 75 nm, 100 nm, 150 nm, 200 nm, 250 nm, 300 nm, 400 nm, 450 nm, 500 nm, 550 nm, 600 nm, 650 nm, 700 nm, 750 nm, 800 nm, 850 nm, 900 nm, 950 nm, 1000 nm, 1250 nm, 1500 nm, 1750 nm, or 2000 nm. In some embodiments, a compound described herein may be covalently coupled to a polymer used in the nanoparticle, for example a polystyrene particle, PLGA particle, PLA particle, or other nanoparticle.

[0132] The pharmaceutical compositions can be formulated for oral administration. These compositions can contain any amount of active compound that achieves the desired result, for example between 0.1 and 99 weight % (wt. %) of the

compound and usually at least about 5 wt. % of the compound. Some embodiments contain at least about 10%, 15%, 20%, 25 wt. % to about 50 wt. % or from about 5 wt. % to about 75 wt. % of the compound.

[0133] Pharmaceutical compositions suitable for rectal administration are typically presented as unit dose suppositories. These may be prepared by admixing the active compound with one or more conventional solid carriers, for example, cocoa butter, and then shaping the resulting mixture.

[0134] Pharmaceutical compositions suitable for topical application to the skin preferably take the form of an ointment, cream, lotion, paste, gel, spray, aerosol, or oil. Carriers which may be used include petroleum jelly, lanoline, polyethylene glycols, alcohols, transdermal enhancers, and combinations of two or more thereof.

[0135] Pharmaceutical compositions suitable for transdermal administration may be presented as discrete patches adapted to remain in intimate contact with the epidermis of the recipient for a prolonged period of time. Pharmaceutical compositions suitable for transdermal administration may also be delivered by iontophoresis (see, for example, Pharmaceutical Research 3 (6):318 (1986)) and typically take the form of an optionally buffered aqueous solution of the active compound. In one embodiment, microneedle patches or devices are provided for delivery of drugs across or into biological tissue, particularly the skin. The microneedle patches or devices permit drug delivery at clinically relevant rates across or into skin or other tissue barriers, with minimal or no damage, pain, or irritation to the tissue.

Pharmaceutical compositions suitable for administration to the lungs can be delivered by a wide range of passive breath driven and active power driven single-/multiple dose dry powder inhalers (DPI). The devices most commonly used for respiratory delivery include nebulizers, metered-dose inhalers, and dry powder inhalers. Several types of nebulizers are available, including jet nebulizers, ultrasonic nebulizers, and vibrating mesh nebulizers. Selection of a suitable lung delivery device depends on parameters, such as nature of the drug and its formulation, the site of action, and pathophysiology of the lung.

[0136] Additional non-limiting examples of inhalation drug delivery devices and methods include, for example, US 7,383,837 titled "Inhalation device" (SmithKline Beecham Corporation); WO/2006/033584 titled "Powder inhaler" (Glaxo SmithKline Pharmaceuticals SA); WO/2005/044186 titled "Inhalable pharmaceutical formulations employing desiccating agents and methods of administering the same" (Glaxo Group Ltd and SmithKline Beecham Corporation); US9,095,670 titled "Inhalation device and method of dispensing medicament", US 8,205,611 titled "Dry powder inhaler" (Astrazeneca AB); WO/2013/038170 titled "Inhaler" (Astrazeneca AB and Astrazeneca UK Ltd.); US/2014/0352690 titled "Inhalation Device with Feedback System", US 8,910,625 and US/2015/0165137 titled "Inhalation Device for Use in Aerosol Therapy" (Vectura GmbH); US 6,948,496 titled "Inhalers", US/2005/0152849 titled "Powders comprising anti-adherent materials for use in dry powder inhalers", US 6,582,678, US 8,137,657, US/2003/0202944, and US/2010/0330188 titled "Carrier particles for use in dry powder inhalers", US 6,221,338 titled "Method of producing particles for use in dry powder inhalers", US 6,989,155 titled "Powders", US/2007/0043030 titled "Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation", US 7,845,349 titled "Inhaler", US/2012/0114709 and US 8,101,160 titled "Formulations for Use in Inhaler Devices", US/2013/0287854 titled "Compositions and Uses", US/2014/0037737 and US 8,580,306 titled "Particles for Use in a Pharmaceutical Composition", US/2015/0174343 titled "Mixing Channel for an Inhalation Device", US 7,744,855 and US/2010/0285142 titled "Method of making particles for use in a pharmaceutical composition", US 7,541,022, US/2009/0269412, and US/2015/0050350 titled "Pharmaceutical formulations for dry powder inhalers" (Vectura Limited).

[0137] Many methods and devices for drug delivery to the eye are known in the art. Non-limiting examples are described in the following patents and patent applications. Examples are US 8,192,408 titled "Ocular trocar assembly" (Psvida Us, Inc.); US 7,585,517 titled "Transcleral delivery" (Macusight, Inc.); US 5,710,182 and US 5,795,913 titled "Ophthalmic composition" (Santen OY); US 8,663,639 titled "Formulations for treating ocular diseases and conditions", US 8,486,960 titled "Formulations and methods for vascular permeability-related diseases or conditions", US 8,367,097 and US 8,927,005 titled "Liquid formulations for treatment of diseases or conditions", US 7,455,855 titled "Delivering substance and drug delivery system using the same" (Santen Pharmaceutical Co., Ltd.); WO/2011/050365 titled "Conformable Therapeutic Shield For Vision and Pain" and WO/2009/145842 titled "Therapeutic Device for Pain Management and Vision" (Forsight Labs, LLC); US 9,066,779 and US 8,623,395 titled "Implantable therapeutic device", WO/2014/160884 titled "Ophthalmic Implant for Delivering Therapeutic Substances", US 8,399,006, US 8,277,830, US 8,795,712, US 8,808,727, US 8,298,578, and WO/2010/088548 titled "Posterior segment drug delivery", WO/2014/152959 and US20140276482 titled "Systems for Sustained Intraocular Delivery of Low Solubility Compounds from a Port Delivery System Implant", US 8,905,963 and US 9,033,911 titled "Injector apparatus and method for drug delivery", WO/2015/057554 titled "Formulations and Methods for Increasing or Reducing Mucus", US 8,715,712 and US 8,939,948 titled "Ocular insert apparatus and methods", WO/2013/116061 titled "Insertion and Removal Methods and Apparatus for Therapeutic Devices", WO/2014/066775 titled "Ophthalmic System for Sustained Release of Drug to the Eye", WO/2015/085234 and WO/2012/019176 titled "Implantable Therapeutic Device", WO/2012/065006 titled "Methods and Apparatus to determine Porous Structures for Drug Delivery", WO/2010/141729 titled "Anterior Segment Drug Delivery", WO/2011/050327 titled "Corneal Denervation for Treatment of Ocular Pain", WO/2013/022801 titled "Small Molecule Delivery with Implantable Therapeutic Device", WO/2012/019047 titled "Subconjunctival Implant for Posterior

Segment Drug Delivery", WO/2012/068549 titled "Therapeutic Agent Formulations for Implanted Devices", WO/2012/019139 titled "Combined Delivery Methods and Apparatus", WO/2013/040426 titled "Ocular Insert Apparatus and Methods", WO/2012/019136 titled "Injector Apparatus and Method for Drug Delivery", WO/2013/040247 titled "Fluid Exchange Apparatus and Methods" (ForSight Vision4, Inc.).

[0138] Additional non-limiting examples of how to deliver the active compounds are provided in WO/2015/085251 titled "Intracameral Implant for Treatment of an Ocular Condition" (Envisia Therapeutics, Inc.); WO/2011/008737 titled "Engineered Aerosol Particles, and Associated Methods", WO/2013/082111 titled "Geometrically Engineered Particles and Methods for Modulating Macrophage or Immune Responses", WO/2009/132265 titled "Degradable compounds and methods of use thereof, particularly with particle replication in non-wetting templates", WO/2010/099321 titled "Interventional drug delivery system and associated methods", WO/2008/100304 titled "Polymer particle composite having high fidelity order, size, and shape particles", WO/2007/024323 titled "Nanoparticle fabrication methods, systems, and materials" (Liquidia Technologies, Inc. and the University of North Carolina at Chapel Hill); WO/2010/009087 titled "Iontophoretic Delivery of a Controlled-Release Formulation in the Eye", (Liquidia Technologies, Inc. and Eyegate Pharmaceuticals, Inc.) and WO/2009/132206 titled "Compositions and Methods for Intracellular Delivery and Release of Cargo", WO/2007/133808 titled "Nano-particles for cosmetic applications", WO/2007/056561 titled "Medical device, materials, and methods", WO/2010/065748 titled "Method for producing patterned materials", WO/2007/081876 titled "Nanostructured surfaces for biomedical/biomaterial applications and processes thereof" (Liquidia Technologies, Inc.).

[0139] Additional non-limiting examples of methods and devices for drug delivery to the eye include, for example, WO2011/106702 and US 8,889,193 titled "Sustained delivery of therapeutic agents to an eye compartment", WO2013/138343 and US 8,962,577 titled "Controlled release formulations for the delivery of HIF-1 inhibitors", WO/2013/138346 and US2013/0272994 titled "Non-Linear Multiblock Copolymer-Drug Conjugates for the Delivery of Active Agents", WO2005/072710 and US 8,957,034 titled "Drug and Gene Carrier Particles that Rapidly Move Through Mucus Barriers", WO2008/030557, US2010/0215580, US2013/0164343 titled "Compositions and Methods for Enhancing Transport Through Mucous", WO2012/061703, US2012/0121718, and US2013/0236556 titled "Compositions and Methods Relating to Reduced Mucoadhesion", WO2012/039979 and US2013/0183244 titled "Rapid Diffusion of Large Polymeric Nanoparticles in the Mammalian Brain", WO2012/109363 and US2013/0323313 titled "Mucus Penetrating Gene Carriers", WO 2013/090804 and US2014/0329913 titled "Nanoparticles with enhanced mucosal penetration or decreased inflammation", WO2013/110028 titled "Nanoparticle formulations with enhanced mucosal penetration", WO2013/166498 and US2015/0086484 titled "Lipid-based drug carriers for rapid penetration through mucus linings" (The Johns Hopkins University); WO2013/166385 titled "Pharmaceutical Nanoparticles Showing Improved Mucosal Transport", US2013/0323179 titled "Nanocrystals, Compositions, And Methods that Aid Particle Transport in Mucus" (The Johns Hopkins University and Kala Pharmaceuticals, Inc.); WO/2015/066444 titled "Compositions and methods for ophthalmic and/or other applications", WO/2014/020210 and WO/2013/166408 titled "Pharmaceutical nanoparticles showing improved mucosal transport" (Kala Pharmaceuticals, Inc.); US 9,022,970 titled "Ophthalmic injection device including dosage control device", WO/2011/153349 titled "Ophthalmic compositions comprising pbo-peo-pbo block copolymers", WO/2011/140203 titled "Stabilized ophthalmic galactomannan formulations", WO/2011/068955 titled "Ophthalmic emulsion", WO/2011/037908 titled "Injectable aqueous ophthalmic composition and method of use therefor", US2007/0149593 titled "Pharmaceutical Formulation for Delivery of Receptor Tyrosine Kinase Inhibiting (RTKi) Compounds to the Eye", US 8,632,809 titled "Water insoluble polymer matrix for drug delivery" (Alcon, Inc.).

[0140] Additional non-limiting examples of drug delivery devices and methods include, for example, US20090203709 titled "Pharmaceutical Dosage Form For Oral Administration Of Tyrosine Kinase Inhibitor" (Abbott Laboratories); US20050009910 titled "Delivery of an active drug to the posterior part of the eye via subconjunctival or periocular delivery of a prodrug", US 20130071349 titled "Biodegradable polymers for lowering intraocular pressure", US 8,481,069 titled "Tyrosine kinase microspheres", US 8,465,778 titled "Method of making tyrosine kinase microspheres", US 8,409,607 titled "Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods", US 8,512,738 and US 2014/0031408 titled "Biodegradable intravitreal tyrosine kinase implants", US 2014/0294986 titled "Microsphere Drug Delivery System for Sustained Intraocular Release", US 8,911,768 titled "Methods For Treating Retinopathy With Extended Therapeutic Effect" (Allergan, Inc.); US 6,495,164 titled "Preparation of injectable suspensions having improved injectability" (Alkermes Controlled Therapeutics, Inc.); WO 2014/047439 titled "Biodegradable Microcapsules Containing Filling Material" (Akina, Inc.); WO 2010/132664 titled "Compositions And Methods For Drug Delivery" (Baxter International Inc. Baxter Healthcare SA); US20120052041 titled "Polymeric nanoparticles with enhanced drugloading and methods of use thereof" (The Brigham and Women's Hospital, Inc.); US20140178475, US20140248358, and US20140249158 titled "Therapeutic Nanoparticles Comprising a Therapeutic Agent and Methods of Making and Using Same" (BIND Therapeutics, Inc.); US 5,869,103 titled "Polymer microparticles for drug delivery" (Danbiosyst UK Ltd.); US 8628801 titled "Pegylated Nanoparticles" (Universidad de Navarra); US2014/0107025 titled "Ocular drug delivery system" (Jade Therapeutics, LLC); US 6,287,588 titled "Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof", US 6,589,549 titled "Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles" (Macromed, Inc.); US 6,007,845 and US

5,578,325 titled "Nanoparticles and microparticles of non-linear hydrophilichydrophobic multiblock copolymers" (Massachusetts Institute of Technology); US20040234611, US20080305172, US20120269894, and US20130122064 titled "Ophthalmic depot formulations for periocular or subconjunctival administration (Novartis Ag); US 6,413,539 titled "Block polymer" (Poly-Med, Inc.); US 20070071756 titled "Delivery of an agent to ameliorate inflammation" (Peyman); US 20080166411 titled "Injectable Depot Formulations And Methods For Providing Sustained Release Of Poorly Soluble Drugs Comprising Nanoparticles" (Pfizer, Inc.); US 6,706,289 titled "Methods and compositions for enhanced delivery of bioactive molecules" (PR Pharmaceuticals, Inc.); and US 8,663,674 titled "Microparticle containing matrices for drug delivery" (Surmodics).

USES OF ACTIVE COMPOUNDS FOR TREATMENT OF SELECTED DISORDERS

[0141] The references to the methods of treatment by therapy or surgery or in vivo diagnostic methods herein are to be interpreted as references to compounds, pharmaceutical compositions, combinations and/or medicaments for use in those methods.

[0142] In one aspect, an effective amount of an active compound or its salt or composition as described herein is used to treat a medical disorder which is an inflammatory or immune condition, a disorder mediated by the complement cascade (including a dysfunctional cascade) including a complement factor D-related disorder or alternative complement pathway-related disorder, a disorder or abnormality of a cell that adversely affects the ability of the cell to engage in or respond to normal complement activity, or an undesired complement-mediated response to a medical treatment, such as surgery or other medical procedure or a pharmaceutical or biopharmaceutical drug administration, a blood transfusion, or other allogenic tissue or fluid administration.

[0143] In one embodiment, the disorder is selected from fatty liver and conditions stemming from fatty liver, such as nonalcoholic steatohepatitis (NASH), liver inflammation, cirrhosis and liver failure. In one embodiment of the present invention, a method is provided for treating fatty liver disease in a host by administering an effective amount of an active compound or its salt or composition as described herein.

[0144] In another embodiment, an active compound or its salt or composition as described herein is used to modulate an immune response prior to or during surgery or other medical procedure. One non-limiting example is use in connection with acute or chronic graft versus host disease, which is a common complication as a result of allogeneic tissue transplant, and can also occur as a result of a blood transfusion.

[0145] In one embodiment, the present invention provides a method of treating or preventing dermatomyositis by administering to a subject in need thereof an effective amount of an active compound or its salt or composition as described herein.

[0146] In one embodiment, the present invention provides a method of treating or preventing amyotrophic lateral sclerosis by administering to a subject in need thereof an effective amount of an active compound or its salt or composition as described herein.

[0147] In one embodiment, the present invention provides a method of treating or preventing abdominal aortic aneurysm, hemodialysis complications, hemolytic anemia, or hemodialysis by administering to a subject in need thereof an effective amount of an active compound or its salt or composition as described herein.

[0148] In another embodiment, a method is provided for the treatment or prevention of cytokine or inflammatory reactions in response to the administration of pharmaceutical or biotherapeutic (e.g. CAR T-cell therapy or monoclonal antibody therapy) in a host by administering an effective amount of an active compound or its salt or composition as described herein. Various types of cytokine or inflammatory reactions may occur in response to a number of factors, such as the administrations of biotherapeutics. In one embodiment, the cytokine or inflammatory reaction is cytokine release syndrome. In one embodiment, the cytokine or inflammatory reaction is tumor lysis syndrome (which also leads to cytokine release). Symptoms of cytokine release syndrome range from fever, headache, and skin rashes to bronchospasm, hypotension and even cardiac arrest. Severe cytokine release syndrome is described as cytokine storm, and can be fatal.

[0149] Fatal cytokine storms have been observed in response to infusion with several monoclonal antibody therapeutics. See, Abramowicz D, et al. "Release of tumor necrosis factor, interleukin-2, and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients" *Transplantation* (1989) 47(4):606-8; Chatenoud L, et al. "In vivo cell activation following OKT3 administration. Systemic cytokine release and modulation by corticosteroids" *Transplantation* (1990) 49(4):697-702; and Lim LC, Koh LP, and Tan P. "Fatal cytokine release syndrome with chimeric anti-CD20 monoclonal antibody rituximab in a 71-year-old patient with chronic lymphocytic leukemia" *J. Clin Oncol.* (1999) 17(6):1962-3.

[0150] Also contemplated herein, is the use of an active compound or its salt or composition as described herein to mediate an adverse immune response in patients receiving bi-specific T-cell engagers (BiTE). A bi-specific T-cell engager directs T-cells to target and bind with a specific antigen on the surface of a cancer cell. For example, Blinatumomab (Amgen), a BiTE has recently been approved as a second line therapy in Philadelphia chromosome-negative relapsed or refractory acute lymphoblastic leukemia. Blinatumomab is given by continuous intravenous infusion in 4-week cycles. The

use of BiTE agents has been associated with adverse immune responses, including cytokine release syndrome. The most significantly elevated cytokines in the CRS associated with ACT include IL-10, IL-6, and IFN- γ (Klinger et al., Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. *Blood* (2012) 119:6226-6233).

[0151] In another embodiment, the disorder is episcleritis, idiopathic episcleritis, anterior episcleritis, or posterior episcleritis. In one embodiment, the disorder is idiopathic anterior uveitis, HLA-B27 related uveitis, herpetic keratouveitis, Posner Schlossman syndrome, Fuch's heterochromic iridocyclitis, or cytomegalovirus anterior uveitis.

[0152] In one embodiment, the present invention provides a method of treating or preventing a C3 glomerulopathy by administering to a subject in need thereof an effective amount of an active compound or its salt or composition as described herein. In one embodiment, the disorder is selected from dense deposit disease (DDD) and C3 glomerulonephritis (C3GN).

[0153] In one embodiment, the present invention provides a method of treating or preventing a IC-MPGN by administering to a subject in need thereof an effective amount of an active compound or its salt or composition as described herein.

[0154] In one embodiment, the present invention provides a method of treating or preventing a paroxysmal nocturnal hemoglobinuria (PNH) by administering to a subject in need thereof an effective amount of an active compound or its salt or composition as described herein.

[0155] In one embodiment, the present invention provides a method of treating or preventing age-related macular degeneration (AMD) by administering to a subject in need thereof an effective amount of an active compound or its salt or composition as described herein.

[0156] In one embodiment, the present invention provides a method of treating or preventing rheumatoid arthritis by administering to a subject in need thereof an effective amount of an active compound or its salt or composition as described herein.

[0157] In one embodiment, the present invention provides a method of treating or preventing multiple sclerosis by administering to a subject in need thereof an effective amount of an active compound or its salt or composition as described herein.

[0158] In one embodiment, the present invention provides a method of treating or preventing myasthenia gravis by administering to a subject in need thereof an effective amount of an active compound or its salt or composition as described herein.

[0159] In one embodiment, the present invention provides a method of treating or preventing atypical hemolytic uremic syndrome (aHUS) by administering to a subject in need thereof an effective amount of an active compound or its salt or composition as described herein.

[0160] In one embodiment, the present invention provides a method of treating or preventing neuromyelitis optica (NMO) by administering to a subject in need thereof an effective amount of an active compound or its salt or composition as described herein.

[0161] In yet another embodiment, the present invention provides a method of treating or preventing a disorder as described below by administering to a subject in need thereof an effective amount of an active compound or its salt or composition as described herein, including:

vitritis, sarcoidosis, syphilis, tuberculosis, or Lyme disease; retinal vasculitis, Eales disease, tuberculosis, syphilis, or toxoplasmosis; neuroretinitis, viral retinitis, or acute retinal necrosis; varicella zoster virus, herpes simplex virus, cytomegalovirus, Epstein-Barr virus, lichen planus, or Dengue-associated disease (e.g., hemorrhagic Dengue Fever); Masquerade syndrome, contact dermatitis, trauma induced inflammation, UVB induced inflammation, eczema, granuloma annulare, or acne.

[0162] In an additional embodiment, the disorder is selected from: acute myocardial infarction, aneurysm, cardiopulmonary bypass, dilated cardiomyopathy, complement activation during cardiopulmonary bypass operations, coronary artery disease, restenosis following stent placement, or percutaneous transluminal coronary angioplasty (PTCA); antibody-mediated transplant rejection, anaphylactic shock, anaphylaxis, allogeneic transplant, humoral and vascular transplant rejection, graft dysfunction, graft-versus-host disease, Graves' disease, adverse drug reactions, or chronic graft vasculopathy; allergic bronchopulmonary aspergillosis, allergic neuritis, drug allergy, radiation-induced lung injury, eosinophilic pneumonia, radiographic contrast media allergy, bronchiolitis obliterans, or interstitial pneumonia; parkinsonism-dementia complex, sporadic frontotemporal dementia, frontotemporal dementia with Parkinsonism linked to chromosome 17, frontotemporal lobar degeneration, tangle only dementia, cerebral amyloid angiopathy, cerebrovascular disorder, certain forms of frontotemporal dementia, chronic traumatic encephalopathy (CTE), PD with dementia (PDD), argyrophilic grain dementia, dementia pugilistica, dementia with Lewy Bodies (DLB), or multi-infarct dementia; Creutzfeldt-Jakob disease, Huntington's disease, multifocal motor neuropathy (MMN), prion protein cerebral amyloid angiopathy, polymyositis, postencephalitic parkinsonism, subacute sclerosing panencephalitis, non-Guamanian motor neuron

disease with neurofibrillary tangles, neural regeneration, or diffuse neurofibrillary tangles with calcification.

[0163] In one embodiment, the disorder is selected from: atopic dermatitis, dermatitis, dermatomyositis bullous pemphigoid, scleroderma, sclerodermatomyositis, psoriatic arthritis, pemphigus vulgaris, Discoid lupus erythematosus, cutaneous lupus, chilblain lupus erythematosus, or lupus erythematosus-lichen planus overlap syndrome; cryoglobulinemic vasculitis, mesenteric/enteric vascular disorder, peripheral vascular disorder, antineutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV), IL-2 induced vascular leakage syndrome, or immune complex vasculitis; angioedema, low platelets (HELLP) syndrome, sickle cell disease, platelet refractoriness, red cell casts, or typical or infectious hemolytic uremic syndrome (tHUS); hematuria, hemorrhagic shock, drug-induced thrombocytopenia, autoimmune hemolytic anemia (AIHA), azotemia, blood vessel and/or lymph vessel inflammation, rotational atherectomy, or delayed hemolytic transfusion reaction; British type amyloid angiopathy, Buerger's disease, bullous pemphigoid, C1q nephropathy, cancer, or catastrophic antiphospholipid syndrome.

[0164] In another embodiment, the disorder is selected from: wet (exudative) AMD, dry (non-exudative) AMD, choroidretinal degeneration, choroidal neovascularization (CNV), choroiditis, loss of RPE function, loss of vision (including loss of visual acuity or visual field), loss of vision from AMD, retinal damage in response to light exposure, retinal degeneration, retinal detachment, retinal dysfunction, retinal neovascularization (RNV), retinopathy of prematurity, pathological myopia, or RPE degeneration; pseudophakic bullous keratopathy, symptomatic macular degeneration related disorder, optic nerve degeneration, photoreceptor degeneration, cone degeneration, loss of photoreceptor cells, pars planitis, scleritis, proliferative vitreoretinopathy, or formation of ocular drusen; chronic urticaria, Churg-Strauss syndrome, cold agglutinin disease (CAD), corticobasal degeneration (CBD), cryoglobulinemia, cyclitis, damage of the Bruch's membrane, Degos disease, diabetic angiopathy, elevated liver enzymes, endotoxemia, epidermolysis bullosa, or epidermolysis bullosa acquisita; essential mixed cryoglobulinemia, excessive blood urea nitrogen-BUN, focal segmental glomerulosclerosis, Gerstmann-Straussler-Scheinker disease, giant cell arteritis, gout, Hallervorden-Spatz disease, Hashimoto's thyroiditis, Henoch-Schonlein purpura nephritis, or abnormal urinary sediments; hepatitis, hepatitis A, hepatitis B, hepatitis C or human immunodeficiency virus (HIV), a viral infection more generally, for example selected from Flaviviridae, Retroviruses, Coronaviridae, Poxviridae, Adenoviridae, Herpesviridae, Caliciviridae, Reoviridae, Picornaviridae, Togaviridae, Orthomyxoviridae, Rhabdoviridae, or Hepadnaviridae; Neisseria meningitidis, shiga toxin E. coli-related hemolytic uremic syndrome (STEC-HUS), hemolytic uremic syndrome (HUS); Streptococcus, or poststreptococcal glomerulonephritis.

[0165] In a further embodiment, the disorder is selected from: hyperlipidemia, hypertension, hypoalbuminemia, hypobolemic shock, hypocomplementemic urticarial vasculitis syndrome, hypophosphatosis, hypovolemic shock, idiopathic pneumonia syndrome, or idiopathic pulmonary fibrosis; inclusion body myositis, intestinal ischemia, iridocyclitis, iritis, juvenile chronic arthritis, Kawasaki's disease (arteritis), or lipiduria; membranoproliferative glomerulonephritis (MPGN) I, microscopic polyangiitis, mixed cryoglobulinemia, molybdenum cofactor deficiency (MoCD) type A, pancreatitis, panniculitis, Pick's disease, polyarteritis nodosa (PAN), progressive subcortical gliosis, proteinuria, reduced glomerular filtration rate (GFR), or renovascular disorder; multiple organ failure, multiple system atrophy (MSA), myotonic dystrophy, Niemann-Pick disease type C, chronic demyelinating diseases, or progressive supranuclear palsy; spinal cord injury, spinal muscular atrophy, spondyloarthropathies, Reiter's syndrome, spontaneous fetal loss, recurrent fetal loss, pre-eclampsia, synucleinopathy, Takayasu's arteritis, post-partum thyroiditis, thyroiditis, Type I cryoglobulinemia, Type II mixed cryoglobulinemia, Type III mixed cryoglobulinemia, ulcerative colitis, uremia, urticaria, venous gas embolus (VGE), or Wegener's granulomatosis; von Hippel-Lindau disease, histoplasmosis of the eye, hard drusen, soft drusen, pigment clumping, or photoreceptor and/or retinal pigmented epithelia (RPE) loss.

In one embodiment, an active compound or its salt or composition as described herein is useful for treating or preventing a disorder selected from autoimmune oophoritis, endometriosis, autoimmune orchitis, Ord's thyroiditis, autoimmune enteropathy, coeliac disease, Hashimoto's encephalopathy, antiphospholipid syndrome (APLS) (Hughes syndrome), aplastic anemia, autoimmune lymphoproliferative syndrome (Canale-Smith syndrome), autoimmune neutropenia, Evans syndrome, pernicious anemia, pure red cell aplasia, thrombocytopenia, adipose dolorosa (Dercum's disease), adult onset Still's disease, ankylosing spondylitis, CREST syndrome, drug-induced lupus, eosinophilic fasciitis (Shulman's syndrome), Felty syndrome, IgG4-related disease, mixed connective tissue disease (MCTD), palindromic rheumatism (Hench-Rosenberg syndrome), Parry-Romberg syndrome, Parsonage-Turner syndrome, relapsing polychondritis (Meyenburg-Altherr-Uehlinger syndrome), retroperitoneal fibrosis, rheumatic fever, Schnitzler syndrome, fibromyalgia, neuromyotonia (Isaac's disease), paraneoplastic degeneration, autoimmune inner ear disease, Meniere's disease, interstitial cystitis, autoimmune pancreatitis, zika virus-related disorders, chikungunya virus-related disorders, subacute bacterial endocarditis (SBE), IgA nephropathy, IgA vasculitis, polymyalgia rheumatic, rheumatoid vasculitis, alopecia areata, autoimmune progesterone dermatitis, dermatitis herpetiformis, erythema nodosum, gestational pemphigoid, hidradenitis suppurativa, lichen sclerosus, linear IgA disease (LAD), morphea, myositis, pityriasis lichenoides et varioliformis acuta, vitiligo post-myocardial infarction syndrome (Dressler's syndrome), post-pericardiotomy syndrome, autoimmune retinopathy, Cogan syndrome, Graves ophthalmopathy, ligneous conjunctivitis, Mooren's ulcer, opsoclonus myoclonus syndrome, optic neuritis, retinocochleocerebral vasculopathy (Susac's syndrome), sympathetic ophthalmia, Tolosa-Hunt syndrome, interstitial lung disease, antisynthetase syndrome, Addison's disease, autoimmune polyendo-

crine syndrome (APS) type I, autoimmune polyendocrine syndrome (APS) type II, autoimmune polyendocrine syndrome (APS) type III, disseminated sclerosis (multiple sclerosis, pattern II), rapidly progressing glomerulonephritis (RPGN), juvenile rheumatoid arthritis, enthesitis-related arthritis, reactive arthritis (Reiter's syndrome), autoimmune hepatitis or lupoid hepatitis, primary biliary cirrhosis (PBS), primary sclerosing cholangitis, microscopic colitis, latent lupus (undifferentiated connective tissue disease (UCTD)), acute disseminated encephalomyelitis (ADEM), acute motor axonal neuropathy, anti-n-methyl-D-aspartate receptor encephalitis, Balo concentric sclerosis (Schilders disease), Bickerstaff's encephalitis, chronic inflammatory demyelinating polyneuropathy, idiopathic inflammatory demyelinating disease, Lambert-Eaton myasthenic syndrome, Oshtoran syndrome, pediatric autoimmune neuropsychiatric disorder associated with streptococcus (PANDAS), progressive inflammatory neuropathy, restless leg syndrome, stiff person syndrome, Sydenhem syndrome, transverse myelitis, lupus vasculitis, leukocytoclastic vasculitis, Microscopic Polyangiitis, polymyositis or ischemic-reperfusion injury of the eye.

[0166] Examples of eye disorders that may be treated according to the compositions and methods disclosed herein include amoebic keratitis, fungal keratitis, bacterial keratitis, viral keratitis, onchocercal keratitis, bacterial keratoconjunctivitis, viral keratoconjunctivitis, corneal dystrophic diseases, Fuchs' endothelial dystrophy, Sjogren's syndrome, Stevens-Johnson syndrome, autoimmune dry eye diseases, environmental dry eye diseases, corneal neovascularization diseases, post-corneal transplant rejection prophylaxis and treatment, autoimmune uveitis, infectious uveitis, posterior uveitis (including toxoplasmosis), pan-uveitis, an inflammatory disease of the vitreous or retina, endophthalmitis prophylaxis and treatment, macular edema, macular degeneration, age related macular degeneration, proliferative and non-proliferative diabetic retinopathy, hypertensive retinopathy, an autoimmune disease of the retina, primary and metastatic intraocular melanoma, other intraocular metastatic tumors, open angle glaucoma, closed angle glaucoma, pigmentary glaucoma and combinations thereof.

[0167] In a further embodiment, the disorder is selected from glaucoma, diabetic retinopathy, blistering cutaneous diseases (including bullous pemphigoid, pemphigus, and epidermolysis bullosa), ocular cicatricial pemphigoid, uveitis, adult macular degeneration, diabetic retinopathy retinitis pigmentosa, macular edema, diabetic macular edema, Behcet's uveitis, multifocal choroiditis, Vogt-Koyangi-Harada syndrome, intermediate uveitis, birdshot retino-choroiditis, sympathetic ophthalmia, ocular cicatricial pemphigoid, ocular pemphigus, nonarteritic ischemic optic neuropathy, postoperative inflammation, and retinal vein occlusion, or central retinal vein occlusion (CVRO).

[0168] In some embodiments, complement mediated diseases include ophthalmic diseases (including early or neovascular age-related macular degeneration and geographic atrophy), autoimmune diseases (including arthritis, rheumatoid arthritis), respiratory diseases, cardiovascular diseases. In other embodiments, the compounds of the invention are suitable for use in the treatment of diseases and disorders associated with fatty acid metabolism, including obesity and other metabolic disorders.

[0169] Disorders that may be treated or prevented by an active compound or its salt or composition as described herein also include, but are not limited to: hereditary angioedema, capillary leak syndrome, hemolytic uremic syndrome (HUS), neurological disorders, Guillain Barre Syndrome, diseases of the central nervous system and other neurodegenerative conditions, glomerulonephritis (including membrane proliferative glomerulonephritis), SLE nephritis, proliferative nephritis, liver fibrosis, tissue regeneration and neural regeneration, or Barraquer-Simons Syndrome; inflammatory effects of sepsis, systemic inflammatory response syndrome (SIRS), disorders of inappropriate or undesirable complement activation, interleukin-2 induced toxicity during IL-2 therapy, inflammatory disorders, inflammation of autoimmune diseases, system lupus erythematosus (SLE), lupus nephritides, arthritis, immune complex disorders and autoimmune diseases, systemic lupus, or lupus erythematosus; ischemia/ reperfusion injury (I/R injury), myocardial infarction, myocarditis, post-ischemic reperfusion conditions, balloon angioplasty, atherosclerosis, post-pump syndrome in cardiopulmonary bypass or renal bypass, renal ischemia, mesenteric artery reperfusion after aortic reconstruction, antiphospholipid syndrome, autoimmune heart disease, ischemia-reperfusion injuries, obesity, or diabetes; Alzheimer's dementia, stroke, schizophrenia, traumatic brain injury, trauma, Parkinson's disease, epilepsy, transplant rejection, prevention of fetal loss, biomaterial reactions (e.g. in hemodialysis, implants), hyperacute allograft rejection, xenograft rejection, transplantation, psoriasis, burn injury, thermal injury including burns or frostbite, or crush injury; asthma, allergy, acute respiratory distress syndrome (ARDS), cystic fibrosis, adult respiratory distress syndrome, dyspnea, hemoptysis, chronic obstructive pulmonary disease (COPD), emphysema, pulmonary embolisms and infarcts, pneumonia, fibrogenic dust diseases, inert dusts and minerals (e.g., silicon, coal dust, beryllium, and asbestos), pulmonary fibrosis, organic dust diseases, chemical injury (due to irritant gases and chemicals, e.g., chlorine, phosgene, sulfur dioxide, hydrogen sulfide, nitrogen dioxide, ammonia, and hydrochloric acid), smoke injury, thermal injury (e.g., burn, freeze), bronchoconstriction, hypersensitivity pneumonitis, parasitic diseases, Goodpasture's Syndrome (anti-glomerular basement membrane nephritis), pulmonary vasculitis, Pauci-immune vasculitis, or immune complex-associated inflammation.

[0170] In one embodiment, a method for the treatment of sickle cell in a host is provided that includes the administration of an effective amount of an active compound or its salt or composition as described herein. In one embodiment, a method for the treatment of immunothrombocytopenic purpura (ITP), thrombotic thrombocytopenic purpura (TTP), or idiopathic thrombocytopenic purpura (ITP) in a host is provided that includes the administration of an effective amount of an active

compound or its salt or composition as described herein. In one embodiment, a method for the treatment of ANCA-vasculitis in a host is provided that includes the administration of an effective amount of an active compound or its salt or composition as described herein. In one embodiment, a method for the treatment of IgA nephropathy in a host is provided that includes the administration of an effective amount of an active compound or its salt or composition as described herein.

In one embodiment, a method for the treatment of rapidly progressing glomerulonephritis (RPGN), in a host is provided that includes the administration of an effective amount of an active compound or its salt or composition as described herein. In one embodiment, a method for the treatment of lupus nephritis, in a host is provided that includes the administration of an effective amount of an active compound or its salt or composition as described herein. In one embodiment, a method for the treatment of hemorrhagic dengue fever, in a host is provided that includes the administration of an effective amount of an active compound or its salt or composition as described herein.

[0171] In an additional alternative embodiment, an active compound or its salt or composition as described herein is used in the treatment of an autoimmune disorder.

The complement pathway enhances the ability of antibodies and phagocytic cells to clear microbes and damaged cells from the body. It is part of the innate immune system and in healthy individuals is an essential process. Inhibiting the complement pathway will decrease the body's immune system response. Therefore, it is an object of the present invention to treat autoimmune disorders by administering an effective dose of an active compound or its salt or composition as described herein to a subject in need thereof.

[0172] In one embodiment the autoimmune disorder is caused by activity of the complement system. In one embodiment the autoimmune disorder is caused by activity of the alternative complement pathway. In one embodiment the autoimmune disorder is caused by activity of the classical complement pathway. In another embodiment the autoimmune disorder is caused by a mechanism of action that is not directly related to the complement system, such as the over-proliferation of T-lymphocytes or the over-production of cytokines.

Non-limiting examples of autoimmune disorders include: lupus, allograft rejection, autoimmune thyroid diseases (such as Graves' disease and Hashimoto's thyroiditis), autoimmune uveoretinitis, giant cell arteritis, inflammatory bowel diseases (including Crohn's disease, ulcerative colitis, regional enteritis, granulomatous enteritis, distal ileitis, regional ileitis, and terminal ileitis), diabetes, multiple sclerosis, pernicious anemia, psoriasis, rheumatoid arthritis, sarcoidosis, and scleroderma.

[0173] In one embodiment, an active compound or its salt or composition as described herein is used in the treatment of lupus. Non-limiting examples of lupus include lupus erythematosus, cutaneous lupus, discoid lupus erythematosus, chilblain lupus erythematosus, or lupus erythematosus-lichen planus overlap syndrome.

[0174] Lupus erythematosus is a general category of disease that includes both systemic and cutaneous disorders. The systemic form of the disease can have cutaneous as well as systemic manifestations. However, there are also forms of the disease that are only cutaneous without systemic involvement. For example, SLE is an inflammatory disorder of unknown etiology that occurs predominantly in women, and is characterized by articular symptoms, butterfly erythema, recurrent pleurisy, pericarditis, generalized adenopathy, splenomegaly, as well as CNS involvement and progressive renal failure. The sera of most patients (over 98%) contain antinuclear antibodies, including anti-DNA antibodies. High titers of anti-DNA antibodies are essentially specific for SLE. Conventional treatment for this disease has been the administration of corticosteroids or immunosuppressants.

[0175] There are three forms of cutaneous lupus: chronic cutaneous lupus (also known as discoid lupus erythematosus or DLE), subacute cutaneous lupus, and acute cutaneous lupus. DLE is a disfiguring chronic disorder primarily affecting the skin with sharply circumscribed macules and plaques that display erythema, follicular plugging, scales, telangiectasia and atrophy. The condition is often precipitated by sun exposure, and the early lesions are erythematous, round scaling papules that are 5 to 10 mm in diameter and display follicular plugging. DLE lesions appear most commonly on the cheeks, nose, scalp, and ears, but they may also be generalized over the upper portion of the trunk, extensor surfaces of the extremities, and on the mucous membranes of the mouth. If left untreated, the central lesion atrophies and leaves a scar. Unlike SLE, antibodies against double-stranded DNA (e.g., DNA-binding test) are almost invariably absent in DLE.

[0176] Multiple Sclerosis is an autoimmune demyelinating disorder that is believed to be T lymphocyte dependent. MS generally exhibits a relapsing-remitting course or a chronic progressive course. The etiology of MS is unknown, however, viral infections, genetic predisposition, environment, and autoimmunity all appear to contribute to the disorder. Lesions in MS patients contain infiltrates of predominantly T lymphocyte mediated microglial cells and infiltrating macrophages. CD4+ T lymphocytes are the predominant cell type present at these lesions. The hallmark of the MS lesion is plaque, an area of demyelination sharply demarcated from the usual white matter seen in MRI scans. Histological appearance of MS plaques varies with different stages of the disease. In active lesions, the blood-brain barrier is damaged, thereby permitting extravasation of serum proteins into extracellular spaces. Inflammatory cells can be seen in perivascular cuffs and throughout white matter. CD4+ T-cells, especially Th1, accumulate around postcapillary venules at the edge of the plaque and are also scattered in the white matter. In active lesions, up-regulation of adhesion molecules and markers of lymphocyte and monocyte activation, such as IL2-R and CD26 have also been observed. Demyelination in active lesions is not accompanied by destruction of oligodendrocytes. In contrast, during chronic phases of the disease, lesions are

characterized by a loss of oligodendrocytes and hence, the presence of myelin oligodendrocyte glycoprotein (MOG) antibodies in the blood.

[0177] Diabetes can refer to either type 1 or type 2 diabetes. In one embodiment an active compound or its salt or composition as described herein is provided at an effective dose to treat a patient with type 1 diabetes. In one embodiment an active compound or its salt or composition as described herein is provided at an effective dose to treat a patient with type 2 diabetes.

Type 1 diabetes is an autoimmune disease. An autoimmune disease results when the body's system for fighting infection (the immune system) attacks a part of the body. In the case of diabetes type 1, the pancreas then produces little or no insulin.

COMBINATION THERAPY

[0178] In one embodiment an active compound or its salt or composition as described herein may be provided in combination or alternation with or preceded by, concomitant with or followed by, an effective amount of at least one additional therapeutic agent, for example, for treatment of a disorder listed herein. Non-limiting examples of second active agents for such combination therapy are provided below.

[0179] In one embodiment, an active compound or its salt or composition as described herein may be provided in combination or alternation with at least one additional inhibitor of the complement system or a second active compound with a different biological mechanism of action. In the description below and herein generally, whenever any of the terms referring to an active compound or its salt or composition as described herein are used, it should be understood that pharmaceutically acceptable salts, or compositions are considered included, unless otherwise stated or inconsistent with the text.

[0180] In non-limiting embodiments, an active compound or its salt or composition as described herein may be provided together with a protease inhibitor, a soluble complement regulator, a therapeutic antibody (monoclonal or polyclonal), complement component inhibitor, receptor agonist, or siRNA.

[0181] In other embodiments, an active compound described herein is administered in combination or alternation with an antibody against tumor necrosis factor (TNF), including but not limited to infliximab (Remicade), adalimumab, certolizumab, golimumab, or a receptor fusion protein such as etanercept (Enbrel).

[0182] In another embodiment, an active compound as described herein can be administered in combination or alternation with an anti-CD20 antibody, including but not limited to rituximab (Rituxan), adalimumab (Humira), ofatumumab (Arzerra), tositumomab (Bexxar), obinutuzumab (Gazyva), or ibritumomab (Zevalin).

[0183] In an alternative embodiment, an active compound as described herein can be administered in combination or alternation with an anti-IL6 antibody, including but not limited to tocilizumab (Actemra) and siltuximab (Sylvant).

[0184] In an alternative embodiment, an active compound as described herein can be administered in combination or alternation with an IL17 inhibitor, including but not limited to secukinumab (Cosentyx).

[0185] In an alternative embodiment, an active compound as described herein can be administered in combination or alternation with a p40 (IL12/IL23) inhibitor, including but not limited to ustekinumab (Stelara).

[0186] In an alternative embodiment, an active compound as described herein can be administered in combination or alternation with an IL23 inhibitor, including but not limited to risankizumab.

[0187] In an alternative embodiment, an active compound as described herein can be administered in combination or alternation with an anti-interferon α antibody, for example but not limited to sifalimumab.

[0188] In an alternative embodiment, an active compound as described herein can be administered in combination or alternation with a kinase inhibitor, for example but not limited to a JAK1/JAK3 inhibitor, for example but not limited to tofacitinib (Xeljanz). In an alternative embodiment, an active compound as described herein can be administered in combination or alternation with a JAK1/JAK2 inhibitor, for example but not limited to baricitinib.

[0189] In an alternative embodiment, an active compound as described herein can be administered in combination or alternation with an anti-VEGF agent, for example but not limited to: aflibercept (Eylea[®]; Regeneron Pharmaceuticals); ranibizumab (Lucentis[®]; Genentech and Novartis); pegaptanib (Macugen[®]; OSI Pharmaceuticals and Pfizer); bevacizumab (Avastin; Genentech/Roche); lapatinib (Tykerb); sunitinib (Sutent); axitinib (Inlyta); pazopanib; sorafenib (Nexavar); ponatinib (Inclusig); regorafenib (Stivarga); cabozantinib (Abometyx; Cometriq); vandetanib (Caprelsa); ramucirumab (Cyramza); lenvatinib (Lenvima); ziv-aflibercept (Zaltrap); cediranib (Recentin); anecortane acetate, squalamine lactate, and corticosteroids.

[0190] In another embodiment, an active compound as described herein can be administered in combination or alternation with an immune checkpoint inhibitor. Non-limiting examples of checkpoint inhibitors include anti-PD-1 or anti-PDL1 antibodies, for example, nivolumab (Opdivo), pembrolizumab (Keytruda), pidilizumab, AMP-224 (AstraZeneca and MedImmune), PF-06801591 (Pfizer), MEDI0680 (AstraZeneca), PDR001 (Novartis), REGN2810 (Regeneron), SHR-12-1 (Jiangsu Hengrui Medicine Company and Incyte Corporation), TSR-042 (Tesar), and the PD-L1/VISTA inhibitor CA-170 (Curis Inc.), atezolizumab, durvalumab, and KN035, or anti-CTLA4 antibodies, for example Ipilimumab,

Tremelimumab, AGEN1884 and AGEN2041 (Agenus).

[0191] Non-limiting examples of active agents that can be used in combination with active compounds described herein are:

Protease inhibitors: plasma-derived **C1-INH** concentrates, for example **Cetor**[®] (Sanquin), **Beriner-P**[®] (CSL Behring, Lev Pharma), and Cinryze[®]; recombinant human C1-inhibitors, for example Rhucin[®]; ritonavir (Norvir[®], Abbvie, Inc.);

Soluble complement regulators: **Soluble complement receptor 1 (TP10)** (Avant Immunotherapeutics); sCR1-sLe^x/TP-20 (Avant Immunotherapeutics); **MLN-2222 /CAB-2** (Millenium Pharmaceuticals); Mirococept (Inflazyme Pharmaceuticals);

Therapeutic antibodies: Eculizumab/Soliris (Alexion Pharmaceuticals); Pexelizumab (Alexion Pharmaceuticals); Ofatumumab (Genmab A/S); TNX-234 (Tanox); TNX-558 (Tanox); TA106 (Taligen Therapeutics); Neutrazumab (G2 Therapies); Anti-properdin (Novelmed Therapeutics); HuMax-CD38 (Genmab A/S);

Complement component inhibitors: Compstatin/POT-4 (Potentia Pharmaceuticals); ARC1905 (Archemix); 4(1MEW) APL-1, APL-2 (Appellis); CP40/AMY-101, PEG-Cp40 (Amyndas);

PDGF inhibitors: Sorafenib Tosylate; Imatinib Mesylate (STI571); Sunitinib Malate; Ponatinib (AP24534); Axitinib; Imatinib (STI571); Nintedanib (BIBF 1120); Pazopanib HCl (GW786034 HCl); Dovitinib (TKI-258, CHIR-258); Linifanib (ABT-869); Crenolanib (CP-868596); Masitinib (AB1010); Tivozanib (AV-951); Motesanib Diphosphate (AMG-706); Amuvatinib (MP-470); TSU-68 (SU6668, Orantinib); CP-673451; Ki8751; Telatinib; PP121; Pazopanib; KRN 633; Dovitinib (TKI-258) Dilactic Acid; MK-2461; Tyrphostin (AG 1296); Dovitinib (TKI258) Lactate; Sennoside B; Sunitinib; AZD2932; and Trapidil;

Anti-factor H or anti-factor B agents: Anti-FB siRNA (Alnylam); FCFD4514S (Genentech/Roche) SOMAmers for CFB and CFD (SomaLogic); TA106 (Alexion Pharmaceuticals); 5C6, and AMY-301 (Amyndas);

Complement C3 or CAP C3 Convertase targeting molecules: TT30 (CR2/CFH) (Alexion); TT32 (CR2/CR1) (Alexion Pharmaceuticals); Nafamostat (FUT-175, Futhan) (Torri Pharmaceuticals); Bikacimab, NM9308 (Novelmed); CVF, HC-1496 (InCode) ALXN1102/ALXN1103 (TT30) (Alexion Pharmaceuticals); rFH (Optherion); H17 C3 (C3b/iC3b) (EluSys Therapeutics); Mini-CFH (Amyndas) Mirococept (APT070); sCR1 (CDX-1135) (Celldex); CR1g/CFH; Anti-CR3, anti-MASP2, anti C1s, and anti-C1n molecules: Cynryze (ViroPharma/Baxter); TNT003 (True North); OMS721 (Omeros); OMS906 (Omeros); and Imprime PGG (Biothera);

Receptor agonists: PMX-53 (Peptech Ltd.); JPE-137 (Jerini); JSM-7717 (Jerini);

Others: Recombinant human MBL (rhMBL; Enzon Pharmaceuticals); Imides and glutarimide derivatives such as thalidomide, lenalidomide, pomalidomide; Additional non-limiting examples that can be used in combination or alternation with an active compound or its salt or composition as described herein include the following.

Non-limiting examples of potential therapeutics for combination therapy

Name	Target	Company	Class of Molecule
LFG316	C5	Novartis/Morphosys	Monoclonal antibody
4(1MEW)APL-1, APL-2	C3/C3b	Apellis	Compstatin Family
4(1MeW)POT-4	C3/C3b	Potentia	Compstatin Family
Anti-C5 siRNA	C5	Alnylam	Si-RNA
Anti-FB siRNA	CFB	Alnylam	SiRNA
ARC1005	C5	Novo Nordisk	Aptamers
ATA	C5	N.A.	Chemical
Coversin	C5	Volution Immuno-Pharmaceuticals	Small animal protein
CP40/AMY-101, PEG-Cp40	C3/C3b	Amyndas	Compstatin Family
CR1g/CFH	CAP C3 convertase	NA	CFH-based protein
Cynryze	C1n/C1s	ViroPharma/Baxter	Human purified protein
FCFD4514S	CFD	Genentech/Roche	Monoclonal antibody

(continued)

Non-limiting examples of potential therapeutics for combination therapy			
Name	Target	Company	Class of Molecule
H17	C3 (C3b/iC3b)	EluSys Therapeutics	Monoclonal antibody
Mini-CFH	CAP C3 convertase	Amyndas	CFH-based protein
Mirococept (APT070)	CAP and CCP C3	NA	CR1-based protein
Mubodine	C5	Adienne	Monoclonal antibody
RA101348	C5	Rapharma	Small molecule
sCR1 (CDX-1135)	CAP and CP C3	Celldex	CR1-based protein
SOBI002	C5	Swedish Orphan Biovitrum	Affibody
SOMAmers	C5	SomaLogic	Aptamers
SOMAmers	CFB and CFD	SomaLogic	Aptamers (SELEX)
TA106	CFB	Alexion Pharmaceuticals	Monoclonal antibody
TNT003	C1s	True North	Monoclonal antibody
TT30 (CR2/CFH)	CAP C3 convertase	Alexion	CFH-based protein
TT32 (CR2/CR1)	CAP and CCP C3	Alexion Pharmaceuticals	CR1-based protein
Nafamostat (FUT-175, Futhan)	Cl _s , CFD, other pro-teases	Torri Pharmaceuticals	Small molecule
OMS721	MASP-2	Omeros	Monoclonal antibody
OMS906	MASP-2	Omeros	Monoclonal antibody
Bikaciomab, NM9308	CFB	Novelmed	Monoclonal antibody
NM9401	Properdin	Novelmed	Monoclonal antibody
CVF, HC-1496	C3	InCode	Recombinant peptide
ALXN 1102/ALXN 1103 (TT30)	C3-conv, C3b	Alexion Pharmaceuticals	Regulator
rFH	C3-conv, C3b	Optherion	Regulator
5C6, AMY-301	CFH	Amyndas	Regulator
Erdigna	C5	Adienne Pharma	Antibody
ARC1905	C5	Ophtotech	Monoclonal Antibody
MEDI7814	C5/C5a	MedImmune	Monoclonal Antibody
NOX-D19	C5a	Noxxon	Aptamer (Spiegelmer)
IFX-1, CaCP29	C5a	InflaRx	Monoclonal Antibody
PMX53, PMX205	C5aR	Cephalon, Teva	Peptidomimetic
CCX168	C5aR	ChemoCentryx	Small molecule
ADC-1004	C5aR	Alligator Bioscience	Small molecule
Anti-C5aR-151, NN8209; Anti-C5aR-215, NN8210	C5aR	Novo Nordisk	Monoclonal Antibody
Imprime PGG	CR3	Biothera	Soluble beta-glucan
ANX005; ANX007	Cl _q	Annexon	Monoclonal Antibody
Lampalizumab	fD	Roche	Monoclonal Antibody
avacincaptad pegol	C5	Ophtotech	Aptamer
regenemab	C6	Regenesance	Monoclonal Antibody

(continued)

Non-limiting examples of potential therapeutics for combination therapy			
Name	Target	Company	Class of Molecule
BIVV020	C1s	Bioverativ	Monoclonal Antibody
PRO-02	C2	Broteio/Argen-x	Monoclonal Antibody
5C6, compsorbin	fH	Amyndas	Peptide
SOBI005	C5	Sobi	Protein
ISU305	C5	ISU ABXIS	Monoclonal Antibody
Mubodina	C5	Adienne	Monoclonal Antibody
IFX-2, IFX-3	C5a	InflaRx	Monoclonal Antibody
ALS-205	C5aR1	Alsonex	Peptide
DF2593A	C5aR1	Dompé	Small Molecule
IPH5401	C5aR1	Innate Pharma	Monoclonal Antibody
C6-LNA	C6	Regenesance	Oligonucleotide
SKY59	C5	Roche	Monoclonal Antibody
REGN3918	C5	Regeneron	Monoclonal Antibody
Aptamers to Factor D	fD	Vitrisa Therapeutics	Aptamer
CLG561	Properdin	Novartis	Monoclonal Antibody
Tesidolumab; LFG316	C5	Novartis and MorphoSys	Monoclonal Antibody

[0192] In one embodiment, an active compound or its salt or composition as described herein may be provided together with a compound that inhibits an enzyme that metabolizes an administered protease inhibitor. In one embodiment, a compound or salt may be provided together with ritonavir.

[0193] In one embodiment, an active compound or its salt or composition as described herein may be provided in combination with a complement C5 inhibitor or C5 convertase inhibitor. In another embodiment, an active compound or its salt or composition as described herein may be provided in combination with eculizumab, a monoclonal antibody directed to the complement factor C5 and manufactured and marketed by Alexion Pharmaceuticals under the tradename Soliris. Eculizumab has been approved by the U.S. FDA for the treatment of PNH and aHUS.

[0194] In one embodiment, an active compound or its salt or composition as described herein may be provided together with a compound that inhibits Complement Factor D. In one embodiment of the invention, an active compound or its salt or composition as described herein as described herein can be used in combination or alternation with a compound described in Biocryst Pharmaceuticals US Pat. No. 6,653,340 titled "Compounds useful in the complement, coagulate and kallikrein pathways and method for their preparation" describes fused bicyclic ring compounds that are potent inhibitors of Factor D; Novartis PCT patent publication WO2012/093101 titled "Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration" describes certain Factor D inhibitors; Novartis PCT patent publications WO2013/164802, WO2013/192345, WO2014/002051, WO2014/002052, WO2014/002053, WO2014/002054, WO2014/002057, WO2014/002058, WO2014/002059, WO2014/005150, WO2014/009833, WO2014/143638, WO2015/009616, WO2015/009977, WO2015/066241, Bristol-Myers Squibb PCT patent publication WO2004/045518 titled "Open chain prolyl urea-related modulators of androgen receptor function"; Japan Tobacco Inc. PCT patent publication WO1999/048492 titled "Amide derivatives and nociceptin antagonists"; Ferring B.V. and Yamanouchi Pharmaceutical Co. LTD. PCT patent publication WO1993/020099 titled "CCK and/or gastrin receptor ligands"; Alexion Pharmaceuticals PCT patent publication WO1995/029697 titled "Methods and compositions for the treatment of glomerulonephritis and other inflammatory diseases"; or Achillion Pharmaceuticals filed PCT Patent Application No. PCT/US2015/017523 and U.S. Patent Application No. 14/631,090 titled "Alkyne Compounds for Treatment of Complement Mediated Disorders"; PCT Patent Application No. PCT/US2015/017538 and U.S. Patent Application No. 14/631,233 titled "Amide Compounds for Treatment of Complement Mediated Disorders"; PCT Patent Application No. PCT/US2015/017554 and U.S. Patent Application No. 14/631,312 titled "Amino Compounds for Treatment of Complement Mediated Disorders"; PCT Patent Application No. PCT/US2015/017583 and U.S. Patent Application No. 14/631,440 titled "Carbamate, Ester, and Ketone Compounds for Treatment of Complement Mediated Disorders"; PCT Patent Application No. PCT/US2015/017593 and U.S. Patent Application No. 14/631,625 titled "Aryl, Heteroaryl, and Hetero-

cyclic Compounds for Treatment of Complement Mediated Disorders"; PCT Patent Application No. PCT/US2015/017597 and U.S. Patent Application No. 14/631,683 titled "Ether Compounds for Treatment of Complement Mediated Disorders"; PCT Patent Application No. PCT/US2015/017600 and U.S. Patent Application No. 14/631,785 titled "Phosphonate Compounds for Treatment of Complement Mediated Disorders"; and PCT Patent Application No. PCT/US2015/017609 and U.S. Patent Application No. 14/631,828 titled "Compounds for Treatment of Complement Mediated Disorders."

[0195] In one embodiment, an active compound or its salt or composition as described herein is administered in combination with an anti-inflammatory drug, antimicrobial agent, antiangiogenesis agent, immunosuppressant, antibody, steroid, ocular antihypertensive drug or combinations thereof. Examples of such agents include amikacin, anecortane acetate, anthracenedione, anthracycline, an azole, amphotericin B, bevacizumab, camptothecin, cefuroxime, chloramphenicol, chlorhexidine, chlorhexidine digluconate, clotrimazole, a clotrimazole cephalosporin, corticosteroids, dexamethasone, desamethasone, econazole, eftazidime, epipodophyllotoxin, fluconazole, flucytosine, fluoropyrimidines, fluoroquinolones, gatifloxacin, glycopeptides, imidazoles, itraconazole, ivermectin, ketoconazole, levofloxacin, macrolides, miconazole, miconazole nitrate, moxifloxacin, natamycin, neomycin, nystatin, ofloxacin, polyhexamethylene biguanide, prednisolone, prednisolone acetate, pegaptanib, platinum analogues, polymyxin B, propamidine isethionate, pyrimidine nucleoside, ranibizumab, squalamine lactate, sulfonamides, triamcinolone, triamcinolone acetonide, triazoles, vancomycin, anti-vascular endothelial growth factor (VEGF) agents, VEGF antibodies, VEGF antibody fragments, vinca alkaloid, timolol, betaxolol, travoprost, latanoprost, bimatoprost, brimonidine, dorzolamide, acetazolamide, pilocarpine, ciprofloxacin, azithromycin, gentamycin, tobramycin, cefazolin, voriconazole, gancyclovir, cidofovir, foscarnet, diclofenac, nepafenac, ketorolac, ibuprofen, indomethacin, fluoromethalone, rimexolone, anecortave, cyclosporine, methotrexate, tacrolimus, anti-PDGR molecule, and combinations thereof.

[0196] In one embodiment of the present invention, an active compound or its salt or composition as described herein can be administered in combination or alternation with at least one immunosuppressive agent. The immunosuppressive agent as non-limiting examples, may be a calcineurin inhibitor, e.g. a cyclosporin or an ascomycin, e.g. Cyclosporin A (NEORAL®), FK506 (tacrolimus), pimecrolimus, a mTOR inhibitor, e.g. rapamycin or a derivative thereof, e.g. Sirolimus (RAPAMUNE®), Everolimus (Certican®), temsirolimus, zotarolimus, biolimus-7, biolimus-9, a rapalog, e.g. ridaforolimus, azathioprine, campath 1H, a S1P receptor modulator, e.g. fingolimod or an analogue thereof, an anti IL-8 antibody, mycophenolic acid or a salt thereof, e.g. sodium salt thereof, e.g. Mycophenolate Mofetil (CELLCEPT®), OKT3 (ORTHOCLONE OKT3®), Prednisone, ATGAM®, THYMOGLOBULIN®, Brequinar Sodium, OKT4, T10B9.A-3A, 33B3.1, 15-deoxyspergualin, tresperimus, Leflunomide ARAVA®, CTLA4-Ig, anti-CD25, anti-IL2R, Basiliximab (SIMULECT®), Daclizumab (ZENAPAX®), mizoribine, methotrexate, dexamethasone, ISAtx-247, SDZ ASM 981 (pimecrolimus, Elidel®), CTLA4Ig (Abatacept), belatacept, LFA3Ig, etanercept (sold as Enbrel® by Immunex), adalimumab (Humira®), infliximab (Remicade®), an anti-LFA-1 antibody, natalizumab (Antegren®), Enlimomab, gavilimomab, antithymocyte immunoglobulin, siplizumab, Alefacept efalizumab, pentasa, mesalazine, asacol, codeine phosphate, benorylate, fenbufen, naprosyn, diclofenac, etodolac and indomethacin, tocilizumab (Actemra), siltuximab (Sylvant), secukibumab (Cosentyx), ustekinumab (Stelara), risankizumab, sifalimumab, aspirin and ibuprofen.

[0197] Examples of anti-inflammatory agents include methotrexate, dexamethasone, dexamethasone alcohol, dexamethasone sodium phosphate, fluromethalone acetate, fluromethalone alcohol, lotoprendol etabonate, medrysone, prednisolone acetate, prednisolone sodium phosphate, difluprednate, rimexolone, hydrocortisone, hydrocortisone acetate, lodoxamide tromethamine, aspirin, ibuprofen, suprofen, piroxicam, meloxicam, flubiprofen, naproxen, ketoprofen, tenoxicam, diclofenac sodium, ketotifen fumarate, diclofenac sodium, nepafenac, bromfenac, flurbiprofen sodium, suprofen, celecoxib, naproxen, rofecoxib, glucocorticoids, diclofenac, and any combination thereof. In one embodiment, an active compound or its salt or composition as described herein is combined with one or more non-steroidal anti-inflammatory drugs (NSAIDs) selected from naproxen sodium (Anaprox), celecoxib (Celebrex), sulindac (Clinoril), oxaprozin (Daypro), salsalate (Disalcid), diflunisal (Dolobid), piroxicam (Feldene), indomethacin (Indocin), etodolac (Lodine), meloxicam (Mobic), naproxen (Naprosyn), nabumetone (Relafen), ketorolac tromethamine (Toradol), naproxen/esomeprazole (Vimovo), and diclofenac (Voltaren), and combinations thereof.

[0198] In one embodiment, an active compound or its salt or composition as described herein is administered in combination or alteration with an omega-3 fatty acid or a peroxisome proliferator-activated receptor (PPARs) agonist. Omega-3 fatty acids are known to reduce serum triglycerides by inhibiting DGAT and by stimulating peroxisomal and mitochondrial beta oxidation. Two omega-3 fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have been found to have high affinity for both PPAR-alpha and PPAR-gamma. Marine oils, e.g., fish oils, are a good source of EPA and DHA, which have been found to regulate lipid metabolism. Omega-3 fatty acids have been found to have beneficial effects on the risk factors for cardiovascular diseases, especially mild hypertension, hypertriglyceridemia and on the coagulation factor VII phospholipid complex activity. Omega-3 fatty acids lower serum triglycerides, increase serum HDL-cholesterol, lower systolic and diastolic blood pressure and the pulse rate, and lower the activity of the blood coagulation factor VII-phospholipid complex. Further, omega-3 fatty acids seem to be well tolerated, without giving rise to any severe side effects. One such form of omega-3 fatty acid is a concentrate of omega-3, long chain, polyunsaturated fatty acids from fish oil containing DHA and EPA and is sold under the trademark Omacor®. Such a form of omega-3 fatty acid is

described, for example, in U.S. Patent Nos. 5,502,077, 5,656,667 and 5,698,594.

[0199] Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear hormone receptor superfamily ligand-activated transcription factors that are related to retinoid, steroid and thyroid hormone receptors. There are three distinct PPAR subtypes that are the products of different genes and are commonly designated PPAR-alpha, PPAR-beta/delta (or merely, delta) and PPAR-gamma. General classes of pharmacological agents that stimulate peroxisomal activity are known as PPAR agonists, e.g., PPAR-alpha agonists, PPAR-gamma agonists and PPAR-delta agonists. Some pharmacological agents are combinations of PPAR agonists, such as alpha/gamma agonists, etc., and some other pharmacological agents have dual agonist/antagonist activity. Fibrates such as fenofibrate, bezafibrate, clofibrate and gemfibrozil, are PPAR-alpha agonists and are used in patients to decrease lipoproteins rich in triglycerides, to increase HDL and to decrease atherogenic-dense LDL. Fibrates are typically orally administered to such patients. Fenofibrate or 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid, 1-methylethyl ester, has been known for many years as a medicinally active principle because of its efficacy in lowering blood triglyceride and cholesterol levels.

[0200] In one embodiment, the present invention provides a method of treating or preventing age-related macular degeneration (AMD) by administering to a subject in need thereof an effective amount of an active compound or its salt or composition as described herein in combination with an anti-VEGF agent. Non-limiting examples of anti-VEGF agents include, but are not limited to, aflibercept (Eylea®; Regeneron Pharmaceuticals); ranibizumab (Lucentis®: Genentech and Novartis); pegaptanib (Macugen®; OSI Pharmaceuticals and Pfizer); bevacizumab (Avastin; Genentech/Roche); lapatinib (Tykerb); sunitinib (Sutent); axitinib (Inlyta); pazopanib; sorafenib (Nexavar); ponatinib (Inclusig); regorafenib (Stivarga); Cabozantinib (Abometyx; Cometriq); vandetanib (Caprelsa); ramucirumab (Cyramza); lenvatinib (Lenvima); ziv-aflibercept (Zaltrap); cediranib (Recentin); anecortane acetate, squalamine lactate, and corticosteroids, including, but not limited to, triamcinolone acetonide.

[0201] In one embodiment, the present invention provides a method of treating or preventing age-related macular degeneration (AMD) by administering to a subject in need thereof an effective amount of an active compound or its salt or composition as described herein in combination with a complement C5 inhibitor, for example, a complement C5 inhibitor described herein and in the table above titled Non-limiting examples of potential therapeutics for combination therapy, including, but not limited to, eculizumab; LFG316 (Novartis/Morphosys); Anti-C5 siRNA (Alnylam); ARC1005 (Novo Nordisk); Coversin (Volusion Immuno-Pharmaceuticals); Mubodine (Adienne Pharma); RA101348 (Ra Pharma); SOBI002 (Swedish Orphan Biovitrum); SOMAmers (SomaLogic); Erdigna (Adienne Pharma); ARC1905 (Ophotech); MEDI7814 (MedImmune); NOX-D19 (Noxxon); IFX-1, CaCP29 (InflaRx); PMX53, PMX205 (Cephalon, Teva); CCX168 (ChemoCentryx); ADC-1004 (Alligator Bioscience); and Anti-C5aR-151, NN8209; Anti-C5aR-215, NN8210 (Novo Nordisk).

[0202] In one embodiment, the present invention provides a method of treating or preventing age-related macular degeneration (AMD) by administering to a subject in need thereof an effective amount of an active compound or its salt or composition as described herein in combination with anti-properidin agent, for example, an anti-properidin agent as described above, including but not limited to NM9401 (Novelmed).

[0203] In one embodiment, the present invention provides a method of treating or preventing age-related macular degeneration (AMD) by administering to a subject in need thereof an effective amount of an active compound or its salt or composition as described herein in combination with a complement C3 inhibitor for example, a complement C3 inhibitor described above, including, but not limited to, a compstatin or compstatin analogue, for example Compstatin/POT-4 (Potentia Pharmaceuticals); ARC1905 (Archemix); 4(1MEW)APL-1, APL-2 (Appelis); CP40/AMY-101, PEG-Cp40 (Amyndas) Complement C3 or CAP C3 Convertase targeting molecules: TT30 (CR2/CFH) (Alexion); TT32 (CR2/CR1) (Alexion Pharmaceuticals); Nafamostat (FUT-175, Futhan) (Torri Pharmaceuticals); Bikacimab, NM9308 (Novelmed); CVF, HC-1496 (InCode) ALXN1102/ALXN1103 (TT30) (Alexion Pharmaceuticals); rFH (Optherion); H17 C3 (C3b/iC3b) (EluSys Therapeutics); Mini-CFH (Amyndas) Mirococept (APT070); sCR1 (CDX-1135) (Celldex); and CRIg/CFH.

[0204] In one embodiment, the present invention provides a method of treating or preventing age-related macular degeneration (AMD) by administering to a subject in need thereof an effective amount of an active compound or its salt or composition as described herein in combination with an anti-factor H or anti-factor B agent selected from Anti-FB siRNA (Alnylam); FCFD4514S (Genentech/Roche) SOMAmers for CFB and CFD (SomaLogic); TA106 (Alexion Pharmaceuticals); 5C6, and AMY-301 (Amyndas).

[0205] In one embodiment, the present invention provides a method of treating or preventing age-related macular degeneration (AMD) by administering to a subject in need thereof an effective amount of an active compound or its salt or composition as described herein in combination with an anti-MASP2, anti-C1s or anti-CR3 molecules, for example, but not limited to: Cynryze (ViroPharma/Baxter); TNT003 (True North); OMS721 (Omeros); OMS906 (Omeros); and Imprime PGG (Biothera).

[0206] In one embodiment, the present invention provides a method of treating or preventing age-related macular degeneration (AMD) by administering to a subject in need thereof an effective amount of an active compound or its salt or composition as described herein in combination with an PDGF inhibitor, for example as described herein including but not limited to Sorafenib Tosylate; Imatinib Mesylate (STI571); Sunitinib Malate; Ponatinib (AP24534); Axitinib; Imatinib

(STI571); Nintedanib (BIBF 1120); Pazopanib HCl (GW786034 HCl); Dovitinib (TKI-258, CHIR-258); Linifanib (ABT-869); Crenolanib (CP-868596); Masitinib (AB1010); Tivozanib (AV-951); Motesanib Diphosphate (AMG-706); Amuvatinib (MP-470); TSU-68 (SU6668, Orantinib); CP-673451; Ki8751; Telatinib; PP121; Pazopanib; KRN 633; Dovitinib (TKI-258) Dilactic Acid; MK-2461; Tyrphostin (AG 1296); Dovitinib (TKI258) Lactate; Sennoside B; Sunitinib; AZD2932; and Trepidil.

[0207] In one embodiment, the present invention provides a method of treating or preventing paroxysmal nocturnal hemoglobinuria (PNH) by administering to a subject in need thereof an effective amount of an active compound or its salt or composition as described herein with an additional inhibitor of the complement system or another active compound with a different biological mechanism of action. In another embodiment, the present invention provides a method of treating or preventing paroxysmal nocturnal hemoglobinuria (PNH) by administering to a subject in need thereof an effective amount of an active compound or its salt or composition as described herein in combination or alternation with eculizumab. In another embodiment, the present invention provides a method of treating or preventing paroxysmal nocturnal hemoglobinuria (PNH) by administering to a subject in need thereof an effective amount of an active compound or its salt or composition as described herein in combination or alternation with CP40. In one embodiment, the additional agent is PEGylated-CP40. CP40 is a peptide inhibitor that shows a strong binding affinity for C3b and inhibits hemolysis of paroxysmal nocturnal hemoglobinuria (PNH) erythrocytes. In one embodiment, the additional agent is a complement component inhibitor, for example but not limited to Compstatin/POT-4 (Potentia Pharmaceuticals); ARC1905 (Archemix); 4(1MEW)APL-1, APL-2 (Appellis); CP40/AMY-101, PEG-Cp40 (Amyndas); a PDGF inhibitor, for example, but not limited to Sorafenib Tosylate; Imatinib Mesylate (STI571); Sunitinib Malate; Ponatinib (AP24534); Axitinib; Imatinib (STI571); Nintedanib (BIBF 1120); Pazopanib HCl (GW786034 HCl); Dovitinib (TKI-258, CHIR-258); Linifanib (ABT-869); Crenolanib (CP-868596); Masitinib (AB1010); Tivozanib (AV-951); Motesanib Diphosphate (AMG-706); Amuvatinib (MP-470); TSU-68 (SU6668, Orantinib); CP-673451; Ki8751; Telatinib; PP121; Pazopanib; KRN 633; Dovitinib (TKI-258) Dilactic Acid; MK-2461; Tyrphostin (AG 1296); Dovitinib (TKI258) Lactate; Sennoside B; Sunitinib; AZD2932; and Trepidil; an anti-factor H or anti-factor B agent, for example anti-FB siRNA (Alnylam); FCFD4514S (Genentech/Roche) SOMAmers for CFB and CFD (SomaLogic); TA106 (Alexion Pharmaceuticals); 5C6, and AMY-301 (Amyndas); a complement C3 or CAP C3 convertase targeting molecule, for example but not limited to TT30 (CR2/CFH) (Alexion); TT32 (CR2/CR1) (Alexion Pharmaceuticals); Nafamostat (FUT-175, Futhan) (Torri Pharmaceuticals); Bikacimab, NM9308 (Novelmed); CVF, HC-1496 (InCode) ALXN1102/ALXN1103 (TT30) (Alexion Pharmaceuticals); rFH (Optherion); H17 C3 (C3b/iC3b) (EluSys Therapeutics); Mini-CFH (Amyndas) Mirococept (APT070); sCR1 (CDX-1135) (Celldex); CRIg/CFH, an anti-CR3, anti-MASP2, anti C1s, or anti-C1n molecule, for example but not limited to Cynryze (ViroPharma/Baxter); TNT003 (True North); OMS721 (Omeros); OMS906 (Omeros); and Imprime PGG (Biothera)

[0208] In one embodiment, the present invention provides a method of treating or preventing rheumatoid arthritis by administering to a subject in need thereof an effective amount of a composition comprising an active compound or its salt or composition as described herein in combination or alternation with an additional inhibitor of the complement system, or an active agent that functions through a different mechanism of action. In another embodiment, the present invention provides a method of treating or preventing rheumatoid arthritis by administering to a subject in need thereof an effective amount of an active compound or its salt or composition as described herein in combination or alternation with methotrexate. In certain embodiments, an active compound or its salt or composition as described herein is administered in combination or alternation with at least one additional therapeutic agent selected from: salicylates including aspirin (Anacin, Ascriptin, Bayer Aspirin, Ecotrin) and salsalate (Mono-Gesic, Salgesic); nonsteroidal anti-inflammatory drugs (NSAIDs); nonselective inhibitors of the cyclo-oxygenase (COX-1 and COX-2) enzymes, including diclofenac (Cataflam, Voltaren), ibuprofen (Advil, Motrin), ketoprofen (Orudis), naproxen (Aleve, Naprosyn), piroxicam (Feldene), etodolac (Lodine), indomethacin, oxaprozin (Daypro), nabumetone (Relafen), and meloxicam (Mobic); selective cyclo-oxygenase-2 (COX-2) inhibitors including Celecoxib (Celebrex); diseasemodifying antirheumatic drugs (DMARDs), including azathioprine (Imuran), cyclosporine (Sandimmune, Neoral), gold salts (Ridaura, Solganal, Aurolate, Myochrysine), hydroxychloroquine (Plaquenil), leflunomide (Arava), methotrexate (Rheumatrex), penicillamine (Cuprimine), and sulfasalazine (Azulfidine); biologic drugs including abatacept (Orencia), etanercept (Enbrel), infliximab (Remicade), adalimumab (Humira), and anakinra (Kineret); corticosteroids including betamethasone (Celestone Soluspan), cortisone (Cortone), dexamethasone (Decadron), methylprednisolone (SoluMedrol, DepoMedrol), prednisolone (Delta-Cortef), prednisone (Deltasone, Orasone), and triamcinolone (Aristocort); gold salts, including Auranofin (Ridaura); Aurothioglucose (Solganal); Aurolate; Myochrysine; or any combination thereof.

[0209] In one embodiment, the present invention provides a method of treating or preventing multiple sclerosis by administering to a subject in need thereof an effective amount of an active compound or its salt or composition as described herein in combination or alternation with an additional inhibitor of the complement system, or an active agent that functions through a different mechanism of action. In another embodiment, the present invention provides a method of treating or preventing multiple sclerosis by administering to a subject in need thereof an effective amount of an active compound or its salt or composition as described herein in combination or alternation with a corticosteroid. Examples of corticosteroids include, but are not limited to, prednisone, dexamethasone, solumedrol, and methylprednisolone. In one embodiment, an

active compound or its salt or composition as described herein is combined with at least one anti-multiple sclerosis drug, for example, selected from: Aubagio (teriflunomide), Avonex (interferon beta-1a), Betaseron (interferon beta-1b), Copaxone (glatiramer acetate), Extavia (interferon beta-1b), Gilenya (fingolimod), Lemtrada (alemtuzumab), Novantrone (mitoxantrone), Plegridy (peginterferon beta-1a), Rebif (interferon beta-1a), Tecfidera (dimethyl fumarate), Tysabri (natalizumab), Solu-Medrol (methylprednisolone), High-dose oral Deltasone (prednisone), H.P. Acthar Gel (ACTH), or a combination thereof.

[0210] In one embodiment, an active compound or its salt or composition as described herein is useful in a combination with another pharmaceutical agent to ameliorate or reduce a side effect of the agent. For example, in one embodiment, an active compound or its salt or composition as described herein may be used in combination with adoptive cell transfer therapies to reduce an associated inflammatory response associated with such therapies, for example, a cytokine mediated response such as cytokine release syndrome. In one embodiment, the adoptive cell transfer therapy includes the use of a chimeric antigen receptor T-Cell (CAR T). In one embodiment, the adoptive cell transfer therapy includes the use of a chimeric antigen receptor T-Cell (CART) or a dendritic cell to treat a hematologic or solid tumor, for example, a B-cell related hematologic cancer. In one embodiment, the hematologic or solid tumor is acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), pancreatic cancer, glioblastoma, or a cancer that expresses CD19.

[0211] In an additional alternative embodiment, an active compound or its salt or composition as described herein may be provided in combination with eculizumab for the treatment of PNH, aHUSs, STEC-HUS, ANCA-vasculitis, AMD, CAD, C3 glomerulopathy, for example DDD or C3GN, chronic hemolysis, neuromyelitis optica, or transplantation rejection. In one embodiment, an active compound or its salt or composition as described herein may be provided in combination with compstatin or a compstatin derivative for the treatment of PNH, aHUSs, STEC-HUS, ANCA-vasculitis, AMD, CAD, C3 glomerulopathy, for example DDD or C3GN, chronic hemolysis, neuromyelitis optica, or transplantation rejection. In one embodiment, the additional agent is a complement component inhibitor, for example but not limited to Compstatin/POT-4 (Potentia Pharmaceuticals); ARC1905 (Archemix); 4(1MEW)APL-1, APL-2 (Appelis); CP40/AMY-101, PEG-Cp40 (Amyndas); a PDGF inhibitor, for example, but not limited to Sorafenib Tosylate; Imatinib Mesylate (STI571); Sunitinib Malate; Ponatinib (AP24534); Axitinib; Imatinib (STI571); Nintedanib (BIBF 1120); Pazopanib HCl (GW786034 HCl); Dovitinib (TKI-258, CHIR-258); Linifanib (ABT-869); Crenolanib (CP-868596); Masitinib (AB1010); Tivozanib (AV-951); Motesanib Diphosphate (AMG-706); Amuvatinib (MP-470); TSU-68 (SU6668, Orantinib); CP-673451; Ki8751; Telatinib; PP121; Pazopanib; KRN 633; Dovitinib (TKI-258) Dilactic Acid; MK-2461; Tyrphostin (AG 1296); Dovitinib (TKI258) Lactate; Sennoside B; Sunitinib; AZD2932; and Trepidil; an anti-factor H or anti-factor B agent, for example anti-FB siRNA (Alnylam); FCFD4514S (Genentech/Roche) SOMAmers for CFB and CFD (SomaLogic); TA106 (Alexion Pharmaceuticals); 5C6, and AMY-301 (Amyndas); a complement C3 or CAP C3 convertase targeting molecule, for example but not limited to TT30 (CR2/CFH) (Alexion); TT32 (CR2/CR1) (Alexion Pharmaceuticals); Nafamostat (FUT-175, Futhan) (Torri Pharmaceuticals); Bikacimab, NM9308 (Novelmed); CVF, HC-1496 (InCode) ALXN1102/ALXN1103 (TT30) (Alexion Pharmaceuticals); rFH (Optherion); H17 C3 (C3b/iC3b) (EluSys Therapeutics); Mini-CFH (Amyndas) Mirococept (APT070); sCR1 (CDX-1135) (Celldex); CR1g/CFH, an anti-CR3, anti-MASP2, anti C1s, or anti-C1n molecule, for example but not limited to Cynryze (ViroPharma/Baxter); TNT003 (True North); OMS721 (Omeros); OMS906 (Omeros); and Imprime PGG (Biothera).

[0212] In one embodiment, an active compound or its salt or composition as described herein may be provided in combination with rituxan for the treatment of a complement mediated disorder. In one embodiment, the complement mediated disorder is, for example, rheumatoid arthritis, Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis), and Microscopic Polyangiitis (MPA). In one embodiment, the disorder is Lupus.

[0213] In one embodiment, an active compound or its salt or composition as described herein may be provided in combination with cyclophosphamide for the treatment of a complement mediated disorder. In one embodiment, the disorder is an autoimmune disease. In one embodiment, the complement mediated disorder is, for example, rheumatoid arthritis, Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis), and Microscopic Polyangiitis (MPA). In one embodiment, the disorder is Lupus.

[0214] In one embodiment, an active compound or its salt or composition as described herein is dosed in combination with a conventional DLE treatment for the treatment of lupus to a subject in need thereof.

[0215] Examples of conventional DLE treatments include topical corticosteroid ointments or creams, such as triamcinolone acetonide, fluocinolone, flurandrenolide, betamethasone valerate, or betamethasone dipropionate. Resistant plaques can be injected with an intradermal corticosteroid. Other potential DLE treatments include calcineurin inhibitors such as pimecrolimus cream or tacrolimus ointment. Particularly resistant cases can be treated with systemic antimalarial drugs, such as hydroxychloroquine (PLAQUENIL).

[0216] In one embodiment, an active compound or its salt or composition as described herein may be provided in combination with methotrexate for the treatment of Lupus.

[0217] In one embodiment, an active compound or its salt or composition as described herein may be provided in combination with azathioprine for the treatment of Lupus.

[0218] In one embodiment, an active compound or its salt or composition as described herein may be provided in combination with a non-steroidal anti-inflammatory drug for the treatment of Lupus.

[0219] In one embodiment, an active compound or its salt or composition as described herein may be provided in combination with a corticosteroid for the treatment of Lupus.

[0220] In one embodiment, an active compound or its salt or composition as described herein may be provided in combination with a belimumab (Benlysta) for the treatment of Lupus.

[0221] In one embodiment, an active compound or its salt or composition as described herein may be provided in combination with hydroxychloroquine (Plaquenil) for the treatment of Lupus.

[0222] In one embodiment, an active compound or its salt or composition as described herein may be provided in combination with sifalimumab for the treatment of Lupus.

[0223] In one embodiment, an active compound or its salt or composition as described herein may be provided in combination with OMS721 (Omeros) for the treatment of a complement mediated disorder. In one embodiment, an active compound or its salt or composition as described herein may be provided in combination with OMS906 (Omeros) for the treatment of a complement mediated disorder. In one embodiment, the complement mediated disorder is, for example, thrombotic thrombocytopenic purpura (TTP) or aHUS.

[0224] In one embodiment, an active compound or its salt or composition as described herein may be provided in combination with an anti-inflammatory agent, immunosuppressive agent, or anti-cytokine agent for the treatment or prevention of cytokine or inflammatory reactions in response to the administration of pharmaceuticals or biotherapeutics (e.g. adoptive T-cell therapy (ACT) such as CAR T-cell therapy, or monoclonal antibody therapy). In one embodiment, an active compound or its salt or composition as described herein may be provided in combination with a corticosteroid, for example prednisone, dexamethasone, solumedrol, and methylprednisolone, and/or anti-cytokine compounds targeting, e.g., IL-4, IL-10, IL-11, IL-13 and TGF β . In one embodiment, an active compound or its salt or composition as described herein may be provided in combination with an anti-cytokine inhibitor including, but are not limited to, adalimumab, infliximab, etanercept, protopic, efalizumab, alefacept, anakinra, siltuximab, secukinumab, ustekinumab, golimumab, and tocilizumab, or a combination thereof. Additional anti-inflammatory agents that can be used in combination with an active compound or its salt or composition as described herein include, but are not limited to, non-steroidal anti-inflammatory drug(s) (NSAIDs); cytokine suppressive anti-inflammatory drug(s) (CSAIDs); CDP-571/BAY-10-3356 (humanized anti-TNF α antibody; Celltech/Bayer); cA2/infliximab (chimeric anti-TNF α antibody; Centocor); 75 kD TNFR-IgG/etanercept (75 kD TNF receptor-IgG fusion protein; Immunex); 55 kD TNF-IgG (55 kD TNF receptor-IgG fusion protein; Hoffmann-LaRoche); IDEC-CE9.1/SB 210396 (non-depleting primatized anti-CD4 antibody; IDEC/SmithKline); DAB 486-IL-2 and/or DAB 389-IL-2 (IL-2 fusion proteins; Seragen); Anti-Tac (humanized anti-IL-2R α ; Protein Design Labs/Roche); IL-4 (anti-inflammatory cytokine; DNAX/Schering); IL-10 (SCH 52000; recombinant IL-10, anti-inflammatory cytokine; DNAX/Schering); IL-4; IL-10 and/or IL-4 agonists (e.g., agonist antibodies); IL-1RA (IL-1 receptor antagonist; Synergen/Amgen); anakinra (Kineret[®]/Amgen); TNF-bp/s-TNF (soluble TNF binding protein); R973401 (phosphodiesterase Type IV inhibitor); MK-966 (COX-2 Inhibitor); Iloprost, leflunomide (anti-inflammatory and cytokine inhibitor); tranexamic acid (inhibitor of plasminogen activation); T-614 (cytokine inhibitor); prostaglandin E1; Tenidap (non-steroidal anti-inflammatory drug); Naproxen (non-steroidal anti-inflammatory drug); Meloxicam (non-steroidal anti-inflammatory drug); Ibuprofen (non-steroidal anti-inflammatory drug); Piroxicam (non-steroidal anti-inflammatory drug); Diclofenac (non-steroidal anti-inflammatory drug); Indomethacin (nonsteroidal anti-inflammatory drug); Sulfasalazine; Azathioprine; ICE inhibitor (inhibitor of the enzyme interleukin-1 β converting enzyme); zap-70 and/or lck inhibitor (inhibitor of the tyrosine kinase zap-70 or lck); TNF-convertase inhibitors; anti-IL-12 antibodies; anti-IL-18 antibodies; interleukin-11; interleukin-13; interleukin-17 inhibitors; gold; penicillamine; chloroquine; chlorambucil; hydroxychloroquine; cyclosporine; cyclophosphamide; anti-thymocyte globulin; anti-CD4 antibodies; CD5-toxins; orally-administered peptides and collagen; lobenzarit disodium; Cytokine Regulating Agents (CRAB) HP228 and HP466 (Houghten Pharmaceuticals, Inc.); ICAM-1 antisense phosphorothioate oligo-deoxynucleotides (ISIS 2302; Isis Pharmaceuticals, Inc.); soluble complement receptor 1 (TP10; T Cell Sciences, Inc.); prednisone; orgotein; glycosaminoglycan polysulphate; minocycline; anti-IL2R antibodies; marine and botanical lipids (fish and plant seed fatty acids); auranofin; phenylbutazone; meclofenamic acid; flufenamic acid; intravenous immune globulin; zileuton; azaribine; mycophenolic acid (RS-61443); tacrolimus (FK-506); sirolimus (rapamycin); amiprilose (therafectin); cladribine (2-chlorodeoxyadenosine).

[0225] In a specific embodiment, an active compound or its salt or composition as described herein may be provided in combination with a corticosteroid for the treatment or prevention of cytokine or inflammatory reactions in response to the administration of pharmaceuticals or biotherapeutics. In another embodiment, an active compound or its salt or composition as described herein may be provided in combination with etanercept for the treatment or prevention of cytokine or inflammatory reactions in response to the administration of pharmaceuticals or biotherapeutics. In another embodiment, an active compound or its salt or composition as described herein may be provided in combination with tocilizumab for the treatment or prevention of cytokine or inflammatory reactions in response to the administration of pharmaceuticals or biotherapeutics. In another embodiment, an active compound or its salt or composition as described herein may be provided in combination with etanercept and tocilizumab for the treatment or prevention of cytokine or

inflammatory reactions in response to the administration of pharmaceuticals or biotherapeutics. In another embodiment, an active compound or its salt or composition as described herein may be provided in combination with infliximab for the treatment or prevention of cytokine or inflammatory reactions in response to the administration of pharmaceuticals or biotherapeutics. In another embodiment, an active compound or its salt or composition as described herein may be provided in combination with golimumab for the treatment or prevention of cytokine or inflammatory reactions in response to the administration of pharmaceuticals or biotherapeutics.

COMBINATIONS FOR PROPHYLACTIC OR CONCOMITANT ANTI-BACTERIAL THERAPY

[0226] In one aspect of the present invention, a method is provided for treating a host in need thereof that comprises administering an effective amount of a prophylactic anti-bacterial vaccine prior to administration of an active compound or its salt or composition for any of the disorders described herein. In another aspect of the present invention, a method is provided for treating a host in need thereof that comprises administering an effective amount of a prophylactic anti-bacterial drug, such as a pharmaceutical drug, prior to administration of an active compound or its salt or composition for any of the disorders described herein. In one aspect of the present invention, a method is provided for treating a host in need thereof that comprises administering an effective amount of an anti-bacterial vaccine after administration of an active compound or its salt or composition for any of the disorders described herein. In another aspect of the present invention, a method is provided for treating a host in need thereof that comprises administering an effective amount of an anti-bacterial drug, such as a pharmaceutical drug, after administration of an active compound or its salt or composition for any of the disorders described herein. In one embodiment, the disorder is PNH, C3G, or aHUS. In one embodiment, the host has received an organ or other tissue or biological fluid transplant. In one embodiment, the host is also administered eculizumab.

[0227] In one aspect of the present invention, an active compound or its salt or composition as described herein is administered to a host concomitantly to a subject following the prophylactic administration of a vaccine against a bacterial infection. In one embodiment, the complement mediated disorder is PNH, C3G, or aHUS. In one embodiment, the subject has received an organ or other tissue or biological fluid transplant. In one embodiment, the subject is also administered eculizumab.

[0228] In one aspect of the present invention, an active compound or its salt or composition as described herein is administered to a subject concomitantly with the prophylactic administration of a vaccine against a bacterial infection. In one embodiment, the complement mediated disorder is PNH, C3G, or aHUS. In one embodiment, the subject has received an organ or other tissue or biological fluid transplant. In one embodiment, the subject is also administered eculizumab.

[0229] In one aspect of the present invention, an active compound or its salt or composition as described herein is administered to a subject and, during the administration period of the compound or salt, a vaccine against a bacterial infection is administered to the subject. In one embodiment, the complement mediated disorder is PNH, C3G, or aHUS. In one embodiment, the subject has received an organ or other tissue or biological fluid transplant. In one embodiment, the subject is also administered eculizumab.

[0230] In one aspect of the present invention, the subject is administered an active compound or its salt or composition as described herein in combination with an antibiotic compound for the duration of Factor D inhibitor administration. In one embodiment, the complement mediated disorder is PNH, C3G, or aHUS. In one embodiment, the subject has received an organ or other tissue or biological fluid transplant. In one embodiment, the subject is also administered eculizumab.

[0231] In one aspect of the present invention, an active compound or its salt or composition as described herein is administered to a subject following the prophylactic administration of a vaccine against a bacterial infection, and in combination with an antibiotic compound for the duration of Factor D inhibitor administration. In one embodiment, the complement mediated disorder is PNH or aHUS. In one embodiment, the subject has received an organ or other tissue or biological fluid transplant. In one embodiment, the subject is also administered eculizumab. In one embodiment, the subject, prior to receiving an active compound or its salt or composition as described herein, is vaccinated against a bacterial infection caused by the bacterium *Neisseria meningitidis*. In one embodiment, the subject is vaccinated against a bacterial infection caused by the bacterium *Haemophilus influenzae*. In one embodiment, the *Haemophilus influenzae* is *Haemophilus influenzae* serotype B (Hib). In one embodiment, the subject is vaccinated against a bacterial infection caused by *Streptococcus pneumoniae*. In one embodiment, the subject is vaccinated against a bacterial infection caused by the bacterium *Neisseria meningitidis*, *Haemophilus influenzae*, or *Streptococcus pneumoniae*, or a combination of one or more of *Neisseria meningitidis*, *Haemophilus influenzae*, or *Streptococcus pneumoniae*. In one embodiment, the subject is vaccinated against a bacterial infection caused by the bacterium *Neisseria meningitidis*, *Haemophilus influenzae*, and *Streptococcus pneumoniae*.

[0232] In other embodiments, the subject is vaccinated against a bacterial infection caused by a bacterium selected from a Gram-negative bacterium. In one embodiment, the subject is vaccinated against a bacterial infection caused by a bacterium selected from a Gram-positive bacterium. In one embodiment, the subject is vaccinated against a bacterial infection caused by the bacterium *Neisseria meningitidis*, *Haemophilus influenzae*, or *Streptococcus pneumoniae*, or a

combination of one or more of *Nisseria meningitidis*, *Haemophilus influenzae*, or *Streptococcus pneumoniae*, and one or more of, but not limited to, *Bacillus anthracis*, *Bordetella pertussis*, *Clostridium tetani*, *Corynebacterium diphtheria*, *Coxiella burnetii*, *Mycobacterium tuberculosis*, *Salmonella typhi*, *Vibrio cholerae*, *Anaplasma phagocytophilum*, *Ehrlichia ewingii*, *Ehrlichia chaffeensis*, *Ehrlichia canis*, *Neorickettsia sennetsu*, *Mycobacterium leprae*, *Borrelia burgdorferi*, *Borrelia mayonii*, *Borrelia afzelii*, *Borrelia garinii*, *Mycobacterium bovis*, *Staphylococcus aureus*, *Streptococcus pyogenes*, *Treponema pallidum*, *Francisella tularensis*, *Yersinia pestis*,

[0233] In one embodiment, the subject is vaccinated with one or more vaccines selected from, but not limited to, typhoid vaccine, live (Vivotif Berna Vaccine, PaxVax), typhoid Vi polysaccharide vaccine (Typhim Vi, Sanofi), pneumococcal 23-valent vaccine, PCV13 (Pneumovax 23, Merck), pneumococcal 7-valent vaccine, PCV7 (Pneumovax, Pfizer), pneumococcal 13-valent vaccine, PCV13 (Pneumovax 13, Pfizer), haemophilus b conjugate (prp-t) vaccine (ActHIB, Sanofi; Hibrix, GSK), haemophilus b conjugate (hboc) vaccine (HibTITER, Neuron Biotech), haemophilus b conjugate (prp-omp) vaccine (PedvaxHIB, Merck), haemophilus b conjugate (prp-t) vaccine/meningococcal conjugate vaccine (MenHibrix, GSK), haemophilus b conjugate (prp-t) vaccine/meningococcal conjugate vaccine/Hepatitis B vaccine (Comvax, Merck), meningococcal polysaccharide vaccine (Menomune A / C / Y / W-135, Sanofi), meningococcal conjugate vaccine/diphtheria CRM197 conjugate (Menveo, GSK; Menactra, Sanofi), meningococcal group B vaccine (Bexsero, GSK; Trumenba, Pfizer), anthrax vaccine adsorbed (Biothrex, Emergent Biosolutions), tetanus toxoid (Te Anatoxal Berna, Hendricks Regional Health), *Bacillus Calmette and Guérin*, live, intravesical (TheraCys, Sanofi; Tice BCG, Organon), cholera vaccine, live, oral (Vachora, Sanofi; Dukoral, SBL Vaccines; ShanChol, Shantha Biotech; Micromedex, Truven Health), tetanus toxoids and diphtheria absorbed (Tdap; Decavac, Sanofi; Tenivac, Sanofi; td, Massachusetts Biological Labs), diphtheria and tetanus toxoids and pertussis (DTap; Daptacel, Sanofi; Infanrix, GSK; Tripedia, Sanofi), diphtheria and tetanus toxoids and pertussis/polio (Kinrix, GSK; Quadracel, Sanofi), diphtheria and tetanus toxoids and pertussis tetanus/hepatitis B/polio (Pediarix, GSK), diphtheria and tetanus toxoids and pertussis/polio, haemophilus influenza tybe b (Pentacel, Sanofi), and/or diphtheria, and pertussis (Tdap; Boostrix, GSK; Adacel, Sanofi), or a combination thereof.

[0234] As described above, a subject receiving a compound of the present invention to treat a disorder is prophylactically administered an antibiotic compound in addition to a Factor D inhibitor described herein. In one embodiment, the subject is administered an antibiotic compound for the duration of administration of the active compound to reduce the development of a bacterial infection. Antibiotic compounds for concomitant administration with a Factor D inhibitor described herein can be any antibiotic useful in preventing or reducing the effect of a bacterial infection. Antibiotics are well known in the art and include, but are not limited to, amikacin (Amikin), gentamicin (Garamycin), kanamycin (Kantrex), neomycin (Neo-Fradin), netilmicin (Netromycin), tobramycin (Nebcin), paromomycin (Humatin), streptomycin, spectinomycin (Trobicin), geldanamycin, herbimycin, rifaximin (Xifaxan), loracarbef (Lorabid), ertapenem (Invanz), doripenem (Doribax), imipenem/cilastatin (Primaxin), meropenem (Merrem), cefadroxil (Duricef), cefazolin (Ancef), cefalotin/cefalothin (Keflin), cephalixin (Keflex), cefaclor (Distaclor), cefamandole (Mandol), cefoxitin (Mefoxin), cefprozil (Cefzil), cefuroxime (Ceftin, Zinnat), cefixime (Cefspan), cefdinir (Omnicef, Cefdiel), cefditoren (Spectracef, Meiact), cefoperazone (Cefobid), cefotaxime (Claforan), cefpodoxime (Vantin) ceftazidime (Fortaz), ceftibuten (Cedax), ceftizoxime (Cefizox), ceftriaxone (Rocephin), cefepime (Maxipime), ceftaroline fosamil (Teflaro), ceftobiprole (Zeftera), teicoplanin (Targocid), vancomycin (Vancocin), telavancin (Vibativ), dalbavancin (Dalvance), oritavancin (Orbactiv), clindamycin (Cleocin), lincomycin (Lincocin), daptomycin (Cubicin), azithromycin (Zithromax, Sumamed, Xithrone), clarithromycin (Biaxin), dirithromycin (Dynabac), erythromycin (Erythocin, Erythroped), roxithromycin, troleandomycin (Tao), telithromycin (Ketek), spiramycin (Rovamycin), aztreonam (Azactam), furazolidone (Furoxone), nitrofurantoin (Macrochantin, Macrobid), linezolid (Zyvox), posizolid, radezolid, torezolid, amoxicillin (Novamox, Amoxil), ampicillin (Principen), azlocillin, carbenicillin (Geocillin), cloxacillin (Tegopen), dicloxacillin (Dynapen), flucloxacillin (Floxapen), mezlocillin (Mezlin), methicillin (Staphcillin), nafcillin (Unipen), oxacillin (Prostaphlin), penicillin G (Pentids), penicillin V (Veetids (Pen-Vee-K), piperacillin (Pipracil), penicillin G (Pfizerpen), temocillin (Negaban), ticarcillin (Ticar), amoxicillin/clavulanate (Augmentin), ampicillin/sulbactam (Unasyn), piperacillin/tazobactam (Zosyn), ticarcillin/clavulanate (Timentin), bacitracin, colistin (Coly-Mycin-S), polymyxin B, ciprofloxacin (Cipro, Ciproxin, Ciprobay), enoxacin (Penetrex), gatifloxacin (Tequin), gemifloxacin (Factive), levofloxacin (Levaquin), lomefloxacin (Maxaquin), moxifloxacin (Avelox), nalidixic acid (NegGram), norfloxacin (Noroxin), ofloxacin (Floxin, Ocuflox), trovafloxacin (Trovan), grepafloxacin (Raxar), sparfloxacin (Zagam), temafloxacin (Omniflox), mafenide (Sulfamylon), sulfacetamide (Sulamyd, Bleph-10), sulfadiazine (Micro-Sulfon), silver sulfadiazine (Silvadene), sulfamethoxine (Di-Methox, Albon), sulfamethizole (Thiosulfil Forte), sulfamethoxazole (Gantanol), sulfanilamide, sulfasalazine (Azulfidine), sulfisoxazole (Gantrisin), trimethoprim-sulfamethoxazole (Co-trimoxazole) (TMP-SMX) (Bactrim, Septra), sulfonamido-chrysoidine (Prontosil), demeclocycline (Declomycin), doxycycline (Vibramycin), minocycline (Minocin), oxytetracycline (Terramycin), tetracycline (Sumycin, Achromycin V, Steclin), clofazimine (Lamprene), dapsone (Avlo-sulfon), capreomycin (Capastat), cycloserine (Seromycin), ethambutol (Myambutol), ethionamide (Trecator), isoniazid (I.N.H.), pyrazinamide (Aldinamide), rifampicin (Rifadin, Rimactane), rifabutin (Mycobutin), rifapentine (Priftin), streptomycin, arspenamine (Salvarsan), chloramphenicol (Chloromycetin), fosfomycin (Monurol, Monuril), fusidic acid (Fucidin), metronidazole (Flagyl), mupirocin (Bactroban), platensimycin, quinupristin/dalfopristin (Synercid), thiamphenicol, tigecycline (Tigacyl), tinidazole (Tindamax Fasigyn), trimethoprim (Proloprim, Trimplex), and/or teixobactin, or a combina-

tion thereof.

[0235] In one embodiment, the subject is administered a prophylactic antibiotic selected from cephalosporin, for example, ceftriaxone or cefotaxime, ampicillin-sulbactam, Penicillin G, ampicillin, chloramphenicol, fluoroquinolone, aztreonam, levofloxacin, moxifloxacin, gemifloxacin, vancomycin, clindamycin, cefazolin, azithromycin, meropenem, ceftaroline, tigecycline, clarithromycin, moxifloxacin, trimethoprim/sulfamethoxazole, cefuroxime, axetil, ciprofloxacin, rifampin, minocycline, spiramycin, and cefixime, or a combination of two or more thereof.

PROCESS OF PREPARATION OF COMPOUNDS OF OF THE PRESENT INVENTION ABBREVIATIONS

[0236]

ACN	Acetonitrile
Ac	Acetyl
Ac ₂ O	Acetic anhydride
AcOEt, EtOAc	ethyl acetate
AcOH	Acetic acid
Boc ₂ O	di-tert-butyl dicarbonate
Bu	Butyl
CAN	Ceric ammonium nitrate
CBz	Carboxybenzyl
CDI	Carbonyldiimidazole
CH ₃ OH, MeOH	Methanol
CsF	Cesium fluoride
CuI	Cuprous iodide
DCM, CH ₂ Cl ₂	Dichloromethane
DIEA, DIPEA	N,N-diisopropylethylamine
DMA	N,N-dimethylacetamide
DMAP	4-Dimethylaminopyridine
DMF	N,N-dimethylformamide
DMS	Dimethyl sulfide
DMSO	Dimethylsulfoxide
DPPA	Diphenyl phosphoryl azide
EDCI	1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide
EEDQ	N-Ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline
Et	Ethyl

	Et ₃ N, TEA	Triethylamine
	EtOAc	Ethylacetate
5	EtOH	Ethanol
	HATU	1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium3-oxide hexafluorophosphate
	HCl	Hydrochloric acid
10	HOBT	Hydroxybenzotriazole
	iBu, i-Bu, isoBu	Isobutyl
15	iPr, i-Pr, isoPr	Isopropyl
	iPr ₂ NEt	N,N-diisopropylethylamine
	K ₂ CO ₃	Potassium carbonate
20	K ₂ CO ₃	Potassium carbonate
	LiOH	Lithium hydroxide
25	Me	Methyl
	MeI	Methyl iodide
	Ms	Mesyl
30	MsCl	Mesylchloride
	MTBE	Methyl ^t butylether
35	Na ₂ SO ₄	Sodium sulfate
	NaCl	Sodium chloride
	NaH	Sodium hydride
40	NaHCO ₃	Sodium bicarbonate
	NBS	N-bromo succinimide
45	NCS	N-chloro succinimide
	NEt ₃	Trimethylamine
	NMP	N-Methyl-2-pyrrolidone
50	PCC	Pyridinium chlorochromate
	Pd (OAc) ₂	Palladium acetate
55	Pd(dppf)Cl ₂	[1,1'-Bis(diphenylphosphino) ferrocene]dichloropalladium(II)
	Pd(PPh ₃) ₂ Cl ₂	Bis(triphenylphosphine)palladium(II) dichloride

	Pd(PPh ₃) ₄	Tetrakis(triphenylphosphine)palladium(0)
	Pd/C	Palladium on carbon
5	Pd ₂ (dba) ₃	Tris(dibenzylideneacetone)dipalladium(0)
	PMB	4-Methoxybenzyl ether
	PPh ₃	Triphenylphosphine
10	Pr	Propyl
	Py, py	Pyridine
15	RT	Room temperature
	T3P	Propane phosphonic acid anhydride
	TBAF	Tetra-n-butylammonium fluoride
20	TBAT	Tetrabutylammonium difluorotriphenylsilicate
	tBu, t-Bu	<i>tert</i> butyl
25	tBuOK	Potassium tert-butoxide
	TEA	Trimethylamine
	Tf ₂ O	Trifluoromethanesulfonic anhydride
30	TFA	Trifluoroacetic acid
	THF	Tetrahydrofuran
35	TMS	Trimethylsilane
	TMSBr	Bromotrimethylsilane
	<i>t</i> _R	Retention time
40	Troc	2,2,2-Trichloroethoxycarbonyl chloride
	Zn (CN) ₂	Zinc cyanide

45 GENERAL METHODS

[0237] All nonaqueous reactions were performed under an atmosphere of dry argon or nitrogen gas using anhydrous solvents. The progress of reactions and the purity of target compounds were determined using one of the two liquid chromatography (LC) methods listed below. The structure of starting materials, intermediates, and final products was confirmed by standard analytical techniques, including NMR spectroscopy and mass spectrometry.

LC Method A

[0238]

Instrument: Waters Acquity Ultra Performance LC
 Column: ACQUITY UPLC BEH C18 2.1 × 50 mm, 1.7 μm
 Column Temperature: 40 °C

EP 3 589 628 B1

Mobile Phase: Solvent A: H₂O + 0.05% FA; Solvent B: CH₃CN + 0.05% FA
Flow Rate: 0.8 mL/min
Gradient: 0.24 min @ 15% B, 3.26 min gradient (15-85% B), then 0.5 min @ 85% B.
Detection: UV (PDA), ELS, and MS (SQ in EI mode)

LC Method B

[0239]

Instrument: Shimadzu LC-2010A HT
Column: Athena, C18-WP, 50 × 4.6 mm, 5 μm
Column Temperature: 40 °C
Mobile Phase: Solvent A: H₂O/CH₃OH/FA = 90/10/0.1; Solvent B: H₂O/CH₃OH/FA = 10/90/0.1
Flow Rate: 3 mL/min
Gradient: 0.4 min @ 30% B, 3.4 min gradient (30-100% B), then 0.8 min @ 100% B
Detection: UV (220/254 nm)

LC Method C

[0240]

Instrument: Agilent 1100 / 1200 series LC system with DAD detector
Column: Atlantis dC18 (250 × 4.6) mm, 5 μm
Column Temperature: Ambient
Mobile Phase A: 0.1% TFA in water, Mobile Phase B: Acetonitrile
Flow Rate: 1.0 mL/min
Gradient:

Time (min)	0.0	15	20	23	30
% B	10	100	100	10	10

Detection: (210-400 nm)

LC Method D

[0241]



Instrument: Shimadzu LC 20AD system with PDA detector
Column: Phenomenex Gemini NX C18 (150 × 4.6) mm, 5 μm
Column Temperature: Ambient
Mobile Phase A: 10mM NH₄OAC in water, Mobile Phase B: Acetonitrile
Flow Rate: 1.0 mL/min
Gradient:

Time (min)	0.0	15	20	23	30
% B	10	100	100	10	10

Detection: (210-400 nm)

EXAMPLE 1. GENERAL ROUTE OF SYNTHESIS



[0242] A compound of the present invention can be prepared, for example, from a central core. In one embodiment, for example, the central core Structure 1 is an N-protected aminoacid where X¹ is nitrogen and PG = protecting group. In one embodiment, the central core is coupled to an amine to generate an amide of Structure 2 (wherein L-B includes a C(O)N moiety). Structure 2 can then be deprotected to generate Structure 3. Structure 3 is coupled to Structure 4 (A-COOH) to generate a second amide bond, forming a compound within Formula I. The chemistry is illustrated in Route 1.



25


Route 1

30 [0243] In an alternative embodiment, central core Structure 5 is reacted with a heterocyclic or heteroaryl compound to generate a compound of Structure 6. In one embodiment, Structure 6 is deprotected to generate a carboxylic acid, Structure 7. In one embodiment, Structure 7 is coupled to an amine to generate a compound of Formula I. This chemistry is illustrated in Route 2.




Route 2

[0244] In an alternative embodiment, Structure 8 is deprotected to generate an amine which is Structure 9. Structure 9 is then coupled to generate an amide which is Structure 6. Structure 6 is then deprotected to generate a carboxylic acid which is Structure 7. Structure 7 is then coupled to form the amide which falls within Formula I. The chemistry is illustrated in Route 3.




[0245] In an alternate embodiment, a heteroaryl or aryl moiety, 4-1, is coupled to a central core to generate 4-2. The protected acid, 4-2 is deblocked to form the carboxylic acid, 4-3. The carboxylic acid is then coupled to form an amide (L-B) which is 4-4. The heteroaryl or aryl moiety, A', can then be further derivitized to add substituents at the X^{11} , X^{12} , X^{13} and X^{14} positions to generate compounds of Formula I. This chemistry is illustrated in Route 4.




[0246] In an alternate embodiment, Structure 5-1 is coupled to an acid, Structure 5-2, to generate Structure 5-3. The carboxylic acid, Structure 5-3, is deblocked to generate a carboxylic acid which is Structure 5-4. Carboxylic acid Structure

5-4 is coupled to an amine to form the product amide (L-B) which is a compound within Formula I. This chemistry is illustrated in Route 5.




Route 5


[0247] In an alternate embodiment, a heteroaryl compound of Structure 10 is acylated to generate a compound of Structure 11, wherein LG is a leaving group. As an example, the leaving group can be a halide, for example bromide. Structure 11 is coupled to Structure 12 to generate Structure 13. In some embodiments, LG₁ is a leaving group. In some embodiments, the LG₁ is a halide. Structure 13 is coupled to an aryl, heteroaryl or heterocyclic compound to generate Structure 14. In some embodiments, Structure 13 is treated with an aryl, heteroaryl or heterocyclic boronic acid, an organometallic catalyst, a base and an organic solvent. In some embodiments, the organometallic catalyst is tetra-kis(triphenylphosphine)palladium (0). In some embodiments, the base is cesium carbonate. In some embodiments, the organic solvent is DMF. Structure 14 is treated with an organic acid such as, but not limited to, trifluoroacetic acid to generate Structure 15. Structure 15 is coupled to Structure 3 from Route 1 to generate a compound within Formula I. This chemistry is illustrated in Route 6.




Structure 10




Structure 11




Structure 12




Structure 13



Structure 14



Structure 15




Formula I


Route 6

[0248] In an alternate embodiment, a heteroaryl compound of Structure 17 is acylated to generate a compound of Structure 18, wherein LG is a leaving group. As an example, the leaving group can be a halide, for example bromide. Structure 18 is coupled to an activated ester, Structure 12 from Route 6, wherein LG₁ can be a halogen to generate Structure 19.


[0249] Structure 19 is coupled to an aryl, heteroaryl or heterocyclic compound to generate Structure 20. In some embodiments, Structure 19 is treated with an aryl, heteroaryl or heterocyclic boronic acid, an organometallic catalyst, a base and an organic solvent. In some embodiments, the organometallic catalyst is tetrakis(triphenylphosphine)palladium (0). In some embodiments, the base is cesium carbonate. In some embodiments, the organic solvent is DMF. Structure 20 is treated with an organic acid such as, but not limited to, trifluoroacetic acid to generate Structure 21. Structure 21 is coupled to Structure 3 from Route 1 to generate a compound within Formula I. This chemistry is illustrated in Route 7.




Structure 17




Structure 18




Structure 12





Structure 19



Structure 20



Structure 21



Formula I

Route 7

[0250] In an alternate embodiment, a heteroaryl compound of Structure 8-1 is acylated to generate a compound of Structure 8-2, wherein LG is a leaving group. As an example, the leaving group can be a halide, for example bromide. Structure 8-2 is coupled to Structure 8-3 to generate Structure 8-4. In some embodiments, LG₁ is a leaving group. In some embodiments, the LG₁ is a halide.

[0251] Structure 8-4 is coupled to an aryl, heteroaryl or heterocyclic compound to generate Structure 8-5. In some embodiments, Structure 8-4 is treated with an aryl, heteroaryl or heterocyclic boronic acid, an organometallic catalyst, a base and an organic solvent. In some embodiments, the organometallic catalyst is tetrakis(triphenylphosphine)palladium (0). In some embodiments, the base is cesium carbonate. In some embodiments, the organic solvent is DMF. Structure 8-5 is treated with an organic acid such as, but not limited to, trifluoroacetic acid to generate Structure 8-6. Structure 8-6 is coupled to Structure 3 from Route 1 to generate a compound within Formula I. This chemistry is illustrated in Route 8.

5

10

15

20

25


30

35


40

45


50




Structure 8-1




Structure 8-2




Structure 8-3





Structure 8-4



Structure 8-5



Structure 8-6




Formula I


Route 8

[0252] In an alternate embodiment, a heteroaryl compound of Structure 9-1 is acylated to generate a compound of Structure 9-2, wherein LG is a leaving group. As an example, the leaving group can be a halide, for example bromide. Structure 9-2 is coupled to an activated ester, Structure 9-3, wherein LG₁ can be a halide to generate Structure 9-4. Structure 9-4 is coupled to an aryl, heteroaryl or heterocyclic compound to generate Structure 9-5. In some embodiments, Structure 9-4 is treated with an aryl, heteroaryl or heterocyclic boronic acid, an organometallic catalyst, a base and an organic solvent. In some embodiments, the organometallic catalyst is tetrakis(triphenylphosphine)palladium (0). In some embodiments, the base is cesium carbonate. In some embodiments, the organic solvent is DMF. Structure 9-5 is treated


with an organic acid such as, but not limited to, trifluoroacetic acid to generate Structure 9-6. Structure 9-6 is coupled to Structure 3 from Route 1 to generate a compound within Formula I. This chemistry is illustrated in Route 9.




Structure 9-1




Structure 9-2




Structure 9-3





Structure 9-4



Structure 9-5




Structure 9-6




Formula I

Route 9


[0253] In an alternate embodiment, Structure 10-1 is coupled to an amine to generate an amide (L-B), and Structure 10-2. Structure 10-2, is coupled to an amine to generate compounds within Formula I. This chemistry is illustrated in Route 10.



10-1



10-2




Formula I

Route 10


EXAMPLE 2. EXAMPLES OF CENTRAL SYNTHONS

[0254]

[0255] Z^A is halogen.

[0256] In one embodiment, deuterated L-proline synthons are disclosed. Deuterated synthons include, but are not limited to, for example, the following compounds:


55



[0257] Structure A can be treated with deuterium oxide to generate Structure B. See, Barraclough, P. et al. Tetrahedron Lett. 2005, 46, 4653-4655; Barraclough, P. et al. Org. Biomol. Chem. 2006, 4, 1483-1491 and WO 2014/037480 (p.103). Structure B can be reduced to generate Structure C. See, Barraclough, P. et al. Tetrahedron Lett. 2005, 46, 4653-4655; Barraclough, P. et al. Org. Biomol. Chem. 2006, 4, 1483-1491. Structure C can be treated with Mitsunobu reaction conditions to generate Structure D. Structure B can be treated with DAST to generate Structure E. See, WO 2014/037480. Structure A can be treated with sodium borodeuteride to generate Structure F. See, Dormoy, J. -R.; Castro, B. Synthesis 1986, 81-82. Compound F can be used to generate Structure K. See, Dormoy, J. -R.; Castro, B. Synthesis 1986, 81-82. Structure B can be treated with a deuterated reducing agent, for example sodium borodeuteride to generate Structure G. Structure G can be treated with DAST to generate Structure H. Structure F can be used to generate Structure K. See, Dormoy, J. -R.; Castro, B. Synthesis 1986, 81-82. Structure G can be used to generate Structure I. Structure J can be prepared according to Hruby, V. J. et al. J. Am. Chem. Soc. 1979, 101, 202-212. Structures A-J can be used to prepare compounds of Formula I.

EXAMPLE 3. PREPARATION OF CENTRAL-L-B SYNTHONS

[0258]




[0259] Routes 1a, 1b and 1c.

[0260] In Route 1a, 5-azaspiro[2.4]heptane-4,5-dicarboxylic acid, 5-(1,1-dimethylethyl) ester, (4S)-, CAS 209269-08-9, can be prepared as described in Tandon, M. et al. Bioorg. Med. Chem. Lett. 1998, 8, 1139-1144. In Step 2, the protected azaspiro[2.4]heptane is coupled to an amine in the presence of an organic solvent, a base and a coupling reagent to generate an amide bond; the L-B moiety. In one embodiment, the amine is (3-chloro-2-fluorophenyl) methanamine. In one embodiment, the organic solvent is DMF. In one embodiment, the base is diisopropylethylamine. In one embodiment, the coupling reagent is HATU. In Step 3, the protecting group is removed. In one embodiment, the starting material is reacted with an acid in the presence of an organic solvent. In one embodiment, the acid is 4N hydrochloric acid. In one embodiment, the organic solvent is dioxane.

[0261] In Route 1b, (4S) 4-oxazolidinecarboxylic acid, hydrochloride is treated with an amine protecting reagent. In one embodiment, the amine protecting reagent is di-tert-butyl dicarbonate. In another embodiment, 3,4-oxazolidinedicarboxylic acid, 3-(1,1-dimethylethyl) ester, (4S)-, is commercially available from JPM2 Pharmaceuticals. In one embodiment the reaction is carried out in an organic solvent in the presence of a base. In one embodiment, the organic solvent is acetonitrile. In one embodiment, the base is 4-dimethylaminopyridine (DMAP). In Step 2, the protected 4-oxazolidinecarboxylic acid is coupled to an amine in the presence of an organic solvent, a base and a coupling reagent to generate an amide bond; the L-B moiety. In one embodiment, the amine is (3-chloro-2-fluorophenyl) methanamine. In one embodiment, the organic solvent is DMF. In one embodiment, the base is diisopropylethylamine. In one embodiment, the coupling reagent is HATU. In Step 3, the protecting group is removed. In one embodiment, the starting material is reacted with an acid in the presence of an organic solvent. In one embodiment, the acid is 4N hydrochloric acid. In one embodiment, the organic solvent is dioxane.

[0262] In Route 1c, (S)-5-(tert-Butoxycarbonyl)-5-azaspiro[2.4]heptane-6-carboxylic acid, CAS 1129634-44-1, is commercially available from Ark Pharm. In Step 2, the carboxylic acid is coupled to an amine in the presence of an organic solvent, a base and a coupling reagent to generate an amide bond; the L-B moiety. In one embodiment, the amine is (3-chloro-2-fluorophenyl) methanamine. In one embodiment, the organic solvent is DMF. In one embodiment, the base is diisopropylethylamine. In one embodiment, the coupling reagent is HATU. In Step 3, the protecting group is removed. In one embodiment, the starting material is reacted with an acid in the presence of an organic solvent. In one embodiment, the acid is 4N hydrochloric acid. In one embodiment, the organic solvent is dioxane.




[0263] In Route 2a, commercially available Boc-L-proline is coupled to an amine in the presence of an organic solvent, a base and a coupling reagent to generate an amide bond; the L-B moiety. In one embodiment, the amine is (3-chloro-2-fluorophenyl) methanamine. In one embodiment, the organic solvent is DMF. In one embodiment, the base is diisopropylethylamine. In one embodiment, the coupling reagent is HATU. In Step 2, the Boc protecting group is removed. In one embodiment, the starting material is reacted with an acid in the presence of an organic solvent. In one embodiment, the acid is 4N hydrochloric acid. In one embodiment, the organic solvent is dioxane.

[0264] In Route 2b, commercially available (1R, 3S, 5R)-2-[(*tert*-butoxycarbonyl)-2-azabicyclo[3.1.0]hexane-3-carboxylic acid, from Enamine, is coupled to an amine in the presence of an organic solvent, a base and a coupling reagent to generate an amide bond; the L-B moiety. In one embodiment, the amine is (3-chloro-2-fluorophenyl) methanamine. In one embodiment, the organic solvent is DMF. In one embodiment, the base is diisopropylethylamine. In one embodiment, the coupling reagent is HATU. In Step 2, the Boc protecting group is removed. In one embodiment, the starting material is reacted with an acid in the presence of an organic solvent. In one embodiment, the acid is 4N hydrochloric acid. In one embodiment, the organic solvent is dioxane.

[0265] In Route 2c, commercially available (2S,4R)-1-(*tert*-butoxycarbonyl)-4-fluoropyrrolidine-2-carboxylic acid, from Manchester Organics, is coupled to an amine in the presence of an organic solvent, a base and a coupling reagent to generate an amide bond; the L-B moiety. In one embodiment, the amine is (3-chloro-2-fluorophenyl) methanamine. In one embodiment, the organic solvent is DMF. In one embodiment, the base is diisopropylethylamine. In one embodiment, the coupling reagent is HATU. In Step 2, the Boc protecting group is removed. In one embodiment, the starting material is reacted with an acid in the presence of an organic solvent. In one embodiment, the acid is 4N hydrochloric acid. In one embodiment, the organic solvent is dioxane.


[0266] In Route 2d, commercially available (S)-1-(*tert*-butoxycarbonyl)indoline-2-carboxylic acid, from Chem-Impex, is coupled to an amine in the presence of an organic solvent, a base and a coupling reagent to generate an amide bond; the L-B moiety. In one embodiment, the amine is (3-chloro-2-fluorophenyl) methanamine. In one embodiment, the organic solvent is DMF. In one embodiment, the base is diisopropylethylamine. In one embodiment, the coupling reagent is HATU. In Step 2, the Boc protecting group is removed. In one embodiment, the starting material is reacted with an acid in the presence of an organic solvent. In one embodiment, the acid is 4N hydrochloric acid. In one embodiment, the organic solvent is dioxane. This chemistry is illustrated in Scheme 2.

[0267] Additional starting materials that can readily be converted to Central-L-B-Synthons include, but are not limited to: (S)-1-(*tert*-butoxycarbonyl)-2,3-dihydro-1H-pyrrole-2-carboxylic acid, CAS 90104-21-5, available from Ark Pharm; cyclopent-1-ene-1,2-dicarboxylic acid, CAS 3128-15-2, purchased from Ark Pharm; imidazole, 1H-imidazole-1,2-dicarboxylic acid, 1-(1,1-dimethylethyl) 2-ethyl ester, CAS 553650-00-3, commercially available from FCH Group; Boc-L-octahydroindole-2-carboxylic acid can be purchased from Chem Impex. The compound,



can be prepared according to the procedures disclosed in WO 2004/111041; (S)-Boc-5-oxopyrrolidine-2-carboxylic acid is available from the Aldrich Chemical Co.; (1S,2S,5R)-3-(*tert*-butoxycarbonyl)-3-azabicyclo[3.3.0]hexane-2-carboxylic acid is available from Ark Pharm; (S)-3-Boc-thiazolidine-2-carboxylic acid is available from Alfa Aesar; (2S,4R)-1-(*tert*-butoxycarbonyl)-4-chloropyrrolidine-2-carboxylic acid is available from Arch Bioscience; (1S,3aR,6a-S)-2-(*tert*-butoxycarbonyl)octahydrocyclopenta[c]pyrrole-1-carboxylic acid is available from Ark Pharm; 1,2-pyrrolidine-dicarboxylic acid, 3-[[[(phenylmethoxy)carbonyl]amino]-, 1-(1,1-dimethylethyl) ester, (2S,3R) can be prepared as disclosed in WO 2004/007501. The Cbz group can be removed and the amino group can be alkylated to generate central core compounds of the present invention.

[0268] The compound




can be prepared as disclosed by Braun, J.V.; Heymons, Albrecht Berichte der Deutschen Chemischen Gesellschaft [Abteilung] B: Abhandlungen (1930) 63B, 502-7.

[0269] The compounds (2S,3S,4S)-4-fluoro-3-methoxy-pyrrolidine-1,2-dicarboxylic acid 1-*tert*-butyl ester and (2R,3R,4R)-3-fluoro-4-methoxy-pyrrolidine-1,2-dicarboxylic acid 1-*tert*-butyl ester can be prepared as a mixture according to WO 2012/093101 to Novartis and the regioisomers can be ultimately separated once coupled to generate the central core-L-B synthons. The compound (S)-Boc-5-oxopyrrolidine-2-carboxylic acid is available from the Aldrich Chemical Co.

EXAMPLE 4. SYNTHESIS OF L-B MOIETIES

[0270]

Scheme 4-1




[0271] Scheme 4-1: In Step 1 the appropriately substituted dibromo species is coupled with an appropriate boronic acid as known in the art to form a mixture of biaryl and triaryl products from which the desired biaryl compound is isolated. In Step 2 the appropriately substituted biaryl species is converted to the Grignard reagent with activated magnesium. In Step 3 the appropriately substituted aldehyde is treated with the previously prepared Grignard reagent to form an alcohol. In Step 4 the appropriately substituted alcohol is converted to a bromide as known in the art with carbon tetrabromide and triphenyl phosphine. In Step 5 the appropriately substituted bromide is converted to the Grignard reagent with activated magnesium.


EXAMPLE 5. SYNTHESIS OF C-L-B MOIETIES

[0272]

Scheme 5-1



Scheme 5-1 cont.




1. Herdeis, C., et al. (1994). Liebigs Ann. Chem.(11): 1117-1120.

[0273] Scheme 5-1: In Step 1 the appropriately substituted carboxylic acid is coupled to the appropriately substituted amine as known in the art to form an amide. In Step 2 the appropriately substituted Boc-protected species is deprotected with acid to liberate the free amine. In Step 3 the appropriately substituted amine is Cbz-protected as known in the art to form a protected carboxylic acid. In Step 4 the appropriately substituted carboxylic acid can be orthogonally protected as known in the art to form an ester. In Step 5 the appropriately substituted and protected alkene is subjected to a carbene to form a bicyclic ring. In Step 6 the appropriately substituted ester is saponified with acid to liberate the carboxylic acid. In

Step 7 the appropriately substituted Cbz-protected species is deprotected with hydrogen to liberate the free amine.


Scheme 5-2



1. Vasil'eva, T. P. (2003). Russ. Chem. Bull. 52(4): 958-960.


[0274] Scheme 5-2: In Step 1 the appropriately substituted sulfide is oxidized to a sulfoxide as known in the art. Alternatively, in Step 2 the appropriately substituted sulfide is oxidized to a sulfone as known in the art. In Step 3 the appropriately substituted carboxylic acid is coupled to the appropriately substituted amine as known in the art to form an amide. In Step 4 the appropriately substituted Boc-protected species is deprotected with acid to liberate the free amine.

Scheme 5-3




[0275] Scheme 5-3: In Step 1 the appropriately substituted carboxylic acid is converted to the acyl chloride as known in the art. In Step 2 the appropriately substituted acyl chloride is converted to the Weinreb amide as known in the art. In Step 3 the appropriately substituted Weinreb amide is reacted with a Grignard reagent to afford a ketone. The synthesis of complex Grignard reagents is described in Example 4. In Step 4 the appropriately substituted carbamate protected amine is deprotected to liberate the free amine.

Scheme 5-4




[0276] Scheme 5-4: In Step 1 the appropriately substituted amide is converted to a thioamide with Lawesson's reagent. In Step 2 the appropriately substituted Boc-protected amine is deprotected with acid to liberate the free amine.

Scheme 5-5



[0277] Scheme 5-5: In Step 1 the appropriately substituted carboxylic acid is converted to a Weinreb amide as known in the art. In Step 2 the appropriately substituted Weinreb amide is reduced as known in the art to afford an aldehyde. In Step 3 the appropriately substituted aldehyde is subjected to an amine to form a Schiff base which is subsequently quenched in Step 4. In Step 4 the appropriately substituted Schiff base is subjected to an appropriate nucleophile to form a complex amine. In Step 5 the appropriately substituted Boc-protected species is deprotected with acid to liberate the free amine.

Scheme 5-6




1. Prosser, A. R. and D. C. Liotta (2015). *Tetrahedron Lett.* 56(23): 3005-3007.

[0278] Scheme 5-6: In Step 1 the appropriately substituted alcohol is subjected to TMS-Cl as known in the art to afford a silyl ether. In Step 2 the appropriately substituted silyl ether is subjected with sodium cyanide to afford a cyano species. In Step 3 the appropriately substituted cyano species is reduced as known in the art to afford an aldehyde. In Step 4 the appropriately substituted aldehyde is further reduced with borane to afford an alcohol. In Step 5 the appropriately substituted alcohol is oxidized as known in the art to afford a carboxylic acid. In Step 6 the appropriately substituted carboxylic acid is coupled to the appropriately substituted amine as known in the art to form an amide. In Step 7 the appropriately substituted ester is converted to a methyl ketone by insitu formation of the Weinreb amide with subsequent attack by the methyl Grignard reagent. In Step 8 the appropriately substituted methyl ketone is subjected to bromine to afford a bromide. By choice of the appropriate starting material all mixtures of chiral centers may be prepared as described.

EXAMPLE 7. SYNTHESIS OF L3-A MOIETIES


[0279]

Scheme 7-1



[0280] Scheme 7-1: In Step 1 the appropriately substituted aryl compound is subjected to a bromide to afford a sulfonic acid substituted species. In Step 2 the appropriately substituted sulfonic acid species is chlorinated as known in the art.

Scheme 7-2




[0281] Scheme 7-2: In Step 1 the appropriately substituted aryl compound is subjected to a chloride to afford a phosphonic acid substituted species. In Step 2 the appropriately substituted phosphonic acid species is chlorinated as known in the art.

EXAMPLE 8. NON-LIMITING SYNTHETIC EXAMPLES OF PRODRUG COMPOUNDS OF THE PRESENT INVENTION

[0282]

Scheme 1. Synthesis of (((2*S*,4*R*)-1-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-4-fluoropyrrolidine-2-carbonyl)amino)methyl)-*o*-carborane (1) &

Lithium salt of ((2*S*,4*R*)-1-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-4-fluoropyrrolidine-2-carbonyl)amino)methyl)-*nido*-dodecahydroundecaborate (8)



[0283] Step 1: (((2*S*,4*R*)-1-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-4-fluoropyrrolidine-2-carbonyl)amino)methyl)-*o*-carborane (1): To a solution of (((2*S*,4*R*)-4-fluoropyrrolidine-2-carbonyl)amino)methyl)-*o*-carborane hydrochloride (8-S1, 1 equiv) in DMF (10 vol) at 0 °C under nitrogen atmosphere was added 2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetic acid (8-S2, 1.2 equiv), HATU (1.5 equiv) and DIPEA (3 equiv). The reaction mixture was stirred at room temperature for 16 hours. After completion of the reaction, the reaction mixture was quenched with water. The resulting mixture was extracted with DCM. The organic layer was separated, washed with brine, dried over anhydrous Na₂SO₄, filtered and then concentrated. The residue was purified by column chromatography on silica gel using DCM/MeOH to afford compound 1. ¹H NMR (400 MHz, DMSO-*d*₆) δ: 9.04 (s, 2H), 8.86 (t, *J* = 6.2 Hz, 1H), 8.43 (s, 1H), 7.88 - 7.81 (m, 2H), 5.86 - 5.82 (m, 1H), 5.61 - 5.47 (m, 2H), 4.68 - 4.67 (m, 1H), 4.38 (t, *J* = 8.6 Hz, 1H), 4.25 - 4.16 (m, 1H), 3.92 - 3.77 (m, 4H), 2.69 (s, 3H), 2.65 (s, 3H), 2.30 - 1.30 (br, 10H).

[0284] Step 2: Lithium ((2*S*,4*R*)-1-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-4-fluoropyrrolidine-2-carbonyl)amino)methyl)-*nido*-dodecahydroundecaborate (8): To a solution of compound 1 (1 equiv) in EtOH (10 vol) at room temperature was added lithium hydroxide mono hydrate (0.9 equiv). The reaction mixture was stirred at 80 °C for 16 hours. After completion of the reaction, the reaction mixture was concentrated and the residue was purified by preparative HPLC to afford compound 8. ¹H NMR (400 MHz, D₂O) δ: 8.30 (s, 2H), 7.66 - 7.60 (m, 1H), 7.16 - 6.95 (m, 2H), 5.47 - 4.99 (m, 3H), 4.67 - 4.65 (m, 2H), 4.62 - 3.95 (m, 2H), 3.49 - 3.09 (m, 3H), 2.49 (s, 3H), 2.47 (s, 3H), 2.02 - 1.30 (br, 10H).

Scheme 2: Synthesis of (1*S*,3*aS*,6*aR*)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromopyridin-2-yl)octahydrocyclopenta[*c*]pyrrole-1-carboxamide (2)

5

10

15

20

25


30

35

40

45

50



[0285] Step 1: (S)-Methyl 4-(methylthio)-2-(prop-2-yn-1-ylamino)butanoate (2-S2): To a mixture of LiOH·H₂O (6.6 g, 157.7 mmol), 4 Å molecular sieves (39 g), and DMF (70 mL) that was stirred at 0 °C for 20 minutes was added L-methionine methyl ester hydrochloride (2-S1, 15.0 g, 75.1 mmol). The mixture was stirred for 45 minutes at 0 °C and then to this mixture was added 3-bromoprop-1-yne (10.6 g, 90.1). The resulting mixture was stirred at room temperature overnight and filtered. The filtrate was partitioned between EtOAc (100 mL) and water (200 mL). The organic layer was washed with brine, dried over Na₂SO₄, and concentrated to dryness. The remaining residue was purified by column chromatography on silica gel (eluted with PE/EtOAc = 20:1 to 15:1) to afford 2-S2 (8.8 g, 58.6% yield) as light oil. LC/MS (ESI) m/z: 202 (M+H)⁺.

[0286] Step 2: (S)-Methyl 2-(((benzyloxy)carbonyl)(prop-2-yn-1-yl)amino)-4-(methylthio)butanoate (2-S3): To a mixture of (S)-methyl 4-(methylthio)-2-(prop-2-yn-1-ylamino)butanoate (**2-S2**, 8.8 g, 43.8 mmol), K₂CO₃ (18.1 g, 131.4 mmol), EtOAc (150 mL), and water (150 mL) was added CbzCl (11.2 g, 65.7 mmol) dropwise at 0 °C. The reaction mixture was stirred at 0 °C overnight. The mixture was quenched by the addition of 10% aqueous HCl until pH ~3 at 0 °C. The mixture was extracted with EtOAc (2 × 100 mL) and the combined organic layers were washed with brine, dried over Na₂SO₄, and concentrated under reduced pressure. The remaining residue was purified by column chromatography on silica gel (eluted with PE/EtOAc = 10:1) to afford **2-S3** (12.9 g, 87.9% yield) as light oil. LC/MS (ESI) m/z: 336 (M+H)⁺.

[0287] Step 3: (2S)-Methyl 2-(((benzyloxy)carbonyl)(prop-2-yn-1-yl)amino)-4-(methylsulfinyl)butanoate (2-S4): To a solution of (S)-methyl 2-(((benzyloxy)carbonyl)(prop-2-yn-1-yl)amino)-4-(methylthio)butanoate (**2-S3**, 12.9 g, 38.5 mmol) in MeOH (100 mL) and water (100 mL) was added NaIO₄ (8.7 g, 40.4 mmol) in portions at 0 °C. The mixture was stirred at this temperature for 4 hours. The mixture was extracted with EtOAc (2 × 50 mL) and the combined layers were washed with brine, dried over Na₂SO₄, and evaporated under reduced pressure to afford **S4** (12 g, 88.8% yield) as a yellow oil. This crude product was carried forward in the next synthetic step without further purification. LC/MS (ESI) m/z: 352 (M+H)⁺.

[0288] Step 4: (S)-Methyl 2-(((benzyloxy)carbonyl)(prop-2-yn-1-yl)amino)but-3-enoate (2-S5): A solution of (2S)-methyl 2-(((benzyloxy)carbonyl)(prop-2-yn-1-yl)amino)-4-(methylsulfinyl)butanoate (**2-S4**, 2.0 g, 5.69 mmol) in xylene (8 mL) was stirred at 140 °C for 2 days. The mixture was evaporated under reduced pressure and the remaining residue was purified by column chromatography on silica gel (eluted with PE/EtOAc = 25:1 to 20:1) to afford **2-S5** (480 mg, 23.5% yield) as a yellow oil. LC/MS (ESI) m/z: 288 (M+H)⁺.

[0289] Step 5: (1S)-2-Benzyl 1-methyl 5-oxo-1,5,6,6a-tetrahydrocyclopenta[c]pyrrole-1,2(3H)-dicarboxylate (2-S6): To a solution of (S)-methyl 2-(((benzyloxy)carbonyl)(prop-2-yn-1-yl)amino)but-3-enoate (**2-S5**, 480 mg, 1.65 mmol) in THF (8 mL) was added Co₂(CO)₈ (81.4 mg, 0.24 mmol). The reaction mixture was pressurized with a CO atmosphere (50 psi) and mixed at 100 °C overnight. The mixture was filtered and the filtrate was evaporated under reduced pressure. The remaining residue was purified by column chromatography on silica gel (eluted with PE/EtOAc = 4:1 to 2:1) to afford **2-S6** (130 mg, 18.8% yield) as a brown oil. LC/MS (ESI) m/z: 316 (M+H)⁺.

[0290] Step 6: (1S,3aS,6aR)-2-Benzyl 1-methyl 5-oxohexahydrocyclopenta[c]pyrrole-1,2(1H)-dicarboxylate (2-S7): To a solution of (1S)-2-benzyl 1-methyl 5-oxo-1,5,6,6a-tetrahydrocyclopenta[c]pyrrole-1,2(3H)-dicarboxylate (**2-S6**, 130 mg, 0.41 mmol) in MeOH (1 mL) and THF (1 mL) was added Pd/C (13 mg) and the reaction mixture was stirred at 0 °C under an atmosphere of hydrogen (balloon) for 30 minutes. The mixture was filtered and the filtrate was evaporated under reduced pressure to afford **2-S7** (120 mg, 92.6% yield) as a yellow oil. This crude product was carried forward in the next synthetic step without further purification. LC/MS (ESI) m/z: 318 (M+H)⁺.

[0291] Step 7: (1S,3aS,6aR)-2-Benzyl 1-methyl 5-hydroxyhexahydrocyclopenta[c]pyrrole-1,2(1H)-dicarboxylate (2-S8): To a solution of (1S,3aS,6aR)-2-benzyl 1-methyl 5-oxohexahydrocyclopenta[c]pyrrole-1,2(1H)-dicarboxylate (**2-S7**, 120 mg, 0.38 mmol) in MeOH (3 mL) was added NaBH₄ (14.3 mg) at 0 °C under an atmosphere of nitrogen and the reaction mixture was stirred at 0 °C for 30 minutes. The mixture was quenched by the addition of aqueous NH₄Cl solution (15 mL) and extracted with EtOAc (2 × 10 mL). The combined organic layers were washed with brine, dried over Na₂SO₄, and evaporated under reduced pressure. The remaining residue was purified by column chromatography on silica gel (eluted with PE/EtOAc = 3:1 to 2:1) to afford **2-S8** (90 mg, yield 74.4%) as a yellow oil. LC/MS (ESI) m/z: 320 (M+H)⁺.

[0292] Step 8: (1S,3aS,6aR)-2-Benzyl 1-methyl 5-(((4-fluorophenoxy)carbonothioyl)oxy)hexahydrocyclopenta[c]pyrrole-1,2(1H)-dicarboxylate (2-S9): To a solution of (1S,3aS,6aR)-2-benzyl 1-methyl 5-hydroxyhexahydrocyclopenta[c]pyrrole-1,2(1H)-dicarboxylate (**2-S8**, 143 mg, 0.45 mmol) in DCM (5 mL) were added 4-fluorophenylthionochloroformate (127.7 mg, 0.67 mmol) and DMAP (164.3 mg, 1.34 mmol). The reaction mixture was stirred at room temperature overnight. The mixture was diluted with DCM (20 mL), washed successively with 0.5 N aqueous HCl (10 mL), water (10 mL), and brine, dried over Na₂SO₄, filtered, and concentrated to dryness. The remaining residue was purified by column chromatography on silica gel (PE/EtOAc=20:1 to 4:1) to afford **2-S9** (110 mg, yield 51.6%) as a white solid. LC/MS (ESI) m/z: 496 (M+Na)⁺.

[0293] Step 9: (1S,3aS,6aR)-2-Benzyl 1-methyl hexahydrocyclopenta[c]pyrrole-1,2(1H)-dicarboxylate (2-S10): To a solution of (1S,3aS,6aR)-2-benzyl 1-methyl 5-(((4-fluorophenoxy)carbonothioyl)oxy)hexahydrocyclopenta[c]pyrrole-1,2(1H)-dicarboxylate (**2-S9**, 110 mg, 0.23 mmol) in 1,4-dioxane (3 mL) were added 1,1'-azobis(cyclohexanecarbonitrile) (Vazo, 18.9 mg, 0.12 mmol) and tris(trimethylsilyl)silane (86.8 mg, 0.35 mmol). The reaction mixture was stirred at 105 °C for 40 minutes. The reaction mixture was concentrated to dryness and the remaining residue was purified by column chromatography on silica gel (eluted with PE/EtOAc = 40:1 to 10:1) to afford **2-S10** (68 mg, 97.5% yield) as light oil. LC/MS (ESI) m/z: 304 (M+H)⁺.

[0294] Step 10: (1S,3aS,6aR)-2-((Benzyloxy)carbonyl)octahydrocyclopenta[c]pyrrole-1-carboxylic acid (2-S11): To a solution of (1S,3aS,6aR)-2-benzyl 1-methyl hexahydrocyclopenta[c]pyrrole-1,2(1H)-dicarboxylate (**2-S10**, 68 mg, 0.22 mmol) in THF (3 mL) was added a 1 M aqueous NaOH solution (0.44 mL, 0.44 mmol) at 0 °C and the reaction mixture was stirred at room temperature for 2 hours. The mixture was diluted with water (15 mL) and concentrated under reduced pressure. The remaining residue was washed with Et₂O (2 × 10 mL). The aqueous layer was acidified with 2 N


aqueous HCl until pH ~3 and extracted with EtOAc (2 × 15 mL). The combined organic layers were dried over Na₂SO₄ and concentrated under reduced pressure to afford **2-S11** (40 mg, 61.7% yield) as light oil. This crude product was carried forward without further purification. LC/MS (ESI) m/z: 290 (M+H)⁺.

[0295] Step 11: (1S,3aS,6aR)-Benzyl 1-((6-bromopyridin-2-yl)carbamoyl)hexahydrocyclopenta[c] pyrrole-2(1H)-carboxylate (2-S12): To a mixture of (1S,3aS,6aR)-2-((benzyloxy)carbonyl)octahydrocyclopenta[c]pyrrole-1-carboxylic acid (**2-S11**, 40 mg, 0.14 mmol), 6-bromopyridin-2-amine (25 mg, 0.14 mmol), and EEDQ (69.2 mg, 0.28 mmol) in DCE (4 mL) was added DIPEA (54.2 mg, 0.42 mmol) and the reaction mixture was stirred at 90 °C under an atmosphere of nitrogen overnight. The mixture was concentrated to dryness and the remaining residue was purified by column chromatography on silica gel (eluted with PE/EtOAc = 20:1 to 10:1) to afford **2-S12** (30 mg, 48.4% yield) as a light oil. LC/MS (ESI) m/z: 444 (M+H)⁺.

[0296] Step 12: (1S,3aS,6aR)-N-(6-Bromopyridin-2-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide (2-S13): To a solution of (1S,3aS,6aR)-benzyl 1-((6-bromopyridin-2-yl)carbamoyl)hexahydrocyclopenta[c] pyrrole-2(1H)-carboxylate (**2-S12**, 30 mg, 0.07 mmol) in AcOH (1.5 mL) was added a 30% HBr/AcOH solution (0.3 mL) at 0 °C and the reaction mixture was stirred at room temperature for 1 hour. The mixture was poured into ice-cooled aqueous NaHCO₃ solution and extracted with EtOAc (2 × 15 mL). The combined organic layers were dried over Na₂SO₄ and concentrated under reduced pressure to afford **2-S13** (25 mg, crude) as a brown oil. This crude product was used directly in the next reaction without further purification. LC/MS (ESI) m/z: 310 (M+H)⁺.

[0297] Step 13: (1S,3aS,6aR)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridin-2-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide (2): To a mixture of (1S,3aS,6aR)-N-(6-bromopyridin-2-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide (**2-S13**, 25 mg, 0.08 mmol), 2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl) acetic acid (25 mg, 0.08 mmol), and HATU (45.6 mg, 0.12 mmol) in DMF (2 mL) was added DIPEA (31 mg, 0.24 mmol). The reaction mixture was stirred at room temperature overnight. The mixture was partitioned with EtOAc and water. The organic layer was washed with brine, dried over Na₂SO₄, and concentrated under reduced pressure. The remaining residue was purified by preparative HPLC to afford **2** (5 mg, 16.6% yield) as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.97 (s, 1H), 9.04 (s, 2H), 8.43 (s, 1H), 8.05 (d, *J* = 8.2 Hz, 1H), 7.87-7.85 (m, 2H), 7.72 (t, *J* = 8.0 Hz, 1H), 7.32 (d, *J* = 7.7 Hz, 1H), 5.74 (d, *J* = 17.3 Hz, 1H), 5.62 (d, *J* = 17.2 Hz, 1H), 4.42 (d, *J* = 2.8 Hz, 1H), 4.09-4.03 (m, 1H), 3.67-3.63 (m, 1H), 2.87-2.84 (m, 1H), 2.69 (s, 3H), 2.65 (s, 3H), 1.98-1.58 (m, 7H). LC/MS (ESI) m/z: 602 (M+H)⁺.

Scheme 3: Synthesis of (S)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[2.2.2]octane-3-carboxamide (3)



[0298] The above scheme and following detailed description depicts one non-limiting method for synthesizing compounds via the following steps: 1) the formation of an amide bond between the B-ring and the C-ring by utilizing a coupling reagent such as EEDQ or HATU; 2) the removal of the Boc-group using an acid; and, 3) the formation of an amide bond between the C-ring (already linked to the B-ring) and A-ring utilizing HATU. The skilled artisan will recognize that the C- and

B-ring synthetic intermediate can be replaced with other synthetic intermediates to afford additional compounds of the present invention. The skilled artisan will also recognize that the A-ring synthetic intermediate can be replaced with other synthetic intermediates to afford additional compounds of the present invention.


[0299] Step 1: (S)-tert-Butyl 3-(6-bromo-3-methylpyridin-2-ylcarbamoyl)-2-azabicyclo[2.2.2]octane-2-carboxylate (3-S2): To a mixture of **3-S1** (230 mg, 0.902 mmol), 6-bromo-3-methylpyridin-2-amine (169 mg, 0.902 mmol), and EEDQ (446 mg, 1.80 mmol) in DCE (10 mL) was added DIPEA (0.6 mL, 3.61 mmol). The reaction mixture was stirred at 90 °C overnight. The mixture was then concentrated under reduced pressure and the remaining residue was purified by column chromatography on silica gel (eluted with PE/EtOAc = 20:1 to 10:1) to afford **3-S2** (100 mg, 26.2% yield) as a yellow solid. LC/MS (ESI) m/z: 424 (M+H)⁺.

[0300] Step 2: (S)-N-(6-Bromo-3-methylpyridin-2-yl)-2-azabicyclo[2.2.2]octane-3-carboxamide (3-S3): To a solution of **3-S2** (100 mg, 0.236 mmol) in dioxane (2 mL) was added HCl/dioxane solution (1 mL, 2 M) at 0 °C and the reaction mixture was stirred at room temperature for 1 hour. The mixture was concentrated to dryness to afford **3-S3** (105 mg, 100% yield) as a brown solid, which was used in the next synthetic step without further purification. LC/MS (ESI) m/z: 324 (M+H)⁺.

[0301] Step 3: (S)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[2.2.2]octane-3-carboxamide (3): To a mixture of 2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetic acid (24 mg, 0.078 mmol) in DMF were added DIPEA (0.03 mL, 0.195 mmol), HATU (37.0 mg, 0.097 mmol), and **3-S3** (21.0 mg, 0.065 mmol). The reaction mixture was stirred at room temperature overnight. The mixture was diluted with EtOAc, washed with water and brine, dried over Na₂SO₄, and concentrated under reduced pressure. The remaining residue was purified by preparative HPLC to afford **3** (2.5 mg, 6.27% yield) as a white solid. ¹H NMR (400 MHz, CD₃OD) δ 9.01 (s, 2H), 8.54 (s, 1H), 7.79 (s, 2H), 7.54 (d, J = 7.9 Hz, 1H), 7.36 (d, J = 7.9 Hz, 1H), 5.63 (q, J = 16.8 Hz, 2H), 4.50 (s, 1H), 4.22 (s, 1H), 2.75 (s, 3H), 2.71-2.66 (m, 3H), 2.41 (s, 1H), 2.30 (d, J = 15.1 Hz, 1H), 2.09 (m, 3H), 1.88 (m, 5H), 1.69 (d, J = 6.7 Hz, 1H), 1.34 (m, 1H). LC/MS (ESI) m/z: 616 (M+H)⁺.

[0302] (1R,3S,5S)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-(methoxymethyl)pyridin-2-yl)-5-(methoxymethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (49): ¹H NMR (400 MHz, CD₃OD) δ 9.01 (d, J = 6.9 Hz, 2H), 8.54 (s, 1H), 8.04 (d, J = 8.2 Hz, 1H), 7.80 (d, J = 9.8 Hz, 2H), 7.27 (d, J = 8.1 Hz, 1H), 5.81 (d, J = 17.2 Hz, 1H), 5.66 (d, J = 17.1 Hz, 1H), 4.76 (s, 1H), 4.46 (s, 2H), 3.79 (s, 1H), 3.74-3.69 (m, 1H), 3.63 (d, J = 10.2 Hz, 1H), 3.51 (d, J = 10.3 Hz, 1H), 3.43 (s, 3H), 3.40 (s, 3H), 2.75 (s, 3H), 2.70 (s, 3H), 2.59 (dd, J = 16.6, 6.7 Hz, 2H), 2.19 (t, J = 7.6 Hz, 1H), 1.16-1.11 (m, 1H), 0.90 (t, J = 6.8 Hz, 1H). LC/MS (ESI) m/z: 662 (M+H)⁺.

Scheme 4: Synthesis of (3*S*,5*R*)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-methylpyridin-2-yl)-5-(piperidin-1-ylmethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (4)



[0303] The above scheme and following detailed description depicts one non-limiting method for synthesizing compounds with nucleophilic R²⁰¹ groups on the C-ring. The skilled artisan will recognize that piperidine can be replaced with other nucleophilic reagents to afford additional compounds of the present invention. Non-limiting examples of groups the skilled artisan can use instead of piperidine include azetidine, 6-azaspiro[2.5]octane, and 2-azaspiro[3.3]heptane.

[0304] Step 1: (3*S*)-tert-Butyl 3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-5-(piperidin-1-ylmethyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (4-S2): To a mixture of 4-S1 (25 mg, 0.05 mmol) in MeCN (2 mL) were added DIPEA (0.035 mL, 0.2 mmol), piperidine (4 mg, 0.055 mmol), and NaI at 0 °C. The reaction mixture was stirred at room temperature for 4 hours. The mixture was concentrated, diluted with DCM, and washed with water and brine. The organic layer was dried over anhydrous Na₂SO₄, filtered, and concentrated. The remaining residue was purified by column chromatography on silica gel (eluted with DCM/MeOH = 40:1 to 30:1) to afford the title compound (8 mg, 33.3% yield) as a yellow solid. LC/MS (ESI) m/z: 493 (M+H)⁺.

[0305] Step 2: (3*S*)-*N*-(6-Bromo-3-methylpyridin-2-yl)-5-(piperidin-1-ylmethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (4-S3): To a solution of 4-S2 (8 mg, 0.016 mmol) in dioxane (1 mL) was added HCl/dioxane (1 mL) at 0 °C. The reaction mixture was stirred at room temperature for 2 hours. The mixture was concentrated to dryness to afford the title compound (10 mg, 100% yield) as a brown solid. The crude material was carried forward in the next synthetic step without further purification. LC/MS (ESI) m/z: 393 (M+H)⁺.

[0306] Step 3: (3*S*,5*R*)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-methylpyridin-2-yl)-5-(piperidin-1-ylmethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (4): To a solution of 4-S3 (10 mg, 0.025 mmol) and 4-S4 (7.75 mg, 0.025 mmol) in DMF (2 mL) was added HATU (17.1 mg, 0.045 mmol) and DIPEA (0.018 mL, 0.10 mmol) at 0 °C. The reaction mixture was stirred at room temperature overnight. The mixture was diluted with EtOAc and washed with 10% aqueous LiCl solution and brine. The organic layer was dried over anhydrous Na₂SO₄ and concentrated to dryness. The remaining residue was purified by preparative HPLC to afford 4 (2.1 mg, 12.3% yield) as a white solid. ¹H NMR (400 MHz, CD₃OD) δ 9.02 (s, 2H), 8.56 (s, 1H), 7.81 (s, 2H), 7.57 (d, *J* = 7.9 Hz, 1H), 7.41 (d, *J* = 7.9 Hz, 1H), 5.82 (d, *J* = 17.2 Hz, 1H), 5.67 (d, *J* = 17.2 Hz, 1H), 5.35-5.33 (m, 1H), 4.68 (t, *J* = 7.2 Hz, 1H), 3.04 (d, *J* = 7.3 Hz, 2H), 2.75 (s, 3H), 2.70 (d, *J* = 2.0 Hz, 4H), 2.66 (d, *J* = 8.4 Hz, 2H), 2.20 (t, *J* = 7.2 Hz, 2H), 2.13 (s, 3H), 2.04 (s, 2H), 1.83 (s, 4H), 1.60 (s, 4H). LC/MS (ESI) m/z: 685 (M+H)⁺.

[0307] (3*S*)-5-(6-Azaspiro[2.5]octan-6-ylmethyl)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)

acetyl)-*N*-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (**5**): ^1H NMR (400 MHz, CD_3OD) δ 9.01 (s, 2H), 8.57 (s, 1H), 7.80 (s, 2H), 7.59 (d, $J = 8.2$ Hz, 1H), 7.42 (d, $J = 8.0$ Hz, 1H), 5.82 (d, $J = 17.1$ Hz, 1H), 5.67 (d, $J = 16.9$ Hz, 1H), 2.75 (s, 3H), 2.70 (s, 3H), 2.67 (s, 1H), 2.13 (s, 3H), 1.48 (s, 2H), 1.33 (s, 2H), 1.29 (s, 6H), 0.90 (s, 3H), 0.51 (s, 3H). LC/MS (ESI) m/z : 711 ($\text{M}+\text{H}$) $^+$.


[0308] (3*S*)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-5-(azetidin-1-ylmethyl)-*N*-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (**6**): ^1H NMR (400 MHz, CD_3OD) δ 9.01 (s, 2H), 8.56 (s, 1H), 7.80 (s, 2H), 7.59 (d, $J = 7.9$ Hz, 1H), 7.43 (d, $J = 8.0$ Hz, 1H), 5.81 (d, $J = 17.2$ Hz, 1H), 5.66 (d, $J = 17.1$ Hz, 1H), 5.35 (d, $J = 5.0$ Hz, 1H), 4.72-4.65 (m, 1H), 4.30 (s, 2H), 3.53 (d, $J = 13.3$ Hz, 1H), 3.46 (t, $J = 6.8$ Hz, 2H), 2.75 (s, 3H), 2.70 (s, 3H), 2.66-2.59 (m, 1H), 2.54-2.50 (m, 1H), 2.20 (dd, $J = 15.8, 8.3$ Hz, 2H), 2.12 (s, 3H), 2.04 (s, 2H), 1.60 (s, 2H), 1.41 (d, $J = 6.2$ Hz, 1H), 1.10-1.08 (m, 1H). LC/MS (ESI) m/z : 657 ($\text{M}+\text{H}$) $^+$.

[0309] (3*S*)-5-(3-Azabicyclo[3.1.1]heptan-3-ylmethyl)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (**13**): ^1H NMR (400 MHz, CD_3OD) δ 9.01 (s, 2H), 8.55 (s, 1H), 7.84-7.76 (m, 2H), 7.59 (d, $J = 8.2$ Hz, 1H), 7.42 (d, $J = 8.0$ Hz, 1H), 5.88 (d, $J = 17.2$ Hz, 1H), 5.64 (d, $J = 17.2$ Hz, 1H), 4.64 (dd, $J = 9.0, 4.2$ Hz, 1H), 4.22 (s, 3H), 4.01 (d, $J = 3.2$ Hz, 1H), 3.52-3.37 (m, 2H), 2.75 (s, 3H), 2.69 (s, 3H), 2.61 (d, $J = 9.2$ Hz, 1H), 2.54 (d, $J = 3.8$ Hz, 1H), 2.34 (s, 4H), 2.12 (s, 3H), 1.90 (t, $J = 7.6$ Hz, 2H), 1.40 (s, 1H), 1.10-1.08 (m, 1H). LC/MS (ESI) m/z : 697 ($\text{M}+\text{H}$) $^+$.

[0310] (3*S*)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-methylpyridin-2-yl)-5-((4-methylpiperazin-1-yl)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (**24**): ^1H NMR (400 MHz, CD_3OD) δ 9.01 (s, 2H), 8.56 (s, 1H), 7.80 (d, $J = 1.2$ Hz, 2H), 7.56 (d, $J = 7.8$ Hz, 1H), 7.40 (d, $J = 7.9$ Hz, 1H), 5.80 (d, $J = 17.2$ Hz, 1H), 5.66 (d, $J = 17.2$ Hz, 1H), 4.65-4.61 (m, 4.7 Hz, 1H), 3.66-3.64 (m, 1H), 3.28 (s, 3H), 2.99 (s, 4H), 2.75 (s, 4H), 2.72 (s, 1H), 2.69 (s, 4H), 2.65 (s, 3H), 2.54-2.44 (m, 2H), 2.12 (s, 3H), 1.20-1.02 (m, 2H). LC/MS (ESI) m/z : 700 ($\text{M}+\text{H}$) $^+$.

[0311] (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-methylpyridin-2-yl)-5-((4-methylpiperazin-1-yl)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (**69**): ^1H NMR (400 MHz, CD_3OD) δ 8.99 (s, 2H), 8.40 (s, 1H), 7.50-7.53 (m, 2H), 7.35 (d, $J = 8.0$ Hz, 1H), 5.87 (s, 2H), 4.85-5.03 (m, 1H), 3.63-3.66 (m, 1H), 3.29-3.33 (m, 5H), 2.67-2.92 (m, 17H), 2.32-2.48 (m, 2H), 2.04 (s, 3H), 1.72-1.74 (m, 1H), 1.03-1.06 (m, 1H). LC/MS (ESI) m/z : 714/716 ($\text{M}+\text{H}$) $^+$.

Scheme 5: Synthesis of (3*S*)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-5-(azetidin-1-ylmethyl)-*N*-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (9**)**



[0312] The above scheme and following detailed description depicts one non-limiting method for synthesizing compounds via the formation of an amide bond between the C-ring (already linked to the B-ring) and A-ring utilizing HATU or a different peptide coupling reagent, such as TBTU. The skilled artisan will recognize that the C- and B-ring synthetic intermediate can be replaced with other synthetic intermediates to afford additional compounds of the present invention. The skilled artisan will also recognize that the A-ring synthetic intermediate can be replaced with other synthetic intermediates to afford additional compounds of the present invention.

[0313] To a solution of **9-S1** (45 mg, 0.086 mmol) and **9-S2** (26.7 mg, 0.086 mmol) in DMF (2 mL) was added HATU (58.9 mg, 0.155 mmol) and DIPEA (0.06 mL, 0.344 mmol) at 0 °C. The reaction mixture was stirred at room temperature

overnight. The mixture was diluted with EtOAc and washed with 10% aqueous LiCl solution and brine. The organic layer was dried over anhydrous Na₂SO₄ and concentrated to dryness. The remaining residue was purified by preparative HPLC to afford **9** (23 mg, 41.5% yield) as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ: 10.35 (s, 1H), 9.51 (s, 1H), 9.05 (s, 2H), 8.45 (s, 1H), 7.87 (s, 2H), 7.63 (d, *J* = 8.1 Hz, 1H), 7.45 (d, *J* = 7.9 Hz, 1H), 5.94 (d, *J* = 17.3 Hz, 1H), 5.62 (d, *J* = 17.3 Hz, 1H), 4.47 (dd, *J* = 9.0, 5.0 Hz, 1H), 2.82 (s, 2H), 2.69 (s, 3H), 2.66 (s, 3H), 2.66-2.64 (m, 1H), 2.51 (d, *J* = 1.7 Hz, 6H), 2.42-2.31 (m, 2H), 2.04 (s, 3H), 2.00 (d, *J* = 7.7 Hz, 1H), 1.34 (d, *J* = 6.1 Hz, 1H). LC/MS (ESI) *m/z*: 645 (M+H)⁺.

[0314] (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(2-fluoro-3-(trifluoromethoxy)phenyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (33): ¹H NMR (400 MHz, CD₃OD) δ: 9.01 (s, 2H), 8.42 (s, 1H), 7.92-7.89 (m, 1H), 7.54 (s, 1H), 7.21-7.19 (m, 2H), 5.98 (d, *J* = 17.6 Hz, 1H), 5.82 (d, *J* = 17.6 Hz, 1H), 4.60 (m, 1H), 3.57-3.55 (m, 1H), 2.76 (s, 3H), 2.74 (s, 3H), 2.71 (s, 3H), 2.63-2.57 (m, 1H), 2.28-2.23 (m, 1H), 1.42 (s, 3H), 1.15-1.13 (m, 1H), 1.00-0.99 (m, 1H).

[0315] (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-((*S*)-3-fluoro-4-methylpent-3-en-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (34): ¹H NMR (400 MHz, CD₃OD) δ: 9.00 (s, 2H), 8.42 (s, 1H), 7.54 (s, 1H), 5.92 (d, *J* = 17.6 Hz, 1H), 5.78 (d, *J* = 17.6 Hz, 1H), 4.36-4.32 (m, 1H), 3.48-3.46 (m, 1H), 2.76 (s, 3H), 2.74 (s, 3H), 2.69 (s, 3H), 2.50-2.47 (m, 1H), 2.12-2.00 (m, 1H), 1.67 (s, 3H), 1.57 (s, 3H), 1.40 (s, 3H), 1.24 (s, 3H), 1.22-1.21 (m, 1H), 1.10-1.09 (m, 1H), 0.92-0.90 (m, 1H).

[0316] (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-5-methyl-*N*-(1-(2,2,2-trifluoroethyl)-1*H*-pyrazol-3-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (35): ¹H NMR (400 MHz, CD₃OD) δ: 9.01 (s, 2H), 8.42 (s, 1H), 7.61 (s, 1H), 7.55 (s, 1H), 6.67 (s, 1H), 5.98 (d, *J* = 18.0 Hz, 1H), 5.83 (d, *J* = 18.0 Hz, 1H), 4.81-4.76 (m, 1H), 4.51-4.47 (m, 1H), 3.56-3.54 (m, 1H), 2.77 (s, 3H), 2.76 (s, 3H), 2.70 (s, 3H), 2.62-2.56 (m, 1H), 2.22-2.17 (m, 1H), 1.40 (s, 3H), 1.22-1.20 (m, 1H), 1.19-1.10 (m, 1H), 0.97-0.99 (m, 1H).

[0317] (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-5-methyl-*N*-(6-(trifluoromethyl)pyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (36): ¹H NMR (400 MHz, CD₃OD) δ: 9.01 (s, 2H), 8.42-8.36 (m, 2H), 7.99-7.95 (m, 1H), 7.54 (s, 1H), 7.48 (d, *J* = 7.6 Hz, 1H), 6.01 (d, *J* = 18.0 Hz, 1H), 5.81 (d, *J* = 20.0 Hz, 1H), 4.54-4.52 (m, 1H), 3.59-3.58 (m, 1H), 2.78 (s, 3H), 2.75 (s, 3H), 2.68 (s, 3H), 2.61-2.59 (m, 1H), 2.23-2.19 (m, 1H), 1.40 (s, 3H), 1.14-1.11 (m, 1H), 1.00-0.98 (m, 1H).

[0318] (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-5-methyl-*N*-(6-(trifluoromethoxy)pyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (37): ¹H NMR (400 MHz, CD₃OD) δ: 9.05-9.02 (m, 2H), 8.43 (s, 1H), 8.11-8.09 (m, 1H), 7.91-7.87 (m, 1H), 7.54 (s, 1H), 6.83 (d, *J* = 7.6 Hz, 1H), 6.00 (d, *J* = 18.0 Hz, 1H), 5.80 (d, *J* = 17.6 Hz, 1H), 4.55-4.54 (m, 1H), 3.74-3.58 (m, 1H), 3.57-3.56 (m, 1H), 2.77 (s, 3H), 2.75 (s, 3H), 2.74-2.73 (m, 2H), 2.61-2.57 (m, 1H), 2.21-2.16 (m, 1H), 1.40 (s, 3H), 1.14-1.11 (m, 1H), 0.98-0.97 (m, 1H).

[0319] (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(2'-chloro-2-fluoro-[1,1'-biphenyl]-3-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (38): ¹H NMR (400 MHz, DMSO-*d*₆) δ: 9.80 (s, 1H), 9.01 (s, 2H), 8.31 (s, 1H), 7.95-7.94 (m, 1H), 7.61-7.37 (m, 5H), 7.13-7.21 (m, 1H), 7.07-7.06 (m, 1H), 6.08 (d, *J* = 18.0 Hz, 1H), 5.67 (d, *J* = 18.0 Hz, 1H), 4.55-4.52 (m, 1H), 3.63-3.61 (m, 1H), 2.69 (s, 3H), 2.68 (s, 3H), 2.63 (s, 3H), 2.11-2.09 (m, 1H), 1.32 (s, 3H), 1.26-1.24 (m, 1H), 0.94-0.92 (m, 1H), 0.86-0.83 (m, 1H).

[0320] (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(2'-chloro-2-fluoro-[1,1'-biphenyl]-3-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (39): ¹H NMR (400 MHz, DMSO-*d*₆) δ: 9.77 (s, 1H), 9.03 (s, 2H), 8.43 (s, 1H), 7.91-7.80 (m, 3H), 7.57 (d, *J* = 8.0 Hz, 1H), 7.45-7.37 (m, 3H), 7.25-7.21 (m, 1H), 7.08-7.06 (m, 1H), 5.95 (d, *J* = 17.2 Hz, 1H), 5.58 (d, *J* = 17.2 Hz, 1H), 4.58-4.56 (m, 1H), 3.62-3.60 (m, 1H), 2.69 (s, 3H), 2.64 (s, 3H), 2.47-2.46 (m, 1H), 2.11-2.09 (m, 1H), 1.32 (s, 3H), 1.01-1.00 (m, 1H), 0.86-0.83 (m, 1H).

[0321] 1-(2-((1*R*,3*S*,5*R*)-3-((6-Bromo-3-methylpyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-5-(2-methylpyrimidin-5-yl)-1*H*-indazole-3-carboxamide (55): ¹H NMR (400 MHz, DMSO-*d*₆) δ: 10.28 (s, 1H), 9.03 (s, 2H), 8.44 (s, 1H), 7.83-7.76 (m, 3H), 7.62 (d, *J* = 8.0 Hz, 1H), 7.49-7.44 (m, 2H), 5.82 (d, *J* = 17.6 Hz, 1H), 5.49 (d, *J* = 17.2 Hz, 1H), 4.41-4.37 (m, 1H), 3.58-3.56 (m, 1H), 2.68 (s, 3H), 2.57-2.54 (m, 1H), 2.04 (s, 3H), 2.03-2.00 (m, 1H), 1.32 (s, 3H), 1.00-0.96 (m, 2H).

[0322] 1-(2-((1*R*,2*S*,5*S*)-2-((6-Bromo-3-methylpyridin-2-yl)carbamoyl)-3-azabicyclo[3.1.0]hexan-3-yl)-2-oxoethyl)-5-(2-methylpyrimidin-5-yl)-1*H*-indazole-3-carboxamide (56): ¹H NMR (400 MHz, DMSO-*d*₆) δ: 10.31 (s, 1H), 9.03 (s, 2H), 8.42 (s, 1H), 7.79-7.74 (m, 2H), 7.69 (s, 1H), 7.59 (d, *J* = 8.0 Hz, 1H), 7.47 (s, 1H), 7.41 (d, *J* = 7.6 Hz, 1H), 5.58-5.47 (m, 2H), 4.58-4.57 (m, 1H), 4.01-4.00 (m, 1H), 3.88-3.81 (m, 1H), 2.77 (s, 3H), 2.03 (s, 3H), 2.02-2.01 (m, 1H), 1.89-1.82 (m, 1H), 0.92-0.69 (m, 2H).

[0323] (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-((*R*)-1-((*R*)-2,2-dichlorocyclopropyl)ethyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (52): ¹H NMR (400 MHz, DMSO-*d*₆) δ: 9.03 (s, 2H), 8.32 (s, 1H), 7.98 (d, *J* = 8.0 Hz, 1H), 7.63 (s, 1H), 5.97 (d, *J* = 18.0 Hz, 1H), 5.70 (d, *J* = 18.0 Hz, 1H), 4.25-4.22 (m, 1H), 3.52-3.51 (m, 2H), 2.68 (s, 3H), 2.65 (s, 6H), 2.45-2.42 (m, 1H), 1.96-1.92 (m, 2H), 1.74-1.72 (m, 1H), 1.45-1.43 (m, 1H), 1.41-1.31 (m, 2H), 1.27-1.24 (m, 2H), 1.15-1.13 (m, 2H), 1.09-1.08 (m, 1H), 1.04-0.88 (m, 1H).

[0324] (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-5-methylpyrazin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (54): ¹H NMR (400 MHz, DMSO-*d*₆) δ:

11.06 (s, 1H), 9.13 (s, 1H), 9.03 (s, 2H), 8.31 (s, 1H), 7.62 (s, 1H), 6.07 (d, $J = 18.0$ Hz, 1H), 5.67 (d, $J = 18.0$ Hz, 1H), 4.45 - 4.41 (m, 1H), 3.65 - 3.64 (m, 1H), 2.73 (s, 3H), 2.69 (s, 3H), 2.68 (s, 3H), 2.61 (s, 3H), 2.60 - 2.59 (m, 1H), 2.04 - 2.00 (m, 1H), 1.31 (s, 3H), 0.99 - 0.98 (m, 2H).

[0325] 1-(2-((1*R*,3*S*,5*R*)-3-((6-Bromo-3-methylpyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-7-methyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazole-3-carboxamide (57): ^1H NMR (400 MHz, DMSO- d_6) δ : 10.33 (s, 1H), 9.02 (s, 2H), 8.32 (s, 1H), 7.73 (s, 1H), 7.62 (d, $J = 8.0$ Hz, 1H), 7.56 (s, 1H), 7.46 - 7.42 (m, 2H), 5.94 (d, $J = 18.0$ Hz, 1H), 5.59 (d, $J = 17.6$ Hz, 1H), 4.41 - 4.37 (m, 1H), 3.60 - 3.58 (m, 1H), 2.68 (s, 3H), 2.66 (s, 3H), 2.66 - 2.53 (m, 1H), 2.01 (s, 3H), 2.00 - 1.99 (m, 1H), 1.32 (s, 3H), 1.03 - 1.00 (m, 1H), 0.89 - 0.88 (m, 1H).

[0326] 1-(2-((1*R*,3*S*,5*R*)-3-((6-Bromopyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-7-methyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazole-3-carboxamide (58): ^1H NMR (400 MHz, DMSO- d_6) δ : 10.82 (s, 1H), 9.00 (s, 2H), 8.30 (s, 1H), 8.03 (d, $J = 8.0$ Hz, 1H), 7.74 - 7.70 (m, 2H), 7.56 (s, 1H), 7.46 (s, 1H), 7.32 (d, $J = 7.6$ Hz, 1H), 5.97 (d, $J = 18.0$ Hz, 1H), 5.57 (d, $J = 18.0$ Hz, 1H), 4.40 (t, $J = 14.8$ Hz, 1H), 3.62 (t, $J = 8.8$ Hz, 1H), 2.67 (s, 6H), 2.00 - 1.96 (m, 1H), 1.30 (s, 3H), 1.29 - 1.27 (m, 1H), 1.00 - 0.84 (m, 2H).

[0327] (2*S*,4*R*)-1-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-methylpyridin-2-yl)-4-fluoro-4-(fluoromethyl)pyrrolidine-2-carboxamide (66): ^1H NMR (400 MHz, CD_3OD) δ : 9.02 (s, 2H), 8.44 (s, 1H), 7.56 (d, $J = 7.8$ Hz, 2H), 7.39 (d, $J = 8.0$ Hz, 1H), 5.84 (d, $J = 17.6$ Hz, 1H), 5.74 (d, $J = 17.5$ Hz, 1H), 4.74 - 4.70 (m, 2H), 4.35 - 4.31 (m, 1H), 4.17 - 4.15 (m, 1H), 4.10 - 4.07 (m, 1H), 2.77 (s, 6H), 2.70 (s, 3H), 2.50 - 2.44 (m, 1H), 2.42 - 2.36 (m, 1H), 2.12 (s, 3H). LC/MS (ESI) m/z : 640 ($\text{M} + \text{H}$) $^+$.

[0328] (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(3,3-dimethylbutyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (80): ^1H NMR (400 MHz, DMSO- d_6) δ : 9.03 (s, 2H), 8.32 (s, 1H), 7.75 - 7.73 (m, 1H), 7.63 (s, 1H), 5.96 (d, $J = 17.2$ Hz, 1H), 5.67 (d, $J = 17.2$ Hz, 1H), 4.14 - 4.12 (m, 1H), 3.86 - 3.75 (m, 4H), 3.50 - 3.49 (m, 1H), 3.06 - 3.00 (m, 2H), 2.66 (s, 3H), 2.61 (s, 3H), 2.49 - 2.33 (m, 1H), 1.90 - 1.89 (m, 1H), 1.30 - 1.28 (s, 5H), 1.00 - 0.99 (m, 1H), 0.98 (s, 9H).

[0329] (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-5-methyl-*N*-(2-(trifluoromethoxy)ethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (81): ^1H NMR (400 MHz, DMSO- d_6) δ : 9.03 (s, 2H), 8.31 (s, 1H), 8.15 - 8.12 (m, 1H), 7.62 (s, 1H), 5.96 (d, $J = 18$ Hz, 1H), 5.67 (d, $J = 18$ Hz, 1H), 4.22 - 4.02 (m, 4H), 3.51 - 3.49 (m, 1H), 3.36 - 3.24 (m, 2H), 2.68 (s, 3H), 2.64 (s, 3H), 2.49 - 2.33 (m, 3H), 1.89 - 1.85 (m, 1H), 1.26 (s, 3H), 1.00 - 0.99 (m, 1H), 0.88 - 0.87 (m, 1H).

[0330] (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-methoxypyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (82): ^1H NMR (400 MHz, DMSO- d_6) δ : 10.20 (s, 1H), 9.01 (s, 2H), 8.30 (s, 1H), 7.67 - 7.61 (m, 3H), 6.49 (d, $J = 7.6$ Hz, 1H), 6.08 (d, $J = 16$ Hz, 1H), 5.65 (d, $J = 17.6$ Hz, 1H), 4.51 - 4.48 (m, 1H), 3.78 (s, 3H), 3.63 - 3.62 (m, 1H), 2.67 (s, 3H), 2.61 (s, 3H), 2.55 (s, 3H), 2.02 - 1.97 (m, 1H), 1.31 (s, 3H), 0.88 - 0.86 (m, 3H).

[0331] (1*R*,3*S*,5*S*)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-methylpyridin-2-yl)-5-(methoxymethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (98): ^1H NMR (400 MHz, CD_3OD) δ : 9.00 (s, 2H), 8.42 (d, $J = 1.1$ Hz, 1H), 7.57 - 7.51 (m, 2H), 7.39 (d, $J = 8.0$ Hz, 1H), 5.98 (d, $J = 16.0$ Hz, 1H), 5.82 (d, $J = 16.0$ Hz, 1H), 4.64 (m, 1H), 3.73 (m, 1H), 3.58 (d, $J = 1.2$ Hz, 2H), 3.43 (s, 3H), 2.76 (s, 6H), 2.70 (s, 3H), 2.62 (m, 1H), 2.54 (m, 1H), 2.14 (s, 3H), 1.34 (t, $J = 5.5$ Hz, 1H), 1.09 (m, 1H). LC/MS (ESI) m/z : 646 ($\text{M} + \text{H}$) $^+$.

[0332] (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-hydroxypyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (105): ^1H NMR (400 MHz, DMSO- d_6) δ : 10.20 (s, 1H), 9.02 (s, 2H), 8.31 (s, 1H), 7.55 (s, 1H), 7.53 - 7.50 (m, 1H), 7.21 - 7.20 (m, 1H), 6.27 - 6.26 (m, 1H), 6.08 (d, $J = 20$ Hz, 1H), 5.66 (d, $J = 20$ Hz, 1H), 4.47 - 4.43 (m, 2H), 3.77 - 3.62 (m, 1H), 2.68 (s, 9H), 2.04 - 2.00 (m, 1H), 1.24 (s, 3H), 1.01 - 0.98 (m, 1H), 0.89 - 0.88 (m, 1H).

[0333] (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-5-(2-hydroxypyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (106): ^1H NMR (400 MHz, DMSO- d_6) δ : 10.29 (s, 1H), 8.66 (s, 2H), 8.30 (s, 1H), 7.90 - 7.72 (m, 2H), 7.63 (d, $J = 7.6$ Hz, 1H), 7.45 (d, $J = 7.6$ Hz, 1H), 5.90 (d, $J = 17.6$ Hz, 1H), 5.55 (d, $J = 17.6$ Hz, 1H), 4.42 - 4.38 (m, 1H), 3.59 - 3.58 (m, 1H), 2.64 (s, 3H), 2.04 (s, 3H), 1.32 - 1.24 (m, 5H), 1.03 - 1.00 (m, 2H).

[0334] (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-5-(2-methoxypyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromopyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (108): ^1H NMR (400 MHz, DMSO- d_6) δ : 10.77 (s, 1H), 8.94 (s, 1H), 8.37 (s, 1H), 8.07 (d, $J = 8.0$ Hz, 1H), 7.85 - 7.79 (m, 2H), 7.72 - 7.70 (m, 1H), 7.31 (d, $J = 8.0$ Hz, 1H), 5.94 (d, $J = 17.2$ Hz, 1H), 5.55 (d, $J = 17.2$ Hz, 1H), 4.43 - 4.39 (m, 1H), 3.97 (s, 3H), 3.67 - 3.61 (m, 1H), 2.68 (s, 3H), 2.00 - 1.96 (m, 1H), 1.29 (s, 3H), 0.95 - 0.83 (m, 3H).

[0335] (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-5-(2-hydroxypyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromopyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (109): ^1H NMR (400 MHz, DMSO- d_6) δ : 10.79 (s, 1H), 8.74 (s, 2H), 8.30 (s, 1H), 8.04 (d, $J = 8.4$ Hz, 1H), 7.82 - 7.69 (m, 2H), 7.33 (d, $J = 8.0$ Hz, 1H), 5.94 (d, $J = 17.2$ Hz, 1H), 5.55 (d, $J = 17.2$ Hz, 1H), 4.43 - 4.39 (m, 1H), 3.64 - 3.62 (m, 1H), 2.67 (s, 3H), 2.01 - 1.96 (m, 1H), 1.30 (s, 3H), 0.97 - 0.86 (m, 3H).

[0336] (1*R*,3*S*,5*S*)-2-(2-(3-Acetyl-7-(methoxymethyl)-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-

bromo-3-methylpyridin-2-yl)-5-(methoxymethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (114): ¹H NMR (400 MHz, CD₃OD) δ 9.04 (s, 2H), 8.61 (d, *J* = 2.0 Hz, 1H), 7.75 (d, *J* = 2.0 Hz, 1H), 7.56 (d, *J* = 8.0 Hz, 1H), 7.39 (d, *J* = 8.0 Hz, 1H), 6.04 (d, *J* = 16.0 Hz, 1H), 5.89 (d, *J* = 16.0 Hz, 1H), 4.98 (d, *J* = 12.0 Hz, 1H), 4.71 (d, *J* = 12.0 Hz, 1H), 4.63 (m, 1H), 3.69 (m, 1H), 3.58 (m, 2H), 3.43 (s, 3H), 3.39 (s, 3H), 2.77 (s, 3H), 2.71 (s, 3H), 2.58 (m, 2H), 2.15 (s, 3H), 1.33 (m, 1H), 1.15 (m, 1H). LC/MS (ESI) *m/z*: 676 (M+H)⁺.

[0337] (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-5-(2-hydroxypyrimidin-5-yl)-7-methyl-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (121): ¹H NMR (400 MHz, DMSO-*d*₆) δ: 10.32 (s, 1H), 8.72 (s, 2H), 8.19 (s, 1H), 7.62 (d, *J* = 8.0 Hz, 1H), 7.49 (s, 1H), 7.44 (d, *J* = 8.0 Hz, 1H), 6.01 (d, *J* = 17.6 Hz, 1H), 5.66 (d, *J* = 18.0 Hz, 1H), 4.42 - 4.38 (m, 1H), 2.67 (s, 3H), 2.64 (s, 3H), 2.63 - 2.58 (m, 1H), 2.04 (s, 3H), 2.01 - 1.99 (m, 1H), 1.32 (s, 3H), 1.01 - 0.94 (m, 2H).

[0338] (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-4-fluoro-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (130): ¹H NMR (400 MHz, CD₃OD) δ 8.92 (d, *J* = 1.1 Hz, 2H), 7.60 (m, 3H), 7.38 (d, *J* = 7.9 Hz, 1H), 5.80 (m, 1H), 5.65 (m, 1H), 4.53 (m, 1H), 3.53 (m, 1H), 2.76 (s, 3H), 2.71 (s, 3H), 2.63 (m, 1H), 2.31 (m, 1H), 2.12 (s, 3H), 1.40 (s, 3H), 1.10 (m, 1H), 1.00 (m, 1H). LC/MS (ESI) *m/z*: 620 (M+H)⁺.


[0339] (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-7-cyclopropyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (131): ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.31 (s, 1H), 9.03 (s, 2H), 8.32 (d, *J* = 1.2 Hz, 1H), 7.62 (d, *J* = 7.6 Hz, 1H), 7.48 (s, 1H), 7.44 (d, *J* = 7.6 Hz, 1H), 6.14 (d, *J* = 17.6 Hz, 1H), 5.87 (d, *J* = 17.6 Hz, 1H), 4.42 - 4.38 (m, 1H), 3.61 - 3.59 (m, 1H), 2.68 (s, 3H), 2.65 (s, 3H), 2.58 - 2.52 (m, 1H), 2.30 (m, 1H), 2.04 (m, 4H), 1.32 (m, 3H), 1.04 - 1.00 (m, 4H), 0.91 - 0.89 (m, 2H). LC/MS (ESI) *m/z*: 642 (M+H)⁺.

[0340] (1*R*,3*S*,5*S*)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-(methoxymethyl)pyridin-2-yl)-5-(methoxymethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (152): ¹H NMR (400 MHz, CD₃OD) δ 8.99 (s, 2H), 8.53 (s, 1H), 7.78 (d, *J* = 1.2 Hz, 2H), 7.75 (d, *J* = 8.0 Hz, 1H), 7.46 (d, *J* = 8.0 Hz, 1H), 5.81 (d, *J* = 16.0 Hz, 1H), 5.66 (d, *J* = 16.0 Hz, 1H), 4.58 (m, 1H), 4.28 (m, 2H), 3.73 (m, 1H), 3.55 (m, 2H), 3.42 (s, 3H), 3.17 (s, 3H), 2.75 (s, 3H), 2.69 (s, 3H), 2.63 - 2.50 (m, 2H), 1.32 (d, *J* = 4.0 Hz, 1H), 1.11 (m, 1H). LC/MS (ESI) *m/z*: 662 (M+H)⁺.

[0341] (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-methylpyridin-2-yl)-5-((2,2-difluorocyclopentanecarboxamido)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (159): ¹H NMR (400 MHz, CD₃OD) δ 8.93 (s, 2H), 8.47 (s, 1H), 7.71 (s, 2H), 7.47 (d, *J* = 7.9 Hz, 1H), 7.31 (dd, *J* = 7.9, 2.2 Hz, 1H), 5.69 (m, 1H), 5.57 (m, 1H), 4.54 (m, 1H), 3.67 - 3.29 (m, 3H), 3.05 - 2.88 (m, 1H), 2.66 (s, 3H), 2.61 (s, 3H), 2.18 - 1.88 (m, 6H), 1.94 - 1.73 (m, 2H), 1.65 (m, 1H), 1.21 (m, 1H), 1.06 - 0.93 (m, 1H). LC/MS (ESI) *m/z*: 749 (M+H)⁺.

[0342] (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1*H*-pyrazolo[4,3-*b*]pyridin-1-yl)acetyl)-*N*-(6-bromo-5-fluoro-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (185): ¹H NMR (400 MHz, DMSO-*d*₆) δ 0.96 - 1.08 (m, 2H), 1.31 - 1.35 (m, 3H), 2.07 (s, 4H), 2.53 - 2.60 (m, 1H), 2.73 (s, 3H), 2.82 (s, 3H), 3.53 - 3.60 (m, 1H), 4.35 - 4.43 (m, 1H), 5.61 (d, *J* = 17.2 Hz, 1H), 5.93 (d, *J* = 17.2 Hz, 1H), 7.83 (d, *J* = 8.4 Hz, 1H), 8.23 (d, *J* = 9.0 Hz, 1H), 8.35 (d, *J* = 8.9 Hz, 1H), 9.44 (s, 2H), 10.26 (s, 1H).

Scheme 6: (1*S*,3*S*,5*S*)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-methylpyridin-2-yl)-5-((dimethylamino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (10)



[0343] Step 1: (3*S*)-*tert*-Butyl 3-(6-bromo-3-methylpyridin-2-ylcarbamoyl)-5-((1,3-dioxoisindolin-2-yl)methyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (10-S2): To a solution of 10-S1 (1 g, 2.34 mmol), isoindoline-1,3-dione (517 mg, 3.52 mmol), and PPh₃ (1.22 g, 4.68 mmol) in THF (15 mL) was added DIAD (0.92 mL, 4.68 mmol) dropwise at 0 °C under an atmosphere of nitrogen. The reaction mixture was stirred at room temperature for 16 hours. The resulting mixture was partitioned with EtOAc and water. The organic layer was washed with brine, dried over anhydrous Na₂SO₄, and concentrated under reduced pressure. The remaining residue was purified by column chromatography on silica gel (eluted with PE/EtOAc = 10:1 to 3:1) to afford the title compound (1.25 g, 96.1% yield) as a light yellow solid. LC/MS (ESI) *m/z*: 555/557 (M+H)⁺.

[0344] Step 2: (3*S*)-*tert*-Butyl 5-(aminomethyl)-3-(6-bromo-3-methylpyridin-2-ylcarbamoyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (10-S3): To a solution of 10-S2 (1.2 g, 2.16 mmol) in EtOH (10 mL) was added hydrazine hydrate (1 mL, 85%). The reaction mixture was stirred at 60 °C for 3 hours and then cooled to room temperature. The mixture was filtered, the filtrate was concentrated to dryness, and the remaining crude product was purified by column chromatography on silica gel (eluted with DCM/MeOH = 80:1 to 5:1) to afford 10-S3 (500 mg, 52.4% yield) as a light yellow oil. LC/MS (ESI) *m/z*: 425/427 (M+H)⁺.

[0345] Step 3: (3*S*)-*tert*-Butyl 3-(6-bromo-3-methylpyridin-2-ylcarbamoyl)-5-((dimethylamino)methyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (10-S4): To a solution of 10-S3 (500 mg, 1.18 mmol) in MeOH (5 mL) were added NaBH₃CN (148 mg, 2.36 mmol) and 15% aqueous formaldehyde solution (0.3 mL). The reaction mixture was stirred at room temperature for 1 hour and concentrated to dryness. The remaining residue was purified by column chromatography


on silica gel (eluted with DCM/MeOH = 30:1) followed by preparative HPLC to afford **10-S4** (90 mg, 16.8% yield) as a white solid. LC/MS (ESI) *m/z*: 453/455 (*M*+*H*)⁺.

[0346] Step 4: (1*R*,3*S*,5*R*)-*N*-(6-Bromo-3-methylpyridin-2-yl)-5-((dimethylamino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (10-S5): To a solution of **10-S4** (90 mg, 0.21 mmol) in DCM (3 mL) was added TFA (1 mL).

The reaction mixture was stirred at room temperature for 1.5 hours and then concentrated under reduced pressure to afford **10-S5** (65 mg, 94.6% yield) as a yellow solid. The crude material was carried forward in the next synthetic step without further purification. LC/MS (ESI) *m/z*: 353/355 (*M*+*H*)⁺.

[0347] Step 5: (1*S*,3*S*,5*S*)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-methylpyridin-2-yl)-5-((dimethylamino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (10): To a solution of **10-S5** (90 mg, 0.20 mmol), 2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetic acid (75 mg, 0.24 mmol), and HATU (152 mg, 0.40 mmol) in DMF (3 mL) was added DIPEA (0.13 mL, 0.80 mmol). The reaction mixture was stirred at room temperature for 16 hours. The mixture was partitioned with EtOAc and water. The organic layer was washed with brine, dried over anhydrous Na₂SO₄, and concentrated under reduced pressure. The crude product was purified by preparative TLC to afford **10** (35 mg, 27.3% yield) as a white solid. ¹H NMR (400 MHz, CD₃OD) δ 8.99 (s, 2H), 8.52 (s, 1H), 7.75 (s, 2H), 7.53 (d, *J* = 7.6 Hz, 1H), 7.37 (d, *J* = 8.0 Hz, 1H), 5.78-5.82 (m, 1H), 5.62-5.67 (m, 1H), 5.10-5.12 (m, 1H), 3.82-3.85 (m, 1H), 3.42-3.48 (m, 1H), 2.73-2.86 (m, 10H), 2.69 (s, 3H), 2.47-2.52 (m, 1H), 2.06 (s, 3H), 1.79-1.81 (m, 1H), 0.89-0.92 (m, 2H). LC/MS (ESI) *m/z*: 645/647 (*M*+*H*)⁺.

Scheme 7: Synthesis of (3*S*)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-methylpyridin-2-yl)-5-((hexahydrocyclopenta[*c*]pyrrol-2(1*H*)-yl)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (11)



[0348] Step 1: (3aR,6aS)-tert-Butyl 5-(((4-fluorophenoxy)carbonothioyl)oxy)hexahydrocyclopenta[c] pyrrole-2(1H)-carboxylate (11-S2): To a solution of (3aR,6aS)-tert-butyl 5-hydroxy-3a-methylhexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate (**11-S1**, 300 mg, 0.94 mmol) in DCM (5 mL) were added 4-fluorophenylthionochloroformate (213.5 mg, 1.12 mmol) and DMAP (344.6 mg, 2.82 mmol). The reaction mixture was stirred at room temperature overnight. The mixture was diluted with DCM (20 mL), washed with 0.5 N aqueous HCl (10 mL), water (10 mL), and brine, dried over Na₂SO₄, filtered, and concentrated to dryness. The remaining residue was purified by column chromatography on silica gel (eluted with PE/EtOAc = 20:1 to 10:1) to afford **11-S2** (338 mg, 94.3% yield) as a white solid. LC/MS (ESI) m/z: 404 (M+Na)⁺.

[0349] Step 2: (3aR,6aS)-tert-Butyl hexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate (11-S3): To a solution of (3aR,6aS)-tert-butyl 5-(((4-fluorophenoxy)carbonothioyl)oxy)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate (**11-S2**, 338 mg, 0.89 mmol) in 1,4-dioxane (3 mL) were added 1,1'-azobis(cyclohexanecarbonitrile) (Vazo, 73.0 mg, 0.45 mmol) and tris(trimethylsilyl)silane (330.9 mg, 1.33 mmol). The reaction mixture was stirred at 105 °C for 40 minutes at room temperature for 30 minutes. The mixture was concentrated to dryness to afford the crude product, which was purified by column chromatography on silica gel (eluted with PE/EtOAc = 40:1 to 10:1) to afford **11-S3** (73 mg, 38.8% yield) as a yellow oil. LC/MS (ESI) m/z: 156 (M+H-56)⁺.


[0350] Step 3: (3aR,6aS)-Octahydrocyclopenta[c]pyrrole (11-S4): To a solution of (3aR,6aS)-tert-butyl hexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate (**11-S3**, 73 mg, 0.14 mmol) in DCM (3 mL) was added TFA (1 mL) at 0 °C and the reaction mixture was stirred at room temperature for 1 hour. The mixture was evaporated under reduced pressure to afford **11-S4** (70 mg, 100% yield). This crude material was carried forward in the next synthetic step without further purification. LC/MS (ESI) m/z: 112 (M+H)⁺.

[0351] Step 4: (3S)-tert-Butyl 3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-5-((hexahydrocyclopenta [c]pyrrol-2(1H)-yl)methyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (11-S6): To a mixture of (3aR,6aS)-octahydrocyclopenta[c]pyrrole (**11-S4**, 35 mg, 0.3 mmol) and DIPEA (77.4 mmol, 0.6 mmol) in MeCN (3 mL) was added (3S)-tert-butyl 3-((6-bromo-3-methylpyridin-2-yl) carbamoyl)-5-(((methylsulfonyl)oxy)methyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (**S5**, 100 mg, 0.20 mmol) and NaI (32 mg, 0.2 mmol) at 0 °C. After stirring at room temperature overnight, the mixture was evaporated under reduced pressure and the remaining residue was purified by column chromatography on silica gel (PE/EtOAc=5:1 to 1:1) to afford **11-S6** (30 mg, 28.9% yield) as a brown oil. LC/MS (ESI) m/z: 519 (M+H)⁺.

[0352] Step 5: (3S)-N-(6-Bromo-3-methylpyridin-2-yl)-5-((hexahydrocyclopenta[c]pyrrol-2(1H) -yl)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (11-S7): To a solution of (3S)-tert-butyl 3-((6-bromo-3-methylpyridin-2-yl) carbamoyl)-5- ((hexahydrocyclopenta[c]pyrrol-2(1H)-yl)methyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (**11-S6**, 30 mg) in 1,4-dioxane (1 mL) was added a 4 N solution of HCl in 1,4-dioxane (1 mL) at 0 °C and the reaction mixture was stirred at room temperature for 1 hour. The mixture was concentrated to dryness to afford **11-S7** (30 mg, 100% yield), which was used in the next synthetic step without further purification.

[0353] Step 6: (3S)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((hexahydrocyclopenta[c]pyrrol-2(1H)-yl)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (11): To a mixture of (3S)-N-(6-bromo-3-methylpyridin-2-yl)-5-((hexahydrocyclopenta[c]pyrrol-2(1H) -yl)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (**11-S7**, 20 mg, 0.05 mmol), 2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl) acetic acid (14.8 mg, 0.05 mmol), and HATU (28.5 mg, 0.08 mmol) in DMF (2 mL) was added DIPEA (19.3 mg, 0.15 mmol) and the mixture was stirred at room temperature overnight. The mixture was partitioned with EtOAc and water. The organic layer was washed with brine, dried over Na₂SO₄, and concentrated under reduced pressure. The remaining residue was purified by preparative TLC to afford **11** (1.1 mg, 3.1% yield) as a white solid. ¹H NMR (400 MHz, CD₃OD) δ 9.01 (d, J = 2.8 Hz, 2H), 8.56 (d, J = 5.3 Hz, 1H), 7.79-7.76 (m, 2H), 7.58-7.54 (m, 1H), 7.44-7.39 (m, 1H), 5.83-5.79 (d, 1H), 5.69-5.64 (s, 1H), 3.93-3.86 (m, 2H), 3.49-3.46 (m, 1H), 2.97-2.93 (m, 2H), 2.75 (s, 3H), 2.70 (s, 3H), 2.10 (d, J = 18.6 Hz, 3H), 1.40-1.26 (m, 13H). LC/MS (ESI) m/z: 711 (M+H)⁺.

Scheme 8: Synthesis of (3S)-5-(3-Azabicyclo[3.1.1]heptan-3-ylmethyl)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (12)



[0354] Step 1: Methyl 1-benzyl-6-oxo-1,4,5,6-tetrahydropyridine-3-carboxylate (12-S2): To a solution of benzylamine (6 g, 56.1 mmol) in THF (50 mL) was added **12-S1** (4.55 g, 56.1 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 3 hours. The mixture was concentrated under reduced pressure and dissolved in THF (100 mL). Acryloyl chloride (5.55 g, 61.7 mmol) was added to the solution at 0 °C and the reaction mixture was stirred at room temperature overnight. The solution was diluted with EtOAc and washed with saturated aqueous NaHCO_3 . The organic layer was dried over anhydrous Na_2SO_4 and concentrated under reduced pressure. The remaining residue was purified by column chromatography on silica gel (eluted with PE/EtOAc = 5:1 to 3:1) to afford the title compound (3.5 g, 25.5% yield) as a yellow oil. LC/MS (ESI) m/z : 246 ($\text{M}+\text{H}$)⁺.

[0355] Step 2: Methyl 1-benzyl-6-oxopiperidine-3-carboxylate (12-S3): To a solution of **12-S2** (3.5 g, 14.3 mmol) in EtOH (30 mL) was added Pd/C (10% mol, 151 mg). The mixture was purged with nitrogen, purged with hydrogen, and stirred under an atmosphere of hydrogen (balloon) at room temperature for 1.5 hours. The mixture was filtered through a pad of Celite and washed with EtOH. The filtrate was concentrated to dryness to afford the title compound (3.2 g, 90.2%

yield) as a colorless oil. LC/MS (ESI) m/z: 248 (M+H)⁺.

[0356] Step 3: 1-Benzyl-5-(hydroxymethyl)piperidin-2-one (12-S4): To a solution of **12-S3** (3.2 g, 13.0 mmol) in THF (45 mL) was added LiBH₄ (566 mg, 26.0 mmol) at 0 °C. The reaction mixture was stirred under an atmosphere of nitrogen at room temperature overnight. The reaction mixture was quenched with water and extracted with EtOAc (50 mL). The organic phase was washed with brine, dried over anhydrous Na₂SO₄, and concentrated. The remaining residue was purified by column chromatography on silica gel (eluted with DCM/MeOH = 50:1) to afford the title compound (2.2 g, 77.3% yield) as a yellow oil. LC/MS (ESI) m/z: 220 (M+H)⁺.

[0357] Step 4: 1-Benzyl-5-(iodomethyl)piperidin-2-one (12-S5): To a solution of **12-S4** (2.2 g, 10.0 mmol) in DCM (45 mL) under an atmosphere of nitrogen were added Et₃N (3.47 mL, 25.0 mmol) and MsCl (1.72 g, 15 mmol) at 0 °C. The reaction mixture was stirred at room temperature overnight under an atmosphere of nitrogen. Ice water was added and the organic layer was separated, washed with brine, dried over anhydrous Na₂SO₄, and filtered. The filtrate was concentrated and diluted with acetone (25 mL). After NaI (4.50 g, 30.0 mmol) was added, the mixture was stirred at reflux for 24 hours. The mixture was cooled to room temperature and concentrated. The remaining residue was diluted with water and extracted with EtOAc. The combined organic phases were washed with brine, dried over anhydrous Na₂SO₄, and concentrated. The remaining residue was purified by column chromatography on silica gel (eluted with PE/EtOAc = 5:1 to 3:1) to afford the title compound (1.5 g, 45.5% yield) as a yellow oil. LC/MS (ESI) m/z: 330 (M+H)⁺.

[0358] Step 5: 3-Benzyl-3-azabicyclo[3.1.1]heptan-2-one (12-S6): To a solution of **12-S5** (1.5 g, 4.56 mmol) in THF (45 mL) under an atmosphere of nitrogen was added LiHMDS (1 M solution in THF, 13.68 mL, 13.68 mmol) at -20 °C. The reaction mixture was stirred at -20 °C for 1.5 hours under an atmosphere of nitrogen. The reaction mixture was quenched by addition of water and extracted with EtOAc (50 mL). The organic phase was washed with brine, dried with anhydrous Na₂SO₄, and concentrated. The remaining residue was purified by column chromatography on silica gel (eluted with PE/EtOAc = 8:1) to afford the title compound (600 mg, 65.5% yield) as a colorless oil. LC/MS (ESI) m/z: 202 (M+H)⁺.

[0359] Step 6: 3-Benzyl-3-azabicyclo[3.1.1]heptane (12-S7): To a solution of **12-S6** (600 mg, 2.99 mmol) in THF (45 mL) under an atmosphere of nitrogen was added BH₃·THF (1 M solution in THF, 8.97 mL, 8.97 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 3 hours under an atmosphere of nitrogen. The reaction mixture was quenched with MeOH at 0 °C and concentrated. The remaining residue was diluted with EtOH (4.5 mL) and water (0.5 mL) and then stirred at 100 °C for 3 hours. The mixture was concentrated, diluted with EtOAc, and washed with water and brine. The organic phase was dried over anhydrous Na₂SO₄ and concentrated to dryness. The remaining residue was purified by column chromatography on silica gel (eluted with DCM/MeOH = 50:1) to afford the title compound (300 mg, 53.7% yield) as a colorless oil. LC/MS (ESI) m/z: 188 (M+H)⁺.

[0360] Step 7: 3-Benzyl-3-azabicyclo[3.1.1]heptane hydrochloride (12-S8): To a solution of compound **12-S7** (300 mg, 1.6 mmol) and concentrated HCl (0.27 mL) in EtOH (35 mL) was added Pd/C (60 mg). The mixture was purged with nitrogen and stirred under an atmosphere of hydrogen (balloon) at room temperature for 2 hours. The mixture was filtered and filtrate was evaporated to afford the title compound (180 mg, 65.9% yield) as a light brown solid. LC/MS (ESI) m/z: 98 (M+H)⁺.

[0361] Step 8: (3S)-tert-Butyl 5-(azetidin-1-ylmethyl)-3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (12-S10): To a solution of **12-S9** (80 mg, 0.19 mmol) in MeCN (2 mL) were added DIPEA (0.13 mL, 0.76 mmol), **12-S8** (18.5 mg, 0.19 mmol), and NaI at 0 °C. The reaction mixture was stirred at room temperature for 4 hours. The mixture was concentrated and the remaining residue was diluted with DCM and washed with water. The organic layer was dried over anhydrous Na₂SO₄, filtered, and concentrated to dryness. The remaining residue was purified by column chromatography on silica gel (eluted with DCM/MeOH = 50:1) to afford the title compound (21 mg, 21.9% yield) as a yellow solid. LC/MS (ESI) m/z: 505 (M+H)⁺.

[0362] Step 9: (3S)-5-(Azetidin-1-ylmethyl)-N-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (12-S11): To a solution of **12-S10** (21 mg, 0.042 mmol) in dioxane (1 mL) was added HCl/dioxane (1 mL) at 0 °C. The reaction mixture was stirred at room temperature for 2 hours. The mixture was concentrated to dryness to afford the title compound (25 mg, 100% yield) as a brown solid. LC/MS (ESI) m/z: 405 (M+H)⁺.

[0363] Step 10: (3S)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-(azetidin-1-ylmethyl)-N-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (12): To a solution of **12-S11** (25 mg, 0.042 mmol) and **12-S12** (13.02 mg, 0.042 mmol) in DMF (2 mL) were added HATU (28.7 mg, 0.076 mmol) and DIPEA (0.029 mL, 0.168 mmol) at 0 °C. The reaction mixture was stirred at room temperature overnight. The mixture was diluted with EtOAc and washed with 10% aqueous LiCl solution and brine. The organic layer was dried over anhydrous Na₂SO₄ and concentrated to dryness. The remaining residue was purified by preparative HPLC to afford **12** (2.1 mg, 7.2% yield) as a white solid. ¹H NMR (400 MHz, CD₃OD) δ 9.01 (s, 2H), 8.56 (s, 1H), 7.80 (s, 2H), 7.58 (d, J = 8.2 Hz, 1H), 7.41 (d, J = 8.0 Hz, 1H), 5.82 (d, J = 17.1 Hz, 1H), 5.67 (d, J = 17.1 Hz, 1H), 5.34 (t, J = 4.6 Hz, 1H), 4.70 (d, J = 4.2 Hz, 1H), 2.75 (d, J = 5.0 Hz, 4H), 2.70 (s, 3H), 2.57-2.47 (m, 4H), 2.38-2.27 (m, 4H), 2.22-2.17 (m, 2H), 2.12 (s, 3H), 2.02 (d, J = 7.8 Hz, 2H), 1.49-1.46 (m, 1H), 1.39 (d, J = 6.8 Hz, 1H), 1.10-1.08 (m, 1H). LC/MS (ESI) m/z: 697 (M+H)⁺.

Scheme 9. Synthesis of (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-isopropylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (14)

5

10

15


20

25

30

35

40



45

[0364] Step 1: 2-Bromo-5-isopropyl-1-(oxidanyl)-pyridine (14-S2): To a stirred solution of 2-bromo-5-isopropylpyridine (**14-S1**, 3g, 1equiv) in CHCl_3 (200 mL) was added 3-chlorobenzoperoxoic acid (10g, 3 equiv). The reaction mixture was heated to 50 °C until completion. The reaction mixture was cooled and saturated aqueous NaHCO_3 solution (100mL) was added. The organic and aqueous layers were separated and the organic layer was washed with saturated aqueous NaHCO_3 (100mL x 3). The combined organic layers were concentrated to dryness. The residue was purified by column chromatography on SiO_2 gel (eluted with 5% MeOH in DCM) to afford **14-S2** (2.6g, 80 %).

50

[0365] Step 2: 5-Bromo-N-(tert-butyl)-2-isopropylaniline (14-S3): To a stirred solution of **14-S2** (812 mg, 1 equiv) and 2-methylpropan-2-amine (1.97 mL, 5 equiv) in DCM (100 mL), trifluoroacetic anhydride (0.7mL, 1.1 equiv) was added dropwise at 0-5 °C under an atmosphere of argon. The reaction mixture was stirred at 0-5 °C for 1 hour and TFAA solution was added (0.7 mL in 5 mL DCM, 1 equiv) followed by 2-methylpropan-2-amine (0.4 mL, 1 equiv). The reaction mixture was neutralized with aqueous saturated NaHCO_3 solution (50 mL). The organic layer was washed with brine (50 mL), dried over Na_2SO_4 , and concentrated to dryness. The residue was purified by column chromatography on silica gel (eluted by hexanes/ EtOAc=3:1 to afford **14-S3** (397mg, 39%).

55

[0366] Step 3: 5-Bromo-N-(tert-butyl)-2-isopropylaniline (14-S4): TFA (10 mL) was added to **14-S3** (397 mg) and the


reaction mixture was heated at 70 °C. The reaction mixture was concentrated to dryness and the residue was dissolved in DCM (15mL), washed with aqueous saturated NaHCO₃ solution (15 mL). The organic layer was dried over Na₂SO₄ and concentrated to dryness to afford **14-S4** (316 mg, quantitative yield)

[0367] Step 4: *tert*-Butyl (1*R*,3*S*,5*R*)-3-((6-Bromo-3-isopropylpyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexane-2-carboxylate (14-S5): To a stirred solution of (1*R*, 3*S*, 5*R*)-2-(*tert*-butoxycarbonyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxylic acid (99 mg, 1equiv), **14-S4** (89 mg, 1 equiv) in DCM (8 mL) and pyridine (0.17 mL, 5 equiv) was added. POCl₃ was then added dropwise (0.04 mL, 2 equiv) at 0-5 °C under an atmosphere of argon. The reaction mixture was warmed to room temperature and stirred for 2 hours. The reaction was then diluted with DCM (10 mL), neutralized with aqueous saturated NaHCO₃ solution (10 mL), and the aqueous layer was extracted with DCM (1x 10 mL). The combined organic layers were washed with brine (10 mL), dried over Na₂SO₄, and concentrated to dryness. The residue was purified by column chromatography on silica gel (eluted by 5% MeOH in DCM gradient) to afford **14-S5** (130mg, 73 %).

[0368] Step 5: (1*R*,3*S*,5*R*)-*N*-(6-Bromo-3-isopropylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide hydrochloride (14-S6): To a solution of **14-S5** (130 mg) in DCM (5 mL) was added TFA (5 mL). The resulting solution was stirred at room temperature for 3 hours. The reaction mixture was concentrated to dryness to afford **14-S6** as TFA salt (135 mg, quantitative yield).

[0369] Step 6: (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-isopropylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (14): To a solution of **14-S6** (72 mg, 1 equiv), 2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetic acid (50 mg, 1.2 equiv) in DMF (8 mL) and DIPEA (0.17ml, 5 equiv) was added HATU (70 mg, 1.2 equiv) at 0°C under an atmosphere of argon. The reaction mixture was stirred at room temperature for 3 hours before it was diluted with EtOAc (25 mL) and water (15mL). The aqueous layer was extracted with EtOAc (15mL) and the combined organic layers were washed with brine, dried over anhydrous Na₂SO₄, and concentrated to dryness. The residue was purified by column chromatography on silica gel (eluted by DCM/MeOH=10:1) to afford **14** (84 mg, 82%). ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.11 (s, 1H), 9.05 (s, 2H), 8.45 (s, 1H), 7.87 (s, 2H), 7.75 (d, 1H, J=8.3 Hz), 7.54 (d, 1H, J = 8.3 Hz), 5.91 (d, 1H, J=17.5 Hz), 5.59 (d, 1H, J=17.5Hz), 4.41-4.46 (m, 1H), 3.58(t, 1H, J=5.4 Hz), 3.16-3.19 (m, 1H), 2.89-2.97 (m, 1H), 2.70 (s, 3H), 2.68 (s, 3H), 2.54-2.58 (m, 1H), 2.01 - 2.09 (m, 1H), 1.33 (s, 3H), 1.16-1.27 (m, 1H), 1.03-1.09 (m, 6H).

Scheme 10. Synthesis of (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1*H*-pyrazolo[3,4-*c*]pyridin-1-yl)acetyl)-*N*-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (15)



[0370] The above scheme and following detailed description depicts one non-limiting method for synthesizing compounds via the following steps: 1) the formation of an amide bond between the B-ring and the C-ring by first generating an acyl chloride B-ring with POCl₃; 2) the removal of the Boc-group using an acid; and, 3) the formation of an amide bond between the C-ring (already linked to the B-ring) and A-ring utilizing HATU. The skilled artisan will recognize that the C- and B-ring synthetic intermediate can be replaced with other synthetic intermediates to afford additional compounds of the present invention. The skilled artisan will also recognize that the A-ring synthetic intermediate can be replaced with other synthetic intermediates to afford additional compounds of the present invention. The skilled artisan will further recognize that the B-ring linked to the C-ring can be further functionalized prior to the HATU coupling. Additional functionalization includes a Stille cross-coupling and an Ullmann cross-coupling.

[0371] Step 1: *tert*-Butyl (1*R*,3*S*,5*R*)-3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexane-2-carboxylate (15-S3): (1*R*,3*S*,5*R*)-2-(*tert*-Butoxycarbonyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxylic acid (15-S1, 483mg, 2.0 mmol) and 6-bromo-3-methylpyridin-2-amine (15-S2, 374mg, 2.0mmol) were dissolved in anhydrous DCM (15mL). The reaction was cooled in an ice bath and dry pyridine (0.5mL, 6.0mmol) was added in one portion, followed by POCl₃ (200μL, 2.0 mmol). After completion of the addition, the mixture was stirred for 4 hours at 0°C, and the reaction was quenched with water (15 mL). The aqueous phase was extracted with DCM (15mL×2) and the combined organic layers was washed with brine dried over MgSO₄. The solution was filtered and concentrated and the resulting residue was purified to afford 15-S3 (595 mg). ¹H NMR (400 MHz, DMSO-*d*₆): (major rotamer) δ 0.61 (dd, *J* = 2.4, 5.3 Hz, 1H), 0.68 (t, *J* = 5.6 Hz, 1H), 1.20 (s, 3H), 1.38 (s, 9H), 1.88-1.98 (m, 1H), 2.11 (s, 3H), 2.37-2.45 (m, 1H), 3.12 (s, 1H), 4.06 (dd, *J* = 6.6, 8.9 Hz, 1H), 7.44 (d, *J* = 7.9 Hz, 1H), 7.63 (d, *J* = 7.9 Hz, 1H), 10.17 (s, 1H) ppm.

[0372] Step 2: (1*R*,3*S*,5*R*)-*N*-(6-Bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide hydrochloride (15-S4): *tert*-Butyl (1*R*,3*S*,5*R*)-3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexane-2-carboxylate (15-S3, 595mg) was taken up in 4N HCl dioxane (3.0 mL) and the resulting reaction mixture was stirred at room temperature for 2 hours. After completion of the reaction (as monitored by HPLC), the solvent was removed under reduced pressure. The remaining residue (15-S4) was carried forward without additional purification and used directly in the next step.

[0373] Step 3: (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1*H*-pyrazolo[3,4-*c*]pyridin-1-yl)acetyl)-*N*-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (**15**): To the solution of (1*R*,3*S*,5*R*)-*N*-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide hydrochloride (**15-S4**, 87mg, 0.25mmol), 2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1*H*-pyrazolo[3,4-*c*]pyridin-1-yl)acetic acid (**15-S5**, 78mg, 0.25mmol) in DMF (2.0 mL), HATU (114mg, 0.3mmol) was added, followed by the dropwise addition of DIEA (4.0eq) at room temperature. The mixture was stirred for 1 hour at room temperature before the volatiles were evaporated. The residue was diluted with 10% sodium carbonate (50 mL) and extracted with EtOAc. The combined organic solutions were successively washed with water, brine, and dried over MgSO₄. The solution was filtered and the solvent was removed. The residue was purified to afford **15** (136.1 mg). ¹H NMR (400 MHz, DMSO-*d*₆): (major rotamer) δ 1.02 (t, *J* = 5.4 Hz, 1H), 1.07 - 1.13 (m, 1H), 1.33 (s, 3H), 2.04 (s, 3H), 2.05 - 2.11 (m, 1H), 2.56 (dd, *J* = 9.2, 13.3 Hz, 1H), 2.69 (s, 3H), 2.70 (s, 3H), 3.54 - 3.62 (m, 1H), 4.35 - 4.48 (m, 1H), 5.72 (d, *J* = 17.2 Hz, 1H), 6.04 (d, *J* = 17.3 Hz, 1H), 7.44 (d, *J* = 7.9 Hz, 1H), 7.62 (d, *J* = 8.0 Hz, 1H), 8.60 (s, 1H), 9.30 (s, 1H), 9.34 (s, 2H), 10.27 (s, 1H) ppm. LC (method A): *t*_R = 1.71 min. LC/MS (EI) *m/z*: [M + H]⁺ 605.44.


[0374] (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(3-bromoisouquinolin-1-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (**73**): ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.75 (s, 1H), 9.04 (s, 2H), 8.46 (s, 1H), 8.09 (s, 1H), 7.82-7.96 (m, 4H), 7.74-7.80 (m, 1H), 7.51 (t, 1H, *J* = 7.7 Hz), 5.97 (d, 1H, *J* = 17.5 Hz), 5.62 (d, 1H, *J* = 17.5 Hz), 4.51 - 4.58 (m, 1H), 3.64-3.67 (m, 1H), 2.70 (s, 3H), 2.66 (s, 3H), 2.61-2.65 (m, 1H), 2.14-2.20 (m, 1H), 1.38 (s, 3H), 1.00-1.10 (m, 2H).

Scheme 11. Synthesis of (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*n*-((*E*)-2-fluoro-3-phenylbut-2-en-1-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (17**)**

[0375] The three-part synthesis shown below and the accompanying detailed description depicts one non-limiting method for synthesizing compounds by first generating intermediate **17-S7** by using Ghosez's reagent to generate an amide bond. Intermediate **17-S7** is the coupled to the A-ring using a coupling reagent, such as HATU. The skilled artisan will recognize that the A-ring synthetic intermediate shown below can be replaced with other A-ring synthetic intermediates to afford additional compounds of the present invention.

Synthesis of *tert*-Butyl (1*R*,3*S*,5*R*)-3-(((*E*)-2-fluoro-3-phenylbut-2-en-1-yl)carbamoyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (Intermediate **17-S7)**

[0376]



[0377] Step 1: Ethyl (*E*)-2-fluoro-3-phenylbut-2-enoate (S2**) and Ethyl (*Z*)-2-fluoro-3-phenylbut-2-enoate (**17-****

S3): Ethyl 2-(diethoxyphosphoryl)-2-fluoroacetate (5 g) was added dropwise to a stirred solution of NaH (0.9 g, 60 % in mineral oil) in DMF (50 mL) at 0 °C. The cooling bath was removed and the reaction mixture was stirred at room temperature for 1 hour. Benzaldehyde (3.6 mL) was added at room temperature and the reaction mixture was stirred at 90 °C overnight. The reaction mixture was cooled to room temperature, diluted with ether, washed with water, dried (Na₂SO₄), and concentrated. The resultant residue was purified by silica gel flash column chromatography (eluent: 0-0.5 % EtOAc in hexanes). Ethyl (Z)-2-fluoro-3-phenylbut-2-enoate (**17-S3**) eluted first as colorless liquid (0.37 g) and ethyl (E)-2-fluoro-3-phenylbut-2-enoate (**17-S2**) eluted second as light yellow liquid (1.3 g). (Ref. WO 2014/002052 and J. Org. Chem. 2009, 74, 4124-4131)

[0378] Step 2: (E)-2-Fluoro-3-phenylbut-2-en-1-ol (17-S4): To a stirred solution of LAH (0.221 g) in ether (20 mL) at room temperature, ethyl (E)-2-fluoro-3-phenylbut-2-enoate (**17-S2**) (1.3 g) in ether (10 mL) was added dropwise. The reaction mixture was stirred at room temperature for 1 hour and quenched with the careful addition of saturated aqueous NH₄Cl solution. The heterogeneous mixture was then extracted with ether, washed with water and brine, and dried with Na₂SO₄. Upon concentration of the organic layer, the residue was carried forward without additional purification and carried forward in the next step.


[0379] Step 3: (E)-2-(2-Fluoro-3-phenylbut-2-en-1-yl)isoindoline-1,3-dione (17-S5): DEAD (1.52 mL) was added dropwise to a stirred solution of (E)-2-fluoro-3-phenylbut-2-en-1-ol (1 g), phthalimide (1.06 g) and triphenylphosphine (2.4 g) in THF (20 mL). After stirring for 16 hours at room temperature, the reaction mixture was concentrated under reduced pressure. The residue obtained was purified by silica gel flash column chromatography (eluent: 0-2.5 % EtOAc in hexanes) to afford 1.5 g of **17-S5** as white solid.

[0380] Step 4: (E)-2-Fluoro-3-phenylbut-2-en-1-amine hydrochloride (17-S6): Hydrazine hydrate (0.74 mL) was added to heterogeneous solution of (E)-2-(2-fluoro-3-phenylbut-2-en-1-yl)isoindoline-1,3-dione (1.7 g) in EtOH (30 mL) and stirred at room temperature overnight. The precipitate was filtered off and the filtrate was concentrated. The residue was triturated with 4N HCl in dioxane (10 mL) and the volatiles were removed under reduced pressure. The resulting white solid was dried under high vacuum to afford **17-S6**.

[0381] Step 5: tert-Butyl (1R,3S,5R)-3-(((E)-2-fluoro-3-phenylbut-2-en-1-yl)carbamoyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (17-S7): To an ice cold solution of (1R,3S,5R)-2-(tert-butoxycarbonyl)-2-azabicyclo[3.1.0]hexane-3-carboxylic acid (**17-S6a**) (0.25 g) in 6 mL of CH₂Cl₂, 1-chloro-N,N,2-trimethyl-1-propenylamine (0.16 mL, 1.1 equiv.) was added dropwise with stirring. After stirring for 3 hours at same temperature, solid (E)-2-fluoro-3-phenylbut-2-en-1-amine hydrochloride (**17-S6**) (0.2 g, 1.0 equiv.) was added followed by 0.7 mL of DIPEA (4 equiv.). The cooling bath was removed and the reaction mixture was stirred overnight at room temperature. The solvent was co-evaporated with MeOH (1 mL) and the crude product was purified by silica gel flash column chromatography (eluent: 0-0.5 % MeOH in CH₂Cl₂) to afford 0.18 g of a colorless resin.

Synthesis of tert-Butyl 2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetate (Intermediate 17-S12)

[0382]



[0383] Step 6: 7-Methyl-5-(2-methylpyrimidin-5-yl)-1H-indazole (17-S9): A mixture of 0.5 g of bromoindazole (1 equiv), 2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine (0.782 g, 1.5 equiv), cesium carbonate (2.315 g, 3 equiv) in dioxane (10 mL) and water (1.0 mL) was purged with argon in a pressure vessel for 5 minutes. Tetrakis(triphenylphosphine)palladium (0) (0.550 g, 0.2 equiv) was then added under argon and the pressure vessel was sealed and heated at 90 °C overnight. The reaction mixture was cooled to room temperature and the solvent was removed under reduced pressure. The crude product was purified by silica gel flash column chromatography (eluent: 0-3 % MeOH in CH_2Cl_2) to afford 0.395 g of the product as a white solid.


[0384] Step 7: 3-Bromo-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazole (17-S10): To a stirred solution of indazole 17-S9 (1.75 g) in DMF (20 mL), NBS (1.05 g) was added. The reaction mixture was stirred at room temperature for 2 hours and additional NBS (0.209 g) was added followed by stirring for 30 minutes at room temperature. The reaction mixture was poured into water and the precipitate was isolated by filtration, dried and purified by silica gel flash column chromatography (eluent: 0-5 % MeOH in CH_2Cl_2) to afford 17-S10 as a white solid.

[0385] Step 8: tert-Butyl 2-(3-bromo-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetate (17-S11): A mixture of 3-bromo-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazole (0.215 g), tert-butyl bromoacetate (115 μL), and potassium carbonate (0.196 g) in anhydrous acetonitrile (10 mL) was refluxed for 4 hours. The reaction mixture was then cooled to room temperature and the solvent was removed under reduced pressure. The residue was purified by silica gel flash column chromatography (eluent: 0-1 % MeOH in CH_2Cl_2) to afford the product as a white foam.

[0386] Step 9: tert-Butyl 2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetate (17-S12): A solution of tert-butyl 2-(3-bromo-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetate (17-S11) (0.170 g 1 equiv), tri-butyl(1-ethoxyvinyl)tin 0.249 g, 2 equiv) and $\text{PdCl}_2(\text{PPh}_3)_2$ (28 mg, 0.1 equiv) in DMF (3 mL) was heated at 80°C overnight under argon atmosphere. The mixture was concentrated under reduced pressure, diluted with CH_2Cl_2 , and washed with cold aqueous HCl (1N). The organic layer was dried (Na_2SO_4), filtered and concentrated. The residue was purified by silica gel flash column chromatography (eluent: 0-1 % MeOH in CH_2Cl_2) to afford a yellow solid.

Synthesis of (1R,3S,5R)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-((E)-2-fluoro-3-phenylbut-2-en-1-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (17)

[0387]



[0388] Step 10: (1R,3S,5R)-N-((E)-2-Fluoro-3-phenylbut-2-en-1-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide TFA salt (17-S13): *tert*-Butyl (1R,3S,5R)-3-(((E)-2-fluoro-3-phenylbut-2-en-1-yl)carbamoyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (0.1 g) was dissolved in CH₂Cl₂ (1 mL) and an equal volume of TFA was added. The mixture was stirred for 30 minutes at room temperature. Then the volatiles were removed under reduced pressure and the residue was carried forward without additional purification in the next step.

[0389] Step 11: 2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetic acid (17-S14): *tert*-Butyl 2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetate (17-S12, 0.13 g) was stirred in CH₂Cl₂ (1 mL) and TFA (2 mL). After completion of the reaction (monitored by HPLC), the solvent was removed under reduced pressure and the remaining residue was used in the next synthetic step without purification.

[0390] Step 12: (1R,3S,5R)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-((E)-2-fluoro-3-phenylbut-2-en-1-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (17): Compound 17-S14 was dissolved in DMF (1 mL) and *i*Pr₂NEt (0.297 mL, 5 equiv) was added, followed by the addition 17-S13 at 5 °C. HATU (0.156 g, 1.2 equiv) was then added slowly at 5 °C and the reaction mixture was stirred for 30 minutes at room temperature. The reaction mixture was poured into water and the precipitate was isolated by filtration. The solid was dried and purified by silica gel flash column chromatography (eluent: 0-2.5 % MeOH in CH₂Cl₂) to afford 17 as a cream colored solid. ¹H NMR (400 MHz, DMSO) δ 0.65-0.71 (m, 1H), 0.78 (s, 3H), 1.02-1.07 (m, 1H), 1.15-1.26 (m, 1H), 1.81 - 1.98 (m, 1H), 1.93 (d, *J* = 3.2 Hz, 3H), 2.06-2.12 (m, 1H), 2.23-2.26 (m, 1H), 2.64 (s, 3H), 2.68 (s, 6H), 3.70 - 3.93 (m, 2H), 4.24 (dd, *J* = 5.0, 9.1 Hz, 1H), 5.70 (d, *J* = 17.7 Hz, 1H), 6.03 (d, *J* = 17.8 Hz, 1H), 7.20 - 7.33 (m, 5H), 7.63 (s, 1H), 8.15 (t, *J* = 5.3 Hz, 1H), 8.32 (d, *J* = 1.6 Hz, 1H), 9.02 (s, 2H). ¹⁹F-NMR (DMSO-*d*₆): δ - 113.2.

Scheme 12: Synthesis of (2S,4R)-1-(2-(3-Acetyl-7-((dimethylamino)methyl)-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide (19)



45

50

55

119

THF (50 mL) was added LiAlH₄ (1.49 g, 39.2 mmol) in portions at 0 °C. The reaction mixture was stirred at 0 °C for 30 minutes and at room temperature for 1 hour. The mixture was then quenched with water (1.5 mL), 10% aqueous NaOH solution (3 g), and water (4.5 mL). The mixture was filtered and the filter cake was washed with EtOAc. The filtrate was dried and concentrated to afford the crude product, which was purified by column chromatography on silica gel (eluted with DCM/MeOH = 100:0 to 20:1) to afford **19-S5** (3.36 g, 76.1% yield) as a white solid. LC/MS (ESI) m/z: 227 (M+H)⁺.

[0395] Step 5: (5-Bromo-3-iodo-1H-indazol-7-yl) methanol (19-S6): To a solution of **19-S5** (2.27 g, 10 mmol) in DMF (25 mL) were added KOH (1.26 g, 22.5 mmol) and I₂ (3.81 g, 15 mmol) at 0 °C. The mixture was stirred at room temperature for 16 hours. The mixture was then quenched with 5% aqueous Na₂S₂O₃ solution and extracted with EtOAc. The organic layer was separated, dried, and concentrated to afford the crude product, which was recrystallized with EtOAc/PE (1:2) to afford **19-S6** (2.85 g, 81.0% yield) as a brown solid. LC/MS (ESI) m/z: 353 (M+H)⁺.

[0396] Step 6: Methyl 2-(5-bromo-7-(hydroxymethyl)-3-iodo-1H-indazol-1-yl)acetate (19-S7): To a solution of **19-S6** (1.98 g, 5.6 mmol) in DMF (20 mL) was added K₂CO₃ (1.38 g, 10 mmol) and methyl 2-bromoacetate (900 mg, 5.88 mmol). The reaction mixture was stirred at room temperature for 2.5 hours. The mixture was diluted with EtOAc, washed with 10% aqueous LiCl solution, dried, and concentrated to afford the crude product, which was purified by column chromatography on silica gel (eluted with PE/EtOAc = 10:1 to 3:1) to afford **19-S7** (1.34 g, 56.4% yield) as colorless oil. LC/MS (ESI) m/z: 425 (M+H)⁺.

[0397] Step 7: Methyl 2-(5-bromo-7-(chloromethyl)-3-iodo-1H-indazol-1-yl)acetate (19-S8): To a mixture of **19-S7** (424 mg, 1 mmol) in dry DCM (10 mL) was added Et₃N (250 mg, 2.5 mmol) followed by dropwise addition of MsCl (173 mg, 1.5 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 16 hours. The mixture was quenched with saturated aqueous NaHCO₃ solution and extracted with EtOAc. The organic layer was separated, dried, and concentrated to afford the crude product, which was purified by column chromatography on silica gel (eluted with PE/EtOAc = 100:0 to 15:1) to afford **19-S8** (360 mg, 81.1% yield) as a brown solid. LC/MS (ESI) m/z: 443 (M+H)⁺.


[0398] Step 8: Methyl 2-(5-bromo-7-((dimethylamino)methyl)-3-iodo-1H-indazol-1-yl)acetate (19-S9): To a solution of **19-S8** (360 mg, 0.82 mmol) in MeCN (10 mL) were added Et₃N (249 mg, 2.46 mmol) and dimethylamine hydrochloride (133 mg, 1.64 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 3 hours. The mixture was quenched with saturated aqueous NaHCO₃ solution and extracted with EtOAc. The organic layer was separated, dried, and concentrated to afford the crude product, which was purified by column chromatography on silica gel (eluted with PE/EtOAc = 20:1 to 10:1) to afford **19-S9** (328 mg, 88.5% yield) as a brown solid. LC/MS (ESI) m/z: 452 (M+H)⁺.

[0399] Step 9: 2-(3-Acetyl-5-bromo-7-((dimethylamino)methyl)-1H-indazol-1-yl)acetic acid (19-S10): To a mixture of **19-S9** (68 mg, 0.15 mmol) in dry toluene (10 mL) were added tributyl(1-ethoxyvinyl)stannane (82 mg, 0.226 mmol) and Pd(PPh₃)₄ (14 mg, 0.012 mmol). The reaction mixture was stirred at 95 °C for 16 hours under an atmosphere of nitrogen. After cooling, the mixture was quenched with 1 N aqueous HCl solution and the mixture was stirred at room temperature for 15 minutes. The mixture was extracted with DCM/MeOH (20:1), dried over anhydrous Na₂SO₄, filtered, and concentrated to afford the crude product, which was purified by preparative TLC (DCM/MeOH = 20:1) to afford **19-S10** (38 mg, 71.7% yield) as colorless oil. LC/MS (ESI) m/z: 354 (M+H)⁺.

[0400] Step 10: 2-(3-Acetyl-7-((dimethylamino)methyl)-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetic acid (19-S11): To a solution of **19-S10** (38 mg, 0.11 mmol) in 1,4-dioxane/H₂O (7 mL, 6:1) were added 2-methylpyrimidin-5-ylboronic acid (23 mg, 0.162 mmol), K₂CO₃ (46 mg, 0.33 mmol), and Pd(PPh₃)₄ (12 mg, 0.011 mmol). The reaction mixture was stirred at 90 °C for 16 hours under an atmosphere of nitrogen. After cooling, the mixture was acidified with 10% aqueous HCl solution and extracted with DCM/MeOH (10:1). The organic layer was separated, dried, and concentrated to afford the crude product, which was purified by preparative TLC (DCM/MeOH = 5:1) to afford **19-S11** (21 mg, 52.0% yield) as a yellow solid. LC/MS (ESI) m/z: 368 (M+H)⁺.

[0401] Step 11: (2S,4R)-1-(2-(3-Acetyl-7-((dimethylamino)methyl)-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide (19): To a mixture of **19-S11** (21 mg, 0.057 mmol) and (2S,4R)-N-(6-bromopyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide hydrochloride (19 mg, 0.057 mmol) in DMF (1 mL) were added DIPEA (23 mg, 0.171 mmol) followed by HATU (43 mg, 0.114 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 1 h. The mixture was diluted with EtOAc, washed with 10% aqueous LiCl solution and brine, dried, and concentrated to afford the crude product, which was purified by preparative HPLC to afford **19** (6 mg, 16.7% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 11.12 (s, 1H), 9.10 (s, 2H), 8.50 (d, J = 1.7 Hz, 1H), 8.09 (d, J = 8.3 Hz, 1H), 7.73-7.83 (m, 2H), 7.39 (d, J = 7.7 Hz, 1H), 6.31 (d, J = 17.4 Hz, 1H), 6.09 (d, J = 17.3 Hz, 1H), 5.55-5.68 (m, 1H), 4.80 (t, J = 8.7 Hz, 1H), 4.30-4.39 (m, 1H), 3.86-3.99 (m, 2H), 3.43-3.48 (m, 1H), 2.73 (s, 3H), 2.68 (s, 3H), 2.57-2.66 (m, 1H), 2.29 (s, 6H), 2.13-2.19 (m, 1H). LC/MS (ESI) m/z: 637 (M+H)⁺.

Scheme 13: Synthesis of (2*S*,4*R*)-1-(2-(3-Acetyl-7-(fluoromethyl)-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromopyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide (20)



[0402] The above scheme and following detailed description depicts one non-limiting method for synthesizing compounds by 1) a Stille carbonylative cross-coupling using tributyl(1-ethoxyvinyl)stannane to functionalize the R⁶ position of the A-ring; 2) a Suzuki cross-coupling to functionalize the R³² of the A-ring; and, 3) the formation of an amide bond between the C-ring (already linked to the B-ring) and A-ring utilizing HATU. The skilled artisan will recognize that the C- and B-ring synthetic intermediate can be replaced with other synthetic intermediates to afford additional compounds of the present invention. The skilled artisan will also recognize that the A-ring synthetic intermediate can be replaced with other synthetic intermediates to afford additional compounds of the present invention.

[0403] Step 1: Methyl 2-(5-bromo-7-(fluoromethyl)-3-iodo-1*H*-indazol-1-yl)acetate (20-S2): To a solution of **20-S1** (85 mg, 0.2 mmol) in dry DCM (6 mL) was added DAST (64 mg, 0.4 mmol) dropwise at -30 °C. The resulting mixture was stirred from -30 °C to room temperature for 1 hour. The mixture was then quenched with saturated aqueous NaHCO₃ solution and extracted with EtOAc. The organic layer was separated, dried, and concentrated to dryness. The remaining residue was purified by column chromatography on silica gel (eluted with PE/EtOAc = 20:1 to 10:1) to afford **20-S2** (73 mg, 85.7% yield) as a yellow oil. LC/MS (ESI) *m/z*: 427 (M+H)⁺.

[0404] Step 2: 2-(3-Acetyl-7-(fluoromethyl)-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetic acid (20-S3): To a mixture of **20-S2** (73 mg, 0.171 mol) in dry toluene (8 mL) were added tributyl(1-ethoxyvinyl)stannane (87 mg, 0.24 mmol) and Pd(PPh₃)₄ (16 mg, 0.0137 mmol). The reaction mixture was stirred at 95 °C for 16 hours under an atmosphere of nitrogen. After cooling, the mixture was quenched with 1 N aqueous HCl solution and the mixture was stirred at room temperature for 15 minutes. The mixture was then extracted with DCM/MeOH (15:1), the organic layer was separated, dried, and concentrated to afford the crude product, which was purified by preparative TLC (DCM/MeOH = 15:1) to afford **20-S3** (50 mg, 88.8% yield) as colorless oil. LC/MS (ESI) *m/z*: 329 (M+H)⁺.

[0405] Step 3: 2-(3-Acetyl-7-(fluoromethyl)-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetic acid (2-S4) and 2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-7-((2-methylpyrimidin-5-yl)methyl)-1*H*-indazol-1-yl)acetic acid (20-S4A): To a mixture of **20-S3** (50 mg, 0.152 mol) in 1,4-dioxane/H₂O (7 mL, 6:1) was added 2-methylpyrimidin-5-ylboronic acid (26 mg, 0.182 mmol), K₂CO₃ (63 mg, 0.456 mmol), and Pd(PPh₃)₄ (18 mg, 0.0152 mmol). The reaction mixture was stirred at 90 °C for 16 hours under an atmosphere of nitrogen. After cooling, the mixture was acidified with 10% aqueous HCl solution and extracted with DCM/MeOH (10:1). The organic layer was separated, dried, and concentrated to afford the crude product, which was purified by preparative TLC (DCM/MeOH = 5:1) to afford **20-S4** (30 mg, 57.5% yield) and **20-S4A** (25 mg, 39.4% yield) as colorless oils. LC/MS (ESI) *m/z*: 343(M+H)⁺, 417(M+H)⁺.


[0406] Step 4: (2*S*,4*R*)-1-(2-(3-Acetyl-7-(fluoromethyl)-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromopyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide (20):

bromopyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide (20): To a mixture of **20-S4** (30 mg, 0.088 mmol) and (2*S*,4*R*)-*N*-(6-bromopyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide hydrochloride (30 mg, 0.088 mmol) in DMF (1 mL) was added DIPEA (36 mg, 0.264 mmol) followed by HATU (52 mg, 0.132 mmol) at 0 °C. The reaction mixture was stirred at room temperature overnight. The mixture was diluted with EtOAc, washed with 10% aqueous LiCl solution and brine, dried, and concentrated to afford the crude product, which was purified by preparative HPLC to afford **20** (6 mg, 11.1% yield) as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 11.07 (s, 1H), 9.06 (s, 2H), 8.55 (s, 1H), 8.06-7.94 (m, 2H), 7.72 (t, *J* = 8.0 Hz, 1H), 7.33 (d, *J* = 7.3 Hz, 1H), 5.94 (d, *J* = 18.0 Hz, 1H), 5.78-5.88 (m, 1H), 5.47-5.71 (m, 3H), 4.68-4.74 (m, 1H), 4.24-4.33 (m, 1H), 3.86-4.02 (m, 1H), 2.69 (s, 3H), 2.67 (s, 3H), 2.18-2.27 (m, 1H), 2.07-2.16 (m, 1H). LC/MS (ESI) *m/z*: 612 (M+H)⁺.

[0407] (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-4-fluoro-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-methylpyridin-2-yl)-5-((dimethylamino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (155): ¹H NMR (400 MHz, CD₃OD) δ 8.84 (s, 2H), 7.61-7.44 (m, 3H), 7.30 (d, *J* = 7.9 Hz, 1H), 5.73 (d, *J* = 17.3 Hz, 1H), 5.58 (d, *J* = 17.5 Hz, 1H), 4.55 (m, 1H), 3.63 (m, 1H), 2.96 (m, 1H), 2.67 (s, 3H), 2.62 (s, 3H), 2.59-2.47 (m, 3H), 2.44 (m, 6H), 2.04 (s, 3H), 1.20 (d, *J* = 19.2 Hz, 2H). LC/MS (ESI) *m/z*: 662 (M+H)⁺.


[0408] (1*S*,3*S*,5*S*)-2-(2-(3-Acetyl-4-fluoro-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-methylpyridin-2-yl)-5-((dimethylamino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (156): ¹H NMR (400 MHz, CD₃OD) δ 8.83 (s, 2H), 7.57-7.44 (m, 3H), 7.28 (d, *J* = 7.9 Hz, 1H), 5.74 (d, *J* = 17.0 Hz, 1H), 5.55 (d, *J* = 17.1 Hz, 1H), 4.99 (d, *J* = 9.5 Hz, 1H), 3.59 (s, 1H), 2.81 (s, 1H), 2.67 (s, 3H), 2.62 (s, 3H), 2.33 (m, 9H), 1.99 (m, 3H), 1.60 (m, 1H), 1.01 (m, 1H). LC/MS (ESI) *m/z*: 662 (M+H)⁺.

Scheme 14: Synthesis of (2*S*,4*R*)-1-(2-(3-Acetyl-7-((5-methylpyrimidin-2-yl)methyl)-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromopyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide (21)



[0409] The title compound (**21**) was prepared according to the procedure described in Step 4 of Scheme 13 using appropriate starting materials. ¹H NMR (400 MHz, DMSO-*d*₆) δ 11.11 (s, 1H), 8.94 (s, 2H), 8.55 (s, 2H), 8.37-8.44 (m, 1H), 8.01 (d, *J* = 8.0 Hz, 1H), 7.73 (t, *J* = 8.0 Hz, 1H), 7.35 (d, *J* = 7.3 Hz, 1H), 7.24 (s, 1H), 5.92 (d, *J* = 18.1 Hz, 1H), 5.45-5.61 (m, 2H), 4.67-4.76 (m, 1H), 4.51 (d, *J* = 16.9 Hz, 1H), 4.34 (d, *J* = 16.7 Hz, 1H), 4.23 (dd, *J* = 20.8, 13.0 Hz, 1H), 3.84-3.94 (m, 1H), 2.68 (s, 3H), 2.62 (s, 3H), 2.52 (s, 3H), 2.18-2.26 (m, 1H), 2.06-2.15 (m, 1H). LC/MS (ESI) *m/z*: 686 (M+H)⁺.

Scheme 15: (3*S*)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-methylpyridin-2-yl)-5-(piperazin-1-ylmethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide. (22)



Step 1: 1-Allyl 4-tert-butyl piperazine-1,4-dicarboxylate (22-S2)

50 **[0410]** To a solution of **22-S1** (375 mg, 2.02 mmol) in DCM (10 mL) were added DIPEA (0.032 mL, 10.10 mmol) and allyl chloroformate (727 mg, 6.06 mmol) at 0 °C. The reaction mixture was stirred at room temperature overnight. The mixture was washed with water and brine. The organic phase was dried over anhydrous Na₂SO₄, filtered, and concentrated to dryness. The remaining residue was purified by column chromatography on silica gel (eluted with PE/EtOAc = 30:1 to 20:1) to afford the title compound (400 mg, 73.4% yield) as a yellow oil. LC/MS (ESI) m/z: 271 (M+H)⁺.

55 **[0411] Step 2: Allyl piperazine-1-carboxylate hydrochloride (22-S3):** To a solution of **22-S2** (400 mg, 1.48 mmol) in dioxane (1 mL) was added HCl/dioxane (1 mL) at 0 °C. The reaction mixture was stirred at room temperature for 2 hours. The mixture was concentrated to dryness to afford the title compound (450 mg, 100% yield) as a brown oil. LC/MS (ESI) m/z: 171 (M+H)⁺.


[0412] Step 3: (3S)-tert-Butyl 5-((4-((allyloxy)carbonyl)piperazin-1-yl)methyl)-3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (22-S5): To a solution of **22-S4** (280 mg, 0.66 mmol) in MeCN (5 mL) were added DIPEA (0.45 mL, 2.64 mmol), **22-S3** (179 mg, 0.66 mmol), and NaI at 0 °C. The reaction mixture was stirred at room temperature overnight. The mixture was concentrated, diluted with DCM, and washed with water. The organic layer was dried over anhydrous Na₂SO₄, filtered, and concentrated. The remaining residue was purified by column chromatography on silica gel (eluted with DCM/MeOH = 20:1) to afford the title compound (45 mg, 11.8% yield) as a yellow solid. LC/MS (ESI) m/z: 578 (M+H)⁺.


[0413] Step 4: Allyl 4-(((3S)-3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-2-azabicyclo[3.1.0]hexan-5-yl)methyl)piperazine-1-carboxylate (22-S6): To a solution of **22-S5** (45 mg, 0.078 mmol) in dioxane (2 mL) was added HCl/dioxane (2 mL) at 0 °C. The reaction mixture was stirred at room temperature for 2 hours. The mixture was concentrated to dryness to afford the title compound (65 mg, 100% yield) as a brown oil. LC/MS (ESI) m/z: 477 (M+H)⁺.

[0414] Step 5: Allyl 4-(((3S)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-2-azabicyclo[3.1.0]hexan-5-yl)methyl)piperazine-1-carboxylate (22-S8): To a solution of **22-S6** (65 mg, 0.078 mmol) and **22-S7** (24.18 mg, 0.078 mmol) in DMF (3 mL) were added HATU (53.4 mg, 0.14 mmol) and DIPEA (0.054 mL, 0.312 mmol) at 0 °C. The reaction mixture was stirred at room temperature overnight. The mixture was diluted with water and extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous Na₂SO₄, and concentrated to dryness. The remaining residue was purified by column chromatography on silica gel (eluted with DCM/MeOH = 20:1) to afford the title compound (30 mg, 50.0% yield) as a white solid. LC/MS (ESI) m/z: 697 (M+H)⁺.

[0415] Step 6: (3S)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-(piperazin-1-ylmethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (22): To a solution of **22-S8** (30 mg, 0.039 mmol) in dry THF (5 mL) were added morpholine (33.93 mg, 0.39 mmol) and Pd(PPh₃)₄ (2.3 mg, 0.0020 mmol) under an atmosphere of nitrogen at 0 °C. The reaction mixture continued to stir at room temperature overnight. The mixture was diluted with EtOAc and washed with 10% aqueous LiCl solution and brine. The organic layer was dried over anhydrous Na₂SO₄ and concentrated to dryness. The remaining residue was purified by preparative HPLC to afford **22** (3.5 mg, 13.1% yield) as a white solid. ¹H NMR (400 MHz, CD₃OD) δ 9.01 (s, 2H), 8.56 (s, 1H), 7.80 (d, J = 1.2 Hz, 2H), 7.55 (d, J = 8.0 Hz, 1H), 7.38 (d, J = 7.9 Hz, 1H), 5.80 (d, J = 17.2 Hz, 1H), 5.66 (d, J = 17.1 Hz, 1H), 4.65-4.62 (m, 1H), 3.64-3.66 (m, 1H), 2.93 (t, J = 4.9 Hz, 4H), 2.75 (s, 3H), 2.72-2.61 (m, 6H), 2.56 (d, J = 6.9 Hz, 5H), 2.14 (d, J = 8.2 Hz, 3H), 1.15 (t, J = 5.6 Hz, 1H), 1.10-1.08 (m, 1H). LC/MS (ESI) m/z: 686 (M+H)⁺.

Scheme 16. Synthesis of (2S,4R)-1-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-(cyanomethyl)pyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide (23)





[0416] Step 1: 2-(6-Bromo-1-(1-oxidanyl)-pyridin-3-yl)acetonitrile (23-S2): To a stirred solution of 2-(6-bromopyridin-3-yl) acetonitrile (**23-S1**, 1g, 1equiv) in CHCl_3 (100 mL) was added 3-chlorobenzoperoxoic acid (1.72 g, 77%, 1.5 equiv). The reaction mixture was heated to 50 °C. The reaction mixture was cooled and neutralized with saturated aqueous NaHCO_3 solution (100mL). The organic layer was washed with brine, dried over Na_2SO_4 , and concentrated to dryness. The residue was purified by chromatography on silica gel (5% CH_3OH in DCM, gradient) to afford **23-S2** (99mg, 10%).

[0417] Step 2: 2-(6-Bromo-2-(tert-butylamino)pyridin-3-yl)acetonitrile (23-S3): To a stirred solution of **23-S2** (99 mg, 1 equiv) and 2-methylpropan-2-amine (0.24mL, 5 equiv) in DCM (8 mL) was added trifluoroacetic anhydride (0.08 mL, 1.1 equiv) solution in DCM (3mL) dropwise at 0-5 °C under an atmosphere of argon. The reaction mixture was stirred at 0-5 °C for 1 hour and TFAA (0.07 mL, 1equiv) was added followed by 2-methylpropan-2-amine (0.02 mL, 1 equiv). The reaction mixture was diluted with DCM (25mL) and neutralized with aqueous saturated NaHCO_3 solution (10 mL). The organic layers were washed with brine (10 mL), dried over Na_2SO_4 and concentrated to dryness. The residue was purified by column chromatography on silica gel (eluted by hexanes/ EtOAc =3/1) to afford **23-S3** (80mg, 30%)


[0418] Step 3: 2-(2-Amino-6-bromopyridin-3-yl)acetonitrile (23-S4): TFA (10 mL) was added to solid **23-S3** (80 mg) and the reaction mixture was heated at 70 °C. The reaction mixture was concentrated to dryness. The residue was dissolved in DCM (15 mL) and washed with an aqueous saturated solution of NaHCO_3 (8mL). The organic layer was dried over Na_2SO_4 and concentrated to dryness to afford **23-S4** (63mg, quantitative yield)

[0419] Step 4: tert-Butyl (2S,4R)-2-((6-bromo-3-(cyanomethyl)pyridin-2-yl)carbamoyl)-4-fluoropyrrolidine-1-carboxylate (23-S5): To a stirred solution of (2S, 4R)-1-(tert-butoxycarbonyl)-4-fluoropyrrolidine-2-carboxylic acid (69 mg, 1 equiv) and **23-S4** (63 mg, 1 equiv) in DCM (10 mL), was added pyridine (0.12 mL, 5 equiv). The reaction was cooled to 0-5 °C and POCl_3 was added dropwise (0.024 mL, 2 equiv) under an atmosphere of argon. The reaction mixture was warmed to room temperature, diluted with DCM (10 mL) and neutralized with aqueous saturated NaHCO_3 solution (10 mL). The aqueous layer was extracted with DCM (1x 10 mL) and the combined organic layers were washed with brine (10 mL), dried over Na_2SO_4 and concentrated to dryness. The residue was purified by column chromatography on silica gel (eluted by 5% MeOH in DCM gradient) to afford **23-S5** (56mg, 26%).

[0420] Step 5: (2S,4R)-N-(6-Bromo-3-(cyanomethyl)pyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide hydrochloride (23-S6): To a solution of **23-S5** was added 4N HCl in dioxane (10 mL). The resulting solution was stirred at room temperature for 6 hours and then concentrated to dryness to afford **23-S6** (61mg).

[0421] Step 6: (2S,4R)-1-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-(cyanomethyl)pyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide (23): To a solution of **23-S6** (61 mg, 1 equiv), 2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetic acid (50 mg, 1.2 equiv) in DMF (8 ml) and DIPEA (0.12 mL, 5 equiv) was added HATU (63 mg, 1.2 equiv) at 0°C under an atmosphere of argon. The reaction mixture was stirred at room temperature for 3 hours before it was diluted with EtOAc (25 mL) and water (15 mL). The aqueous layer was extracted with EtOAc (15 mL) and the combined organic layers were washed with brine (15mLx3), dried over anhydrous Na_2SO_4 and concentrated to dryness. The residue was purified by column chromatography on silica gel (eluted by DCM/MeOH =10:1) to afford **23**. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 10.93 (s, 1H), 9.04 (s, 2H), 8.45 (s, 1H), 7.77-7.90 (m, 3H), 7.63 (d, 1H, J = 8.2 Hz), 5.52 - 5.89 (m, 3H), 4.57-4.64 (m, 1H), 4.19 - 4.31 (m, 1H), 3.95 - 4.13 (m, 1H), 3.61-3.74 (m, 2H), 2.70 (s, 3H), 2.66 (s, 3H), 2.65-2.68 (m, 1H), 2.24 - 2.33 (m, 1H), 0.84-0.90 (m, 2H); ^{19}F NMR (376 MHz, $\text{DMSO}-d_6$) δ -176.02 (s, 1F).

Scheme 17. Synthesis of Methyl 3-acetyl-1-(2-((2S,4R)-2-((6-bromopyridin-2-yl)carbamoyl)-4-fluoropyrrolidin-1-yl)-2-oxoethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazole-7-carboxylate (25)



[0422] Step 1: Methyl 5-(2-methylpyrimidin-5-yl)-1H-indazole-7-carboxylate (25-S2): A mixture of methyl 5-bromo-1H-indazole-7-carboxylate (0.95 g), 2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine (1.231 g, 1.5 equiv), cesium carbonate (3.64 g, 3 equiv) in dioxane (20 mL) and water (2.0 mL) was purged with argon in a pressure vessel for 5 minutes. Tetrakis(triphenylphosphine)palladium (0) (0.842 g, 0.2 equiv) was added under argon and the pressure vessel was sealed and heated at 90 °C overnight. The reaction mixture was cooled to room temperature and the solvent was removed under reduced pressure. The crude product was purified by silica gel flash column chromatography (eluent: 0-4.5 % MeOH in CH₂Cl₂) to afford 0.538 g of the product as white solid.

[0423] Step 2: Methyl 3-bromo-5-(2-methylpyrimidin-5-yl)-1H-indazole-7-carboxylate (25-S3): To an ice cooled solution of methyl 5-(2-methylpyrimidin-5-yl)-1H-indazole-7-carboxylate (0.538 g) in DMF (15 mL), bromine (113 µL) was added dropwise. The resulting slurry was stirred at room temperature for 2 hours and quenched with the addition of saturated sodium thiosulfate solution. The solid was isolated by filtration, washed with water, and dried. The material was carried forward in the next step without additional purification.

[0424] Step 3: Methyl 3-bromo-1-(2-(tert-butoxy)-2-oxoethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazole-7-carboxylate (25-S4): A mixture of methyl 3-bromo-5-(2-methylpyrimidin-5-yl)-1H-indazole-7-carboxylate (0.150 g), tert-


butyl bromoacetate (67 μ L) and potassium carbonate (0.090 g) in anhydrous acetonitrile (10 mL) and DMF (1 mL) was refluxed for 4 hours. The reaction mixture was then cooled to room temperature and the solvent was removed under reduced pressure. The residue was triturated with water, filtered and dried. The material was carried forward in the next step without additional purification.

[0425] Step 4: Methyl 3-acetyl-1-(2-(*tert*-butoxy)-2-oxoethyl)-5-(2-methylpyrimidin-5-yl)-1*H*-indazole-7-carboxylate (25-S5): A solution of methyl 3-bromo-1-(2-(*tert*-butoxy)-2-oxoethyl)-5-(2-methylpyrimidin-5-yl)-1*H*-indazole-7-carboxylate (0.100 g 1 equiv), tri-butyl(1-ethoxyvinyl)tin 0.15 mL, 2 equiv) and $\text{PdCl}_2(\text{PPh}_3)_2$ (15 mg, 0.1 equiv) in DMF (2 mL) was heated at 80°C overnight under argon atmosphere. The reaction was then concentrated under reduced pressure and diluted with CH_2Cl_2 and washed with cold aqueous HCl (1N). The organic layer was dried (Na_2SO_4), filtered, concentrated, and the residue was purified by silica gel flash column chromatography (eluent: 0-1.5 % MeOH in CH_2Cl_2) to afford a yellow solid.

[0426] Step 5: 2-(3-Acetyl-7-(methoxycarbonyl)-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetic acid (25-S6): Methyl 3-acetyl-1-(2-(*tert*-butoxy)-2-oxoethyl)-5-(2-methylpyrimidin-5-yl)-1*H*-indazole-7-carboxylate (**25-S5**) (0.08 g) was stirred in CH_2Cl_2 (1 mL) and TFA (2 mL). After completion of the reaction (monitored by HPLC), the solvent was removed under reduced pressure and the remaining residue was used directly in the next synthetic step without purification.

[0427] Step 6: Methyl 3-acetyl-1-(2-((2*S*,4*R*)-2-((6-bromopyridin-2-yl)carbamoyl)-4-fluoropyrrolidin-1-yl)-2-oxoethyl)-5-(2-methylpyrimidin-5-yl)-1*H*-indazole-7-carboxylate (25): Compound **25-S6** from above was dissolved in DMF (1 mL) and $i\text{Pr}_2\text{NEt}$ (0.164 mL, 5 equiv) was added, followed by the addition of **25-S7** at 5 °C. HATU (86 mg, 1.2 equiv) was then added slowly at 5 °C and the reaction mixture was stirred for 30 minutes at room temperature. The reaction mixture was poured into water and the precipitate was isolated by filtration. The solid was dried and purified by silica gel flash column chromatography (eluent: 0-2.0 % MeOH in CH_2Cl_2) to afford **25** as white solid. ^1H NMR (400 MHz, DMSO) δ 2.05-2.23 (m, 1H), 2.50-2.59 (m, 1H), 2.68 (s, 3H), 2.69 (s, 3H), 3.88-4.03 (m, 1H), 3.94 (s, 3H), 4.19 (dd, J = 12.4, 21.8 Hz, 1H), 4.64 (t, J = 8.4 Hz, 1H), 5.54 (d, J = 52 Hz, 1H), 5.76 (d, J = 17.4 Hz, 1H), 5.95 (d, J = 17.4 Hz, 1H), 7.31 (d, J = 7.7 Hz, 1H), 7.70 (t, J = 8.0 Hz, 1H), 8.00 (d, J = 8.2 Hz, 1H), 8.22 (d, J = 2 Hz, 1H), 8.70 (d, J = 1.8 Hz, 1H), 9.06 (s, 2H), 10.95 (s, 1H). ^{19}F NMR (DMSO- d_6): δ -176.1.


Scheme 19. Synthesis of (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-5-fluoro-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (27)



[0428] HATU (128mg, 1.2 equiv) was added at 0°C under an atmosphere of argon to a solution of **27-S6** (102 mg, 1 equiv), 2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetic acid (92mg, 1.2 equiv), and DIPEA (0.24 mL, 5 equiv) in DMF (8 mL). The reaction mixture was stirred at room temperature for 3 hours before it was diluted with EtOAc (30 mL) and water (15 mL). The organic layer was washed with brine, dried over anhydrous Na_2SO_4 , and concentrated to dryness. The residue was purified by column chromatography on silica gel (eluted with DCM/MeOH=10:1) to afford **27** (70mg, 39 %). ^1H NMR (400 MHz, DMSO- d_6) δ 10.31 (s, 1H), 9.03 (s, 2H), 8.35 (s, 1H), 7.82 (d, 1H, J =8.4 Hz), 7.62 (s, 1H), 6.03 (d, 1H, J =18.0 Hz), 5.69 (d, 1H, J =18.0 Hz), 4.37-4.43 (m, 1H), 3.59-3.62 (m, 1H), 2.69 (s, 6H), 2.65 (s, 3H), 2.53-2.60 (m, 1H), 2.08 (s, 3H), 2.02-2.10 (m, 1H), 1.33 (s, 3H), 0.93-1.05 (m, 2H). ^{19}F NMR (376 MHz, DMSO- d_6): δ

-119.12 (s, 1F).

Scheme 20. Synthesis of (1*S*,3*S*,5*R*)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-5-((allyloxy)methyl)-*N*-(3-((allyloxy)methyl)-6-bromopyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (29)



[0429] Step 1: 2-(*tert*-Butyl) 3-ethyl (1*S*,3*S*,5*R*)-5-(hydroxymethyl)-2-azabicyclo[3.1.0]hexane-2,3-dicarboxylate (29-S4): Anhydrous DCM (12.5mL) was cooled in an ice bath, and to the flask, a solution of ZnEt₂ in hexane (1.0M) (2.27 mL, 2.27 mmol) was added, followed by the careful dropwise addition of CH₂I₂ (4.54 mmol) under an argon atmosphere. After completion of the addition, the mixture was stirred at 0 °C for 10 minutes at which time a white precipitate appeared. A solution of 1-(*tert*-butyl) 2-ethyl (S)-4-(hydroxymethyl)-2,3-dihydro-1*H*-pyrrole-1,2-dicarboxylate (29-S1, 279 mg, 1.03 mmol) and *L*-dioxaborolane 29-S2 (316 mg, 1.17 mmol) was added quickly and the mixture was stirred for 30 minutes at 0 °C. The reaction was then allowed to warm to room temperature and stir for 2 hours. The reaction was quenched with saturated aqueous NH₄Cl (15mL) at 0 °C and the aqueous phase was extracted with DCM (15mL × 2). The combined DCM solutions were washed with brine and dried over MgSO₄. The solution was filtered and concentrated and the resulting residue was purified to afford 29-S4 (153 mg).

[0430] Step 2: 2-(*tert*-Butyl) 3-ethyl (1*S*,3*S*,5*R*)-5-((allyloxy)methyl)-2-azabicyclo[3.1.0]hexane-2,3-dicarboxylate (29-S5): To the solution of 2-(*tert*-butyl) 3-ethyl (1*S*,3*S*,5*R*)-5-(hydroxymethyl)-2-azabicyclo[3.1.0]hexane-2,3-dicarboxylate (29-S4, 153 mg, 0.53 mmol) in THF at 0 °C, NaH (60%, 2.65mmol) was added under argon. The mixture was stirred for 30 minutes, allyl bromide (3.0 mmol) was added, and the reaction was warmed to 40 °C for 4 hours. The reaction

was cooled in an ice bath and quenched carefully with aqueous NH_4Cl . The mixture was extracted with ethyl acetate ($15\text{mL} \times 3$) and the combined organic layers were washed with water, brine, and dried over MgSO_4 . The solution was concentrated and the residue was purified to afford **29-S5** (137 mg). ^1H NMR (400 MHz, DMSO-d_6 , 300 K): δ 0.77-0.85 (m, 1H), 1.18-1.94 (m, 1H), 1.27 (t, $J=7.2\text{Hz}$, 3H), 1.41 (s, 9H), 2.09-2.14 (m, 1H), 2.57-2.71 (m, 1H), 3.33-3.45 (m, 3H), 3.97 (d, $J=5.2\text{Hz}$, 2H), 4.10-4.20 (m, 2H), 4.52-4.64 (m, 1H), 5.18 (d, $J=10.4\text{Hz}$, 1H), 5.26 (d, $J=17.2\text{Hz}$, 1H), 5.84-5.93 (m, 1H) ppm.


[0431] Step 3: (1S,3S,5R)-5-((Allyloxy)methyl)-2-(tert-butoxycarbonyl)-2-azabicyclo[3.1.0]hexane-3-carboxylic acid (29-S6): Compound **29-S5** (137 mg, 0.42 mmol) was dissolved in a mixture of CH_3OH -THF- H_2O (2 mL-2 mL-2 mL) and treated with LiOH (40 mg, 1.67 mmol). The reaction mixture was stirred overnight at room temperature before the volatiles were evaporated under reduced pressure and the remaining residue was acidified with 10% citric acid (10 mL). The mixture was extracted with ethyl acetate ($15\text{mL} \times 3$) and the combined organic layers were washed with water, brine and dried over MgSO_4 . The solution was concentrated and the residue **29-S6** (108 mg) was dried and carried forward without additional purification. LC (method A): $t_R = 1.66$ min. LC/MS (EI) m/z : $[\text{M} + \text{H}]^+$ 298.4

[0432] Step 4: tert-Butyl (1S,3S,5R)-5-((allyloxy)methyl)-3-((3-((allyloxy)methyl)-6-bromopyridin-2-yl)carbamoyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (29-S8): (1S,3S,5R)-5-((Allyloxy)methyl)-2-(tert-butoxycarbonyl)-2-azabicyclo[3.1.0]hexane-3-carboxylic acid (**29-S6**, 108 mg, 0.36 mmol), 3-((allyloxy)methyl)-6-bromopyridin-2-amine (**29-S7**, 97mg, 0.40mmol) were dissolved in anhydrous DCM (5mL) in a pre-dried flask. The flask was cooled using an ice bath and dry pyridine (0.25mL) was added in one portion, followed by POCl_3 (100 μL , 1.0 mmol). After completion of the addition, the mixture was stirred for 4 hours at 0°C and the reaction was quenched with water (15 mL). The DCM layer was collected and the aqueous phase was extracted with DCM ($15\text{mL} \times 2$). The combined DCM solutions were washed with brine and dried over MgSO_4 . The solution was filtered and concentrated and the resulting residue was purified to afford **29-S8** (126 mg). ^1H NMR (400 MHz, Chloroform- d) δ 0.75-0.92 (m, 1H), 1.02-1.17 (m, 1H), 1.51 (s, 9H), 2.35-2.80 (m, 2H), 3.42 (d, $J = 10.4\text{ Hz}$, 1H), 3.52-3.63 (m, 2H), 3.90-4.11 (m, 4H), 4.36-4.44 (m, 2H), 4.74-4.87 (br, 1H), 5.18-5.31 (m, 4H), 5.85-5.92 (m, 2H), 7.29 (d, $J = 8.0\text{ Hz}$, 1H), 7.62 (d, $J = 7.9\text{ Hz}$, 1H), 9.16 (s, 1H) ppm. LC (method A): $t_R = 2.68$ min. LC/MS (EI) m/z : $[\text{M} + \text{H}]^+$ 524.44

[0433] Step 5: (1S,3S,5R)-5-((Allyloxy)methyl)-N-(3-((allyloxy)methyl)-6-bromopyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide TFA salt (29-S9): tert-Butyl (1S,3S,5R)-5-((allyloxy)methyl)-3-((3-((allyloxy)methyl)-6-bromopyridin-2-yl)carbamoyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (**29-S8**, 104 mg) was dissolved in DCM (4 mL) and treated with TFA (1mL). The mixture was stirred overnight at room temperature. The volatiles were evaporated under reduced pressure. The remaining material was co-evaporated with toluene twice and the residue (**29-S9**) was carried forward in the next step without additional purification.

[0434] Step 6: (1S,3S,5R)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-((allyloxy)methyl)-N-(3-((allyloxy)methyl)-6-bromopyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (29): To the solution of (1S,3S,5R)-5-((allyloxy)methyl)-N-(3-((allyloxy)methyl)-6-bromopyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide TFA salt (**29-S9**, 0.2 mmol), 2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetic acid (**29-S10**, 62 mg, 0.2 mmol) in DMF (2.0 mL), HATU (114mg, 0.3mmol) was added, followed by the dropwise addition of DIEA (5.0 eq) at room temperature. The mixture was stirred for 1 hour at room temperature and the volatiles were evaporated. The residue was diluted with 10% sodium carbonate (50 mL) and extracted with ethyl acetate. The combined organic solution was successively washed with water and brine and dried over MgSO_4 . The solution was filtered and the solvent was removed. The residue was purified to afford **29** (31.1 mg). ^1H NMR (400 MHz, DMSO-d_6): (major rotamer) δ 1.05 (t, $J = 5.7\text{ Hz}$, 1H), 1.44-1.46 (m, 1H), 2.07 (dd, $J = 13.5, 3.6\text{ Hz}$, 1H), 2.64 (s, 3H), 2.68 (s, 4H), 3.41-3.76 (m, 4H), 3.79 (dd, $J = 6.0, 2.6\text{ Hz}$, 1H), 4.03 (d, $J = 5.5\text{ Hz}$, 2H), 4.16 (s, 2H), 4.91 (dd, $J = 11.4, 3.6\text{ Hz}$, 1H), 4.96-5.13 (m, 2H), 5.20-5.36 (m, 2H), 5.58 (d, $J = 17.2\text{ Hz}$, 1H), 5.69-5.74 (m 1H), 5.91-5.98 (m, 2H), 7.52 (d, $J = 8.0\text{ Hz}$, 1H), 7.75 - 7.88 (m, 3H), 8.43 (s, 1H), 9.03 (s, 2H), 10.55 (s, 1H) ppm. LC (method A): $t_R = 2.28$ min. LC/MS (EI) m/z : $[\text{M} + \text{H}]^+$ 714.44, 716.47.

Scheme 21: Synthesis of 1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-7-(fluoromethyl)-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (31)




[0435] Step 1: *tert*-Butyl 2-(3-acetyl-7-(fluoromethyl)-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetate (31-S2): To a mixture of **31-S1** (163 mg, 0.38 mmol) in dry DCM (10 mL) was added DAST (124 mg, 0.76 mmol) at -30 °C under an atmosphere of nitrogen. The reaction mixture was stirred at room temperature for 1 hour. The reaction mixture was quenched with saturated aqueous NaHCO₃ solution and extracted with DCM twice. The combined organic layers were washed with brine, dried over anhydrous Na₂SO₄, and concentrated under reduced pressure to afford **31-S2** (140 mg, 92% yield) as a white solid, which was used in the next synthetic step without further purification. LC/MS (ESI) *m/z*: 399 (M+H)⁺.

[0436] Step 2: 2-(3-Acetyl-7-(fluoromethyl)-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetic acid (31-S3): To a solution of **31-S2** (65 mg, 0.16 mmol) in THF/H₂O (3:1 v/v, 4 mL) was added NaOH (14 mg, 0.32 mmol). The reaction mixture was stirred at room temperature for 1 hour. The mixture was diluted with water and washed with diethyl ether twice. The aqueous layer was adjusted to pH 5 with 10% aqueous HCl solution and extracted with DCM twice. The organic layer was dried over Na₂SO₄ and concentrated to afford **31-S3** (35 mg, 63.8% yield) as a white solid, which was used in the next synthetic step without further purification. LC/MS (ESI) *m/z*: 343 (M+H)⁺.

[0437] Step 3: (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-7-(fluoromethyl)-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (31): To a solution of **31-S3** (35 mg, 0.1 mmol), (1*R*,3*S*,5*R*)-*N*-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (46 mg, 0.13 mmol), and HATU (57 mg, 0.15 mmol) in DMF (3 mL) was added DIPEA (39 mg, 0.3 mmol). The reaction mixture was stirred at room temperature for 16 hours. The mixture was diluted with EtOAc, washed successively with 10% aqueous LiCl solution and brine, dried over anhydrous Na₂SO₄, and concentrated under reduced pressure. The remaining residue was purified by preparative HPLC (eluted with MeCN/water) to afford **31** (8 mg, 12.6% yield) as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.34 (s, 1H), 9.08 (s, 2H), 8.58 (s, 1H), 8.01 (s, 1H), 7.63 (d, *J* = 8.1 Hz, 1H), 7.45 (d, *J* = 7.9 Hz, 1H), 5.95 (t, *J* = 5.7 Hz, 1H), 5.81-5.91 (m, 1H), 5.72-5.78 (m, 1H), 5.61-5.69 (m, 1H), 4.38-4.44 (m, 1H), 3.58 (d, *J* = 2.9 Hz, 1H), 2.69 (s, 3H), 2.66 (s, 3H), 2.55-2.62 (m, 1H), 1.98-2.13 (m, 4H), 1.33 (s, 3H), 0.97-1.06 (m, 2H). LC/MS (ESI) *m/z*: 634 (M+H)⁺.

Scheme 22. Synthesis of (1*R*,3*S*,5*S*)-2-(2-(3-Acetyl-7-(methoxymethyl)-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromopyridin-2-yl)-5-(methoxymethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (32)



[0438] Step 1: 2-(*tert*-Butyl) 3-ethyl (3*S*)-5-(methoxymethyl)-2-azabicyclo[3.1.0]hexane-2,3-dicarboxylate (32-S2**):** To a solution of **32-S1** (500 mg, 1.75 mmol) in THF (5 mL) was added NaH (105.4 mg, 4.39 mmol) at 0 °C under an atmosphere of nitrogen and the mixture was stirred at 0 °C for 20 minutes. Iodomethane (740 mg, 5.25 mmol) was added and the resulting mixture was stirred at 0 °C under an atmosphere of nitrogen for 3 hours. The reaction mixture was quenched by aqueous NH₄Cl solution and diluted with EtOAc. The mixture was washed with water and brine, dried over Na₂SO₄, filtered, and concentrated to dryness. The remaining residue was purified by column chromatography on silica gel (eluted with PE/EtOAc = 5:1) to afford **32-S2** (160 mg, 30.5% yield) as a colorless oil. LC/MS (ESI) *m/z*: 300 (M+H)⁺.

[0439] Step 2: (3*S*)-2-(*tert*-Butoxycarbonyl)-5-(methoxymethyl)-2-azabicyclo[3.1.0]hexane-3-carboxylic acid (32-S3**):** To a mixture of **32-S2** (160 mg, 0.5 mmol) in THF (2 mL) and water (2 mL) was added LiOH (62.7 mg, 1.5 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 3 hours. The mixture was concentrated to half volume and washed with EtOAc twice. The mixture was acidified by 2 N aqueous HCl and extracted with DCM twice. The combined organic layers were concentrated to dryness to afford **32-S3** (120 mg, 88.9% yield) as a colorless oil. LC/MS (ESI) *m/z*: 272 (M+H)⁺.


[0440] Step 3: *tert*-Butyl (3*S*)-3-((6-bromopyridin-2-yl)carbamoyl)-5-(methoxymethyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (32-S4**):** To a mixture of **32-S3** (100 mg, 0.37 mmol) and 6-bromopyridin-2-amine (24.6 mg, 0.37 mmol) in DCE (5 mL) were added DIPEA (0.25 mL, 1.48 mmol) and EEDQ (183 mg, 0.74 mmol) at 0 °C. The reaction mixture was stirred at 90 °C overnight. The mixture was concentrated to dryness and the remaining residue was purified by column chromatography on silica gel (eluted with PE/EtOAc = 1:1) to afford **32-S4** (110 mg, 69.8% yield) as a yellow solid.

LC/MS (ESI) m/z : 426 (M+H)⁺.

[0441] Step 4: (3S)-N-(6-Bromopyridin-2-yl)-5-(methoxymethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (32-S5): To a solution of **32-S4** (95 mg, 0.223 mmol) in dioxane (2 mL) was added HCl/dioxane (2 mL, 2 M) at 0 °C. The reaction mixture was stirred at room temperature for 2 hours. The mixture was concentrated to dryness to afford **32-S5** (114 mg, 100% yield) as a brown syrup, which was used in the next synthetic step without purification. LC/MS (ESI) m/z : 326 (M+H)⁺.


[0442] Step 5: (3S)-2-(2-(3-Acetyl-7-(methoxymethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridin-2-yl)-5-(methoxymethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (32): To a mixture of **32-S5** (57 mg, 0.11 mmol), 2-(3-acetyl-7-(methoxymethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetic acid (39 mg, 0.078 mmol), and HATU (75 mg, 0.198 mmol) in DMF (3 mL) was added DIPEA (0.076 mL, 0.44 mmol) at 0 °C. The reaction mixture was stirred at room temperature overnight. The mixture was diluted with EtOAc, washed with 10% aqueous LiCl solution and brine, dried over Na₂SO₄, and concentrated to dryness. The remaining residue was purified by preparative HPLC to afford **32** (19 mg, 50.4% yield) as a white solid. ¹H NMR (400 MHz, CD₃OD) δ 9.02 (s, 2H), 8.59 (d, J = 1.7 Hz, 1H), 8.08 (d, J = 7.9 Hz, 1H), 7.73 (d, J = 1.7 Hz, 1H), 7.61 (t, J = 8.0 Hz, 1H), 7.25 (d, J = 7.3 Hz, 1H), 6.04 (d, J = 17.5 Hz, 1H), 5.86 (d, J = 17.4 Hz, 1H), 4.99 (s, 1H), 4.72 (d, J = 12.6 Hz, 1H), 4.56 (d, J = 9.0 Hz, 1H), 3.69 (dd, J = 5.7, 2.6 Hz, 1H), 3.53 (q, J = 10.3 Hz, 2H), 3.39 (d, J = 3.1 Hz, 6H), 2.75 (s, 3H), 2.70 (d, J = 2.5 Hz, 3H), 2.53 (dd, J = 13.5, 9.2 Hz, 1H), 2.41 (dd, J = 12.8, 5.1 Hz, 1H), 1.15-1.11 (m, 1H), 0.90 (t, J = 6.8 Hz, 1H). LC/MS (ESI) m/z : 662 (M+H)⁺.

Scheme 23. Synthesis of 3-Acetyl-1-(2-((2S,4R)-2-((6-bromopyridin-2-yl)carbamoyl)-4-fluoropyrrolidin-1-yl)-2-oxoethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazole-7-carboxylic acid (41)



[0443] To a suspension of methyl 3-acetyl-1-(2-((2S,4R)-2-((6-bromopyridin-2-yl)carbamoyl)-4-fluoropyrrolidin-1-yl)-2-oxoethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazole-7-carboxylate (**25**, 0.13 g) in THF (3 mL) was added a solution of LiOH (25 mg) in water (1 mL). The resulting homogeneous solution was stirred overnight at room temperature. The organic solvent was removed and the residue was diluted with water (2 mL). The white solid obtained by the acidification of the aqueous solution with 2N aqueous HCl was isolated and purified by reverse phase HPLC to afford **41**. ¹H NMR (400 MHz, DMSO) δ 2.03-2.25 (m, 1H), 2.50-2.58 (m, 1H), 2.68 (s, 3H), 2.69 (s, 3H), 3.56-3.68 (m, 1H), 3.91-4.13 (m, 2H), 4.64 (t, J = 8.4 Hz, 1H), 5.53 (d, J = 52.4 Hz, 1H), 5.74 (d, J = 17.1 Hz, 1H), 6.10 (d, J = 17.1 Hz, 1H), 7.30 (d, J = 7.7 Hz, 1H), 7.68 (t, J = 8.0 Hz, 1H), 7.99 (d, J = 8.3 Hz, 1H), 8.26 (d, J = 1.8 Hz, 1H), 8.69 (d, J = 1.8 Hz, 1H), 9.05 (s, 2H), 10.96 (s, 1H), 13.72 (s, 1H). ¹⁹F-NMR (DMSO-d₆): δ -175.2.

Scheme 24. Synthesis of (3*S*)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-methylpyridin-2-yl)-5-((methylamino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (42)



[0444] The above scheme and following detailed description depicts one non-limiting method for synthesizing compounds with nucleophilic R²⁰¹ groups on the C-ring. The skilled artisan will recognize that MeNH₂ can be replaced with other nucleophilic reagents to afford additional compounds of the present invention. Non-limiting examples of groups the skilled artisan can use instead of MeNH₂ include ethanamine, 2-fluoroethan-1-amine, 2,2,2-trifluoroethanamine, N-ethylpropan-1-amine, cyclopropanamine, piperazine, azetidine, azetidin-3-ol, 3,3-difluoroazetidine, 2-azaspiro[3.3]heptane, 2-azaspiro[3.4]octane, (3*aR*,6*aS*)-octahydrocyclopenta[*c*]pyrrole, 2-oxa-6-azaspiro[3.3]heptane, 2-azaspiro[3.4]octane, phenylmethanamine, (2-fluorophenyl)methanamine, and sodium cyanide

[0445] To a solution of **42-S1** (84 mg, 0.12 mmol) in MeCN (3 mL) were added DIPEA (0.04 mL, 0.24 mmol), NaI (18 mg, 0.12 mmol), and MeNH₂.HCl (16 mg, 0.24 mmol). The reaction mixture was stirred at 30 °C overnight. The mixture was partitioned with EtOAc and water. The organic layer was washed with brine, dried over anhydrous Na₂SO₄, and concentrated under reduced pressure. The remaining residue was purified by column chromatography on silica gel (eluted with DCM/MeOH = 10:1) and further purified by preparative HPLC to afford **42** (1.5 mg, 3.3% yield) as a white solid. ¹H NMR (400 MHz, CD₃OD) δ 9.01 (s, 2H), 8.57 (s, 1H), 7.76-7.83 (m, 2H), 7.58 (d, *J* = 8.0 Hz, 1H), 7.42 (d, *J* = 8.0 Hz, 1H), 5.65-5.79 (m, 2H), 4.72-4.75 (m, 1H), 3.85-3.87 (m, 1H), 2.61-2.79 (m, 11H), 2.59-2.60 (m, 2H), 2.12 (s, 3H), 1.28-1.45 (m, 2H). LC/MS (ESI) *m/z*: 631/633 (M+H)⁺.

[0446] **(1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-methylpyridin-2-yl)-5-(piperazin-1-ylmethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (88)**: ¹H NMR (400 MHz, CD₃OD) δ 9.02 (s, 2H), 8.55 (s, 1H), 8.45 (s, 1H), 7.58 (d, *J* = 8.5 Hz, 2H), 7.41 (d, *J* = 7.9 Hz, 1H), 6.00 (m, 1H), 5.83 (m, 1H), 4.66 (m, 1H), 3.68 (m, 1H), 3.25 (m, 4H), 2.91 (m, 2H), 2.77 (d, *J* = 4.9 Hz, 6H), 2.74 (d, *J* = 3.9 Hz, 2H), 2.70 (s, 3H), 2.68 (s, 2H), 2.51 (m, 2H), 2.14 (s, 3H), 1.20 (m, 1H), 1.10 (m, 1H). LC/MS (ESI) *m/z*: 700 (M+H)⁺.

[0447] **(1*R*,3*S*,5*R*)-5-(2-Azaspiro[3.3]heptan-2-ylmethyl)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (89)**: ¹H NMR (400 MHz, CD₃OD) δ 9.02 (s, 2H), 8.45 (s, 1H), 7.64-7.52 (m, 2H), 7.42 (d, *J* = 7.9 Hz, 1H), 5.99 (m, 1H), 5.82 (m, 1H), 4.64 (m, 1H), 3.79 (m, 4H), 3.16-3.06 (m, 1H), 2.77 (d, *J* = 2.9 Hz, 6H), 2.70 (s, 3H), 2.66 (s, 2H), 2.63-2.49 (m, 2H), 2.26 (m, 4H), 2.15 (s, 3H), 1.93-1.85 (m, 2H), 1.35 (m, 1H), 1.16 (m, 1H). LC/MS (ESI) *m/z*: 711 (M+H)⁺.

[0448] **(1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-methylpyridin-2-yl)-5-((methylamino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (94)**: ¹H NMR (400 MHz, CD₃OD) δ 9.02 (s, 2H), 8.45 (d, *J* = 6.7 Hz, 1H), 7.67-7.45 (m, 2H), 7.40 (m, 1H), 6.03-5.77 (m, 2H), 3.84 (s, 1H), 3.15 (m, 1H), 2.93 (m, 1H), 2.79 (d, *J* = 10.8 Hz, 2H), 2.75 (m, 4H), 2.77-2.68 (m, 4H), 2.70-2.63 (m, 2H), 2.66-2.56 (m, 1H), 2.47 (dd, *J* = 13.8, 3.5 Hz, 1H), 2.10 (m, 3H), 1.79 (m, 1H), 1.30 (m, 2H). LC/MS (ESI) *m/z*: 645 (M+H)⁺.

[0449] **(1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-methylpyridin-2-yl)-5-((2-fluoroethylamino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (113)**: ¹H NMR (400 MHz, CD₃OD) δ 9.01 (s, 2H), 8.43 (s, 1H), 7.66-7.47 (m, 3H), 7.41 (d, *J* = 7.9 Hz, 2H), 5.99 (m, 1H), 5.82 (m, 1H), 4.71 (m, 1H), 4.66 (m, 1H), 4.60 (m, 1H), 3.77 (m, 1H), 3.19 (m, 1H), 3.15-3.09 (m, 2H), 3.00 (d, *J* = 12.9 Hz, 1H), 2.76 (s, 6H), 2.70 (s, 3H), 2.63 (m, 2H), 2.14 (s, 3H), 1.18 (m, 1H), 0.92 (m, 1H). LC/MS (ESI) *m/z*: 677 (M+H)⁺.

[0450] **(1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-methylpyridin-2-yl)-5-((diethylamino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (118)**: ¹H NMR (400 MHz, CD₃OD) δ 8.89 (s, 2H), 8.33 (s, 1H), 7.51-7.42 (m, 2H), 7.30 (d, *J* = 7.9 Hz, 1H), 5.80 (dd, *J* = 18.0, 18.0 Hz, 2H), 4.59 (dd, *J* = 8.9, 4.5 Hz, 1H), 3.76 (d, *J* = 3.2 Hz, 1H), 3.36 (d, *J* = 14.6 Hz, 1H), 3.10 (s, 5H), 2.65 (d, *J* = 5.3 Hz, 6H),

2.57 (d, $J = 7.6$ Hz, 4H), 2.48 (dd, $J = 13.3, 4.3$ Hz, 1H), 2.06 (s, 6H), 2.02 (s, 3H), 1.40-1.36 (m, 1H), 0.82-0.78 (m, 1H). LC/MS (ESI) m/z : 687 (M+H)⁺.

[0451] (1R,3S,5R)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-(((3aR,6aS)-hexahydrocyclopenta[c]pyrrol-2(1H)-yl)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (119): ¹H NMR (400 MHz, CD₃OD) δ 8.92 (s, 2H), 8.47 (s, 1H), 7.72 (s, 2H), 7.49 (d, $J = 8.2$ Hz, 1H), 7.32 (d, $J = 8.0$ Hz, 1H), 5.74 (d, $J = 16.7$ Hz, 1H), 5.57 (d, $J = 17.2$ Hz, 1H), (dd, $J = 8.9, 4.5$ Hz, 1H), 3.80 (d, $J = 5.2$ Hz, 1H), 3.63 (s, 2H), 3.54 (s, 2H), 3.40-3.38 (m, 1H), 3.04 - 3.03 (m, 1H), 2.80 (s, 3H), 2.66 (s, 4H), 2.62-2.55 (m, 6H), 2.04 (s, 3H), 1.64 (s, 4H), 1.50 (s, 2H), 1.36 - 1.31 (m, 1H), 1.21 - 1.18 (s, 1H). LC/MS (ESI) m/z : 711 (M+H)⁺.

[0452] (1R,3S,5R)-5-(2-Oxa-6-azaspiro[3.3]heptan-6-ylmethyl)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (127): ¹H NMR (400 MHz, CD₃OD) δ 8.98 (s, 2H), 8.41 (s, 1H), 7.57 (d, $J = 8.0$ Hz, 1H), 7.53 (s, 1H), 7.40 (d, $J = 8.0$ Hz, 1H), 5.94-5.99 (m, 1H), 5.76-5.81 (m, 1H), 4.80 (s, 4H), 4.63-4.65 (m, 1H), 4.08-4.15 (m, 4H), 3.81-3.83 (m, 1H), 3.13 (s, 2H), 2.74 (s, 6H), 2.65 (s, 3H), 2.49-2.59 (m, 2H), 2.12 (s, 3H), 1.30-1.33 (m, 1H), 0.95-0.98 (m, 1H). LC/MS (ESI) m/z : 713 (M+H)⁺.

[0453] (1R,3S,5R)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-(((3aR,6aS)-hexahydrocyclopenta[c]pyrrol-2(1H)-yl)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (128): ¹H NMR (400 MHz, CD₃OD) δ 8.98 (s, 2H), 8.41 (s, 1H), 7.53-7.58 (m, 2H), 7.40 (d, $J = 8.0$ Hz, 1H), 5.96-6.01 (m, 2H), 5.77-5.81 (m, 1H), 4.66-4.70 (m, 1H), 3.86-3.89 (m, 3H), 2.63-2.89 (m, 17H), 2.12 (s, 3H), 1.59-1.76 (m, 6H), 1.43-1.46 (m, 1H), 1.27-1.30 (m, 1H). LC/MS (ESI) m/z : 725 (M+H)⁺.

[0454] (1R,3S,5R)-5-(2-Azaspiro[3.4]octan-2-ylmethyl)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (129): ¹H NMR (400 MHz, CD₃OD) δ 8.98 (s, 2H), 8.41 (s, 1H), 7.58 (d, $J = 8.0$ Hz, 1H), 7.52 (s, 1H), 7.41 (d, $J = 8.0$ Hz, 1H), 5.97 (m, 1H), 5.79 (m, 1H), 4.67 (m, 1H), 4.07-4.04 (m, 1H), 4.03-3.90 (m, 1H), 3.44 (q, $J = 13.6$ Hz, 2H), 2.74 (m, 6H), 2.67 (s, 3H), 2.61-2.55 (m, 1H), 2.12 (s, 3H), 1.94 (m, 4H), 1.66 (m, 5H), 1.45 (m, 1H), 1.29-1.20 (m, 1H). LC/MS (ESI) m/z : 725 (M+H)⁺.

[0455] (1R,3S,5R)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((ethylamino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (132): ¹H NMR (400 MHz, CD₃OD) δ 9.00 (s, 2H), 8.44 (s, 1H), 7.60-7.44 (m, 2H), 7.43 (d, $J = 7.9$ Hz, 1H), 5.98 (d, $J = 17.6$ Hz, 1H), 5.83 (d, $J = 17.6$ Hz, 1H), 4.74 (dd, $J = 8.3, 4.4$ Hz, 1H), 3.91 (dd, $J = 5.8, 2.8$ Hz, 1H), 3.28-3.07 (m, 3H), 2.77 (s, 6H), 2.70 (s, 3H), 2.68-2.59 (m, 2H), 2.14 (s, 3H), 1.50 (d, $J = 5.9$ Hz, 1H), 1.39 (t, $J = 7.3$ Hz, 3H), 1.35 (dd, $J = 5.9, 2.8$ Hz, 1H). LC/MS (ESI) m/z : 658 (M+H)⁺.

[0456] (1R,3S,5R)-5-(2-Azaspiro[3.4]octan-2-ylmethyl)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (142): ¹H NMR (400 MHz, CD₃OD) δ 8.99 (s, 2H), 8.53 (s, 1H), 7.77 (s, 2H), 7.57 (d, $J = 8.0$ Hz, 1H), 7.41 (d, $J = 8.0$ Hz, 1H), 5.77-5.81 (m, 1H), 5.62-5.66 (m, 1H), 4.65-4.68 (m, 1H), 3.99-4.07 (m, 4H), 3.88-3.90 (m, 1H), 3.36 (s, 2H), 2.75 (s, 3H), 2.68 (s, 3H), 2.57-2.60 (m, 2H), 2.12 (s, 3H), 1.91-1.95 (m, 4H), 1.63-1.67 (m, 4H), 1.37-1.39 (m, 1H), 1.23-1.25 (m, 1H). LC/MS (ESI) m/z : 711 (M+H)⁺.

[0457] (1R,3S,5R)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-(azetidin-1-ylmethyl)-N-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (149): ¹H NMR (400 MHz, CD₃OD) δ 9.00 (s, 2H), 8.42 (s, 1H), 7.58 (d, $J = 8.0$ Hz, 1H), 7.55 (s, 1H), 7.42 (d, $J = 8.0$ Hz, 1H), 5.96-6.01 (m, 1H), 5.78-5.83 (m, 1H), 4.64-4.68 (m, 1H), 4.04-4.09 (m, 4H), 3.86-3.88 (m, 1H), 3.32-3.34 (m, 1H), 3.18-3.21 (m, 1H), 2.76 (s, 6H), 2.71 (s, 4H), 2.44-2.53 (m, 3H), 2.13 (s, 3H), 1.39-1.42 (m, 1H), 1.21-1.23 (m, 1H). LC/MS (ESI) m/z : 671 (M+H)⁺.

[0458] (1R,3S,5R)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((3,3-difluoroazetidin-1-yl)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (150): ¹H NMR (400 MHz, CD₃OD) δ 9.01 (s, 2H), 8.43 (s, 1H), 7.55-7.57 (m, 2H), 7.38 (d, $J = 8.0$ Hz, 1H), 5.97-6.02 (m, 1H), 5.78-5.83 (m, 1H), 4.59-4.63 (m, 1H), 3.67-3.82 (m, 5H), 2.70-2.81 (m, 11H), 2.58-2.60 (m, 2H), 2.16 (s, 3H), 1.24-1.27 (m, 1H), 1.03-1.05 (m, 1H). LC/MS (ESI) m/z : 707 (M+H)⁺.

[0459] (1R,3S,5R)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((cyclopropylamino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (151): ¹H NMR (400 MHz, CD₃OD) δ 9.03 (s, 2H), 8.58 (s, 1H), 7.81 (s, 2H), 7.58 (d, $J = 8.0$ Hz, 1H), 7.41 (d, $J = 7.9$ Hz, 1H), 5.82 (d, $J = 17.2$ Hz, 1H), 5.68 (d, $J = 17.1$ Hz, 1H), 4.68-4.57 (m, 1H), 3.69 (s, 1H), 3.16-3.01 (m, 1H), 2.84 (d, $J = 12.7$ Hz, 1H), 2.77 (s, 3H), 2.72 (s, 3H), 2.66-2.56 (m, 2H), 2.35 (s, 1H), 1.30 (s, 1H), 1.13 (s, 1H), 0.58 (d, $J = 5.5$ Hz, 2H), 0.47 (s, 2H). LC/MS (ESI) m/z : 657 (M+H)⁺.


[0460] (1R,3S,5R)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-((benzylamino)methyl)-N-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (161): ¹H NMR (400 MHz, CD₃OD) δ 8.85 (s, 2H), 8.27 (s, 1H), 7.28-7.46 (m, 8H), 5.81-5.86 (m, 1H), 5.64-5.69 (m, 1H), 4.56-4.58 (m, 1H), 4.01-4.11 (m, 2H), 3.71-3.74 (m, 1H), 3.01 (s, 2H), 2.63 (s, 6H), 2.56 (s, 3H), 2.50-2.54 (m, 2H), 1.99 (s, 3H), 1.29-1.31 (m, 1H), 1.14-1.17 (m, 1H). LC/MS (ESI) m/z : 721 (M+H)⁺.

[0461] (1R,3S,5R)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-

methylpyridin-2-yl)-5-(cyanomethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (162): ^1H NMR (400 MHz, CD_3OD) δ 8.99 (s, 2H), 8.41 (s, 1H), 7.53-7.56 (m, 2H), 7.39 (d, J = 8.0 Hz, 1H), 5.96-6.00 (m, 1H), 5.77-5.82 (m, 1H), 4.62-4.66 (m, 1H), 3.82-3.84 (m, 1H), 3.04-3.08 (m, 1H), 2.87-2.91 (m, 1H), 2.69-2.78 (m, 10H), 2.46-2.50 (m, 1H), 2.14 (s, 3H), 1.40-1.43 (m, 1H), 1.22-1.25 (m, 1H). LC/MS (ESI) m/z : 641 ($\text{M}+\text{H}$) $^+$.

[0462] (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-methylpyridin-2-yl)-5-((3-hydroxyazetidin-1-yl)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (164): ^1H NMR (400 MHz, CD_3OD) δ 9.01 (s, 2H), 8.44 (s, 1H), 7.63-7.53 (m, 2H), 7.42 (d, J = 7.9 Hz, 1H), 6.00 (d, J = 17.7 Hz, 1H), 5.82 (d, J = 17.7 Hz, 1H), 4.70-4.48 (m, 2H), 4.15 (d, J = 26.0 Hz, 2H), 3.81 (s, 1H), 3.50 (s, 2H), 3.24-3.12 (m, 1H), 3.03 (d, J = 13.0 Hz, 1H), 2.77 (d, J = 2.9 Hz, 6H), 2.70 (s, 3H), 2.61 (d, J = 8.8 Hz, 1H), 2.53 (dd, J = 13.5, 4.8 Hz, 1H), 2.14 (s, 3H), 1.34 (d, J = 22.4 Hz, 2H), 1.17 (s, 1H). LC/MS (ESI) m/z : 687 ($\text{M}+\text{H}$) $^+$.

Scheme 25. Synthesis of (1*S*,3*S*,5*S*)-5-(Acetamidomethyl)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromopyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (43) and (1*R*,3*S*,5*R*)-5-(Acetamidomethyl)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromopyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (44)



[0463] Step 1: (3*S*)-*tert*-Butyl 3-(6-bromopyridin-2-ylcarbamoyl)-5-((1,3-dioxoisindolin-2-yl)methyl)-2-azabi-

cyclo[3.1.0]hexane-2-carboxylate (44-S2): To a solution of **44-S1** (250 mg, 0.64 mmol) and 6-bromopyridin-2-amine (123 mg, 0.71 mmol) in DCE (5 mL) were added DIPEA (0.43 mL, 2.58 mmol) and EEDQ (319 mg, 1.29 mmol). The reaction mixture was stirred at 90 °C overnight and concentrated under vacuum. The remaining residue was purified by column chromatography on silica gel (eluted with PE/EtOAc = 4:1) to afford **44-S2** (300 mg, 85.9% yield) as a white solid. LC/MS (ESI) m/z: 541/543 (M+H)⁺.

[0464] Step 2: (3S)-tert-Butyl 5-(aminomethyl)-3-(6-bromopyridin-2-ylcarbamoyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (44-S3): To a solution of **44-S2** (300 mg, 0.55 mmol) in EtOH (6 mL) was added hydrazine hydrate (0.3 mL, 85% w/w). The reaction mixture was stirred at 75 °C for 2 hours and then cooled to room temperature. The mixture was filtered, the filtrate was concentrated to dryness, and the remaining crude product was purified by column chromatography on silica gel (eluted with DCM/MeOH = 10:1) to afford **44-S3** (210 mg, 92.5% yield) as light a yellow oil. LC/MS (ESI) m/z: 411/413 (M+H)⁺.

[0465] Step 3: (3S)-tert-Butyl 5-(Acetamidomethyl)-3-(6-bromopyridin-2-ylcarbamoyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (44-S4): To a mixture of **44-S3** (100 mg, 0.24 mmol) in dry DCM (3 mL) were added DIPEA (0.08 mL, 0.48 mmol) and acetyl chloride (0.02 mL, 0.28 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 1 hour. The mixture was then diluted with water (20 mL) and extracted with DCM (4 mL × 2). The combined organic phases were washed with brine, dried over anhydrous Na₂SO₄, filtered, and concentrated. The remaining crude product was purified by column chromatography on silica gel (eluted with DCM/MeOH = 30:1) to afford **44-S4** (94 mg, 85.4% yield) as a white solid. LC/MS (ESI) m/z: 453/455 (M+H)⁺.


[0466] Step 4: (3S)-5-(Acetamidomethyl)-N-(6-bromopyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (44-S5): To a solution of **44-S4** (90 mg, 0.2 mmol) in DCM (2.5 mL) was added TFA (1 mL). The reaction mixture was stirred at room temperature for 1.5 hours and then concentrated under reduced pressure to afford **44-S5** (80 mg, 100.0% yield) as a yellow solid, which was carried forward in the next synthetic step without further purification. LC/MS (ESI) m/z: 353/355 (M+H)⁺.

[0467] Step 5: (1S,3S,5S)-5-(Acetamidomethyl)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (43) and (1R,3S,5R)-5-(Acetamidomethyl)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (44): To a solution of **44-S5** (35 mg, 0.078 mmol), 2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetic acid (**44-S6**, 29 mg, 0.093 mmol), and HATU (59 mg, 0.155 mmol) in DMF (2 mL) was added DIPEA (0.065 mL, 0.40 mmol). The reaction mixture was stirred at room temperature for 16 hours. The mixture was partitioned with EtOAc and water. The organic layer was washed with brine, dried over anhydrous Na₂SO₄, and concentrated under reduced pressure. The crude product was purified by preparative HPLC to afford **43** (25 mg, 49.8% yield) and **44** (2 mg, 3.98% yield) as white solids.

[0468] (1S,3S,5S)-5-(acetamidomethyl)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (43): ¹H NMR (400 MHz, DMSO-d₆) δ 10.91 (s, 1H), 9.04 (s, 2H), 8.48 (s, 1H), 8.02-8.05 (m, 2H), 7.83-7.89 (m, 2H), 7.70 (t, J = 8.0 Hz, 1H), 7.31 (d, J = 7.6 Hz, 1H), 5.86-5.90 (m, 1H), 5.58-5.63 (m, 1H), 4.92-4.95 (m, 1H), 3.72-3.74 (m, 1H), 3.37-3.40 (m, 2H), 2.62-2.68 (m, 6H), 2.01-2.05 (m, 1H), 1.86 (s, 3H), 1.40-1.42 (m, 1H), 0.89-1.01 (m, 2H). LC/MS (ESI) m/z: 645/647 (M+H)⁺.

[0469] (1R,3S,5R)-5-(acetamidomethyl)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (44): ¹H NMR (400 MHz, CD₃OD) δ 9.00 (s, 2H), 8.54 (s, 1H), 8.08-8.10 (m, 1H), 7.79 (s, 2H), 7.62 (t, J = 8.0 Hz, 1H), 7.26 (d, J = 7.6 Hz, 1H), 5.77-5.82 (m, 1H), 5.63-5.68 (m, 1H), 4.57-4.62 (m, 1H), 3.70-3.72 (m, 1H), 3.46-3.50 (m, 1H), 3.20-3.23 (m, 1H), 2.73-2.75 (m, 6H), 2.30-2.52 (m, 2H), 1.92 (s, 3H), 1.26-1.29 (m, 1H), 1.06-1.08 (m, 1H). LC/MS (ESI) m/z: 645/647 (M+H)⁺.

Scheme 26. Synthesis of Methyl (2S)-1-(((3S)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-3-(6-bromopyridin-2-ylcarbamoyl)-2-azabicyclo[3.1.0]hexan-5-yl)methylamino)-3-methyl-1-oxobutan-2-ylcarbamate (45)



[0470] Step 1: (3S)-tert-Butyl 3-(6-bromopyridin-2-ylcarbamoyl)-5-(((S)-2-(methoxycarbonylamino)-3-methylbutanamido)methyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (45-S2): To a mixture of 45-S1 (100 mg, 0.24 mmol), (S)-2-(methoxycarbonylamino)-3-methylbutanoic acid (51 mg, 0.29 mmol), and HATU (182 mg, 0.48 mmol) in DMF (2 mL) was added DIPEA (0.16 mL, 0.96 mmol). The reaction mixture was stirred at room temperature for 16 hours. The mixture was partitioned with EtOAc and water. The organic layer was washed with brine, dried over anhydrous Na₂SO₄, and concentrated under reduced pressure. The remaining residue product was purified by column chromatography on silica gel (eluted with DCM/MeOH = 30:1) to afford 45-S2 (105 mg, 76.0% yield) as a white solid. LC/MS (ESI) m/z: 568/570 (M+H)⁺.

[0471] Step 2: Methyl (2S)-1-(((3S)-3-(6-Bromopyridin-2-ylcarbamoyl)-2-azabicyclo[3.1.0]hexan-5-yl)methylamino)-3-methyl-1-oxobutan-2-ylcarbamate (S3): To a solution of 45-S2 (105 mg, 0.18 mmol) in DCM (2.5 mL) was added TFA (1 mL). The reaction mixture was stirred at room temperature for 1.5 hours and then concentrated under reduced pressure to afford 45-S3 (85 mg, 100.0% yield) as a yellow solid, which was carried forward in the next synthetic step without further purification. LC/MS (ESI) m/z: 468/470 (M+H)⁺.

[0472] Step 3: Methyl (2S)-1-(((3S)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-3-(6-bromopyridin-2-ylcarbamoyl)-2-azabicyclo[3.1.0]hexan-5-yl)methylamino)-3-methyl-1-oxobutan-2-ylcarbamate (45): To a solution of 45-S3 (35 mg, 0.074 mmol), 2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetic acid (45-S4, 28 mg, 0.089 mmol) and HATU (57 mg, 0.15 mmol) in DMF (2 mL) was added DIPEA (0.05 mL, 0.29 mmol). The reaction mixture was stirred at room temperature for 16 hours. The mixture was partitioned with EtOAc and water. The organic layer was washed with brine, dried over anhydrous Na₂SO₄, and concentrated under reduced pressure. The remaining residue was purified by preparative HPLC (eluted with MeCN/water) to afford 45 (39 mg, 68.6% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 10.9 (s, 1H), 9.04 (s, 2H), 8.47 (s, 1H), 8.01-8.25 (m, 2H), 7.70-7.89 (m, 3H), 7.30-7.33 (m, 1H), 7.11-7.24 (m, 1H), 5.84-5.91 (m, 1H), 5.57-5.64 (m, 1H), 4.92-4.95 (m, 1H), 3.71-3.79 (m, 2H), 3.49 (s, 4H), 3.29-3.33 (m, 1H), 2.65-2.68 (m, 7H), 1.97-2.02 (m, 2H), 1.05-1.36 (m, 2H), 0.87-0.95 (m, 6H). LC/MS (ESI) m/z: 760/762 (M+H)⁺.

Scheme 27. Synthesis of (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-7-ethyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (47)

5

10

15


20

25

30

35

40



[0473] Step 1: 4-Bromo-2-ethyl-6-methylaniline (47-S2): To a solution of **47-S1** (12 g, 88.7 mmol) in AcOH (250 mL) was added dropwise Br₂ (5.1 mL) at 0 °C. The reaction mixture was stirred at room temperature for 2 hours. The mixture was filtered and the filter cake was washed with diethyl ether. The solid was suspended in water and neutralized with saturated aqueous K₂CO₃ solution. The mixture was extracted with EtOAc twice and the combined organic layers were dried over anhydrous Na₂SO₄ and concentrated to dryness to afford **47-S2** (12.2 g, 57.0% yield) as a purple oil. LC/MS (ESI) m/z: 214 (M+H)⁺.

[0474] Step 2: 5-Bromo-7-ethyl-1*H*-indazole (47-S3): To a solution of **47-S2** (6 g, 28.2 mmol) and KOAc (3.3 g 33.8 mmol) in CHCl₃ (60 mL) was added dropwise acetic anhydride (8.6 g, 86.4 mmol) at 0 °C under an atmosphere of nitrogen and the resulting mixture was stirred at room temperature for 1 hour. The reaction mixture was heated to 60 °C and tert-butyl nitrite (5.8 g, 56.4 mmol) was added. The resulting mixture was stirred at 60 °C overnight. The mixture was diluted with DCM and washed with water and brine. The organic layer was dried over anhydrous Na₂SO₄ and concentrated. The remaining residue was dissolved in MeOH and 6 N aqueous HCl (20 mL) and the mixture was stirred at room temperature for 4 hours. The reaction mixture was basified with 2 N aqueous NaOH solution and extracted with DCM twice. The combined organic layers were washed with brine, dried over anhydrous Na₂SO₄, and concentrated to afford **47-S3** (5.0 g, 79.2% yield) as a light a yellow solid. LC/MS (ESI) m/z: 225 (M+H)⁺.

[0475] Step 3: 5-Bromo-7-ethyl-3-iodo-1H-indazole (47-S4): To a solution of **47-S3** (4.5 g, 20.1 mmol) in DMF (50 mL) were added KOH (2.53 g, 45.23 mmol) and iodine (7.65 g, 30.15 mmol) at 0 °C. The reaction mixture was stirred at 0 °C for 30 minutes. The reaction mixture was quenched by addition of saturated aqueous Na₂S₂O₃ solution (15 mL). The mixture was diluted with DCM and washed with 10% aqueous LiCl solution and brine. The organic layer was dried over anhydrous Na₂SO₄ and concentrated to dryness to afford **47-S4** (6.56 g, 93.2% yield) as a white solid. LC/MS (ESI) m/z: 351 (M+H)⁺.

[0476] Step 4: *tert*-Butyl 2-(5-bromo-7-ethyl-3-iodo-1H-indazol-1-yl)acetate (47-S5): To a solution of **47-S4** (6.56 g, 18.75 mmol) in DMF (70 mL) were added K₂CO₃ (7.76 g, 56.2 mmol) and *tert*-butyl 2-bromoacetate (2.73 mL, 18.75 mmol). The reaction mixture was stirred at room temperature overnight. The mixture was diluted with EtOAc and washed with 10% aqueous LiCl solution and brine. The organic layer was dried over anhydrous Na₂SO₄ and concentrated to dryness. The remaining residue was purified by column chromatography on silica gel (eluted with PE/EtOAc = 10:1) to afford **47-S5** (3.5 g, 40.2% yield) as a yellow solid. LC/MS (ESI) m/z: 465 (M+H)⁺.


[0477] Step 5: *tert*-Butyl 2-(3-acetyl-5-bromo-7-ethyl-1H-indazol-1-yl)acetate (47-S6): To a solution of **47-S5** (1.5 g, 3.23 mmol) in toluene (15 mL) were added tributyl(1-ethoxyvinyl)stannane (1.75 g, 4.85 mmol) and Pd(PPh₃)₄ (373 mg, 0.32 mmol). The mixture was stirred at 100 °C under an atmosphere of nitrogen overnight. The mixture was cooled to room temperature and 0.5 M aqueous HCl was added. The resulting mixture was stirred for another 30 minutes, diluted with EtOAc, and washed with brine. The organic layer was dried over anhydrous Na₂SO₄ and concentrated to dryness. The remaining residue was purified by column chromatography on silica gel (eluted with PE/EtOAc = 60:1) to afford **47-S6** (976 mg, 79.5% yield) as a brown solid. LC/MS (ESI) m/z: 381 (M+H)⁺.

[0478] Step 6: *tert*-Butyl 2-(3-acetyl-7-ethyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetate (47-S7): To a solution of **47-S6** (500 mg, 1.32 mmol) and (2-methylpyrimidin-5-yl)boronic acid (182 mg, 1.32 mmol) in dioxane (6 mL) and water (0.6 mL) were added K₂CO₃ (455 mg, 3.3 mmol) and Pd(PPh₃)₄. The reaction mixture was stirred at 90 °C under an atmosphere of nitrogen overnight. The mixture was diluted with EtOAc, washed with water and brine, dried over Na₂SO₄ and concentrated to afford **47-S7** (210 mg, 40.4% yield) as a white solid. LC/MS (ESI) m/z: 395 (M+H)⁺.

[0479] Step 7: 2-(3-Acetyl-7-ethyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetic acid (47-S8): To a solution of **47-S7** (170 mg, 0.43 mmol) in THF (3 mL) was added 1 M aqueous NaOH solution (0.86 mL, 0.86 mmol) and the reaction mixture was stirred at room temperature overnight. The mixture was concentrated to dryness, diluted with water, and washed with diethyl ether twice. The aqueous layer was acidified by addition of 1 N aqueous HCl and extracted with DCM twice. The combined organic layers were washed with brine, dried over anhydrous Na₂SO₄, and concentrated to dryness to afford **47-S8** (106 mg, 72.9% yield) as a white solid. LC/MS (ESI) m/z: 339 (M+H)⁺.

[0480] Step 8: (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-7-ethyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-*N*-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (47): To a solution of **47-S8** (30 mg, 0.089 mmol), **47-S9** (32 mg, 0.093 mmol), and HATU (50.0 mg, 0.133 mmol) in DMF (3 mL) was added DIPEA (34 mg, 0.267 mmol) and the reaction mixture was stirred at room temperature under an atmosphere of nitrogen for 2 hours. The mixture was diluted with EtOAc and washed with 10% aqueous LiCl solution and brine. The organic layer was dried over anhydrous Na₂SO₄ and concentrated to dryness. The remaining residue was purified by preparative HPLC to afford **47** (8 mg, 10.7% yield) as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.32 (s, 1H), 9.04 (s, 2H), 8.35 (d, *J* = 1.5 Hz, 1H), 7.64-7.60 (m, 2H), 7.45 (d, *J* = 8.0 Hz, 1H), 5.96 (d, *J* = 16.0 Hz, 1H), 5.68 (d, *J* = 20.0 Hz, 1H), 4.40 (m, 1H), 3.60 (m, 2H), 3.03-2.97 (m, 2H), 2.69 (s, 3H), 2.65 (s, 3H), 2.58 (m, 2H), 2.04 (s, 4H), 1.33 (d, *J* = 8.0 Hz, 6H), 1.06 (t, *J* = 5.3 Hz, 1H), 0.93 (m, 1H). LC/MS (ESI) m/z: 630 (M+H)⁺.

Scheme 28. Synthesis of Methyl 5-(3-acetyl-1-(2-((1*R*,3*S*,5*R*)-3-(6-bromo-3-methylpyridin-2-ylcarbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-7-methyl-1*H*-indazol-5-yl)-2-methylpyrimidine 1-oxide (50)




[0481] Step 1: 5-(3-Acetyl-1-(2-*tert*-butoxy-2-oxoethyl)-7-methyl-1*H*-indazol-5-yl)-2-methylpyrimidine 1-oxide (50-S2): To a mixture of 50-S1 (130 mg, 0.39 mmol) in CHCl_3 (10 mL) was added *m*-CPBA (67 mg, 0.39 mmol). The reaction mixture was stirred at room temperature for 16 hours. The mixture was adjusted to pH 10 with aqueous NaHCO_3 . The mixture was partitioned with DCM/MeOH (20:1) and water. The organic layer was washed with brine, dried over anhydrous Na_2SO_4 , and concentrated under reduced pressure. The remaining residue was purified by column chromatography on silica gel (eluted with DCM/MeOH = 120:1) to afford the title product (77 mg, 49.2% yield) as a white solid. LC/MS (ESI) m/z : 397 ($\text{M}+\text{H}$)⁺.

[0482] Step 2: 5-(3-Acetyl-1-(carboxymethyl)-7-methyl-1*H*-indazol-5-yl)-2-methylpyrimidine 1-oxide (50-S3): To a solution of 50-S2 (77 mg, 0.18 mmol) in DCM (2 mL) was added TFA (2 mL). The reaction mixture was stirred at room temperature for 1.5 hours and then concentrated under reduced pressure to afford the title product (60 mg, 88.4% yield) as a yellow solid, which was carried forward in the next synthetic step without further purification. LC/MS (ESI) m/z : 341 ($\text{M}+\text{H}$)⁺.

[0483] Step 3: 5-(3-Acetyl-1-(2-((1*R*,3*S*,5*R*)-3-(6-bromo-3-methylpyridin-2-ylcarbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-7-methyl-1*H*-indazol-5-yl)-2-methylpyrimidine 1-oxide (50): To a solution of 50-S3 (60 mg, 0.145 mmol), (1*R*,3*S*,5*R*)-*N*-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (50 mg, 0.145 mmol), and HATU (84 mg, 0.22 mmol) in DMF (3 mL) was added DIPEA (57 mg, 0.43 mmol). The reaction mixture was stirred at room temperature for 1 hour. The mixture was partitioned with DCM/MeOH (20:1) and water. The organic layer was washed with brine, dried over anhydrous Na_2SO_4 , and concentrated under reduced pressure. The remaining residue was purified by preparative HPLC (eluted with MeCN/water) to afford 50 (2.2 mg, 1.6% yield) as a white solid. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 10.32 (s, 1H), 8.95 (d, J = 1.9 Hz, 1H), 8.57 (d, J = 1.9 Hz, 1H), 8.35 (s, 1H), 7.62 (d, J = 8.0 Hz, 2H), 7.44 (d, J = 7.9 Hz, 1H), 6.03 (d, J = 17.9 Hz, 1H), 5.69 (d, J = 17.8 Hz, 1H), 4.41 (dd, J = 9.1, 5.5 Hz, 1H), 3.56-3.61 (m, 1H), 2.67 (s, 3H), 2.65 (s, 3H), 2.61 (s, 3H), 2.53-2.59 (m, 1H), 2.04 (s, 3H), 1.97 - 2.03 (m, 1H), 1.33 (s, 3H), 1.00 - 1.05 (m, 1H), 0.91-0.97 (m, 1H). LC/MS (ESI) m/z : 632/634 ($\text{M}+\text{H}$)⁺.

Scheme 29. Synthesis of (3*S*)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl) acetyl)-*N*-(6-bromo-3-methylpyridin-2-yl)-5-((dimethylamino) methyl)-2-azabicyclo [3.1.0] hexane-3-carboxamide (51)



[0484] Step 1: 5-Bromo-7-methyl-1*H*-indazole (51-S2**):** To a solution of 4-bromo-2,6-dimethylaniline (**51-S1**, 10 g, 0.05 mol) and potassium acetate (5.88 g, 0.06 mol) in CHCl_3 (120 mL) was added acetic anhydride (15.3 g, 0.15 mol) dropwise at 0°C under an atmosphere of nitrogen and the resulting mixture was stirred at room temperature for 1 hour. The reaction mixture was heated to 60°C and *tert*-butyl nitrite (10.3 g, 0.1 mol) was added dropwise. The resulting mixture was stirred overnight at 60°C . The mixture was cooled to room temperature, diluted with H_2O , and extracted with DCM twice. The combined organic layers were washed by brine, dried over anhydrous Na_2SO_4 , and concentrated to dryness. The remaining residue was dissolved in MeOH and 6 N aqueous HCl (50 mL, v/v= 1:1) and the resulting mixture was stirred at room temperature for 4 hour. The reaction mixture was basified with 10 N aqueous NaOH and extracted with DCM. The organic layer was washed by brine, dried over anhydrous Na_2SO_4 , and concentrated to afford **51-S2** (10.1 g, 95.7% yield)

as light a yellow solid. LC/MS (ESI) m/z : 212 (M+H)⁺.

[0485] Step 2: 5-Bromo-3-iodo-7-methyl-1H-indazole (51-S3): To a solution of **51-S2** (10 g, 0.047 mol) in DMF (50 mL) was added KOH (6.63 g, 0.18 mol) followed by I₂ (18.06 g, 0.071 mol) at 0 °C. The mixture was stirred at room temperature for 1.5 hour. The reaction mixture was quenched by aqueous Na₂S₂O₃ and diluted with EtOAc. The mixture was washed with water and brine, dried over anhydrous Na₂SO₄, and concentrated to dryness. The remaining residue was washed with a mixture of PE/EtOAc (50 mL, 5:1) and dried under vacuum to afford **51-S3** (15.1 g, 94.6% yield) as light a yellow solid. LC/MS (ESI) m/z : 338 (M+H)⁺.

[0486] Step 3: *tert*-Butyl 2-(5-bromo-3-iodo-7-methyl-1H-indazol-1-yl) acetate (51-S4): To a solution of **51-S3** (6.9 g, 0.02 mol) in DMF (20 mL) were added K₂CO₃ (8.48 g, 0.06 mol) and *tert*-butyl 2-bromoacetate (3.97 g, 0.02 mol) and the resulting mixture was stirred at room temperature overnight. The mixture was diluted with EtOAc, washed with water and brine, dried over anhydrous Na₂SO₄, and concentrated to dryness. The remaining crude product was purified by column chromatography on silica gel (eluted with PE/EtOAc = 200:1 to 70:1) to afford **51-S4** (5.66 g, 61.3% yield) as light a yellow solid. LC/MS (ESI) m/z : 452 (M+H)⁺.


[0487] Step 4: *tert*-Butyl 2-(3-acetyl-5-bromo-7-methyl-1H-indazol-1-yl) acetate (51-S5): To a solution of **51-S4** (4.63 g, 10.27 mmol) in dry toluene (25 mL) were added tributyl(1-ethoxyvinyl)stannane (5.19 g, 14.38 mmol) and Pd(PPh₃)₄ (0.83 g, 0.72 mmol). The reaction mixture was degassed with nitrogen and stirred at 100 °C under an atmosphere of nitrogen overnight. The mixture was cooled to room temperature, 0.5 M aqueous HCl (20 mL) was added, and then stirred at room temperature for 20 minutes. The reaction mixture was diluted with H₂O and extracted with EtOAc twice. The combined organic layers were washed by brine, dried over anhydrous Na₂SO₄, and concentrated. The remaining crude product was purified by column chromatography on silica gel (eluted with PE/EtOAc = 150:1 to 60:1) to afford **51-S5** (2.63 g, 70.0% yield) as milky a white solid. LC/MS (ESI) m/z : 367 (M+H)⁺.

[0488] Step 5: *tert*-Butyl 2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl) acetate (51-S6): A round-bottom flask was charged with **51-S5** (2.63 g, 7.18 mmol), 2-methylpyrimidin-5-ylboronic acid (0.99 g, 7.18 mmol), K₂CO₃ (2.48 g, 17.96 mmol), and dioxane/H₂O (20 mL, v/v = 9:1) under an atmosphere of nitrogen. To this mixture was added tetrakis(triphenylphosphine) palladium(0) (0.42 g, 0.36 mmol) and the resulting mixture was stirred at 90 °C overnight under an atmosphere of nitrogen. The mixture was diluted with EtOAc and filtered. The filtrate was diluted with EtOAc, washed with brine, dried over anhydrous Na₂SO₄, and concentrated to dryness. The remaining crude product was purified by column chromatography on silica gel (eluted with PE/EtOAc = 100:1 to 3:1) to afford **51-S6** (1.93 g, 70.7% yield) as light a yellow solid. LC/MS (ESI) m/z : 381 (M+H)⁺.

[0489] Step 6: 2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl) acetic acid (51-S7): Compound **51-S6** (1.45 g, 3.81 mmol) was treated with HCl/dioxane (9 mL) and stirred at room temperature for 2 hours. The reaction mixture was concentrated to dryness and the remaining residue was washed with ether and dried under vacuum to afford **51-S7** (1.23 g, 99.8% yield) as light a yellow solid. LC/MS (ESI) m/z : 324 (M+H)⁺.

[0490] Step 7: (3S)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl) acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((dimethylamino) methyl)-2-azabicyclo [3.1.0] hexane-3- carboxamide (51): To a mixture of **51-S7** (30 mg, 0.093 mmol) and **51-S8** (33 mg, 0.093 mmol) in DMF (1 mL) was added DIPEA (60 mg, 0.46 mmol) followed by HATU (77 mg, 0.20 mmol). The reaction mixture was stirred at room temperature for 1 hour. The mixture was diluted with EtOAc, washed with 10% aqueous LiCl solution and brine, dried, and concentrated to afford the crude product, which was purified by preparative HPLC to afford **51** (2 mg, 3.28% yield) as a white solid. ¹H NMR (400 MHz, CD₃OD) δ 9.02 (s, 2H), 8.46 (s, 1H), 7.64-7.55 (m, 2H), 7.43 (d, J = 8.0 Hz, 1H), 6.01 (d, J = 17.6 Hz, 1H), 5.83 (d, J = 17.6 Hz, 1H), 4.72 (dd, J = 8.8, 4.4 Hz, 1H), 3.95 (dd, J = 5.6, 2.8 Hz, 1H), 3.59 (d, J = 14.0 Hz, 1H), 3.24 (d, J = 13.6 Hz, 1H), 2.98 (s, 6H), 2.78 (s, 3H), 2.77 (s, 3H), 2.75-2.73 (m, 1H), 2.70 (s, 3H), 2.59 (dd, J = 13.6, 4.0 Hz, 1H), 2.14 (s, 3H), 1.52 (t, J = 5.6 Hz, 1H), 1.42-1.39 (m, 1H). LC/MS (ESI) m/z : 660 (M+H)⁺.

Scheme 31. Synthesis of (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-5-((allyl(methyl)amino)methyl)-*N*-(3-((allyloxy)methyl)-6-bromopyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (70)



[0491] Step 1: 2-(*tert*-Butyl) 3-ethyl (1*R*,3*S*,5*R*)-5-((allyl(methyl)amino)methyl)-2-azabicyclo[3.1.0]hexane-2,3-dicarboxylate (70-S2): K_2CO_3 (1 g) was added to a mixture of 2-(*tert*-butyl) 3-ethyl (1*R*,3*S*,5*S*)-5-(((methylsulfonyl)oxy)methyl)-2-azabicyclo[3.1.0]hexane-2,3-dicarboxylate (70-S1, 0.77 mmol) and *N*-methylprop-2-en-1-amine (0.663 mL, 6.93 mmol) in ACN (8 mL) and the reaction was heated at 40 °C under argon for 4 hours. EtOAc was added and the diluted reaction mixture was filtered through Celite to remove any solids. Solvents were removed under reduced pressure and the residue was purified by column chromatography on silica gel with MeOH in DCM (0-10%) as the eluent to afford 2-(*tert*-butyl) 3-ethyl (1*R*,3*S*,5*R*)-5-((allyl(methyl)amino)methyl)-2-azabicyclo[3.1.0]hexane-2,3-dicarboxylate 70-S2 (0.211 g) as yellow amorphous solid.

[0492] Step 2: (1*R*,3*S*,5*R*)-5-((Allyl(methyl)amino)methyl)-2-(*tert*-butoxycarbonyl)-2-azabicyclo[3.1.0]hexane-3-carboxylic acid (70-S3): 2-(*tert*-Butyl) 3-ethyl (1*R*,3*S*,5*R*)-5-((allyl(methyl)amino)methyl)-2-azabicyclo[3.1.0]hexane-2,3-dicarboxylate (70-S2, 0.211 g, 0.624 mmol) was dissolved in a mixture of THF-EtOH-water (3 mL-0.75 mL-0.7 mL) and treated with LiOH monohydrate (32 mg, 0.75mmol). The reaction stirred at room temperature for 6 hours before Amberlite (weakly acidic cation exchanger H form, 1g) was added. After stirring for 20 minutes, the reaction was


filtered and the resulting resin was washed with MeOH. The combined filtrates were concentrated under reduced pressure and the residue was purified by column chromatography on silica gel with MeOH in DCM (0-10%) as an eluent to afford (1*R*,3*S*,5*R*)-5-((allyl(methyl)amino)methyl)-2-(*tert*-butoxycarbonyl)-2-azabicyclo[3.1.0]hexane-3-carboxylic acid **70-S3** (0.188 g) as colorless amorphous solid.

[0493] Step 3: *tert*-Butyl (1*R*,3*S*,5*R*)-5-((allyl(methyl)amino)methyl)-3-((3-((allyloxy)methyl)-6-bromopyridin-2-yl)carbamoyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (70-S5): To a mixture of **70-S3** (188 mg, 0.61 mmol) and **70-S4** (148 mg, 0.61 mmol) in DCM (10 mL), pyridine (0.246 mL, 3.05 mmol) was added followed by POCl₃ (0.057 mL, 0.61 mmol) at 0 °C under argon. The reaction mixture was stirred at room temperature for 2 hours before NaHCO₃ aqueous solution was added and the mixture was extracted with DCM. After washing with brine, the organic layer was dried over anhydrous Na₂SO₄. The solution was filtered and the solvent was removed under reduced pressure. The remaining residue was purified by column chromatography on silica gel with MeOH in DCM (0-10%) as eluent to afford *tert*-butyl (1*R*,3*S*,5*R*)-5-((allyl(methyl)amino)methyl)-3-((3-((allyloxy)methyl)-6-bromopyridin-2-yl)carbamoyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (**70-S5**, 173.5 mg).

[0494] Step 4: (1*R*,3*S*,5*R*)-5-((allyl(methyl)amino)methyl)-*N*-(3-((allyloxy)methyl)-6-bromopyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide TFA salt (70-S6): *tert*-Butyl (1*R*,3*S*,5*R*)-5-((allyl(methyl)amino)methyl)-3-((3-((allyloxy)methyl)-6-bromopyridin-2-yl)carbamoyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (**70-S5**, 29.5 mg) in DCM (2 mL) was treated with TFA (2 mL) at room temperature for 1 hour. The volatiles were removed under reduced pressure and the residue was co-evaporated with toluene (5 mL) twice to afford (1*R*,3*S*,5*R*)-5-((allyl(methyl)amino)methyl)-*N*-(3-((allyloxy)methyl)-6-bromopyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide TFA salt **70-S6**. The material was carried forward without additional purification.

[0495] Step 5: (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-5-((allyl(methyl)amino)methyl)-*N*-(3-((allyloxy)methyl)-6-bromopyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (70): To a mixture of (1*R*,3*S*,5*R*)-5-((allyl(methyl)amino)methyl)-*N*-(3-((allyloxy)methyl)-6-bromopyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide TFA salt **70-S6** and 2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetic acid (**70-S7**, 17 mg, 0.055 mmol) in DMF (1 mL), TBTU (26.5 mg) was added at room temperature followed by the addition of DIEA (0.096 mL) with stirring. After the reaction was complete, NaHCO₃ aqueous solution (10 mL) was added to form a precipitation that was collected by filtration and purified by column chromatography on silica gel with MeOH in DCM (0-10%) as the eluent to afford **70** (29 mg) as an off-white solid. ¹H NMR (400 MHz, Chloroform-*d*) δ 8.89 (s, 3H), 8.56 (dd, *J* = 1.7, 0.9 Hz, 1H), 7.61 (qd, *J* = 8.7, 1.3 Hz, 2H), 7.48 (d, *J* = 8.0 Hz, 1H), 7.23 (d, *J* = 7.8 Hz, 1H), 5.91 - 5.76 (m, 2H), 5.50 (d, *J* = 2.7 Hz, 2H), 5.25 - 5.11 (m, 4H), 4.95 (s, 1H), 4.41 - 4.26 (m, 2H), 3.88 (d, *J* = 5.7 Hz, 2H), 3.29 (dd, *J* = 5.5, 2.5 Hz, 1H), 3.06 (dt, *J* = 6.4, 1.4 Hz, 2H), 2.80 (m, 6H), 2.72 (s, 3H), 1.21 (t, *J* = 5.6 Hz, 1H), 0.99 (dd, *J* = 5.5, 2.5 Hz, 1H). LC (method A): *t*_R = 1.35 min. LC/MS (EI) *m/z*: [M + H]⁺ 727.

Scheme 32. Synthesis of (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-7-(fluoromethyl)-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-methylpyridin-2-yl)-5-((dimethylamino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (74) and (1*S*,3*S*,5*S*)-2-(2-(3-Acetyl-7-(fluoromethyl)-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-methylpyridin-2-yl)-5-((dimethylamino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (75)




[0496] **Step 1: (3S)-N-(6-Bromo-3-methylpyridin-2-yl)-5-((dimethylamino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (75-S2):** To a solution of **75-S1** (150 mg, 0.33 mmol) in dioxane (1.5 mL) was added HCl/dioxane (1.5 mL, 2 M). The reaction mixture was stirred at room temperature for 30 minutes. The mixture was concentrated to dryness, diluted with DCM, washed with aqueous NaHCO₃ solution, dried over anhydrous Na₂SO₄, and concentrated to dryness. The remaining residue was purified by column chromatography on silica gel (DCM/MeOH = 60:1) to afford **75-S2** (100 mg, 86.2% yield) as a yellow oil. LC/MS (ESI) m/z: 352 (M+H)⁺.

[0497] **Step 2: (1R,3S,5R)-2-(2-(3-Acetyl-7-(fluoromethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((dimethylamino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (74) and (1S,3S,5S)-2-(2-(3-Acetyl-7-(fluoromethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((dimethylamino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (75):** To a solution of **75-S2** (40 mg, 0.105 mmol), **75-S3** (30 mg, 0.087 mmol), and HATU (50.0 mg, 0.13 mmol) in DMF (3 mL) was added DIPEA (34 mg, 0.26 mmol). The reaction mixture was stirred at room temperature under an atmosphere of nitrogen for 2 hours. The mixture was diluted with EtOAc, washed with 10% aqueous LiCl solution and brine, dried over anhydrous Na₂SO₄, and concentrated to dryness. The remaining residue was purified by preparative HPLC to afford **74** (2.0 mg, 3.4% yield) and **75** (2.2 mg, 3.8% yield) as white solids.

[0498] **Compound 74:** ¹H NMR (400 MHz, DMSO-d₆) δ 10.34 (s, 1H), 9.07 (s, 2H), 8.58 (s, 1H), 8.01 (s, 1H), 7.63 (d, J = 8.0 Hz, 1H), 7.45 (d, J = 8.0 Hz, 1H), 5.97-5.93 (m, 1H), 5.85-5.76 (m, 1H), 5.75-5.62 (m, 2H), 4.46 (m, 1H), 3.63 (m, 1H), 2.69 (d, J = 8.0 Hz, 6H), 2.46-2.31 (m, 4H), 2.24 (s, 6H), 2.05 (s, 3H), 1.09-1.02 (m, 2H).

[0499] **Compound 75:** ¹H NMR (400 MHz, DMSO-d₆) δ 10.46 (s, 1H), 9.05 (s, 2H), 8.56 (s, 1H), 7.98 (s, 1H), 7.60 (d, J = 8.0 Hz, 1H), 7.42 (d, J = 8.0 Hz, 1H), 6.09 (d, J = 20.0 Hz, 1H), 5.96 (m, 1H), 5.78-5.65 (m, 1H), 5.64-5.59 (m, 1H), 4.92 (d, J = 8.0 Hz, 1H), 3.73-3.68 (m, 1H), 2.77 (t, J = 12.0 Hz, 1H), 2.68 (d, J = 4.0 Hz, 6H), 2.38 (s, 2H), 2.23 (s, 6H), 2.00 (m, 1H), 1.96 (s, 3H), 1.46 (d, J = 4.0 Hz, 1H), 0.93 (m, 1H).

Scheme 33. Synthesis of (2*S*,4*R*)-1-(2-(3-Acetyl-5-(2-((1,1-dioxidothietan-3-yl)oxy)pyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-methylpyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide (84)




[0500] Step 1: (2*S*,4*R*)-1-(2-(3-Acetyl-5-(2-methoxypyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-methylpyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide (84-S3**):** To a solution of 2-(3-acetyl-5-(2-methoxypyrimidin-5-yl)-1*H*-indazol-1-yl)acetic acid (**84-S1**, 1 equiv) in DMF (10 vol) at 0 °C under nitrogen atmosphere was added (2*S*,4*R*)-*N*-(6-bromo-3-methylpyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide (**84-S2**, 1.2 equiv), HATU (1.5 equiv) and DIPEA (5 equiv). The reaction mixture was stirred at room temperature for 16 hours. After completion of the reaction, the reaction mixture was quenched with water. The resulting mixture was extracted with DCM. The organic layer was washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated. The residue was purified by column chromatography on silica gel using DCM/ MeOH to afford compound **84-S3**.

[0501] Step 2: (2*S*,4*R*)-1-(2-(3-Acetyl-5-(2-hydroxypyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-methylpyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide (84-S4**):** To a solution of compound **84-S3** (1 equiv) in ACN (10 vol) at 0 °C under nitrogen atmosphere was added TMS-Cl (2.5 equiv) and NaI (2 equiv). The reaction mixture was stirred at room temperature for 16 hours. After completion of the reaction, the reaction mixture was concentrated and quenched with water. The resulting solid was filtered and dried to afford compound **84-S4**.

[0502] Step 3: (2*S*,4*R*)-1-(2-(3-Acetyl-5-(2-((1,1-dioxidothietan-3-yl)oxy)pyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-methylpyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide (84**):** To a solution of compound **84-S4** (1 equiv) in ACN (10 vol) was added cesium carbonate (3 equiv) and 3-bromothietane 1,1-dioxide (**84-S5**, 2 equiv). The reaction mixture was stirred at room temperature for 16 hours. After completion of the reaction, the reaction mixture was concentrated and quenched with water. The resulting solid was filtered, dried and then purified by preparative purification to afford compound **84**. ¹H NMR (400 MHz, DMSO-*d*₆) δ: 10.84 (s, 1H), 9.02 (s, 1H), 8.59 (s, 1H), 8.36 (s, 1H), 7.78 - 7.72 (m, 2H), 7.61 (d, *J* = 8.0 Hz, 1H), 7.43 (d, *J* = 7.6 Hz, 1H), 5.83 (d, *J* = 17.2 Hz, 1H), 5.62 (d, *J* = 17.2 Hz, 1H), 5.58 - 5.50 (m, 1H), 5.30 - 5.28 (m, 1H), 5.02 - 4.96 (m, 2H), 4.61 - 4.55 (m, 3H), 4.28 - 3.88 (m, 2H), 2.63 (s, 3H), 2.30 - 2.12 (m, 1H), 2.00 (s, 3H), 0.98 - 0.95 (m, 1H).

Scheme 34. Synthesis of (1*R*,3*S*,5*S*)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-5-((allyloxy)methyl)-*N*-(6-bromo-3-vinylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (93)



[0503] Step 1: 2-Amino-6-bromonicotinaldehyde (93-S2): (2-Amino-6-bromopyridin-3-yl)methanol (**93-S1**, 1.0 g, 4.93 mmol) was treated with activated MnO_2 (4.29 g, 49.3 mmol) in DCM (50 mL) at room temperature overnight. The mixture was filtered through Celite and the solvent was removed under reduced pressure to afford 2-amino-6-bromonicotinaldehyde **93-S2** (0.9 g) as a yellow solid.

[0504] Step 2: 6-Bromo-3-vinylpyridin-2-amine (93-S3): Into a suspension of methyltriphenylphosphonium bromide (1.28 g, 3.6 mmol) in THF (10 mL), *n*-BuLi (1.6M in hexane, 2.25 mL, 3.6 mmol) was added with stirring at 0 °C under argon. After 1 hour, 2-amino-6-bromonicotinaldehyde (**93-S2**, 0.18 g, 0.9 mmol) in THF (5 mL) was added and the mixture was stirred at room temperature for 2 hours. The reaction was cooled in an ice bath and saturated NH_4Cl aqueous solution (10 mL) was added. The mixture was extracted with EtOAc and the organic layer was washed with water and brine, and dried over anhydrous Na_2SO_4 . Solvent was removed under reduced pressure and the residue was purified by column chromatography on silica gel with MeOH in DCM (0-10%) as the eluent to afford 6-bromo-3-vinylpyridin-2-amine **93-S3** (0.13 g) as a white solid.


[0505] Step 3: *tert*-Butyl (1*R*,3*S*,5*S*)-5-((Allyloxy)methyl)-3-((6-bromo-3-vinylpyridin-2-yl)carbamoyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (93-S5): To a mixture of **93-S4** (97 mg, 0.33 mmol) and **93-S3** (65 mg, 0.33 mmol) in DCM (4 mL), pyridine (0.133 mL) was added followed by POCl_3 (0.031 mL, 0.33 mmol) at 0 °C under argon. The reaction mixture was stirred overnight at room temperature. Water was added and the mixture was extracted with AcOEt. After washing with brine, the organic layer was dried over anhydrous Na_2SO_4 . The solution was filtered and the solvent was removed under reduced pressure. The remaining residue was purified by column chromatography on silica gel with EtOAc in hexane (0-50%) as the eluent to afford *tert*-butyl (1*R*,3*S*,5*S*)-5-((allyloxy)methyl)-3-((6-bromo-3-vinylpyridin-2-yl)carbamoyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate **93-S5** (88 mg) as colorless oil.

[0506] Step 4: (1*R*,3*S*,5*S*)-5-((Allyloxy)methyl)-*N*-(6-bromo-3-vinylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide TFA salt (93-S6): *tert*-Butyl (1*R*,3*S*,5*S*)-5-((allyloxy)methyl)-3-((6-bromo-3-vinylpyridin-2-yl)carbamoyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (**93-S5**, 23 mg, 0.048 mmol) was dissolved in DCM (2 mL) and treated with TFA (1 mL) at room temperature. The reaction was stirred for 1 hour and the volatiles were removed under reduced pressure. The residue was co-evaporated with toluene (5 mL) twice to afford (1*R*,3*S*,5*S*)-5-((allyloxy)methyl)-*N*-(6-bromo-3-vinylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide TFA salt **93-S6**. The crude material was carried forward in the next step without additional purification.

[0507] Step 5: (1*R*,3*S*,5*S*)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-5-((allyloxy)methyl)-*N*-(6-bromo-3-vinylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (93):

methyl)-N-(6-bromo-3-vinylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (93): To a mixture of (1*R*,3*S*,5*S*)-5-((allyloxy)methyl)-N-(6-bromo-3-vinylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide TFA salt **93-S6** and 2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetic acid (**S7** 15.5 mg, 0.05 mmol) in DMF (1 mL), TBTU (32.1 mg, 0.1 mmol) followed by DIEA (0.0435 mL) was added at room temperature with stirring. After 1h, NaHCO₃ aqueous solution (10 mL) was added to form precipitation. Solid was collected by filtration and purified by column chromatography on silica gel with MeOH in DCM (0-10%) as eluent to afford **93** (21 mg). ¹H NMR (400 MHz, Chloroform-*d*) δ 8.90 (s, 2H), 8.75 (s, 1H), 8.58 (dd, *J* = 1.7, 0.9 Hz, 1H), 7.71 - 7.58 (m, 3H), 7.30 (d, *J* = 8.1 Hz, 1H), 6.45 (dd, *J* = 17.4, 11.0 Hz, 1H), 5.89 (ddt, *J* = 17.3, 10.4, 5.7 Hz, 1H), 5.65 (dd, *J* = 17.5, 0.8 Hz, 1H), 5.52 (s, 2H), 5.32 - 5.15 (m, 3H), 4.91 (dd, *J* = 8.8, 2.9 Hz, 1H), 4.01 (dq, *J* = 5.7, 1.5 Hz, 2H), 3.73 (d, *J* = 9.8 Hz, 1H), 3.56 (d, *J* = 9.8 Hz, 1H), 3.42 (dd, *J* = 5.6, 2.6 Hz, 1H), 2.80 (s, 3H), 2.72 (s, 3H), 2.29 (dd, *J* = 13.8, 8.8 Hz, 1H), 1.46 (t, *J* = 5.5 Hz, 1H), 0.99 (dd, *J* = 5.5, 2.7 Hz, 1H). LC (method A): *t*_R = 2.01 min. LC/MS (EI) *m/z*: [M + H]⁺ 670.

Scheme 35: Synthesis of (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((2-fluorocyclopent-1-enecarboxamido)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (95)




[0508] Step 1: (1*R*,3*S*,5*R*)-tert-Butyl 3-(6-bromo-3-methylpyridin-2-ylcarbamoyl)-5-((2-fluorocyclopent-1-enecarboxamido)methyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (95-S2): To a mixture of **95-S1** (30 mg, 0.07 mmol), 2,2-difluorocyclopentanecarboxylic acid (11 mg, 0.07 mmol), and HATU (40 mg, 0.48 mmol) in DMF (2 mL) was added DIPEA (0.03 mL, 0.21 mmol). The reaction mixture was stirred at room temperature for 16 hours. The mixture was partitioned with EtOAc and water. The organic layer was washed with brine, dried over anhydrous Na₂SO₄, and concentrated under reduced pressure. The remaining residue was purified by column chromatography on silica gel (eluted with DCM/MeOH = 80:1) to afford **95-S2** (15 mg, 40.0% yield) as a white solid. LC/MS (ESI) *m/z*: 537 (M+H)⁺.

[0509] Step 2: (1*R*,3*S*,5*R*)-N-(6-Bromo-3-methylpyridin-2-yl)-5-((2-fluorocyclopent-1-enecarboxamido)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (95-S3): To a solution of **95-S2** (15 mg, 0.03 mmol) in dioxane (0.5 mL) was added HCl/dioxane (2 M, 2 mL). The reaction mixture was stirred at room temperature for 1 hour. The reaction mixture was concentrated under reduced pressure to afford **95-S3** (15 mg, 100% yield) as a white solid, which was carried

forward in the next synthetic step without purification. LC/MS (ESI) m/z : 437 ($M+H$)⁺.

[0510] Step 3: (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-methylpyridin-2-yl)-5-((2-fluorocyclopent-1-enecarboxamido)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (95): To a mixture of **95-S3** (15 mg, 0.03 mmol), 2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetic acid (19 mg, 0.05 mmol), and HATU (27 mg, 0.07 mmol) in DMF (3 mL) was added DIPEA (0.02 mL, 0.11 mmol). The reaction mixture was stirred at room temperature for 16 hours. The mixture was partitioned with EtOAc and water. The organic layer was washed with brine, dried over anhydrous Na₂SO₄, and concentrated under reduced pressure. The remaining residue was purified by column chromatography on silica gel (eluted with DCM/MeOH = 30:1) and further purified by preparative HPLC to afford **95** (4.0 mg, 15.0% yield) as a white solid. ¹H NMR (400 MHz, CD₃OD) δ 8.91 (s, 2H), 8.33 (d, J = 1.1 Hz, 1H), 7.46 (d, J = 8.0 Hz, 2H), 7.29 (d, J = 7.9 Hz, 1H), 5.88 (m, 1H), 5.72 (m, 1H), 4.54 (m, 1H), 3.68-3.53 (m, 2H), 2.67 (m, 6H), 2.60 (s, 3H), 2.53-2.34 (m, 6H), 2.03 (s, 3H), 1.80 (dt, J = 15.4, 7.9 Hz, 2H), 1.24 (m, 2H), 0.98 (m, 1H). LC/MS (ESI) m/z : 743 ($M+H$)⁺.

Scheme 36. Synthesis of (1*R*,3*S*,5*R*)-5-(Acetamidomethyl)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (96)




[0511] Step 1: (1*R*,3*S*,5*R*)-tert-Butyl 5-(acetamidomethyl)-3-(6-bromo-3-methylpyridin-2-ylcarbamoyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (96-S2): To a solution of **96-S1** (30 mg, 0.071 mmol) in DCM (2 mL) was added DIPEA (18 mg, 0.14 mmol) followed by acetyl chloride (7 mg, 0.089 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 1 hour. The mixture was diluted with DCM, washed with water and brine, dried over Na₂SO₄, and concentrated to dryness. The remaining residue was purified by column chromatography on silica gel (eluted with DCM/MeOH = 30:1) to afford **96-S2** (31 mg, 93.9% yield) as a white solid. LC/MS (ESI) m/z : 467 ($M+H$)⁺.

[0512] Step 2: (1*R*,3*S*,5*R*)-5-(Acetamidomethyl)-*N*-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (96-S3): To a solution of **96-S2** (31 mg, 0.067 mmol) in DCM (2.5 mL) was added TFA (1 mL). The reaction mixture was stirred at room temperature for 1.5 hours and then concentrated under reduced pressure to afford **96-S3** (24 mg, 100.0% yield) as light a yellow solid, which was carried forward in the next synthetic step without further purification. LC/MS (ESI) m/z : 367 ($M+H$)⁺.

[0513] Step 3: (1*R*,3*S*,5*R*)-5-(Acetamidomethyl)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (96): To a solution of **96-S3** (24 mg, 0.066 mmol), 2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetic acid (23 mg,

0.071 mmol), and HATU (50 mg, 0.13 mmol) in DMF (2 mL) was added DIPEA (25 mg, 0.20 mmol) at 0 °C. The reaction mixture was stirred at room temperature overnight. The mixture was diluted with EtOAc, washed with 10% aqueous LiCl solution and brine, dried over Na₂SO₄, and concentrated to dryness. The remaining residue was purified by preparative HPLC to afford **96** (5.5 mg, 12.5% yield) as a white solid. ¹H NMR (400 MHz, CD₃OD) δ 8.89 (d, *J* = 3.3 Hz, 2H), 8.32 (s, 1H), 7.53-7.57 (m, 2H), 7.29 (d, *J* = 8 Hz, 1H), 5.86 (d, *J* = 17.6 Hz, 1H), 5.71 (d, *J* = 17.6 Hz, 1H), 4.53 (m, 1H), 3.61 (m, 1H), 3.45 (d, *J* = 14.2 Hz, 1H), 3.18-3.05 (m, 1H), 2.66 (s, 3H), 2.65 (s, 3H), 2.58 (s, 3H), 2.42 (m, 2H), 2.02 (s, 3H), 1.90 (s, 3H), 1.22 (m, 1H), 0.98 (m, 1H). LC/MS (ESI) *m/z*: 673 (M+H)⁺.

Scheme 37. Synthesis of (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((2-fluorobenzamido)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (97**)**




[0514] Step 1: (1*R*,3*S*,5*R*)-tert-Butyl 3-(6-bromo-3-methylpyridin-2-ylcarbamoyl)-5-((2-fluorobenzamido)methyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (97-S2**):** To a mixture of **97-S1** (30 mg, 0.071 mmol), 2-fluorobenzoic acid (12 mg, 0.086 mmol), and HATU (54 mg, 0.14 mmol) in DMF (2 mL) was added DIPEA (27 mg, 0.21 mmol) at 0 °C. The reaction mixture was stirred at room temperature overnight. The mixture was diluted with EtOAc, washed with 10% aqueous LiCl solution and brine, dried over Na₂SO₄, and concentrated to dryness. The remaining residue was purified by column chromatography on silica gel (eluted with DCM/MeOH = 20:1) to afford **97-S2** (31 mg, 80.3% yield) as a white solid. LC/MS (ESI) *m/z*: 547 (M+H)⁺.

[0515] Step 2: (1*R*,3*S*,5*R*)-N-(6-Bromo-3-methylpyridin-2-yl)-5-((2-fluorobenzamido)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (97-S3**):** To a solution of **97-S2** (31 mg, 0.057 mmol) in dioxane (2 mL) was added HCl/dioxane (2 mL, 2 M) at 0 °C. The reaction mixture was stirred at room temperature for 2 hours. The mixture was concentrated to dryness to afford **97-S3** (25 mg, 100% yield) as a brown oil, which was carried forward in the next synthetic step without purification. LC/MS (ESI) *m/z*: 447 (M+H)⁺.

[0516] Step 3: (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((2-fluorobenzamido)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (97**):** To a

solution of **97-S3** (25 mg, 0.056 mmol), 2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetic acid (20 mg, 0.062 mmol), and HATU (32 mg, 0.084 mmol) in DMF (2 mL) was added DIPEA (15 mg, 0.12 mmol) at 0 °C. The reaction mixture was stirred at room temperature overnight. The mixture was diluted with EtOAc, washed with 10% aqueous LiCl solution and brine, dried over Na₂SO₄, and concentrated to dryness. The remaining residue was purified by preparative HPLC to afford **97** (4.2 mg, 10.0% yield) as a white solid. ¹H NMR (400 MHz, CD₃OD) δ 9.01 (s, 2H), 8.44 (s, 1H), 7.72 (td, *J* = 7.5, 1.7 Hz, 1H), 7.52 (m, 3H), 7.38 (d, *J* = 7.9 Hz, 1H), 7.27-7.15 (m, 2H), 6.00 (d, *J* = 18 Hz, 1H), 5.84 (d, *J* = 18 Hz, 1H), 4.64 (m, 1H), 3.85-3.75 (m, 2H), 3.58-3.49 (m, 1H), 2.78 (s, 3H), 2.76 (s, 3H), 2.70 (s, 3H), 2.67-2.54 (m, 2H), 2.09 (s, 3H), 1.42 (m, 1H), 1.13 (m, 1H). LC/MS (ESI) *m/z*: 753(M+H)⁺.

Scheme 38: Synthesis of (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-methylpyridin-2-yl)-5-(methylsulfonamidomethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (101**)**




[0517] Step 1: (1*R*,3*S*,5*R*)-*tert*-Butyl 3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-5-(methylsulfonamidomethyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (101-S2**):** To a solution of **101-S1** (40 mg, 0.09 mmol) in dry DCM (3 mL) was added Et₃N (0.03 mL, 0.18 mmol) followed by methanesulfonyl chloride (0.01 mL, 0.11 mmol) at 0 °C. The reaction mixture was stirred at 0 °C for 1 hour. The mixture was then diluted with water (4 mL) and extracted with DCM (3 mL × 2). The combined organic phases were washed with brine, dried over anhydrous Na₂SO₄, filtered, and concentrated. The crude product was purified by column chromatography on silica gel (eluted with DCM/MeOH = 60:1) to afford **101-S2** (30 mg, 62.5% yield) as a light yellow oil. LC/MS (ESI) *m/z*: 503 (M+H)⁺.

[0518] Step 2: (1*R*,3*S*,5*R*)-*N*-(6-Bromo-3-methylpyridin-2-yl)-5-(methylsulfonamidomethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (101-S3**):** To a solution of **101-S2** (30 mg, 0.06 mmol) in DCM (0.5 mL) was added TFA (0.2 mL). The reaction mixture was stirred at room temperature for 1.5 hours and then concentrated under reduced pressure to afford **101-S3** (24 mg, 100.0% yield) as a yellow oil, which was carried forward in the next synthetic step without further purification. LC/MS (ESI) *m/z*: 403 (M+H)⁺.

[0519] Step 3: (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-methylpyridin-2-yl)-5-(methylsulfonamidomethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (101**):** To a solution of **101-S3** (24 mg, 0.06 mmol), 2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetic acid (**101-S4**, 23 mg, 0.07 mmol), and HATU (45 mg, 0.12 mmol) in DMF (2 mL) was added DIPEA (0.04 mL, 0.24 mmol).

The reaction mixture was stirred at room temperature for 2 hours. The mixture was partitioned with EtOAc and water. The organic layer was washed with brine, dried over anhydrous Na₂SO₄, and concentrated under reduced pressure. The remaining residue was purified by preparative HPLC (eluted with MeCN/water) to afford **101** (5.3 mg, 12.6% yield) as a white solid. ¹H NMR (400 MHz, CD₃OD) δ 8.99 (s, 2H), 8.41 (s, 1H), 7.52-7.56 (m, 2H), 7.38 (d, *J* = 8.0 Hz, 1H), 5.94-5.99 (m, 1H), 5.78-5.83 (m, 1H), 4.63-4.65 (m, 1H), 3.72-3.75 (m, 1H), 3.35-3.43 (m, 2H), 3.01 (s, 3H), 2.76 (s, 6H), 2.69 (s, 3H), 2.53-2.59 (m, 2H), 2.15 (s, 3H), 1.36-1.39 (m, 1H), 1.11-1.13 (m, 1H). LC/MS (ESI) *m/z*: 709 (M+H)⁺.

Scheme 39: Synthesis of (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-methylpyridin-2-yl)-5-((3,3,3-trifluoropropanamido)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (102**)**




[0520] Step 1: (3*S*)-*tert*-Butyl 3-(6-bromopyridin-2-ylcarbamoyl)-5-(((*S*)-2-(methoxycarbonylamino)-3-methylbutanamido)methyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (102-S2**):** To a mixture of **102-S1** (70 mg, 0.16 mmol), 3,3,3-trifluoropropanoic acid (25 mg, 0.19 mmol), and HATU (122 mg, 0.32 mmol) in DMF (2 mL) was added DIPEA (0.05 mL, 0.32 mmol). The reaction mixture was stirred at room temperature for 16 hours. The mixture was partitioned with EtOAc and water. The organic layer was washed with brine, dried over anhydrous Na₂SO₄, and concentrated under reduced pressure. The remaining residue product was purified by column chromatography on silica gel (eluted with DCM/MeOH = 80:1) to afford **102-S2** (75 mg, 85.2% yield) as a white solid. LC/MS (ESI) *m/z*: 535 (M+H)⁺.

[0521] Step 2: (1*R*,3*S*,5*R*)-*N*-(6-Bromo-3-methylpyridin-2-yl)-5-((3,3,3-trifluoropropanamido)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (102-S3**):** To a solution of **102-S2** (75 mg, 0.14 mmol) in DCM (2.5 mL) was added TFA (1 mL). The reaction mixture was stirred at room temperature for 1.5 hours and then concentrated under reduced pressure to afford **102-S3** (61 mg, 100.0% yield) as a yellow oil, which was carried forward in the next synthetic step without further purification. LC/MS (ESI) *m/z*: 435 (M+H)⁺.

[0522] Step 3: (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-methylpyridin-2-yl)-5-((3,3,3-trifluoropropanamido)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (102**):** To a solution of **102-S3** (30 mg, 0.07 mmol), 2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetic acid (**102-S4**, 27 mg, 0.08 mmol), and HATU (53 mg, 0.14 mmol) in DMF (2 mL) was added DIPEA (0.06 mL, 0.35 mmol). The reaction mixture was stirred at room temperature for 2 hours. The mixture was partitioned with EtOAc and water. The organic layer was washed with brine, dried over anhydrous Na₂SO₄, and concentrated under reduced pressure. The

remaining residue was purified by preparative HPLC (eluted with MeCN/water) to afford **102** (4.5 mg, 12.8% yield) as a white solid. ¹H NMR (400 MHz, CD₃OD) δ 9.01 (s, 2H), 8.36 (s, 1H), 7.45-7.47 (m, 2H), 7.29 (d, *J* = 8.0 Hz, 1H), 5.85-5.89 (m, 1H), 5.69-5.73 (m, 1H), 4.75-4.79 (m, 1H), 3.62-3.64 (m, 1H), 3.24-3.46 (m, 4H), 2.69 (s, 3H), 2.63 (s, 3H), 2.58 (s, 3H), 2.39-2.47 (m, 2H), 1.23-1.25 (m, 1H), 1.00-1.02 (m, 1H). LC/MS (ESI) *m/z*: 741 (M+H)⁺

Scheme 40. Synthesis of (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-5-(2-((dimethylamino)methyl)pyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (103**)**



[0523] Step 1: *tert*-Butyl 2-(3-acetyl-5-(2-(hydroxymethyl)pyrimidin-5-yl)-1*H*-indazol-1-yl)acetate (103-S3**):** To a solution of (5-bromopyrimidin-2-yl)methanol (**103-S2**, 1 equiv) in DMF/H₂O (9:1, 10 vol) was added compound **103-S1** (1 equiv), K₂CO₃ (2 equiv) and tetrakis(triphenylphosphine)palladium (0.1 equiv). The reaction mixture was stirred at 90°C for 5 hours and concentrated under reduced pressure. The remaining residue was purified by column chromatography on silica gel to afford compound **103-S3**.


[0524] Step 2: *tert*-Butyl 2-(3-acetyl-5-(2-((dimethylamino)methyl)pyrimidin-5-yl)-1*H*-indazol-1-yl)acetate (103-S4**):** To a mixture of compound **103-S3** (1 equiv) in dry DCM (10 vol) was added Et₃N (1 equiv) followed by the drop-wise addition of MsCl (1.5 equiv) at 0 °C and the reaction mixture was stirred for 2 hours at same temperature. Dimethylamine hydrochloride (1.1 equiv) at 0 °C was added and the reaction mixture was stirred at room temperature for 3 hours. The reaction mixture was quenched with saturated aqueous NaHCO₃ solution and extracted with DCM. The combined organic layers were separated, dried, and concentrated to afford crude product, which was purified by silica gel column (eluted with DCM/EtOAc) to afford compound **103-S4**.

[0525] Step 3: 2-(3-Acetyl-5-(2-((dimethylamino)methyl)pyrimidin-5-yl)-1*H*-indazol-1-yl)acetic acid (103-S5**):** To

a solution of compound **103-S4** (1 equiv) under an atmosphere of argon was added 4N dioxane HCl (10 vol). The reaction mixture was stirred at room temperature for 3 hours and concentrated to dryness. The remaining material was used directly in the next synthetic step.

[0526] Step 4: (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-5-(2-((dimethylamino)methyl)pyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (103): To a solution of compound **103-S5** (1 equiv) in DMF (10 vol) at 0 °C under an atmosphere of argon were added (1*R*,3*S*,5*R*)-*N*-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (1 equiv), HATU (2.1 equiv), and DIPEA (5 equiv). The reaction mixture was stirred at room temperature for 3 hours and then quenched with water (30 vol). The resulting mixture was extracted with DCM. The organic layer was washed with brine, dried over anhydrous Na₂SO₄, filtered, and concentrated to dryness. The remaining residue was purified by column chromatography on silica gel (eluted with DCM/MeOH) to afford compound 103. ¹H NMR (400 MHz, DMSO-*d*₆) δ 1.05-1.13 (m, 2H), 1.39 (s, 3H), 2.07-2.16 (m, 4H), 2.54-2.60 (m, 1H), 2.73 (s, 3H), 3.01 (s, 6H), 3.64-3.74 (m, 1H), 4.47 (dd, *J*=5.2, 9.3 Hz, 1H), 4.78 (s, 2H), 5.66 (d, *J*=17.2 Hz, 1H), 6.02 (d, *J*=17.3 Hz, 1H), 7.52 (d, *J*=7.9 Hz, 1H), 7.69 (d, *J*=7.9 Hz, 1H), 7.99 (q, *J*=8.8 Hz, 2H), 8.60 (s, 1H), 9.36 (s, 2H), 10.36 (s, 1H).

Scheme 42. Synthesis of (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-5-(2-((1,1-dioxidothietan-3-yl)oxy)pyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (107)




[0527] Step 1: (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-5-(2-methoxypyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (107-S3): To a solution of 2-(3-acetyl-5-(2-methoxypyrimidin-5-yl)-1*H*-indazol-1-yl)acetic acid (**107-S1**, 1 equiv) in DMF (10 vol) at 0 °C under nitrogen atmosphere was added (1*R*,3*S*,5*R*)-*N*-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (**107-S2**, 1.2 equiv), HATU (1.5 equiv) and DIPEA (5 equiv). The reaction mixture was stirred at room temperature for 16 hours. After completion of the reaction, the reaction mixture was quenched with water. The resulting mixture was extracted with DCM. The organic layer was washed with brine, dried over anhydrous Na₂SO₄, filtered and then concentrated. The residue was purified by column chromatography on silica gel using DCM/ MeOH to afford compound **107-S3**.

[0528] Step 2: (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-5-(2-hydroxypyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-

methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (107-S4): To a solution of compound **107-S3** (1 equiv) in ACN (10 vol) at 0 °C under nitrogen atmosphere was added TMSCl (2.5 equiv) and NaI (2 equiv). The reaction mixture was stirred at room temperature for 16 hours. After completion of the reaction, the reaction mixture was concentrated and quenched with water. The resulting solid was filtered and dried to afford compound **107-S4**.

[0529] Step 3: (1R,3S,5R)-2-(2-(3-Acetyl-5-(2-((1,1-dioxidothietan-3-yl)oxy)pyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (107): To a solution of compound **107-S4** (1 equiv) in ACN (10 vol) was added cesium carbonate (3 equiv) and 3-bromothietane 1,1-dioxide (**107-S5**, 2 equiv). The reaction mixture was stirred at room temperature for 16 hours. After completion of the reaction, the reaction mixture was concentrated and quenched with water. The resulting solid was filtered, dried and purified by preparative purification to afford compound **107**. ¹H NMR (400 MHz, DMSO-*d*₆) δ: 10.29 (s, 1H), 9.03 (s, 1H), 8.60 (s, 1H), 8.37 (s, 1H), 7.82 - 7.14 (m, 2H), 7.63 (d, *J* = 8.0 Hz, 1H), 7.46 (d, *J* = 8.0 Hz, 1H), 5.91 (d, *J* = 17.6 Hz, 1H), 5.56 (d, *J* = 17.6 Hz, 1H), 5.29 - 5.27 (m, 1H), 5.02 - 4.97 (m, 2H), 4.62 - 4.56 (m, 2H), 4.42 - 4.38 (m, 1H), 2.67 (s, 3H), 2.05 (s, 3H), 1.32 (s, 3H), 1.04 - 1.00 (m, 2H), 0.99 - 0.85 (m, 2H).

Scheme 43: Synthesis of (1R,3S,5R)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-cyclopropylpyridin-2-yl)-5-((dimethylamino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (112)



[0530] Step 1: (1R,3S,5R)-tert-Butyl 3-((6-bromo-3-cyclopropylpyridin-2-yl)carbamoyl)-5-((1,3-dioxoisindolin-2-yl)methyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (112-S2): To a mixture of **112-S1** (100 mg, 0.26 mmol) and 6-bromo-3-cyclopropylpyridin-2-amine (55.1 mg, 0.26 mmol) in dry DCM (3 mL) was added pyridine (0.1 mL, 1.30 mmol) followed by POCl_3 (39.8 mg, 0.26 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 30

minutes. The mixture was poured into ice water and extracted with DCM twice. The organic layers were washed with brine, dried over Na₂SO₄, and concentrated under reduced pressure. The remaining residue was purified by silica gel chromatography (PE/EtOAc = 6:1 to 2:1) to afford **112-S2** (127 mg, 84.2% yield) as a white solid. LC/MS (ESI) m/z: 581 (M+H)⁺.


[0531] Step 2: (1R,3S,5R)-tert-Butyl 5-(aminomethyl)-3-((6-bromo-3-cyclopropylpyridin-2-yl)carbamoyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (112-S3): To a solution of **112-S2** (127 mg, 0.22 mmol) in EtOH (3 mL) was added hydrazine hydrate (21.9 mg, 0.44 mmol). The reaction mixture was stirred at 75 °C for 2 hours and then cooled to room temperature. The mixture was filtered and the filtrate was concentrated under reduced pressure. The remaining residue was purified by column chromatography on silica gel (eluted with DCM/MeOH = 5:1) to afford **112-S3** (79 mg, 79.8% yield) as a white solid. LC/MS (ESI) m/z: 451 (M+H)⁺.

[0532] Step 3: (1R,3S,5R)-tert-Butyl 3-((6-bromo-3-cyclopropylpyridin-2-yl)carbamoyl)-5-((dimethylamino)methyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (112-S4): To a solution of **112-S3** (79 mg, 0.18 mmol) in MeOH (3 mL) was added aqueous HCHO solution (42.6 mg, 0.53 mmol, ~37% wt) and NaBH₃CN (22 mg, 0.35 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 1 hour. The mixture was then diluted with water (20 mL) and extracted with DCM (5 mL × 2). The combined organic phases were washed with brine, dried over anhydrous Na₂SO₄, filtered, and concentrated. The remaining crude product was purified by column chromatography on silica gel (eluted with DCM/MeOH = 10:1) to afford **112-S4** (55 mg, 63.9% yield) as a light oil. LC/MS (ESI) m/z: 479 (M+H)⁺.

[0533] Step 4: (1R,3S,5R)-N-(6-bromo-3-cyclopropylpyridin-2-yl)-5-((dimethylamino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (112-S5): To a solution of **112-S4** (55 mg, 0.12 mmol) in DCM (2 mL) was added TFA (1 mL). The reaction mixture was stirred at room temperature for 1.5 hours and then concentrated under reduced pressure to afford **112-S5** (43 mg) as a yellow solid, which was carried forward in the next synthetic step without further purification. LC/MS (ESI) m/z: 379 (M+H)⁺.

[0534] Step 5: (1R,3S,5R)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-cyclopropylpyridin-2-yl)-5-((dimethylamino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (112): To a mixture of **112-S5** (43 mg, 0.113 mmol), 2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetic acid (**112-S6**, 36.6 mg, 0.118 mmol), and HATU (64.6 mg, 0.17 mmol) in DMF (2 mL) was added DIPEA (0.06 mL, 0.339 mmol). The reaction mixture was stirred at room temperature for 16 hours. The mixture was partitioned with EtOAc and water. The organic layer was washed with brine, dried over anhydrous Na₂SO₄, and concentrated under reduced pressure. The crude product was purified by preparative HPLC to afford **112** (6.5 mg, 8.57% yield) as a white solid. ¹H NMR (400 MHz, CD₃OD) δ 9.02 (s, 2H), 8.56 (s, 1H), 7.80 (d, J = 1.2 Hz, 2H), 7.38 (d, J = 8.1 Hz, 1H), 7.30 (d, J = 8.1 Hz, 1H), 5.82 (d, J = 17.2 Hz, 1H), 5.67 (d, J = 17.1 Hz, 1H), 4.71 (t, J = 7.0 Hz, 1H), 3.68-3.66 (m, 1H), 2.95-2.90 (m, 1H), 2.77 (s, 3H), 2.71 (s, 3H), 2.66-2.60 (m, 2H), 2.40 (s, 6H), 2.35-2.30 (m, 1H), 1.87-1.84 (m, 1H), 1.28-1.25 (m, 1H), 1.22-1.20 (m, 1H), 0.87-0.84 (m, 2H), 0.60-0.568 (m, 2H). LC/MS (ESI) m/z: 671 (M+H)⁺.

Scheme 44. Synthesis of (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-4-fluoropyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (116)



[0535] Step 1: 2-Bromo-4-fluoro-1-oxidanylpuridine (116-S2): To a stirred solution of 2-bromo-4-fluoropyridine (**116-S1**, 2g, 1equiv) in CHCl_3 (130 mL) was added 3-chlorobenzoperoxoic acid (5g, 2 equiv). The reaction mixture was heated to 50 °C. The reaction was cooled and neutralized with saturated aqueous NaHCO_3 solution (100 mL). The organic layer was washed with saturated aqueous NaHCO_3 (50mL $\times$ 2) and the combined organic layers were washed with brine, dried over Na_2SO_4 , and concentrated to dryness. The residue was purified by column chromatography on silica gel (eluted by 5% CH_3OH in DCM, gradient) to afford **116-S2** (622mg, 31%).

[0536] Step 2: 6-Bromo-N-(tert-butyl)-4-fluoropyridin-2-amine (116-S3): To a stirred solution of **116-S2** (622 mg, 1 equiv), 2-methylpropan-2-amine (1.7 mL, 5 equiv) in DCM (100mL) was added trifluoroacetic anhydride solution (1.1 mL, 1.1 equiv) in DCM (10 mL) dropwise at 0-5 °C under an atmosphere of argon. The reaction mixture was stirred at 0-5 °C for 1 hour before TFA solution (1mL, 1 equiv) in DCM (10 mL) was added followed by 2-methylpropan-2-amine (0.4 mL, 1.1 equiv). The reaction mixture was neutralized with aqueous saturated NaHCO_3 solution (20 mL) and the organic layer was washed with brine, dried over Na_2SO_4 , and concentrated to dryness. The residue was purified by column chromatography on silica gel (eluted by 30% EtOAc in hexanes) to afford **116-S3** (81 mg, 10%).

[0537] Step 3: 6-Bromo-4-fluoropyridin-2-amine (116-S4): TFA (6 mL) was added to solid **116-S3** and the reaction mixture was heated at 70°C until completion. The reaction mixture was concentrated to dryness and the residue was dissolved in DCM (15 mL) and washed with aqueous saturated NaHCO_3 solution (10mL). The organic layer was washed with brine, dried over Na_2SO_4 and concentrated to dryness to afford **116-S4** (63mg).


[0538] Step 4: tert-Butyl (1*R*,3*S*,5*R*)-3-((6-bromo-4-fluoropyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexane-2-carboxylate (116-S5): POCl_3 (0.04 mL, 2 equiv) was added dropwise at 0-5 °C under an atmosphere of argon to a stirred solution of (1*R*,3*S*,5*R*)-2-(tert-butoxycarbonyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxylic acid (79 mg, 1equiv) and **116-S4** (63 mg, 1 equiv) in DCM (15 mL) and pyridine (0.13mL, 5 equiv). The reaction mixture was stirred at room temperature for 2 hours before the reaction was diluted with DCM (10 mL) and neutralized with aqueous saturated NaHCO_3 solution (10 mL). The aqueous layer was extracted with DCM (1x 10 mL) and the combined organic layers were

washed with brine (10 mL), dried over Na₂SO₄, and concentrated to dryness. The residue was purified by column chromatography on silica gel (eluted by 5% MeOH in DCM gradient) to afford **116-S5** (97 mg, 71 %).

[0539] Step 5: (1*R*,3*S*,5*R*)-*N*-(6-Bromo-4-fluoropyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide hydrochloride (116-S6): To a solution of **116-S5** (97 mg) was added 4*N* HCl in dioxane (10mL) and the resulting solution was stirred at room temperature for 6 hours. The reaction mixture was concentrated to dryness to afford **116-S6** (75 mg).

[0540] Step 6: (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-4-fluoropyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (116): HATU (109 mg, 1.2 equiv) was added at 0°C under an atmosphere of argon to a solution of **116-S6** (75 mg, 1 equiv), 2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetic acid (78 mg, 1.1 equiv), and DIPEA (0.21 mL, 5 equiv) in DMF (8 mL). The reaction mixture was stirred at room temperature for 3 hours before it was diluted with EtOAc (35mL) and water (15mL). The aqueous layer was extracted with EtOAc (15 mL) and the combined organic layers were washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated. The residue was purified by column chromatography on silica gel (eluted by DCM/MeOH=10:1) to afford **116** (87 mg, 53 %). ¹H NMR (400 MHz, DMSO-*d*₆) δ 11.11 (s, 1H), 9.02 (s, 2H), 8.31 (s, 1H), 7.86 (d, 1H, *J*=10.6Hz), 7.63 (s, 1H), 7.43 (d, 1H, *J*=7.6 Hz), 6.08 (d, 1H, *J*=17.6 Hz), 5.67 (d, 1H, *J*=17.6 Hz), 4.39 - 4.45 (m, 1H), 3.62-3.66 (m, 1H), 2.70 (s, 3H), 2.69 (s, 3H), 2.65 (s, 3H), 2.08 (s, 3H), 1.98-2.03 (m, 1H), 1.31 (s, 3H), 1.17-1.21 (m, 1H), 0.86-1.03 (m, 2H); ¹⁹F NMR (376 MHz, DMSO-*d*₆) δ -98.11 (s, 1F).

Scheme 45. Synthesis of Methyl 2-(2-((2*S*,4*R*)-1-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-4-fluoropyrrolidine-2-carboxamido)-6-bromopyridin-3-yl)acetate (61) and 2-(2-((2*S*,4*R*)-1-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-4-fluoropyrrolidine-2-carboxamido)-6-bromopyridin-3-yl)acetic acid (62) and (2*S*,4*R*)-1-(2-(3-Acetyl-5-(2-Methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-(2-(dimethylamino)-2-oxoethyl)pyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide (117)



5


10

15

20

25

30



35

40

45

50

55

[0541] Step 1: Methyl 2-(6-bromo-1-oxidanyl)-pyridin-3-yl)acetate (117-S2): To a stirred solution of methyl 2-(6-bromopyridin-3-yl) acetate (**117-S1**, 1g, 1 equiv) in CHCl₃ (100mL) was added 3-chlorobenzoperoxoic acid (1.93g, 2 equiv). The reaction mixture was heated to 50 °C until it was complete. The reaction was cooled and neutralized with saturated aqueous NaHCO₃ solution (50 mL). The organic layer was washed with brine, dried over Na₂SO₄ and concentrated to dryness. The residue was purified by column chromatography on silica gel (5% CH₃OH in DCM, gradient) to afford **117-S2** (848mg, 80%).

[0542] Step 2: Methyl 2-(6-bromo-2-(*tert*-butylamino)pyridin-3-yl)acetate (117-S3): To a stirred solution of **117-S2** (848 mg, 1 equiv) and 2-methylpropan-2-amine (1.8 mL, 5 equiv) in DCM (90mL) was added trifluoroacetic anhydride solution (0.87 mL, 1.5 equiv) in DCM (10 mL) at 0-5 °C dropwise under an atmosphere of argon. The reaction mixture was stirred at 0-5 °C for 2 hours before it was neutralized with a solution of aqueous saturated NaHCO₃ (20 mL). The organic layer was washed with aqueous saturated NaHCO₃ (40 mL) and brine (40 mL), dried over Na₂SO₄, and concentrated to dryness. The residue was purified by column chromatography on silica gel (eluted by 30% EtOAc in hexanes, gradient) to afford **117-S3** (104mg, 10%).

[0543] Step 3: Methyl 2-(2-amino-6-bromopyridin-3-yl)acetate (117-S4): TFA (10 mL) was added to solid **117-S3** (104 mg) and the reaction mixture was heated at 70 °C. The reaction was concentrated to dryness and the residue was dissolved in DCM (25 mL) and neutralized with aqueous saturated NaHCO₃ (20 mL). The organic layer was washed with brine, dried over Na₂SO₄ and concentrated to dryness to afford **117-S4** (96 mg).

[0544] Step-4: *tert*-Butyl (2*S*,4*R*)-2-((6-bromo-3-(2-methoxy-2-oxoethyl)pyridin-2-yl)carbamoyl)-4-fluoropyrrolidine-1-carboxylate (117-S5): POCl₃ (0.08 mL, 2 equiv) was added dropwise at 0-5 °C under an atmosphere of argon to a solution of (2*S*,4*R*)-1-(*tert*-butoxycarbonyl)-4-fluoropyrrolidine-2-carboxylic acid (91 mg, 1equiv) and **117-S4** (96mg, 1 equiv) in DCM (10 mL) and pyridine (0.16 mL, 5 equiv). The reaction mixture was warmed to room temperature and stirred until complete. The reaction was diluted with DCM (10 mL) and neutralized with aqueous saturated NaHCO₃ solution (10 mL). The aqueous layer was extracted with DCM (1x 10 mL) and the combined organic layers were washed with brine (10 mL), dried over Na₂SO₄, and concentrated to dryness. The residue was purified by column chromatography on silica gel (eluted by 5% MeOH in DCM gradient) to afford **117-S5** (146 mg, 82 %).

[0545] Step 5: Methyl 2-(6-bromo-2-((2*S*,4*R*)-4-fluoropyrrolidine-2-carboxamido)pyridin-3-yl)acetate hydrochloride (117-S6): To a solution of **117-S5** (146 mg) was added 4N HCl in Dioxane (10mL). The resulting solution


was stirred at room temperature for 6 hours. The reaction mixture was concentrated to dryness to afford 117-S6 (117mg).

[0546] Step 6: Methyl 2-(2-((2*S*,4*R*)-1-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-4-fluoropyrrolidine-2-carboxamido)-6-bromopyridin-3-yl)acetate (61**):** To a solution of **117-S6** (117mg, 1equiv), 2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetic acid (92 mg, 1 equiv) and DIPEA (0.25mL, 5 equiv) in DMF (15 mL) was added HATU (137 mg, 1.2 equiv) at 0°C under an atmosphere of argon. The reaction mixture was stirred at room temperature for 3 hours before the reaction mixture was diluted with EtOAc (35mL) and water (15mL). The aqueous layer was extracted with EtOAc (15 mL). The combined organic layers were washed with brine, dried over anhydrous Na₂SO₄ and concentrated to dryness. The residue was purified by column chromatography on silica gel (eluted by DCM/MeOH=10:1) to afford **61** (99mg, 50 %). ¹H NMR (400 MHz, DMSO-d₆) δ 10.58 (s, 1H), 9.04 (s, 2H), 8.40 (s, 1H), 7.79-7.90 (m, 2H), 7.68 (d, 1H, J=8.1 Hz), 7.52 (d, 1H, J=8.1 Hz), 5.49-5.88 (m, 3H), 4.56-4.62 (m, 1H), 4.19-4.29 (m, 1H), 3.94-4.30 (m, 1H), 3.55 (s, 2H), 3.44 (s, 3H), 2.70 (s, 3H), 2.65 (s, 3H), 2.07-2.34 (m, 1H), 0.85-0.92 (m, 1H); ¹⁹F NMR (376 MHz, DMSO-d₆) δ -176.07 (s, 1F).

[0547] Step 7: 2-(2-((2*S*,4*R*)-1-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-4-fluoropyrrolidine-2-carboxamido)-6-bromopyridin-3-yl)acetic acid (62**):** To a solution of **61** (45mg, 1 equiv) in methanol (6 mL) was added aqueous LiOH solution in water (3mL, 1M, 1.2 equiv) and the reaction mixture was stirred at room temperature. After completion of the reaction, the reaction mixture was acidified with HCl (1N) and extracted with DCM (10 mL). The organic layer was washed with brine, dried over anhydrous Na₂SO₄, filtered, and concentrated to dryness to afford **62** (15 mg, 34 %). ¹H NMR (400 MHz, DMSO-d₆) δ 10.48 (s, 1H), 8.98 (s, 2H), 8.36 (s, 1H), 7.69-7.82 (m, 2H), 7.60 (d, 1H, J=8.2 Hz), 7.44 (d, 1H, J=8.2 Hz), 5.42-5.77 (m, 3H), 4.52-4.58 (m, 1H), 4.11-4.23 (m, 1H), 3.86-4.01 (m, 1H), 3.41 (s, 2H), 2.62 (s, 3H), 2.58 (s, 3H), 2.46-2.56 (m, 1H), 2.01-2.21 (m, 1H); ¹⁹F NMR (376 MHz, DMSO-d₆) δ -176.12 (s, 1F).

[0548] Step-8: (2*S*,4*R*)-1-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-(2-(dimethylamino)-2-oxoethyl)pyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide (117**):** To a solution of **62** (44 mg, 1.2 equiv), dimethyl amine hydrochloride (33 mg, 1.0 equiv), and DIPEA (0.08 mL, 5 equiv) in DMF (10 mL) was added HATU (32 mg, 1.2 equiv) at 0°C under an atmosphere of argon. The reaction mixture was stirred at room temperature for 3 hours before the reaction mixture was diluted with EtOAc (20 mL) and water (10mL). The aqueous layer was extracted with EtOAc (15mL) and the combined organic layers were washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated to dryness. The residue was purified by column chromatography on silica gel (eluted by DCM/MeOH =10:1) to afford **117** (32mg, 50%). ¹H NMR (400 MHz, DMSO-d₆) δ 10.46 (s, 1H), 8.98 (s, 2H), 8.38 (s, 1H), 7.70-7.84 (m, 1H), 7.78 (s, 1H), 7.48 (d, 1H, J=8.0Hz), 7.40 (d, 1H, J=8.0Hz), 5.42-5.81 (m, 3H), 4.46-4.52 (m, 1H), 4.11-4.21 (m, 1H), 3.89-4.04 (m, 1H), 2.57 (s, 2H), 2.61 (s, 3H), 2.58 (s, 3H), 2.51 (s, 3H), 2.36 (s, 3H), 1.96-2.15 (m, 2H); ¹⁹F NMR (376 MHz, DMSO-d₆) δ -175.89 (s, 1F).

Scheme 46. Synthesis of (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-5-(2-(methylamino)pyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (120**)**



[0549] The above scheme and following detailed description depicts one non-limiting method for synthesizing compounds with a substituted pyrimidine in the R³² position via a Suzuki crosscoupling reaction where the A-ring is functionalized with a boronic ester. The skilled artisan will recognize that the aryl halide 5-bromo-N-methylpyrimidin-2-amine shown above can be replaced with other aryl halides to afford additional compounds of the present invention. Non-limiting examples of aryl halides that the skilled artisan can use include 5-bromo-2-methylpyrimidine.


[0550] Step 1: *tert*-Butyl 2-(3-acetyl-5-(2-(methylamino)pyrimidin-5-yl)-1H-indazol-1-yl)acetate (120-S3): To a solution of 5-bromo-N-methylpyrimidin-2-amine (**120-S2**, 1 equiv) in DMF/H₂O (9:1, 10 vol) was added compound **120-S1** (1 equiv), K₂CO₃ (2 equiv) and tetrakis(triphenylphosphine)palladium (0.1 equiv). The reaction mixture was stirred at 90 °C for 5 hours and concentrated under reduced pressure. The remaining residue was purified by column chromatography on silica gel (eluted with DCM/ MeOH) to afford compound **120-S3**.

[0551] Step 2: 2-(3-Acetyl-5-(2-(methylamino)pyrimidin-5-yl)-1H-indazol-1-yl)acetic acid (120-S4): To a solution of compound **120-S3** (1 equiv) in DCM (10 vol) at 0 °C under an atmosphere of argon was added TFA (5 vol). The reaction mixture was stirred at room temperature for 3 hours and concentrated to dryness. The remaining material was used directly in the next synthetic step.

[0552] Step 3: (1R,3S,5R)-2-(2-(3-Acetyl-5-(2-(methylamino)pyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (120): To a solution of compound **120-S4** (1 equiv) in DMF (10 vol) at 0 °C under an atmosphere of argon were added (1R,3S,5R)-N-(6-bromo-3-

methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (1 equiv), HATU (2.1 equiv), and DIPEA (5 equiv). The reaction mixture was stirred at room temperature for 3 hours and then quenched with water (30 vol). The resulting mixture was extracted with DCM. The organic layer was washed with brine, dried over anhydrous Na₂SO₄, filtered, and concentrated to dryness. The remaining residue was purified by column chromatography on silica gel (eluted with DCM/MeOH) to afford compound **120**. ¹H NMR (400 MHz, DMSO-d₆) δ 0.97 - 1.06 (m, 2H), 1.33 (s, 3H), 2.05 (s, 4H), 2.53 - 2.58 (m, 1H), 2.65 (s, 3H), 2.87 (d, *J* = 4.5 Hz, 3H), 3.55 - 3.64 (m, 1H), 4.33 - 4.47 (m, 1H), 5.55 (d, *J* = 17.2 Hz, 1H), 5.88 (d, *J* = 17.3 Hz, 1H), 7.26 (q, *J* = 4.9 Hz, 1H), 7.45 (d, *J* = 7.9 Hz, 1H), 7.63 (d, *J* = 8.0 Hz, 1H), 7.69 - 7.80 (m, 2H), 8.29 (s, 1H), 8.64 (s, 2H), 10.26 (s, 1H).

Scheme 47. Synthesis of (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-vinylpyridin-2-yl)-5-((hex-5-en-1-yl(methyl)amino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (123**)**



[0553] Step 1: 2-(tert-Butyl) 3-ethyl (1*R*,3*S*,5*R*)-5-((hex-5-en-1-yl(methyl)amino)methyl)-2-azabicyclo[3.1.0]hexane-2,3-dicarboxylate (123-S2**):** Cs₂CO₃ (0.8 g) was added to a mixture of 2-(tert-butyl) 3-ethyl (1*R*,3*S*,5*S*)-5-(((methylsulfonyl)oxy)methyl)-2-azabicyclo[3.1.0]hexane-2,3-dicarboxylate (**123-S1**, 0.807 mmol) and *N*-methylhex-5-en-1-amine HCl salt (0.145 g, 0.968 mmol) in ACN (10 mL). The reaction was heated and stirred in the presence at 50 °C under argon overnight. EtOAc was added and the diluted reaction mixture was filtered through Celite to remove solids. Solvents were removed under reduced pressure and the residue was purified by column chromatography on silica gel with MeOH in DCM (0-10%) as the eluent to afford 2-(tert-butyl) 3-ethyl (1*R*,3*S*,5*R*)-5-((hex-5-en-1-yl(methyl)amino)methyl)-2-azabicyclo[3.1.0]hexane-2,3-dicarboxylate (**123-S2**).

methyl)-2-azabicyclo[3.1.0]hexane-2,3-dicarboxylate **123-S2** (0.193 g) as a yellowish oil.


[0554] Step 2: (1R,3S,5R)-5-((Hex-5-en-1-yl(methyl)amino)methyl)-2-(tert-butoxycarbonyl)-2-azabicyclo[3.1.0]hexane-3-carboxylic acid (123-S3): 2-(tert-Butyl) 3-ethyl (1R,3S,5R)-5-((hex-5-en-1-yl(methyl)amino)methyl)-2-azabicyclo[3.1.0]hexane-2,3-dicarboxylate (**123-S2**, 0.193 g, 0.508 mmol) was dissolved in a mixture of THF-EtOH-water (3 mL-0.5 mL-0.5 mL) and treated with LiOH monohydrate (25.6 mg, 0.609 mmol). The reaction was stirred at room temperature for 24 hours before Amberlite (the weakly acidic cation exchanger H form, 1g) was added. After stirred for 5 minutes, the reaction was filtered and the resulting resin was washed with MeOH. The combined filtrates were concentrated under reduced pressure to afford (1R,3S,5R)-5-((hex-5-en-1-yl(methyl)amino)methyl)-2-(tert-butoxycarbonyl)-2-azabicyclo[3.1.0]hexane-3-carboxylic acid **123-S3** (0.171 g) as a colorless amorphous solid.


[0555] Step 3: tert-Butyl (1R,3S,5R)-3-((6-bromo-3-vinylpyridin-2-yl)carbamoyl)-5-((hex-5-en-1-yl(methyl)amino)methyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (123-S5): To a mixture of **123-S3** (171 mg, 0.486 mmol) and **123-S4** (77 mg, 0.389 mmol) in DCM (10 mL), pyridine (0.196 mL, 2.43 mmol) was added followed by POCl₃ (0.045 mL, 0.486 mmol) at 0 °C under argon. The reaction mixture was stirred at room temperature for 2 hours. NaHCO₃ aqueous solution was added and the mixture was extracted with DCM. After washing with brine, the organic layer was dried over anhydrous Na₂SO₄. The solution was filtered and the solvent was removed under reduced pressure. The remaining residue was purified by column chromatography on silica gel with MeOH in DCM (0-10%) as the eluent to afford *tert*-butyl (1R,3S,5R)-3-((6-bromo-3-vinylpyridin-2-yl)carbamoyl)-5-((hex-5-en-1-yl(methyl)amino)methyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate **123-S5** (99 mg).

[0556] Step 4: (1R,3S,5R)-N-(6-Bromo-3-vinylpyridin-2-yl)-5-((hex-5-en-1-yl(methyl)amino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide TFA salt (123-S6): *tert*-Butyl (1R,3S,5R)-3-((6-bromo-3-vinylpyridin-2-yl)carbamoyl)-5-((hex-5-en-1-yl(methyl)amino)methyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (**123-S5**, 5.7 mg) in DCM (1 mL) was treated with TFA (1 mL) at room temperature. The reaction stirred for 1 hour before the volatiles were removed under reduced pressure and the residue was co-evaporated with toluene (5 mL) twice to afford (1R,3S,5R)-N-(6-bromo-3-vinylpyridin-2-yl)-5-((hex-5-en-1-yl(methyl)amino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide TFA salt **123-S6**. The material was carried forward without additional purification.

[0557] Step 5: (1R,3S,5R)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-vinylpyridin-2-yl)-5-((hex-5-en-1-yl(methyl)amino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (123): To a mixture of (1R,3S,5R)-N-(6-bromo-3-vinylpyridin-2-yl)-5-((hex-5-en-1-yl(methyl)amino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide TFA salt **123-S6** and 2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetic acid (**123-S7**, 3.4 mg, 0.011 mmol) in DMF (0.5 mL), TBTU (7.1 mg) was added followed by DIEA (0.0096 mL) with stirring. After the reaction was complete, NaHCO₃ aqueous solution (10 mL) was added to form a precipitate that was collected by filtration and purified by column chromatography on silica gel with MeOH in DCM (0-10%) as the eluent to afford (1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-vinylpyridin-2-yl)-5-((hex-5-en-1-yl(methyl)amino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (**123**) (6.2 mg) as an off-white solid. ¹H NMR (400 MHz, Chloroform-d) δ 8.90 (s, 2H), 8.67 (s, 1H), 8.58 (dd, *J* = 0.9, 1.6 Hz, 1H), 7.69 - 7.59 (m, 4H), 7.30 (d, *J* = 8.1 Hz, 1H), 6.46 (dd, *J* = 11.0, 17.4 Hz, 1H), 5.80 (ddt, *J* = 6.7, 10.2, 16.9 Hz, 1H), 5.66 (dd, *J* = 0.8, 17.4 Hz, 1H), 5.51 (d, *J* = 1.1 Hz, 2H), 5.27 (d, *J* = 11.1 Hz, 1H), 5.05 - 4.91 (m, 2H), 4.88 (d, *J* = 8.6 Hz, 1H), 3.25 (dd, *J* = 2.5, 5.8 Hz, 1H), 2.91 (t, *J* = 14.1 Hz, 2H), 2.80 (s, 3H), 2.72 (s, 3H), 2.41 (tt, *J* = 5.7, 13.0 Hz, 1H), 2.28 (s, 4H), 2.11 - 2.01 (m, 2H), 1.54 - 1.34 (m, 4H), 1.30 (s, 0H), 1.02 (dt, *J* = 2.1, 4.1 Hz, 1H), 0.93 - 0.76 (m, 1H). LC (method A): *t*_R = 1.48 min. LC/MS (EI) *m/z*: [M + H]⁺ 725.

Scheme 48. Synthesis of (1R,3S,5R)-2-(2-(3-Acetyl-7-cyano-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (124)





[0558] Step 1: 5-Bromo-1H-indazole-7-carboxamide (124-S2): 5-Bromo-1H-indazole-7-carboxylic acid (1 g) was dissolved in DMF (10 mL) and *i*Pr₂NEt (3.42 mL, 5 equiv) was added, followed by the addition of NH₄Cl (1.2 g) at 5 °C. HATU (1.8 g, 1.2 equiv) was added slowly at 5 °C and the reaction mixture was stirred overnight at room temperature. Then the reaction mixture was poured into water and the precipitate was isolated by filtration. The white solid was dried and carried forward without additional purification in the next step.

[0559] Step 2: 5-Bromo-1H-indazole-7-carbonitrile (124-S3): To a heterogeneous mixture of 5-bromo-1H-indazole-7-carboxamide (0.6 g) in CH₂Cl₂ (6 mL) and pyridine (6 mL), TFAA (0.87 mL) was added dropwise. The resulting homogeneous solution was stirred for 10 minutes at room temperature. The volatiles were removed and the residue was poured into water (60 mL). The precipitated white product was isolated by filtration, washed with water, and dried *in vacuo*. The solid carried forward without additional purification in the next step.

[0560] Step 3: 5-(2-Methylpyrimidin-5-yl)-1H-indazole-7-carbonitrile (124-S4): A mixture of 5-bromo-1H-indazole-7-carbonitrile (0.32 g equiv), 2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine (0.708 g), cesium carbonate (1.4 g) in dioxane (12 mL) and water (3.0 mL) was purged with argon in a pressure vessel for 5 minutes. PdCl₂(dppf) (0.4 g) was added under argon and the pressure vessel was sealed and heated at 90 °C overnight. The reaction mixture was cooled to room temperature and the solvent was removed under reduced pressure. The crude product was

purified by silica gel flash column chromatography (eluent: 0-30 % MeOH in CH₂Cl₂) to afford 0.24 g of **124-S4** as white solid.

[0561] Step 4: 3-Bromo-5-(2-methylpyrimidin-5-yl)-1H-indazole-7-carbonitrile (124-S5): To a stirred solution of 5-(2-methylpyrimidin-5-yl)-1H-indazole-7-carbonitrile (0.24 g) in DMF (4 mL), NBS (0.2 g) was added. The reaction mixture was stirred at room temperature for 30 minutes. The reaction mixture was then poured into water and the precipitate was isolated by filtration, washed with water, and dried. The solid carried forward without additional purification in the next step.


[0562] Step 5: *tert*-Butyl 2-(3-bromo-7-cyano-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetate (124-S6): A mixture of 3-bromo-5-(2-methylpyrimidin-5-yl)-1H-indazole-7-carbonitrile (0.3 g), *tert*-butyl bromoacetate (148 µl) and potassium carbonate (0.264 g) in anhydrous acetonitrile (5 mL) was refluxed for 2 hours. The reaction mixture was then cooled to room temperature and the solvent was removed under reduced pressure. The residue was purified by silica gel flash column chromatography (eluent: 0-1.5 % MeOH in CH₂Cl₂) to afford **124-S6** as white foam.

[0563] Step 6: *tert*-Butyl 2-(3-acetyl-7-cyano-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetate (124-S7): A solution of *tert*-butyl 2-(3-bromo-7-cyano-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetate (0.06 g 1 equiv), tri-butyl(1-ethoxyvinyl)tin (0.101 g, 2 equiv) and PdCl₂(PPh₃)₂ (10 mg, 0.1 equiv) in DMF (5 mL) was heated at 80°C overnight under an argon atmosphere. The reaction mixture was concentrated under reduced pressure, diluted with CH₂Cl₂, and washed with cold aqueous HCl (1N). The organic layer was dried (Na₂SO₄), filtered and concentrated. The residue was purified by silica gel flash column chromatography (eluent: 0-1.5 % MeOH in CH₂Cl₂) to afford the title compound.

[0564] Step 7: 2-(3-Acetyl-7-cyano-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetic acid (124-S8): *tert*-Butyl 2-(3-acetyl-7-cyano-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetate (**124-S7**, 45 mg) was stirred in CH₂Cl₂ (0.5 mL) and TFA (1 mL). After completion of the reaction (monitored by HPLC), the solvent was removed under reduced pressure and the remaining residue was carried forward without additional purification in the next synthetic step.

[0565] Step 8: (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-7-cyano-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-*N*-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (124): Compound **124-S8** was dissolved in DMF (1 mL) and *i*Pr₂NEt (60 µL, 3 equiv) was added, followed by the addition of the TFA salt of (1*R*,3*S*,5*R*)-*N*-(6-bromopyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (**124-S9**, obtained by stirring 47 mg of *tert*-butyl (1*R*,3*S*,5*R*)-3-((6-bromopyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexane-2-carboxylate in 0.5 mL of TFA and 0.5 mL of CH₂Cl₂ for 15 minutes at room temperature and evaporating the volatiles) at 5 °C. HATU (48 mg, 1.2 equiv) was then added slowly at this same temperature and the reaction mixture was stirred for 30 minutes at room temperature. The reaction mixture was poured into water and the precipitate was isolated by filtration. The solid was dried and purified by silica gel flash column chromatography (eluent: 0-2.0 % MeOH in CH₂Cl₂) to afford **124** as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 1.01-1.06 (m, 2H), 1.32 (s, 3H), 2.05 (s, 3H), 2.07 (t, *J* = 5.6 Hz, 1H), 2.51-2.56 (m, 1H), 2.69 (s, 3H), 2.70 (s, 3H), 3.59 (t, *J* = 3.8 Hz, 1H), 4.41 (dd, *J* = 5.3, 9.1 Hz, 1H), 5.88 (d, *J* = 17.9 Hz, 1H), 6.09 (d, *J* = 17.9 Hz, 1H), 7.43 (d, *J* = 7.8 Hz, 1H), 7.62 (d, *J* = 7.9 Hz, 1H), 8.52 (s, 1H), 8.78 (s, 1H), 9.12 (s, 2H), 10.26 (s, 1H).

Scheme 49. Synthesis of (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-5-(2-(dimethylamino)pyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-*N*-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (125)




[0566] Step 1: tert-Butyl 2-(3-acetyl-5-(2-(dimethylamino)pyrimidin-5-yl)-1H-indazol-1-yl)acetate (125-S3): To a solution of 5-bromo-N,N-dimethylpyrimidin-2-amine (**125-S2**, 1 equiv) in DMF/H₂O (9:1, 10 vol) was added compound (**125-S1**, 1 equiv), K₂CO₃ (2 equiv) and tetrakis(triphenylphosphine)palladium (0.1 equiv). The reaction mixture was stirred at 90 °C for 5 hours and concentrated under reduced pressure. The remaining residue was purified by column chromatography on silica gel (eluted with DCM/ MeOH) to afford compound **125-S3**.

[0567] Step 2: 2-(3-Acetyl-5-(2-(dimethylamino)pyrimidin-5-yl)-1H-indazol-1-yl)acetic acid (125-S4): To a solution of compound **125-S3** (1 equiv) in DCM (10 vol) at 0 °C under an atmosphere of argon was added TFA (5 vol). The reaction mixture was stirred at room temperature for 3 hours and concentrated to dryness. The remaining material was carried forward without additional purification and used directly in the next synthetic step.

[0568] Step 3: (1R,3S,5R)-2-(2-(3-Acetyl-5-(2-(dimethylamino)pyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (125): To a solution of compound **125-S4** (1 equiv) in DMF (10 vol) at 0 °C under an atmosphere of argon was added (1R,3S,5R)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (1 equiv), HATU (2.1 equiv), and DIPEA (5 equiv). The reaction mixture was stirred at room temperature for 3 hours and then quenched with water (30 vol). The resulting mixture was extracted with DCM. The organic layer was washed with brine, dried over anhydrous Na₂SO₄, filtered, and concentrated to dryness. The remaining residue was purified by column chromatography on silica gel (eluted with DCM/MeOH) to afford compound **125**. ¹H NMR (400 MHz, DMSO-d₆) δ 0.97 - 1.05 (m, 2H), 1.33 (s, 3H), 2.05 (s, 4H), 2.53 - 2.58 (m, 1H), 2.65 (s, 3H), 3.19 (s, 6H), 3.54 - 3.62 (m, 1H), 4.41 (dd, J = 5.1, 9.3 Hz, 1H), 5.55 (d, J = 17.2 Hz, 1H),

5.88 (d, $J = 17.3$ Hz, 1H), 7.45 (d, $J = 7.9$ Hz, 1H), 7.63 (d, $J = 7.9$ Hz, 1H), 7.71 - 7.81 (m, 2H), 8.30 (s, 1H), 8.71 (s, 2H), 10.26 (s, 1H).

Scheme 50: Synthesis of (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-7-(trifluoromethyl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (133)



[0569] Step 1: 4-Bromo-2-methyl-6-(trifluoromethyl)aniline (133-S2): To a solution of **133-S1** (1.0 g, 5.7 mmol) in MeCN (15 mL) was added N-bromosuccinimide (1.0 g, 5.7 mmol) in portions at 0 °C. The reaction mixture was allowed to stir for 1 hour at room temperature. The reaction mixture was poured into water and extracted with EtOAc twice. The combined organics were washed with brine, dried over Na₂SO₄, filtered, and concentrated. The remaining residue was purified by chromatography on silica gel (eluted with PE) to afford **133-S2** (1.3 g, 90.3% yield) as a brown oil. LC/MS (ESI) m/z : 254 (M+H)⁺.

[0570] Step 2: 5-Bromo-7-(trifluoromethyl)-1*H*-indazole (133-S3): To a mixture of **133-S2** (700 mg, 2.77 mmol) and potassium acetate (325.8 mg, 3.32 mmol) in CHCl₃ (20 mL) was added dropwise acetic anhydride (846.6 mg, 8.30 mmol) at 0 °C. The resulting mixture was stirred at room temperature for 1 hour. The reaction mixture was heated to 60 °C and *tert*-butyl nitrite (570.6 mg, 5.54 mmol) was added. After stirring overnight at 60 °C, the mixture was diluted with water and extracted with DCM twice. The combined organic layers were washed with brine, dried over anhydrous Na₂SO₄, and

concentrated under reduced pressure. The remaining residue was dissolved in MeOH (5 mL) and 6 N HCl (5 mL). The mixture was stirred at room temperature for 4 hours, basified with 10 N aqueous NaOH solution, and extracted with DCM twice. The combined organic layers were washed with brine, dried over anhydrous Na₂SO₄, and concentrated under reduced pressure. The remaining residue was purified by column chromatography on silica gel (PE/EtOAc = 10:1 to 3:1) to afford **133-S3** (420 mg, 57.5% yield) as a yellow oil. LC/MS (ESI) m/z: 265 (M+H)⁺.

[0571] Step 3: 5-Bromo-3-iodo-7-(trifluoromethyl)-1H-indazole (133-S4): To a solution of **133-S3** (420 mg, 1.6 mmol) in DMF (6 mL) was added KOH (201.6 mg, 3.6 mmol) followed by I₂ (605.7 mg, 2.4 mmol) in portions at 0 °C. The resulting mixture was stirred at room temperature for 1 hour. The mixture was diluted with water and extracted with EtOAc twice. The combined organic layers were washed with 5% aqueous Na₂S₂O₃ solution and brine, dried over anhydrous Na₂SO₄, and concentrated to afford **133-S4** (610 mg, 97.7% yield) as a yellow solid, which was carried forward without further purification. LC/MS (ESI) m/z: 391 (M+H)⁺.

[0572] Step 4: tert-Butyl 2-(5-bromo-3-iodo-7-(trifluoromethyl)-1H-indazol-1-yl)acetate (133-S5a) and tert-butyl 2-(5-bromo-3-iodo-7-(trifluoromethyl)-2H-indazol-2-yl)acetate (133-S5b): To a solution of **133-S4** (610 mg, 1.57 mmol) in DMF (8 mL) was added K₂CO₃ (541.7 mg, 3.93 mmol) followed by tert-butyl 2-bromoacetate (399.8 mg, 2.05 mmol). The resulting mixture was stirred at room temperature overnight, diluted with water, and extracted with EtOAc twice. The combined organic layers were washed with brine, dried over anhydrous Na₂SO₄, and concentrated under reduced pressure. The remaining residue was purified by chromatography on silica gel (PE/EtOAc = 1:0 to 50:1 to 30:1) to afford **133-S5a** (173 mg, 21.8% yield) and **133-S5b** (433 mg, 54.7% yield) as light yellow solids. LC/MS (ESI) m/z: 505 (M+H)⁺.


[0573] Step 5: tert-Butyl 2-(3-acetyl-5-bromo-7-(trifluoromethyl)-1H-indazol-1-yl)acetate (133-S6): To a solution of **133-S5a** (144 mg, 0.28 mmol) in dry toluene (9 mL) were added tributyl(1-ethoxyvinyl)stannane (155 mg, 0.43 mmol) and Pd(PPh₃)₄ (33 mg, 0.028 mmol). The resulting mixture was stirred at 100 °C under an atmosphere of nitrogen overnight. The cooled reaction mixture was diluted with H₂O and extracted with EtOAc twice. The combined organic layers were washed with brine, dried over anhydrous Na₂SO₄, and concentrated. The remaining crude product was dissolved in THF (0.5 mL) and 0.5 M HCl (5 mL) and stirred for 1.5 hours at room temperature. The reaction mixture was basified with 2 N aqueous NaOH solution and extracted with EtOAc twice. The combined organic layers were washed with brine, dried over anhydrous Na₂SO₄, and concentrated under reduced pressure. The remaining residue was purified by chromatography on silica gel (PE/EtOAc = 50:1 to 30:1) to afford **133-S6** (86 mg, 71.4% yield) as a brown solid. LC/MS (ESI) m/z: 421 (M+H)⁺.

[0574] Step 6: tert-Butyl 2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-7-(trifluoromethyl)-1H-indazol-1-yl)acetate (133-S7): To a mixture of **133-S6** (86 mg, 0.2 mmol), (2-methylpyrimidin-5-yl)boronic acid (42 mg, 0.31 mmol), and K₂CO₃ (70 mg, 0.51 mmol) in 1,4-dioxane (5 mL) and H₂O (1 mL) was added Pd(PPh₃)₄ (23 mg, 0.02 mmol). The reaction mixture was stirred at 90 °C under an atmosphere of nitrogen overnight. The mixture was filtered and the filtrate was diluted with water and extracted with EtOAc twice. The combined organic layers were washed with brine, dried over anhydrous Na₂SO₄, and concentrated under reduced pressure. The remaining residue was purified by chromatography on silica gel (PE/EtOAc = 3:1 to 1:1) to afford **133-S7** (67 mg, 75.5% yield) as a yellow solid. LC/MS (ESI) m/z: 435 (M+H)⁺.

[0575] Step 7: 2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-7-(trifluoromethyl)-1H-indazol-1-yl)acetic acid (133-S8): To a solution of **133-S7** (35 mg, 0.08 mmol) in DCM (2 mL) was added TFA (1 mL). The reaction mixture was stirred at room temperature for 1.5 hours and then concentrated under reduced pressure to afford **133-S8** (31 mg, 100% yield) as a yellow solid, which was carried forward in the next synthetic step without further purification. LC/MS (ESI) m/z: 335 (M+H)⁺.

[0576] Step 8: (1R,3S,5R)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-7-(trifluoromethyl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (133): To a mixture of **133-S8** (26 mg, 0.07 mmol) and **133-S9** (23 mg, 0.07 mmol) in DMF (2 mL) was added DIPEA (0.04 mL, 0.22 mmol) followed by HATU (41.8 mg, 0.11 mmol) and the reaction mixture was stirred at room temperature for 1 hour. The mixture was diluted with EtOAc, washed with 10% aqueous LiCl solution and brine, dried, and concentrated to afford the crude product, which was purified by preparative HPLC to afford **133** (11.0 mg, 3.28% yield) as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.27 (s, 1H), 9.13 (s, 2H), 8.82 (s, 1H), 8.28 (s, 1H), 7.63 (d, *J* = 8.0 Hz, 1H), 7.44 (d, *J* = 7.9 Hz, 1H), 5.99 (d, *J* = 18.1 Hz, 1H), 5.59 (d, *J* = 17.9 Hz, 1H), 4.34-4.31 (m, 1H), 3.59-3.55 (m, 1H), 2.71 (d, *J* = 2.1 Hz, 6H), 2.59-2.53 (m, 1H), 2.09-2.07 (m, 1H), 2.05 (s, 3H), 1.33 (s, 3H), 1.09-1.06 (m, 1H), 0.85-0.83 (m, 1H). LC/MS (ESI) m/z: 670 (M+H)⁺.

Scheme 51. Synthesis of (1R,3S,5R)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(3-((allyloxy)methyl)-6-bromopyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (134)



[0577] Step 1: 2-(*tert*-Butyl) 3-ethyl (1*R*,3*S*,5*S*)-5-formyl-2-azabicyclo[3.1.0]hexane-2,3-dicarboxylate (134-S2):

To the solution of 2-(*tert*-butyl) 3-ethyl (1*R*,3*S*,5*S*)-5-(hydroxymethyl)-2-azabicyclo[3.1.0]hexane-2,3-dicarboxylate (**134-S1**, 67 mg, 0.23 mmol) in DCM (4 mL), Dess-Martin reagent (0.31 mmol) was added at 0°C under argon. The mixture was stirred for an additional 3 hours, the reaction was diluted with DCM (20 mL), and quenched with aqueous NaHCO₃ (10%, 15 mL). The DCM layer was collected and the aqueous phase was extracted with DCM (15 mL × 2). The DCM phase was combined, washed with brine, and dried over magnesium sulfate. The solution was filtered and concentrated to afford crude product **134-S2** (62 mg) that was carried forward without additional purification.

[0578] Step 2: 2-(*tert*-Butyl) 3-ethyl (1*R*,3*S*,5*R*)-5-vinyl-2-azabicyclo[3.1.0]hexane-2,3-dicarboxylate (134-S3):

To the suspension of methyltriphenylphosphonium bromide (111 mg, 0.31 mmol) in 5 mL of dry THF, BuLi (0.31 mmol) was added dropwise at 0°C under argon. The mixture was stirred for 1 hour and a solution of aldehyde **134-S2** (62 mg) in THF (2 mL) was added dropwise. The mixture was warmed to room temperature and stirred overnight. The reaction was quenched with water (10 mL) and extracted with EtOAc (15 mL × 3). The organic phases were combined, washed with brine and dried over magnesium sulfate. The solution was filtered, concentrated and purified to afford **134-S3** (31 mg). ¹H NMR (400 MHz, CDCl₃) δ 0.89-0.94 (m, 1H), 1.04-1.08 (m, 1H), 1.28 (t, *J* = 7.2 Hz, 3H), 1.44 (s, 9H), 2.32 (dd, *J* = 13.2, 7.0 Hz, 1H), 2.43 (dd, *J* = 13.1, 8.8 Hz, 1H), 3.43 (s, 1H), 3.97-4.09 (m, 1H), 4.16-4.26 (m, 2H), 4.99 (d, *J* = 7.8 Hz, 1H), 5.02 (s, 1H), 5.70 (dd, *J* = 17.0, 10.7 Hz, 1H) ppm.

[0579] Step 3: (1*R*,3*S*,5*R*)-2-(*tert*-Butoxycarbonyl)-5-vinyl-2-azabicyclo[3.1.0]hexane-3-carboxylic acid (134-S4):

Compound **134-S3** (31 mg, 0.11 mmol) was dissolved in a mixture of CH₃OH-THF-H₂O (2 mL-2 mL-2 mL) and treated with LiOH (24 mg). The reaction mixture was stirred overnight at room temperature. The volatiles were evaporated under reduced pressure and the remaining residue was acidified with 10% citric acid (10 mL). The mixture was extracted with EtOAc (15 mL × 3) and the combined organic layers were washed with water and brine and dried over MgSO₄. The solution was concentrated and the residue (**134-S4**, 26 mg) was dried and carried forward without additional purification.

[0580] Step 4: *tert*-Butyl (1*R*,3*S*,5*R*)-3-((3-((allyloxy)methyl)-6-bromopyridin-2-yl)carbamoyl)-5-vinyl-2-azabicyclo[3.1.0]hexane-2-carboxylate (134-S5):


(1*R*,3*S*,5*R*)-2-(*tert*-Butoxycarbonyl)-5-vinyl-2-azabicyclo[3.1.0]hexane-3-carboxylic acid (**134-S4**, 26 mg, 0.10 mmol) and 3-((allyloxy)methyl)-6-bromopyridin-2-amine (27 mg, 0.11 mmol) were dissolved in anhydrous DCM (5 mL) in a pre-dried flask. The flask was cooled in an ice bath and dry pyridine (0.25 mL,


3.0mmol) was added in one portion, followed by POCl₃ (100 μ L, 1.0 mmol). After completion of the addition, the mixture was stirred for 4 hours at 0°C, and the reaction was quenched with water (15mL). The DCM layer was collected and the aqueous phase was extracted with DCM (15mL $\times$ 2). The combined DCM solutions were washed with brine, and dried over MgSO₄. The solution was filtered and concentrated and the resulting residue was purified to afford **134-S5** (35 mg).

[0581] Step 5: (1R,3S,5R)-N-(3-((allyloxy)methyl)-6-bromopyridin-2-yl)-5-vinyl-2-azabicyclo[3.1.0]hexane-3-carboxamide hydrochloride (134-S6): *tert*-Butyl (1R,3S,5R)-3-((3-((allyloxy)methyl)-6-bromopyridin-2-yl)carbamoyl)-5-vinyl-2-azabicyclo[3.1.0]hexane-2-carboxylate (**134-S5**, 28 mg, 0.058 mmol) was taken up in 4N HCl dioxane (2.0 mL) and the resulting reaction mixture was stirred at room temperature for 2 hours. After completion of the reaction (as monitored by HPLC), the solvent was removed under reduced pressure. The remaining residue **134-S6** was used carried forward without additional purification.

[0582] Step 6: (1R,3S,5R)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(3-((allyloxy)methyl)-6-bromopyridin-2-yl)-5-vinyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (134): To the solution of (1R,3S,5R)-N-(3-((allyloxy)methyl)-6-bromopyridin-2-yl)-5-vinyl-2-azabicyclo[3.1.0]hexane-3-carboxamide hydrochloride (**134-S6**, 0.058 mmol) and 2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetic acid (**134-S7**, 18 mg, 0.058 mmol) in DMF (2.0 mL), HATU (33mg, 0.087mmol) was added, followed by the dropwise addition of DIEA (5.0 eq) at room temperature. The mixture was stirred for 1 hour at room temperature and then the volatiles were evaporated. The residue was diluted with 10% sodium carbonate (50 mL) and extracted with ethyl acetate. The combined organic solutions were successively washed with water and brine and dried over MgSO₄. The solution was filtered and the solvent was removed. The residue was purified to afford **134** (8.1 mg). ¹H NMR (400 MHz, DMSO-d₆): (major rotamer) δ 1.21 - 1.25 (m, 1H), 1.35 - 1.41 (m, 1H), 2.37-2.44 (m, 1H), 2.52-2.57 (m, 1H), 2.65 (s, 3H), 2.69 (s, 3H), 3.62 - 3.79 (m, 2H), 3.87-3.93 (m, 1H), 4.20 (d, *J* = 3.2 Hz, 2H), 4.42-4.46 (m, 1H), 4.96-5.23 (m, 4H), 5.60 (d, *J* = 17.3 Hz, 1H), 5.65 - 5.79 (m, 1H), 5.84 (dd, *J* = 17.3, 10.6 Hz, 1H), 5.95 (d, *J* = 17.3 Hz, 1H), 7.54 (d, *J* = 8.1 Hz, 1H), 7.78 (d, *J* = 8.1 Hz, 1H), 7.86 (s, 2H), 8.44 (s, 1H), 9.03 (s, 2H), 10.48 (s, 1H) ppm. LC (method A): *t*_R = 2.15 min. LC/MS (EI) *m/z*: [M + H]⁺ 670.20, 672.16

Scheme 52. Synthesis of (1R,3S,5R)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(3-bromoisquinolin-1-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (91) and (1R,3S,5R)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-chloro-3-((dimethylamino)methyl)pyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (135)





[0583] Step 1: 6-Bromo-3-((dimethylamino)methyl)pyridin-2-amine (135-S2): To a stirred solution 6-bromo-3-(chloromethyl)pyridin-2-amine (133 mg, 1 equiv) in acetonitrile (10 mL) was added triethyl amine (0.3 mL, 3equiv) and dimethyl amine hydrochloride (84 mg, 2 equiv) at 0-5 °C under an atmosphere of argon. The reaction mixture was stirred at room temperature before the reaction was diluted with DCM (10 mL) and basified with aqueous saturated NaHCO₃ solution (10 mL). The aqueous layer was extracted with DCM (2x 10 mL) and the combined organic layers were washed with brine (10 mL), dried over Na₂SO₄ and concentrated to dryness to afford **135-S2** (100mg, 99 %).

[0584] Step 2: *tert*-Butyl (1*R*,3*S*,5*R*)-3-((6-bromo-3-((dimethylamino)methyl)pyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexane-2-carboxylate (135-S3): POCl₃ was added dropwise (0.08 mL, 2 equiv) at 0-5 °C under an atmosphere of argon to a stirred solution of (1*R*,3*S*,5*R*)-2-(*tert*-butoxycarbonyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxylic acid (106 mg, 1equiv) and **135-S2** (100 mg, 1 equiv) in DCM (20 mL) and pyridine (0.18 mL, 5 equiv). The reaction mixture was stirred at room temperature until completion before it was diluted with DCM (10 mL) and neutralized with aqueous saturated NaHCO₃ solution (10 mL). The aqueous layer was extracted with DCM (1x 10mL) and the combined organic layers were washed with brine (10 mL), dried over Na₂SO₄, and concentrated to dryness. The residue was purified by column chromatography on silica gel (eluted by 5% MeOH in DCM gradient) to afford **135-S3** (169 mg, 85%).

[0585] Step 3: (1*R*,3*S*,5*R*)-*N*-(6-Bromo-3-((dimethylamino)methyl)pyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide hydrochloride (135-S4) and (1*R*,3*S*,5*R*)-*N*-(6-Chloro-3-((dimethylamino)methyl)pyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide hydrochloride (136-S5): To a solution of **135-S3** (169 mg) was added 4N HCl in dioxane (15mL) and the resulting solution was stirred at room temperature for 6 hours. The reaction mixture was concentrated to dryness to afford **135-S4** (133 mg).


[0586] Step 4: (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(3-bromoisoquinolin-1-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (91) and (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-chloro-3-((dimethylamino)methyl)pyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (135): HATU (233 mg, 1.2 equiv) was added at 0°C under an atmosphere of argon to a solution of **135-S4** and **135-S5** (133 mg, 1 equiv), 2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetic acid (158 mg, 1.2 equiv), and DIPEA (0.53 mL, 5 equiv) in DMF (10 mL). The reaction mixture was stirred at room temperature for 3 hours before it was diluted with EtOAc (30 mL) and water (15mL). The aqueous layer was extracted with EtOAc (20 mL) and the combined organic layers were washed with brine (3x25 mL), dried over anhydrous Na₂SO₄, filtered and concentrated. The residue was purified by reverse phase chromatography on C18 (YMC pack, eluted with acetonitrile and water to afford **91** (60 mg, 24%) and **135** (15 mg).

[0587] Compound 91: ¹H NMR (400 MHz, DMSO-d₆) δ 10.86 (s, 1H), 9.07 (s, 2H), 8.46 (s, 1H), 7.86-7.91 (m, 3H), 7.72 (d, 1H, J=8.3 Hz), 6.01 (d, 1H, J= 17.1 Hz), 5.65 (d, 1H, J=17.1 Hz), 4.27 (t, 1H, J=8.5 Hz), 3.92-4.02 (m, 2H), 3.70-3.74 (m 1H), 2.71 (s, 3H), 2.66 (s, 3H), 2.54-2.61 (m, 1H), 2.32 (s, 3H), 2.16 (s, 3H), 1.98-2.05 (m, 1H), 1.35 (s, 3H), 0.96-1.07 (m,

2H).

[0588] Compound 135: ^1H NMR (400 MHz, DMSO- d_6) δ 10.81 (s, 1H), 9.09 (s, 2H), 8.48 (s, 1H), 8.00 (d, 1H, $J=8.4$ Hz), 7.87-7.95 (m, 2H), 7.60 (d, 1H, $J=8.4$ Hz), 6.02 (d, 1H, $J=16.8$ Hz), 5.65 (d, 1H, $J=16.8$ Hz), 4.27 (t, 1H, $J=8.2$ Hz), 3.94-4.04 (m, 2H), 3.69-3.74 (m, 1H), 2.70 (s, 3H), 2.67 (s, 3H), 2.54-2.61 (m, 1H), 2.31 (s, 3H), 2.16 (s, 3H), 1.98-2.05 (m, 1H), 1.35 (s, 3H), 0.95-1.07 (m, 2H).

Scheme 53. Synthesis of (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-((dimethylamino)methyl)pyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (136) and (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-chloro-3-((dimethylamino)methyl)pyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (137)




[0589] Step 1: (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-((dimethylamino)methyl)pyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (136) and (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-chloro-3-((dimethylamino)methyl)pyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (137): HATU (100 mg, 1.2 equiv) was added at 0 °C under an atmosphere of argon to a solution of **136-S1** and **137-S2** (84 mg, 1equiv), 2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetic acid (71 mg, 1equiv), DIPEA (0.2 mL, 5 equiv) in DMF (10 mL). The reaction mixture was stirred at room temperature for 3 hours before the reaction mixture was diluted with EtOAc (30 mL) and water (15 mL). The aqueous layer was extracted with EtOAc (15 mL) and the combined organic layers were washed with brine, dried over anhydrous Na_2SO_4 , filtered and concentrated. The residue was purified by C18 HPLC column chromatography (eluted by ACN/water/TFA=20:80:0.1) to afford **136** (48 mg) and **137** (32 mg).

[0590] Compound 136: ^1H NMR (400 MHz, DMSO- d_6) δ 10.89 (s, 1H), 9.06 (s, 2H), 8.33 (s, 1H), 7.95 (d, 1H, $J=8.5$ Hz), 7.72 (d, 1H, $J=8.5$ Hz), 7.65 (s, 1H), 6.13 (d, 1H, $J=18.1$ Hz), 5.73 (d, 1H, $J=18.1$ Hz), 4.26-4.31 (m, 1H), 3.91-4.03 (m, 3H), 2.73 (s, 3H), 2.70 (s, 3H), 2.65 (s, 3H), 2.54-2.61 (m, 1H), 2.27 (s, 3H), 2.14 (s, 3H), 1.97-2.00 (m, 1H), 1.35 (s, 3H), 0.96-1.00 (m, 2H).

[0591] Compound 137: ^1H NMR (400 MHz, DMSO- d_6) δ 10.85 (s, 1H), 9.05 (s, 2H), 8.34 (s, 1H), 7.99 (d, 1H, $J=8.0$ Hz),

7.65 (s, 1H), 7.59 (d, 1H, $J=8.0$ Hz), 6.13 (d, 1H, $J=17.9$ Hz), 5.72 (d, 1H, $J=17.9$ Hz), 4.25-4.31 (m, 1H), 3.94-4.03 (m, 3H), 2.73 (s, 3H), 2.70 (s, 3H), 2.66 (s, 3H), 2.55-2.60 (m, 1H), 2.28 (s, 3H), 2.15 (s, 3H), 1.96-2.06 (m, 1H), 1.35 (s, 3H), 0.97-1.03 (m, 2H).

Scheme 54. Synthesis of (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-(morpholinomethyl)pyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (138) and (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-chloro-3-(morpholinomethyl)pyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (139)



[0592] Step 1: 6-Bromo-3-(morpholinomethyl)pyridin-2-amine (139-S2): To a stirred solution 6-bromo-3-(chloromethyl)pyridin-2-amine (241 mg, 1equiv) and triethyl amine (0.48 mL, 3 equiv) in acetonitrile (20 mL) was added morpholine (162 mg, 2 equiv) at 0-5 °C under an atmosphere of argon. The reaction mixture was stirred at room temperature until completion. The reaction was diluted with DCM (25 mL) and basified with aqueous saturated NaHCO₃ solution (10 mL). The aqueous layer was extracted with DCM (2x 10 mL) and the combined organic layers were washed with brine, dried over Na₂SO₄ and concentrated to dryness. The residue was purified by column chromatography on silica gel (eluted by 5% MeOH in DCM gradient) to afford **139-S2** (215 mg, 85%).

[0593] Step 2: *tert*-Butyl (1*R*,3*S*,5*R*)-3-((6-bromo-3-(morpholinomethyl)pyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexane-2-carboxylate (139-S3): POCl₃ was added dropwise (0.03 mL, 2 equiv) at 0-5 °C under

an atmosphere of argon to a stirred solution of (1*R*,3*S*,5*R*)-2-(*tert*-butoxycarbonyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxylic acid (69 mg, 1 equiv) and **139-S2** (78 mg, 1 equiv) in DCM (10 mL) and pyridine (0.12 mL, 5 equiv). The reaction mixture was stirred at room temperature until completion. The reaction mixture was diluted with DCM (10 mL) and neutralized with aqueous saturated NaHCO₃ solution (10 mL). The aqueous layer was extracted with DCM (1 × 10 mL) and the combined organic layers were washed with brine, dried over Na₂SO₄ and concentrated to dryness. The residue was purified by column chromatography on silica gel (eluted by 5% MeOH in DCM gradient) to afford **139-S3** (87 mg, 70%).


[0594] Step 3: (1*R*,3*S*,5*R*)-*N*-(6-Bromo-3-(morpholinomethyl)pyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide hydrochloride (138-S4) and (1*R*,3*S*,5*R*)-*N*-(6-Chloro-3-(morpholinomethyl)pyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide hydrochloride (139-S5): To a solution of **139-S3** (87 mg) was added 4N HCl in dioxane (10 mL) and the resulting solution was stirred at room temperature for 6 hours. The reaction mixture was concentrated to dryness to afford **138-S4** and **139-S5**.

[0595] Step 4: (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-(morpholinomethyl)pyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (138) and (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-chloro-3-(morpholinomethyl)pyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (139): HATU (68 mg, 1.2 equiv) was added at 0°C under an atmosphere of argon to a solution of **138-S4** and **139-S5** (65 mg, 1 equiv), 2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetic acid (47 mg, 1.05 equiv), and DIPEA (0.13 mL, 5 equiv) in DMF (10 mL). The reaction mixture was stirred at room temperature for 3 hours before the reaction mixture was diluted with EtOAc (35 mL) and water (15 mL). The aqueous layer was extracted with EtOAc (20 mL) and the combined organic layers were washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated. The residue was purified by HPLC column chromatography on C18 (eluted with ACN/water/TFA=20/80/0.1) to afford **138** (30 mg) and **139** (12 mg).

[0596] Compound 138: ¹H NMR (400 MHz, DMSO-*d*₆): δ 10.72 (s, 1H), 8.97 (s, 2H), 8.39 (s, 1H), 7.70-7.89 (m, 3H), 7.57 (s, 1H), 5.98 (d, 1H, *J* = 17.5 Hz), 5.55 (d, 1H, *J* = 17.5 Hz), 4.13-4.27 (m, 1H), 3.86-4.02 (m, 4H), 3.63-3.73 (m, 1H), 2.62 (s, 3H), 2.59 (s, 3H), 2.46-2.52 (m, 1H), 2.33 (s, 2H), 2.11-2.24 (m, 4H), 1.89-2.09 (m, 1H), 1.26 (s, 3H), 0.87-0.99 (m, 2H).

[0597] Compound 139: ¹H NMR (400 MHz, DMSO-*d*₆): δ 10.69 (s, 1H), 8.98 (s, 2H), 9.33 (s, 1H), 8.38 (s, 1H), 7.79-7.93 (m, 3H), 7.46 (s, 1H), 5.96 (d, 1H, *J* = 17.2 Hz), 5.55 (d, 1H, *J* = 17.2 Hz), 4.14-4.32 (m, 1H), 3.80-4.02 (m, 1H), 3.57-3.69 (m, 4H), 3.06 (s, 2H), 2.62 (s, 3H), 2.59 (s, 3H), 2.47-2.52 (m, 1H), 1.92-2.13 (m, 5H), 1.28 (s, 3H), 0.89-0.99 (m, 2H).

Scheme 55: Synthesis of (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-7-cyano-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-methylpyridin-2-yl)-5-((dimethylamino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (143) and (1*S*,3*S*)-2-(2-(3-Acetyl-7-cyano-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-methylpyridin-2-yl)-5-((dimethylamino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (144)



[0598] Step 1: tert-Butyl 2-(3-acetyl-7-cyano-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetate (144-S2): A sealable vial was charged with **144-S1** (50 mg, 0.112 mmol), $\text{Zn}(\text{CN})_2$ (53 mg, 0.449 mmol), $\text{Pd}(\text{PPh}_3)_4$ (7 mg, 0.056 mmol), and toluene (3 mL) under an atmosphere of nitrogen. The vial was sealed and irradiated in the microwave reactor at 150 °C for 2 hours. The mixture was diluted with EtOAc and filtered. The filtrate was concentrated and the remaining residue was purified by preparative TLC to afford **144-S2** (42 mg, 95.9% yield) as a white solid. LC/MS (ESI) m/z : 392 ($\text{M}+\text{H}$)⁺.

[0599] Step 2: 2-(3-Acetyl-7-cyano-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetic acid (144-S3): To a solution of **144-S2** (42 mg, 0.102 mmol) in DCM (1 mL) was added TFA (1 mL). The resulting mixture was stirred at room temperature for 2 hours and concentrated to afford **144-S3** (36 mg, 100% yield) as a white solid, which was carried forward in the next synthetic step without purification. LC/MS (ESI) m/z : 336 ($\text{M}+\text{H}$)⁺.


[0600] Step 3: (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-7-cyano-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-methylpyridin-2-yl)-5-((dimethylamino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (143) and (1*S*,3*S*)-2-(2-(3-acetyl-7-cyano-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-methylpyridin-2-yl)-5-((dimethylamino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (144): To a solution of **144-S3** (35 mg, 0.093 mmol), **144-S4** (37 mg, 0.093 mmol), and DIPEA (40 mg, 0.279 mmol) in DMF (1 mL) at room temperature was added HATU (79 mg, 0.186 mmol). The resulting mixture was stirred at room temperature overnight. The mixture was diluted with EtOAc, washed with 5% aqueous LiCl solution and brine, dried over Na_2SO_4 , filtered, and concentrated to dryness. The remaining residue was purified by preparative HPLC to afford **143** (3 mg, yield 4.8% yield) and **144** (1 mg, 1.6% yield) as white solids.

[0601] Compound 143: ^1H NMR (400 MHz, CD_3OD) δ 9.06 (s, 2H), 8.89 (d, J = 1.6 Hz, 1H), 8.32 (d, J = 1.6 Hz, 1H), 7.59 (d, J = 8.1 Hz, 1H), 7.43 (d, J = 7.9 Hz, 1H), 6.08 (d, J = 17.8 Hz, 1H), 6.00 (d, J = 17.8 Hz, 1H), 4.73 (m, 1H), 3.89-3.84 (m, 1H), 3.50 (m, 2H), 3.13 (d, J = 14.0 Hz, 1H), 2.90 (s, 6H), 2.79 (s, 3H), 2.73 (s, 3H), 2.62 (m, 1H), 2.15 (s, 3H), 1.58 (d, J = 3.1 Hz, 1H), 1.50 (m, 1H). LC/MS (ESI) m/z : 670 ($\text{M}+\text{H}$)⁺.

[0602] Compound 144: ^1H NMR (400 MHz, CD_3OD) δ 9.07 (s, 2H), 8.90 (d, J = 1.6 Hz, 1H), 8.34 (d, J = 1.6 Hz, 1H), 7.57 (d, J = 8.1 Hz, 1H), 7.41 (d, J = 7.9 Hz, 1H), 6.18 (d, J = 17.7 Hz, 1H), 5.90 (d, J = 17.6 Hz, 1H), 5.19 (m, 1H), 4.00 (m, 1H), 3.70 (m, 1H), 3.50 (m, 1H), 3.21-3.15 (m, 1H), 2.98 (s, 6H), 2.79 (s, 3H), 2.73 (s, 3H), 2.62 (m, 1H), 2.19-2.08 (m, 3H), 1.90

(s, 1H), 1.42 (m, 1H). LC/MS (ESI) m/z: 670 (M+H)⁺.

Scheme 56: Synthesis of 1-(2-((1*R*,3*S*,5*R*)-3-((6-Bromo-3-methylpyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-4-fluoro-5-(2-methylpyrimidin-5-yl)-1*H*-indazole-3-carboxamide (145)



[0603] Step 1: 5-Bromo-4-fluoro-1*H*-indazole-3-carbonitrile (145-S2): To a solution of **145-S1** (800 mg, 2.346 mmol) in DMA (8 mL) was added Zn powder (18 mg, 0.282 00 mmol), Zn(CN)₂ (138mg, 1.173 mmol), dppf (52 mg, 0.094 mmol), Pd₂(dba)₃ (43 mg, 0.0469 mmol) and the mixture was purged with nitrogen. The reaction mixture was heated at 100 °C overnight under an atmosphere of nitrogen. The solution was cooled to room temperature and partitioned between EtOAc and 0.5 N aqueous HCl. The organic phase was washed twice with 0.5 N aqueous HCl and brine, and dried over Na₂SO₄. The mixture was filtered and concentrated to dryness. The remaining residue was purified by column chromatography on silica gel (eluted with PE/EtOAc = 5:1) to afford **145-S2** (469 mg, 83.3% yield) as a white solid. LC/MS (ESI) m/z: 240 (M+H)⁺.

[0604] Step 2: 5-Bromo-4-fluoro-1*H*-indazole-3-carboxamide (145-S3): To a solution of **145-S2** (469 mg, 1.95 mmol) in MeOH (25 mL) at 0 °C was added an ice-cooled solution of urea hydrogen peroxide (1.8 g, 19.54 mmol) in 1 N aqueous NaOH solution (25 mL, 19.54 mmol) and the reaction mixture was stirred at room temperature overnight. The mixture was concentrated to half volume and extracted with EtOAc twice. The combined organic layers were washed with brine, dried over Na₂SO₄, filtered, and concentrated to dryness to afford **145-S3** (270 mg, 54% yield) as a white solid. LC/MS (ESI) m/z: 258 (M+H)⁺.

[0605] Step 3: *tert*-Butyl 2-(5-bromo-3-carbamoyl-4-fluoro-1*H*-indazol-1-yl)acetate (145-S4): To a solution of **145-S3** (270 mg, 1.05 mmol) in DMF (2 mL) were added *tert*-butyl 2-bromoacetate (0.18 mL, 1.26 mmol) and K₂CO₃ (363 mg, 2.625 mmol). The mixture was stirred at room temperature overnight. The mixture was diluted water, extracted with EtOAc, washed with 10% aqueous LiCl solution and brine, and dried over Na₂SO₄. The mixture was filtered and concentrated to

dryness. The remaining residue was purified by column chromatography on silica gel (eluted with PE/EtOAc = 1:1) to afford **145-S4** (210 mg, 53.7% yield) as a white solid. LC/MS (ESI) *m/z*: 372 (M+H)⁺.


[0606] Step 4: *tert*-Butyl 2-(3-carbamoyl-4-fluoro-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetate (145-S5):

To a solution of **145-S4** (41 mg, 0.11 mmol) and 2-methylpyrimidin-5-ylboronic acid (18 mg, 0.13 mmol) in DMF (2 mL) was added K₃PO₄ (0.17 mL, 2 N, 0.33 mmol) and Pd(dppf)Cl₂ (4 mg, 0.005 mmol) under an atmosphere of nitrogen. The reaction mixture was further purged with nitrogen and stirred at 100 °C for 3 hours. The mixture was poured into ice water and extracted with EtOAc, washed with 10% aqueous LiCl solution and brine, and dried over Na₂SO₄. The mixture was filtered and concentrated to dryness. The remaining residue was purified by column chromatography on silica gel (eluted with DCM/MeOH = 50:1) to afford **145-S5** (32 mg, 76% yield) as a white solid. LC/MS (ESI) *m/z*: 386 (M+H)⁺.

[0607] Step 5: 2-(3-Carbamoyl-4-fluoro-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetic acid (145-S6): To a solution of **145-S5** in DCM (2 mL) was added TFA (1 mL) at 0 °C and the reaction mixture was stirred at room temperature for 3 hours. The mixture was concentrated to dryness under reduced pressure to afford **145-S6** (32 mg, 100% yield), which was carried forward in the next synthetic step without further purification LC/MS (ESI) *m/z*: 330 (M+H)⁺.

[0608] Step 6: 1-(2-((1*R*,3*S*,5*R*)-3-((6-Bromo-3-methylpyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-4-fluoro-5-(2-methylpyrimidin-5-yl)-1*H*-indazole-3-carboxamide (145): To a mixture of **145-S6** (32 mg, 0.097 mmol), **145-S7** (52 mg, 0.126 mmol), and HATU (74 mg, 0.194 mmol) in DMF (1 mL) was added DIPEA (0.1 mL, 0.582 mmol) and the reaction mixture was stirred at room temperature for 2 hours. The mixture was diluted with EtOAc, washed with 10% aqueous LiCl solution and brine, dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The remaining residue was purified by preparative HPLC to afford **145** (7 mg, 12% yield) as a light yellow solid. ¹H NMR (400 MHz, CD₃OD) δ 8.93 (s, 2H), 7.64-7.53 (m, 3H), 7.38 (d, *J*=8 Hz, 1H), 5.76-5.59 (m, 2H), 4.54-4.50 (m, 1H), 3.53-5.50 (m, 1H), 2.73 (s, 3H), 2.65-2.58 (m, 1H), 2.32-2.27 (m, 1H), 2.12 (s, 3H), 1.40 (s, 3H), 1.07 (t, *J*=5.6 Hz, 1H), 0.97-0.95 (m, 1H). LC/MS (ESI) *m/z*: 621 (M+H)⁺.

Scheme 57: Synthesis of (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-7-(difluoromethyl)-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (146)



[0609] Step 1: Methyl 5-bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1*H*-indazole-7-carboxylate (146-S2): To a

solution of **146-S1** (765 mg, 3 mmol) in dry THF (2 mL) was added NaH (144 mg, 3.6 mmol, 60% dispersion in mineral oil) at 0 °C. The reaction mixture was stirred at 0 °C for 30 minutes, SEMCl (648 mg, 3.9 mmol) was added into the above mixture, and the resulting mixture was stirred at room temperature for 2 hours. The mixture was then quenched with saturated NH₄Cl solution and extracted with EtOAc. The organic layer was separated, dried over Na₂SO₄, and concentrated to afford the crude product, which was purified by column chromatography on silica gel (eluted with PE/EtOAc = 100:0 to 7:1) to afford **146-S2** (750 mg, 65.1% yield) as a white solid. LC/MS (ESI) m/z: 385 (M+H)⁺.

[0610] Step 2: (5-Bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-7-yl)methanol (146-S3): To a solution of **146-S2** (750 mg, 1.95 mmol) in dry THF (20 mL) was added LiAlH₄ (148 mg, 3.5 mmol) at 0 °C in small portions. The reaction mixture was stirred at 0 °C for 30 minutes and then warmed to room temperature for 1 hour. The mixture was then quenched slowly with water (0.75 mL), 10% aqueous NaOH solution (1.5 mL), and water (2.25 mL). The resulting mixture was filtered and the filtrate was diluted with EtOAc, dried over Na₂SO₄, and concentrated to afford the crude product, which was purified by column chromatography on silica gel (eluted with PE/EA = 100:1 to 5:1) to afford **146-S3** (494 mg, 71.1% yield) as a colorless oil. LC/MS (ESI) m/z: 357 (M+H)⁺.

[0611] Step 3: (5-(2-Methylpyrimidin-5-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-7-yl)methanol (146-S4): To a solution of **146-S3** (494 mg, 1.384 mmol) in 1,4-dioxane/H₂O (28 mL, 6:1) was added 2-methylpyrimidin-5-ylboronic acid (210 mg, 1.52 mmol), K₂CO₃ (573 mg, 4.152 mmol), and Pd(PPh₃)₄ (128 mg, 0.111 mmol). The reaction mixture was stirred at 95 °C for 16 hours under an atmosphere of nitrogen. After cooling, the mixture was diluted with water and extracted with DCM/MeOH (20:1). The organic layer was separated, dried, and concentrated to afford the crude product, which was purified by column chromatography on silica gel (eluted with DCM/MeOH = 100:0 to 50:1) to afford **146-S4** (288 mg, 56.2% yield) as a colorless oil. LC/MS (ESI) m/z: 371 (M+H)⁺.

[0612] Step 4: 5-(2-Methylpyrimidin-5-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazole-7-carbaldehyde (146-S5): To a solution of **146-S4** (240 mg, 0.65 mmol) in CHCl₃ (12 mL) was added MnO₂ (565 mg, 6.5 mmol). The reaction mixture was stirred at room temperature for 3 hours. The mixture was then filtered and the filtrate was concentrated to afford the crude product, which was purified by column chromatography on silica gel (eluted with DCM/EtOAc = 100:1 to 8:1) to afford **146-S5** (150 mg, 62.7% yield) as a colorless oil. LC/MS (ESI) m/z: 369 (M+H)⁺.

[0613] Step 5: 7-(Difluoromethyl)-5-(2-methylpyrimidin-5-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazole (146-S6): To a solution of **146-S5** (150 mg, 0.41 mmol) in dry DCM (10 mL) was added DAST (198 mg, 1.23 mmol) at 0 °C slowly under an atmosphere of nitrogen. The resulting mixture was stirred from 0 °C to room temperature for 1 hour and then heated to 40 °C for 24 hours. The mixture was then quenched with saturated aqueous NaHCO₃ solution and extracted with EtOAc. The organic layer was separated, dried, and concentrated to dryness. The remaining residue was purified by preparative TLC (eluted with DCM/MeOH = 20:1) to afford **146-S6** (92 mg, 58.2% yield) as a colorless oil. LC/MS (ESI) m/z: 391 (M+H)⁺.

[0614] Step 6: 7-(Difluoromethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazole (146-S7): To a solution of **146-S6** (92 mg, 0.24 mmol) in dry DCM (2 mL) was added TFA (2 mL) at room temperature under an atmosphere of nitrogen. The resulting mixture was stirred at room temperature for 2 hours. The mixture was then concentrated to afford **146-S7** (62 mg, 68.8% yield) as a colorless oil. LC/MS (ESI) m/z: 261 (M+H)⁺.

[0615] Step 7: 7-(Difluoromethyl)-3-iodo-5-(2-methylpyrimidin-5-yl)-1H-indazole (146-S8): To a solution of **146-S7** (62 mg, 0.24 mmol) in DMF (5 mL) were added KOH (41 mg, 0.72 mmol) and I₂ (92 mg, 0.36 mmol) at 0 °C. The mixture was stirred at room temperature for 16 hours. The mixture was then quenched with 5% aqueous Na₂S₂O₃ solution and extracted with EtOAc. The organic layer was separated, dried, and concentrated to afford **146-S8** (85 mg, 91.7% yield) as a colorless oil. LC/MS (ESI) m/z: 387 (M+H)⁺.

[0616] Step 8: tert-Butyl 2-(7-(difluoromethyl)-3-iodo-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetate (146-S9): To a solution of **146-S8** (85 mg, 0.22 mmol) in DMF (6 mL) were added K₂CO₃ (61 mg, 0.44 mmol) and tert-butyl 2-bromoacetate (65 mg, 0.33 mmol). The reaction mixture was stirred at room temperature for 16 hours. The mixture was diluted with EtOAc, washed with 10% aqueous LiCl solution, dried, and concentrated to afford the crude product, which was purified by column chromatography on silica gel (eluted with PE/EtOAc = 100:0 to 4:1) to afford **146-S9** (66 mg, 60.0% yield) as a colorless oil. LC/MS (ESI) m/z: 501 (M+H)⁺.


[0617] Step 9: tert-Butyl 2-(3-acetyl-7-(difluoromethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetate (146-S10): To a mixture of **146-S9** (66 mg, 0.132 mmol) in dry toluene (8 mL) were added tributyl(1-ethoxyvinyl)stannane (67 mg, 0.185 mmol) and Pd(PPh₃)₄ (13 mg, 0.01 mmol). The reaction mixture was stirred at 100 °C for 16 hours under an atmosphere of nitrogen. After cooling, the mixture was quenched with 1 N aqueous HCl solution and the mixture was stirred at room temperature for 15 minutes. The mixture was extracted with EtOAc and the organic layer was washed with brine, dried over Na₂SO₄, filtered, and concentrated to afford the crude product, which was purified by column chromatography on silica gel (eluted with DCM/MeOH = 100:0 to 50:1) to afford **146-S10** (52 mg, 92.8% yield) as a colorless oil. LC/MS (ESI) m/z: 417 (M+H)⁺.


[0618] Step 10: 2-(3-Acetyl-7-(difluoromethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetic acid (146-S11): To a mixture of **146-S10** (52 mg, 0.13 mmol) in THF/H₂O (8 mL, 3:1, v/v) was added LiOH·H₂O (12 mg, 0.26 mmol). The reaction mixture was stirred at room temperature for 20 hours. The mixture was diluted with water, washed with

ether, and the aqueous layer was acidified with aqueous HCl solution (1 N) to pH 5. The resulting mixture was extracted with DCM/MeOH (5 mL $\times$ 2, 10:1 v/v). The combined organic phases were washed with brine, dried over anhydrous Na₂SO₄, filtered, and concentrated to afford **146-S11** (36 mg, yield 76.9%) as a white solid. LC/MS (ESI) m/z: 361 (M+H)⁺.

[0619] Step 11: (1R,3S,5R)-2-(2-(3-Acetyl-7-(difluoromethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (146): To a solution of **146-S11** (36 mg, 0.1 mmol), **146-S12** (45 mg, 0.13 mmol), and HATU (57 mg, 0.15 mmol) in DMF (2 mL) was added DIPEA (40 mg, 0.3 mmol). The reaction mixture was stirred at room temperature for 16 hours. The mixture was then diluted with EtOAc, washed with 10% aqueous LiCl solution and brine, dried, and concentrated to afford the crude product, which was purified via preparative HPLC to afford **146** (15 mg, 23.0% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 10.29 (s, 1H), 9.10 (s, 2H), 8.72 (s, 1H), 8.17 (s, 1H), 7.63 (d, *J* = 7.9 Hz, 1H), 7.27-7.55 (m, 2H), 5.95 (d, *J* = 18.0 Hz, 1H), 5.72 (d, *J* = 17.7 Hz, 1H), 4.35 (dd, *J* = 9.1, 5.2 Hz, 1H), 3.53-3.58 (m, 1H), 2.71 (s, 3H), 2.69 (s, 3H), 2.53-2.59 (m, 1H), 2.05 (s, 3H), 1.96-2.03 (m, 1H), 1.33 (s, 3H), 1.02-1.07 (m, 1H), 0.87-0.94 (m, 1H). LC/MS (ESI) m/z: 652 (M+H)⁺.

Scheme 58. Synthesis of (1R,3S,5R)-2-(2-(3-Acetyl-7-fluoro-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (147)





[0620] Step 1: 7-Fluoro-5-(2-methylpyrimidin-5-yl)-1H-indazole (147-S2): A mixture of 5-bromo-7-fluoro-1H-indazole (0.32 g equiv), 2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine (0.384 g), cesium carbonate (1.14 g) in dioxane (8 mL) and water (2.0 mL) was purged with argon in a pressure vessel for 5 minutes. PdCl₂(dppf) (0.190 g) was added under argon and the pressure vessel was sealed and heated at 90 °C overnight. The reaction mixture was cooled to room temperature and poured into water. The precipitated product was isolated by filtration, washed with water, and dried. The material was carried forward without additional purification and used directly in the next step.


[0621] Step 2: 3-Bromo-7-fluoro-5-(2-methylpyrimidin-5-yl)-1H-indazole (147-S3): To a stirred solution of 7-fluoro-5-(2-methylpyrimidin-5-yl)-1H-indazole (0.39 g) in DMF (5 mL), NBS (0.335 g) was added. The reaction mixture was stirred at room temperature for 1 hour. The reaction mixture was poured into water and the precipitate was isolated by filtration, washed with water, and dried. The material was carried forward without additional purification and used directly in the next step.

[0622] Step 3: *tert*-Butyl 2-(3-bromo-7-fluoro-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetate (147-S4): A mixture of 3-bromo-7-fluoro-5-(2-methylpyrimidin-5-yl)-1H-indazole (0.36 g), *tert*-butyl bromoacetate (181 μL), and potassium carbonate (0.323 g) in anhydrous acetonitrile (5 mL) and DMF (2 mL) was refluxed for 1 hour. The reaction mixture was then cooled to room temperature and the solvent was removed under reduced pressure. The residue was purified by silica gel flash column chromatography (eluent: 0-1.5 % MeOH in CH₂Cl₂) to afford **147-S4** as white solid.

[0623] Step 4: *tert*-Butyl 2-(3-acetyl-7-fluoro-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetate (147-S5): A solution of *tert*-butyl 2-(3-bromo-7-fluoro-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetate (0.25 g 1 equiv), tri-butyl(1-ethoxyvinyl)tin 0.429 g, 2 equiv and PdCl₂(PPh₃)₂ (42 mg, 0.1 equiv) in DMF (3 mL) was heated at 80 °C overnight under argon atmosphere. Then concentrated under reduced pressure and diluted with CH₂Cl₂ and washed with cold aqueous HCl (1N). The organic layer was dried (Na₂SO₄), filtered, and concentrated. The residue was purified by silica gel flash column chromatography (eluent: 0-1.5 % MeOH in CH₂Cl₂) to afford **147-S5**.

[0624] Step 6: (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-7-fluoro-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-*N*-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (147): *tert*-Butyl 2-(3-acetyl-7-fluoro-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetate (70 mg) was stirred in CH₂Cl₂ (0.5 mL) and TFA (1.5 mL). After completion of the reaction (monitored by HPLC), the solvent was removed under reduced pressure. The remaining residue was dissolved in DMF (1 mL) and *i*Pr₂NEt (95 μL, 3 equiv) was added, followed by the addition of the TFA salt of (1*R*,3*S*,5*R*)-*N*-(6-bromopyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide TFA salt (obtained by stirring 74 mg of *tert*-butyl (1*R*,3*S*,5*R*)-3-((6-bromopyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexane-2-carboxylate in 1 mL of TFA and 1 mL of CH₂Cl₂ for 15 minutes at room temperature and evaporating the volatiles) at 5 °C. HATU (76 mg, 1.2 equiv) was added slowly at this same temperature and the reaction mixture was stirred for 30 minutes at room temperature. Then the reaction mixture was poured into water and the precipitate was isolated by filtration. The solid was dried and purified by silica gel flash column chromatography (eluent: 0-2.5 % MeOH in CH₂Cl₂) to afford **147** as a light yellow solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 0.84 - 0.91 (m, 1H), 1.05 (t, *J* = 5.4 Hz, 1H), 1.32 (s, 3H), 2.05 (s, 3H), 2.03-2.07 (m, 1H), 2.52 - 2.58 (m, 1H), 2.67 (s, 3H), 2.69 (s, 3H), 3.56 (d, *J* = 4 Hz, 1H), 4.41 (dd, *J* = 5.2, 9.2 Hz, 1H), 5.65 (d, *J* = 17.4 Hz, 1H), 5.90 (d, *J* = 17.4 Hz, 1H), 7.44 (d, *J* = 7.9 Hz, 1H), 7.62 (d, *J* = 7.9 Hz, 1H), 7.79 (d, *J* = 12.7 Hz, 1H), 8.28 (s, 1H), 9.06 (s, 2H), 10.26 (s, 1H). ¹⁹F NMR (DMSO-*d*₆): δ -131.6.

Scheme 59. Synthesis of (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-5-(2-(2-(dimethylamino)-2-oxoethyl)pyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (148)



[0625] Step 1: *tert*-Butyl 2-(3-acetyl-5-(2-(2-methoxy-2-oxoethyl)pyrimidin-5-yl)-1*H*-indazol-1-yl)acetate (148-S3): To a solution of methyl 2-(5-bromopyrimidin-2-yl)acetate (**148-S2**, 1 equiv) in $\text{DMF}/\text{H}_2\text{O}$ (9:1, 10 vol) was added compound **148-S1** (1 equiv), K_2CO_3 (2 equiv) and tetrakis(triphenylphosphine)palladium (0.1 equiv). The reaction mixture was stirred at 90 °C for 5 hours and concentrated under reduced pressure. The remaining residue was purified by column chromatography on silica gel (eluted with DCM/MeOH) to afford compound **148-S3**.

[0626] Step 2: 2-(3-Acetyl-5-(2-(2-methoxy-2-oxoethyl)pyrimidin-5-yl)-1*H*-indazol-1-yl)acetic acid (148-S4): To a solution of compound **148-S3** (1 equiv) in DCM (10 vol) at 0 °C under an atmosphere of argon was added TFA (5 vol). The reaction mixture was stirred at room temperature for 3 hours and concentrated to dryness. The remaining material was carried forward without further purification and used directly in the next synthetic step.


[0627] Step 3: Methyl 2-(5-(3-acetyl-1-(2-((1*R*,3*S*,5*R*)-3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-1*H*-indazol-5-yl)pyrimidin-2-yl)acetate (148-S6): To a solution of com-


pound **148-S4** (1 equiv) in DMF (10 vol) at 0 °C under an atmosphere of argon was added (1*R*,3*S*,5*R*)-*N*-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (**148-S5**, 1 equiv), HATU (2.1 equiv), and DIPEA (5 equiv). The reaction mixture was stirred at room temperature for 3 hours and quenched with water (30 vol). The resulting mixture was extracted with DCM. The organic layer was washed with brine, dried over anhydrous Na₂SO₄, filtered, and concentrated to dryness. The remaining residue was purified by column chromatography on silica gel (eluted with DCM/MeOH) to afford compound **148-S6**.

[0628] Step 4: 2-(5-(3-Acetyl-1-(2-((1*R*,3*S*,5*R*)-3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-1*H*-indazol-5-yl)pyrimidin-2-yl)acetic acid (148-S7**):** To a solution of methyl 2-(5-(3-acetyl-1-(2-((1*R*,3*S*,5*R*)-3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-1*H*-indazol-5-yl)pyrimidin-2-yl)acetate (**148-S6**, 1 equiv) in THF/H₂O (3:1, 10 vol) was added LiOH (2.1 equiv). The reaction mixture was stirred at room temperature for 5 hours and concentrated under reduced pressure. The remaining residue was neutralized using 2*N* HCl and the precipitated solid was filtered, dried, and directly used in the next synthetic step.

[0629] Step 5: (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-5-(2-(2-(dimethylamino)-2-oxoethyl)pyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (148**):** To a solution of compound **148-S7** (1 equiv) in DMF (10 vol) at 0 °C under an atmosphere of argon was added dimethylamine hydrochloride (1.2 equiv), HATU (2.1 equiv), and DIPEA (5 equiv). The reaction mixture was stirred at room temperature for 3 hours and quenched with water (30 vol). The resulting mixture was extracted with DCM. The organic layer was washed with brine, dried over anhydrous Na₂SO₄, filtered, and concentrated to dryness. The remaining residue was purified by column chromatography on silica gel (eluted with DCM/MeOH) to afford compound **148**. ¹H NMR (400 MHz, DMSO-*d*₆) δ 0.98 - 1.06 (m, 2H), 1.33 (s, 3H), 2.05 (s, 4H), 2.53 - 2.59 (m, 1H), 2.67 (s, 3H), 2.88 (s, 3H), 3.07 (s, 3H), 3.55 - 3.68 (m, 1H), 4.08 (s, 2H), 4.37 - 4.47 (m, 1H), 5.59 (d, *J* = 17.2 Hz, 1H), 5.92 (d, *J* = 17.2 Hz, 1H), 7.45 (d, *J* = 7.9 Hz, 1H), 7.63 (d, *J* = 7.9 Hz, 1H), 7.87 (t, *J* = 6.5 Hz, 2H), 8.47 (s, 1H), 9.10 (s, 2H), 10.26 (s, 1H).

Scheme 60: Synthesis of Methyl ((*S*)-1-(((1*R*,3*S*,5*R*)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-3-((6-bromo-3-(methoxymethyl)pyridin-2-yl)carbamoyl)-2-azabicyclo[3.1.0]hexan-5-yl)methyl)amino)-3-methyl-1-oxobutan-2-yl)carbamate (153**)**





[0630] Step 1: (1*R*,3*S*,5*R*)-*tert*-Butyl 3-((6-bromo-3-(methoxymethyl)pyridin-2-yl)carbamoyl)-5-((1,3-dioxoisindolin-2-yl)methyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (153-S2): To a mixture of **153-S1** (290 mg, 0.75 mmol) and 6-bromo-3-(methoxymethyl)pyridin-2-amine (162 mg, 0.75 mmol) in dry DCM (3 mL) was added pyridine (0.3 mL, 3.75 mmol) followed by POCl₃ (114.7 mg, 0.75 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 30 minutes. The mixture was poured into ice water and extracted with DCM twice. The organic layers were washed with brine, dried over Na₂SO₄, and concentrated under reduced pressure. The remaining residue was purified by silica gel chromatography (PE/EtOAc = 6:1 to 2:1) to afford **153-S2** (180 mg, 41.0% yield) as a white solid. LC/MS (ESI) *m/z*: 585 (M+H)⁺.


[0631] Step 2: (1*R*,3*S*,5*R*)-*tert*-Butyl 5-(aminomethyl)-3-((6-bromo-3-(methoxymethyl)pyridin-2-yl)carbamoyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (153-S3): To a solution of **153-S2** (180 mg, 0.31 mmol) in EtOH (3 mL) was added hydrazine hydrate (72.5 mg, 1.24 mmol). The reaction mixture was stirred at 75 °C for 2 hours and then cooled to room temperature. The mixture was filtered and the filtrate was concentrated under reduced pressure. The remaining residue was purified by column chromatography on silica gel (eluted with DCM/MeOH = 5:1) to afford **153-S3** (130 mg, 92.2% yield) as a white solid. LC/MS (ESI) *m/z*: 455/ (M+H)⁺.

[0632] Step 3: (1*R*,3*S*,5*R*)-*tert*-Butyl 3-((6-bromo-3-(methoxymethyl)pyridin-2-yl)carbamoyl)-5-(((*S*)-2-((methoxycarbonyl)amino)-3-methylbutanamido)methyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (153-S4): To a mixture of **153-S3** (30 mg, 0.066 mmol), (*S*)-2-(methoxycarbonylamino)-3-methylbutanoic acid (13.9 mg, 0.079 mmol), and HATU (37.6 mg, 0.099 mmol) in DMF (2 mL) was added DIPEA (0.04 mL, 0.198 mmol). The reaction mixture was stirred at room temperature for 16 hours. The mixture was partitioned with EtOAc and water. The organic layer was washed with brine, dried over anhydrous Na₂SO₄, and concentrated under reduced pressure. The remaining residue was purified by column chromatography on silica gel (PE/EtOAc = 2:1 to 0:1) to afford **153-S4** (29 mg, 72.0% yield) as a light oil. LC/MS (ESI) *m/z*: 612 (M+H)⁺.

[0633] Step 4: Methyl ((*S*)-1-(((1*R*,3*S*,5*R*)-3-((6-bromo-3-(methoxymethyl)pyridin-2-yl)carbamoyl)-2-azabicyclo[3.1.0]hexan-5-yl)methyl)amino)-3-methyl-1-oxobutan-2-yl)carbamate (153-S5): To a solution of **153-S4** (29 mg, 0.05 mmol) in DCM (2 mL) was added TFA (1 mL). The reaction mixture was stirred at room temperature for 1.5 hours and then concentrated under reduced pressure to afford **153-S5** (25.6 mg, 100% yield) as a yellow solid, which was carried forward in the next synthetic step without further purification. LC/MS (ESI) *m/z*: 512 (M+H)⁺.

[0634] Step 5: Methyl ((*S*)-1-(((1*R*,3*S*,5*R*)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-3-((6-bromo-3-(methoxymethyl)pyridin-2-yl)carbamoyl)-2-azabicyclo[3.1.0]hexan-5-yl)methyl)amino)-3-methyl-1-oxobutan-2-yl)carbamate (153): To a mixture of **153-S5** (25.6 mg, 0.05 mmol), 2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetic acid (**153-S6**, 16.1 mg, 0.05 mmol), and HATU (29.6 mg, 0.08 mmol) in DMF (2 mL) was added DIPEA (0.03 mL, 0.14 mmol). The reaction mixture was stirred at room temperature for 16 hours. The mixture was partitioned with EtOAc and water. The organic layer was washed with brine, dried over anhydrous Na₂SO₄, and concentrated under reduced pressure. The crude product was purified by preparative HPLC to afford **153** (5.2 mg, 12.9% yield) as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.43 (s, 1H), 9.04 (s, 2H), 8.44 (s, 1H), 8.16 (s, 1H), 7.87 (d, *J* = 1.1 Hz, 2H), 7.77 (d, *J* = 8.1 Hz, 1H), 7.55 (d, *J* = 8.0 Hz, 1H), 7.12 (d, *J* = 9.1 Hz, 1H), 5.88 (d, *J* = 17.2 Hz, 1H), 5.61 (d, *J* = 17.1 Hz, 1H), 4.44-4.39 (m, 1H), 4.17 (s, 1H), 3.85-3.79 (m, 1H), 3.76-3.73 (m, 1H), 3.65-3.63 (m, 1H), 3.54 (s, 3H), 3.08 (s, 3H), 3.07-3.05 (m, 1H), 2.69 (s, 3H), 2.68-2.67 (m, 1H), 2.66 (s, 3H), 2.20-2.17 (m, 1H), 1.97-1.94 (m, 1H), 1.24 (s, 1H), 1.17 (t, *J* = 5.6 Hz, 1H), 1.08 (s, 1H), 0.94-0.81 (m, 6H). LC/MS (ESI) *m/z*: 804 (M+H)⁺.

Scheme 61: Synthesis of (1*R*,3*S*,5*S*)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-methylpyridin-2-yl)-5-((2-(dimethylamino)ethoxy)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (157)



[0635] Step 1: (1*R*,3*S*,5*S*)-2-*tert*-Butyl 3-ethyl 5-((2-(dimethylamino)-2-oxoethoxy)methyl)-2-azabicyclo[3.1.0]hexane-2,3-dicarboxylate (157-S2): To a solution of **157-S1** (200 mg, 0.70 mmol) in DMF (3 mL) was added NaH (56 mg, 60% dispersion in mineral oil, 1.40 mmol) at 0 °C, and after 5 minutes, 2-bromo-*N,N*-dimethylacetamide (232 mg, 1.40 mmol) was added. The reaction mixture was stirred at room temperature for 3 hours. The mixture was partitioned with ice water and EtOAc. The organic layer was washed with brine, dried over anhydrous Na₂SO₄, and concentrated under reduced pressure to afford **157-S2** (110 mg, 42.5% yield) as a yellow oil. LC/MS (ESI) *m/z*: 371 (M+H)⁺.

[0636] Step 2: (1*R*,3*S*,5*S*)-2-(*tert*-Butoxycarbonyl)-5-((2-(dimethylamino)-2-oxoethoxy)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxylic acid (157-S3): To a solution of **157-S2** (110 mg, 0.30 mmol) in THF (3 mL) and water (3 mL) was added NaOH (36 mg, 0.90 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 2 hours. The

mixture was concentrated to half volume and washed with EtOAc twice. The mixture was acidified with 2 N aqueous HCl to pH 4 and extracted with DCM three times. The combined organic layers were concentrated to dryness to afford **157-S3** (85 mg, 83.3% yield) as a colorless oil. LC/MS (ESI) m/z: 343 (M+H)⁺.

[0637] Step 3: (1R,3S,5S)-3-Benzyl 2-tert-butyl 5-((2-(dimethylamino)-2-oxoethoxy)methyl)-2-azabicyclo[3.1.0]hexane-2,3-dicarboxylate (157-S4): To a solution of **157-S3** (85 mg, 0.25 mmol) in MeCN (2 mL) were added K₂CO₃ (69 mg, 0.50 mmol) and BnBr (58 mg, 0.34 mmol). The reaction mixture was stirred at room temperature for 16 hours and concentrated under reduced pressure. The remaining residue was purified by column chromatography on silica gel (eluted with PE/EtOAc = 2:1) to afford **157-S4** (95 mg, 88.0% yield) as a colorless oil. LC/MS (ESI) m/z: 433 (M+H)⁺.

[0638] Step 4: (1R,3S,5S)-3-Benzyl 2-tert-butyl 5-((2-(dimethylamino)ethoxy)methyl)-2-azabicyclo[3.1.0]hexane-2,3-dicarboxylate (157-S5): To a solution of **157-S4** (95 mg, 0.22 mmol) in THF (5 mL) was added BH₃.THF (0.66 mL, 0.66 mmol, 1 M). The reaction mixture was stirred at reflux for 16 hours. The reaction mixture was quenched with MeOH and concentrated to dryness. The remaining residue was diluted with EtOH (8 mL) and H₂O (1 mL) and the mixture was stirred at reflux for 4 hours. The mixture was concentrated to dryness and the remaining residue was purified by column chromatography on silica gel (eluted with DCM/MeOH = 30:1) to afford **157-S5** (90 mg, 97.8% yield) as a white solid. LC/MS (ESI) m/z: 419 (M+H)⁺.


[0639] Step 5: (1R,3S,5S)-2-(tert-Butoxycarbonyl)-5-((2-(dimethylamino)ethoxy)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxylic acid (157-S6): To a solution of **157-S5** (90 mg, 0.21 mmol) in MeOH (5 mL) was added Pd/C (10 mg, 10% wt). The reaction mixture was stirred at room temperature for 1 hour. The mixture was filtered and concentrated to dryness to afford **157-S6** (65 mg, 94.3% yield) as a white solid. LC/MS (ESI) m/z: 329 (M+H)⁺.

[0640] Step 6: (1R,3S,5S)-tert-Butyl 3-(6-bromo-3-methylpyridin-2-ylcarbamoyl)-5-((2-(dimethylamino)ethoxy)methyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (157-S7): To a solution of **157-S6** (65 mg, 0.20 mmol) and 6-bromo-3-methylpyridin-2-amine (23 mg, 0.24 mmol) in DCM (5 mL) was added pyridine (24 mg, 1.22 mmol) at 0 °C followed by dropwise addition of POCl₃ (0.02 mL, 0.20 mmol). The reaction mixture was stirred at 0 °C for 30 minutes. The reaction mixture was quenched with ice-cooled water and extracted with DCM twice. The combined organic phases were washed with brine, dried over anhydrous Na₂SO₄, filtered, and concentrated to dryness. The remaining residue was purified by column chromatography on silica gel (eluted with DCM/MeOH = 50:1) to afford **157-S7** (80 mg, 67.2% yield) as a white solid. LC/MS (ESI) m/z: 497 (M+H)⁺.

[0641] Step 7: (1R,3S,5S)-N-(6-Bromo-3-methylpyridin-2-yl)-5-((2-(dimethylamino)ethoxy)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (157-S8): To a solution of **157-S7** (80 mg, 0.14 mmol) in DCM (2.5 mL) was added TFA (1 mL). The reaction mixture was stirred at room temperature for 1.5 hours and then concentrated under reduced pressure to afford **157-S8** (80 mg, 100.0% yield) as a yellow solid, which was carried forward in the next synthetic step without further purification. LC/MS (ESI) m/z: 397 (M+H)⁺.

[0642] Step 8: (1R,3S,5S)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((2-(dimethylamino)ethoxy)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (157): To a solution of **157-S8** (30 mg, 0.08 mmol), 2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetic acid (**157-S9**, 28 mg, 0.089 mmol) and HATU (46 mg, 0.12 mmol) in DMF (2 mL) was added DIPEA (0.04 mL, 0.24 mmol). The reaction mixture was stirred at room temperature for 16 hours. The mixture was partitioned with EtOAc and water. The organic layer was washed with brine, dried over anhydrous Na₂SO₄, and concentrated under reduced pressure. The remaining residue was purified by preparative HPLC to afford **157** (2.9 mg, 5.3% yield) as a white solid. ¹H NMR (400 MHz, CD₃OD) δ 9.04 (s, 2H), 8.59 (s, 1H), 7.85-7.77 (m, 2H), 7.61 (d, J = 7.5 Hz, 1H), 7.44 (d, J = 7.9 Hz, 1H), 5.82 (m, 1H), 5.71 (m, 1H), 5.36 (m, 1H), 4.72 (m, 1H), 3.98-3.89 (m, 2H), 3.87-3.76 (m, 2H), 3.41 (m, 2H), 2.94 (s, 6H), 2.78 (s, 3H), 2.67 (m, 1H), 2.59 (m, 1H), 2.14 (s, 3H), 1.20 (m, 1H), 0.91 (m, 1H). LC/MS (ESI) m/z: 689 (M+H)⁺.

Scheme 62: Synthesis of (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-methylpyridin-2-yl)-5-((2,2-difluorocyclopentanecarboxamido)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (158)




[0643] Step 1: (1*R*,3*S*,5*R*)-*tert*-Butyl 3-(6-bromo-3-methylpyridin-2-ylcarbamoyl)-5-((2,2-difluorocyclopentanecarboxamido)methyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (158-S2): To a solution of **158-S1** (50 mg, 0.12 mmol) and 2,2-difluorocyclopentanecarboxylic acid (18 mg, 0.12 mmol) in DCM (3 mL) was added DCC (36 mg, 0.18 mmol) at 0 °C followed by DMAP (2 mg, 0.01 mmol). The reaction mixture was stirred at room temperature for 1 hour. The mixture was concentrated under vacuum and the remaining residue was purified by silica gel chromatography (DCM/MeOH = 80:1) to afford **158-S2** (60 mg, 89.8% yield) as a white solid. LC/MS (ESI) *m/z*: 557 (M+H)⁺.

[0644] Step 2: (1*R*,3*S*,5*R*)-*N*-(6-Bromo-3-methylpyridin-2-yl)-5-((2,2-difluorocyclopentanecarboxamido)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (158-S3): To a solution of **158-S2** (60 mg, 0.11 mmol) in dioxane (1.5 mL) was added HCl/dioxane (2 M, 0.4 mL). The reaction mixture was stirred at room temperature for 1 hour. The reaction mixture was concentrated to afford **158-S3** (60 mg, 100% yield) as a white solid, which was carried forward in the next synthetic step without purification. LC/MS (ESI) *m/z*: 457 (M+H)⁺.


[0645] Step 3: (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-methylpyridin-2-yl)-5-((2,2-difluorocyclopentanecarboxamido)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (158): To a solution of **158-S3** (30 mg, 0.08 mmol) and 2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetic acid (27 mg, 0.08 mmol) in DCM (3 mL) was added DCC (25 mg, 0.12 mmol) at 0 °C followed by DMAP (2 mg, 0.01 mmol). The reaction mixture was stirred at room temperature for 1 hour. The mixture was concentrated to dryness and the remaining residue was purified by preparative HPLC to afford **158** (10.1 mg, 16.6% yield) as a white solid. ¹H NMR (400 MHz, CD₃OD) δ 8.99 (s, 2H), 8.40 (s, 1H), 7.61-7.48 (m, 2H), 7.39 (d, *J* = 8.1 Hz, 1H), 5.96 (m, 1H), 5.80 (m, 1H), 4.65 (m, 1H), 3.58 (m, 3H), 3.13-3.00 (m, 1H), 2.76 (s, 6H), 2.69 (s, 3H), 2.62-2.41 (m, 2H), 2.21-2.06 (m, 6H), 1.99-1.86 (m, 2H), 1.73 (m, 1H), 1.34 (m, 1H), 1.10 (m, 1H). LC/MS (ESI) *m/z*: 763 (M+H)⁺.

Scheme 63: Synthesis of (1*R*,3*S*,5*S*)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-methylpyridin-2-yl)-5-(fluoromethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (163)



[0646] A solution of **163-S1** (40 mg, 0.056 mmol) in TBAF/THF (3 mL, 1 M) was stirred at 60 °C for 1 hour. The mixture was partitioned with EtOAc and water. The organic layer was washed with brine, dried over anhydrous Na₂SO₄, and concentrated under reduced pressure. The remaining residue product was purified by preparative HPLC to afford **163** (5 mg, 13.8% yield) as a white solid. ¹H NMR (400 MHz, CD₃OD) δ 8.98 (s, 2H), 8.40 (s, 1H), 7.52-7.55 (m, 2H), 7.37 (d, *J* = 8.0 Hz, 1H), 5.94-5.99 (m, 1H), 5.78-5.83 (m, 1H), 4.64-4.68 (m, 1H), 4.59 (s, 1H), 4.47 (s, 1H), 3.81-3.83 (m, 1H), 2.74 (s, 6H), 2.69 (s, 4H), 2.56-2.59 (m, 1H), 2.12 (s, 3H), 1.38-1.42 (m, 1H), 1.18-1.20 (m, 1H). LC/MS (ESI) *m/z*: 634 (M+H)⁺.

Scheme 64: Synthesis of (1*R*,3*S*,5*R*)-5-(Acetamidomethyl)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-(methoxymethyl)pyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (165)




[0647] Step 1: (1*R*,3*S*,5*R*)-*tert*-Butyl 5-(acetamidomethyl)-3-((6-bromo-3-(methoxymethyl)pyridin-2-yl)carbamoyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (165-S2): To a mixture of 165-S1 (40 mg, 0.088 mmol) in dry DCM (3 mL) was added DIPEA (0.03 mL, 0.176 mmol) followed by a solution of acetyl chloride (8.3 mg, 0.106 mmol) in DCM (0.5 mL) at 0 °C. The reaction mixture was stirred at room temperature for 1 hour. The mixture was then diluted with water (20 mL) and extracted with DCM (4 mL × 2). The combined organic phases were washed with brine, dried over anhydrous Na₂SO₄, filtered, and concentrated. The crude was purified by column chromatography on silica gel (eluted with DCM/MeOH = 240:1) to afford 165-S2 (40 mg, 91.7% yield) as a white solid. LC/MS (ESI) *m/z*: 497 (M+H)⁺.

[0648] Step 2: (1*R*,3*S*,5*R*)-5-(Acetamidomethyl)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-(methoxymethyl)pyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (165-S3): To a solution of 165-S2 (40 mg, 0.08 mmol) in DCM (2 mL) was added TFA (1 mL). The reaction mixture was stirred at room temperature for 1.5 hours and then concentrated under reduced pressure to afford 165-S3 (35.6 mg, 100% yield) as a yellow solid, which was carried forward in the next synthetic step without further purification. LC/MS (ESI) *m/z*: 397 (M+H)⁺.

[0649] Step 3: (1*R*,3*S*,5*R*)-5-(Acetamidomethyl)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-(methoxymethyl)pyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (165): To a mixture of 165-S3 (35.6 mg, 0.09 mmol), 2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetic acid (26.9 mg, 0.09 mmol), and HATU (49.6 mg, 0.13 mmol) in DMF (2 mL) was added DIPEA (0.04 mL, 0.26 mmol). The reaction mixture was stirred at room temperature for 16 hours. The mixture was partitioned with EtOAc and water. The organic layer was washed with brine, dried over anhydrous Na₂SO₄, and concentrated under reduced pressure. The crude product was purified by preparative HPLC to afford 165 (15.5 mg, 25.0% yield) as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.39 (s, 1H), 9.04 (s, 2H), 8.44 (s, 1H), 8.03 (t, *J* = 5.9 Hz, 1H), 7.87 (d, *J* = 1.6 Hz, 2H), 7.77 (d, *J* = 8.1 Hz, 1H), 7.55 (d, *J* = 8.0 Hz, 1H), 5.88 (d, *J* = 17.3 Hz, 1H), 5.61 (d, *J* = 17.2 Hz, 1H), 4.44-4.41 (m, 1H), 4.21-4.12 (m, 2H), 3.71-3.69 (m, 1H), 3.34-3.32 (m, 1H), 3.25-3.23 (m, 1H), 3.10 (s, 3H), 2.69 (s, 3H), 2.65 (s, 3H), 2.47-2.43 (m, 1H), 2.24-2.21 (m, 1H), 1.86 (s, 3H), 1.16-1.14 (m, 1H), 1.09-1.07 (m, 1H). LC/MS (ESI) *m/z*: 689 (M+H)⁺.

Scheme 65: Synthesis of (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-(methoxymethyl)pyridin-2-yl)-5-((dimethylamino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (166)




[0650] Step 1: (1*R*,3*S*,5*R*)-*tert*-Butyl 3-((6-bromo-3-(methoxymethyl)pyridin-2-yl)carbamoyl)-5-((dimethylamino)methyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (166-S2): To a solution of 166-S1 (67 mg, 0.147 mmol) in MeOH (3 mL) were added aqueous HCHO solution (13.3 mg, 0.443 mmol) and NaBH₃CN (18.5 mg, 0.294 mmol) at 0 °C. The reaction mixture was stirred at room temperature overnight. The mixture was then diluted with water (20 mL) and extracted with DCM (5 mL × 2). The combined organic phases were washed with brine, dried over anhydrous Na₂SO₄, filtered, and concentrated. The remaining residue was purified by column chromatography on silica gel (eluted with DCM/MeOH = 20:1) to afford 166-S2 (60 mg, 84.6% yield) as a white solid. LC/MS (ESI) *m/z*: 483 (M+H)⁺.

[0651] Step 2: (1*R*,3*S*,5*R*)-*N*-(6-Bromo-3-(methoxymethyl)pyridin-2-yl)-5-((dimethylamino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (166-S3): To a solution of 166-S2 (38.5 mg, 0.08 mmol) in DCM (2 mL) was added TFA (1 mL). The reaction mixture was stirred at room temperature for 1.5 hours and then concentrated under reduced pressure to afford 166-S3 (38 mg, 100% yield) as a yellow solid, which was carried forward in the next synthetic step without further purification. LC/MS (ESI) *m/z*: 383 (M+H)⁺.

[0652] Step 3: (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-(methoxymethyl)pyridin-2-yl)-5-((dimethylamino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (166):

To a mixture of 166-S3 (30.5 mg, 0.08 mmol), 2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetic acid (25.3 mg, 0.08 mmol), and HATU (44.3 mg, 0.12 mmol) in DMF (2 mL) was added DIPEA (0.04 mL, 0.24 mmol). The reaction mixture was stirred at room temperature for 2 hours. The mixture was partitioned with EtOAc and water. The organic layer was washed with brine, dried over anhydrous Na₂SO₄, and concentrated under reduced pressure. The crude product was purified by preparative HPLC to afford 166 (6.5 mg, 12.1% yield) as a white solid. ¹H NMR (400 MHz, CD₃OD) δ 8.99 (s, 2H), 8.53 (s, 1H), 7.78 (s, 2H), 7.75 (d, *J* = 8.1 Hz, 1H), 7.48 (d, *J* = 8.0 Hz, 1H), 5.82 (d, *J* = 17.2 Hz, 1H), 5.66 (d, *J* = 17.1 Hz, 1H), 4.67 (d, *J* = 4.0 Hz, 1H), 4.30-4.22 (m, 2H), 3.87 (d, *J* = 2.9 Hz, 1H), 3.46 (d, *J* = 13.2 Hz, 1H), 3.14 (s, 3H), 3.03 (d, *J* = 13.3 Hz, 1H), 2.83 (s, 6H), 2.76 (s, 3H), 2.70 (s, 3H), 2.67 (s, 1H), 2.59-2.55 (m, 1H), 1.46-1.43 (m, 1H), 1.37-1.35 (m, 1H). LC/MS (ESI) *m/z*: 675 (M+H)⁺.

Scheme 66: Synthesis of (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-7-((dimethylamino)methyl)-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (167)



[0653] Step 1: *tert*-Butyl 2-(3-acetyl-7-(hydroxymethyl)-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetate (167-S2**):** To a solution of **167-S1** (1.19 g, 3.1 mmol) in dioxane/ H_2O (20 mL) was added $\text{Pd(PPh}_3)_4$ (358 mg, 0.31 mmol), K_2CO_3 (1.28 g, 9.3 mmol), and 2-methylpyrimidin-5-ylboronic acid (470 mg, 3.4 mmol). The reaction mixture was purged with nitrogen and stirred at 90 °C for 16 hours under an atmosphere of nitrogen. The mixture was partitioned with EtOAc and water. The organic layer was washed with brine, dried over anhydrous Na_2SO_4 , and concentrated under reduced pressure. The remaining residue was purified by silica gel chromatography (DCM/EtOAc = 5:1) to afford **167-S2** (400 mg, 32.5% yield) as a white solid. LC/MS (ESI) m/z : 397 ($\text{M}+\text{H}$)⁺.

[0654] Step 2: *tert*-Butyl 2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-7-((methylsulfonyloxy)methyl)-1*H*-indazol-1-yl)acetate (167-S3**):** To a solution of **167-S2** (200 mg, 0.51 mmol) in dry DCM (8 mL) was added Et_3N (128 mg, 1.26 mmol) followed by dropwise addition of MsCl (88 mg, 0.77 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 1 hour under an atmosphere of nitrogen. The mixture was diluted with DCM, washed with saturated aqueous NaHCO_3 solution and brine, dried over anhydrous Na_2SO_4 , and concentrated under reduced pressure to afford **167-S3** (220 mg, 90.8% yield) as a white solid, which was used in the next synthetic step without further purification. LC/MS (ESI) m/z : 475 ($\text{M}+\text{H}$)⁺.


[0655] Step 3: *tert*-Butyl 2-(3-acetyl-7-((dimethylamino)methyl)-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetate (167-S4**):** To a solution of **167-S3** (110 mg, 0.3 mmol) in dry DCM (8 mL) were added Et_3N (90 mg, 0.9 mmol)

and dimethylamine hydrochloride (60 mg, 0.54 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 16 hours under an atmosphere of nitrogen. The mixture was partitioned with DCM and NaHCO₃. The organic layer was washed with brine, dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The remaining residue was purified by column chromatography on silica gel (eluted with PE/EtOAc = 5:1) to afford **167-S4** (62 mg, 48.7% yield) as a white solid. LC/MS (ESI) m/z: 424 (M+H)⁺.

[0656] Step 4: 2-(3-Acetyl-7-(methoxycarbonyl)-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetic acid (167-S5): To a solution of **167-S4** (62 mg, 0.15 mmol) in MeOH/THF/H₂O (2:1:1, 4 mL) was added NaOH (18 mg, 0.45 mmol). The reaction mixture was stirred at room temperature for 1 hour. The mixture was diluted with water and washed with diethyl ether twice. The aqueous layer was adjusted to pH 5 with 10% aqueous HCl solution and extracted with DCM twice. The combined organic layers were dried over Na₂SO₄ and concentrated to afford **167-S5** (50 mg, 90.6% yield) as a white solid, which was carried forward in the next synthetic step without further purification. LC/MS (ESI) m/z: 368 (M+H)⁺.

[0657] Step 5: (1R,3S,5R)-2-(2-(3-Acetyl-7-((dimethylamino)methyl)-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (167): To a solution of **167-S5** (30 mg, 0.08 mmol) and (1R,3S,5R)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide hydrochloride (28 mg, 0.08 mmol) in DMF (3 mL) were added DIPEA (42 mg, 0.32 mmol) and HATU (61 mg, 0.16 mmol). The reaction mixture was stirred at room temperature for 16 hours. The mixture was diluted with EtOAc, washed with 10% aqueous LiCl solution and brine successively, dried over anhydrous Na₂SO₄, and concentrated under reduced pressure. The remaining residue was purified by preparative HPLC (eluted with MeCN/water) to afford **167** (10 mg, 18.9% yield) as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.34 (s, 1H), 9.05 (s, 2H), 8.46 (d, *J* = 1.6 Hz, 1H), 7.72 (s, 1H), 7.62 (d, *J* = 8.0 Hz, 1H), 7.43 (d, *J* = 7.9 Hz, 1H), 6.49 (d, *J* = 17.3 Hz, 1H), 5.82 (d, *J* = 17.1 Hz, 1H), 4.43 (dd, *J* = 9.0, 5.5 Hz, 1H), 3.79 (d, *J* = 12.8 Hz, 1H), 3.46-3.54 (m, 2H), 2.69 (s, 3H), 2.65 (s, 3H), 2.54-2.58 (m, 1H), 2.23 (s, 6H), 2.04 (s, 3H), 1.97-2.02 (m, 1H), 1.32 (s, 3H), 0.96 - 1.04 (m, 2H). LC/MS (ESI) m/z: 661 (M+H)⁺.

Scheme 67: Synthesis of (1R,3S,5R)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((2,2,2-trifluoroacetamido)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (168)




[0658] Step 1: (1R,3S,5R)-tert-Butyl 3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-5-((2,2,2-trifluoroacetamido)methyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (168-S2): To a mixture of **168-S1** (40 mg, 0.094 mmol), Et₃N (23 mg, 0.24 mmol), and DMAP (1 mg, cat. amount) in dry DCM (2 mL) was added 2,2,2-trifluoroacetic anhydride (40 mg, 0.19 mmol) at 0 °C under an atmosphere of nitrogen. The reaction mixture was stirred at 0 °C for 2 hours. The mixture was

diluted with DCM, washed with brine, dried, and concentrated to afford the crude product, which was purified by chromatography on silica gel (PE/EtOAc=10:1 to 5:1 to 4:1) to afford **168-S2** (35 mg, 71.5% yield) as a light oil. LC/MS (ESI) m/z : 521 (M+H)⁺.

[0659] Step 2: 3-(6-Bromo-3-methyl-pyridin-2-ylcarbamoyl)-5-[(2,2,2-trifluoro-acetyl-amino)-methyl]-2-aza-bicyclo[3.1.0]hexane-2-carboxylic acid tert-butyl ester (168-S3): To a solution of **168-S2** (35 mg, 0.067 mmol) in DCM (2 mL) was added TFA (1 mL) at 0 °C. The reaction mixture was stirred at room temperature for 1 hour. The mixture was concentrated under reduced pressure to afford **168-S3** (28 mg, 99.5% yield) as a light oil, which was carried forward in the next synthetic step without further purification. LC/MS (ESI) m/z : 421 (M+H)⁺.

[0660] Step 3: 2-{2-[3-Acetyl-7-methyl-5-(2-methyl-pyrimidin-5-yl)-indazol-1-yl]-acetyl}-5-[(2,2,2-trifluoro-acetyl-amino)-methyl]-2-aza-bicyclo[3.1.0]hexane-3-carboxylic acid (6-bromo-3-methyl-pyridin-2-yl)-amide (168): To a mixture of **168-S3** (28 mg, 0.067 mmol), **168-S4** (22 mg, 0.067 mmol), and HATU (38 mg, 0.10 mmol) in DMF (3 mL) was added DIPEA (26 mg, 0.20 mmol). The reaction mixture was stirred at room temperature for 2 hours. The mixture was diluted with EtOAc, washed with 10% aqueous LiCl solution and brine, dried, and concentrated to afford the crude product, which was purified with preparative HPLC to afford **168** (5.5 mg, 11.3% yield) as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.34 (s, 1H), 9.68 (s, 1H), 9.03 (s, 2H), 8.32 (s, 1H), 7.63 (d, *J*=8.0 Hz, 2H), 7.44 (d, *J*=8.0 Hz, 1H), 6.00 (d, *J*=20.0 Hz, 1H), 5.71 (d, *J*=20.0 Hz, 1H), 4.47 (m, 1H), 3.79 (m, 1H), 3.51 (m, 1H), 2.68 (s, 6H), 2.64 (d, *J*=8.0 Hz, 3H), 2.54 (d, *J*=8.0 Hz, 1H), 2.24 (m, 1H), 2.07 (d, *J*=12.0 Hz, 3H), 1.27-1.04 (m, 3H). LC/MS (ESI) m/z : 727 (M+H)⁺.


Scheme 68: Synthesis of 2-{2-[3-Acetyl-7-methoxymethyl-5-(2-methyl-pyrimidin-5-yl)-indazol-1-yl]-acetyl}-5-methyl-2-aza-bicyclo[3.1.0]hexane-3-carboxylic acid (6-bromo-3-methoxymethyl-pyridin-2-yl)-amide (169)



5

10

15



20

25

30

35

40

45

50

55

[0661] Step 1: 2-Bromo-5-bromomethyl-pyridine (169-S2): To a solution of **169-S1** (5.0 g, 29.1 mmol) in CCl_4 (40 mL) was added NBS (5.22 g, 29.1 mmol) and BPO (350 mg, 1.4 mmol). The reaction mixture was stirred at 80 °C under an atmosphere of nitrogen for 2 hours. The mixture was diluted with DCM, washed with water and brine, dried, and concentrated to dryness. The remaining residue was purified by column chromatography on silica gel (eluted with PE/EtOAc = 120:1) to afford **169-S2** (3.81 g, 52.6% yield) as a yellow oil. LC/MS (ESI) m/z : 250 ($\text{M}+\text{H}$)⁺.

[0662] Step 2: 2-Bromo-5-methoxymethyl-pyridine (169-S3): To a solution of **169-S2** (3.81 g, 15.3 mmol) in MeOH (38 mL) was added MeONa (4.1 mL, 30% wt in MeOH) at 0 °C. The reaction mixture was stirred at room temperature for 3 hours and concentrated to dryness. The remaining material was diluted with EtOAc, washed with water and brine, dried over Na_2SO_4 , and concentrated to dryness. The remaining residue was purified by column chromatography on silica gel (eluted with PE/EtOAc = 100:1) to afford **169-S3** (2.7 g, 87.8% yield) as a yellow oil. LC/MS (ESI) m/z : 202 ($\text{M}+\text{H}$)⁺.

[0663] Step 3: 2-Bromo-5-methoxymethyl-pyridine 1-oxide (169-S4): To a solution of **169-S3** (2.7 g, 13.4 mmol) in DCM (23 mL) was added *m*-CPBA (3.47 g, 20.1 mmol). The reaction mixture was stirred at room temperature overnight. The mixture was filtered and the filtrate was diluted with DCM, washed with 1 N aqueous NaOH solution and brine, dried over Na_2SO_4 , and concentrated to dryness. The remaining residue was purified by column chromatography on silica gel (eluted with DCM/MeOH = 40:1) to afford **169-S4** (2.5 g, 86.2% yield) as a yellow oil. LC/MS (ESI) m/z : 218 ($\text{M}+\text{H}$)⁺.

[0664] Step 4: (6-Bromo-3-methoxymethyl-pyridin-2-yl)-tert-butyl-amine (169-S5): To a solution of **169-S4** (1.0 g, 4.6 mmol) in DCM/toluene (20 mL, $v/v = 5/2$) was added *tert*-butylamine (2.42 g, 33.2 mmol) followed by dropwise addition of a solution of *p*-toluenesulfonic anhydride (4.96 g, 15.2 mmol) in DCM/toluene (240 mL, $v/v = 5/2$) for 4 h at -15 °C. The reaction mixture was stirred at room temperature overnight, washed with aqueous NaHCO_3 solution and brine, dried, and concentrated to dryness. The remaining residue was purified by column chromatography on silica gel (eluted with PE/EtOAc = 400:1) to afford **169-S5** (425 mg, 34.0% yield) as a yellow oil. LC/MS (ESI) m/z : 273 ($\text{M}+\text{H}$)⁺.

[0665] Step 5: 6-Bromo-3-methoxymethyl-pyridin-2-ylamine (169-S6): To a solution of **169-S5** (214 mg, 0.78 mmol) in chloroform (3 mL) was added TFA (3 mL). The mixture was stirred at 90 °C for 20 minutes in a microwave reactor. The mixture was concentrated to dryness and diluted with DCM. The mixture was washed with aqueous NaHCO_3 solution and brine, dried, and concentrated to dryness. The remaining residue was purified by column chromatography on silica gel (eluted with PE/EtOAc = 6:1) to afford **169-S6** (65 mg, 38.4% yield) as a white solid. LC/MS (ESI) m/z : 217 ($\text{M}+\text{H}$)⁺.


[0666] Step 6: 3-(6-Bromo-3-methoxymethyl-pyridin-2-ylcarbonyl)-5-methyl-2-azabicyclo[3.1.0]hexane-2-carboxylic acid tert-butyl ester (169-S8): To a mixture of **169-S6** (40 mg, 0.18 mmol) and **169-S7** (45 mg, 0.186 mmol) in DCM (3 mL) was added pyridine (0.08 mL, 0.93 mmol) and POCl_3 (0.02 mL, 0.186 mmol) under an atmosphere of nitrogen at 0 °C. The mixture was stirred at room temperature for 30 minutes. The mixture was diluted with DCM, washed with aqueous NaHCO_3 solution and brine, dried, and concentrated to dryness. The remaining residue was purified by column chromatography on silica gel (eluted with PE/EtOAc = 3:1) to afford **169-S8** (38 mg, 46.9% yield) as a white solid. LC/MS (ESI) m/z : 440 ($\text{M}+\text{H}$)⁺.

[0667] Step 7: 5-Methyl-2-aza-bicyclo[3.1.0]hexane-3-carboxylic acid (6-bromo-3-methoxymethyl-pyridin-2-yl)-amide (169-S9): To a solution of **169-S8** (38 mg, 0.086 mmol) in DCM (2 mL) was added TFA (1 mL) at 0 °C. The reaction mixture was stirred at room temperature for 1 hour. The mixture was concentrated under reduced pressure to afford **169-S9** (29 mg, 99.5% yield) as a light oil, which was carried forward in the next synthetic step without further purification. LC/MS (ESI) m/z : 340 ($\text{M}+\text{H}$)⁺.

[0668] Step 8: 2-{2-[3-Acetyl-7-methoxymethyl-5-(2-methyl-pyrimidin-5-yl)-indazol-1-yl]-acetyl}-5-methyl-2-aza-bicyclo[3.1.0]hexane-3-carboxylic acid (6-bromo-3-methoxymethyl-pyridin-2-yl)-amide (169): To a mixture of **169-S9** (29 mg, 0.086 mmol), **169-S10** (40 mg, 0.11 mmol), and HATU (49 mg, 0.13 mmol) in DMF (3 mL) was added DIPEA (33 mg, 0.26 mmol). The reaction mixture was stirred at room temperature overnight. The mixture was diluted with EtOAc, washed with 10% aqueous LiCl solution and brine, dried, and concentrated to afford the crude product, which was

purified with preparative HPLC to afford **169** (5.3 mg, 9.1% yield) as a white solid. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 10.48 (s, 1H), 9.05 (s, 2H), 8.49 (d, $J = 2.0$ Hz, 1H), 7.86 (d, $J = 1.5$ Hz, 1H), 7.76 (d, $J = 8.0$ Hz, 1H), 7.54 (d, $J = 12.0$ Hz, 1H), 6.00 (d, $J = 16.0$ Hz, 1H), 5.73 (d, $J = 20.0$ Hz, 1H), 4.84 (d, $J = 12.0$ Hz, 1H), 4.66 (d, $J = 12.0$ Hz, 1H), 4.39 (m, 1H), 4.15 (d, $J = 4.0$ Hz, 2H), 3.56 (m, 1H), 3.34-3.33 (m, 3H), 3.08 (s, 3H), 2.69 (s, 3H), 2.66 (s, 3H), 2.58-2.53 (m, 1H), 2.04 (m, 1H), 1.34 (s, 3H), 1.04-0.99 (m, 2H). LC/MS (ESI) m/z : 676 ($\text{M}+\text{H}$) $^+$.

Scheme 69. (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-5-(2-Methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-vinylpyridin-2-yl)-5-((but-3-en-1-ylsulfonamido)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (171**)**



[0669] Step 1: *tert*-Butyl (1*R*,3*S*,5*R*)-5-(azidomethyl)-3-((6-bromo-3-vinylpyridin-2-yl)carbamoyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (171-S3**):** To a mixture of **171-S1** (135 mg, 0.479 mmol) and **171-S2** (95.3 mg, 0.479 mmol) in DCM (5 mL), pyridine (0.193 mL, 2.4 mmol) was added followed by POCl_3 (0.045 mL, 0.48 mmol) at 0°C under argon. The reaction mixture was stirred at room temperature for 2 hours. NaHCO_3 aqueous solution was added and the mixture was extracted with DCM . After washing with brine, the organic layer was dried over anhydrous Na_2SO_4 . The solution was filtered and the solvent was removed under reduced pressure to afford *tert*-butyl (1*R*,3*S*,5*R*)-5-(azidomethyl)-3-((6-bromo-3-vinylpyridin-2-yl)carbamoyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate **171-S3** (0.23 g) as a foam. The material was carried forward without additional purification.

[0670] Step 2: *tert*-Butyl (1*R*,3*S*,5*R*)-5-(aminomethyl)-3-((6-bromo-3-vinylpyridin-2-yl)carbamoyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (171-S4**):** *tert*-Butyl (1*R*,3*S*,5*R*)-5-(azidomethyl)-3-((6-bromo-3-vinylpyridin-2-yl)carbamoyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (**171-S3**, 0.23 g) was treated with trimethylphosphane (1.0 M in THF , 0.958 mL, 0.958 mmol) in THF (10 mL) in the presence of water (0.017 mL, 0.958 mmol) at room temperature overnight. The mixture was extracted with EtOAc and the organic layer was washed with aqueous NaHCO_3 and brine, and dried over


anhydrous Na₂SO₄. The solvent was removed under reduced pressure to afford *tert*-butyl (1*R*,3*S*,5*R*)-5-(aminomethyl)-3-((6-bromo-3-vinylpyridin-2-yl)carbamoyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate **171-S4** (0.221 g) as pale yellow syrup. The material was carried forward in the next step without additional purification.

[0671] Step 3: *tert*-Butyl (1*R*,3*S*,5*R*)-3-((6-bromo-3-vinylpyridin-2-yl)carbamoyl)-5-((but-3-en-1-ylsulfonamido)methyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (171-S5): *tert*-Butyl (1*R*,3*S*,5*R*)-5-(aminomethyl)-3-((6-bromo-3-vinylpyridin-2-yl)carbamoyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (**171-S4**, 0.221 g) was treated with but-3-ene-1-sulfonyl chloride (46.5 mg, 0.30 mmol) in DCM (5 mL) in the presence of DIEA (0.066 mL, 0.378 mmol). The reaction was stirred at room temperature for 30 minutes before NaHCO₃ aqueous was added and organic layer was washed with brine and dried over anhydrous Na₂SO₄. The solvent was removed under reduced pressure to afford *tert*-butyl (1*R*,3*S*,5*R*)-3-((6-bromo-3-vinylpyridin-2-yl)carbamoyl)-5-((but-3-en-1-ylsulfonamido)methyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate **171-S5** (0.158 g) as a pale yellow syrup. The material was carried forward in the next step without additional purification.

[0672] Step 4: (1*R*,3*S*,5*R*)-*N*-(6-Bromo-3-vinylpyridin-2-yl)-5-((but-3-en-1-ylsulfonamido)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide TFA salt (171-S6): *tert*-Butyl (1*R*,3*S*,5*R*)-3-((6-bromo-3-vinylpyridin-2-yl)carbamoyl)-5-((but-3-en-1-ylsulfonamido)methyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (**171-S5**, 19.8 mg) in DCM (1 mL) was treated with TFA (1 mL). The reaction was stirred at room temperature for 1 hour before the volatiles were removed under reduced pressure and the residue was co-evaporated with toluene (5 mL) twice to afford (1*R*,3*S*,5*R*)-*N*-(6-bromo-3-vinylpyridin-2-yl)-5-((but-3-en-1-ylsulfonamido)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide TFA salt **171-S6**. for the next step. The material was carried forward in the next step without additional purification.

[0673] Step 5: (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-vinylpyridin-2-yl)-5-((but-3-en-1-ylsulfonamido)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (171): To a mixture of (1*R*,3*S*,5*R*)-*N*-(6-bromo-3-vinylpyridin-2-yl)-5-((but-3-en-1-ylsulfonamido)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide TFA salt (**171-S6**, 0.0356 mmol) and 2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetic acid (**171-S7**, 11 mg) in DMF (1.0 mL), TBTU (23 mg) was added followed by DIEA (0.031 mL) with stirring. After the reaction was complete, NaHCO₃ aqueous solution (10 mL) was added to form a precipitate that was collected by filtration and purified by column chromatography on silica gel with MeOH in DCM (0-10%) as the eluent to afford (1*R*,3*S*,5*R*)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-vinylpyridin-2-yl)-5-((but-3-en-1-ylsulfonamido)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (**171**) (17 mg) as a pale yellow solid. ¹H NMR (400 MHz, Chloroform-*d*) δ 8.90 (s, 2H), 8.83 (s, 1H), 8.58 (t, *J* = 1.2 Hz, 1H), 7.69-7.58 (m, 3H), 7.30 (d, *J* = 8.2 Hz, 1H), 6.44 (dd, *J* = 11.0, 17.4 Hz, 1H), 5.81 (ddt, *J* = 6.5, 10.2, 16.8 Hz, 1H), 5.74 (s, 1H), 5.64 (d, *J* = 17.4 Hz, 1H), 5.51 (d, *J* = 3.1 Hz, 2H), 5.28 (d, *J* = 11.1 Hz, 1H), 5.18-5.06 (m, 2H), 4.94 (d, *J* = 8.3 Hz, 1H), 3.58 (dd, *J* = 4.6, 13.7 Hz, 1H), 3.52 (dd, *J* = 2.8, 5.7 Hz, 1H), 3.16-3.08 (m, 3H), 2.80 (s, 4H), 2.72 (s, 3H), 2.56 (q, *J* = 7.0 Hz, 2H), 2.27 (dd, *J* = 8.4, 13.9 Hz, 1H), 1.44 (t, *J* = 5.8 Hz, 1H), 1.12 (dd, *J* = 2.8, 5.9 Hz, 1H). LC (method A): *t*_R = 1.85 min. LC/MS (EI) *m/z*: [M + H]⁺ 747.

Scheme 70. Synthesis of (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-5-(2-Methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-((3,3-difluoroazetidin-1-yl)methyl)pyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (177)




[0674] Step 1: 6-Bromo-3-((3,3-difluoroazetidin-1-yl)methyl)pyridin-2-amine (177-S2): To a stirred solution 6-bromo-3-(chloromethyl)pyridin-2-amine (204 mg, 1equiv) and triethyl amine (0.4, 3 equiv) in acetonitrile (20 mL) was added 3,3-difluoroazetidine hydrochloride (230 mg, 2 equiv) at 0-5 °C under an atmosphere of argon. The reaction mixture was stirred at room temperature until completion. The reaction was diluted with DCM (25 mL) and basified with aqueous saturated NaHCO₃ solution (20 mL). The aqueous layer was extracted with DCM (2x 10 mL) and the combined organic layers were washed with brine (25 mL), dried over Na₂SO₄ and concentrated to dryness to afford **177-S2** (96 mg, 40 %).

[0675] Step 2: *tert*-Butyl (1*R*,3*S*,5*R*)-3-((6-bromo-3-((3,3-difluoroazetidin-1-yl)methyl)pyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexane-2-carboxylate (177-S3): POCl₃ (0.04 mL, 2 equiv) was added dropwise at 0-5 °C under an atmosphere of argon to a stirred solution of (1*R*,3*S*,5*R*)-2-(*tert*-butoxycarbonyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxylic acid (83 mg, 1equiv) and **177-S2** (96 mg, 1 equiv) in DCM (10 mL) and pyridine (0.1mL, 5 equiv). The reaction mixture was stirred at room temperature until completion. The reaction was diluted with DCM (15 mL) and basified with aqueous saturated NaHCO₃ solution (10 mL). The aqueous layer was extracted with DCM (1x 15 mL) and the combined organic layers were washed with brine (20 mL), dried over Na₂SO₄ and concentrated to dryness. The residue was purified by column chromatography on silica gel (eluted by 5% MeOH in DCM gradient) to afford **177-S3** (147 mg, 85 %).

[0676] Step 3: (1*R*,3*S*,5*R*)-*N*-(6-Bromo-3-((3,3-difluoroazetidin-1-yl)methyl)pyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (TFA salt) (177-S4): To a solution of **177-S3** (147 mg) in DCM (5 mL) was added TFA (5 mL). The resulting solution was stirred at room temperature for 2 hours. The reaction mixture was concentrated to dryness to afford **177-S4**.

[0677] Step 4: (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-((3,3-difluoroazetidin-1-yl)methyl)pyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (177): To a solution of **177-S4** (135mg, 1equiv), 2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetic acid (100mg, 1.05 equiv), and DIPEA (0.26, 5 equiv) in DMF (10 mL) was added HATU (146 mg, 1.2 equiv) at 0 °C under an atmosphere of argon. The reaction mixture was stirred at room temperature for 3 hours. The reaction was diluted with EtOAc (40mL) and water (20mL). The aqueous layer was extracted with EtOAc (25 mL) and the combined organic layers were washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated. The residue was purified by column chromatography on silica gel (eluted by DCM/MeOH = 10:1) to afford **177** (25 mg, 12 %). ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.30 (s, 1H), 8.96 (s, 2H), 8.37 (s, 1H), 7.80 (m, 2H), 7.67 (d, 1H, J=8.2 Hz), 7.42 (d, 1H, J=8.2 Hz), 5.87 (d, 1H, J= 17.5 Hz), 5.52 (d, 1H, J=17.5 Hz), 4.29-4.36 (m, 1H), 3.22-3.56 (m, 1H), 3.37-3.45 (m, 2H), 3.25-3.33 (m, 3H), 2.62 (s, 3H), 2.58 (s, 3H), 2.26 (s, 1H), 1.99-2.04 (m, 1H), 1.27 (s, 3H), 0.91-0.99 (m, 3H); ¹⁹F NMR (376 MHz, DMSO-*d*₆) δ -97.89 (2F).

Scheme 71. Synthesis of (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-5-fluoro-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (178)



[0678] Step 1: 2-Bromo-3-fluoro-5-methyl-(1-oxidanyl)-pyridine (178-S2): To a stirred solution of 2-bromo-3-fluoro-5-methylpyridine (**178-S1**, 10 g, 1 equiv) in CHCl_3 (200 mL) was added 3-chlorobenzoperoxoic acid (24 g, 2 equiv). The reaction mixture was heated to 50 °C. The reaction was cooled and neutralized with saturated aqueous NaHCO_3 (100 mL). The organic layer was washed with brine, dried over Na_2SO_4 and concentrated to dryness. The residue was purified by column chromatography silica gel (5% CH_3OH in DCM, gradient) to afford **178-S2** (9.4 g, 87%).

[0679] Step 2: 6-Bromo-*N*-(*tert*-butyl)-5-fluoro-3-methylpyridin-2-amine (178-S3): To a stirred solution of **178-S2** (3.2g, 1 equiv) and 2-methylpropan-2-amine (8.1 mL, 5 equiv) in DCM (100 mL) at 0-5 °C was slowly added trifluoroacetic anhydride (TFAA, 2.7 mL, 1.1 equiv) solution in DCM (20mL) dropwise using an additional funnel over 40 minutes under an atmosphere of argon at 0-5 °C. The reaction mixture was stirred at 0-5 °C for 1 hour and monitored by LC/MS. (If the reaction was not complete after 1 hour, TFAA ((2.5 mL, 1equiv) solution in DCM (20 mL, added over 15 to 20 minutes) and 2-methylpropan-2-amine (1.6 mL, 1 equiv, added once) were added). The reaction was diluted with DCM (60mL) and neutralized with aqueous saturated NaHCO_3 (80 mL). The organic layer was washed with brine (80 mL), dried over Na_2SO_4 and concentrated to dryness. The residue was purified by column chromatography on silica gel (eluted by hexanes/ EtOAc =3:1) to afford **178-S3**.

[0680] Step 3: 6-Bromo-5-fluoro-3-methylpyridin-2-amine (178-S4): TFA (20 mL) was added to solid **178-S3** and the reaction mixture was heated at 70 °C until completion. The reaction was concentrated to dryness and the residue was dissolved in DCM (35 mL), washed with aqueous saturated NaHCO_3 solution (15mLx2) and brine, dried over Na_2SO_4 , and concentrated to afford **178-S4** (838 mg, 26%).


[0681] Step 4: (1*R*,3*S*,5*R*)-*N*-(6-Bromo-5-fluoro-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide hydrochloride (178-S5): POCl₃ (0.1 mL, 2 equiv) was added dropwise to a solution of (1*R*,3*S*,5*R*)-2-(*tert*-butoxycarbonyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxylic acid (121mg, 1equiv) and **178-S4** (101mg, 1 equiv) in DCM (8 mL) and pyridine (0.2mL, 5 equiv) cooled at 0-5 °C under an atmosphere of argon.

The reaction mixture was stirred at room temperature until completion. The reaction was diluted with DCM (10 mL) and neutralized with aqueous saturated NaHCO₃ solution (10 mL). The aqueous layer was extracted with DCM (1x mL) and the combined organic layers were washed with brine (10 mL), dried over Na₂SO₄, and concentrated to dryness. The residue was purified by column chromatography on silica gel (eluted by 5% MeOH in DCM gradient) to afford **178-S5** (131mg, 62%)

[0682] Step 5: (1*R*,3*S*,5*R*)-*N*-(6-Bromo-5-fluoro-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide hydrochloride (178-S6): To a solution of **178-S5** (131mg) was added 4N HCl in dioxane (8 mL). The resulting solution was stirred at room temperature for 6 hours. The reaction mixture was concentrated to dryness to afford 178-S6.

[0683] Step 6: (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-5-fluoro-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (178): To a solution of **178-S6** (137 mg, 1 equiv), 2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetic acid (115mg, 1.2 equiv) and DIPEA (0.3mL, 5 equiv) in DMF (10 mL) was added HATU (141 mg, 1.2 equiv) at 0°C under an atmosphere of argon. The reaction mixture was stirred at room temperature for 3 hours before it was diluted with EtOAc (30 mL) and water (15 mL). The organic layer was washed with brine, dried over anhydrous Na₂SO₄ and concentrated to dryness. The residue was purified by column chromatography on silica gel (eluted by DCM/MeOH=10:1) to afford **178** (79mg, 41 %). ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.11 (s, 1H), 9.06 (s, 2H), 8.46 (s, 1H), 7.87 (s, 1H), 7.81-7.87 (m, 2H), 5.92 (d, 1H, *J*=17.4 Hz), 5.59 (d, 1H, *J*=17.4 Hz), 4.37 - 4.42 (m, 1H), 3.58 (d, 1H, *J*=5.4Hz), 2.70 (s, 3H), 2.67 (s, 3H), 2.54-2.59 (m, 1H), 2.08 (s, 3H), 2.02-2.07 (m, 1H), 1.33 (s, 3H), 0.99-1.06 (m, 2H). ¹⁹F NMR (376 MHz, DMSO-*d*₆) δ -118.95 (s, 1F).

**Scheme 72. Synthesis of (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-5-(2-methylpyrazolo[1,5-
a]pyrimidin-6-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-
azabicyclo[3.1.0]hexane-3-carboxamide (180)**




[0684] Step 1: tert-butyl 2-(3-Acetyl-5-(2-methylpyrazolo[1,5-a]pyrimidin-6-yl)-1*H*-indazol-1-yl)acetate (180-S3): To a solution of 6-bromo-2-methylpyrazolo[1,5-a]pyrimidine (**180-S2**, 1 equiv) in DMF/H₂O (9:1, 10 vol) was added compound 180-S1 (1 equiv), K₂CO₃ (2 equiv) and tetrakis(triphenylphosphine)palladium (0.1 equiv). The reaction mixture was stirred at 90 °C for 5 hours and concentrated under reduced pressure. The remaining residue was purified by column chromatography on silica gel (eluted with DCM/ MeOH) to afford compound **180-S3**.

[0685] Step 2: 2-(3-Acetyl-5-(2-methylpyrazolo[1,5-a]pyrimidin-6-yl)-1*H*-indazol-1-yl)acetic acid (180-S4): To a solution of compound 180-S3 (1 equiv) in DCM (10 vol) at 0 °C under an atmosphere of argon was added TFA (5 vol). The reaction mixture was stirred at room temperature for 3 hours and concentrated to dryness. The remaining material was used directly in the next synthetic step.

[0686] Step 3: (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-5-(2-methylpyrazolo[1,5-a]pyrimidin-6-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (180): To a solution of compound **180-S4** (1 equiv) in DMF (10 vol) at 0 °C under an atmosphere of argon was added (1*R*,3*S*,5*R*)-*N*-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (1 equiv), HATU (2.1 equiv), and DIPEA (5 equiv). The reaction mixture was stirred at room temperature for 3 hours and quenched with water (30 vol). The resulting mixture was extracted with DCM. The organic layer was washed with brine, dried over anhydrous Na₂SO₄, filtered, and concentrated to dryness. The remaining residue was purified by column chromatography on silica gel (eluted with DCM/MeOH) to afford compound **180**. ¹H NMR (400 MHz, DMSO-*d*₆) δ 0.98 - 1.09 (m, 2H), 1.33 (s, 3H), 2.06 (s, 4H), 2.47 (s, 3H), 2.52 - 2.59 (m, 1H), 2.67 (s, 3H), 3.56 - 3.63 (m, 1H), 4.42 (dd, *J* = 5.1, 9.3 Hz, 1H), 5.58 (d, *J* = 17.2 Hz, 1H), 5.92 (d, *J*

= 17.3 Hz, 1H), 6.58 (s, 1H), 7.45 (d, J = 7.9 Hz, 1H), 7.63 (d, J = 7.9 Hz, 1H), 7.84 (d, J = 8.8 Hz, 1H), 7.90 (d, J = 8.8 Hz, 1H), 8.48 (s, 1H), 8.86 (d, J = 2.2 Hz, 1H), 9.35 (d, J = 2.2 Hz, 1H), 10.26 (s, 1H).

Scheme 73. Synthesis of (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-(difluoromethyl)-4-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (187)



[0687] Step 1: 2-Bromo-5-(difluoromethyl)-4-methyl-1-oxidanylpyridine (187-S2): To a stirred solution of 2-bromo-5-(difluoromethyl)-4-methylpyridine (**187-S1**, 1g, 1equiv) in CHCl_3 (150 mL) was added 3-chlorobenzoperoxoic acid (2.1 g, 2 equiv). The reaction mixture was heated to 50 °C until completion. The reaction was cooled and neutralized with saturated aqueous NaHCO_3 solution (60 mL). The organic layer was washed with brine, dried over Na_2SO_4 and concentrated to dryness. The residue was purified by column chromatography on silica gel (eluted by 5% CH_3OH in DCM, gradient) to afford **187-S2** (851mg, 80%).

[0688] Step 2: 6-Bromo-N-(tert-butyl)-3-(difluoromethyl)-4-methylpyridin-2-amine (187-S3): To a stirred solution of **187-S2** (222mg, 1 equiv) and 2-methylpropan-2-amine (0.49 mL, 5 equiv) in DCM (100 mL) was added trifluoroacetic anhydride (0.3 mL, 2 equiv) solution in DCM (5 mL) at 0-5 °C dropwise under an atmosphere of argon. The reaction mixture was stirred at 0-5 °C for 2 hours before the reaction was neutralized with aqueous saturated NaHCO_3 solution (15 mL). The organic layer was washed with brine (15 mL), dried over Na_2SO_4 and concentrated. The crude was purified by column chromatography on silica gel (eluted by 30% EtOAc in hexanes) to afford **187-S3** (130 mg, 48%).

[0689] Step 3: 6-Bromo-3-(difluoromethyl)-4-methylpyridin-2-amine (187-S4): TFA (8 mL) was added to solid **187-S3** (130 mg) and the reaction mixture was heated at 70 °C until completion. The reaction mixture was concentrated to dryness and the residue was dissolved in DCM (15 mL) and neutralized with aqueous saturated NaHCO_3 solution (15 mL). The organic layer was washed with brine, dried over Na_2SO_4 and concentrated to dryness to afford **187-S4** (92 mg, 87 %).


[0690] Step 4: tert-Butyl (1*R*,3*S*,5*R*)-3-((6-bromo-3-(difluoromethyl)-4-methylpyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexane-2-carboxylate (187-S5): POCl_3 was added dropwise (0.05 mL, 2 equiv) at 0-5

°C under an atmosphere of argon to a stirred solution of (1*R*,3*S*,5*R*)-2-(*tert*-butoxycarbonyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxylic acid (94 mg, 1 equiv) and **187-S4** (92 mg, 1 equiv) in DCM (10 mL) and pyridine (0.1 mL, 5 equiv). The reaction mixture was stirred at room temperature until completion. The reaction was diluted with DCM (20 mL) and neutralized with aqueous saturated NaHCO₃ solution (15 mL). The aqueous layer was extracted with DCM (1x 10 mL) and the combined organic layers were washed with brine (10 mL), dried over Na₂SO₄, and concentrated to dryness. The residue was purified by column chromatography on silica gel (eluted by 5% MeOH in DCM gradient) to afford **187-S5** (109 mg, 61 %).

[0691] Step 5: (1*R*,3*S*,5*R*)-*N*-(6-Bromo-3-(difluoromethyl)-4-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (TFA salt) (187-S6**):** To a solution of **S5** (109 mg) in DCM (5 mL) was added TFA (5 mL). The resulting solution was stirred at room temperature for 1 hour. The reaction mixture was concentrated to dryness to afford **187-S6** (65 mg).

[0692] Step 6: (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-(difluoromethyl)-4-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (187**):** To a solution of **187-S6** (65 mg, 1 equiv), 2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetic acid (44 mg, 1.05 equiv), and DIPEA (0.12 mL, 5 equiv) in DMF (8 mL) was added HATU (64 mg, 1.2 equiv) at 0 °C under an atmosphere of argon. The reaction mixture was stirred at room temperature for 3 hours. The reaction mixture was diluted with EtOAc (40 mL) and water (20 mL). The aqueous layer was extracted with EtOAc (20 mL) and the combined organic layers were washed with brine (3x20 mL), dried over anhydrous Na₂SO₄, filtered and concentrated. The residue was purified by column chromatography on silica gel (eluted by DCM/MeOH=10:1) to afford **187** (67 mg, 27%). ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.70 (s, 1H), 9.04 (s, 2H), 8.46 (s, 1H), 7.87 (s, br, 2H), 7.64 (s, 1H), 6.66 (m, 1H), 5.93 (d, 1H, *J*=18.2 Hz), 5.61 (d, 1H, *J*=18.2 Hz), 4.28-4.34 (m, 1H), 3.62-3.66 (m, 1H), 2.69 (s, 3H), 2.66 (s, 3H), 2.46 (s, 3H), 2.53-2.58 (m, 1H), 1.99-2.06 (m, 1H), 1.33 (s, 3H), 0.93-1.05 (m, 2H); ¹⁹F NMR (376 MHz, DMSO-*d*₆) δ -112.35 (1F), -113.24 (1F).

Scheme 74. Synthesis of (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-vinylpyridin-2-yl)-5-((*N*-methylbut-3-en-1-yl)sulfonamido)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (188**)**



[0693] Step 1: *tert*-Butyl (1*R*,3*S*,5*R*)-3-((6-bromo-3-vinylpyridin-2-yl)carbamoyl)-5-((methylamino)methyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (188-S2**):** *tert*-Butyl (1*R*,3*S*,5*R*)-5-(aminomethyl)-3-((6-bromo-3-vinylpyridin-2-yl)carbamoyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (**188-S1**, 0.104 g, 0.238 mmol) was treated with methyl triflate (0.032 mL, 0.286 mmol) in 1,1,1,3,3,3-hexafluoro-2-propanol at room temperature. The reaction stirred at room temperature for 3 hours before EtOAc was added to dilute the reaction. The mixture was washed with NaHCO₃ and brine


and dried over anhydrous Na₂SO₄. The solvent was removed to afford *tert*-butyl (1*R*,3*S*,5*R*)-3-((6-bromo-3-vinylpyridin-2-yl)carbamoyl)-5-((methylamino)methyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate **188-S2**. The material was carried forward in the next step without additional purification.

[0694] Step 2: *tert*-Butyl (1*R*,3*S*,5*R*)-3-((6-bromo-3-vinylpyridin-2-yl)carbamoyl)-5-((*N*-methylbut-3-en-1-ylsulfonamido)methyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (188-S3): *tert*-Butyl (1*R*,3*S*,5*R*)-5-((methylamino)aminomethyl)-3-((6-bromo-3-vinylpyridin-2-yl)carbamoyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate **188-S2** was treated with but-3-ene-1-sulfonyl chloride (44mg, 0.286mmol) in DCM (5 mL) in the presence of DIEA (0.062 mL, 0.357 mmol). The reaction stirred at room temperature for 30 minutes before NaHCO₃ aqueous was added. The organic layer was washed with brine and dried over anhydrous Na₂SO₄. The solvent was removed under reduced pressure to afford a mixture containing *tert*-butyl (1*R*,3*S*,5*R*)-3-((6-bromo-3-vinylpyridin-2-yl)carbamoyl)-5-((*N*-methylbut-3-en-1-ylsulfonamido)methyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate **188-S3**. The material was carried forward in the next step without additional purification.

[0695] Step 3: (1*R*,3*S*,5*R*)-*N*-(6-Bromo-3-vinylpyridin-2-yl)-5-((*N*-methylbut-3-en-1-ylsulfonamido)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide TFA salt (188-S4): *tert*-Butyl (1*R*,3*S*,5*R*)-3-((6-bromo-3-vinylpyridin-2-yl)carbamoyl)-5-((*N*-methylbut-3-en-1-ylsulfonamido)methyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate **188-S3** in DCM (3 mL) was treated with TFA (3 mL) at room temperature for 1 hour. The volatiles were removed under reduced pressure and the residue was co-evaporated with toluene (5 mL) twice to afford a mixture (1*R*,3*S*,5*R*)-*N*-(6-bromo-3-vinylpyridin-2-yl)-5-((*N*-methylbut-3-en-1-ylsulfonamido)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide TFA salt **188-S4**. The material was carried forward in the next step without additional purification.

[0696] Step 4: (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-vinylpyridin-2-yl)-5-((*N*-methylbut-3-en-1-ylsulfonamido)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (188): To a mixture of (1*R*,3*S*,5*R*)-*N*-(6-bromo-3-vinylpyridin-2-yl)-5-((*N*-methylbut-3-en-1-ylsulfonamido)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide TFA salt **188-S4** and 2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetic acid (**188-S5**, 74 mg) in DMF (3.0 mL), TBTU (115 mg) was added followed by DIEA (0.414 mL) with stirring. After the reaction was complete, the mixture was purified by HPLC to afford (1*R*,3*S*,5*R*)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-vinylpyridin-2-yl)-5-((*N*-methylbut-3-en-1-ylsulfonamido)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (**188**, 25.5 mg) as a white powder. ¹H NMR (400 MHz, Chloroform-*d*) δ 8.90 (s, 2H), 8.74 (s, 1H), 8.58 (s, 1H), 7.71 - 7.55 (m, 3H), 7.30 (d, *J* = 8.1 Hz, 1H), 6.44 (dd, *J* = 11.0, 17.4 Hz, 1H), 5.91 - 5.70 (m, 1H), 5.65 (d, *J* = 17.4 Hz, 1H), 5.51 (s, 2H), 5.27 (d, *J* = 11.0 Hz, 1H), 5.19 - 5.02 (m, 2H), 4.93 (d, *J* = 8.4 Hz, 1H), 3.48 (dd, *J* = 6.8, 13.0 Hz, 3H), 3.01 (d, *J* = 18.8 Hz, 5H), 2.80 (s, 4H), 2.72 (s, 3H), 2.54 (q, *J* = 7.3 Hz, 2H), 2.31 (t, *J* = 11.4 Hz, 1H), 1.48 (t, *J* = 5.9 Hz, 1H), 1.06 (dd, *J* = 2.7, 6.0 Hz, 1H). LC (method A): t_R = 2.01 min. LC/MS (EI) *m/z*: [M + H]⁺ 761.

Scheme 75. Synthesis of (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-5-(2-methoxypyrimidin-5-yl)-1*H*-pyrazolo[3,4-*c*]pyridin-1-yl)acetyl)-*N*-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (193)



[0697] The above scheme and following detailed description depicts one non-limiting method for synthesizing compounds with a substituted pyrimidine in the R^{32} position utilizing a boronic ester in a Suzuki cross-coupling. The skilled artisan will recognize that the boronic ester shown above can be replaced with other boronic esters or boronic acids to afford additional compounds of the present invention. The skilled artisan will also recognize that the A-ring shown can be replaced with other A-rings to afford additional compounds of the present invention. Non-limiting examples of boronic esters that the skilled artisan can use include 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-amine and 2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine.


[0698] Step 1: tert-Butyl 2-(3-acetyl-5-(2-methoxypyrimidin-5-yl)-1*H*-pyrazolo[3,4-*c*]pyridin-1-yl)acetate (193-S3): To a solution of 2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine (**193-S2**, 1 equiv) in dioxane/ H_2O (9:1, 10 vol) was added compound **193-S1** (1 equiv), Cs_2CO_3 (2 equiv), and tetrakis(triphenylphosphine)palladium (0.1 equiv). The reaction mixture was stirred at 90 °C for 5 hours and concentrated to dryness. The remaining residue was purified by column chromatography on silica gel (eluted with DCM/ MeOH) to afford compound **193-S3**.

[0699] Step 2: 2-(3-Acetyl-5-(2-methoxypyrimidin-5-yl)-1*H*-pyrazolo[3,4-*c*]pyridin-1-yl)acetic acid (193-S4): To a solution of compound **193-S3** (1 equiv) in DCM (10 vol) at 0 °C under an atmosphere of argon was added TFA (5 vol). The reaction mixture was stirred at room temperature for 3 hours and concentrated to dryness. The remaining material was carried forward without additional purification and used directly in the next synthetic step.

[0700] Step 3: (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-5-(2-methoxypyrimidin-5-yl)-1*H*-pyrazolo[3,4-*c*]pyridin-1-yl)acetyl)-*N*-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (193): To a solution of compound **193-S4** (1 equiv) in DMF (10 vol) at 0 °C under an atmosphere of argon was added (1*R*,3*S*,5*R*)-*N*-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (**193-S5**, 1 equiv), HATU (2.1 equiv), and DIPEA (5 equiv). The reaction mixture was stirred at room temperature for 3 hours and quenched with water (30 vol). The resulting mixture was extracted with DCM. The organic layer was washed with brine, dried over anhydrous Na_2SO_4 , filtered, and then concentrated to dryness. The remaining residue was purified by column chromatography on silica gel (eluted with DCM/MeOH) to afford compound **193**. ^1H NMR (400 MHz, DMSO-d_6) δ 1.02 (t, J = 5.5 Hz, 1H), 1.10 (dd, J = 2.4, 5.3 Hz, 1H), 1.34 (s, 3H), 2.01 - 2.10 (m, 4H), 2.56 (dd, J = 9.3, 13.3 Hz, 1H), 2.69 (s, 3H), 3.58 - 3.65 (m, 1H), 4.01 (s, 3H), 4.35 -

4.52 (m, 1H), 5.72 (d, J = 17.2 Hz, 1H), 6.04 (d, J = 17.3 Hz, 1H), 7.45 (d, J = 7.9 Hz, 1H), 7.63 (d, J = 7.9 Hz, 1H), 8.55 (d, J = 1.3 Hz, 1H), 9.22 - 9.30 (m, 3H), 10.27 (s, 1H).

Scheme 76. Synthesis of (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-5-methyl-*N*-(3-methyl-6-(trifluoromethoxy)pyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (196)



[0701] The above scheme and following detailed description depicts one non-limiting method for synthesizing compounds with a trifluoromethyl group on the B-ring by utilizing Togni reagent to generate the B-ring synthetic intermediate. The skilled artisan will recognize that other B-rings with trifluoromethyl functionality can be prepared to afford additional compounds of the present invention. The skilled artisan will also recognize that other A-rings can be coupled with the C- and B-ring shown above to afford compounds of the present invention.

[0702] Step 1: 5-Methyl-2-(trifluoromethoxy)pyridine (196-S2): A dried glass was charged with 5-methyl-pyridin-2-ol (0.518 g) and Togni reagent (0.5 g) in nitromethane (10 mL). The reaction mixture was stirred at 100 °C for 5 hours in presence of air. After cooling the reaction mixture to room temperature, the reaction was diluted with water and extracted repeatedly with CH₂Cl₂. The combined organic layer was dried (Na₂SO₄) and concentrated to afford **196-S2**, which was carried forward without additional purification in the next synthetic step without purification.

[0703] Step 2: 2-Trifluoromethoxy-2-methyl-pyridine-*N*-oxide (196-S3): Crude 5-methyl-2-(trifluoromethoxy)pyridine (**196-S2**) in CH₂Cl₂ was cooled in an ice bath and solid hydrogen peroxide urea complex (0.688 g) was added followed by the dropwise addition of TFAA (1.7 mL). After the addition was complete, the cooling bath was removed and the reaction mixture was stirred overnight at room temperature. Additional hydrogen peroxide urea complex (0.688 g) and

TFAA (1.7 mL) was added and the reaction mixture was stirred for 24 hours. The reaction mixture was diluted with CH₂Cl₂. The organic layer was washed with water, saturated aqueous sodium metabisulfite solution, and dried (Na₂SO₄). The organic layer was filtered and concentrated to afford **196-S3**, which was carried forward without additional purification and used as such for the next step.

[0704] Step 3. N-(tert-Butyl)-3-methyl-6-(trifluoromethoxy)pyridin-2-amine (196-S4): To a solution of **196-S3** (0.46 g) at -20 °C in CH₂Cl₂ (10 mL), *tert*-butylamine (1.25 mL) was added, followed by the dropwise addition of trifluoromethanesulfonic anhydride (1.2 mL). After stirring for 1 hour at -20 °C, the reaction mixture was quenched with the addition of water. The layers were separated and the organic layer was washed with saturated K₂CO₃ solution, dried, and concentrated. The residue was purified by silica gel column chromatography (eluent: hexanes) to afford **196-S4** as colorless liquid.

[0705] Step 4. 3-Methyl-6-(trifluoromethoxy)pyridin-2-amine TFA salt (196-S5): A solution of **196-S4** (50 mg) in TFA (1.0 mL) was stirred at room temperature for 24 hours. Then the volatiles were removed under reduced pressure and the residue was carried forward without additional purification in the next step (**196-S5**).

[0706] Step 5: tert-Butyl (1R,3S,5R)-5-methyl-3-((3-methyl-6-(trifluoromethoxy)pyridin-2-yl)carbamoyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (196-S7): To an ice cooled solution of **196-S5** (50 mg) and (1R,2S,5S)-3-(*tert*-butoxycarbonyl)-3-azabicyclo[3.1.0]hexane-2-carboxylic acid (**196-S6**, 53 mg) in CH₂Cl₂ (1.5 mL) pyridine (82 µL) was added, followed by the slow dropwise addition of POCl₃ (20 µL) at 5 °C and the reaction mixture was stirred for 3 hours. Then saturated aqueous NaHCO₃ solution was added and stirred for 1 h at room temperature. The organic layer was separated and the aqueous layer was extracted with CH₂Cl₂ (10 mL). The combined organic layers were dried (Na₂SO₄), filtered, and concentrated. The residue was purified by silica gel flash column chromatography (eluent: 0-2 % EtOAc in hexanes) to afford **196-S7**.


[0707] Step 6: (1R,3S,5R)-5-Methyl-N-(3-methyl-6-(trifluoromethoxy)pyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide TFA salt (196-S8): Compound **196-S7** (11 mg) was stirred in TFA (0.25 mL) and CH₂Cl₂ (0.25 mL) for 30 minutes at room temperature. The reaction mixture was evaporated to dryness under reduced pressure and the remaining residue was carried forward without additional purification in the next synthetic step.

[0708] Step 7: (1R,3S,5R)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl-N-(3-methyl-6-(trifluoromethoxy)pyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (196): To a solution of 2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetic acid (12 mg) in DMF (0.5 mL), *i*Pr₂NEt (35 µL, 5 equiv) was added, followed by the addition of **196-S7** (from above) at 5 °C. HATU (16 mg, 1.1 equiv) was added slowly at this same temperature and the reaction mixture was stirred for 30 minutes at room temperature. The reaction mixture was taken to dryness and the residue was dissolved in CH₂Cl₂. The organic layer was washed with 1% aq. LiOH solution and water and dried (Na₂SO₄). After the filtration, the filtrate was concentrated under reduced pressure and the residue was purified by silica gel flash column chromatography (eluent: 0-2.5 % MeOH in CH₂Cl₂) to afford **196** as white solid. ¹H NMR (400 MHz, Chloroform-*d*) δ 0.77 - 0.96 (m, 2H), 1.42 (s, 3H), 2.09 (s, 3H), 2.29 (dd, *J* = 8.8, 13.6 Hz, 1H), 2.71 (s, 3H), 2.66 - 2.77 (m, 1H), 2.81 (s, 3H), 3.20 (dd, *J* = 2.4, 5.4 Hz, 1H), 4.88 (d, *J* = 7.7 Hz, 1H), 5.50 (s, 2H), 6.80 (d, *J* = 8.1 Hz, 1H), 7.53 - 7.66 (m, 3H), 8.58 (s, 1H), 8.68 (s, 1H), 8.90 (s, 2H). ¹⁹F-NMR (Chloroform-*d*): δ -56.6.

[0709] (1R,3S,5R)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indol-1-yl)acetyl)-5-methyl-N-(3-methyl-6-(trifluoromethoxy)pyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide: ¹H-NMR (400 MHz, CDCl₃): δ 0.84 - 0.90 (m, 1H), 1.16 (t, *J* = 5.4 Hz, 1H), 1.43 (s, 3H), 2.12 (s, 3H), 2.35 (t, *J* = 8.4 Hz, 1H), 2.53 (s, 3H), 2.66 (brs, 1H), 2.69 (s, 3H), 2.79 (s, 3H), 3.11 (d, *J* = 4.4 Hz, 1H), 4.93 (s, 1H), 5.35 (d, *J* = 17.6 Hz, 1H), 5.42 (d, *J* = 17.7 Hz, 1H), 6.79 (d, *J* = 8.1 Hz, 1H), 7.17 (s, 1H), 7.57 (d, *J* = 8.1 Hz, 1H), 7.69 (s, 1H), 8.49 (brs, 1H), 8.55 (s, 1H), 8.89 (s, 2H). ¹⁹F (CDCl₃): δ -56.5.

[0710] (1R,3S,5R)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indol-1-yl)acetyl)-5-methyl-N-(3-methyl-6-(trifluoromethyl)pyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide: ¹H NMR (400 MHz, Chloroform-*d*) δ 0.88 (dd, *J* = 2.4, 5.5 Hz, 1H), 1.16 (t, *J* = 5.4 Hz, 1H), 1.43 (s, 3H), 2.22 (s, 3H), 2.36-2.42 (m, 1H), 2.53 (s, 3H), 2.67 (d, *J* = 14 Hz, 1H), 2.72 (s, 3H), 2.79 (s, 3H), 3.13 (d, *J* = 4.0 Hz, 1H), 4.65 (d, *J* = 5.2 Hz, 1H), 5.31 (d, *J* = 17.6 Hz, 1H), 5.48 (d, *J* = 17.5 Hz, 1H), 7.19 (s, 1H), 7.42 (d, *J* = 7.7 Hz, 1H), 7.65 (d, *J* = 8 Hz, 1H), 7.69 (s, 1H), 8.55 (s, 1H), 8.57 (brs, 1H), 8.89 (s, 2H). ¹⁹F: δ -67.6.

Scheme 77. Synthesis of (1*R*,3*S*,5*S*)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-methylpyridin-2-yl)-5-(oxazol-5-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (197)



[0711] Step 1: (1*R*,3*S*,5*S*)-2-(*tert*-Butoxycarbonyl)-5-(oxazol-5-yl)-2-azabicyclo[3.1.0]hexane-3-carboxylic acid (197-S2): To the solution of 2-(*tert*-butyl) 3-ethyl (1*R*,3*S*,5*S*)-5-formyl-2-azabicyclo[3.1.0]hexane-2,3-dicarboxylate (197-S1, 142 mg, 0.50 mmol) and *p*-toluenesulfonylmethyl isocyanide (146.4 mg, 0.75 mmol) in MeOH (15 mL), solid K₂CO₃ (1.50 mmol) was added. The mixture was refluxed overnight under argon. The reaction was cooled to room temperature and the volatiles were evaporated. The residue was loaded on a pad of silica gel and purified to afford 197-S2 (72 mg).


[0712] Step 2: *tert*-Butyl (1*R*,3*S*,5*S*)-3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-5-(oxazol-5-yl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (197-S3): (1*R*,3*S*,5*S*)-2-(*tert*-Butoxycarbonyl)-5-(oxazol-5-yl)-2-azabicyclo[3.1.0]hexane-3-carboxylic acid (197-S1, 72 mg, 0.24 mmol) and 6-bromo-3-methylpyridin-2-amine (197-S2, 46 mg, 0.24 mmol) were dissolved in anhydrous DCM (6.0 mL) in a pre-dried flask. The flask was cooled in an ice bath and dry pyridine (0.25 mL, 3.0 mmol) was added in one portion, followed by POCl₃ (100 μ L, 1.0 mmol). After completion of the addition, the mixture was stirred for 4 hours at 0°C, and then the reaction was quenched with water (15 mL). The DCM layer was collected and the aqueous phase was extracted with DCM (15 mL $\times$ 2). The combined DCM solution was washed with brine and dried over MgSO₄. The solution was filtered and concentrated and the resulting residue was purified to afford 197-S3 (59.3 mg).

[0713] Step 3: (1*R*,3*S*,5*S*)-*N*-(6-bromo-3-methylpyridin-2-yl)-5-(oxazol-5-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide hydrochloride (197-S4): *tert*-Butyl (1*R*,3*S*,5*S*)-3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-5-(oxazol-5-yl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (197-S3, 59.3 mg, 0.13 mmol) was taken up in 4N HCl dioxane (2.0 mL) and the resulting reaction mixture was stirred at room temperature for 2 hours. After completion of the reaction (as monitored by HPLC), the solvent was removed under reduced pressure. The remaining residue 197-S4 was carried forward without additional purification.

[0714] Step 4: (1*R*,3*S*,5*S*)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-methylpyridin-2-yl)-5-(oxazol-5-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (197): To the solution of (1*R*,3*S*,5*S*)-*N*-(6-bromo-3-methylpyridin-2-yl)-5-(oxazol-5-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide hydrochloride (197-S4, 0.13 mmol) and 2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1*H*-pyrazolo[3,4-*c*]pyridin-1-yl)acetic acid (197-S5, 40 mg, 0.13 mmol) in DMF (2.0 mL), HATU (1.5 equiv, 0.20 mmol) was added, followed by the dropwise addition of DIEA (5.0 equiv) at room temperature. The mixture was stirred for 1 hour at room temperature and then the volatiles were evaporated. The residue was diluted with 10% sodium carbonate (50 mL) and extracted with ethyl acetate. The combined organic solutions were successively washed with water and brine and dried over MgSO₄. The solution was filtered and the solvent was removed. The residue was purified to afford 197 (29.2 mg). ¹H NMR (400 MHz, DMSO-*d*₆): (major rotamer) δ


1.71 (d, $J=4.6$ Hz, 2H), 2.03 (s, 3H), 2.59 (dd, $J=13.5, 4.8$ Hz, 1H), 2.66 (s, 3H), 2.69 (s, 3H), 2.82 (dd, $J=13.5, 9.2$ Hz, 1H), 4.20 (t, $J=4.6$ Hz, 1H), 4.60 (dd, $J=9.2, 4.7$ Hz, 1H), 5.65 (d, $J=17.3$ Hz, 1H), 5.97 (d, $J=17.3$ Hz, 1H), 7.15 (s, 1H), 7.44 (d, $J=7.9$ Hz, 1H), 7.62 (d, $J=7.9$ Hz, 1H), 7.87 (s, 2H), 8.31 (s, 1H), 8.45 (s, 1H), 9.04 (s, 2H), 10.38 (s, 1H) ppm. LC (method A): $t_R = 1.55$ min. LC/MS (EI) m/z : $[M + H]^+$ 655.07, 657.16

Scheme 78. Synthesis of (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-7-methyl-5-(2-(oxetan-3-yloxy)pyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (208)



[0715] To a solution of **121** (1 equiv) in DMF (10 vol) was added potassium carbonate (3 equiv) and oxetan-3-yl 4-methylbenzenesulfonate (2 equiv). The reaction mixture was heated to 100 °C for 12 hours. The reaction mixture was quenched with water and the resulting mixture was extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous Na_2SO_4 , filtered and concentrated. The residue was purified by preparative purification to afford **208**. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 10.33 (s, 1H), 8.94 (d, $J=2.6$ Hz, 1H), 8.42 (d, $J=2.3$ Hz, 1H), 8.21 (s, 1H), 7.62 (d, $J=8.0$ Hz, 1H), 7.51 (s, 1H), 7.44 (d, $J=8.0$ Hz, 1H), 6.02 (d, $J=17.3$ Hz, 1H), 5.65 (d, $J=18.0$ Hz, 1H), 5.41 - 5.38 (m, 1H), 4.93 - 4.84 (m, 4H), 4.34 - 4.32 (m, 1H), 3.59 - 3.58 (m, 1H), 2.65 (s, 3H), 2.64 - 2.63 (m, 1H), 2.58 (s, 3H), 2.04 (s, 3H), 2.01 - 1.98 (m, 1H), 1.32 (s, 3H), 1.01 - 0.94 (m, 2H).

Scheme 84: Synthesis of (1*R*, 3*S*, 5*R*)-2-(2-(3-Acetyl-7-(1-fluoroethyl)-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl) acetyl)-*N*-(6-bromo-3-methylpyridin-2-yl)-5-methyl- 2-azabicyclo [3.1.0] hexane-3-carboxamide (220)



[0716] Step 1: 4-Bromo-2-iodo-6-methylaniline (220-S2): To a solution of compound **220-S1** (5 g, 26.88 mmol) in EtOH (100 mL) was added I_2 (6.828 g, 26.88 mmol) and Ag_2SO_4 (8.382 g, 26.88 mmol). The mixture was stirred at room temperature overnight. The mixture was quenched with aqueous $Na_2S_2O_3$ solution and extracted with EtOAc (2x). The combined organic layers were washed with brine, dried over anhydrous Na_2SO_4 , and concentrated. The residue was purified by column chromatography on silica gel eluted with petroleum ether to afford compound **220-S2** (6.31 g, 75.5%) as a light brown solid. LC/MS (ESI) m/z : 312 ($M+H$)⁺.

[0717] Step 2: 5-Bromo-7-iodo-1H-indazole (220-3): To a solution of compound **220-S2** (6.31 g, 20.29 mmol) and potassium acetate (2.386 g, 24.35 mmol) in $CHCl_3$ (100 mL) was added acetic anhydride (6.209 g, 60.87 mmol) dropwise at 0 °C under N_2 atmosphere and the mixture was stirred at room temperature for 1 hour. The reaction mixture was heated to 60 °C and *tert*-butyl nitrite (10.3 g, 0.1 mol) was added and the reaction was stirred at 60 °C overnight. The mixture was diluted with water and extracted with DCM (2x). The combined organic layers were washed with brine, dried over

anhydrous Na₂SO₄, and concentrated. The residue was dissolved in MeOH and 6 N HCl (v/v= 1:1), and the mixture was stirred at room temperature for 5 hours. The mixture was basified with 10 N aqueous NaOH solution and extracted with DCM twice. The combined organic layers were washed with brine, dried over anhydrous Na₂SO₄, and concentrated. The residue was purified by column chromatography on silica gel eluted with petroleum ether/EtOAc (100: 1 to 8: 1) to afford compound **220-S3** (3.73 g, 57.1 %) as a light yellow solid. LC/MS (ESI) m/z: 323 (M+H)⁺.

[0718] Step 3: 5-Bromo-7-vinyl-1H-indazole (220-S4): To a solution of compound **220-S3** (1.9 g, 5.92 mmol) in DME/H₂O (40 mL, v/v=3/1) was added potassium trifluoro(vinyl)borate (0.793 g, 5.92 mmol), K₂CO₃ (0.980 g, 7.10 mmol) and Pd(PPh₃)₄ (0.684 g, 0.59 mmol). The mixture was degassed under N₂ atmosphere three times and stirred at 85 °C under N₂ atmosphere overnight. The mixture was diluted with EtOAc and washed with water and brine, dried over anhydrous Na₂SO₄, and concentrated. The residue was purified by column chromatography on silica gel eluted with petroleum ether/EtOAc (100: 1 to 8: 1) to afford compound **220-S4** (0.78 g, 59.4 %) as a light yellow solid. LC/MS (ESI) m/z: 223 (M+H)⁺.

[0719] Step 4: 1-(5-Bromo-1H-indazol-7-yl) ethanol (220-S5): To a solution of compound **220-S4** (0.78 g, 3.51 mmol) in anhydrous THF (20 mL) was added BH₃-THF (1.13 mL, 1 M in THF) dropwise at 0 °C under N₂ atmosphere and the mixture was stirred at reflux overnight. The mixture was cooled to 0 °C and 3 N aqueous NaOH solution was added followed by 30% H₂O₂. The mixture was stirred at room temperature for 1 hour. The solvent was removed and the residue was dissolved in DCM. The mixture was washed with brine, dried over anhydrous Na₂SO₄, and concentrated. The residue was purified by column chromatography on silica gel eluted with petroleum ether/EtOAc (100: 1 to 6: 1) to afford compound **220-S5** (170 mg, 20.1 %) as a light brown solid. LC/MS (ESI) m/z: 242 (M+H)⁺.

[0720] Step 5: 5-Bromo-7-(1-fluoroethyl)-1H-indazole (220-S6): To a solution of compound **220-S5** (0.16 g, 0.66 mmol) in anhydrous DCM (5 mL) was added DAST (0.22 g, 1.33 mmol) dropwise at - 70 °C under N₂ atmosphere. The reaction mixture was allowed to warm to room temperature and was stirred for 2 hours. The reaction was quenched with aqueous NaHCO₃ solution at 0 °C and diluted with DCM. The layers were separated and the organic layer was washed with brine, dried over anhydrous Na₂SO₄, and concentrated. The residue was purified by column chromatography on silica gel eluted with petroleum ether/EtOAc (100: 1 to 6: 1) to afford compound **220-S6** (70 mg, 43.5 % yield) as a light white solid. LC/MS (ESI) m/z: 244 (M+H)⁺.

[0721] Step 6: 5-Bromo-7-(1-fluoroethyl)-3-iodo-1H-indazole (220-S7): To a solution of compound **220-S6** (70 mg, 0.29 mmol) in DMF (2 mL) was added KOH (40 mg, 0.72 mmol) followed by I₂ (110 mg, 0.43 mmol) at 0 °C and the mixture was stirred at room temperature for 2 hours. The reaction was quenched with aqueous Na₂S₂O₃ solution, diluted with water, and extracted with EtOAc twice. The combined organic layers were washed with brine, dried over anhydrous Na₂SO₄, and concentrated. The residue was purified by column chromatography on silica gel eluted with petroleum ether/EtOAc (80: 1 to 6: 1) to afford compound **220-S7** (80 mg, 75.5 % yield) as a light yellow solid. LC/MS (ESI) m/z: 370 (M+H)⁺.

[0722] Step 7: tert-Butyl 2-(5-bromo-7-(1-fluoroethyl)-3-iodo-1H-indazol-1-yl) acetate (220-S8): To a solution of compound **220-S7** (80 mg, 0.22 mmol) in DMF (2 mL) was added K₂CO₃ (75 mg, 0.54 mmol) and tert-butyl 2-bromoacetate (46 mg, 0.24 mmol). The mixture was stirred at room temperature overnight and then diluted with H₂O and extracted with EtOAc twice. The combined organic layers were washed with brine, dried over anhydrous Na₂SO₄, and concentrated. The obtained crude product was purified by column chromatography on silica gel eluted with petroleum ether/EtOAc (100: 1 to 20: 1) to afford compound **220-S8** (50 mg, 47.7 % yield) as a light yellow solid. LC/MS (ESI) m/z: 485 (M+H)⁺.

[0723] Step 8: tert-Butyl 2-(3-acetyl-5-bromo-7-(1-fluoroethyl)-1H-indazol-1-yl) acetate (220-S9): To a solution of compound **220-S8** (50 mg, 0.10 mmol) in dry toluene (3 mL) was added tributyl(1-ethoxyvinyl)stannane (45 mg, 0.12 mmol) and Pd(PPh₃)₄ (12 mg, 0.01 mmol). The mixture was stirred at 100 °C under N₂ atmosphere overnight. The mixture was cooled to room temperature, 0.5 M aqueous HCl was added, and the mixture was stirred at room temperature for 30 minutes. The reaction mixture was diluted with EtOAc and washed with water and brine, dried over anhydrous Na₂SO₄, and concentrated. The obtained crude product is purified by column chromatography on silica gel eluted with petroleum ether/EtOAc (80: 1 to 8: 1) to afford compound **220-S9** (30 mg, 73.2 % yield) as a milky white solid. LC/MS (ESI) m/z: 399 (M+H)⁺.


[0724] Step 9: tert-Butyl 2-(3-acetyl-7-(1-fluoroethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl) acetate (220-S10): A round-bottom flask was charged with compound **220-S9** (30 mg, 0.075 mmol), 2-methylpyrimidin-5-ylboronic acid (11 mg, 0.083 mmol), K₂CO₃ (26 mg, 0.19 mmol) in dioxane/H₂O (2 mL, v/v = 5: 1). Tetrakis(triphenylphosphine) palladium(0) (9 mg, 0.008 mmol) was added to the mixture under N₂ atmosphere and the reaction was stirred at 90 °C overnight under N₂ atmosphere. The mixture was diluted with EtOAc and washed with brine, dried over anhydrous Na₂SO₄, and concentrated to dryness. The residue was purified by column chromatography on silica gel eluted with petroleum ether/EtOAc (50: 1 to 3: 1) to afford compound **220-S10** (18 mg, 58.1 % yield) as a light yellow solid. LC/MS (ESI) m/z: 413 (M+H)⁺.


[0725] Step 10: 2-(3-Acetyl-7-(1-fluoroethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl) acetic acid (220-S11): To a solution of compound **220-S10** (18 mg, 0.044 mol) in DCM (1 mL) was added TFA (0.5 mL) and the mixture was stirred at room temperature for 1.5 hours. The solvent was removed and the residue was washed with ether and dried under

vacuum to afford compound **220-S11** (10 mg, 64.3 % yield) as a light yellow solid. LC/MS (ESI) m/z : 357 (M+H)⁺.

[0726] Step 11: (1*R*, 3*S*, 5*R*)-2-(2-(3-Acetyl-7-(1-fluoroethyl)-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl) acetyl)-*N*-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo [3.1.0] hexane-3-carboxamide (220**):** To a mixture of compound **220-S11** (9 mg, 0.025 mmol) and compound **220-S12** (10 mg, 0.032 mmol) in DMF (1 mL) was added DIPEA (15 mg, 0.12 mmol) followed by HATU (24 mg, 0.064 mmol). The reaction was stirred at room temperature for 2 hours. The mixture was diluted with EtOAc and washed with 10% aqueous LiCl solution and brine, dried, and concentrated to afford crude product, which was purified by prep-HPLC to afford **220** (2 mg, 12.5 %) as a white solid. ¹H NMR (400 MHz, CD₃OD) δ 9.03 (s, 2H), 8.68 - 8.62 (m, 1H), 7.83 (s, 1H), 7.54 (d, J = 8.0 Hz, 1H), 7.38 (d, J = 8.0 Hz, 1H), 6.44 - 6.05 (m, 1H), 6.03 - 5.78 (m, 2H), 4.58 - 4.46 (m, 1H), 3.52 (dd, J = 5.6, 2.4 Hz, 1H), 2.76 (s, 3H), 2.70 (d, J = 1.6 Hz, 3H), 2.63 (dd, J = 13.2, 9.2 Hz, 1H), 2.35 - 2.26 (m, 1H), 2.11 (s, 3H), 1.96 - 1.82 (m, 3H), 1.42 (s, 3H), 1.16 - 1.10 (m, 1H), 1.03 - 0.97 (m, 1H). LC/MS (ESI) m/z : 648 (M+H)⁺.

Scheme 86: Synthesis of (2*S*,4*S*)-1-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-methylpyridin-2-yl)-4-(trifluoromethyl)pyrrolidine-2-carboxamide (223**)**





[0727] **Step 1: (2S,4R)-1-tert-Butyl 2-methyl 4-hydroxypyrrolidine-1,2-dicarboxylate (223-S2):** To a solution of compound **223-S1** (10 g, 43.7 mmol) in DMF (100 mL) was added K_2CO_3 (18.1 g, 131.3 mmol) followed by MeI (9.31 g, 65.6 mmol) at 0 °C and the reaction was stirred at room temperature overnight. The mixture was diluted with EtOAc and washed with 10% aqueous LiCl solution and brine, dried over Na_2SO_4 , and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluted with petroleum ether: ethyl acetate = 5: 1 to 2: 1) to afford compound **223-S2** (10.1 g, 94.4% yield) as white solid. LC/MS (ESI) m/z: 246 (M+H)⁺.

[0728] **Step 2: (S)-1-tert-Butyl 2-methyl 4-oxopyrrolidine-1,2-dicarboxylate (223-S3):** To a solution of compound **223-S2** (10 g, 41.2 mmol) in DCM (100 mL) was added TCCA (10.04 g, 43.2 mmol) followed by TEMPO (64.3 mg, 0.41 mmol) at 0 °C and the reaction mixture was stirred at room temperature for 1 hour. The mixture was filtered, the filtrate was washed with saturated potassium carbonate solution and brine, dried over Na_2SO_4 , and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (petroleum ether: ethyl acetate = 10: 1) to afford compound **223-S3** (8 g, 80.7% yield) as a white solid. LC/MS (ESI) m/z: 244 (M+H)⁺.

[0729] **Step 3: (2S)-1-tert-Butyl 2-methyl 4-hydroxy-4-(trifluoromethyl)pyrrolidine-1,2-dicarboxylate (223-S4):** To a solution of compound **223-S3** (6 g, 24.7 mmol) in THF (100 mL) was added $TMSCF_3$ (5.26 g, 37.0 mmol) followed by TBAF (0.15 mL, 0.15 mmol, 1 mol/L in THF) at 0 °C and the reaction was stirred at room temperature overnight. The reaction was quenched with aqueous NH_4Cl solution and extracted with EtOAc twice. The combined organic layers were washed with water and brine, dried over Na_2SO_4 , and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (petroleum ether: ethyl acetate = 20: 1) to afford compound **223-S4** (4.4 g, 56.8% yield) as a yellow oil. LC/MS (ESI) m/z: 314 (M+H)⁺.

[0730] **Step 4: (2S)-tert-Butyl 4-hydroxy-2-(hydroxymethyl)-4-(trifluoromethyl)pyrrolidine-1-carboxylate (223-S5):** To a solution of compound **223-S4** (4.4 g, 14.1 mmol) in THF (56 mL) was added LiCl (1.31 g, 30.91 mmol) and $NaBH_4$ (1.33 g, 35.1 mmol) followed by the dropwise addition of EtOH (112 mL) at 0 °C. The reaction mixture was stirred at 0 °C for 1 hour and was allowed to warm to room temperature and stir overnight. The mixture was cooled at 0 °C and acidified to pH=4 with 10% aqueous citric acid solution. The mixture was extracted with DCM and washed with water and brine, dried over Na_2SO_4 , and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (petroleum ether: ethyl acetate = 15: 1) to afford compound **223-S5** (3.4 g, 85.0% yield) as a yellow oil. LC/MS (ESI) m/z: 286 (M+H)⁺.

[0731] **Step 5: (2S)-tert-Butyl 2-(((tert-butyldimethylsilyl)oxy)methyl)-4-hydroxy-4-(trifluoromethyl)pyrrolidine-1-carboxylate (223-S6):** To a solution of compound **223-S5** (3.4 g, 11.9 mmol) in DCM (50 mL) was added TEA (1.2 g, 11.9 mmol) and TBDMSCl (2.15 g, 14.28 mmol) at 0 °C and the reaction was stirred at room temperature overnight under N_2 atmosphere. The reaction mixture was diluted with DCM, washed with saturated aqueous NH_4Cl solution and brine, dried over Na_2SO_4 , and concentrated under reduced pressure to remove the volatiles. The residue was purified by chromatography on silica gel (petroleum ether: ethyl acetate = 60: 1) to afford compound **223-S6** (4.2 g, 88.3% yield) as yellow oil. LC/MS (ESI) m/z: 400 (M+H)⁺.

[0732] **Step 6: (2S)-tert-Butyl 2-(((tert-butyldimethylsilyl)oxy)methyl)-4-(tosyloxy)-4-(trifluoromethyl)pyrrolidine-1-car-**

boxylate (223-S7): To a solution of compound 223-S6 (4 g, 10.0 mmol) in THF (40 mL) was added NaH (802 mg, 20.0 mmol) at 0 °C. The mixture was stirred at room temperature for 30 minutes and tosyl chloride (3.82 g, 20.0 mmol) was added in portions at 0 °C. The reaction mixture was stirred at room temperature overnight under N₂ atmosphere. The reaction was quenched with saturated aqueous NH₄Cl solution and the mixture was diluted with EtOAc, washed with water and brine, dried over Na₂SO₄, and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (petroleum ether: ethyl acetate = 80: 1) to afford compound **223-S7** (4.9 g, 88.5%) as yellow oil. LC/MS (ESI) m/z: 554 (M+H)⁺.

[0733] Step 7: (S)-tert-Butyl 2-(((tert-butyldimethylsilyl)oxy)methyl)-4-(trifluoromethyl)-2,3-dihydro-1H-pyrrole-1-carboxylate (223-S8): To a solution of compound **223-S7** (4.2 g, 7.59 mmol) in THF (40 mL) was added *t*-BuOK (1.70 g, 15.19 mmol) at -78 °C and the reaction was stirred at room temperature for 2 hours under N₂ atmosphere. The reaction was quenched with cooled water and the mixture was diluted with EtOAc, washed with water and brine, dried over Na₂SO₄, and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (petroleum ether: ethyl acetate = 80: 1) to afford compound **223-S8** (1.6 g, 55.3% yield) as a yellow oil. LC/MS (ESI) m/z: 382 (M+H)⁺.

[0734] Step 8: (2S,4S)-tert-Butyl 2-(((tert-butyldimethylsilyl)oxy)methyl)-4-(trifluoromethyl)pyrrolidine-1-carboxylate (223-S9): To a solution of compound **223-S8** (300 mg, 0.78 mmol) in EtOAc (5 mL) was added Pd/C (15 mg, 10% wt). The reaction mixture was stirred under a H₂ balloon at room temperature for 2 hours. The mixture was filtered and concentrated to dryness to afford compound **223-S9** (280 mg, 93.3%) as a brown oil. LC/MS (ESI) m/z: 384 (M+H)⁺.

[0735] Step 9: (2S,4S)-tert-Butyl 2-(hydroxymethyl)-4-(trifluoromethyl)pyrrolidine-1-carboxylate (223-S10): To a solution of compound **223-S9** (280 mg, 0.73 mmol) in THF (5 mL) was added TBAF (1 mL/L in THF) (3.65 mL, 3.65 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 1 hour under a nitrogen atmosphere. The reaction mixture was diluted with EtOAc, washed with saturated NH₄Cl and brine, dried over Na₂SO₄, and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (petroleum ether: ethyl acetate = 20: 1) to afford compound **223-S10** (200 mg, 96.6% yield) as a yellow oil. LC/MS (ESI) m/z: 270 (M+H)⁺.


[0736] Step 10: (2S,4S)-1-(tert-Butoxycarbonyl)-4-(trifluoromethyl)pyrrolidine-2-carboxylic acid (223-S11): To a solution of compound **223-S10** (200 mg, 0.72 mmol) in THF (5 mL) was added NMO (842 mg, 7.20 mmol) and TPAP (25.2 mg, 0.073 mmol). The reaction mixture was stirred at room temperature for 2 hours under a nitrogen atmosphere. The reaction mixture was diluted with EtOAc, washed with water and brine, dried over Na₂SO₄, and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (DCM: CH₃OH = 50: 1) to afford compound **223-S11** (150 mg, 71.4%) as a yellow oil. LC/MS (ESI) m/z: 284 (M+H)⁺.

[0737] Step 11: (2S,4S)-tert-Butyl 2-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-4-(trifluoromethyl)pyrrolidine-1-carboxylate (223-S12): To a solution of compound **223-S11** (50 mg, 0.18 mmol) and 6-bromo-3-methylpyridin-2-amine (33.3 mg, 0.18 mmol) in DCM (3 mL) was added pyridine (71.1 mg, 0.90 mmol) at 0 °C followed by the dropwise addition of POCl₃ (27.54 mg, 0.18 mmol). The reaction mixture was stirred at 0 °C for 30 minutes. The reaction mixture was quenched with ice-cooled water and extracted with DCM twice. The combined organic phases were washed with brine, dried over anhydrous Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by silica gel column (eluted with DCM / MeOH = 50 / 1) to afford compound **223-S12** (45 mg, 57.0%) as a white solid. LC/MS (ESI) m/z: 452/454 (M+H)⁺.

[0738] Step 12: (2S,4S)-N-(6-Bromo-3-methylpyridin-2-yl)-4-(trifluoromethyl)pyrrolidine-2-carboxamide TFA salt (223-S13): To a solution of compound **223-S12** (45 mg, 0.10 mmol) in DCM (2.5 mL) was added TFA (1 mL). The reaction was stirred at room temperature for 1.5 hours and then concentrated under reduced pressure to afford compound **223-S13** (50 mg, 100.0% yield) as a yellow solid, which was directly carried forward in the next step without additional purification. LC/MS (ESI) m/z: 352/354 (M+H)⁺.

[0739] Step 13: (2S,4S)-1-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-4-(trifluoromethyl)pyrrolidine-2-carboxamide (223): To a solution of the compound **223-S13** (50 mg, 0.10 mmol), compound **223-S14** (32.4 mg, 0.10 mmol) and HATU (76.0 mg, 0.20 mmol) in DMF (2 mL) was added DIPEA (0.07 mL, 0.40 mmol) at 0 °C. The reaction was stirred at room temperature overnight. The mixture was diluted with EtOAc and washed with 10% aqueous LiCl solution and brine, dried over Na₂SO₄, and concentrated to dryness. The residue was purified by prep-HPLC to afford **223** (5.2 mg, 7.9% yield) as a white solid. ¹H NMR (400 MHz, CD₃OD) δ 8.99 (d, *J* = 3.4 Hz, 2H), 8.41 (s, 1H), 7.53 (d, *J* = 8.4 Hz, 2H), 7.37 (d, *J* = 7.9 Hz, 1H), 5.78 (s, 2H), 4.72 (t, *J* = 8.3 Hz, 1H), 4.37-4.29 (m, 1H), 3.87 (t, *J* = 10.4 Hz, 1H), 3.48 (s, 1H), 2.74 (s, 7H), 2.67 (s, 3H), 2.28 (d, *J* = 5.8 Hz, 1H), 2.08 (s, 3H). LC/MS (ESI) m/z: 658/660 (M+H)⁺.

Scheme 87: Synthesis of (1R,3S,5R)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-((bis(2-fluoroethyl)amino)methyl)-N-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (227)



[0740] Step 1: *tert*-Butyl 2-fluoroethylcarbamate (227-S2**):** To a solution of **227-S1** (500 mg, 5.03 mmol) in THF (5 mL)/H₂O (5 mL) was added NaHCO₃ (1.69 g, 20.1 mmol) and Boc₂O (1.31 g, 6.03 mmol) at 0 °C. The reaction mixture was stirred at room temperature overnight. The mixture was diluted with EtOAc and washed with H₂O solution and brine, dried over Na₂SO₄, and concentrated to dryness. The residue was purified by silica gel column (eluted with PE: EtOAc = 20: 1 to 10: 1) to afford compound **227-S2** (400 mg, 48.8 %) as a white solid. LC/MS (ESI) m/z: 108(M-56+H)⁺.

[0741] Step 2: *tert*-Butyl bis(2-fluoroethyl)carbamate (227-S3**):** To a solution of **227-S2** (200 mg, 1.23 mmol) in DMF (5 mL) was added NaH (59 mg, 1.47 mmol) at 0 °C. After stirring at room temperature for 30 minutes, 1-fluoro-2-iodoethane (235 mg, 1.35 mmol) was added. The reaction mixture was stirred at room temperature for 2 hours. The mixture was diluted with H₂O at 0 °C, extracted with EtOAc, washed with water and brine, dried over Na₂SO₄, and concentrated to dryness. The residue was purified by silica gel column (eluted with PE: EtOAc = 30: 1 to 20: 1) to afford compound **227-S3** (130 mg, 50.6 %) as a white solid. LC/MS (ESI) m/z: 154(M-56+H)⁺.

[0742] Step 3: Bis(2-fluoroethyl)amine (227-S4**):** To a solution of compound **227-S3** (130 mg, 0.62 mmol) in dioxane (1 mL) was added HCl/dioxane (1 mL, 4 M) and the reaction mixture was stirred at room temperature for 2 hours. The mixture was concentrated to dryness to afford compound **227-S4** (120 mg, 100%) as a white solid, which was directly used in the next reaction without further purification. LC/MS (ESI) m/z: 110 (M+H)⁺.

[0743] Step 4: (1*R*,3*S*,5*R*)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-5-((bis(2-fluoroethyl)amino)methyl)-*N*-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (227**):** To a solution of compound **227-S5** (30 mg, 0.05 mmol) in MeCN (3 mL) was added DIPEA (0.03 mL, 0.21 mmol), NaI (8 mg, 0.05 mmol) and compound **227-S4** (120 mg, 0.62 mmol). The reaction mixture was stirred at 60 °C overnight. The mixture was partitioned with EtOAc and water. The organic layer was washed with brine, dried over anhydrous Na₂SO₄, and concentrated under reduced pressure. The residue was purified by silica gel column (eluted with DCM/MeOH = 20/1) and further purified by prep-HPLC to afford **227** (1.3 mg, 3.6%) as a white solid. ¹H NMR (400 MHz, CD₃OD) δ 8.97 (s, 2H), 8.39 (d, *J* = 1.0 Hz, 1H), 7.58 - 7.46 (m, 2H), 7.36 (d, *J* = 7.9 Hz, 1H), 5.95 (m, 1H), 5.77 (m, 1H), 4.62 (m, 3H), 4.50 (m, 2H), 3.61 (m, 1H), 3.10 - 2.87 (m, 5H), 2.74 (s, 7H), 2.67 (s, 3H), 2.64 - 2.48 (m, 2H), 2.12 (s, 3H), 1.06 (m, 1H), 0.90 (m, 1H). LC/MS (ESI) m/z: 723/725 (M+H)⁺.

Scheme 89: Synthesis of (1*R*,3*S*,5*S*)-2-(2-(3-Acetyl-7-allyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-5-(allyloxymethyl)-*N*-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (229)

5

10

15

20

25

30


35

40

45

50

55



[0744] Step 1: *tert*-Butyl 2-(3-acetyl-7-allyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetate (229-3): To a mixture of compound **229-S1** (267 mg, 0.6 mmol) and compound **229-S2** (222 mg, 1.32 mmol) in toluene (10 mL) and H_2O (2 mL) was added K_3PO_4 (382 mg, 1.8 mmol) followed by the addition of Pd(dppf)Cl_2 (44 mg, 0.06 mmol). The reaction was stirred at 100 °C for 16 hours under N_2 atmosphere. The mixture was cooled, diluted with EtOAc, and washed with water and brine. The organic layer was separated, dried and concentrated to afford crude product, which was purified by silica gel

column (eluted with PE: EtOAc = 20: 1 to 2: 1) to afford compound **229-S3** (194 mg, 79.5 %) as a white solid. LC/MS (ESI) m/z : 407(M+H)⁺.

[0745] Step 2: 2-(3-Acetyl-7-allyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetic acid (229-S4): To a mixture of compound **229-S3** (130 mg, 0.32 mmol) in MeOH/THF (4 mL, 1:1) was added aqueous NaOH solution (39 mg, 0.96 mmol in 2 mL of water). The mixture was stirred at room temperature for 4 hours and then diluted with water (3 mL) and extracted with ether. The aqueous layer was collected and acidified with aqueous HCl solution (1 N) to a pH of approximately 5. The resulting mixture was extracted with DCM/MeOH (20 mL x 2, 10: 1, V/V) and the combined organic phases were washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated to afford compound **229-S4** (73 mg, 65.2 %) as a white solid. LC/MS (ESI) m/z : 351(M+H)⁺.

[0746] Step 3: (1R,3S,5S)-2-tert-Butyl 3-ethyl 5-(allyloxymethyl)-2-azabicyclo[3.1.0]hexane-2,3-dicarboxylate (229-S7): To a mixture of compound **229-S5** (1.37 g, 4.8 mmol) in dry DMF (20 mL) was added NaH (384 mg, 9.6 mmol) at 0 °C under N₂ atmosphere and the mixture was stirred at room temperature for 40 minutes before compound **229-S6** (3.24 g, 19.2 mmol) was added at 0 °C in portions. The mixture was stirred at room temperature for 2 hours and the mixture was quenched with saturated aqueous NH₄Cl solution. The reaction was extracted with DCM and the organic layer was dried and concentrated to afford crude compound **229-S7** (1.56 g, 99.9 % yield) as a colorless oil, which was carried forward without additional purification. LC/MS (ESI) m/z : 348(M+Na)⁺.


[0747] Step 4: (1R,3S,5S)-5-(Allyloxymethyl)-2-(tert-butoxycarbonyl)-2-azabicyclo[3.1.0]hexane-3-carboxylic acid (229-S8): To a mixture of compound **229-S7** (1.56 g, 4.8 mmol) in MeOH/THF (20 mL, 1: 1) was added aqueous NaOH solution (384 mg, 9.6 mmol in 10 mL of water). The mixture was stirred at room temperature for 4 hours and then diluted with water (20 mL). The reaction was extracted with ether and the aqueous layer was collected and acidified with aqueous HCl solution (1 N) to a pH of approximately 5. The mixture was extracted with DCM/MeOH (20 mL x 2, 10:1, V/V) and the combined organic phases were washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated to afford compound **229-S8** (630 mg, 44.0 %) as a colorless oil. LC/MS (ESI) m/z : 320(M+Na)⁺.

[0748] Step 5: (1R,3S,5S)-tert-Butyl 5-(allyloxymethyl)-3-(6-bromo-3-methylpyridin-2-ylcarbamoyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (229-S10): To a solution of compound **229-S8** (210 mg, 0.71 mmol) and 6-bromo-3-methylpyridin-2-amine (133 mg, 0.71 mmol) in dry DCM (6 mL) was added pyridine (280 mg, 3.55 mmol) at 0 °C followed by the dropwise addition of POCl₃ (120 mg, 0.78 mmol). The reaction mixture was stirred at room temperature for 30 minutes and then quenched with ice-cooled water and extracted with DCM twice. The combined organic phases were washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated to dryness. The residue was purified by silica gel column (eluted with PE: EtOAc = 12: 1) to afford compound **229-S10** (150 mg, 67.2%) as a colorless oil. LC/MS (ESI) m/z : 466/468 (M+H)⁺.

[0749] Step 6: (1R,3S,5S)-5-(Allyloxymethyl)-N-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (229-S11): To a solution of compound **229-S10** (150 mg, 0.32 mmol) in DCM (2 mL) was added TFA (2 mL) at room temperature under N₂ atmosphere. The resulting mixture was stirred at room temperature for 2 hours and the mixture was concentrated to afford compound **229-S11** (100 mg, 85.5 %) as a colorless oil, which was directly used in the next reaction without additional purification. LC/MS (ESI) m/z : 366(M+H)⁺.

[0750] Step 7: (1R,3S,5S)-2-(2-(3-Acetyl-7-allyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-(allyloxymethyl)-N-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (229): To a solution of the compound **229-S11** (100 mg, 0.21 mmol), compound **229-S4** (73 mg, 0.21 mmol) and HATU (160 mg, 0.42 mmol) in DMF (2 mL) was added DIPEA (110 mg, 0.84 mmol). The reaction was stirred at room temperature for 16 hours. The mixture was diluted with EtOAc and washed with 10% aqueous LiCl solution and brine, dried, and concentrated to afford crude product, which was purified by silica gel column chromatography (eluted with DCM: MeOH = 100: 0 to 80: 1) to afford compound **229** (130 mg, 88.4 %) as a white solid. ¹H-NMR (400 MHz, DMSO-d₆) δ 10.32 (s, 1H), 9.03 (s, 2H), 8.40 (d, *J* = 1.7 Hz, 1H), 7.56 - 7.66 (m, 2H), 7.45 (d, *J* = 7.9 Hz, 1H), 6.17 - 6.26 (m, 1H), 5.86 - 5.97 (m, 2H), 5.65 (d, *J* = 17.5 Hz, 1H), 5.29 (dd, *J* = 17.3, 1.9 Hz, 1H), 5.18 (t, *J* = 9.9 Hz, 2H), 4.91 (d, *J* = 17.1 Hz, 1H), 4.48 (dd, *J* = 9.4, 5.1 Hz, 1H), 4.07 (dd, *J* = 13.2, 5.4 Hz, 1H), 3.99 (dd, *J* = 13.2, 5.3 Hz, 1H), 3.78 - 3.86 (m, 1H), 3.67 - 3.75 (m, 2H), 3.58 (d, *J* = 10.6 Hz, 1H), 3.47 (d, *J* = 10.7 Hz, 1H), 2.69 (s, 3H), 2.66 (s, 3H), 2.24 - 2.35 (m, 2H), 2.05 (s, 3H), 1.17 - 1.21 (m, 1H), 1.03 - 1.08 (m, 1H). LC/MS (ESI) m/z : 698/700 (M+H)⁺.

Scheme 90: Synthesis of (2*S*,4*R*)-1-(2-(3-Acetyl-5-(2-((3-methyloxetan-3-yl)methylsulfonyl)ethoxy)-1*H*-indazol-1-yl)acetyl)-*N*-(6-bromo-3-methylpyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide (230)



[0751] Step 1: *tert*-Butyl 2-(3-acetyl-7-(but-3-enyl)-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetate (230-3):

To a mixture of compound **230-S1** (444 mg, 1 mmol) and compound **230-S2** (200 mg, 2 mmol) in toluene (15 mL) and H₂O (3 mL) was added K₃PO₄ (637 mg, 3 mmol) followed by the addition of Pd(dppf)Cl₂ (74 mg, 0.1 mmol). The reaction was stirred at 100 °C for 16 hours under N₂ atmosphere before the mixture was cooled, diluted with EtOAc, and washed with water and brine. The organic layer was separated, dried and concentrated to afford crude product, which was purified by silica gel column (eluted with PE: acetone =20: 1 to 12: 1) to afford compound **230-S3** (354 mg, 84.1%) as a white solid. LC/MS (ESI) *m/z*: 421(M+H)⁺.

[0752] Step 2: 2-(3-Acetyl-7-allyl-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetic acid (230-S4): To a mixture of compound **230-S3** (354 mg, 0.843 mmol) in MeOH/THF (12 mL, 1:1) was added 3 mL of aqueous NaOH solution (101 mg, 2.53 mmol). The mixture was stirred at room temperature for 4 hours before the mixture was diluted with water (15 mL) and extracted with ether. The aqueous layer was collected and acidified with aqueous HCl solution (1 N) to a pH of approximately 5. The resulting mixture was extracted with DCM/MeOH (20 mL x 2, 10:1, V/V). The combined organic phases were washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated to afford compound **230-S4** (280 mg, 90.9 %) as a white solid. LC/MS (ESI) *m/z*: 365(M+H)⁺.




[0753] Step 3: (1*R*,3*S*,5*S*)-2-(2-(3-Acetyl-7-(but-3-enyl)-5-(2-methylpyrimidin-5-yl)-1*H*-indazol-1-yl)acetyl)-5-(allyloxymethyl)-*N*-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (230): To a solution of the compound **230-S4** (210 mg, 0.44 mmol), compound **230-S5** (160 mg, 0.44 mmol) and HATU (334 mg, 0.88 mmol) in DMF (4 mL) was added DIPEA (286 mg, 2.2 mmol). The reaction was stirred at room temperature for 16 hours. The mixture was diluted with EtOAc and washed with 10% aqueous LiCl solution and brine, dried, and concentrated to afford crude product, which was purified by silica gel column (eluted with DCM: MeOH =100: 0 to 80: 1) to afford compound **230** (250 mg, 79.9 %) as a white solid. ¹H-NMR (400 MHz, DMSO-*d*₆) δ 10.32 (d, *J* = 8.1 Hz, 1H), 8.95-9.10 (m, 2H), 8.36-8.40 (m, 1H), 7.56-7.64 (m, 2H), 7.45 (d, *J* = 7.9 Hz, 1H), 6.19-6.32 (m, 1H), 5.84-6.00 (m, 2H), 5.63-5.75 (m, 1H), 5.26-5.35 (m, 1H), 5.06-5.18 (m, 2H), 4.87-4.98 (m, 1H), 4.44-4.51 (m, 1H), 3.93-4.06 (m, 3H), 3.72-3.81 (m, 2H), 3.59 (d, *J* = 10.5 Hz, 1H), 3.46-3.51 (m, 1H), 2.71 (s, 3H), 2.65 (s, 3H), 2.19-2.36 (m, 2H), 2.05 (s, 3H), 1.63-1.70 (m, 1H), 1.41-1.50 (m, 1H), 1.16-1.25 (m, 1H), 0.92-1.06 (m, 1H). LC/MS (ESI) *m/z*: 712/714 (M+H)⁺.

[0754] (1R,3S,5R)-5-((1H-1,2,4-Triazol-1-yl)methyl)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide: ¹H NMR (400 MHz, Chloroform-*d*) δ 8.90 (d, *J* = 2.6 Hz, 2H), 8.81 (s, 1H), 8.56 (t, *J* = 2.2 Hz, 1H), 8.20 (s, 1H), 7.98 (d, *J* = 2.0 Hz, 1H), 7.67 - 7.55 (m, 2H), 7.38 - 7.30 (m, 1H), 7.23 (d, *J* = 8.0 Hz, 1H), 5.61 - 5.41 (m, 2H), 4.91 (d, *J* = 8.2 Hz, 1H), 4.62 (d, *J* = 14.0 Hz, 1H), 4.30 (d, *J* = 14.4 Hz, 1H), 3.58 (dd, *J* = 5.9, 2.8 Hz, 1H), 2.80 (d, *J* = 2.0 Hz, 3H), 2.71 (d, *J* = 2.1 Hz, 3H), 2.21 (q, *J* = 15.8, 13.0 Hz, 2H), 2.03 (d, *J* = 2.5 Hz, 3H), 1.38 (t, *J* = 5.8 Hz, 1H), 1.12 (dd, *J* = 6.1, 2.9 Hz, 1H). LC (method A): *t*_R = 1.36 min. LC/MS (EI) *m/z*: [M + H]⁺ 669.




EXAMPLE 9. NON-LIMITING EXAMPLES OF COMPOUNDS OF THE PRESENT INVENTION

[0755] Table 6, Table 7, and Table 8 show illustrative Factor D inhibitors with characterizing data. The assay of Example 10 was used to determine the IC₅₀'s of the compounds. Other standard factor D inhibition assays are also available. Three ***s are used to denote compounds with an IC₅₀ less than 1 micromolar; two **s indicate compound with an IC₅₀ between 1 micromolar and 10 micromolar, and one * denotes compounds with an IC₅₀ greater than 10 micromolar.

Table 6. Non-limiting Examples of Compounds of the Present Invention

Cmp No.	Structure	Name	IC ₅₀	RT min (Method A,B,C or D)	MS (M+1)
1			***	12.55 (D)	580 (M-1)
2		(1S,3aS,6aR)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridin-2-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide	**	3.52 (B)	602
3		(1s,4s)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[2.2.2]octane-3-carboxamide	***	3.07 (B)	616

(continued)

Cmp No.	Structure	Name	IC ₅₀	RT min (Method A,B,C or D)	MS (M+1)
4		(3S)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-(piperidin-1-ylmethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	3.66 (B)	685
5		(3S)-5-(6-azaspiro[2.5]octan-6-ylmethyl)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	3.82 (B)	711
6		(3S)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-(azetidin-1-ylmethyl)-N-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	3.57 (B)	657

(continued)

Cmp No.	Structure	Name	IC ₅₀	RT min (Method A,B,C or D)	MS (M+1)
7		(2S,4R)-1-((2S,4R)-1-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-4-fluoropyrrolidine-2-carbonyl)-N-(6-bromopyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide	**	1.68(A)	695
8			***	13.19 (C)	570
9		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((dimethylamino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.17 (B)	645
10		(1S,3S,5S)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((dimethylamino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	**	2.35 (B)	645

(continued)

Cmp No.	Structure	Name	IC ₅₀	RT min (Method A,B,C or D)	MS (M+1)
11		(3S)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((hexahydrocyclopenta[c]pyrrol-2(1H)-yl)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	0.36 (B)	711
12		(3S)-5-(3-azabicyclo[3.1.1]heptan-3-ylmethyl)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	3.63 (B)	697
13		(3S)-5-(2-azaspiro[3.3]heptan-2-ylmethyl)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	3.58 (B)	697




(continued)

Cmp No.	Structure	Name	IC ₅₀	RT min (Method A,B,C or D)	MS (M+1)
14		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-isopropylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.06 (A)	630
15		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.71 (A)	605
16		(2S,4R)-1-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(cubane-1-ylmethyl)-4-fluoropyrrolidine-2-carboxamide	**	10.52 (D)	541
17		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-((E)-2-fluoro-3-phenylbut-2-en-1-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.08 (A)	581

(continued)

Cmp No.	Structure	Name	IC ₅₀	RT min (Method A,B,C or D)	MS (M+1)
18		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	12.76 (C)	605 (M+2)
19		(2S,4R)-1-(2-(3-acetyl-7-((dimethylamino)methyl)-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide	***	2.31 (B)	637
20		(2S,4R)-1-(2-(3-acetyl-7-(fluoromethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide	***	3.29 (B)	612
21		(2S,4R)-1-(2-(3-acetyl-7-((5-methylpyrimidin-2-yl)methyl)-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide	***	3.18 (B)	686

(continued)

Cmp No.	Structure	Name	IC ₅₀	RT min (Method A,B,C or D)	MS (M+1)
22		(3S)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-(piperazin-1-ylmethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	3.77 (B)	686
23		(2S,4R)-1-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-(cyanomethyl)pyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide	***	1.50 (A)	619
24		(3S)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((4-methylpiperazin-1-yl)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	3.70 (B)	700

(continued)

Cmp No.	Structure	Name	IC ₅₀	RT min (Method A,B,C or D)	MS (M+1)
25		methyl 3-acetyl-1-(2-((2S,4R)-2-((6-bromopyridin-2-yl)carbamoyl)-4-fluoropyrrolidin-1-yl)-2-oxoethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazole-7-carboxylate	***	1.94 (A)	638
26		(3S)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-(aminomethyl)-N-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	**	2.49 (B)	617
27		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-5-fluoro-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.01 (A)	634
28		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(3-chloro-2-fluorobenzyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	11.61 (C)	590

(continued)

Cmp No.	Structure	Name	IC ₅₀	RT min (Method A,B,C or D)	MS (M+1)
29		(1S,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-((allyloxy)methyl)-N-(3-((allyloxy)methyl)-6-bromopyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.28 (A)	714
30		(1R,3S,5R)-2-(2-(3-acetyl-7-(fluoromethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide		3.69 (B)	620
31		(1R,3S,5R)-2-(2-(3-acetyl-7-(fluoromethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	3.48 (B)	634





(continued)

Cmp No.	Structure	Name	IC ₅₀	RT min (Method A,B,C or D)	MS (M+1)
32		(3S)-2-(2-(3-acetyl-7-(methoxymethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridin-2-yl)-5-(methoxymethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	3.47 (B)	662
33		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(2-fluoro-3-(trifluoromethoxy)phenyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	13.96 (C)	625
34		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-((S)-3-fluoro-4-methylpent-3-en-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	10.92 (D)	547
35		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl-N-(1-(2,2,2-trifluoroethyl)-1H-pyrazol-3-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	10.92 (D)	595

(continued)

Cmp No.	Structure	Name	IC ₅₀	RT min (Method A,B,C or D)	MS (M+1)
36		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl-N-(6-(trifluoromethyl)pyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	12.55 (D)	592
37		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl-N-(6-(trifluoromethoxy)pyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	14.96 (C)	608
38		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(2'-chloro-2-fluoro-[1,1'-biphenyl]-3-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	15.94 (C)	652

(continued)

Cmp No.	Structure	Name	IC ₅₀	RT min (Method A,B,C or D)	MS (M+1)
39		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(2'-chloro-2-fluoro-[1,1'-biphenyl]-3-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	12.84 (D)	636 (M-1)
40		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxylic acid	*	1.31 (A)	434
41		3-acetyl-1-(2-((2S,4R)-2-((6-bromopyridin-2-yl)carbamoyl)-4-fluoropyrrolidin-1-yl)-2-oxoethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazole-7-carboxylic acid	***		624
42		(3S)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((methylamino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	4.42 (B)	631

(continued)

Cmp No.	Structure	Name	IC ₅₀	RT min (Method A,B,C or D)	MS (M+1)
43		(1S,3S,5S)-5-(acetamidomethyl)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	**	3.00 (B)	645
44		(1R,3S,5R)-5-(acetamidomethyl)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	3.08 (B)	645
45		methyl ((2S)-1-((((3S)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-3-((6-bromopyridin-2-yl)carbamoyl)-2-azabicyclo[3.1.0]hexan-5-yl)methyl)amino)-3-methyl-1-oxobutan-2-yl)carbamate	***	3.32 (B)	760

(continued)

Cmp No.	Structure	Name	IC ₅₀	RT min (Method A,B,C or D)	MS (M+1)
46		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-5-fluoropyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	3.77 (B)	620
47		(1R,3S,5R)-2-(2-(3-acetyl-7-ethyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	3.59 (B)	630
48		methyl ((2S)-1-((((3S)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-3-((3-bromo-6-(methoxymethyl)pyridin-2-yl)carbamoyl)-2-azabicyclo[3.1.0]hexan-5-yl)methyl)amino)-3-methyl-1-oxobutan-2-yl)carbamate	*	3.20 (B)	804

(continued)

Cmp No.	Structure	Name	IC ₅₀	RT min (Method A,B,C or D)	MS (M+1)
49		(3S)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(3-bromo-6-(methoxymethyl)pyridin-2-yl)-5-(methoxymethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	3.07 (B)	662
50		5-(3-acetyl-1-(2-((1R,3S,5R)-3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-7-methyl-1H-indazol-5-yl)-2-methylpyrimidine 1-oxide	***	3.15 (B)	632
51		(3S)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((dimethylamino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide		2.08 (B)	659
52		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-((R)-1-((R)-2,2-dichlorocyclopropyl)ethyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	11.25 (D)	584

(continued)

Cmp No.	Structure	Name	IC ₅₀	RT min (Method A,B,C or D)	MS (M+1)
53		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyrazin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide		11.10 (C)	604
54		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-5-methylpyrazin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	14.12 (C)	615 (M-2)
55		1-(2-((1R,3S,5R)-3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazole-3-carboxamide	***	8.30 (C)	601 (M-2)
56		1-(2-((1R,2S,5S)-2-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-3-azabicyclo[3.1.0]hexan-3-yl)-2-oxoethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazole-3-carboxamide	***	8.30 (D)	591 (M+2)





(continued)

Cmp No.	Structure	Name	IC ₅₀	RT min (Method A,B,C or D)	MS (M+1)
57		1-(2-((1R,3S,5R)-3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazole-3-carboxamide	***	8.84 (C)	619 (M+2)
58		1-(2-((1R,3S,5R)-3-((6-bromopyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazole-3-carboxamide	***	12.45 (C)	605 (M+2)
59		(2S,4R)-1-(2-(3-acetyl-5-(2-hydroxypyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide		7.92 (D)	597
60		(1R,2S,5S)-3-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-3-azabicyclo[3.1.0]hexane-2-carboxylic acid		1.10 (A)	420

(continued)

Cmp No.	Structure	Name	IC ₅₀	RT min (Method A,B,C or D)	MS (M+1)
61		methyl 2-(2-((2S,4R)-1-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-4-fluoropyrrolidine-2-carboxamido)-6-bromopyridin-3-yl)acetate	***	1.50 (A)	651
62		2-(2-((2S,4R)-1-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-4-fluoropyrrolidine-2-carboxamido)-6-bromopyridin-3-yl)acetic acid	***	1.27 (A)	638
63		3-acetyl-1-(2-((3S)-3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-5-((dimethylamino)methyl)-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazole-7-carboxylic acid		2.07 (B)	689

(continued)

Cmp No.	Structure	Name	IC ₅₀	RT min (Method A,B,C or D)	MS (M+1)
64		5-(3-acetyl-1-(2-((1R,3S,5R)-3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-1H-indazol-5-yl)-2-methylpyrimidine 1-oxide	***	3.06 (B)	618
65		(1R,3S,5S)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-(hydroxymethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.46 (B)	618
66		(2S,4R)-1-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-4-fluoro-4-(fluoromethyl)pyrrolidine-2-carboxamide	***	2.88 (B)	640
67		(1R,3S,5R)-5-(2-azaspiro[3.3]heptan-2-yl)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.78 (B)	697

(continued)

Cmp No.	Structure	Name	IC ₅₀	RT min (Method A,B,C or D)	MS (M+1)
68		(1S,3S,5S)-S-(2-azaspiro[3.3]heptan-2-ylmethyl)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.71 (B)	697
69		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((4-methylpiperazin-1-yl)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.56 (B)	714
70		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-((allyl(methyl)amino)methyl)-N-(3-((allyloxy)methyl)-6-bromopyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.35 (A)	727

(continued)

Cmp No.	Structure	Name	IC ₅₀	RT min (Method A,B,C or D)	MS (M+1)
71		(1R,2S,5S)-N-(6-bromo-3-methylpyridin-2-yl)-3-(2-(3-(1-hydroxyethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-3-azabicyclo[3.1.0]hexane-2-carboxamide	**	1.33 (A)	592
72		(1R,3S,5R)-N-(6-bromo-3-methylpyridin-2-yl)-2-(2-(3-(1-hydroxyethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	**	1.52 (A)	604
73		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(3-bromoisquinolin-1-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.04 (A)	638
74		(1R,3S,5R)-2-(2-(3-acetyl-7-(fluoromethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((dimethylamino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.19 (B)	677

(continued)

Cmp No.	Structure	Name	IC ₅₀	RT min (Method A,B,C or D)	MS (M+1)
75		(1S,3S,5S)-2-(2-(3-acetyl-7-(fluoromethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((dimethylamino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.28 (B)	677
76		(2S,4R)-1-(2-(3-acetyl-7-(fluoromethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-4-fluoro-4-(fluoromethyl)pyrrolidine-2-carboxamide	***	3.22 (B)	658
77		(1S,3S,5S)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-7-(trifluoromethyl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	*	3.66 (B)	670

(continued)

Cmp No.	Structure	Name	IC ₅₀	RT min (Method A,B,C or D)	MS (M+1)
78		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-((4-acetylpiperazin-1-yl)methyl)-N-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[3.1.0] hexane-3-carboxamide	***	3.69 (B)	728
79		(1S,3S,5S)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-((4-acetylpiperazin-1-yl)methyl)-N-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[3.1.0] hexane-3-carboxamide	**	3.74 (B)	728
80		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(3,3-dimethylbutyl)-5-methyl-2-azabicyclo[3.1.0] hexane-3-carboxamide	***	11.05 (D)	531

(continued)

Cmp No.	Structure	Name	IC ₅₀	RT min (Method A,B,C or D)	MS (M+1)
81		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl-N-(2-(trifluoromethoxy)ethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	10.79 (D)	559
82		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-methoxypyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	11.79 (D)	554
83		(2S,4R)-1-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-4-fluoro-N-(6-hydroxypyridin-2-yl)pyrrolidine-2-carboxamide	**	6.71 (C)	518
84		(2S,4R)-1-(2-(3-acetyl-5-(2-((1,1-dioxidothietan-3-yl)oxy)pyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide	***	8.16 (C)	698 (M-2)




(continued)

Cmp No.	Structure	Name	IC ₅₀	RT min (Method A,B,C or D)	MS (M+1)
86		(1R,3S,5R)-2-(2-(3-acetyl-7-(methoxymethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(3-bromo-6-(methoxymethyl)pyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	*	3.24 (B)	676
88		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-(piperazin-1-ylmethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.03 (B)	700
89		(1R,3S,5R)-5-(2-azaspiro[3.3]heptan-2-ylmethyl)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.55 (B)	711

(continued)

Cmp No.	Structure	Name	IC ₅₀	RT min (Method A,B,C or D)	MS (M+1)
90		(1S,3S,5S)-2-(2-(3-acetyl-7-cyclopropyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	3.81 (B)	642
91		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-((dimethylamino)methyl)pyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.15 (A)	645
92		(1R,2S,5S)-3-((1R,2S,5S)-3-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-3-azabicyclo[3.1.0]hexane-2-carbonyl)-N-(6-bromo-3-methylpyridin-2-yl)-3-azabicyclo[3.1.0]hexane-2-carboxamide	**	1.77 (A)	713




(continued)

Cmp No.	Structure	Name	IC ₅₀	RT min (Method A,B,C or D)	MS (M+1)
93		(1R,3S,5S)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-((allyloxy)methyl)-N-(6-bromo-3-vinylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.01 (A)	670
94		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((methylamino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	3.06 (B)	645
95		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((2-fluorocyclopent-1-ene-1-carboxamido)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	3.47 (B)	743

(continued)

Cmp No.	Structure	Name	IC ₅₀	RT min (Method A,B,C or D)	MS (M+1)
96		(1R,3S,5R)-5-(acetamidomethyl)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.96 (B)	673
97		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((2-fluorobenzamido)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	3.52 (B)	753
98		(1R,3S,5S)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-(methoxymethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	3.26 (B)	646

(continued)

Cmp No.	Structure	Name	IC ₅₀	RT min (Method A,B,C or D)	MS (M+1)
99		methyl ((S)-1-((((1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-2-azabicyclo[3.1.0]hexan-5-yl)methyl)amino)-3-methyl-1-oxobutan-2-yl)carbamate	***	3.36 (B)	788
100		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((dimethylamino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.55 (B)	659
101		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-(methylsulfonamidomethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.47 (B)	709

(continued)

Cmp No.	Structure	Name	IC ₅₀	RT min (Method A,B,C or D)	MS (M+1)
102		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((3,3,3-trifluoropropylamido)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	3.45 (B)	741
103		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-((dimethylamino)methyl)pyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.28 (A)	645
104		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-5-fluoro-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.76 (A)	621
105		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-hydroxypyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	8.61 (D)	540

(continued)

Cmp No.	Structure	Name	IC ₅₀	RT min (Method A,B,C or D)	MS (M+1)
106		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-hydroxypyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	8.16 (C)	603 (M-1)
107		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-((1,1-dioxidothietan-3-yl)oxy)pyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	9.30 (C)	706 (M-2)
108		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methoxypyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	12.23 (D)	606 (M+2)
109		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-hydroxypyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	9.82 (D)	588 (M-2)

(continued)

Cmp No.	Structure	Name	IC ₅₀	RT min (Method A,B,C or D)	MS (M+1)
110		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-((1,1-dioxidothietan-3-yl)oxy)pyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	10.49 (C)	692 (M-2)
111		(1R,2S,5S)-3-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-3-azabicyclo[3.1.0]hexane-2-carboxylic acid	*	1.23 (A)	434
112		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-cyclopropylpyridin-2-yl)-5-((dimethylamino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.37 (B)	671
113		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((2-fluoroethyl)amino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.21 (B)	677

(continued)

Cmp No.	Structure	Name	IC ₅₀	RT min (Method A,B,C or D)	MS (M+1)
114		(1R,3S,5S)-2-(2-(3-acetyl-7-(methoxymethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-(methoxymethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.36 (B)	676
115		(1R,2S,5S)-N-(6-bromo-3-methylpyridin-2-yl)-3-(2-(3-(1-hydroxyethyl)-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-3-azabicyclo[3.1.0]hexane-2-carboxamide	**	1.47 (A)	604
116		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-4-fluoropyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.31 (A)	620
117		(2S,4R)-1-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-(2-(dimethylamino)-2-oxoethyl)pyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide	***	1.33 (A)	665




(continued)

Cmp No.	Structure	Name	IC ₅₀	RT min (Method A,B,C or D)	MS (M+1)
118		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((diethylamino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	3.76 (B)	687
119		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-(((3aR,6a-S)-hexahydrocyclopenta[c]pyrrol-2(1H)-yl)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.82 (B)	711
120		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-(methylamino)pyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.77 (A)	617

(continued)

Cmp No.	Structure	Name	IC ₅₀	RT min (Method A,B,C or D)	MS (M+1)
121		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-hydroxypyrimidin-5-yl)-7-methyl-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.52 (A)	617
122		(1S,3S,5S)-2-(2-(3-acetyl-7-(fluoromethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide		2.06 (A)	633
123		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-vinylpyridin-2-yl)-5-((hex-5-en-1-yl(methyl)amino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.47 (A)	725

(continued)

Cmp No.	Structure	Name	IC ₅₀	RT min (Method A,B,C or D)	MS (M+1)
124		(1R,3S,5R)-2-(2-(3-acetyl-7-cyano-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.94 (A)	629
125		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-(dimethylamino)pyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.13 (A)	631
126		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxylic acid	*	1.42 (A)	448

(continued)

Cmp No.	Structure	Name	IC ₅₀	RT min (Method A,B,C or D)	MS (M+1)
127		(1R,3S,5R)-5-(2-oxa-6-azaspiro[3.3]heptan-6-ylmethyl)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.35 (B)	713
128		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-(((3aR,6aS)-hexahydrocyclopenta[c]pyrrol-2(1H)-yl)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.90 (B)	725
129		(1R,3S,5R)-5-(2-azaspiro[3.4]octan-2-ylmethyl)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.78 (B)	725

(continued)

Cmp No.	Structure	Name	IC ₅₀	RT min (Method A,B,C or D)	MS (M+1)
130		(1R,3S,5R)-2-(2-(3-acetyl-4-fluoro-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	3.41 (B)	620
131		(1R,5R)-2-(2-(3-acetyl-7-cyclopropyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	3.66 (B)	642
132		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((ethylamino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.31 (B)	659
133		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-7-(trifluoromethyl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	3.72 (B)	670




(continued)

Cmp No.	Structure	Name	IC ₅₀	RT min (Method A,B,C or D)	MS (M+1)
134		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(3-((allyloxy)methyl)-6-bromopyridin-2-yl)-5-vinyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.15 (A)	670
135		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-chloro-3-((dimethylamino)methyl)pyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.12 (A)	601
136		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-((dimethylamino)methyl)pyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.24 (A)	659
137		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-chloro-3-((dimethylamino)methyl)pyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.21 (A)	615

(continued)

Cmp No.	Structure	Name	IC ₅₀	RT min (Method A,B,C or D)	MS (M+1)
138		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-(morpholinomethyl)pyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.21 (A)	687
139		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-chloro-3-(morpholinomethyl)pyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.19(A)	643
140		(1R,3S,5R)-N-(6-bromo-3-methylpyridin-2-yl)-2-(2-(3-(1-hydroxyethyl)-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.63 (A)	618
141		(1R,2S,5S)-3-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-3-azabicyclo[3.1.0]hexane-2-carboxamide	***	1.46 (A)	589




(continued)

Cmp No.	Structure	Name	IC ₅₀	RT min (Method A,B,C or D)	MS (M+1)
142		(1R,3S,5R)-5-(2-azaspiro [3.4]octa n-2-yl-methyl)-2-(2-(3-acetyl-5-(2-methylpyrimidin -5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[3.1.0] hex-ane-3-carboxamide	***	2.49 (B)	711
143		(1R,3S,5R)-2-(2-(3-acetyl-7-cyano-5-(2-methylpyrimidin -5-yl)-1H-indazol-1-yl) acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((di-methylamino)methyl)-2-azabicyclo[3.1.0] hexane-3-carboxamide	***	2.59 (B)	670
144		(1S,3S,5S)-2-(2-(3-acetyl-7-cyano-5-(2-methylpyrimidin -5-yl)-1H-indazol-1-yl) acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((di-methylamino)methyl)-2-azabicyclo[3.1.0] hexane-3-carboxamide	**	2.65 (B)	670

(continued)

Cmp No.	Structure	Name	IC ₅₀	RT min (Method A,B,C or D)	MS (M+1)
145		1-(2-((1R,3S,5R)-3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-4-fluoro-5-(2-methylpyrimidin-5-yl)-1H-indazole-3-carboxamide	***	2.40 (B)	621
146		(1R,3S,5R)-2-(2-(3-acetyl-7-(difluoromethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	3.72 (B)	652
147		(1R,3S,5R)-2-(2-(3-acetyl-7-fluoro-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.92 (A)	620
148		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-(2-(dimethylamino)-2-oxoethyl)pyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.66 (A)	673

(continued)

Cmp No.	Structure	Name	IC ₅₀	RT min (Method A,B,C or D)	MS (M+1)
149		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-(azetidin-1-yl-methyl)-N-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.34 (B)	671
150		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((3,3-difluoroazetidin-1-yl)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.46 (B)	707
151		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((cyclopropylamino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	3.82 (B)	657




(continued)

Cmp No.	Structure	Name	IC ₅₀	RT min (Method A,B,C or D)	MS (M+1)
152		(1R,3S,5S)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-(methoxymethyl)pyridin-2-yl)-5-(methoxymethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	3.33 (B)	662
153		methyl ((S)-1-((((1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-3-((6-bromo-3-(methoxymethyl)pyridin-2-yl)carbamoyl)-2-azabicyclo[3.1.0]hexan-5-yl)methyl)amino)-3-methyl-1-oxobutan-2-yl)carbamate	***	2.95 (B)	804
154		(1R,3S,5S)-2-(2-(3-acetyl-7-allyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-((allyloxy)methyl)-N-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	3.71 (B)	698

(continued)

Cmp No.	Structure	Name	IC ₅₀	RT min (Method A,B,C or D)	MS (M+1)
155		(1R,3S,5R)-2-(2-(3-acetyl-4-fluoro-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((dimethylamino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.33 (B)	663
156		(1S,3S,5S)-2-(2-(3-acetyl-4-fluoro-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((dimethylamino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	*	2.51 (B)	663
157		(1R,3S,5S)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((2-(dimethylamino)ethoxy)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.08 (A)	688

(continued)

Cmp No.	Structure	Name	IC ₅₀	RT min (Method A,B,C or D)	MS (M+1)
158		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((2,2-difluorocyclopentane-1-carboxamido)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.87 (A)	762
159		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((2,2-difluorocyclopentane-1-carboxamido)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.79 (A)	748
160		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-(((2,2,2-trifluoroethyl)amino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.70 (A)	712




(continued)

Cmp No.	Structure	Name	IC ₅₀	RT min (Method A,B,C or D)	MS (M+1)
161		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-((benzylamino)methyl)-N-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.36 (A)	720
162		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-(cyanomethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.65 (A)	640
163		(1R,3S,5S)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-(fluoromethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.77 (A)	633

(continued)

Cmp No.	Structure	Name	IC ₅₀	RT min (Method A,B,C or D)	MS (M+1)
164		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((3-hydroxyazetidin-1-yl)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.05 (A)	686
165		(1R,3S,5R)-5-(acetamidomethyl)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-(methoxymethyl)pyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.36 (A)	688
166		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-(methoxymethyl)pyridin-2-yl)-5-((dimethylamino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.02 (A)	674

(continued)

Cmp No.	Structure	Name	IC ₅₀	RT min (Method A,B,C or D)	MS (M+1)
167		(1R,3S,5R)-2-(2-(3-acetyl-7-((dimethylamino)methyl)-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.27 (A)	658
168		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((2,2,2-trifluoroacetamido)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.89 (A)	726
169		(1R,3S,5R)-2-(2-(3-acetyl-7-(methoxymethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-(methoxymethyl)pyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.01 (A)	675

(continued)

Cmp No.	Structure	Name	IC ₅₀	RT min (Method A,B,C or D)	MS (M+1)
170		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-(((2-fluorobenzyl)amino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.35 (A)	738
171		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-vinylpyridin-2-yl)-5-((but-3-en-1-yl)sulfonamido)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.85 (A)	748
172		(1R,2S,5S)-3-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-5-fluoro-3-methylpyridin-2-yl)-3-azabicyclo[3.1.0]hexane-2-carboxamide	***	1.55 (A)	607

(continued)

Cmp No.	Structure	Name	IC ₅₀	RT min (Method A,B,C or D)	MS (M+1)
173		(1R,3S,5S)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N3-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3,5-dicarboxamide	*	3.02 (B)	645
174		(1R,3S,5S)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-cyano-2-azabicyclo[3.1.0]hexane-3-carboxamide	*	3.35 (B)	627
175		(2S,4S)-1-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-4-(trifluoromethyl)pyrrolidine-2-carboxamide	***	3.36 (B)	658

(continued)

Cmp No.	Structure	Name	IC ₅₀	RT min (Method A,B,C or D)	MS (M+1)
176		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-((bis(2-fluoroethyl)amino)methyl)-N-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.48 (B)	723
177		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-((3,3-difluoroazetidin-1-yl)methyl)pyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.83 (A)	693
178		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-5-fluoro-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.87 (A)	620

(continued)

Cmp No.	Structure	Name	IC ₅₀	RT min (Method A,B,C or D)	MS (M+1)
179		(1R,3S,5R)-2-(2-(3-acetyl-7-(2-fluoro-1-hydroxyethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.70(B)	604
180		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrazolo[1,5-a]pyrimidin-6-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.04 (A)	641
181		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-b]pyridin-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide		1.70 (A)	603
182		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-b]pyridin-1-yl)acetyl)-N-(6-bromo-5-fluoro-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.79 (A)	621

(continued)

Cmp No.	Structure	Name	IC ₅₀	RT min (Method A,B,C or D)	MS (M+1)
183		(1R,2S,5S)-3-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-b]pyridin-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-3-azabicyclo[3.1.0]hexane-2-carboxamide	***	1.47 (A)	589
184		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[4,3-b]pyridin-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	**	1.55 (A)	603
185		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[4,3-b]pyridin-1-yl)acetyl)-N-(6-bromo-5-fluoro-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	**	1.64 (A)	621
187		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-(difluoromethyl)-4-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.04 (A)	652





(continued)

Cmp No.	Structure	Name	IC ₅₀	RT min (Method A,B,C or D)	MS (M+1)
188		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-vinylpyridin-2-yl)-5-(((N-methylbut-3-en-1-yl)sulfonamido)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.01 (A)	761
189		(1R,3S,5S)-2-(2-(3-acetyl-7-(but-3-en-1-yl)-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-((allyloxy)methyl)-N-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.36 (A)	711
190		(1R,3S,5R)-2-(2-(3-acetyl-7-(1-fluoroethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.05 (A)	647




(continued)

Cmp No.	Structure	Name	IC ₅₀	RT min (Method A,B,C or D)	MS (M+1)
191		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-7-(oxetan-3-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide			
192		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-3-(morpholinomethyl)pyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.10 (A)	688
193		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methoxypyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.84 (A)	619

(continued)

Cmp No.	Structure	Name	IC ₅₀	RT min (Method A,B,C or D)	MS (M+1)
194		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-aminopyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.49 (A)	604
195		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-aminopyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-5-fluoro-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.58 (A)	622
196		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl-N-(3-methyl-6-(trifluoromethoxy)pyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.04 (A)	608
197		(1R,3S,5S)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-(oxazol-5-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.55 (A)	655

(continued)

Cmp No.	Structure	Name	IC ₅₀	RT min (Method A,B,C or D)	MS (M+1)
198		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methoxypyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-5-fluoro-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.92 (A)	637
199		1-(2-((1R,3S,5R)-3-((6-bromo-5-fluoro-3-methylpyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridine-3-carboxamide	***	1.39 (A)	623
200		5-(3-acetyl-1-(2-((1R,3S,5R)-3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-1H-pyrazolo[3,4-c]pyridin-5-yl)-2-methylpyrimidin-1-oxide	***	2.97(B)	619

(continued)

Cmp No.	Structure	Name	IC ₅₀	RT min (Method A,B,C or D)	MS (M+1)
201		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((4-cyclopropyl-1H-1,2,3-triazol-1-yl)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.65 (A)	709
202		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((4-(trimethylsilyl)-1H-1,2,3-triazol-1-yl)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.99 (A)	741
203		(1R,3S,5R)-5-((1H-1,2,3-triazol-1-yl)methyl)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.41 (A)	669





(continued)

Cmp No.	Structure	Name	IC ₅₀	RT min (Method A,B,C or D)	MS (M+1)
204		(1R,3S,5R)-N-(3-(2-oxa-6-azaspiro[3.3]heptan-6-ylmethyl)-6-bromopyridin-2-yl)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.16 (A)	699
205		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.78 (A)	617
206		(1S,3S,5S)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-(((3aR,6aS)-hexahydrocyclopenta[c]pyrrol-2(1H)-yl)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.15(B)	712

(continued)

Cmp No.	Structure	Name	IC ₅₀	RT min (Method A,B,C or D)	MS (M+1)
207		(1S,3S,5S)-5-((2-azaspiro[3.4]octa n-2-yl)methyl)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.16(B)	712
208		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-(oxetan-3-yloxy)pyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	9.30(D)	676 (M +2)
209		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-5-fluoro-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.86 (A)	635

(continued)

Cmp No.	Structure	Name	IC ₅₀	RT min (Method A,B,C or D)	MS (M+1)
210		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[4,3-b]pyridin-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	*	1.80 (A)	617
211		1-(2-((2S,4R)-2-((6-bromopyridin-2-yl)carbamoyl)-4-fluoropyrrolidin-1-yl)-2-oxoethyl)-5-(pyridin-3-yl)-1H-pyrazole-3-carboxamide	***	0.97 (A)	516
212		(1R,3S,5R)-N-(6-bromo-3-methylpyridin-2-yl)-2-(2-(3-carbamoyl-5-(furan-2-yl)-1H-pyrazol-1-yl)acetyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.56 (A)	527
213		(1R,3S,5R)-N-(6-bromo-3-methylpyridin-2-yl)-2-(2-(5-carbamoyl-3-(furan-2-yl)-1H-pyrazol-1-yl)acetyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	**	1.67 (A)	527

(continued)

Cmp No.	Structure	Name	IC ₅₀	RT min (Method A,B,C or D)	MS (M+1)
214		(1R,3S,5R)-N-(6-bromo-3-methylpyridin-2-yl)-2-(2-(3-carbamoyl-5-(thiophen-2-yl)-1H-pyrazol-1-yl)acetyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.65 (A)	543
215		1-(2-((2S,4R)-2-((6-bromopyridin-2-yl)carbamoyl)-4-fluoropyrrolidin-1-yl)-2-oxoethyl)-5-(2-methylpyrimidin-5-yl)-1H-pyrazole-3-carboxamide	*	1.15 (A)	531
216		1-(2-((2S,4R)-2-((6-bromopyridin-2-yl)carbamoyl)-4-fluoropyrrolidin-1-yl)-2-oxoethyl)-3-(2-methylpyrimidin-5-yl)-1H-pyrazole-5-carboxamide	**	1.04 (A)	531

(continued)




Cmp No.	Structure	Name	IC ₅₀	RT min (Method A,B,C or D)	MS (M+1)
217		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-7-(trifluoromethyl)-2H-indazol-2-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	*	3.62 (B)	670
218		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((3,3-difluoroazetidin-1-yl)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide			
219		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrazolo[1,5-a]pyrimidin-6-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.94 (A)	642

(continued)




Cmp No.	Structure	Name	IC ₅₀	RT min (Method A,B,C or D)	MS (M+1)
231		(1S,3S,5S)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-(cyanomethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide		2.45(B)	628
232		(1S,3R,5S)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-(cyanomethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide		2.34(B)	628
233		(1R,2S,5S)-3-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-3-azabicyclo[3.1.0]hexane-2-carboxamide		1.58 (A)	603

Table 7. Additional Non-limiting Examples of Compounds of the Present Invention

Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
234		(1S,3S,5S)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((3,3-difluoroazetidin-1-yl)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide			
235		(1S,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-(fluoromethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	3.06 (B)	621
237		(1R,3S,5R)-2-(2-(3-acetyl-7-(1,2-difluoroethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	3.12 (B)	666

Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B ,C or D)	MS (M+1)
238		(1R,3S,5R)-2-(2-(3-acetyl-7-(2-fluoro-1-hydroxyethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.70 (B)	664
239		(1S,3S,5S)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-(cyanomethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	**	2.45 (B)	628
240		(1S,3R,5S)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-(cyanomethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	**	2.34 (B)	628




Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
241		(1R,2S,5S)-3-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-3-azabicyclo[3.1.0]hexane-2-carboxamide	***	1.58 (A)	603
245		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-(((3aR,6aS)-hexahydrocyclopenta[c]pyrrol-2(1H)-yl)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.44 (B)	712
246		(1R,3S,5R)-5-(2-azaspiro[3.4]octan-2-ylmethyl)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.49 (B)	712




Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
247		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((4-cyclopropyl-1H-1,2,3-triazol-1-yl)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.56 (A)	710
248		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-5-((bis(2-hydroxyethyl)amino)methyl)-N-(6-bromo-5-fluoro-3-methylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.11 (B)	724
249		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-5-fluoro-3-methylpyridin-2-yl)-5-(cyanomethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	3.04 (B)	646




Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B ,C or D)	MS (M+1)
250		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-5-fluoro-3-methylpyridin-2-yl)-5-((3,3-difluoroazetidin-1-yl)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.07 (B)	712
251		(1R,3S,5S)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-5-fluoro-3-methylpyridin-2-yl)-5-(fluoromethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.88 (B)	639
252		(1R,3S,5R)-5-(2-azaspiro[3.4]octan-2-ylmethyl)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-5-fluoro-3-methylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.32 (B)	730




Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
253		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-5-fluoro-3-methylpyridin-2-yl)-5-(((3aR,6aS)-hexahydrocyclopenta[c]pyrrol-2(1H)-yl)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.26 (B)	730
254		5-(3-acetyl-1-(2-(((1R,3S,5R)-3-((6-bromo-5-fluoro-3-methylpyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-1H-pyrazolo[3,4-c]pyridin-5-yl)-2-methylpyrimidine 1-oxide	***	2.50 (B)	637
255		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-3-((2-fluoroethoxy)methyl)pyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.77 (A)	666

Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
256		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-5-methyl-N-(3-methyl-6-(trifluoromethoxy)pyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.93 (A)	609
257		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-((S)-3-fluoro-4-methylpent-3-en-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.16 (A)	533
258		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-3-isobutylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.05 (A)	645




Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
259		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-((R)-1-((R)-2,2-dichlorocyclopropyl)ethyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.11 (A)	569
260		(1R,3S,5S)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-(fluoromethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.95 (B)	621
261		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((3,3-difluoroazetidin-1-yl)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.47 (B)	694




Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
262		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-5-((bis(2-hydroxyethyl)amino)methyl)-N-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.34 (B)	706
263		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-5-fluoro-3-methylpyridin-2-yl)-5-((dimethylamino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.56 (B)	677
264		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-5-fluoro-3-methylpyridin-2-yl)-5-((dimethylamino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.33 (B)	664




Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
265		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-3-((3,4-dihydroisoquinolin-2(1H)-yl)methyl)pyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.46 (A)	734
269		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-7-(trifluoromethyl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	3.54 (B)	671
270		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((3-hydroxyazetidin-1-yl)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.84 (B)	674

Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
271		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-7-(trifluoromethyl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-5-fluoro-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	3.68 (B)	689
272		(1R,3S,5S)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((E)-(hydroxyimino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.37 (B)	632
273		(1R,3S,5S)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-cyano-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.87 (B)	614




Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
274		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-(cyanomethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.43 (B)	628
275		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methoxypyrimidin-5-yl)-7-methyl-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.96 (A)	633
277		(1R,3S,5R)-N-(3-(2-oxa-5-azabicyclo[2.2.1]heptan-5-ylmethyl)-6-bromopyridin-2-yl)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.14 (A)	700




Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
278		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-(methoxymethyl)pyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.77 (A)	632
279		(1R,3R,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	*	2.23 (A)	601
280		(1S,3S,5S)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.22 (A)	601




Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
281		(1S,3R,5S)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	*	2.14 (A)	601
282		(1R,3S,5S)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((S)-1,2-dihydroxyethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.77 (B)	649
283		(1R,3S,5S)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((S)-2-oxo-1,3-dioxolan-4-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide		2.45 (B)	675




Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
284		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-ethyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	3.28 (B)	617
285		(1R,3S,5S)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	3.38 (B)	689
286		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-ethyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	3.22 (B)	616




Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
287		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-(2-(S-methylsulfonimidoyl)ethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.56 (B)	707
288		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-(2-(methylsulfonyl)ethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.96 (B)	708
289		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-3-((3,3,5,5-tetramethylmorpholino)methyl)pyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.91 (A)	744




Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
290		(1R,3S,5R)-2-(2-(3-hydroxyoxetan-3-yl)pyrimidin-5-yl)-7-methyl-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.15 (A)	673
291		(1R,3S,5R)-2-(2-(3-fluorooxetan-3-yl)pyrimidin-5-yl)-7-methyl-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.41 (A)	675
292		(1R,3S,5R)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-(2-(7-methyl-5-(2-methylpyrimidin-5-yl)-3-(oxetan-3-yl)-1H-indazol-1-yl)acetyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.07 (A)	629

Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
293		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-fluoro-6-methylpyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.09 (A)	620
294		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-(methoxymethyl)pyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.66 (A)	633
295		(1R,3S,5S)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-(methoxymethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	3.04 (B)	633

Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
296		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-(pyrrolidin-1-ylmethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.23 (B)	685
297		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((isopropylamino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.91 (B)	673
298		methyl (((1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-2-azabicyclo[3.1.0]hexan-5-yl)methyl)-L-prolinate	***	2.92 (B)	743




Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
299		((((1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-2-azabicyclo[3.1.0]hexan-5-yl)methyl)-L-proline	***	2.85 (B)	729
300		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((tert-butylamino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.16 (B)	687
301		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-((2-fluoroethoxy)methyl)pyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.89 (A)	664




Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
302		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-((2,2,6,6-tetramethylpiperidin-1-yl)methyl)pyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***		
303		(1R,3S,5R)-2-(2-(3-acetyl-5-(5-methylpyrazin-2-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.91 (A)	603
304		(2S,4R)-4-((1H-1,2,3-triazol-1-yl)methyl)-1-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide	***	3.03 (B)	675

Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
305		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-(morpholinomethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.03 (B)	703
306		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((4,4-difluoropiperidin-1-yl)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.95 (B)	737
307		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((tert-butylamino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.26 (B)	675

Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
308		(1R,3S,5R)-N-(3-(2-azabicyclo[2.2.1]heptan-2-ylmethyl)-6-bromopyridin-2-yl)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***		
309		(1R,3S,5S)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-(1-isopropyl-1H-1,2,3-triazol-4-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.71 (A)	699
310		(1R,3S,5R)-5-((1H-pyrazol-1-yl)methyl)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.62 (A)	670




Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
311		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((3-(tert-butyl)-1H-pyrazol-1-yl)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.22 (A)	726
312		(1R,3S,5R)-5-((1H-1,2,4-triazol-1-yl)methyl)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.36 (A)	671
313		(1R,3S,5R)-5-((1H-1,2,4-triazol-1-yl)methyl)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.27 (A)	672




Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
314		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((4-methyl-1H-imidazol-1-yl)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.12 (A)	684
315		(1R,3R,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((4-methyl-1H-imidazol-1-yl)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	**	1.19 (A)	684
316		(1R,3S,5R)-2-(2-(3-acetyl-7-ethyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((dimethylamino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.17 (B)	675




Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
319		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-(3-fluoropropyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	3.05 (B)	651
320		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((dimethylamino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.23 (B)	648
321		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-3-((4-fluoro-4-methylpiperidin-1-yl)methyl)pyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.26 (A)	718

Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
322		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-((4-fluoro-4-methylpiperidin-1-yl)methyl)pyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***		
323		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-3-(3-fluoropropyl)pyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***		
324		(1R,3S,5R)-2-(2-(3-acetyl-7-cyclopropyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.07 (A)	643




Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
325		(1R,3S,5R)-2-(2-(3-acetyl-7-(1,2-difluoroethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((dimethylamino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.09 (B)	709
326		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-(2-fluoroethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	3.31 (B)	635
327		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-(3,3-difluoropropyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	3.56 (B)	667




Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
328		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-(2,2-difluoroethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	3.37 (B)	653
330		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-((3,3-difluoropiperidin-1-yl)methyl)pyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.65 (A)	722
331		(1R,3S,5R)-2-(2-(3-acetyl-5-(2,4-dimethylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.81 (A)	618




Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
332		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-5-methyl-N-(3-methyl-6-(trifluoromethoxy)pyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.03 (A)	623
333		(1R,3S,5S)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-(3-isopropylisoxazol-5-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.13 (A)	699
334		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromopyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.91 (A)	589

Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
335		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromopyrazin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.71 (A)	592
336		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromopyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.02 (A)	603
337		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromopyrazin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.82 (A)	604




Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
338		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((4-(tert-butyl)thiazol-2-yl)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.40 (A)	741
339		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((4-ethylthiazol-2-yl)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.99 (A)	713
340		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-5-methyl-N-(3-methyl-6-(trifluoromethyl)pyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.82 (A)	593

Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
341		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-5-methyl-N-(3-methyl-6-(trifluoromethyl)pyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.92 (A)	607
342		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-(((3-fluoropropyl)amino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	3.62 (B)	691
344		(1R,3S,5R)-5-(2-azaspiro[3.3]heptan-2-ylmethyl)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.71 (B)	712

Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B ,C or D)	MS (M+1)
345		(1R,3S,5R)-2-(2-(3-acetyl-7-(fluoromethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-(3-(dimethylamino)propyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.61 (B)	705
346		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-5-(azetidin-1-ylmethyl)-N-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.31 (B)	672
347		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-(pyrrolidin-1-ylmethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	3.29 (B)	686

Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
348		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((dimethylamino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.56 (B)	660
349		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((5-isopropylthiazol-2-yl)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.20 (A)	729
350		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((3,3-dimethylazetidin-1-yl)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.47 (B)	699

Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
351		(1R,3S,5R)-2-(2-(3-acetyl-7-(fluoromethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-(pyrrolidin-1-ylmethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	4.28 (B)	703
352		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((3,3-dimethylazetidin-1-yl)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	4.25 (B)	700
353		(1R,3S,5R)-2-(2-(3-acetyl-7-(fluoromethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-(azetidin-1-ylmethyl)-N-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	4.46 (B)	689

Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B ,C or D)	MS (M+1)
354		(1R,3S,5R)-5-(2-azaspiro[3.3]heptan-2-ylmethyl)-2-(2-(3-acetyl-7-(fluoromethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.26 (B)	729
355		(1R,3S,5R)-2-(2-(3-acetyl-7-(fluoromethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((3,3-dimethylazetidin-1-yl)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.95 (B)	717
356		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-3-((3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methyl)pyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***		




Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
357		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-((3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methyl)pyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***		
359		(1R,3S,5R)-5-((1,3,4-oxadiazol-2-yl)methyl)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.87 (B)	684
360		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((5-methyl-1,3,4-oxadiazol-2-yl)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.98 (B)	698

Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
361		1-(2-((1R,3S,5R)-3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridine-3-carboxamide	***	2.50 (B)	604
362		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-(5-isopropyl-1,3,4-oxadiazol-2-yl)pyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	**	1.93 (A)	700
363		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methoxypyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.80 (A)	620

Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
364		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-((3-fluoroazetidin-1-yl)methyl)pyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.74 (B)	675
365		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-(cyanomethyl)pyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	3.39 (B)	641
366		(1R,3S,5R)-5-(5-azaspiro[2.3]hexan-5-ylmethyl)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.74 (B)	697




Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
367		(1R,3S,5R)-N-(6-bromo-3-methylpyridin-2-yl)-2-(2-(3-(cyanomethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	*	3.05 (B)	599
368		(1R,3S,5R)-N-(6-bromo-3-methylpyridin-2-yl)-2-(2-(3-(2-cyanopropan-2-yl)-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	*	3.74 (B)	627
369		(1R,3S,5R)-5-(5-azaspiro[2.3]hexan-5-ylmethyl)-2-(2-(3-acetyl-7-(fluoromethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.65 (B)	715

Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
370		(1R,3S,5R)-5-(5-azaspiro[2.3]hexan-5-ylmethyl)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.67 (B)	698
371		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-(((4,5-dihydrooxazol-2-yl)amino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.53 (B)	687
372		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-(((3-methyl-1,2,4-oxadiazol-5-yl)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	3.00 (B)	698

Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
373		(1R,3S,5R)-2-(2-(3-acetyl-6-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.89 (A)	616
374		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-3-((5-butyl-1,3,4-oxadiazol-2-yl)methyl)pyridin-2-yl)-5-vinyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.04 (A)	741
375		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-3-(1,2-dihydroxyethyl)pyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.19 (B)	649

Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
376		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-(2,3-dihydroxypropyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.44 (B)	663
377		(1R,3S,5R)-2-(2-(3-acetyl-7-(fluoromethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-(2-(dimethylamino)ethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.42 (B)	691
378		(1R,3S,5R)-2-(2-(3-acetyl-7-(fluoromethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-(4-(dimethylamino)butyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.24 (B)	719




Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
380		(1R,3S,5R)-2-(2-(3-acetyl-7-(fluoromethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-(3-(dimethylamino)propyl)-N-(3-methyl-6-(trifluoromethyl)pyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.95 (B)	695
381		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-3-(2,2-dimethyl-1,3-dioxolan-4-yl)pyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	3.29 (B)	689
382		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-propyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	3.40 (B)	631




Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
383		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-3-(2-oxo-1,3-dioxolan-4-yl)pyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.70 (B)	675
384		(1R,3S,5S)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((difluoromethoxy)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.86 (B)	669
385		(1R,3R,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-isobutyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	*	3.55 (B)	645

Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
386		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-chloropyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	3.35 (B)	622
387		(1R,3S,5R)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-(2-(5-(2-methylpyrimidin-5-yl)-3-vinyl-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.78 (A)	586
388		(1R,2S,5S)-3-(2-(3-acetyl-7-isopropyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-3-azabicyclo[3.1.0]hexane-2-carboxamide	***	2.01 (A)	633





Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
389		(1R,3S,5R)-2-(2-(3-(1H-imidazole-2-carbonyl)-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	*	8.79 (D)	656 (M+2)
390		(1R,3S,5R)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-(2-(7-methyl-5-(2-methylpyrimidin-5-yl)-3-(2-azaspiro[3.3]heptane-2-carbonyl)-1H-indazol-1-yl)acetyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	*	11.51 (D)	695 (M-2)
393		(1R,2S,5S)-3-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-5-fluoro-3-methylpyridin-2-yl)-3-azabicyclo[3.1.0]hexane-2-carboxamide	***	1.73 (A)	623




Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
394		(1R,3S,5R)-2-(2-(3-acetyl-6-methoxy-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.88 (A)	632
395		methyl 3-acetyl-1-(2-((1R,3S,5R)-3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazole-6-carboxylate	***	1.87 (A)	660
396		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(3-((bis(3,3,3-trifluoropropyl)amino)methyl)-6-bromopyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.62 (A)	810




Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
397		(1R,3S,5R)-N-(3-((2H-tetrazol-5-yl)methyl)-6-bromopyridin-2-yl)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.94 (B)	671
398		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-(2-oxopropyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.77 (B)	645
399		(1R,3S,5R)-2-(2-(3-acetyl-6-chloro-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-((dimethylamino)methyl)pyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.77 (B)	679




Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
400		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-3-(3-morpholinopropyl)pyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.48 (B)	716
401		(1R,3S,5R)-N-(6-bromo-5-fluoro-3-methylpyridin-2-yl)-2-(2-(3-(1-hydroxyethyl)-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.62 (A)	636
402		(1R,3S,5R)-N-(6-bromo-3-methylpyridin-2-yl)-2-(2-(3-(1-hydroxyethyl)-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	**	1.42 (A)	607




Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
407		(1R,3S,5R)-N-(6-bromo-3-methylpyridin-2-yl)-2-(2-(3-cyano-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	11.21 (D)	601 (M+2)
408		(1R,3S,5R)-2-(2-(3-acetyl-7-chloro-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-((dimethylamino)methyl)pyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	3.00 (B)	679
409		(1R,3S,5R)-2-(2-(3-acetyl-7-(fluoromethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((3-methyl-1,2,4-oxadiazol-5-yl)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.92 (B)	716

Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
410		(2S,4R)-1-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-4-fluoro-4-(fluoromethyl)pyrrolidine-2-carboxamide	***	3.02 (B)	641
411		(1R,2S,5S)-3-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(3-chloro-2-fluorobenzyl)-3-azabicyclo[3.1.0]hexane-2-carboxamide	***	3.29 (B)	576
412		(1R,2S,5S)-3-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(3-chloro-2-fluorobenzyl)-3-azabicyclo[3.1.0]hexane-2-carboxamide	***	3.28 (B)	561
413		(1R,2S,5S)-3-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(3-chloro-2-fluorobenzyl)-3-azabicyclo[3.1.0]hexane-2-carboxamide	***	3.41 (B)	575




Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
415		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((diisopropylamino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.81 (B)	715
416		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.70 (A)	603
417		(2S,4R)-1-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-5-fluoro-3-methylpyridin-2-yl)-4-fluoro-4-(fluoromethyl)pyrrolidine-2-carboxamide	***	3.11 (B)	659

Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B ,C or D)	MS (M+1)
418		(2S,4R)-1-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromopyrazin-2-yl)-4-fluoro-4-(fluoromethyl)pyrrolidine-2-carboxamide	***	3.13 (B)	628
419		(2S,4S)-4-((1H-1,2,3-triazol-1-yl)methyl)-1-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide	***	2.97 (B)	675
420		(2S,4R)-1-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-4-((dimethylamino)methyl)-4-fluoropyrrolidine-2-carboxamide	**	2.16 (B)	651

Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
421		(2S,4S)-1-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-4-fluoro-4-(methoxymethyl)pyrrolidine-2-carboxamide	***	3.22 (B)	638
422		(2S,4S)-1-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-4-fluoro-4-(fluoromethyl)pyrrolidine-2-carboxamide	***	2.67 (B)	626
423		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-5-fluoro-3-methylpyridin-2-yl)-5-((3-methyl-1,2,4-oxadiazol-5-yl)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	3.44 (B)	717




Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
424		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-5-fluoro-3-methylpyridin-2-yl)-5-((3-methyl-1,2,4-oxadiazol-5-yl)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	3.54 (B)	716
425		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-((3-methyl-1,2,4-oxadiazol-5-yl)methyl)-N-(3-methyl-6-(trifluoromethyl)pyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	3.66 (B)	688
426		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.78 (A)	615




Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B ,C or D)	MS (M+1)
427		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(3-chloro-2-fluorobenzyl)-5-((3-methyl-1,2,4-oxadiazol-5-yl)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	3.62 (B)	671
428		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-chloropyridin-2-yl)-5-((3-methyl-1,2,4-oxadiazol-5-yl)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	3.35 (B)	720
429		(1R,3S,5R)-2-(2-(3-acetyl-7-(fluoromethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((5-methyl-1,3,4-oxadiazol-2-yl)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	3.22 (B)	716

Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
430		(2S,4R)-1-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-4-fluoro-4-methylpyrrolidine-2-carboxamide	***	3.18 (B)	608
431		1-(2-(((1R,3S,5R)-3-((6-bromo-5-fluoro-3-methylpyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridine-3-carboxamide	***	1.55 (A)	636
432		(2S,4R)-1-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-4-fluoro-4-methylpyrrolidine-2-carboxamide	***	2.84 (B)	623

Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
433		(2S,4R)-1-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-4-fluoro-4-methylpyrrolidine-2-carboxamide	***	2.96 (B)	622
434		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(3-chloro-2-fluorobenzyl)-5-((5-methyl-1,3,4-oxadiazol-2-yl)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	3.15 (B)	671
435		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-((5-methyl-1,3,4-oxadiazol-2-yl)methyl)-N-(3-methyl-6-(trifluoromethyl)pyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	3.27 (B)	688




Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
436		1-(2-(((1R,2S,5S)-2-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-3-azabicyclo[3.1.0]hexan-3-yl)-2-oxoethyl)-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridine-3-carboxamide	***	1.30 (A)	604
437		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.46 (A)	602
438		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-5-fluoro-3-((methylthio)methyl)pyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***		

Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
439		(2S,4R)-1-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-4-fluoro-N-(6-iodopyridin-2-yl)pyrrolidine-2-carboxamide	***	2.93 (B)	628
440		(2S,4R)-1-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-4-fluoro-N-(pyridin-2-yl)pyrrolidine-2-carboxamide	***	1.63 (B)	502
441		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-(((1-(2,2,2-trifluoroethyl)-1H-pyrazol-3-yl)amino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	3.23 (B)	779

Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B ,C or D)	MS (M+1)
444		(2S,4R)-N-(6-bromopyridin-2-yl)-4-fluoro-1-(2-(5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)pyrrolidine-2-carboxamide	**	2.68 (B)	538
445		(2S,4R)-N-(6-bromopyridin-2-yl)-1-(2-(3-ethyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-4-fluoropyrrolidine-2-carboxamide	**	3.18 (B)	566
446		(2S,4R)-1-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridin-2-yl)-4-fluoro-N-methylpyrrolidine-2-carboxamide	*	3.05 (B)	594

Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
447		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyrazin-2-yl)-5-((3-methyl-1,2,4-oxadiazol-5-yl)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	3.33 (B)	685
448		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indol-1-yl)acetyl)-5-methyl-N-(3-methyl-6-(trifluoromethoxy)pyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.04 (A)	621
449		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl-N-(6-(pyridin-2-yloxy)pyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	3.16 (B)	617

Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
450		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl-N-(5-methyl-[2,2'-bipyridin]-6-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	**	2.31 (B)	601
451		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl-N-(2-oxo-2H-[1,2'-bipyridin]-6'-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	3.00 (B)	617
452		(1R,3S,5R)-2-(2-(3-acetyl-5-(pyridin-4-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.26 (B)	587

Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
453		(1R,3S,5R)-2-(2-(3-acetyl-5-(5-methylpyridin-2-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.20 (B)	601
454		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-4-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide		3.36 (B)	603
455		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-4-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	3.48 (B)	617

Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B ,C or D)	MS (M+1)
456		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-4-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	3.50 (B)	616
457		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indol-1-yl)acetyl)-N-(6-bromo-5-fluoro-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.89 (B)	619
458		((1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carbonyl)-L-leucine	***	2.98 (B)	561

Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
459		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indol-1-yl)acetyl)-5-methyl-N-(3-methyl-6-(trifluoromethyl)pyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.92 (A)	605
460		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl-N-(2-oxo-2H-[1,2'-bipyridin]-3-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	3.35 (B)	617
461		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(2-bromo-5-fluoropyridin-4-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	**	3.48 (B)	607

Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B ,C or D)	MS (M+1)
462		((1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carbonyl)-D-phenylalanine	**	3.50 (B)	595
463		((1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carbonyl)-L-phenylalanine		3.48 (B)	595
464		((1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carbonyl)-D-leucine	**	3.30 (B)	561




Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
465		(1R,3S,5R)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-(2-(5-(2-methylpyrimidin-5-yl)-3-(2,2,2-trifluoroacetyl)-1H-indol-1-yl)acetyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	3.51 (B)	655
466		(1R,3S,5R)-2-(2-(3-acetyl-6-fluoro-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	3.28 (B)	620
467		methyl 1-(2-((1R,3S,5R)-3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazole-3-carboxylate	***		




Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
468		(1R,3S,5R)-2-(((1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carbonyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide			
469		1-(2-(((1R,3S,5R)-3-(((6-bromo-3-methylpyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazole-3-carboxylic acid	*	1.52 (A)	604
470		(1R,3S,5R)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-(2-(5-(2-methylpyrimidin-5-yl)-3-(2,2,2-trifluoroacetyl)-1H-pyrrolo[2,3-c]pyridin-1-yl)acetyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.67 (B)	656




Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
471		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)acetyl)-N-(6-bromo-5-fluoro-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.95 (B)	634
472		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.88 (B)	616
473		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-4-fluoropyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	3.68 (B)	621

Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
474		1-(2-((1R,3S,5R)-3-methyl-2-oxo-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-N-ethyl-5-(2-methylpyrimidin-5-yl)-1H-indazole-3-carboxamide	***	1.71 (A)	631
481		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-3-fluoropyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	3.03 (B)	607
482		(1R,3S,5R)-2-(2-(3-acetyl-6-fluoro-5-(2-methylpyrimidin-5-yl)-1H-indol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	3.34 (B)	619




Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
483		(1R,3S,5R)-2-(2-(3-acetyl-2-methyl-5-(2-methylpyrimidin-5-yl)-1H-indol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	3.29 (B)	615
484		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-5-fluoro-3-methylpyridin-2-yl)-5-((5-methyl-1,3,4-oxadiazol-2-yl)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	3.04 (B)	716
485		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-5-fluoro-3-methylpyridin-2-yl)-5-((5-methyl-1,3,4-oxadiazol-2-yl)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.97 (B)	717




Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
486		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-chloropyridin-2-yl)-5-((5-methyl-1,3,4-oxadiazol-2-yl)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.92 (B)	720
487		1-(2-((1R,3S,5R)-5-methyl-3-(propylcarbamoyl)-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-5-(2-methylpyrimidin-5-yl)-N-propyl-1H-indazole-3-carboxamide	**	1.57 (A)	518
488		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-butyl-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.67 (A)	489

Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B ,C or D)	MS (M+1)
492		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-4-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	3.49 (B)	602
493		2-((1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamido)-6-bromoisonicotinic acid	***	3.37 (B)	632
494		(1R,3S,5R)-2-(2-(3-acetyl-7-methoxy-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	3.39 (B)	632

Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
495		((1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carbonyl)glycine	**	2.88 (B)	505
496		1-(2-((1R,3S,5R)-3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-N-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazole-3-carboxamide	***	1.31 (A)	461
497		3-((1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamido)propanoic acid	***	2.92 (B)	519




Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
498		4-(((1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamido)butanoic acid	***	3.09 (B)	533
501		(1R,3S,5R)-2-(((1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carbonyl)-N-(3,6-dimethylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide			
502		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(2-(3-chloro-2-fluorophenyl)propan-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.31 (A)	617




Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
503		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-4-carbamoylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.80 (B)	631
504		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(4-(benzyloxy)-6-bromopyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	4.42 (B)	694
505		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(1,3-diphenylpropan-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	**	3.87 (B)	641

Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
506		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-ethyl-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.42 (A)	474
507		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl-N-propyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.58 (A)	488
508		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-butyl-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.77 (A)	502

Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
509		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl-N-pentyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.94 (A)	516
510		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(cyclopropylmethyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.64 (A)	500
511		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl-N-neopentyl-2-azabicyclo[3.1.0]hexane-3-carboxamide		1.92 (A)	516

Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
512		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-isobutyl-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.75 (A)	502
513		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N,5-dimethyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***		
514		2-(2-((1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamido)-6-bromopyridin-4-yl)acetic acid	***	3.23 (B)	646

Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
516		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-4-propylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	**	4.10 (B)	630
517		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(2,6-dimethylheptan-4-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	4.30 (B)	573
518		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(3-aminopropyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	*	0.89 (A)	489




Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
519		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl-N-(3-(methylamino)propyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	**	0.91 (A)	503
520		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(3-(dimethylamino)propyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	**	0.93 (A)	517
521		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl-N-propyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.48 (A)	474

Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
522		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl-N-pentyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.86 (A)	502
523		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl-N-neopentyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.81 (A)	502
524		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-benzyl-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.74 (A)	522

Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
525		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-hexyl-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.12 (A)	530
526		(1R,3S,5R)-2-(2-(3-acetyl-7-(hydroxymethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.68 (A)	632
529		(3-acetyl-1-(2-((1R,3S,5R)-3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazol-7-yl)methyl acetate	***	1.95 (A)	674

Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B ,C or D)	MS (M+1)
532		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-4-ethylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	3.71 (B)	616
533		2-((1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamido)-2-phenethyl-4-phenylbutanoic acid	*	3.96 (B)	713
534		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(4-(2-amino-2-oxoethyl)-6-bromopyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.81 (B)	645




Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
536		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl-N-phenethyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.94 (A)	550
537		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl-N-(3-phenylpropyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.03 (A)	564
541		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-4-isopropylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	3.93 (B)	630

Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
542		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-4-isobutylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	4.45 (B)	644
543		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-4-cyanopyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.95 (B)	613
544		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-4-(1H-tetrazol-5-yl)pyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	3.65 (B)	656

Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
545		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-4-isopentylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	4.65 (B)	658
546		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-4-(methoxymethyl)pyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	3.68 (B)	632
547		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-4-phenylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	4.45 (B)	664




Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
548		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-4-phenethylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	4.45 (B)	692
549		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-4-butylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	4.53 (B)	644
550		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-4-(trifluoromethyl)pyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***		

Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
551		1-(2-(((1R,3S,5R)-3-methyl-2-oxo-2-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-N-cyclopropyl-5-(2-methylpyrimidin-5-yl)-1H-indazole-3-carboxamide	***	1.73 (A)	642
552		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(3,3-dimethylbutyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***		
553		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl-N-((S)-1-phenylethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***		

Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
554		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl-N-((S)-1-(trifluoromethoxy)propan-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***		
555		(1R,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(4-benzyl-6-bromopyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***		
556		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-4-(2-hydroxyphenyl)pyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***		

Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
557		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(4-((benzyloxy)methyl)-6-bromopyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***		
558		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl-N-((R)-1-phenylethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***		
559		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-((E)-2-fluoro-3-phenylbut-2-en-1-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.14 (A)	581

Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
560		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)acetyl)-N-((E)-2-fluoro-3-phenylbut-2-en-1-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.85 (A)	581
561		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-((E)-2-fluoro-3-phenylbut-2-en-1-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.23 (A)	595
562		1-(2-(((1R,3S,5R)-3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-N-isopropyl-5-(2-methylpyrimidin-5-yl)-1H-indazole-3-carboxamide	**	1.87 (A)	644

Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
563		N-allyl-1-(2-(((1R,3S,5R)-3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazole-3-carboxamide	***	1.80 (A)	642
564		1-(2-(((1R,3S,5R)-3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-5-(2-methylpyrimidin-5-yl)-N-(prop-2-yn-1-yl)-1H-indazole-3-carboxamide	***	1.73 (A)	640
565		(1R,3S,5R)-N-(6-bromo-3-methylpyridin-2-yl)-2-(2-(3-iodo-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.15 (A)	699

Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
566		1-(2-((1R,3S,5R)-3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-N-(1-cyclopropylethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazole-3-carboxamide	***	2.07 (A)	670
567		1-(2-((1R,3S,5R)-3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-N-(2-methylbut-3-yn-2-yl)-5-(2-methylpyrimidin-5-yl)-1H-indazole-3-carboxamide	*	1.99 (A)	668
568		1-(2-((1R,3S,5R)-3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-N-(2-cyclopropylpropan-2-yl)-5-(2-methylpyrimidin-5-yl)-1H-indazole-3-carboxamide	*	2.30 (A)	684

Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
570		1-(2-((1R,3S,5R)-3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-N-(tert-butyl)-5-(2-methylpyrimidin-5-yl)-1H-indazole-3-carboxamide	*	2.14 (A)	658
571		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-((4-(methylsulfonyl)piperidin-1-yl)methyl)pyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.28 (A)	776
572		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-4-(2,2,2-trifluoroethyl)pyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***		




Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
573		1-(2-((1R,3S,5R)-3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-N-(but-3-yn-2-yl)-5-(2-methylpyrimidin-5-yl)-1H-indazole-3-carboxamide	***	1.87 (A)	654
574		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-benzyl-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.88 (A)	536
575		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(2-methoxybenzyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.94 (A)	566

Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
576		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(3-methoxybenzyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.86 (A)	566
577		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(4-methoxybenzyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.90 (A)	566
578		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl-N-((R)-1-(trifluoromethoxy)propan-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide			




Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
579		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl-N-(2-(trifluoromethoxy)ethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***		
580		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl-N-((S)-1-phenylethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.93 (A)	550
581		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl-N-((R)-1-phenylethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.92 (A)	550

Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
582		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(2-fluorobenzyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.87 (A)	554
583		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(3-fluorobenzyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.86 (A)	554
584		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(4-fluorobenzyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.88 (A)	554




Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
585		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl-N-(2-methylbenzyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.95 (A)	550
586		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl-N-(3-methylbenzyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.96 (A)	550
587		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl-N-(4-methylbenzyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.96 (A)	550

Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
588		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-((S)-4,4-dimethylpentan-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	**		
589		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-((R)-4,4-dimethylpentan-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***		
590		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-((S)-1-(3-chloro-2-fluorophenyl)ethyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***		

Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
591		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl-N-(pyrimidin-2-ylmethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.37 (A)	538
592		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl-N-(pyrimidin-4-ylmethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	**	1.32 (A)	538
593		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl-N-(pyrimidin-5-ylmethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.31 (A)	538

Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
594		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl-N-(pyridin-2-ylmethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.24 (A)	537
595		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl-N-(pyridin-3-ylmethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.15 (A)	537
596		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl-N-(pyridin-4-ylmethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.13 (A)	537

Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
597		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl-N-(pyridazin-3-ylmethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.26 (A)	538
598		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl-N-((S)-1-(p-tolyl)ethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	**		
599		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-((S)-1-(3-chlorophenyl)ethyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***		
600		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-((S)-1-(2-fluorophenyl)ethyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***		

Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
601		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-((R)-1-(3-chloro-2-fluorophenyl)ethyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***		
602		(1R,3S,5R)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-(2-(5-(2-methylpyrimidin-5-yl)-3-(methylsulfonyl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide		1.53 (A)	640
603		2-((1R,3S,5R)-2-(2-(3-acetyl-7-(aminomethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamido)-6-bromoisonicotinic acid	***	1.39 (A)	660



Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
604		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(2-cyclohexylethyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.29 (A)	556
605		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl-N-(2-(piperidin-1-yl)ethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	*	1.23 (A)	557
606		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl-N-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	**	1.55 (A)	558

Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
607		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl-N-(2-morpholinoethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	**	1.14 (A)	559
608		(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(2-cyclopentylethyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide		2.14 (A)	542
609		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-isopentyl-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide			
610		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl-N-((S)-3-methylbutan-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide			




Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
611		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-((S)-3,3-dimethylbutan-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide			
612		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl-N-((S)-pentan-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide			
613		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-((S)-hexan-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide			
614		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-((S)-heptan-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide			

Cmp No.	Structure	Name	IC ₅ (Stars)	RT min (A,B,C or D)	MS (M+1)
615		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-((S)-1-(4-fluorophenyl)ethyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide			
616		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-((S)-1-(2,3-dimethylphenyl)ethyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide			
617		(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrazolo[1,5-a]pyrimidin-6-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	1.94 (A)	642



Table 8. Additional Non-limiting Examples of Compounds of the Present Invention

Cmp No.	Structure and Name	IC ₅₀	RT min (A,B,C or D)	MS (M+1)
236	 (1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-7-(2H-tetrazol-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	3.34 (B)	670
242	 (S)-1-(5-(3-acetyl-1-(2-((1R,3S,5R)-3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-1H-indazol-5-yl)pyrimidin-2-yl)-24-carboxy-3,12,21,26-tetraoxo-5,8,14,17-tetraoxa-2,11,20,25-tetraazatetracontan-43-oic acid	***	15.30 (C)	1334



(continued)

Cmp No.	Structure and Name	IC ₅₀	RT min (A,B,C or D)	MS (M+1)
243	 (5S,8S)-7-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-3-phenyl-1-oxa-2,7-diazaspiro[4.4]non-2-ene-8-carboxamide	**	3.73 (B)	721
244	 (8S)-7-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-3-cyclohexyl-1-oxa-2,7-diazaspiro[4.4]non-2-ene-8-carboxamide	***	3.82 (B)	727
266	 (1R,3S,5R)-2-(2-(3-acetyl-7-(but-3-en-1-yl)-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-(hex-5-enamido-methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	3.73 (B)	767


(continued)

Cmp No.	Structure and Name	IC ₅₀	RT min (A,B,C or D)	MS (M+1)
317	 (1R,3S,5R)-2-(2-(3-acetyl-7-cyclopropyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((dimethylamino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.18 (B)	687
318	 (1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-7-(trifluoromethyl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((dimethylamino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.39 (B)	715


(continued)

Cmp No.	Structure and Name	IC ₅₀	RT min (A,B,C or D)	MS (M+1)
329	 (S)-methyl 1-(5-(3-acetyl-1-(2-(((1R,3S,5R)-3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-1H-indazol-5-yl)pyrimidin-2-yl)-24-(methoxycarbonyl)-3,12,21,26-tetraoxo-5,8,14,17-tetraoxa-2,11,20,25-tetraazatritetracontan-43-oate	***	14.33 (D)	1363 (M+2)
343	 (1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-7-(oct-7-en-1-yl)-1H-indazol-1-yl)acetyl)-N-(3-allyl-6-bromopyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	4.43 (B)	738


(continued)

Cmp No.	Structure and Name	IC ₅₀	RT min (A,B,C or D)	MS (M+1)
358	 (S)-methyl 1-((1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-2-azabicyclo[3.1.0]hexan-5-yl)-24-(methoxycarbonyl)-3,12,21,26-tetraoxo-5,8,14,17-tetraoxa-2,11,20,25-tetraazatritetracontan-43-oate	*	14.18 (D)	1363 (M+2)


(continued)

Cmp No.	Structure and Name	IC ₅₀	RT min (A,B,C or D)	MS (M+1)
379	 (S)-1-((1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-2-azabicyclo[3.1.0]hexan-5-yl)-24-carboxy-3,12,21,26-tetraoxo-5,8,14,17-tetra-oxa-2,11,20,25-tetraazatritetracontan-43-oic acid	***	2.41 (A)	1332



(continued)

Cmp No.	Structure and Name	IC ₅₀	RT min (A,B,C or D)	MS (M+1)
391	 (S)-methyl 1-((1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-2-azabicyclo[3.1.0]hexan-5-yl)-24-(methoxycarbonyl)-3,12,21,26-tetraoxo-5,8,14,17-tetraoxa-2,11,20,25-tetraazatritetracontan-43-oate	***	13.74 (D)	1377 (M+2)


(continued)

Cmp No.	Structure and Name	IC ₅₀	RT min (A,B,C or D)	MS (M+1)
392	 (S)-1-((1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-2-azabicyclo[3.1.0]hexan-5-yl)-24-carboxy-3,12,21,26-tetraoxo-5,8,14,17-tetra-oxa-2,11,20,25-tetraazatritetracontan-43-oic acid	***	12.83 (C)	1345 (M-2)


(continued)

Cmp No.	Structure and Name	IC ₅₀	RT min (A,B,C or D)	MS (M+1)
403	 (S)-methyl 1-(5-(3-acetyl-1-(2-((1R,3S,5R)-3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-7-methyl-1H-indazol-5-yl)pyrimidin-2-yl)-24-(methoxycarbonyl)-3,12,21,26-tetraoxo-5,8,14,17-tetraoxa-2,11,20,25-tetraazatritetracontan-43-oate	***	13.95 (D)	1377 (M+2)
404	 (S)-1-(5-(3-acetyl-1-(2-((1R,3S,5R)-3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-7-methyl-1H-indazol-5-yl)pyrimidin-2-yl)-24-carboxy-3,12,21,26-tetraoxo-5,8,14,17-tetraoxa-2,11,20,25-tetraazatritetracontan-43-oic acid	***	13.32 (C)	1349 (M+2)


(continued)

Cmp No.	Structure and Name	IC ₅₀	RT min (A,B,C or D)	MS (M+1)
405	 (S)-methyl 1-(5-(3-acetyl-1-(2-((1R,3S,5R)-3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyrimidin-2-yl)-24-(methoxycarbonyl)-3,12,21,26-tetraoxo-5,8,14,17-tetraoxa-2,11,20,25-tetraazatritetracontan-43-oate	***	14.41 (D)	1364 (M+2)



(continued)

Cmp No.	Structure and Name	IC ₅₀	RT min (A,B,C or D)	MS (M+1)
406	 (S)-methyl 1-(((1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-2-azabicyclo[3.1.0]hexan-5-yl)-24-(methoxycarbonyl)-3,12,21,26-tetraoxo-5,8,14,17-tetraoxa-2,11,20,25-tetraazatritetracontan-43-oate	***	13.42 (D)	1364 (M+2)




(continued)

Cmp No.	Structure and Name	IC ₅₀	RT min (A,B,C or D)	MS (M+1)
414	 (S)-1-(5-(3-acetyl-1-(2-((1R,3S,5R)-3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyrimidin-2-yl)-24-carboxy-3,12,21,26-tetraoxo-5,8,14,17-tetraoxa-2,11,20,25-tetraazatritetracontan-43-oic acid	***	9.04 (D)	1336 (M+2)




(continued)

Cmp No.	Structure and Name	IC ₅₀	RT min (A,B,C or D)	MS (M+1)
442	 (S)-1-((1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-2-azabicyclo[3.1.0]hexan-5-yl)-24-carboxy-3,12,21,26-tetraoxa-5,8,14,17-tetraoxa-2,11,20,25-tetraazatetracontan-43-oic acid	***	4.92 (D)	1336 (M+2)
443	(Structure is shown below) (4S,7S,10S,13S,16S,19S,22S)-22-acetamido-4-((((1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-2-azabicyclo[3.1.0]hexan-5-yl)methyl)carbamoyl)-10,16-bis(2-carboxyethyl)-7,19-bis(4-hydroxybenzyl)-6,9,12,15,18,21-hexaoxo-13-(4-palmitamidobutyl)-5,8,11,14,17,20-hexaazapentacosanedioic acid	**	14.70 (C)	1884 (M+2)
475	 1-((1R,3S,5R)-3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-5-(2-methylpyrimidin-5-yl)-N-propyl-1H-indazole-3-carboxamide	***	1.89 (A)	645




(continued)

Cmp No.	Structure and Name	IC ₅₀	RT min (A,B,C or D)	MS (M+1)
476	 1-(2-(((1R,3S,5R)-3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-N-butyl-5-(2-methylpyrimidin-5-yl)-1H-indazole-3-carboxamide	***		
477	 1-(2-(((1R,3S,5R)-3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-5-(2-methylpyrimidin-5-yl)-N-pentyl-1H-indazole-3-carboxamide	*	2.26 (A)	673
478	 1-(2-(((1R,3S,5R)-3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-N-(cyclopropylmethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazole-3-carboxamide	***	1.95 (A)	657




(continued)

Cmp No.	Structure and Name	IC ₅₀	RT min (A,B,C or D)	MS (M+1)
479	 1-(2-(((1R,3S,5R)-3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-N-(cyclobutylmethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazole-3-carboxamide	**	2.14 (A)	671
480	 1-(2-(((1R,3S,5R)-3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-5-(2-methylpyrimidin-5-yl)-N-neopentyl-1H-indazole-3-carboxamide	*	2.21 (A)	673
489	 N-(2-aminoethyl)-1-(2-(((1R,3S,5R)-3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazole-3-carboxamide	**	1.29 (A)	646




(continued)

Cmp No.	Structure and Name	IC ₅₀	RT min (A,B,C or D)	MS (M+1)
490	 1-(2-(((1R,3S,5R)-3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-N-(2-(methylamino)ethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazole-3-carboxamide	**	1.31 (A)	660
491	 1-(2-(((1R,3S,5R)-3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-N-(2-(dimethylamino)ethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazole-3-carboxamide	*	1.33 (A)	674
499	 1-(2-(((1R,3S,5R)-3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-5-(2-methylpyrimidin-5-yl)-N-(2,2,2-trifluoroethyl)-1H-indazole-3-carboxamide	***		



(continued)

Cmp No.	Structure and Name	IC ₅₀	RT min (A,B,C or D)	MS (M+1)
500	 1-(2-((1R,3S,5R)-3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-N-isobutyl-5-(2-methylpyrimidin-5-yl)-1H-indazole-3-carboxamide	***		
515	 1-(2-((1R,3S,5R)-3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-7-cyano-5-(2-methylpyrimidin-5-yl)-1H-indazole-3-carboxamide	***	3.15 (B)	628
527	 (1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-heptyl-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	***		



(continued)

Cmp No.	Structure and Name	IC ₅₀	RT min (A,B,C or D)	MS (M+1)
528	 (1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl-N-octyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	**	2.50 (A)	558
530	 (1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl-N-nonyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	**	2.68 (A)	572
531	 (1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-decyl-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide	*	2.87 (A)	586

(continued)

Cmp No.	Structure and Name	IC ₅₀	RT min (A,B,C or D)	MS (M+1)
535	(Structure is shown below) (4S,7S,10S,13S,16S,19S,22S)-22-acetamido-4-(((1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-2-azabicyclo[3.1.0]hexan-5-yl)-3-oxo-6,9,12,15,18,21,24,27,30,33,36,39,42,45,48,51,54,57,60,63,66,69,72,75-tetracosaoxa-2-azaheptaheptacontan-77-yl)carbamoyl)-10,16-bis(2-carboxyethyl)-7,19-bis(4-hydroxybenzyl)-6,9,12,15,18,21-hexaoxo-13-(4-palmitamidobutyl)-5,8,11,14,17,20-hexaazapentacosanedioic acid	**	1.51 ()	1506 ((M+2)/2)
538	 (1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl-N-(4-phenylbutyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.18 (A)	578
539	 (1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl-N-(5-phenylpentyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	***	2.34 (A)	592

(continued)

Cmp No.	Structure and Name	IC ₅₀	RT min (A,B,C or D)	MS (M+1)
540	 (1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl-N-(6-phenylhexyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide	**	2.49 (A)	606
569	 1-(2-(((1R,3S,5R)-3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-N-(sec-butyl)-5-(2-methylpyrimidin-5-yl)-1H-indazole-3-carboxamide	**	2.05 (A)	658

EXAMPLE 10. HUMAN FACTOR D ASSAY

[0756] Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various concentrations for 5 min at room temperature in 50 mM Tris, 1M NaCl, pH 7.5. A synthetic substrate Z-L-Lys-SBzl and DTNB (Ellman's reagent) are added to final concentrations of 100 μ M each. Absorbance at 405 nm (A_{405}) is recorded at 30 second intervals for 30 min using a microplate spectrophotometer. IC₅₀ values are calculated by nonlinear regression of complement Factor D reaction rates as a function of test compound concentration.

EXAMPLE 11. HEMOLYSIS ASSAY


[0757] The hemolysis assay was previously described by G. Ruiz-Gomez, et al., J. Med. Chem. (2009) 52: 6042-6052. Prior to the assay, the optimum concentration of Normal Human Serum (NHS) needed to achieve 100% lysis of rabbit erythrocytes (RE) is determined by titration. In the assay, NHS (Complement Technology) is diluted in GVB⁰ Buffer (0.1 % gelatin, 5 mM Veronal, 145 mM NaCl, 0.025 % NaN₃, pH 7.3, Complement Technology) plus 10 mM Mg-EGTA and incubated with test compound at various concentrations for 15 min at 37°C. RE (Complement Technology) freshly suspended in GVB⁰ plus 10 mM Mg-EGTA are added to a final concentration of 1×10^8 cells/mL and reactions are incubated for 30 min at 37°C. Positive control reactions (100% lysis) consist of GVB⁰ plus 10 mM Mg-EGTA with NHS and RE but without test compound; negative control reactions (0% lysis) consist of GVB⁰ plus 10 mM Mg-EGTA with RE only.

Samples are centrifuged at 2000g for 3 min and supernatants collected. Absorbance at 405 nm (A_{405}) is recorded using a microplate spectrophotometer. IC_{50} values are calculated by nonlinear regression from the percentage of hemolysis as a function of test compound concentration.

[0758] This specification has been described with reference to embodiments of the invention. However, one of ordinary skill in the art appreciates that various modifications and changes can be made without departing from the scope of the invention as set forth in the claims below. Accordingly, the specification is to be regarded in an illustrative rather than a restrictive sense, and all such modifications are intended to be included within the scope of invention.

Claims


1. A compound selected from:



5

10


15



20

25


30



35

40

45



50

55

5

10

15

20

25

30




35

40

45

50

55



5

10

15

20

25

30


35

40

45

50

55



5

10

15

20

25

30




35

40

45

50

55



5

10

15

20

25

30


35

40

45

50




55



5

10




15



20

25

30






35

40

45

50



55

5

10

15

20

25

30


35

40

45

50

55



5

10

15

20

25

30




35


40

45

50

55





5

10

15

20

25

30


35

40

45

50

55



5

10

15

20

25

30


35

40

45

50

55



5

10

15

20

25

30


35

40

45

50


55



5

10


15



20

25

30




35

40

45

50



55

5

10

15

20

25

30


35


40

45

50

55





5

10

15

20

25

30


35


40

45

50

55





or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
3. A compound of claim 1, or a pharmaceutically acceptable salt thereof, or pharmaceutical composition according to claim 2 for use in a method of treating a Complement Factor D mediated disorder in a subject.
4. The compound or composition for use of claim 3, wherein the subject is a human.
5. The compound or composition for use of claim 3 or 4, wherein the disorder is selected from hereditary angioedema; capillary leak syndrome; hemolytic uremic syndrome (HUS); neurological disorders; Guillain Barre Syndrome; a disease of the central nervous system or a neurodegenerative condition; glomerulonephritis, preferably membrane proliferative glomerulonephritis; SLE nephritis; proliferative nephritis; liver fibrosis; tissue regeneration; neural regeneration Barraquer-Simons Syndrome; inflammatory effects of sepsis; systemic inflammatory response syndrome (SIRS); a disorder of inappropriate or undesirable complement activation; interleukin-2 induced toxicity during IL-2 therapy; an inflammatory disorder; inflammation of autoimmune diseases; system lupus erythematosus (SLE); lupus nephritis; arthritis; an immune complex disorder; an autoimmune disease; systemic lupus; lupus erythematosus; ischemia/reperfusion injury (I/R injury); myocardial infarction; myocarditis; a post-ischemic reperfusion condition; balloon angioplasty; atherosclerosis; post-pump syndrome in cardiopulmonary bypass or renal bypass; renal ischemia; mesenteric artery reperfusion after aortic reconstruction; antiphospholipid syndrome; autoimmune heart disease; obesity; diabetes; Alzheimer's dementia; stroke; schizophrenia; traumatic brain injury; trauma; Parkinson's disease; epilepsy; transplant rejection; fetal loss; a biomaterial reactions, preferably in hemodialysis or implants; hyperacute allograft rejection; xenograft rejection; transplantation rejection; psoriasis; burn injury; thermal injury, preferably a burn or frostbite; crush injury; asthma; allergy; acute respiratory distress syndrome (ARDS); cystic fibrosis; adult respiratory distress syndrome; dyspnea; hemoptysis; chronic obstructive pulmonary disease (COPD); emphysema; a pulmonary embolism or infarction; pneumonia; a fibrogenic dust disease, preferably caused by an inert dust or mineral, more preferably caused by silicon, coal dust, beryllium, or asbestos; pulmonary fibrosis; an organic dust disease; a chemical injury, preferably a chemical injury caused by an irritant gas or chemical, more preferably a chemical injury caused by chlorine, phosgene, sulfur dioxide, hydrogen sulfide, nitrogen dioxide, ammonia, or hydrochloric acid; a smoke injury; bronchoconstriction, hypersensitivity pneumonitis; a parasitic diseases; Goodpasture's Syndrome (anti-glomerular basement membrane nephritis); pulmonary vasculitis; Pauci-immune vasculitis; and immune complex- associated inflammation.
6. The compound or composition for use of claim 3 or 4, wherein the disorder is selected from abdominal aortic aneurysm; hemodialysis complications; hemolytic anemia; hemodialysis; acute myocardial infarction; aneurysm; cardiopulmonary bypass; dilated cardiomyopathy; complement activation during cardiopulmonary bypass operations; coronary artery disease; restenosis following stent placement; percutaneous transluminal coronary angioplasty (PTCA); antibody-mediated transplant rejection; anaphylactic shock; anaphylaxis; allogenic transplant; humoral and vascular transplant rejection; graft dysfunction; graft-versus-host disease; Graves' disease (Graves' ophthalmopathy); adverse drug reactions; chronic graft vasculopathy; allergic bronchopulmonary aspergillosis; allergic neuritis; drug allergy; radiation- induced lung injury; eosinophilic pneumonia; radiographic contrast media allergy; bronchiolitis

obliterans; interstitial pneumonia; parkinsonism-dementia complex; sporadic frontotemporal dementia; frontotemporal dementia with Parkinsonism linked to chromosome 17; frontotemporal lobar degeneration; tangle only dementia; cerebral amyloid angiopathy; a cerebrovascular disorder; frontotemporal dementia, chronic traumatic encephalopathy (CTE); PD with dementia (PDD); argyrophilic grain dementia, dementia pugilistica, dementia with Lewy Bodies (DLB), or multi-infarct dementia; Creutzfeldt-Jakob disease; Huntington's disease; multifocal motor neuropathy (MMN); prion protein cerebral amyloid angiopathy; polymyositis; postencephalitic parkinsonism; subacute sclerosing panencephalitis; non-Guamanian motor neuron disease with neurofibrillary tangles; neural regeneration; diffuse neurofibrillary tangles with calcification; atopic dermatitis; dermatitis; dermatomyositis bullous pemphigoid; scleroderma; sclerodermatomyositis; psoriatic arthritis; pemphigus vulgaris; Discoid lupus erythematosus; cutaneous lupus; chilblain lupus erythematosus; lupus erythematosus-lichen planus overlap syndrome; cryoglobulinemic vasculitis; mesenteric/enteric vascular disorder; peripheral vascular disorder; antineutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV); IL-2 induced vascular leakage syndrome; immune complex vasculitis; angioedema; low platelets (HELLP) syndrome; sickle cell disease; platelet refractoriness; red cell casts; typical or infectious hemolytic uremic syndrome (tHUS); hematuria, hemorrhagic shock; drug-induced thrombocytopenia; autoimmune hemolytic anemia (AIHA); azotemia; blood vessel and/or lymph vessel inflammation; rotational atherectomy; delayed hemolytic transfusion reaction; British type amyloid angiopathy; Buerger's disease; bullous pemphigoid; C1q nephropathy; cancer; catastrophic antiphospholipid syndrome; wet (exudative) AMD; dry (non-exudative) AMD; chorioretinal degeneration; choroidal neovascularization (CNV); choroiditis; loss of RPE function; loss of vision, preferably loss of visual acuity, loss of visual field, or loss of vision from AMD; retinal damage in response to light exposure; retinal degeneration; retinal detachment; retinal dysfunction; retinal neovascularization (RNV); retinopathy of prematurity; pathological myopia; RPE degeneration; pseudophakic bullous keratopathy; a symptomatic macular degeneration related disorder; optic nerve degeneration; photoreceptor degeneration; cone degeneration; loss of photoreceptor cells; pars planitis; scleritis; proliferative vitreoretinopathy; formation of ocular drusen; chronic urticaria; Churg-Strauss syndrome; cold agglutinin disease (CAD); corticobasal degeneration (CBD); cryoglobulinemia; cyclitis; damage of the Bruch's membrane; Degos disease; diabetic angiopathy; elevated liver enzymes; endotoxemia; epidermolysis bullosa; epidermolysis bullosa acquisita; essential mixed cryoglobulinemia; excessive blood urea nitrogen-BUN; focal segmental glomerulosclerosis; Gerstmann-Straussler-Scheinker disease; giant cell arteritis; gout; Hallervorden-Spatz disease; Hashimoto's thyroiditis; Henoch-Schonlein purpura nephritis; abnormal urinary sediments; a viral infection, preferably an infection by hepatitis virus, hepatitis A virus, hepatitis B virus, hepatitis C virus, human immunodeficiency virus (HIV), Flaviviridae, Retroviruses, Coronaviridae, Poxviridae, Adenoviridae, Herpesviridae, Caliciviridae, Reoviridae, Picornaviridae, Togaviridae, Orthomyxoviridae, Rhabdoviridae, or Hepadnaviridae; Neisseria meningitidis; shiga toxin E. coli-related hemolytic uremic syndrome (STEC-HUS); hemolytic uremic syndrome (HUS); a Streptococcus infection; poststreptococcal glomerulonephritis; hyperlipidemia; hypertension; hypoalbuminemia; hypobolemic shock; hypocomplementemic urticarial vasculitis syndrome; hypophosphatosis; hypovolemic shock; idiopathic pneumonia syndrome; idiopathic pulmonary fibrosis; inclusion body myositis; intestinal ischemia; iridocyclitis; iritis; juvenile chronic arthritis; Kawasaki's disease (arteritis); lipiduria; membranoproliferative glomerulonephritis (MPGN) I; microscopic polyangiitis; mixed cryoglobulinemia; molybdenum cofactor deficiency (MoCD) type A; pancreatitis; panniculitis; Pick's disease; polyarteritis nodosa (PAN); progressive subcortical gliosis; proteinuria; reduced glomerular filtration rate (GFR); a renovascular disorder; multiple organ failure; multiple system atrophy (MSA); myotonic dystrophy; Niemann-Pick disease type C; chronic demyelinating diseases; progressive supranuclear palsy; spinal cord injury; spinal muscular atrophy; spondyloarthropathies; Reiter's syndrome; spontaneous fetal loss; recurrent fetal loss; pre-eclampsia; synucleinopathy; Takayasu's arteritis; post-partum thyroiditis; thyroiditis; Type I cryoglobulinemia; Type II mixed cryoglobulinemia; Type III mixed cryoglobulinemia; ulcerative colitis; uremia; urticaria; venous gas embolus (VGE); Wegener's granulomatosis; von Hippel-Lindau disease; histoplasmosis of the eye; hard drusen; soft drusen; pigment clumping; photoreceptor and/or retinal pigmented epithelia (RPE) loss; autoimmune oophoritis; endometriosis; autoimmune orchitis; Ord's thyroiditis; autoimmune enteropathy; coeliac disease; Hashimoto's encephalopathy; antiphospholipid syndrome (APLS) (Hughes syndrome); aplastic anemia; autoimmune lymphoproliferative syndrome (Canale-Smith syndrome); autoimmune neutropenia; Evans syndrome; pernicious anemia; pure red cell aplasia; thrombocytopenia; adipose dolorosa (Dercum's disease); adult onset Still's disease; ankylosing spondylitis; CREST syndrome; drug-induced lupus; eosinophilic fasciitis (Shulman's syndrome); Felty syndrome; IgG4-related disease; mixed connective tissue disease (MCTD); palindromic rheumatism (Hench-Rosenberg syndrome); Parry-Romberg syndrome; Parsonage-Turner syndrome; relapsing polychondritis (Meyenburg-Altherr-Uehlinger syndrome); retroperitoneal fibrosis; rheumatic fever; Schnitzler syndrome; fibromyalgia; neuromyotonia (Isaac's disease); paraneoplastic degeneration; autoimmune inner ear disease; Meniere's disease; interstitial cystitis; autoimmune pancreatitis; a Zika virus-related disorder; a chikungunya virus-related disorder; subacute bacterial endocarditis (SBE); IgA nephropathy; IgA vasculitis; polymyalgia rheumatic; rheumatoid vasculitis; alopecia areata; autoimmune progesterone dermatitis; dermatitis herpetiformis; erythema nodosum; gestational pemphigoid; hidradenitis suppurativa; lichen sclerosus;

linear IgA disease (LAD); morphea; myositis; pityriasis lichenoides et varioliformis acuta; vitiligo post-myocardial infarction syndrome (Dressler's syndrome); post-pericardiectomy syndrome; autoimmune retinopathy; Cogan syndrome; ligneous conjunctivitis, Mooren's ulcer; opsoclonus myoclonus syndrome; optic neuritis; retinocochleocerebral vasculopathy (Susac's syndrome); sympathetic ophthalmia; Tolosa-Hunt syndrome; interstitial lung disease; antisynthetase syndrome; Addison's disease; autoimmune polyendocrine syndrome (APS) type I; autoimmune polyendocrine syndrome (APS) type II; autoimmune polyendocrine syndrome (APS) type III; disseminated sclerosis (multiple sclerosis, pattern II); rapidly progressing glomerulonephritis (RPGN); juvenile rheumatoid arthritis; enthesitis-related arthritis; reactive arthritis (Reiter's syndrome); autoimmune hepatitis or lupoid hepatitis; primary biliary cirrhosis (PBS); primary sclerosing cholangitis; microscopic colitis; latent lupus (undifferentiated connective tissue disease (UCTD)); acute disseminated encephalomyelitis (ADEM); acute motor axonal neuropathy; anti-n-methyl-D-aspartate receptor encephalitis; Baló concentric sclerosis (Schilder's disease); Bickerstaff's encephalitis; chronic inflammatory demyelinating polyneuropathy; idiopathic inflammatory demyelinating disease; Lambert-Eaton myasthenic syndrome; Oshtoran syndrome; pediatric autoimmune neuropsychiatric disorder associated with streptococcus (PANDAS); progressive inflammatory neuropathy; restless leg syndrome; stiff person syndrome; Sydenham syndrome; transverse myelitis; lupus vasculitis; leukocytoclastic vasculitis; microscopic polyangiitis; polymyositis or ischemic reperfusion injury of the eye; glaucoma; diabetic retinopathy; a blistering cutaneous disease, preferably bullous pemphigoid, pemphigus, or epidermolysis bullosa; ocular cicatricial pemphigoid; uveitis; adult macular degeneration; retinitis pigmentosa; macular edema; diabetic macular edema; Behcet's uveitis; multifocal choroiditis; Vogt-Koyangi-Harada syndrome; intermediate uveitis; birdshot retino-choroiditis; sympathetic ophthalmia; ocular cicatricial pemphigoid; ocular pemphigus; nonarteritic ischemic optic neuropathy; postoperative inflammation; retinal vein occlusion, and central retinal vein occlusion (CVRO).

7. The compound or composition for use of claim 3 or 4, wherein the disorder is paroxysmal nocturnal hemoglobinuria.

8. The compound or composition for use of claim 3 or 4, wherein the disorder is C3 glomerulopathy, optionally C3 glomerulonephritis, or dense deposit disease.

9. The compound or composition for use of claim 3 or 4, wherein the disorder is atypical hemolytic uremic syndrome.

10. The compound or composition for use of claim 3 or 4, wherein the disorder is age-related macular degeneration (AMD).

11. The compound or composition for use of claim 3 or 4, wherein the disorder is selected from fatty liver or a condition stemming from fatty liver, nonalcoholic steatohepatitis (NASH), liver inflammation, cirrhosis, liver failure, dermatomyositis, and amyotrophic lateral sclerosis.

12. The compound or composition for use of claim 3 or 4, wherein the disorder is selected from an ophthalmic disease, optionally early or neovascular age-related macular degeneration (AMD) or geographic atrophy; an autoimmune disease, preferably arthritis or rheumatoid arthritis; multiple sclerosis; a respiratory disease; or a cardiovascular disease.

13. The compound or composition for use of claim 12, wherein the disorder is an autoimmune disease elected from lupus; allograft rejection; an autoimmune thyroid disease, preferably Graves' disease or Hashimoto's thyroiditis; autoimmune uveoretinitis; giant cell arteritis; an inflammatory bowel disease, preferably Crohn's disease, ulcerative colitis, regional enteritis, granulomatous enteritis, distal ileitis, regional ileitis, or terminal ileitis; diabetes, multiple sclerosis, pernicious anemia, psoriasis, rheumatoid arthritis, sarcoidosis, and scleroderma.

14. The compound or composition for use of claim 3 or 4, wherein the disorder is IgA nephropathy.

15. The compound or composition for use of claim 3 or 4, wherein the disorder is lupus nephritis.


16. The compound or composition for use of claim 3 or 4, wherein the disorder is myasthenia gravis.

17. The compound or composition for use of claim 3 or 4, wherein the disorder is sickle cell disease.

18. The compound or composition for use of claim 3 or 4, wherein the disorder is neuromyelitis optica.

Patentansprüche

1. Verbindung, ausgewählt aus:



5

10

15

20

25

30


35


40

45

50

55





5

10

15

20

25

30


35

40

45

50

55



5

10

15

20

25

30


35

40

45

50

55



5

10

15

20

25

30


35

40

45

50

55



5

10

15

20

25

30


35

40

45

50

55



5

10

15

20

25

30


35

40

45

50


55



5

10


15



20

25


30



35

40

45



50

55

5

10

15

20

25

30


35

40

45

50

55



5

10

15

20

25

30


35




40

45

50

55





5

10

15

20

25

30


35

40

45

50

55



5

10

15

20

25

30


35

40


45

50

55



und



oder ein pharmazeutisch unbedenkliches Salz davon.

2. Pharmazeutische Zusammensetzung, umfassend eine Verbindung nach Anspruch 1 oder ein pharmazeutisch unbedenkliches Salz davon und einen pharmazeutisch unbedenklichen Träger.
3. Verbindung nach Anspruch 1 oder ein pharmazeutisch unbedenkliches Salz davon oder pharmazeutische Zusammensetzung nach Anspruch 2 zur Verwendung bei einem Verfahren zur Behandlung einer durch Komplementfaktor D vermittelten Störung bei einem Individuum.
4. Verbindung oder Zusammensetzung zur Verwendung nach Anspruch 3, wobei das Individuum ein Mensch ist.
5. Verbindung oder Zusammensetzung zur Verwendung nach Anspruch 3 oder 4, wobei die Störung aus erblichem Angioödem; Kapillarlecksyndrom; hämolytisch-urämischem Syndrom (HUS); neurologischen Störungen; Guillain-Barre-Syndrom; einer Erkrankung des zentralen Nervensystems oder einem neurodegenerativen Leiden; Glomerulonephritis, vorzugsweise membranproliferativer Glomerulonephritis; SLE-Nephritis; proliferativer Nephritis; Leberfibrose; Geweberegeneration; Nervenregeneration; Barraquer-Simons-Syndrom; entzündlichen Effekten von Sepsis; systemischem inflammatorischem Response-Syndrom (SIRS); einer Störung mit unangemessener oder unerwünschter Komplementaktivierung; Interleukin-2-induzierter Toxizität während einer IL-2-Therapie; einer entzündlichen Störung; Entzündung bei Autoimmunerkrankungen; systemischem Lupus erythematodes (SLE); Lupusnephritis; Arthritis; einer Immunkomplexstörung; einer Autoimmunerkrankung; systemischem Lupus; Lupus erythematodes; Ischämie/Reperfusionsverletzung (I/R-Verletzung); Myokardinfarkt; Myokarditis; einer postischämischen Reperfusionsbedingung; Ballonangioplastie; Atherosklerose; Post-Pump-Syndrom bei kardiopulmonalem Bypass oder renalem Bypass; renaler Ischämie; Mesenterialarterienreperfusion nach Aortarekonstruktion; Antiphospholipidsyndrom; autoimmuner Herzerkrankung; Obesitas; Diabetes; Alzheimer-Demenz; Schlaganfall; Schizophrenie; traumatischer Hirnverletzung; Trauma; Parkinson-Krankheit; Epilepsie; Transplantatabstoßung; Fetusverlust; Biomaterialreaktionen, vorzugsweise bei Hämodialyse oder Implantaten; hyperakuter Allotransplantatabstoßung; Xenotransplantatabstoßung; Transplantatabstoßung; Psoriasis; Brandverletzung; thermischer Verletzung, vorzugsweise einer Verbrennung oder Erfrierung; Quetschungsverletzung; Asthma; Allergie; akutem Atemnotsyndrom (ARDS); zystischer Fibrose; Atemnotsyndrom des Erwachsenen; Dyspnoe; Hämoptysis; chronisch-obstruktiver Lungenerkrankung (Chronic Obstructive Pulmonary Disease, COPD); Emphysem; Lungenembolie oder einem Lungeninfarkt; Pneumonie; einer fibrogenen Staubkrankheit, vorzugsweise verursacht durch einen inerten Staub oder ein Mineral, weiter bevorzugt verursacht durch Silicium, Kohlenstaub, Beryllium oder Asbest; Lungenfibrose; einer durch organische Stäube bedingten Erkrankung; einer chemischen Verletzung, vorzugsweise einer chemischen Verletzung, die durch ein Reizgas oder eine Chemikalie verursacht wird, weiter bevorzugt einer chemischen Verletzung, die durch Chlor, Phosgen, Schwefeldioxid, Schwefelwasserstoff, Stickstoffdioxid, Ammoniak oder Salzsäure verursacht wird; einer Rauchverletzung; Bronchokonstriktion, Hypersensitivitätspneumonitis; einer parasitischen Erkrankung; Goodpasture-Syndrom (Anti-Glomerulusbasalmembran-Nephritis); pulmonaler Vasculitis; pauci-immuner Vaskulitis und immunkomplexassoziierter Entzündung ausgewählt ist.
6. Verbindung oder Zusammensetzung zur Verwendung nach Anspruch 3 oder 4, wobei die Störung aus Bauch-aortenaneurysma; Hämodialysekomplikationen; hämolytischer Anämie; Hämodialyse; akutem Myokardinfarkt; Aneurysma; kardiopulmonalem Bypass; dilatativer Kardiomyopathie; Komplementaktivierung bei kardiopulmonalen Bypass-Operationen; koronarer Herzkrankheit; Restenose nach Stentimplantation; perkutane transluminale Koronarangioplastie (Percutaneous Transluminal Coronary Angioplasty, PTCA); antikörpervermittelter Transplantatabstoßung; anaphylaktischem Schock; Anaphylaxie; allogener Transplantation; humoraler und vaskulärer Transplantatabstoßung; Transplantatdysfunktion; Graftversus-Host-Krankheit; Morbus Basedow (Basedow-Ophthalmopa-

thie); unerwünschten Arzneimittelnebenwirkungen; chronischer Transplantatvaskulopathie; allergischer bronchopulmonaler Aspergilliose; allergischer Neuritis; Arzneimittelallergie; strahlungsinduzierter Lungenverletzung; eosinophiler Pneumonie; Röntgenkontrastmittelallergie; Bronchiolitis obliterans; interstitieller Pneumonie; Parkinsonismus-Demenz-Komplex; sporadischer frontotemporaler Demenz; frontotemporaler Demenz mit Parkinsonismus in Verbindung mit Chromosom 17; Frontotemporallappendegeneration; Tangle-only-Demenz; zerebraler Amyloidangiopathie; einer zerebrovaskulären Störung; frontotemporaler Demenz, chronischer traumatischer Enzephalopathie (Chronic Traumatic Encephalopathy, CTE); PD mit Demenz (PDD); Demenz mit argyrophilen Granula, Boxerenzephalopathie, Demenz mit Lewy-Körperchen (DLB) oder Multiinfarktdemenz; Creutzfeldt-Jakob-Krankheit; Chorea Huntington; multifokaler motorischer Neuropathie (MMN); zerebrale Prionprotein-Amyloid-Angiopathie; Polymyositis; postenzephalitischer Parkinsonismus; subakuter sklerosierender Panenzephalitis; Nicht-Guam-Motoneuronenerkrankung mit neurofibrillären Tangles; Nervenregeneration; diffusen neurofibrillären Tangles mit Verkalkung; atopischer Dermatitis; Dermatitis; Dermatomyositis; bullösem Pemphigoid; Skleroderm; Sklerodermatomyositis; Arthritis psoriatica; Pemphigus vulgaris; diskoidem Lupus erythematodes; kutanem Lupus; Chilblain Lupus erythematodes; Lupus-erythematodes-Lichen-planus-Überlappungssyndrom; kryoglobulinämischer Vaskulitis; mesenterischer/enterischer Gefäßstörung; peripherer Gefäßstörung; ANCA-assoziierte Vaskulitis (AAV) (ANCA = Antineutrophil Cytoplasm Antibody, antineutrophiler zytoplasmatischer Antikörper); IL-2-induziertem Gefäßlecksyndrom; Immunkomplex-Vaskulitis; Angioödem; Syndrom geringer Thrombozytenzahl (HELLP-Syndrom); Sichelzellerkrankung; Thrombozyten-Refraktärität; Erythrozytenzylindern; typischem oder infektiösem hämolytisch-urämischem Syndrom (tHUS); Hämaturie, hämorrhagischem Schock; medikamenteninduzierter Thrombozytopenie; autoimmunhämolytischer Anämie (AIHA); Azotämie; Blutgefäß- und/oder Lymphgefäßentzündung; Rotationsathrektomie; verzögerter hämolytischer Transfusionsreaktion; Amyloidangiopathie vom britischen Typ; Buerger-Krankheit; bullösem Pemphigoid; C1q-Nephropathie; Krebs; katastrophales Antiphospholipidsyndrom; feuchter (exsudativer) AMD; trockener (nicht exsudativer) AMD; chorioretinaler Degeneration; choroidaler Neovaskularisation (CNV); Choroiditis; Verlust der RPE-Funktion; Verlust des Sehvermögens, vorzugsweise Verlust der Sehschärfe, Verlust des Sehfelds oder Verlust des Sehvermögens aufgrund von AMD; Netzhautschädigung als Reaktion auf Lichteinwirkung; Netzhautdegeneration; Netzhautablösung; Netzhautdysfunktion; Netzhautneovaskularisation (RNV); Frühgeborenenretinopathie; pathologischer Myopie; RPE-Degeneration; pseudophaker bullöser Keratopathie; einer mit Symptomen verbundenen Störung, die mit Makuladegeneration in Zusammenhang steht; Optikusdegeneration; Photorezeptordegeneration; Zapfendegeneration; Verlust von Photorezeptorzellen; Pars planitis; Skleritis; proliferativer Vitreoretinopathie; Bildung von Augendrusen; chronischer Urtikaria; Churg-Strauss-Syndrom; Kälteagglutininkrankheit (Cold Agglutinin Disease, CAD); kortikobasaler Degeneration (Corticobasal Degeneration, CBD); Kryoglobulinämie; Zyklitis; Schädigung der Bruch-Membran; Degos-Krankheit; diabetischer Angiopathie; erhöhten Leberenzymen; Endotoxämie; Epidermolysis bullosa; Epidermolysis bullosa acquisita; essentieller gemischter Kryoglobulinämie; übermäßigem Blut-Harnstoff-Stickstoff-BUN; fokaler segmentaler Glomerulosklerose; Gerstmann-Straussler-Scheinker-Krankheit; Riesenzellarteriitis; Gicht; Hallervorden-Spatz-Krankheit; Hashimoto-Thyreoiditis; Henoch-Schonlein-Purpura-Nephritis; abnormalen Harnsedimente; einer Virusinfektion, vorzugsweise einer Infektion mit Hepatitis-Virus, Hepatitis-A-Virus, Hepatitis-B-Virus, Hepatitis-C-Virus, humanem Immundefizienzvirus (HIV), Flaviviridae, Retroviren, Coronaviridae, Poxviridae, Adenoviridae, Herpesviridae, Caliciviridae, Reoviridae, Picornaviridae, Togaviridae, Orthomyxoviridae, Rhabdoviridae oder Hepadnaviridae; Neisseria meningitidis; Shiga-Toxin-E.-coli-assoziiertem hämolytisch-urämischem Syndrom (STEC-HUS); hämolytisch-urämischem Syndrom (HUS); einer Streptokokkeninfektion; poststreptokokkaler Glomerulonephritis; Hyperlipidämie; Hypertonie; Hypoalbuminämie; hypobolämischem Schock; hypokomplementärischem urtikarialem Vaskulitisyndrom; Hypophosphatase; hypovolämischem Schock; idiopathischem Pneumoniesyndrom; idiopathischer Lungenfibrose; Einschlusskörpermyositis; intestinaler Ischämie; Iridozyklitis; Iritis; juveniler chronischer Arthritis; Kawasaki-Krankheit (Arteriitis); Lipidurie; membranoproliferativer Glomerulonephritis (MPGN) I; mikroskopischer Polyangiitis; gemischter Kryoglobulinämie; Molybdän-Cofaktor-Mangel (MoCD) Typ A; Pankreatitis; Pannikulitis; Pick-Krankheit; Polyarteriitis nodosa (PAN); progressiver subkortikaler Gliose; Proteinurie; reduzierter glomerulärer Filtrationsrate (GFR); einer renovaskulären Störung; multiplem Organversagen; multipler Systematrophie (MSA); myotonischer Dystrophie; Niemann-Pick-Krankheit Typ C; chronischen demyelinisierenden Erkrankungen; progressiver supranukleärer Lähmung; Rückenmarksverletzung; spinaler Muskelatrophie; Spondyloarthropathien; Reiter-Syndrom; spontanem Fetusverlust; wiederkehrendem Fetusverlust; Präeklampsie; Synukleinopathie; Takayasu-Arteriitis; postpartaler Thyreoiditis; Thyreoiditis; Kryoglobulinämie Typ I; gemischter Kryoglobulinämie Typ II; gemischter Kryoglobulinämie Typ III; Colitis ulcerosa; Urämie; Urtikaria; venöser Gasembolie (VGE); Wegener-Granulomatose; von-Hippel-Lindau-Krankheit; Histoplasmose des Auges; harten Drusen; weichen Drusen; Pigmentverklumpung; Verlust von Photorezeptoren und/oder retinalen pigmentierten Epithelien (RPE); autoimmuner Oophoritis; Endometriose; Autoimmuner Orchitis; Ord-Thyreoiditis; autoimmuner Enteropathie; Zöliakie; Hashimoto-Enzephalopathie; Antiphospholipidsyndrom (APLS) (Hughes-Syndrom); aplastischer Anämie; autoimmunem lymphoproliferativem Syndrom (Canale-Smith-Syndrom); autoimmuner Neutropenie; Evans-Syndrom; perniziöser Anämie; reiner Erythrozyten-

Aplasie; Thrombozytopenie; Adipositas dolorosa (Dercum-Krankheit); Morbus Still beim Erwachsenen; Spondylitis ankylosans; CREST-Syndrom; arzneimittelinduziertem Lupus; eosinophiler Fasziitis (Shulman-Syndrom); Felty-Syndrom; IgG4-bedingter Erkrankung; gemischter Bindegewebserkrankung (Mixed Connective Tissue Disease, MCTD); palindromischem Rheumatismus (Hench-Rosenberg-Syndrom); Parry-Romberg-Syndrom; Parsonage-Turner-Syndrom; rezidivierender Polychondritis (Meyenburg-Altherr-Uehlinger-Syndrom); retroperitonealer Fibrose; rheumatischem Fieber; Schnitzler-Syndrom; Fibromyalgie; Neuromyotonie (Isaac-Krankheit); paraneoplastischer Degeneration; Autoimmunerkrankung des Innenohrs; Meniere-Krankheit; interstitieller Zystitis; Autoimmunpankreatitis; einer mit dem Zika-Virus zusammenhängenden Störung; einer mit dem Chikungunya-Virus zusammenhängenden Störung; subakuter bakterieller Endokarditis (SBE); IgA-Nephropathie; IgA-Vaskulitis; Polymyalgia rheumatica; rheumatoider Vasculitis; Alopecia areata; Autoimmunprogesterondermatitis; Dermatitis herpetiformis; Erythema nodosum; Gestationspemphigoid; Hidradenitis suppurativa; Lichen sclerosus; linearer IgA-Krankheit (LAD); Morphea; Myositis; Pityriasis lichenoides et varioliformis acuta; Vitiligo; Postmyokardinfarktsyndrom (Dressler-Syndrom); Postperikardiotomiesyndrom; Autoimmunretinopathie; Cogan-Syndrom; holziger Konjunktivitis, Mooren-Ulkus; Opsoklonus-Myoklonus-Syndrom; Optikusneuritis; retinokochleozerebraler Vaskulopathie (Susac-Syndrom); sympathischer Ophthalmie; Tolosa-Hunt-Syndrom; interstitieller Lungenerkrankung; Anti-Synthetase-Syndrom; Morbus Addison; autoimmunem polyendokrinen Syndrom (APS) Typ I; autoimmunem polyendokrinen Syndrom (APS) Typ II; autoimmunem polyendokrinen Syndrom (APS) Typ III; disseminierter Sklerose (multipler Sklerose, Muster II); rasch fortschreitender Glomerulonephritis (Rapidly Progressing Glomerulonephritis, RPGN); juveniler rheumatoider Arthritis; mit Enthesitis zusammenhängender Arthritis; reaktiver Arthritis (Reiter-Syndrom); Autoimmunhepatitis oder lupoider Hepatitis; primärer biliärer Zirrhose (PBS); primärer sklerosierender Cholangitis; mikroskopischer Kolitis; latentem Lupus (undifferenzierte Bindegewebserkrankung (Undifferentiated Connective Tissue Disease, UCTD)); akuter disseminierter Enzephalomyelitis (ADEM); akuter motorischer axonaler Neuropathie; Anti-n-Methyl-D-aspartat-Rezeptor-Enzephalitis; konzentrischer Baló-Sklerose (Schilder-Krankheit); Bickers-taff-Enzephalitis; chronischer entzündlicher demyelinisierender Polyneuropathie; idiopathischer entzündlicher demyelinisierender Erkrankung; Lambert-Eaton-Myasthenia-Syndrom; Oshtoran-Syndrom; pädiatrischer autoimmuner neuropsychiatrischer Störung in Verbindung mit Streptokokken (PANDAS); progressiver entzündlicher Neuropathie; Restless-Leg-Syndrom; Stiff-Person-Syndrom; Sydenham-Syndrom; Querschnittsmyelitis; Lupus vasculitis; leukozytoklastischer Vasculitis; mikroskopischer Polyangiitis; Polymyositis oder Ischämie-Reperfusionverletzung des Auges; Glaukom; diabetischer Retinopathie; einer blasenbildenden Hauterkrankung, vorzugsweise bullösem Pemphigoid, Pemphigus oder Epidermolysis bullosa; okulärem vernarbendem Pemphigoid; Uveitis; Makuladegeneration bei Erwachsenen; Retinitis pigmentosa; Makulaödem; diabetischem Makulaödem; Behcet-Uveitis; multifokaler Choroiditis; Vogt-Koyangi-Harada-Syndrom; intermediärer Uveitis; Birdshot-Retinochoroiditis; sympathischer Ophthalmie; okulärem vernarbendem Pemphigoid; okulärem Pemphigus; nicht arteriitischer ischämischer Optikusneuropathie; postoperativer Entzündung; Netzhautvenenverschluss und Zentralvenenverschluss (Central Retinal Vein Occlusion, CVRO) ausgewählt ist.


7. Verbindung oder Zusammensetzung zur Verwendung nach Anspruch 3 oder 4, wobei es sich bei der Störung um paroxysmale nächtliche Hämoglobinurie handelt.
8. Verbindung oder Zusammensetzung zur Verwendung nach Anspruch 3 oder 4, wobei es sich bei der Störung um **C3**-Glomerulopathie, gegebenenfalls C3-Glomerulonephritis, oder Dense Deposit Disease handelt.
9. Verbindung oder Zusammensetzung zur Verwendung nach Anspruch 3 oder 4, wobei es sich bei der Störung um atypisches hämolytisch-urämisches Syndrom handelt.
10. Verbindung oder Zusammensetzung zur Verwendung nach Anspruch 3 oder 4, wobei es sich bei der Störung um altersbedingte Makuladegeneration (AMD) handelt.
11. Verbindung oder Zusammensetzung zur Verwendung nach Anspruch 3 oder 4, wobei die Störung aus Fettleber oder einem Leiden, das von Fettleber herrührt, nichtalkoholischer Steatohepatitis (NASH), Leberentzündung, Zirrhose, Leberinsuffizienz, Dermatomyositis und amyotropher Lateralsklerose ausgewählt ist.
12. Verbindung oder Zusammensetzung zur Verwendung nach Anspruch 3 oder 4, wobei die Störung aus einer ophthalmischen Erkrankung, gegebenenfalls früher oder neovaskulärer altersbedingter Makuladegeneration (AMD) oder geographischer Atrophie; einer Autoimmunerkrankung, vorzugsweise Arthritis oder rheumatoider Arthritis; multipler Sklerose; einer Atemwegserkrankung oder einer Herz-Kreislauf-Erkrankung ausgewählt ist.
13. Verbindung oder Zusammensetzung zur Verwendung nach Anspruch 12, wobei es sich bei der Erkrankung um eine


Autoimmunerkrankung handelt, die aus Lupus; Allotransplantatabstoßung; einer Autoimmunerkrankung der Schilddrüse, vorzugsweise Morbus Basedow oder Hashimoto-Thyreoiditis; Autoimmunuveoretinitis; Riesenzellerteritis; einer entzündlichen Darmerkrankung, vorzugsweise Morbus Crohn, Colitis ulcerosa, regionaler Enteritis, granulomatöser Enteritis, distaler Ileitis, regionaler Ileitis oder terminaler Ileitis; Diabetes, multipler Sklerose, perniziöser Anämie, Psoriasis, rheumatoider Arthritis, Sarkoidose und Skleroderm ausgewählt ist.

14. Verbindung oder Zusammensetzung zur Verwendung nach Anspruch 3 oder 4, wobei es sich bei der Störung um IgA-Nephropathie handelt.
15. Verbindung oder Zusammensetzung zur Verwendung nach Anspruch 3 oder 4, wobei es sich bei der Störung um Lupusnephritis handelt.
16. Verbindung oder Zusammensetzung zur Verwendung nach Anspruch 3 oder 4, wobei es sich bei der Störung um Myasthenia gravis handelt.
17. Verbindung oder Zusammensetzung zur Verwendung nach Anspruch 3 oder 4, wobei es sich bei der Störung um Sichelzellkrankheit handelt.
18. Verbindung oder Zusammensetzung zur Verwendung nach Anspruch 3 oder 4, wobei es sich bei der Störung um Neuromyelitis optica handelt.

Revendications

1. Composé choisi parmi :





5

10

15

20

25

30


35

40

45

50

55



5

10

15

20

25

30


35

40

45

50

55



5

10

15

20

25

30


35


40


45

50

55







5

10

15

20

25

30


35

40

45

50

55



5

10

15

20

25

30


35

40

45

50

55



5

10

15

20

25

30


35

40

45

50

55



5

10

15

20

25

30


35


40

45

50

55





5

10

15

20

25

30





35

40


45

50

55



, et



ou sel pharmaceutiquement acceptable correspondant.

2. Composition pharmaceutique comprenant un composé selon la revendication 1, ou un sel pharmaceutiquement acceptable correspondant, et un support pharmaceutiquement acceptable.
3. Composé selon la revendication 1, ou sel pharmaceutiquement acceptable correspondant, ou composition pharmaceutique selon la revendication 2, pour une utilisation dans un procédé de traitement d'un trouble médié par le facteur D du complément chez un sujet.
4. Composé ou composition pour une utilisation selon la revendication 3, dans lequel/laquelle le sujet est un humain.
5. Composé ou composition pour une utilisation selon la revendication 3 ou 4, le trouble étant choisi parmi l'angio-œdème héréditaire ; syndrome de fuite capillaire ; syndrome hémolytique et urémique (SHU) ; troubles neurologiques ; syndrome de Guillain-Barré ; une maladie du système nerveux central ou une affection neurodégénérative ; glomérulonéphrite, de préférence une glomérulonéphrite proliférative membranaire ; néphrite du LES ; néphrite proliférative ; fibrose hépatique ; régénération tissulaire ; syndrome de Barraquer-Simons de régénération neurale ; effets inflammatoires de la septicémie ; syndrome de réponse inflammatoire systémique (SIRS) ; un trouble d'activation inappropriée ou indésirable du complément ; toxicité induite par l'interleukine-2 pendant le traitement par IL-2 ; un trouble inflammatoire ; inflammation des maladies autoimmunes ; lupus érythémateux disséminé (LED) ; néphrite lupique ; arthrite ; un trouble du complexe immunitaire ; une maladie auto-immune ; lupus disséminé ; lupus érythémateux ; lésion d'ischémie/reperfusion (lésion d'I/R) ; infarctus du myocarde ; myocardite ; état de reperfusion post-ischémique ; angioplastie par ballonnet ; athérosclérose ; syndrome post-pompe lors d'un pontage cardiopulmonaire ou d'un pontage rénal ; ischémie rénale ; reperfusion de l'artère mésentérique après reconstruction aortique ; syndrome des antiphospholipides ; maladie cardiaque auto-immune ; obésité ; diabète ; démence d'Alzheimer ; accident vasculaire cérébral ; schizophrénie ; traumatisme crânien ; traumatisme ; maladie de Parkinson ; épilepsie ; rejet de greffe ; perte fœtale ; réactions liées à un biomatériau, de préférence en hémodialyse ou lors d'implants ; rejet hyperaigu d'allogreffe ; rejet de xélogreffe ; rejet de transplantation ; psoriasis ; brûlure ; lésion thermique, de préférence une brûlure ou une engelure ; blessure par écrasement ; asthme ; allergie ; syndrome de détresse respiratoire aiguë (SDRA) ; fibrose kystique ; syndrome de détresse respiratoire de l'adulte ; dyspnée ; hémoptysie ; maladie pulmonaire obstructive chronique (MPOC) ; emphysème ; embolie pulmonaire ou infarctus ; pneumonie ; une maladie fibrogène due à la poussière, de préférence causée par une poussière ou un minéral inerte, plus préféra- blement causée par le silicium, la poussière de charbon, le béryllium ou l'amiante ; fibrose pulmonaire ; une maladie due à la poussière organique ; une lésion chimique, de préférence une lésion chimique causée par un gaz ou un produit chimique irritant, plus préféra- blement une lésion chimique causée par le chlore, le phosgène, le dioxyde de soufre, le sulfure d'hydrogène, le dioxyde d'azote, l'ammoniac ou l'acide chlorhydrique ; une lésion due à la fumée ; bronchoconstriction, pneumopathie d'hypersensibilité ; une maladie parasitaire ; syndrome de Goodpasture (néph- rite des anticorps anti-membrane basale glomérulaire) ; vascularite pulmonaire ; vascularite pauci-immune et inflammation associée aux complexes immuns.
6. Composé ou composition pour une utilisation selon la revendication 3 ou 4, le trouble étant choisi parmi l'anévrisme de l'aorte abdominale ; complications de l'hémodialyse ; anémie hémolytique ; hémodialyse ; infarctus aigu du myocarde ; anévrisme ; pontage cardiopulmonaire ; cardiomyopathie dilatée ; activation du complément pendant les opérations de pontage cardiopulmonaire ; maladie coronarienne ; resténose après la pose d'un stent ; angioplastie coronaire transluminale percutanée (ACTP) ; rejet de greffe à médiation par anticorps ; choc anaphylactique ; anaphylaxie ; greffe allogénique ; rejet de greffe humorale et vasculaire ; dysfonctionnement du greffon ; réaction du greffon contre l'hôte ; maladie de Graves (ophtalmopathie de Graves) ; effets indésirables des médicaments ; vasculopathie

chronique du greffon ; aspergillose bronchopulmonaire allergique ; névrite allergique ; allergie médicamenteuse ; lésion pulmonaire radio-induite ; pneumonie éosinophile ; allergie aux produits de contraste radiographiques ; bronchiolite oblitérante ; pneumonie interstitielle ; complexe parkinsonisme-démence ; démence frontotemporale sporadique ; démence frontotemporale avec parkinsonisme lié au chromosome 17 ; dégénérescence lobaire frontotemporale ; démence à enchevêtrement uniquement ; angiopathie amyloïde cérébrale ; trouble cérébrovasculaire ; démence frontotemporale, encéphalopathie traumatique chronique (ETC) ; MP avec démence (DDP) ; démence à grains argyrophiles, démence pugilistique, démence à corps de Lewy (DCL) ou démence à infarctus multiples ; maladie de Creutzfeldt-Jakob ; maladie de Huntington ; neuropathie motrice multifocale (NMM) ; angiopathie amyloïde cérébrale à protéine prion ; polymyosite ; parkinsonisme post-encéphalitique ; panencéphalite sclérosante subaiguë ; maladie du motoneurone non guamanien avec enchevêtrements neurofibrillaires ; régénération neurale ; enchevêtrements neurofibrillaires diffus avec calcification ; dermatite atopique ; dermatite ; dermatomyosite bulleuse pemphigoïde ; sclérodermie ; sclérodermatomyosite ; rhumatisme psoriasique ; pemphigus vulgaire ; lupus érythémateux discoïde ; lupus cutané ; lupus érythémateux avec engelure ; syndrome de chevauchement lupus érythémateux-lichen plan ; vascularite cryoglobulinémique ; trouble vasculaire mésentérique/entérique ; trouble vasculaire périphérique ; vascularite associée aux anticorps anti-cytoplasme des neutrophiles (ANCA) (VAA) ; syndrome de fuite vasculaire induit par l'IL-2 ; vascularite à complexes immuns ; œdème de Quincke ; syndrome de faible numération plaquettaire (HELLP) ; drépanocytose ; état réfractaire plaquettaire ; cylindres de globules rouges ; syndrome hémolytique et urémique typique ou infectieux (SHUt) ; hématurie, choc hémorragique ; thrombocytopénie d'origine médicamenteuse ; anémie hémolytique auto-immune (AHAI) ; azotémie ; inflammation des vaisseaux sanguins et/ou lymphatiques ; athérectomie rotationnelle ; réaction transfusionnelle hémolytique retardée ; angiopathie amyloïde de type britannique ; maladie de Buerger ; pemphigoïde bulleuse ; néphropathie C1q ; cancer ; syndrome catastrophique des antiphospholipides ; DMLA humide (exsudative) ; DMLA sèche (non exsudative) ; dégénérescence chorioretinienne ; néovascularisation choroïdienne (NVC) ; choroïdite ; perte de la fonction de l'EPR ; perte de la vision, de préférence perte d'acuité visuelle, perte du champ visuel ou perte de la vision due à la DMLA ; lésions rétinienues en réponse à une exposition à la lumière ; dégénérescence rétinienne ; décollement de la rétine ; dysfonctionnement rétinien ; néovascularisation rétinienne (NVR) ; rétinopathie du prématuré ; myopie pathologique ; dégénérescence de l'EPR ; kératopathie bulleuse pseudophaque ; trouble symptomatique lié à la dégénérescence maculaire ; dégénérescence du nerf optique ; dégénérescence des photorécepteurs ; dégénérescence des cônes ; perte de cellules photoréceptrices ; pars planite ; sclérite ; vitéo-rétinopathie proliférative ; formation de drusen oculaires ; urticaire chronique ; syndrome de Churg-Strauss ; maladie des agglutinines froides (CAD) ; dégénérescence corticobasale (DCB) ; cryoglobulinémie ; cyclite ; lésion de la membrane de Bruch ; maladie de Degos ; angiopathie diabétique ; enzymes hépatiques élevées ; endotoxémie ; épidermolyse bulleuse ; épidermolyse bulleuse acquise ; cryoglobulinémie mixte essentielle ; excès d'urée sanguine (BUN) ; glomérulosclérose segmentaire focale ; maladie de Gerstmann-Straussler-Scheinker ; artérite à cellules géantes ; goutte ; maladie de Hallervorden-Spatz ; thyroïdite de Hashimoto ; néphrite à purpura de Henoch-Schönlein ; sédiments urinaires anormaux ; une infection virale, de préférence une infection par le virus de l'hépatite, le virus de l'hépatite A, le virus de l'hépatite B, le virus de l'hépatite C, le virus de l'immunodéficience humaine (VIH), les Flaviviridae, les rétrovirus, les Coronaviridae, les Poxviridae, les Adenoviridae, les Herpesviridae, les Caliciviridae, les Reoviridae, les Picornaviridae, les Togaviridae, les Orthomyxoviridae, les Rhabdoviridae ou les Hepadnaviridae ; méningite de Neisseria ; syndrome hémolytique et urémique lié à la toxine Shiga et à E. coli (SHU-STEC) ; syndrome hémolytique et urémique (SHU) ; infection à streptocoque ; glomérulonéphrite poststreptococcique ; hyperlipidémie ; hypertension ; hypoalbuminémie ; choc hypovolémique ; syndrome de vascularite urticarienne hypocomplémentémique ; hypophosphatasie ; choc hypovolémique ; syndrome de pneumonie idiopathique ; fibrose pulmonaire idiopathique ; myosite à inclusions ; ischémie intestinale ; iridocyclite ; iritis ; arthrite chronique juvénile ; maladie de Kawasaki (artérite) ; lipidurie ; glomérulonéphrite membranoproliférative (MPGN) I ; polyangéite microscopique ; cryoglobulinémie mixte ; déficit en cofacteur du molybdène (MoCD) de type A ; pancréatite ; panniculite ; maladie de Pick ; périartérite noueuse (PAN) ; gliose sous-corticale progressive ; protéinurie ; débit de filtration glomérulaire (DFG) réduit ; trouble rénovasculaire ; défaillance multiviscérale ; atrophie multisystémique (AMS) ; dystrophie myotonique ; maladie de Niemann-Pick de type C ; maladies démyélinisantes chroniques ; paralysie supranucléaire progressive ; lésion de la moelle épinière ; atrophie musculaire spinale ; spondylarthropathies ; syndrome de Reiter ; perte fœtale spontanée ; perte fœtale récurrente ; prééclampsie ; synucléinopathie ; artérite de Takayasu ; thyroïdite post-partum ; thyroïdite ; cryoglobulinémie de type I ; cryoglobulinémie mixte de type II ; cryoglobulinémie mixte de type III ; colite ulcéreuse ; urémie ; urticaire ; embolie gazeuse veineuse (EGV) ; granulomatose de Wegener ; maladie de von Hippel-Lindau ; histoplasmosse de l'œil ; drusen durs ; drusen mous ; agglutination pigmentaire ; perte de photorécepteurs et/ou de l'épithélium pigmenté rétinien (EPR) ; ovarite auto-immune ; endométriose ; orchite auto-immune ; thyroïdite d'Ord ; entéropathie auto-immune ; maladie cœliaque ; encéphalopathie de Hashimoto ; syndrome des antiphospholipides (SAPL) (syndrome de Hughes) ; anémie aplasique ; syndrome lymphoprolifératif auto-immun (syndrome de Canale-Smith) ; neutropénie auto-immune ; syndrome d'Evans ; anémie pernicieuse ;

aplasie érythrocytaire pure ; thrombocytopénie ; adipose douloureuse (maladie de Dercum) ; maladie de Still de l'adulte ; spondylarthrite ankylosante ; syndrome CREST ; lupus induit par les médicaments ; fasciite éosinophile (syndrome de Shulman) ; syndrome de Felty ; maladie liée aux IgG4 ; connectivite mixte (MCTD) ; rhumatisme palindromique (syndrome de Hench-Rosenberg) ; syndrome de Parry-Romberg ; syndrome de Parsonage-Turner ;
 5 polychondrite récidivante (syndrome de Meyenburg-Altherr-Uehlinger) ; fibrose rétropéritonéale ; rhumatisme articulaire aigu ; syndrome de Schnitzler ; fibromyalgie ; neuromyotonie (maladie d'Isaac) ; dégénérescence paranéoplasique ; maladie auto-immune de l'oreille interne ; maladie de Ménière ; cystite interstitielle ; pancréatite auto-immune ; une maladie liée au virus Zika ; une maladie liée au virus Chikungunya ; endocardite bactérienne subaiguë (EBS) ; néphropathie à IgA ; vascularite à IgA ; pseudopolyarthrite rhizomélisque ; vascularite rhumatoïde ;
 10 pelade ; dermatite auto-immune à la progestérone ; dermatite herpétiforme ; érythème noueux ; pemphigoïde gestationnelle ; hidradénite suppurée ; lichen scléreux ; maladie linéaire à IgA (LAD) ; morphée ; myosite ; pityriasis lichénoïde et varioliforme aigu ; vitiligo syndrome post-infarctus du myocarde (syndrome de Dressler) ; syndrome post-péricardiectomie ; rétinopathie auto-immune ; syndrome de Cogan ; conjonctivite ligneuse, ulcère de Mooren ; syndrome d'opsoclonie myoclonique ; névrite optique ; vasculopathie rétinocochléocérébrale (syndrome de Susac) ;
 15 ophtalmie sympathique ; syndrome de Tolosa-Hunt ; maladie pulmonaire interstitielle ; syndrome des anti-synthétases ; maladie d'Addison ; syndrome polyendocrinien auto-immun (APS) de type I ; syndrome polyendocrinien auto-immun (APS) de type II ; syndrome polyendocrinien auto-immun (APS) de type III ; sclérose en plaques disséminée (sclérose en plaques, type II) ; glomérulonéphrite à progression rapide (RPGN) ; polyarthrite rhumatoïde juvénile ; arthrite liée à l'entésite ; arthrite réactive (syndrome de Reiter) ; hépatite auto-immune ou hépatite lupoïde ; cirrhose biliaire primitive (PBS) ; cholangite sclérosante primitive ; colite microscopique ; lupus latent (connectivite indifférenciée du tissu conjonctif (UCTD)) ; encéphalomyélite aiguë disséminée (ADEM) ; neuropathie axonale motrice
 20 aiguë ; encéphalite à anticorps antirécepteur du n-méthyl-D-aspartate ; sclérose concentrique de Baló (maladie de Schilder) ; encéphalite de Bickerstaff ; polyneuropathie démyélinisante inflammatoire chronique ; maladie démyélinisante inflammatoire idiopathique ; syndrome myasthénique de Lambert-Eaton ; syndrome d'Oshtoran ; trouble neuropsychiatrique auto-immun pédiatrique associé au streptocoque (PANDAS) ; neuropathie inflammatoire progressive ; syndrome des jambes sans repos ; syndrome de la personne raide ; syndrome de Sydenham ; myélite transverse ; vascularite lupique ; vascularite leucocytoclasique ; polyangéite microscopique ; polymyosite ou lésion ischémique-reperfusion de l'œil ; glaucome ; rétinopathie diabétique ; maladie cutanée bulleuse, de préférence pemphigoïde bulleuse, pemphigus ou épidermolyse bulleuse ; pemphigoïde cicatricielle oculaire ; uvéite ; dégénérescence maculaire de l'adulte ; rétinite pigmentaire ; œdème maculaire ; œdème maculaire diabétique ; uvéite de Behçet ; choroïdite multifocale ; syndrome de Vogt-Koyangi-Harada ; uvéite intermédiaire ; rétino-chorioidite en forme de birdshot ; ophtalmie sympathique ; pemphigoïde cicatricielle oculaire ; pemphigus oculaire ; neuropathie optique ischémique non artéritique ; inflammation postopératoire ; occlusion veineuse rétinienne et occlusion veineuse centrale rétinienne (CVRO).
 30
 35

7. Composé ou composition pour une utilisation selon la revendication 3 ou 4, dans lequel/laquelle le trouble est l'hémoglobinurie nocturne paroxystique.
8. Composé ou composition pour une utilisation selon la revendication 3 ou 4, dans lequel/laquelle le trouble est une
 40 glomérulopathie C3, éventuellement une glomérulonéphrite C3 ou une maladie à dépôts denses.
9. Composé ou composition pour une utilisation selon la revendication 3 ou 4, dans lequel/laquelle le trouble est le syndrome hémolytique et urémique atypique.
- 45 10. Composé ou composition pour une utilisation selon la revendication 3 ou 4, dans lequel/laquelle le trouble est la dégénérescence maculaire liée à l'âge (DMLA).
11. Composé ou composition pour utilisation selon la revendication 3 ou 4, dans lequel/laquelle le trouble est choisi parmi la stéatose hépatique ou un état résultant d'une stéatohépatite non alcoolique (NASH), une inflammation hépatique,
 50 une cirrhose, une insuffisance hépatique, une dermatomyosite et une sclérose latérale amyotrophique.
12. Composé ou composition pour une utilisation selon la revendication 3 ou 4, dans lequel/laquelle le trouble est choisi parmi une maladie ophtalmique, éventuellement une dégénérescence maculaire liée à l'âge (DMLA) précoce ou néovasculaire ou une atrophie géographique ; une maladie auto-immune, de préférence l'arthrite ou la polyarthrite
 55 rhumatoïde ; la sclérose en plaques ; une maladie respiratoire ; ou une maladie cardiovasculaire.
13. Composé ou composition pour une utilisation selon la revendication 12, dans lequel/laquelle le trouble est une maladie auto-immune éluee parmi le lupus ; le rejet d'allogreffe ; une maladie thyroïdienne auto-immune, de

préférence la maladie de Graves ou la thyroïdite de Hashimoto ; l'uvéorétinite auto-immune ; l'artérite à cellules géantes ; une maladie inflammatoire de l'intestin, de préférence la maladie de Crohn, la colite ulcéreuse, l'entérite régionale, l'entérite granulomateuse, l'iléite distale, l'iléite régionale ou l'iléite terminale ; le diabète, la sclérose en plaques, l'anémie pernicieuse, le psoriasis, la polyarthrite rhumatoïde, la sarcoïdose et la sclérodermie.

- 5
14. Composé ou composition pour une utilisation selon la revendication 3 ou 4, dans lequel/laquelle le trouble est une néphropathie à IgA.
- 10
15. Composé ou composition pour une utilisation selon la revendication 3 ou 4, dans lequel/laquelle le trouble est une néphrite lupique.
16. Composé ou composition pour une utilisation selon la revendication 3 ou 4, dans lequel/laquelle le trouble est une myasthénie grave.
- 15
17. Composé ou composition pour une utilisation selon la revendication 3 ou 4, dans lequel/laquelle le trouble est la drépanocytose.
18. Composé ou composition pour une utilisation selon la revendication 3 ou 4, dans lequel/laquelle le trouble est une neuromyéélite optique.
- 20

25

30

35

40

45

50

55




FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6




FIG. 7




FIG. 8




FIG. 9




FIG. 10




FIG. 11




FIG. 12




FIG. 13





FIG. 14






FIG. 15B




FIG. 16




FIG. 17




FIG. 18A




FIG. 18B




FIG. 18C




FIG. 18D




FIG. 18E




FIG. 18F




FIG. 18G




FIG. 18H




FIG. 18I




FIG. 18J




FIG. 18K




FIG. 18L




FIG. 18M




FIG. 18N




FIG. 180




FIG. 18P




FIG. 18Q




FIG. 18R




FIG. 18S




FIG. 18T




FIG. 18U




FIG. 18V




FIG. 19

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- US 6653340 B [0012] [0194]
- WO 2012093101 A [0013] [0194] [0269]
- WO 2013164802 A [0013] [0194]
- WO 2013192345 A [0013] [0194]
- WO 2014002051 A [0013] [0194]
- WO 2014002052 A [0013] [0194] [0377]
- WO 2014002053 A [0013] [0194]
- WO 2014002054 A [0013] [0194]
- WO 2014002057 A [0013] [0024] [0194]
- WO 2014002058 A [0013] [0194]
- WO 2014002059 A [0013] [0194]
- WO 2014005150 A [0013] [0194]
- WO 2014009833 A [0013] [0194]
- WO 2014143638 A [0013] [0194]
- WO 2015009616 A [0013] [0194]
- WO 2015009977 A [0013] [0194]
- WO 2015066241 A [0013] [0194]
- WO 2017098328 A [0015]
- WO 2018015818 A [0015]
- WO 2004045518 A [0016] [0194]
- WO 1999048492 A [0017] [0194]
- WO 1993020099 A [0018] [0194]
- WO 1995029697 A [0019] [0194]
- US 2015017523 W [0020] [0194]
- US 631090 [0020] [0194]
- US 2015017538 W [0020] [0194]
- US 631233 [0020] [0194]
- US 2015017554 W [0020] [0194]
- US 631312 [0020] [0194]
- US 2015017583 W [0020] [0194]
- US 631440 [0020] [0194]
- US 2015017593 W [0020] [0194]
- US 631625 [0020] [0194]
- US 2015017597 W [0020] [0194]
- US 631683 [0020] [0194]
- US 2015017600 W [0020] [0194]
- US 631785 [0020] [0194]
- US 2015017609 W [0020] [0194]
- US 631828 [0020] [0194]
- US 630959 [0020]
- US 9828396 B [0021]
- US 9695205 B [0021]
- US 9598446 B [0021]
- US 9732103 B [0021]
- US 9796741 B [0021]
- US 9732104 B [0021]
- US 9663543 B [0021]
- US 9758537 B [0021]
- US 9643986 B [0021]
- WO 2015130784 A [0021]
- WO 2015130795 A [0021]
- WO 2015130806 A [0021]
- WO 2015130830 A [0021]
- WO 2015130838 A [0021]
- WO 2015130842 A [0021]
- WO 2015130845 A [0021]
- WO 2015130854 A [0021]
- US 20170298084 A [0021]
- US 20160362398 A [0021]
- US 20170189410 A [0021]
- US 20170298085 A [0021]
- US 20180030075 A [0021]
- US 20160362399 A [0021]
- US 20180022766 A [0021]
- US 20160362433 A [0021]
- US 20170260219 A [0021]
- US 20160362432 A [0021]
- US 20180022767 A [0021]
- US 20160361329 A [0021]
- US 20170226142 A [0021]
- WO 2017035353 A [0023]
- US 4983593 A [0111]
- US 5013557 A [0111]
- US 5456923 A [0111]
- US 5576025 A [0111]
- US 5723269 A [0111]
- US 5858411 A [0111]
- US 6254889 B [0111]
- US 6303148 B [0111]
- US 6395302 B [0111]
- US 6497903 B [0111]
- US 7060296 B [0111]
- US 7078057 B [0111]
- US 7404828 B [0111]
- US 8202912 B [0111]
- US 8257741 B [0111]
- US 8263128 B [0111]
- US 8337899 B [0111]
- US 8431159 B [0111]
- US 9028870 B [0111]
- US 9060938 B [0111]
- US 9211261 B [0111]
- US 9265731 B [0111]
- US 9358478 B [0111]
- US 9387252 B [0111]
- GB 929406 B [0124]
- GB 929401 B [0124]
- US 3266987 A [0124]

- US 4794000 A [0124]
- US 4460563 A [0124]
- US 5019400 A, Gombotz [0126]
- US 8691750 B, Consien [0130]
- WO 2012145801 A, Kanwar [0130]
- US 8580311 B, Armes, S. [0130]
- US 8465775 B [0130]
- US 8444899 B [0130]
- US 8420124 B [0130]
- US 8263129 B [0130]
- US 8158728 B [0130]
- US 8268446 B [0130]
- US 5578325 A [0130] [0140]
- US 6007845 A [0130] [0140]
- US 5543158 A, Gref [0130]
- WO 2009051837 A, Von Andrian [0130]
- US 6123727 A [0130]
- US 5804178 A [0130]
- US 5770417 A [0130]
- US 5736372 A [0130]
- US 5716404 A [0130]
- US 6095148 A [0130]
- US 5837752 A [0130]
- US 5902599 A [0130]
- US 5696175 A [0130]
- US 5514378 A [0130]
- US 5512600 A [0130]
- US 5399665 A [0130]
- US 5019379 A [0130]
- US 5010167 A [0130]
- US 4806621 A [0130]
- US 4638045 A [0130]
- US 4946929 A [0130]
- US 6506577 B [0130]
- US 6632922 B [0130]
- US 6686446 B [0130]
- US 6818732 B [0130]
- US 6632671 B, Unger [0130]
- US 7383837 B [0136]
- WO 2006033584 A [0136]
- WO 2005044186 A [0136]
- US 9095670 B [0136]
- US 8205611 B [0136]
- WO 2013038170 A [0136]
- US 20140352690 A [0136]
- US 8910625 B [0136]
- US 20150165137 A [0136]
- US 6948496 B [0136]
- US 20050152849 A [0136]
- US 6582678 B [0136]
- US 8137657 B [0136]
- US 20030202944 A [0136]
- US 20100330188 A [0136]
- US 6221338 B [0136]
- US 6989155 B [0136]
- US 20070043030 A [0136]
- US 7845349 B [0136]
- US 20120114709 A [0136]
- US 8101160 B [0136]
- US 20130287854 A [0136]
- US 20140037737 A [0136]
- US 8580306 B [0136]
- US 20150174343 A [0136]
- US 7744855 B [0136]
- US 20100285142 A [0136]
- US 7541022 B [0136]
- US 20090269412 A [0136]
- US 20150050350 A [0136]
- US 8192408 B [0137]
- US 7585517 B [0137]
- US 5710182 A [0137]
- US 5795913 A [0137]
- US 8663639 B [0137]
- US 8486960 B [0137]
- US 8367097 B [0137]
- US 8927005 B [0137]
- US 7455855 B [0137]
- WO 2011050365 A [0137]
- WO 2009145842 A [0137]
- US 9066779 B [0137]
- US 8623395 B [0137]
- WO 2014160884 A [0137]
- US 8399006 B [0137]
- US 8277830 B [0137]
- US 8795712 B [0137]
- US 8808727 B [0137]
- US 8298578 B [0137]
- WO 2010088548 A [0137]
- WO 2014152959 A [0137]
- US 20140276482 A [0137]
- US 8905963 B [0137]
- US 9033911 B [0137]
- WO 2015057554 A [0137]
- US 8715712 B [0137]
- US 8939948 B [0137]
- WO 2013116061 A [0137]
- WO 2014066775 A [0137]
- WO 2015085234 A [0137]
- WO 2012019176 A [0137]
- WO 2012065006 A [0137]
- WO 2010141729 A [0137]
- WO 2011050327 A [0137]
- WO 2013022801 A [0137]
- WO 2012019047 A [0137]
- WO 2012068549 A [0137]
- WO 2012019139 A [0137]
- WO 2013040426 A [0137]
- WO 2012019136 A [0137]
- WO 2013040247 A [0137]
- WO 2015085251 A [0138]
- WO 2011008737 A [0138]
- WO 2013082111 A [0138]
- WO 2009132265 A [0138]
- WO 2010099321 A [0138]
- WO 2008100304 A [0138]
- WO 2007024323 A [0138]

- WO 2010009087 A [0138]
- WO 2009132206 A [0138]
- WO 2007133808 A [0138]
- WO 2007056561 A [0138]
- WO 2010065748 A [0138]
- WO 2007081876 A [0138]
- WO 2011106702 A [0139]
- US 8889193 B [0139]
- WO 2013138343 A [0139]
- US 8962577 B [0139]
- WO 2013138346 A [0139]
- US 20130272994 A [0139]
- WO 2005072710 A [0139]
- US 8957034 B [0139]
- WO 2008030557 A [0139]
- US 20100215580 A [0139]
- US 20130164343 A [0139]
- WO 2012061703 A [0139]
- US 20120121718 A [0139]
- US 20130236556 A [0139]
- WO 2012039979 A [0139]
- US 20130183244 A [0139]
- WO 2012109363 A [0139]
- US 20130323313 A [0139]
- WO 2013090804 A [0139]
- US 20140329913 A [0139]
- WO 2013110028 A [0139]
- WO 2013166498 A [0139]
- US 20150086484 A [0139]
- WO 2013166385 A [0139]
- US 20130323179 A [0139]
- WO 2015066444 A [0139]
- WO 2014020210 A [0139]
- WO 2013166408 A [0139]
- US 9022970 B [0139]
- WO 2011153349 A [0139]
- WO 2011140203 A [0139]
- WO 2011068955 A [0139]
- WO 2011037908 A [0139]
- US 20070149593 A [0139]
- US 8632809 B [0139]
- US 20090203709 A [0140]
- US 20050009910 A [0140]
- US 20130071349 A [0140]
- US 8481069 B [0140]
- US 8465778 B [0140]
- US 8409607 B [0140]
- US 8512738 B [0140]
- US 20140031408 A [0140]
- US 20140294986 A [0140]
- US 8911768 B [0140]
- US 6495164 B [0140]
- WO 2014047439 A [0140]
- WO 2010132664 A [0140]
- US 20120052041 A [0140]
- US 20140178475 A [0140]
- US 20140248358 A [0140]
- US 20140249158 A [0140]
- US 5869103 A [0140]
- US 8628801 B [0140]
- US 20140107025 A [0140]
- US 6287588 B [0140]
- US 6589549 B [0140]
- US 20040234611 A [0140]
- US 20080305172 A [0140]
- US 20120269894 A [0140]
- US 20130122064 A [0140]
- US 6413539 B [0140]
- US 20070071756 A [0140]
- US 20080166411 A [0140]
- US 6706289 B [0140]
- US 8663674 B [0140]
- US 5502077 A [0198]
- US 5656667 A [0198]
- US 5698594 A [0198]
- WO 2014037480 A [0257]
- WO 2004111041 A [0267]
- WO 2004007501 A [0267]

Non-patent literature cited in the description

- Structure-Based Library Design and Fragment Screening for the Identification of Reversible Complement Factor D Protease Inhibitors. **VULPETTI et al.** *J. Med. Chem.*, Novartis [0014]
- **MAIBAUM et al.** *Nat. Chem. Bio.*, 2016, vol. 12, 1105 [0014]
- **LAU et al.** Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. *J. Med. Chem.*, 2015, vol. 58, 7370-7380 [0033] [0046]
- **DE MARCO, R. et al.** In-peptide synthesis of di-oxazolidinone and dehydroamino acid-oxazolidinone motifs as β -turn inducers. *J. Org. Biomol. Chem.*, 2013, vol. 11, 4316-4326 [0042]
- **HIRSCHMANN, R.F. et al.** The β -D-Glucose Scaffold as a β -Turn Mimetic. *Accounts Chem. Res.*, 2009, vol. 42, 1511-1520 [0042]
- **SMITH, A.B et al.** *Accounts of Chem. Res.*, 2011, vol. 44, 180-193 [0042]
- **NAIR, R.V. et al.** Synthetic turn mimetics and hairpin nucleators: Quo Vadimus?. *Chem. Comm.*, 2014, vol. 50, 13874-13884 [0042]
- **CHAUME, G. et al.** Concise access to enantiopure (S)- or (R)- α -trifluoromethyl pyroglutamic acids from ethyl trifluoropyruvate-base chiral CF₃-oxazolidines (Fox). *J. Fluor. Chem.*, 2008, vol. 129, 1104-1109 [0042]

- **ANDRE, C. et al.** S)-ABOC: A Rigid Bicyclic β -Amino Acid as Turn Inducer. *Org. Lett.*, 2012, vol. 14, 960-963 [0042]
- **TOMASII, C. ; ANGELICIM G. ; CASTELLUCCI, N.** Foldamers Based on Oxazolidin-2-ones. *Eur. J. Org. Chem.*, 2011, 3648-3669 [0042]
- **PAQUETTE, LEO A.** Principles of Modern Heterocyclic Chemistry. W. A. Benjamin, 1968 [0086]
- The Chemistry of Heterocyclic Compounds, A series of Monographs. John Wiley & Sons, 1950, vol. 13,14,16,19,28 [0086]
- *J. Am. Chem. Soc.*, 1960, vol. 82, 5566 [0086]
- Remington's Pharmaceutical Sciences. Mack Publishing Company, 1985, 1418 [0094]
- **JAIN, S.L. et al.** Rhenium-Catalyzed Highly Efficient Oxidations of Tertiary Nitrogen Compounds to N-Oxides Using Sodium Percarbonate as Oxygen Source. *Synlett*, 2006, 2261-2663 [0100]
- **BAHRAMI, M. et al.** TAPC-Promoted Oxidation of sulfides and Deoxygenation of Sulfoxides. *J. Org. Chem.*, 2010, vol. 75, 6208-6213 [0102]
- **KIRIHARA, A. et al.** Tantalum Carbide or Niobium Carbide Catalyzed Oxidation of Sulfides with Hydrogen Peroxide: Highly Efficient and Chemoselective Syntheses of Sulfoxides and Sulfones. *Synlett*, 2010, 1557-1561 [0102]
- **KIRIHARA, A. et al.** Tantalum Carbide or Niobium Carbide Catalyzed Oxidation of Sulfides with Hydrogen Peroxide: Highly Efficient and Chemoselective Syntheses of Sulfoxides and Sulfones. *Synlett*, 2010, 1557-1561 [0102]
- **VARMA, R.S. ; NAICKER, K.P.** The Urea-Hydrogen Peroxide Complex: Solid-State Oxidative Protocols for Hydroxylated Aldehydes and Ketones (Dakin Reaction), Nitriles, Sulfides, and Nitrogen Heterocycles. *Org. Lett.*, 1999, vol. 1, 189-191 [0102]
- **PAPISOV.** ACS Symposium Series, 2001, vol. 786, 301 [0114]
- **ZHANG, L. et al.** Nanoparticles in Medicine: Therapeutic Applications and Developments. *Clin. Pharm. and Ther.*, 2008, vol. 83 (5), 761-769 [0129]
- **MULLER, R.H. et al.** Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. *Eur. J. Pharm. Biopharm.*, 2000, vol. 50, 161-177 [0130]
- **PETROS, R.A. ; DESIMONE, J.M.** Strategies in the design of nanoparticles for therapeutic applications. *Nature Reviews/Drug Discovery*, 2010, vol. 9, 615-627 [0130]
- **PELLEGRINO et al.** *Small*, 2005, vol. 1, 48 [0130]
- **MURRAY et al.** *Ann. Rev. Mat. Sci.*, 2000, vol. 30, 545 [0130]
- **TRINDADE et al.** *Chem. Mat.*, 2001, vol. 13, 3843 [0130]
- Microcapsules and Nanoparticles in Medicine and Pharmacy. CRC Press, 1992 [0130]
- **MATHIOWITZ et al.** *J. Control. Release*, 1987, vol. 5, 13 [0130]
- **MATHIOWITZ et al.** *Reactive Polymers*, 1987, vol. 6, 275 [0130]
- **MATHIOWITZ et al.** *J. Appl. Polymer Sci.*, 1988, vol. 35, 755 [0130]
- **P. PAOLICELLI et al.** Surface-modified PLGA-based Nanoparticles that can Efficiently Associate and Deliver Virus-like Particles. *Nanomedicine.*, 2010, vol. 5 (6), 843-853 [0130]
- **ZAUNER et al.** *Adv. Drug Del. Rev.*, 1998, vol. 30, 97 [0130]
- **KABANOV et al.** *Bioconjugate Chem.*, 1995, vol. 6, 7 [0130]
- **BOUSSIF et al.** *Proc. Natl. Acad. Sci., USA*, 1995, vol. 92, 7297 [0130]
- **KUKOWSKA-LATALLO et al.** *Proc. Natl. Acad. Sci., USA*, 1996, vol. 93, 4897 [0130]
- **TANG et al.** *Bioconjugate Chem.*, 1996, vol. 7, 703 [0130]
- **HAENSLER et al.** *Bioconjugate Chem.*, 1993, vol. 4, 372 [0130]
- **PUTNAM et al.** *Macromolecules*, 1999, vol. 32, 3658 [0130]
- **BARRERA et al.** *J. Am. Chem. Soc.*, 1993, vol. 115, 11010 [0130]
- **KWON et al.** *Macromolecules*, 1989, vol. 22, 3250 [0130]
- **LIM et al.** *J. Am. Chem. Soc.*, 1999, vol. 121, 5633 [0130]
- **ZHOU et al.** *Macromolecules*, 1990, vol. 23, 3399 [0130]
- **WANG et al.** *J. Am. Chem. Soc.*, 2001, vol. 123, 9480 [0130]
- **LIM et al.** *J. Am. Chem. Soc.*, 2001, vol. 123, 2460 [0130]
- **LANGER.** *Acc. Chem. Res.*, 2000, vol. 33, 94 [0130]
- **LANGER.** *J. Control. Release*, 1999, vol. 62, 7 [0130]
- **UHRICH et al.** *Chem. Rev.*, 1999, vol. 99, 3181 [0130]
- Concise Encyclopedia of Polymer Science and Polymeric Amines and Ammonium Salts. Pergamon Press, 1980 [0130]
- **ODIAN.** Principles of Polymerization. John Wiley & Sons, 2004 [0130]
- **ALLCOCK et al.** Contemporary Polymer Chemistry. Prentice-Hall, 1981 [0130]
- **DEMING et al.** *Nature*, 1997, vol. 390, 386 [0130]
- **C. ASTETE et al.** Synthesis and characterization of PLGA nanoparticles. *J. Biomater. Sci. Polymer Edn*, 2006, vol. 17 (3), 247-289 [0130]
- **K. AVGOUSTAKIS.** Pegylated Poly(Lactide) and Poly(Lactide-Co-Glycolide) Nanoparticles: Preparation, Properties and Possible Applications in Drug Delivery. *Current Drug Delivery*, 2004, vol. 1, 321-333 [0130]
- **C. REIS et al.** Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticles. *Nanomedicine*, 2006, vol. 2, 8-21 [0130]

- *Pharmaceutical Research*, 1986, vol. 3 (6), 318 [0135]
- **ABRAMOWICZ D et al.** Release of tumor necrosis factor, interleukin-2, and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients. *Transplantation*, 1989, vol. 47 (4), 606-8 [0149]
- **CHATENOUD L et al.** In vivo cell activation following OKT3 administration. Systemic cytokine release and modulation by corticosteroids. *Transplantation*, 1990, vol. 49 (4), 697-702 [0149]
- **LIM LC ; KOH LP ; TAN P.** Fatal cytokine release syndrome with chimeric anti-CD20 monoclonal antibody rituximab in a 71-year-old patient with chronic lymphocytic leukemia. *J. Clin Oncol.*, 1999, vol. 17 (6), 1962-3 [0149]
- **KLINGER et al.** Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. *Blood*, 2012, vol. 119, 6226-6233 [0150]
- **BARRACLOUGH, P. et al.** *Tetrahedron Lett.*, 2005, vol. 46, 4653-4655 [0257]
- **BARRACLOUGH, P. et al.** *Org. Biomol. Chem.*, 2006, vol. 4, 1483-1491 [0257]
- **DORMOY, J. -R. ; CASTRO, B.** *Synthesis*, 1986, 81-82 [0257]
- **HRUBY, V. J. et al.** *J. Am. Chem. Soc.*, 1979, vol. 101, 202-212 [0257]
- *CHEMICAL ABSTRACTS*, 209269-08-9 [0260]
- **TANDON, M. et al.** *Bioorg. Med. Chem. Lett.*, 1998, vol. 8, 1139-1144 [0260]
- *CHEMICAL ABSTRACTS*, 1129634-44-1 [0262]
- *CHEMICAL ABSTRACTS*, 90104-21-5 [0267]
- *CHEMICAL ABSTRACTS*, 553650-00-3 [0267]
- **BRAUN, J.V.** Heymons. *Albrecht Berichte der Deutschen Chemischen Gesellschaft [Abteilung] B: Abhandlungen*, 1930, vol. 63B, 502-7 [0268]
- *J. Org. Chem.*, 2009, vol. 74, 4124-4131 [0377]
- **G. RUIZ-GOMEZ et al.** *J. Med. Chem.*, 2009, vol. 52, 6042-6052 [0757]